Number O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
lymphocytes O O
and O O
their O O
sensitivity O O
to O O
hormone O O
action O O
. O O

The O O
study O O
demonstrated O O
a O O
decreased O O
level O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
GR B B_PROTEIN[GENE]/B_DISEASE
) O O
in O O
peripheral O O
blood O O
lymphocytes O O
from O O
hypercholesterolemic O O
subjects O O
, O O
and O O
an O O
elevated O O
level O O
in O O
patients O O
with O O
acute O O
myocardial O O
infarction O O
. O O

In O O
the O O
lymphocytes O O
with O O
a O O
high O O
GR B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
number O O
, O O
dexamethasone O O
inhibited O O
[ O O
3H O O
] O O
-thymidine O O
and O O
[ O O
3H O O
] O O
-acetate O O
incorporation O O
into O O
DNA O O
and O O
cholesterol O O
, O O
respectively O O
, O O
in O O
the O O
same O O
manner O O
as O O
in O O
the O O
control O O
cells O O
. O O

On O O
the O O
other O O
hand O O
, O O
a O O
decreased O O
GR B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
number O O
resulted O O
in O O
a O O
less O O
efficient O O
dexamethasone O O
inhibition O O
of O O
the O O
incorporation O O
of O O
labeled O O
compounds O O
. O O

These O O
data O O
showed O O
that O O
the O O
sensitivity O O
of O O
lymphocytes O O
to O O
glucocorticoids O O
changed O O
only O O
with O O
a O O
decrease O O
of O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
level O O
. O O

[ O O
1 B B_DISEASE_ADJECTIVE[DISEASE]
, I I_DISEASE_ADJECTIVE[DISEASE]
25-Dihydroxyvitamin I I_DISEASE_ADJECTIVE[DISEASE]
D3 I I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DISEASE_ADJECTIVE[DISEASE]
in O O
lymphocytes O O
and O O
T- O O
and O O
B-lymphocyte O O
count O O
in O O
patients O O
with O O
glomerulonephritis O O
] O O

Content O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
hormonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
vitamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
D3 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
1.25 O B_MEASURE/B_LOCATION
( O O
OH O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
constituted O O
27.3 O B_MEASURE/B_ENT
fmole/mg O I_MEASURE/I_ENT
of O O
protein O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
in O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
peripheric O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
children O B_PERSON/B_BIO
with O O
glomerulonephritis O B_DISEASE
. O O

In O O
the O O
patients O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
concentration O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
of O O
total O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ionized O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
form O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Ca2+ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
decreased O O
down O O
to O O
2.04 O B_MEASURE
mmole/L O I_MEASURE
and O O
1.09 O B_MEASURE/B_LOCATION
mmole/L O I_MEASURE/I_LOCATION
, O O
respectively O O
, O O
while O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
parathormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
PTH O B_PROTEIN[GENE]/B_LOCATION
) O O
by O O
36 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
and O O
a O O
distinct O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
25 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
OH O O
) O O
D O B_PROTEIN[GENE]
concentration O I_PROTEIN[GENE]
( O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
1.25 O B_MEASURE
ng/ml O I_MEASURE
) O O
was O O
found O O
in O O
blood O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O O
content O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cAMP O B_GENE
was O O
also O O
decreased O O
in O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
33 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
% O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

At O O
the O O
same O B_TIME[MEASURE]/B_LOCATION
time O I_TIME[MEASURE]/I_LOCATION
, O O
total O B_MEASURE/B_ENT
content O I_MEASURE/I_ENT
of O O
T O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphocytes O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
decreased O O
1.5-fold O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
peripheric O B_PERSON/B_DISEASE
blood O I_PERSON/I_DISEASE
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
I-hydroxyvitamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
D3 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
1-1.5 O B_MEASURE
mg O O
daily O O
, O O
within O O
4 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
) O O
led O O
to O O
normalization O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
total O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
ionized O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
form O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Ca2+ O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
of O O
25 O B_MEASURE/B_LOCATION
( O O
OH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
but O O
did O O
not O O
affect O O
the O O
PTH O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
content O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

Concentration O O
of O O
the O O
receptors B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
1.25 O O
( O O
OH O O
) O O
2D3 O O
was O O
elevated O O
up O O
to O O
39.7 O O
fmole/mg O O
after O O
I O O
week O O
of O O
the O O
treatment O O
, O O
whereas O O
it O O
was O O
decreased O O
to O O
the O O
initial O O
level O O
24.8 O O
fmole/mg O O
within O O
4 O O
weeks O O
; O O
simultaneous O O
alteration O O
in O O
the O O
cAMP O O
content O O
was O O
observed O O
in O O
lymphocytes O O
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
1- O B_MEASURE
( O O
OH O O
) O O
D3 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
normalized O O
also O O
the O O
T O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
lymphocytes O O
content O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
peripheric O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

The O O
data O O
obtained O O
suggest O O
that O O
under O O
conditions O O
of O O
glomerulonephritis O O
only O O
high O O
content O O
of O O
receptors B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
1.25 O O
( O O
OH O O
) O O
2D3 O O
in O O
lymphocytes O O
enabled O O
to O O
perform O O
the O O
cell O O
response O O
to O O
the O O
hormone O O
effect O O
. O O

Tumor O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
serum O O
beta-2-microglobulin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
women O B_PERSON/B_BIO
with O O
breast O B_DISEASE/B_LOCATION
cancer O I_DISEASE/I_LOCATION
. O O

To O O
investigate O O
whether O O
the O O
tumor O O
expression O O
of O O
beta-2-microglobulin B B_GENE
( O O
beta B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
could O O
serve O O
as O O
a O O
marker O O
of O O
tumor O O
biologic O O
behavior O O
, O O
the O O
authors O O
studied O O
specimens O O
of O O
breast O O
carcinomas O O
from O O
60 O O
consecutive O O
female O O
patients O O
. O O

Presence O O
of O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
analyzed O O
by O O
immunohistochemistry O O
. O O

No O O
significant O O
correlations O O
were O O
found O O
between O O
tumor B B_GENE
beta I I_GENE
2-M I I_GENE
expression O O
and O O
several O O
histologic O O
attributes O O
such O O
as O O
type O O
, O O
histologic O O
and O O
nuclear O O
grades O O
, O O
mitotic O O
index O O
, O O
necrosis O O
, O O
vascular O O
invasion O O
, O O
and O O
lymphocytic O O
infiltration O O
. O O

Likewise O O
, O O
beta B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
associated O O
with O O
markers O O
of O O
disease O O
extension O O
such O O
as O O
TNM O O
, O O
( O O
UICC O O
, O O
classification O O
of O O
malignant O O
tumors O O
) O O
staging O O
and O O
axillary O O
lymph O O
node O O
involvement O O
or O O
with O O
estrogen O O
, O O
progesterone O O
, O O
and O O
glucocorticoid O O
receptor O O
levels O O
. O O

However O O
, O O
there O O
was O O
a O O
significantly O O
positive O O
association O O
between O O
tumor B B_GENE
beta I I_GENE
2-M I I_GENE
expression O O
and O O
the O O
degree O O
of O O
lymphocytic O O
infiltration O O
in O O
the O O
tumor O O
tissue O O
. O O

Beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum O O
levels O O
were O O
determined O O
by O O
an O O
enzyme-linked O O
immunosorbent O O
assay O O
in O O
samples O O
from O O
22 O O
of O O
the O O
above O O
women O O
. O O

Although O O
some O O
of O O
the O O
highest O O
values O O
had O O
been O O
obtained O O
in O O
women O O
with O O
larger O O
( O O
T4 O O
) O O
primary O O
tumors O O
, O O
the O O
authors O O
failed O O
to O O
detect O O
any O O
statistical O O
relationship O O
between O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
in O O
the O O
tumor O O
with O O
serum O O
levels O O
or O O
between O O
serum B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2-M I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
above O O
histologic O O
, O O
laboratory O O
, O O
and O O
clinical O O
factors O O
. O O

[ O O
Preliminary O O
observation O O
of O O
level O O
free-form B B_GENE
E I I_GENE
receptor I I_GENE
levels O O
in O O
serum O O
of O O
normal O O
childbearing-aged O O
and O O
pregnant O O
women O O
] O O

In O O
137 O O
cases O O
of O O
childbearing-aged O O
and O O
pregnant O O
women O O
, O O
free B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
( O O
sE B B_LOCATION/B_ORGANIZATION
) O O
in O O
serum O O
were O O
measured O O
by O O
ELISA O O
. O O

The O O
level O O
of O O
sE B B_GENE/B_DISEASE
was O O
significantly O O
decreased O O
during O O
the O O
first O O
trimester O O
, O O
slightly O O
higher O O
in O O
the O O
second O O
trimester O O
, O O
and O O
recovered O O
to O O
normal O O
in O O
the O O
third O O
trimester O O
. O O

The O O
level O B_MEASURE
remained O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
29 O B_PERSON
PIH O I_PERSON
women O I_PERSON
but O O
appeared O O
higher O O
in O O
overdue O B_PERSON
pregnancies O I_PERSON
as O O
compared O O
with O O
the O O
normal O B_MEASURE/B_PERSON
3rd O B_MEASURE/I_PERSON
trimester O B_MEASURE/I_PERSON
range O B_MEASURE/I_PERSON
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O O
that O O
there O O
is O O
a O O
relationship O B_PERSON/B_MEASURE
between O O
a O O
change O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
T O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pregnancy O B_DISEASE
. O O

Kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B-specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
role O O
in O O
the O O
regulation O O
of O O
human B B_GENE
interleukin-2 I I_GENE
gene I I_GENE
expression O O
. O O

Transcriptional O O
activation O O
of O O
the O O
human B B_GENE
interleukin-2 I I_GENE
( I I_GENE
IL-2 I I_GENE
) I I_GENE
gene I I_GENE
, O O
like O O
induction O O
of O O
the O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-2R I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
type O O
1 O O
human O O
immunodeficiency O O
virus O O
( O O
HIV-1 O O
) O O
, O O
is O O
shown O O
to O O
be O O
modulated O O
by O O
a O O
kappa B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B-like I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancer I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mutation O O
of O O
a O O
kappa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
B I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
core I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sequence I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
identified O O
in O O
the O O
IL-2 B B_GENE
promoter I I_GENE
( O O
-206 O O
to O O
-195 O O
) O O
partially O O
inhibits O O
both O O
mitogen- O O
and O O
HTLV-I O O
Tax-mediated O O
activation O O
of O O
this O O
transcription B B_GENE/B_LOCATION
unit I I_GENE/I_LOCATION
and O O
blocks O O
the O O
specific O O
binding O O
of O O
two O O
inducible B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cellular I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factors I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

These O O
kappa B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B-specific I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
80 O O
to O O
90 O O
and O O
50 O O
to O O
55 O O
kilodaltons O O
) O O
similarly O O
interact O O
with O O
the O O
functional O O
kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
enhancer I I_GENE/I_LOCATION
present O O
in O O
the O O
IL-2R B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
alpha I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
data O O
suggest O O
that O O
these O O
kappa B B_GENE/B_LOCATION
B-specific I I_GENE/I_LOCATION
proteins I I_GENE/I_LOCATION
have O O
a O O
role O O
in O O
the O O
coordinate O O
regulation O O
of O O
this O O
growth O O
factor-growth O O
factor O O
receptor O O
gene O O
system O O
that O O
controls O O
T O O
cell O O
proliferation O O
. O O

Novel O O
region O O
within O O
the O O
V B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
responsible O O
for O O
tissue O O
and O O
stage-specific O O
expression O O
of O O
immunoglobulin B B_GENE
genes I I_GENE
in O O
human O O
lymphoid O O
neoplasms O O
. O O

Immunoglobulin B B_PERSON/B_GENE
gene-specific I I_PERSON/I_GENE
transacting I I_PERSON/I_GENE
factors I I_PERSON/I_GENE
have O O
been O O
shown O O
to O O
play O O
a O O
role O O
in O O
lymphoid O O
tissue-specific O O
expression O O
of O O
immunoglobulin B B_GENE
genes I I_GENE
. O O

The O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
factors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
B-cell O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
differentiation O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O O
stage-specific O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
these O O
genes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
, O O
however O O
, O O
not O O
fully O O
understood O O
. O O

We O O
have O O
used O O
a O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
human O B_DISEASE
lymphoid O I_DISEASE
neoplasia O I_DISEASE
to O O
address O O
this O O
question O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Different O O
fragments O O
of O O
unrearranged B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
human I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variable I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O O
immunoglobulin B B_GENE
kappa I I_GENE
gene I I_GENE
( O O
V B B_GENE
kappa I I_GENE
) O O
were O O
used O O
for O O
cell-free O O
in O O
vitro O O
transcription O O
and O O
DNA O O
mobility O O
shift O O
assays O O
. O O

Previously O O
described O O
enhancement O O
of O O
in O O
vitro O O
transcription O O
that O O
was O O
only O O
seen O O
with O O
nuclear O O
extracts O O
derived O O
from O O
B-cell O O
neoplasms O O
corresponding O O
to O O
the O O
late O O
stages O O
of O O
B-cell O O
differentiation O O
was O O
shown O O
to O O
be O O
dependent O O
on O O
the O O
actions O O
of O O
these O O
factor O O
( O O
s O O
) O O
on O O
the O O
DNA O O
region O O
within O O
the O O
V B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
region O O
is O O
located O O
within O O
the O O
920 O O
bp O O
fragment O O
located O O
210 O O
bp O O
upstream O O
from O O
the O O
coding O O
region O O
and O O
this O O
fragment O O
represents O O
a O O
possible O O
novel O O
DNA O O
region O O
, O O
which O O
plays O O
a O O
role O O
in O O
the O O
stage- O O
and O O
tissue-specific O O
expression O O
of O O
immunoglobulin B B_GENE
genes I I_GENE
. O O

[ O O
Determination O O
of O O
the O O
sensitivity O O
to O O
glucocorticoids B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
vitro O O
] O O

A O O
modified O O
method O O
for O O
the O O
determination O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
human O O
lymphocytes O O
is O O
suggested O O
. O O

The O O
principal O O
distinction O O
of O O
the O O
method O O
is O O
standardization O O
by O O
the O O
lymphocyte O O
count O O
in O O
a O O
sample O O
( O O
1 O O
mln O O
) O O
and O O
the O O
labeled O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
concentration O O
. O O

The O O
modification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saves O O
time O B_TIME[MEASURE]/B_LOCATION
and O O
money O B_ORGANIZATION/B_MEASURE
, O O
limits O O
the O O
range O B_MEASURE
of O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
variations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
, O O
and O O
makes O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
lesser O B_MEASURE/B_LOCATION
volume O B_MEASURE/I_LOCATION
of O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Examinations O O
of O O
70 O O
children O O
aged O O
4 O O
to O O
15 O O
suffering O O
from O O
the O O
nephrotic O O
form O O
of O O
glomerulonephritis O O
have O O
made O O
it O O
possible O O
to O O
distinguish O O
two O O
groups O O
of O O
patients O O
: O O
with O O
relatively O O
high O O
values O O
of O O
specific O O
binding O O
X O O
= O O
6820.1 O O
+/- O O
530.0 O O
( O O
n O O
= O O
30 O O
, O O
p O O
= O O
0.95 O O
, O O
t O O
= O O
2.04 O O
) O O
, O O
this O O
corresponding O O
to O O
a O O
clinical O O
form O O
of O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-sensitive O O
glomerulonephritis O O
, O O
and O O
with O O
relatively O O
low O O
values O O
of O O
specific O O
binding O O
X O O
= O O
1815.2 O O
+/- O O
302.8 O O
( O O
n O O
= O O
40 O O
, O O
p O O
= O O
0.95 O O
, O O
t O O
= O O
1.96 O O
) O O
, O O
that O O
corresponds O O
to O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-resistant O O
glomerulonephritis O O
. O O

Dynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
not O O
shown O O
any O O
statistically O O
significant O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
binding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
values O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

These O O
results O O
permit O O
regarding O O
the O O
specific O O
binding O O
value O O
as O O
a O O
prognostic O O
criterion O O
in O O
the O O
assessment O O
of O O
corticosteroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O O
; O O
this O O
allows O O
a O O
wide O O
employment O O
of O O
the O O
described O O
method O O
in O O
practical O O
nephrology O O
. O O

Octamer-binding B B_GENE
proteins I I_GENE
from O O
B O O
or O O
HeLa O O
cells O O
stimulate O O
transcription O O
of O O
the O O
immunoglobulin B B_GENE
heavy-chain I I_GENE
promoter I I_GENE
in O O
vitro O O
. O O

The O O
B-cell O O
-type O O
specificity O O
of O O
the O O
immunoglobulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Ig B B_PROTEIN[GENE]/B_LOCATION
) O O
heavy-chain O O
and O O
light-chain O O
promoters O O
is O O
mediated O O
by O O
an O O
octanucleotide B B_GENE
( I I_GENE
OCTA I I_GENE
) I I_GENE
element I I_GENE
, O O
ATGCAAAT O O
, O O
that O O
is O O
also O O
a O O
functional O O
component O O
of O O
other O O
RNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
such O O
as O O
snRNA O O
and O O
histone O O
H2B O O
promoters O O
. O O

Two O O
nuclear B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
bind O O
specifically O O
and O O
with O O
high O O
affinity O O
to O O
the O O
OCTA B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
element I B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
have O O
been O O
identified O O
. O O

NF-A1 B B_GENE
is O O
present O O
in O O
a O O
variety O O
of O O
cell O O
types O O
, O O
whereas O O
the O O
presence O O
of O O
NF-A2 B B_GENE
is O O
essentially O O
confined O O
to O O
B O O
cells O O
, O O
leading O O
to O O
the O O
hypothesis O O
that O O
NF-A2 B B_GENE
activates O O
cell-type-specific O O
transcription O O
of O O
the O O
Ig B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
and O O
NF-A1 B B_GENE/B_LOCATION
mediates O O
the O O
other O O
responses O O
of O O
the O O
OCTA B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
element I B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Extracts O O
of O O
the O O
B-cell O O
line O O
, O O
BJA-B O O
, O O
contain O O
high O O
levels O O
of O O
NF-A2 B B_GENE
and O O
specifically O O
transcribe O O
Ig B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O O
, O O
extracts O O
from O O
HeLa O O
cells O O
transcribed O O
the O O
Ig B B_GENE
promoter I I_GENE
poorly O O
. O O

Surprisingly O O
, O O
addition O O
of O O
either O O
affinity-enriched O O
NF-A2 O O
or O O
NF-A1 O O
to O O
either O O
a O O
HeLa O O
extract O O
or O O
a O O
partially O O
purified O O
reaction O O
system O O
specifically O O
stimulates O O
the O O
Ig B B_GENE
promoter I I_GENE
. O O

This O O
suggests O O
that O O
the O O
constitutive O O
OCTA-binding B B_GENE
factor I I_GENE
NF-A1 I I_GENE
can O O
activate O O
transcription O O
of O O
the O O
Ig B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
and O O
that O O
B-cell O O
-specific O O
transcription O O
of O O
this O O
promoter O O
, O O
at O O
least O O
in O O
vitro O O
, O O
is O O
partially O O
due O O
to O O
a O O
quantitative O O
difference O O
in O O
the O O
amount O O
of O O
OCTA-binding B B_GENE
protein I I_GENE
. O O

Because O O
NF-A1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
stimulate O O
Ig B B_GENE/B_DISEASE
transcription O O
, O O
the O O
inability O O
of O O
this O O
factor O O
to O O
activate O O
in O O
vivo O O
the O O
Ig B B_GENE
promoter I I_GENE
to O O
the O O
same O O
degree O O
as O O
the O O
snRNA B B_GENE/B_MEASURE
promoters I I_GENE/I_MEASURE
probably O O
reflects O O
a O O
difference O O
in O O
the O O
context O O
of O O
the O O
OCTA B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
element I B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
these O O
two O O
types O O
of O O
promoters B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Identification O O
of O O
a O O
putative O O
regulator O O
of O O
early B B_DISEASE
T I I_DISEASE
cell I I_DISEASE
activation I I_DISEASE
genes I I_DISEASE
. O O

Molecules O O
involved O O
in O O
the O O
antigen O O
receptor-dependent O O
regulation O O
of O O
early B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
T I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cell I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O O
investigated O O
with O O
the O O
use O O
of O O
functional O O
sequences O O
of O O
the O O
T B B_GENE/B_LOCATION
cell I I_GENE/I_LOCATION
activation-specific I I_GENE/I_LOCATION
enhancer I I_GENE/I_LOCATION
of O O
interleukin-2 B B_GENE
( O O
IL-2 B B_GENE
) O O
. O O

One O O
of O O
these O O
sequences O O
forms O O
a O O
protein O O
complex O O
, O O
NFAT-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
specifically O O
with O O
nuclear O O
extracts O O
of O O
activated O O
T O O
cells O O
. O O

This O O
complex O O
appeared O O
10 O O
to O O
25 O O
minutes O O
before O O
the O O
activation O O
of O O
the O O
IL-2 B B_GENE
gene I I_GENE
. O O

Studies O O
with O O
inhibitors O O
of O O
protein O O
synthesis O O
indicated O O
that O O
the O O
time O O
of O O
synthesis O O
of O O
the O O
activator O O
of O O
the O O
IL-2 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
in O O
Jurkat O O
T O O
cells O O
corresponds O O
to O O
the O O
time O O
of O O
appearance O O
of O O
NFAT-1 B B_GENE
. O O

NFAT-1 B B_GENE
, O O
or O O
a O O
very O O
similar O O
protein O O
, O O
bound O O
functional O O
sequences O O
of O O
the O O
long B B_GENE
terminal I I_GENE
repeat I I_GENE
( O O
LTR B B_GENE/B_DISEASE
) O O
of O O
the O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
; O O
the O O
LTR B B_GENE/B_DISEASE
of O O
this O O
virus O O
is O O
known O O
to O O
be O O
stimulated O O
during O O
early O O
T O O
cell O O
activation O O
. O O

The O O
binding B B_GENE
site I I_GENE
for O O
this O O
complex O O
activated O O
a O O
linked O O
promoter O O
after O O
transfection O O
into O O
antigen O O
receptor-activated O O
T O O
cells O O
but O O
not O O
other O O
cell O O
types O O
. O O

These O O
characteristics O O
suggest O O
that O O
NFAT-1 B B_GENE
transmits O O
signals O O
initiated O O
at O O
the O O
T B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
cell I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
antigen I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Characterization O O
of O O
thyroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hormone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
IM-9 O O
lymphocytes O O
. O O

Although O O
putatively O O
identified O O
more O O
than O O
10 O O
years O O
ago O O
, O O
thyroid B B_GENE/B_BIO
hormone I I_GENE/I_BIO
receptors I I_GENE/I_BIO
in O O
human O O
tissues O O
remain O O
poorly O O
characterized O O
. O O

As O O
a O O
first O O
step O O
towards O O
understanding O O
the O O
mechanism O O
of O O
thyroid O O
hormone O O
action O O
in O O
man O O
we O O
have O O
characterized O O
T3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
nuclei O O
of O O
the O O
human O O
lymphoblastoid O O
line O O
, O O
IM-9 O O
cells O O
. O O

In O O
whole O O
cell O O
experiments O O
at O O
37 O O
degrees O O
C O O
, O O
nuclear O O
binding O O
of O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
125I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
T3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
saturable O O
( O O
Kd O O
34 O O
+/- O O
6 O O
pmol/l O O
) O O
and O O
of O O
finite O O
capacity O O
( O O
approximately O O
equal O O
to O O
350 O O
sites/cell O O
) O O
. O O

The O O
binding B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
sites I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
were O O
extracted O O
from O O
a O O
nuclear O O
pellet O O
by O O
treatment O O
with O O
0.4 O O
mol/l O O
KCl O O
and O O
sonication O O
. O O

Separation O O
of O O
bound O O
from O O
free O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
125I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
extracts O O
was O O
achieved O O
using O O
the O O
calcium O O
phosphate O O
matrix O O
, O O
hydroxyapatite O O
at O O
a O O
concentration O O
of O O
0.3 O O
ml O O
of O O
a O O
150 O O
g/l O O
slurry O O
. O O

Rectilinear O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Scatchard O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
plots O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
obtained O O
only O O
when O O
the O O
hydroxyapatite O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
washed O O
with O O
a O O
buffer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
0.5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Triton O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X-100 O O
. O O

Under O O
these O O
conditions O O
T3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
nuclear O O
extracts O O
were O O
present O O
at O O
a O O
concentration O O
of O O
22.4 O O
+/- O O
8.6 O O
fmol/mg O O
protein O O
and O O
showed O O
an O O
affinity O O
of O O
( O O
Kd O O
, O O
room O O
temperature O O
) O O
140 O O
+/- O O
10 O O
pmol/l O O
. O O

The O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
used O O
to O O
determine O O
the O O
hierarchy O B_MEASURE
of O O
affinities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
a O O
range O B_LOCATION/B_MEASURE
of O O
natural O B_EDU[ORGANIZATION]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
synthetic O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analogues O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Calling O O
T3 O B_MEASURE/B_PERSON
100 O I_MEASURE/I_PERSON
, O O
the O O
order O B_MEASURE/B_DISEASE
of O O
potencies O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
observed O O
was O O
: O O
Triac O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
500 O B_MEASURE
; O O
3 O B_NUMBER[MEASURE]
, O O
5-diiodo-3'-isopropylthyronine O B_TIME[MEASURE]
, O O
89 O B_MEASURE
; O O
T4 O B_PROTEIN[GENE]
, O O
32 O B_MEASURE
; O O
3 O B_NUMBER[MEASURE]
, O O
5-dimethyl-3'isopropylthyronine O B_TIME[MEASURE]
2 O I_TIME[MEASURE]
; O O
3 O B_NUMBER[MEASURE]
, O O
5-T2 O B_MEASURE
, O O
0.7 O B_MEASURE
, O O
rT3 O B_MEASURE/B_PROTEIN[GENE]
, O O
0.4 O B_MEASURE
; O O
3'5'-T2 O B_PROTEIN[GENE]/B_MEASURE
, O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
0.01 O B_MEASURE/B_LOCATION
. O O

These O O
results O O
suggest O O
that O O
the O O
T3 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
present O O
in O O
human O O
IM-9 O O
lymphocyte O O
nuclei O O
and O O
extracts O O
thereof O O
are O O
thyroid B B_DISEASE_ADJECTIVE[DISEASE]
hormone I I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
cells O O
may O O
be O O
a O O
useful O O
tool O O
to O O
increase O O
our O O
understanding O O
of O O
human B B_DISEASE
T3 I I_DISEASE
receptors I I_DISEASE

Definition O O
of O O
T-cell B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
interact O O
with O O
a O O
3'-silencer B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
CD4+ B B_GENE
T-cell I I_GENE
gene I I_GENE
Rpt-1 I I_GENE
. O O

Analysis O O
of O O
the O O
region O O
3 O O
' O O
to O O
the O O
CD4+ B B_GENE/B_LOCATION
T-cell I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
Rpt-1 I I_GENE/I_LOCATION
( O O
encoding O O
regulatory O O
protein O O
T-lymphocyte B B_PROTEIN[GENE]/B_MEASURE
1 I I_PROTEIN[GENE]/I_MEASURE
) O O
led O O
to O O
the O O
definition O O
of O O
a O O
silencer B B_GENE
element I I_GENE
that O O
inhibits O O
heterologous B B_GENE
gene I I_GENE
expression O O
in O O
certain O O
CD4+ O O
T-cell O O
lines O O
but O O
not O O
in O O
B-cell O O
or O O
non-lymphoid O O
cell O O
lines O O
. O O

Functional O O
silencer B B_GENE
activity O O
in O O
vivo O O
was O O
associated O O
with O O
the O O
presence O O
of O O
a O O
specific O O
silencer-DNA-protein B B_GENE
complex I I_GENE
in O O
electrophoretic O O
mobility O O
shift O O
assays O O
with O O
T-cell O O
extracts O O
. O O

Formation O O
of O O
this O O
complex O O
was O O
selectively O O
inhibited O O
by O O
the O O
region O O
in O O
HIV-1 B B_BIO/B_GENE
containing O O
a O O
silencer B B_GENE
element I I_GENE
. O O

We O O
discuss O O
the O O
possibility O O
that O O
DNA-binding B B_DISEASE/B_GENE
factors I B_DISEASE/I_GENE
may O O
coregulate O O
HIV-1 O O
and O O
Rpt-1 O O
gene O O
expression O O
through O O
a O O
common O O
transcriptional B B_GENE/B_LOCATION
silencer I B_GENE/I_LOCATION
element I B_GENE/I_LOCATION
. O O

Congenital O O
immunodeficiencies O O
associated O O
with O O
absence O O
of O O
HLA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
lymphocytes O O
result O O
from O O
distinct O O
mutations O O
in O O
trans-acting B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Coordinate O O
regulation O O
of O O
HLA B B_GENE/B_BIO
class I I_GENE/I_BIO
II I I_GENE/I_BIO
gene I I_GENE/I_BIO
expression O O
during O O
development O O
and O O
coinduction O O
of O O
class B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
soluble B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggests O O
that O O
common O O
trans-acting B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
s O O
) O O
control O O
expression O O
of O O
these O O
genes O O
. O O

In O O
B-lymphoblastoid O O
cell O O
lines O O
derived O O
from O O
two O O
independent O O
class O O
II-deficient O O
bare O O
lymphocyte O O
syndrome O O
patients O O
, O O
we O O
observed O O
a O O
drastic O O
decrease O O
in O O
transcription O O
rates O O
of O O
the O O
class B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

When O O
these O O
cell O O
lines O O
are O O
fused O O
, O O
class B B_GENE/B_PERSON
II I I_GENE/I_PERSON
genes I I_GENE/I_PERSON
are O O
reexpressed O O
, O O
indicating O O
that O O
immunodeficiencies O O
in O O
bare O O
lymphocyte O O
syndrome O O
patients O O
are O O
the O O
result O O
of O O
two O O
distinct O O
mutations O O
. O O

Further O O
studies O O
show O O
that O O
genes O O
governing O O
the O O
expression O O
of O O
class B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fall O O
into O O
at O O
least O O
three O O
complementation O O
groups O O
; O O
two O O
of O O
these O O
were O O
previously O O
unidentified O O
in O O
mutant O O
cell O O
lines O O
generated O O
in O O
vitro O O
. O O

In O O
addition O O
, O O
we O O
report O O
the O O
identification O O
of O O
two O O
discrete O O
complexes O O
, O O
NFX1.1 B B_GENE
and O O
NFX1.2 B B_GENE
, O O
that O O
bind O O
to O O
the O O
DRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consensus I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Though O O
the O O
mutation O O
in O O
at O O
least O O
one O O
mutant O O
line O O
generated O O
in O O
vitro O O
( O O
RJ2.2.5 O O
) O O
affects O O
products O O
functioning O O
via O O
interaction O O
with O O
the O O
X B B_GENE
box I I_GENE
, O O
clear O O
alterations O O
in O O
either O O
NFX1.1 B B_GENE/B_DISEASE
or O O
NFX1.2 B B_GENE
are O O
not O O
found O O
in O O
any O O
of O O
the O O
mutant O O
cell O O
lines O O
. O O

In O O
vivo O O
responsiveness O O
to O O
glucocorticoid O O
correlated O O
with O O
glucocorticoid B B_GENE
receptor I I_GENE
content O O
in O O
peripheral O O
blood O O
leukocytes O O
in O O
normal O O
humans O O
. O O

Dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loading O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0.1 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dexamethasone/kg O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
iv O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
were O O
performed O O
in O O
18 O B_MEASURE/B_PERSON
normal O I_MEASURE/I_PERSON
males O I_MEASURE/I_PERSON
to O O
evaluate O O
the O O
individual O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responsiveness O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
glucocorticoid O O
. O O

There O O
were O O
inter-individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
peripheral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
polymorphonuclear O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leukocyte O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
count O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
decrease O O
in O O
peripheral O B_DISEASE/B_GENE
blood O B_DISEASE/I_GENE
lymphocyte O B_DISEASE/I_GENE
count O B_DISEASE/I_GENE
, O O
and O O
increase O O
in O O
plasma O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
free O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
fatty O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acids O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
after O O
dexamethasone O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
there O O
was O O
a O O
significant O B_MEASURE/B_PERSON
correlation O I_MEASURE/I_PERSON
between O O
the O O
maximum O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
increase O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
polymorphonuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
leukocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
the O O
maximum O B_MEASURE
decrease O I_MEASURE
in O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
r O B_GENE/B_OTHER
= O O
0.7514 O B_MEASURE
, O O
p O B_MEASURE
less O I_MEASURE
than O O
0.0003 O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

Simultaneous O O
measurements O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
content O O
by O O
whole-cell O O
assay O O
revealed O O
that O O
glucocorticoid B B_GENE
receptor I I_GENE
content O O
in O O
polymorphonuclear O O
leukocytes O O
linearly O O
correlated O O
with O O
that O O
in O O
the O O
corresponding O O
lymphocytes O O
( O O
r O O
= O O
0.9482 O O
, O O
p O O
less O O
than O O
0.0001 O O
) O O
. O O

There O O
were O O
also O O
significant O O
correlations O O
between O O
the O O
maximum O O
increase O O
in O O
polymorphonuclear O O
leukocytes O O
and O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O O
in O O
polymorphonuclear O O
leukocytes O O
( O O
r O O
= O O
0.7239 O O
, O O
p O O
less O O
than O O
0.0007 O O
) O O
, O O
and O O
between O O
the O O
maximum O O
decrease O O
in O O
lymphocytes O O
and O O
glucocorticoid B B_GENE
receptor I I_GENE
content O O
in O O
lymphocytes O O
( O O
r O O
= O O
0.7703 O O
, O O
p O O
less O O
than O O
0.0002 O O
) O O
. O O

These O O
results O O
suggest O O
that O O
individual O O
differences O O
are O O
preserved O O
both O O
in O O
glucocorticoid O O
responsiveness O O
and O O
in O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O O
in O O
peripheral O O
blood O O
leukocytes O O
in O O
normal O O
humans O O
. O O

Estradiol O O
receptors O O
in O O
the O O
cytosol O O
of O O
peripheral O O
blood O O
mononuclear O O
cells O O
in O O
hepatitis O O
B O O
virus O O
carriers O O
treated O O
with O O
interferon-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Estradiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
cytosol O O
of O O
peripheral O O
blood O O
mononuclear O O
cells O O
and O O
the O O
effects O O
of O O
interferon-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IFN-alpha B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
on O O
estradiol B B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors I I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
studied O O
in O O
asymptomatic O O
hepatitis O O
B O O
virus O O
( O O
HBV O O
) O O
carriers O O
, O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
and O O
normal O O
controls O O
. O O

The O O
level O O
of O O
estradiol B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
cytosol O O
of O O
mononuclear O O
cells O O
was O O
significantly O O
lower O O
in O O
asymptomatic O O
HBV O O
carriers O O
and O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
, O O
compared O O
to O O
normal O O
controls O O
. O O

This O O
low O O
level O O
of O O
cytosol O O
estradiol B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
was O O
increased O O
by O O
the O O
administration O O
of O O
IFN-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

In O O
addition O O
, O O
when O O
peripheral O O
blood O O
mononuclear O O
cells O O
from O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
were O O
incubated O O
with O O
IFN-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
vitro O O
, O O
the O O
level O O
of O O
cytosol O O
estradiol B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
increased O O
by O O
increasing O O
the O O
concentration O O
of O O
IFN-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

We O O
previously O O
reported O O
that O O
the O O
response O O
of O O
mononuclear O O
cells O O
to O O
estrogen O O
is O O
impaired O O
in O O
HBV O O
carriers O O
, O O
and O O
our O O
present O O
results O O
suggested O O
that O O
this O O
may O O
be O O
due O O
to O O
the O O
low O O
level O O
of O O
estradiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
cytosol O O
of O O
mononuclear O O
cells O O
. O O

Association O O
of O O
increased O O
lytic O O
effector O O
cell O O
function O O
with O O
high O O
estrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
in O O
tumor-bearing O O
patients O O
with O O
breast O O
cancer O O
. O O

Tumor-bearing O O
patients O B_PERSON/B_SPECIES[BIO]
with O O
breast O B_DISEASE
cancer O I_DISEASE
were O O
assayed O O
for O O
their O O
natural O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
killer O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
NK O B_PROTEIN[GENE]/B_LOCATION
) O O
cell O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
for O O
the O O
function O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
activated O O
cytotoxic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T-cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
assessed O O
by O O
lectin-dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cellular O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytotoxicity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LDCC O B_DISEASE/B_LOCATION
) O O
. O O

Tumor-bearing O O
patients O B_PERSON
with O O
breast O B_DISEASE
cancer O I_DISEASE
had O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
NK O B_DISEASE
activity O I_DISEASE
and O O
in O O
LDCC O B_DISEASE/B_GENE
, O O
as O O
compared O O
with O O
healthy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
individuals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Although O O
the O O
enhanced O O
NK O O
cell O O
activity O O
and O O
LDCC O O
were O O
closely O O
associated O O
with O O
high O O
levels O O
( O O
greater O O
than O O
31 O O
fmol/mg O O
) O O
of O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ER B B_PROTEIN[GENE]/B_LOCATION
) O O
content O O
in O O
the O O
primary O O
tumor O O
, O O
no O O
other O O
clinical O O
or O O
histologic O O
correlation O O
between O O
the O O
increase O O
in O O
either O O
parameter O O
of O O
cytotoxic O O
effector O O
cell O O
function O O
could O O
be O O
found O O
. O O

Thus O O
, O O
ER B B_GENE
levels O O
greater O O
than O O
31 O O
fmol/mg O O
might O O
be O O
associated O O
with O O
increased O O
cytotoxic O O
effector O O
cell O O
function O O
in O O
tumor-bearing O O
patients O O
with O O
breast O O
cancer O O
. O O

Properties O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
Epstein-Barr O O
virus-transformed O O
lymphocytes O O
from O O
patients O O
with O O
familial O O
cortisol O O
resistance O O
. O O

In O O
a O O
previous O O
report O O
of O O
two O O
patients O O
with O O
familial O O
glucocorticoid O O
resistance O O
due O O
to O O
reduced O O
numbers O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GR B B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
we O O
have O O
shown O O
decreased O O
numbers O O
of O O
GR B B_PROTEIN[GENE]/B_DISEASE
in O O
peripheral O O
mononuclear O O
cells O O
and O O
cultured O O
fibroblasts O O
but O O
normal O O
affinity O O
of O O
GR B B_PROTEIN[GENE]/B_DISEASE
in O O
both O O
patients O O
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
these O O
patients O B_PERSON/B_BIO
, O O
one O B_PERSON
patient O I_PERSON
's O I_PERSON
son O I_PERSON
and O O
daughter O B_PERSON
, O O
and O O
normal O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
were O O
transformed O O
with O O
Epstein-Barr O B_DISEASE/B_GENE
virus O B_DISEASE/I_GENE
. O O

Reduced O O
numbers O O
and O O
normal O O
affinity O O
of O O
GR B B_LOCATION/B_ORGANIZATION
were O O
found O O
in O O
the O O
Epstein-Barr O O
virus-transformed O O
lymphocytes O O
from O O
both O O
patients O O
while O O
the O O
son O O
and O O
daughter O O
had O O
normal O O
numbers O O
and O O
affinity O O
of O O
GR B B_PROTEIN[GENE]/B_DISEASE
. O O

The O O
thermal O O
stability O O
of O O
GR B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O O
thermal O O
activation O O
of O O
cytosolic B B_PROTEIN[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
patients O O
were O O
found O O
to O O
be O O
normal O O
. O O

Although O O
the O O
percentages O O
of O O
nuclear O O
bound O O
GR B B_PROTEIN[GENE]/B_DISEASE
were O O
similar O O
in O O
both O O
patients O O
and O O
normal O O
controls O O
, O O
the O O
absolute O O
amounts O O
of O O
nuclear O O
bound O O
GR B B_PROTEIN[GENE]/B_DISEASE
of O O
the O O
patients O O
were O O
about O O
one-half O O
that O O
of O O
normal O O
controls O O
. O O

These O O
abnormal O O
properties O O
of O O
GR B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
( O O
reduced O O
numbers O O
of O O
GR B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
) O O
were O O
preserved O O
in O O
the O O
transformed O O
cells O O
from O O
the O O
patients O O
. O O

Octamer O O
transcription O O
factors O O
1 O O
and O O
2 O O
each O O
bind O O
to O O
two O O
different O O
functional B B_LOCATION/B_BIO
elements I I_LOCATION/I_BIO
in O O
the O O
immunoglobulin B B_GENE
heavy-chain I I_GENE
promoter I I_GENE
. O O

Immunoglobulin B B_PERSON/B_GENE
heavy-chain I I_PERSON/I_GENE
genes I I_PERSON/I_GENE
contain O O
two O O
conserved B B_GENE/B_LOCATION
sequence I B_GENE/I_LOCATION
elements I B_GENE/I_LOCATION
5 O O
' O O
to O O
the O O
site O O
of O O
transcription O O
initiation O O
: O O
the O O
octamer O O
ATGCAAAT O O
and O O
the O O
heptamer O O
CTCATGA O O
. O O

Both O O
of O O
these O O
elements O O
are O O
required O O
for O O
normal B B_GENE
cell-specific I I_GENE
promoter I I_GENE
function O O
. O O

The O O
present O O
study O O
demonstrates O O
that O O
both O O
the O O
ubiquitous B B_GENE/B_LOCATION
and I I_GENE/I_LOCATION
lymphoid-cell-specific I I_GENE/I_LOCATION
octamer I I_GENE/I_LOCATION
transcription I I_GENE/I_LOCATION
factors I I_GENE/I_LOCATION
( O O
OTF-1 B B_GENE
and O O
OTF-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
) O O
interact O O
specifically O O
with O O
each O O
of O O
the O O
two O O
conserved B B_GENE/B_LOCATION
sequence I I_GENE/I_LOCATION
elements I I_GENE/I_LOCATION
, O O
forming O O
either O O
homo- B B_LOCATION/B_PERSON
or I I_LOCATION/I_PERSON
heterodimeric I I_LOCATION/I_PERSON
complexes I I_LOCATION/I_PERSON
. O O

This O O
was O O
surprising O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
since O O
the O O
heptamer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
octamer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
motifs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
bear O O
no O O
obvious O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
similarity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
each O O
other O B_TIME[MEASURE]/B_DISEASE
. O O

Binding O O
of O O
either O O
factor O O
to O O
the O O
octamer B B_LOCATION/B_BIO
element I B_LOCATION/I_BIO
occurred O O
independently O O
. O O

However O O
, O O
OTF B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
interaction O O
with O O
the O O
heptamer B B_GENE/B_LOCATION
sequence I I_GENE/I_LOCATION
appeared O O
to O O
require O O
the O O
presence O O
of O O
an O O
intact O O
octamer O O
motif O O
and O O
occurred O O
with O O
a O O
spacing O O
of O O
either O O
2 B B_LOCATION/B_PERSON
or I I_LOCATION/I_PERSON
14 I I_LOCATION/I_PERSON
base I I_LOCATION/I_PERSON
pairs I I_LOCATION/I_PERSON
between O O
the O O
two O O
elements O O
, O O
suggesting O O
coordinate O O
binding O O
resulting O O
from O O
protein-protein O O
interactions O O
. O O

The O O
degeneracy O O
in O O
sequences O O
recognized O O
by O O
the O O
OTFs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
important O O
in O O
widening O O
the O O
range O O
over O O
which O O
gene O O
expression O O
can O O
be O O
modulated O O
and O O
in O O
establishing O O
cell O O
type O O
specificity O O
. O O

Identification O O
of O O
a O O
novel O O
lymphoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
octamer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
OTF-2B B B_GENE/B_LOCATION
) O O
by O O
proteolytic O O
clipping O O
bandshift O O
assay O O
( O O
PCBA O O
) O O
. O O

The O O
octamer O O
sequence O O
ATGCAAAT O O
is O O
found O O
in O O
the O O
promoters O O
of O O
immunoglobulin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ig I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heavy I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
the O O
heavy B B_GENE
chain I I_GENE
enhancer I I_GENE
and O O
is O O
a O O
major O O
determinant O O
of O O
the O O
cell O O
type O O
specific O O
expression O O
of O O
Ig B B_GENE
genes I I_GENE
in O O
B O O
cells O O
. O O

An O O
apparent O O
paradox O O
is O O
that O O
the O O
same O O
sequence O O
serves O O
as O O
an O O
upstream B B_GENE/B_TIME[MEASURE]
promoter I I_GENE/I_TIME[MEASURE]
or I I_GENE/I_TIME[MEASURE]
enhancer I I_GENE/I_TIME[MEASURE]
element I I_GENE/I_TIME[MEASURE]
in O O
a O O
variety O O
of O O
housekeeping B B_GENE/B_LOCATION
genes I I_GENE/I_LOCATION
such O O
as O O
the O O
histone B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
H2B I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
and I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
U I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
snRNA I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
genes I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
differential O O
usage O O
of O O
this O O
regulatory O O
sequence O O
motif O O
is O O
thought O O
to O O
be O O
mediated O O
by O O
different O O
species O O
of O O
octamer B B_GENE
binding I I_GENE
proteins I I_GENE
. O O

One O O
species O O
of O O
100 O O
kd O O
, O O
designated O O
OTF-1 B B_GENE
, O O
is O O
present O O
in O O
all O O
cell O O
types O O
and O O
may O O
exert O O
its O O
activating O O
function O O
only O O
when O O
it O O
can O O
interact O O
with O O
additional O O
adjacent O O
transcription B B_BIO/B_GENE
factors I I_BIO/I_GENE
. O O

The O O
lymphoid B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
specific I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
octamer I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
60 O O
kd O O
( O O
OTF-2A B B_GENE
) O O
specifically O O
stimulates O O
Ig B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
consist O O
essentially O O
of O O
a O O
TATA-box B B_GENE/B_MEASURE
and O O
an O O
octamer B B_GENE/B_LOCATION
sequence I I_GENE/I_LOCATION
upstream O O
of O O
it O O
. O O

Here O O
we O O
present O O
evidence O O
for O O
yet O O
another O O
B B B_GENE/B_MEASURE
cell I I_GENE/I_MEASURE
specific I I_GENE/I_MEASURE
octamer I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
of O O
75 O O
kd O O
( O O
OTF-2B B B_GENE
) O O
. O O

From O O
several O O
findings O O
, O O
including O O
the O O
absence O O
of O O
OTF-2B B B_GENE
( O O
but O O
not O O
OTF-2A B B_GENE
) O O
from O O
a O O
lymphocyte O O
line O O
that O O
can O O
not O O
respond O O
to O O
the O O
IgH B B_GENE
enhancer I I_GENE
, O O
we O O
propose O O
a O O
role O O
of O O
the O O
novel B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
octamer I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
long O O
range O O
activation O O
by O O
the O O
IgH B B_GENE/B_MEASURE
enhancer I I_GENE/I_MEASURE
. O O

We O O
have O O
used O O
the O O
proteolytic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
clipping O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
bandshift O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
PCBA O B_DISEASE/B_GENE
) O O
technique O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
distinguish O O
the O O
three O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
different O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
forms O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
found O O
in O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

This O O
analysis O O
indicates O O
that O O
the O O
75 O O
kd-species O O
OTF-2B B B_GENE/B_MEASURE
is O O
closely O O
related O O
to O O
the O O
60 B B_MEASURE/B_GENE
kd I I_MEASURE/I_GENE
species I I_MEASURE/I_GENE
OTF-2A I I_MEASURE/I_GENE
. O O

Inhibition O O
of O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
proliferation O O
of O O
cloned O O
murine O O
T O O
cells O O
by O O
glucocorticoids O O
. O O

Possible O O
involvement O O
of O O
an O O
inhibitory B B_PERSON/B_ORGANIZATION
protein I I_PERSON/I_ORGANIZATION
. O O

The O O
ability O O
of O O
glucocorticoids O O
to O O
inhibit O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
IL B B_GENE
2 I I_GENE
) O O
-induced O O
T O O
cell O O
proliferation O O
in O O
two O O
cytotoxic O O
T O O
cell O O
( O O
CTL O O
) O O
clones O O
has O O
been O O
studied O O
. O O

A O O
complete O O
inhibition O O
of O O
DNA O O
synthesis O O
by O O
dexamethasone O O
( O O
Dx O O
) O O
could O O
be O O
observed O O
when O O
IL O O
2-depleted O O
cultures O O
of O O
CTL O O
were O O
either O O
incubated O O
for O O
6 O O
h O O
with O O
the O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prior O O
to O O
the O O
addition O O
of O O
IL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
treated O O
simultaneously O O
with O O
Dx O O
and O O
a O O
low O O
concentration O O
of O O
IL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

No O O
significant O O
reduction O O
in O O
the O O
number O O
and O O
affinity O O
of O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
seen O O
after O O
6 O O
h O O
incubation O O
with O O
Dx O O
. O O

The O O
order O O
of O O
potency O O
observed O O
with O O
the O O
different O O
steroids O O
indicated O O
that O O
this O O
inhibitory O O
effect O O
was O O
mediated O O
through O O
binding O O
to O O
a O O
specific O O
glucocorticoid B B_PROTEIN[GENE]
receptor I I_PROTEIN[GENE]
. O O

The O O
action O O
of O O
these O O
hormones B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possibly O O
involves O O
the O O
synthesis O O
of O O
an O O
inhibitory B B_GENE
protein I I_GENE
( O O
s O O
) O O
, O O
since O O
the O O
presence O O
of O O
cycloheximide O O
during O O
the O O
incubation O O
with O O
Dx O O
prevented O O
the O O
inhibition O O
of O O
DNA O O
synthesis O O
. O O

Furthermore O O
, O O
supernatant O O
from O O
Dx-treated O O
CTL O O
contained O O
a O O
nondialyzable O O
factor O O
which O O
inhibited O O
DNA O O
synthesis O O
and O O
cell O O
growth O O
of O O
CTL O O
clones O O
induced O O
by O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Blocking O O
of O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O O
and O O
IL B B_GENE
2 I I_GENE
receptor I I_GENE
formation O O
have O O
been O O
proposed O O
as O O
one O O
of O O
the O O
major O O
mechanisms O O
of O O
glucocorticoid-induced O O
immunosuppression O O
. O O

Our O O
results O O
indicate O O
that O O
these O O
hormones B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
also O O
affect O O
T O O
cell O O
proliferation O O
by O O
inhibiting O O
IL B B_GENE
2 I I_GENE
activity O O
. O O

Identification O O
and O O
purification O O
of O O
a O O
human B B_GENE/B_MEASURE
immunoglobulin-enhancer-binding I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
( O O
NF-kappa B B_GENE/B_DISEASE
B I I_GENE/I_DISEASE
) O O
that O O
activates O O
transcription O O
from O O
a O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O O
. O O

The O O
enhancer-binding B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
NF-kappa I I_GENE/I_MEASURE
B I I_GENE/I_MEASURE
, O O
which O O
is O O
found O O
only O O
in O O
cells O O
that O O
transcribe O O
immunoglobulin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
light I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
has O O
been O O
purified O O
from O O
nuclear O O
extracts O O
of O O
Namalwa O O
cells O O
( O O
human O O
Burkitt O O
lymphoma O O
cells O O
) O O
by O O
sequence-specific O O
DNA O O
affinity O O
chromatography O O
. O O

The O O
purified O O
NF-kappa B B_GENE
B I I_GENE
has O O
been O O
identified O O
as O O
a O O
51-kDa B B_GENE
polypeptide I I_GENE
by O O
UV-crosslinking O O
analysis O O
. O O

`` O O
Footprint O O
'' O O
and O O
methylation-interference O O
analyses O O
have O O
shown O O
that O O
purified O O
NF-kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
has O O
a O O
binding O O
activity O O
specific O O
for O O
the O O
kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
light I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
purified O O
factor O O
activated O O
in O O
vitro O O
transcription O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
binding O O
to O O
an O O
upstream B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]

Lymphocyte O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
in O O
depression O O
: O O
normal O O
values O O
following O O
recovery O O
. O O

The O O
number O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
sites O O
in O O
lymphocytes O O
and O O
plasma O O
cortisol O O
concentrations O O
were O O
measured O O
in O O
20 O O
patients O O
who O O
had O O
recovered O O
from O O
major O O
depressive O O
disorder O O
and O O
20 O O
healthy O O
control O O
subjects O O
. O O

The O O
number O O
of O O
glucocorticoid B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O O
in O O
lymphocytes O O
from O O
the O O
recovered O O
depressed O O
group O O
was O O
not O O
significantly O O
different O O
from O O
that O O
of O O
the O O
control O O
group O O
. O O

Although O O
the O O
mean O B_MEASURE
plasma O I_MEASURE
cortisol O I_MEASURE
concentration O I_MEASURE
in O O
recovered O O
depressives O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
was O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
in O O
control O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
difference O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
just O O
reached O O
significance O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
study O O
shows O O
that O O
the O O
reduction O O
in O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
numbers O O
which O O
occurs O O
during O O
acute O O
depressive O O
illness O O
does O O
not O O
persist O O
on O O
recovery O O
and O O
is O O
, O O
therefore O O
, O O
state-dependent O O
. O O

Identification O O
and O O
purification O O
of O O
a O O
human B B_PROTEIN[GENE]/B_MEASURE
lymphoid-specific I I_PROTEIN[GENE]/I_MEASURE
octamer-binding I I_PROTEIN[GENE]/I_MEASURE
protein I I_PROTEIN[GENE]/I_MEASURE
( O O
OTF-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
that O O
activates O O
transcription O O
of O O
an O O
immunoglobulin B B_GENE
promoter I I_GENE
in O O
vitro O O
. O O

The O O
octamer O O
sequence O O
5'-ATGCAAAT O O
, O O
in O O
either O O
orientation O O
, O O
serves O O
as O O
an O O
upstream B B_GENE/B_PERSON
element I I_GENE/I_PERSON
in O O
a O O
variety O O
of O O
promoters B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
also O O
occurs O O
as O O
a O O
modular B B_GENE/B_PERSON
enhancer I I_GENE/I_PERSON
element I I_GENE/I_PERSON
. O O

It O O
is O O
of O O
particular O O
interest O O
in O O
immunoglobulin B B_SPECIES[BIO]/B_GENE
genes I I_SPECIES[BIO]/I_GENE
since O O
it O O
is O O
found O O
in O O
the O O
upstream B B_LOCATION/B_GENE
regions I I_LOCATION/I_GENE
of O O
all O O
heavy B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
light I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
the O O
heavy B B_GENE/B_LOCATION
chain I I_GENE/I_LOCATION
enhancer I I_GENE/I_LOCATION
, O O
both O O
of O O
which O O
are O O
known O O
to O O
be O O
necessary O O
for O O
cell-specific O O
expression O O
. O O

We O O
report O O
here O O
the O O
chromatographic O O
separation O O
of O O
ubiquitous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
cell-specific I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
octamer-binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

The O O
B B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
purified O O
to O O
homogeneity O O
using O O
affinity O O
chromatography O O
and O O
consists O O
of O O
three O O
peptides O O
of O O
62 O O
, O O
61 O O
, O O
and O O
58.5 O O
+/- O O
1.5 O O
kd O O
. O O

Each O O
of O O
the O O
polypeptides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
renatured O O
after O O
SDS-PAGE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
shown O O
to O O
bind O O
to O O
the O O
octamer O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
specific O O
DNA O O
binding O O
activity O O
of O O
the O O
pure O O
B B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
cell-specific I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O O
indistinguishable O O
from O O
that O O
of O O
the O O
affinity-purified B B_GENE/B_BIO
ubiquitous I I_GENE/I_BIO
factor I I_GENE/I_BIO
. O O

This O O
B B B_GENE
cell-specific I I_GENE
octamer-binding I I_GENE
factor I I_GENE
, O O
in O O
pure O O
form O O
, O O
activated O O
transcription O O
from O O
a O O
kappa B B_GENE
light I I_GENE
chain I I_GENE
promoter I I_GENE
in O O
vitro O O
, O O
thus O O
demonstrating O O
that O O
it O O
is O O
indeed O O
a O O
B B B_GENE/B_PERSON
cell-specific I I_GENE/I_PERSON
transcription I I_GENE/I_PERSON
factor I I_GENE/I_PERSON
for O O
this O O
gene O O
. O O

In O O
addition O O
to O O
the O O
ubiquitous B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
B I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cell-specific I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
octamer-binding I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factors I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
we O O
identified O O
several O O
additional O O
proteins O O
, O O
one O O
of O O
which O O
is O O
B O O
cell O O
-specific O O
, O O
that O O
interact O O
with O O
the O O
kappa B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
. O O

Decreased O O
deoxyribonucleic O O
acid O O
binding O O
of O O
glucocorticoid-receptor B B_GENE
complex I I_GENE
in O O
cultured O O
skin O O
fibroblasts O O
from O O
a O O
patient O O
with O O
the O O
glucocorticoid O O
resistance O O
syndrome O O
. O O

A O O
patient O B_PERSON
with O O
the O O
syndrome O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
glucocorticoid O B_DISEASE
resistance O I_DISEASE
was O O
studied O O
. O O

A O O
27-yr-old O B_PERSON
woman O I_PERSON
initially O O
was O O
diagnosed O O
as O O
having O O
Cushing O B_DISEASE
's O I_DISEASE
disease O I_DISEASE
, O O
based O O
on O O
the O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
plasma O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
ACTH O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
serum O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
increased O O
urinary O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cortisol O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretion O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
resistance O B_DISEASE_ADJECTIVE[DISEASE]
to O O
adrenal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppression O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
bilateral O B_DISEASE_ADJECTIVE[DISEASE]
adrenal O I_DISEASE_ADJECTIVE[DISEASE]
hyperplasia O I_DISEASE_ADJECTIVE[DISEASE]
by O O
computed O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tomography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
scintigraphy O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
adrenal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
glands O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
she O O
had O O
no O O
signs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
symptoms O B_DISEASE
of O O
Cushing O B_DISEASE
's O I_DISEASE
syndrome O I_DISEASE
. O O

During O O
a O O
5-yr O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
follow-up O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
no O O
clinical O B_DISEASE
abnormalities O I_DISEASE
developed O O
, O O
although O O
hypercortisolism O B_DISEASE
persisted O O
. O O

End-organ O B_DISEASE_ADJECTIVE[DISEASE]
resistance O I_DISEASE_ADJECTIVE[DISEASE]
to O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
suspected O O
. O O

To O O
explain O O
the O O
end-organ O O
resistance O O
to O O
cortisol O O
, O O
the O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
GR B B_PROTEIN[GENE]/B_DISEASE
) O O
in O O
peripheral O O
mononuclear O O
leukocytes O O
and O O
cultured O O
skin O O
fibroblasts O O
from O O
a O O
forearm O O
skin O O
biopsy O O
were O O
characterized O O
and O O
compared O O
with O O
the O O
results O O
of O O
similar O O
studies O O
in O O
normal O O
subjects O O
. O O

The O O
patient O O
's O O
GR B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O O
whole O O
cell O O
assays O O
had O O
an O O
increased O O
dissociation O O
constant O O
( O O
Kd O O
) O O
. O O

In O O
the O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cultured O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
skin O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
fibroblasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O O
the O O
patient O B_PERSON/B_BIO
, O O
there O O
was O O
also O O
decreased O O
binding O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
thermal O B_MEASURE/B_LOCATION
stability O I_MEASURE/I_LOCATION
and O O
the O O
sedimentation O B_MEASURE
coefficient O I_MEASURE
in O O
a O O
sucrose O B_MEASURE
density O I_MEASURE
gradient O I_MEASURE
of O O
the O O
receptors O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
cultured O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
skin O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibroblasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
the O O
patient O B_PERSON/B_DISEASE
and O O
normal O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
were O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

GR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complex O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
analyzed O O
by O O
DEAE-cellulose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
decreased O O
in O O
the O O
patient O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

DNA B B_BIO/B_GENE
binding O O
of O O
the O O
GR B B_GENE
complex I I_GENE
after O O
temperature-induced O O
activation O O
was O O
lower O O
in O O
the O O
patient O O
than O O
in O O
normal O O
subjects O O
. O O

Nuclear O O
translocation O O
of O O
GR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
patient O O
was O O
also O O
slightly O O
decreased O O
. O O

These O O
results O O
suggest O O
that O O
the O O
patient O O
's O O
glucocorticoid O O
resistance O O
was O O
due O O
to O O
a O O
decrease O O
in O O
the O O
affinity O O
of O O
the O O
receptor O O
for O O
glucocorticoids O O
and O O
a O O
decrease O O
in O O
the O O
binding O O
of O O
the O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
complex I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
DNA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Granulocyte-macrophage B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
colony-stimulating I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
factor I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Sensitive O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
receptor-mediated O B_DISEASE_ADJECTIVE[DISEASE]
regulation O I_DISEASE_ADJECTIVE[DISEASE]
by O O
1 O B_MEASURE
, O O
25-dihydroxyvitamin O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D3 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
normal O B_BIO/B_DISEASE
human O I_BIO/I_DISEASE
peripheral O I_BIO/I_DISEASE
blood O I_BIO/I_DISEASE
lymphocytes O I_BIO/I_DISEASE
. O O

We O O
show O O
that O O
1 O O
, O O
25-dihydroxyvitamin O O
D3 O O
( O O
1 O O
, O O
25 O O
[ O O
OH O O
] O O
2D3 O O
) O O
, O O
the O O
most O O
hormonally O O
active O O
metabolite O O
of O O
vitamin O O
D3 O O
, O O
modulates O O
sensitively O O
and O O
specifically O O
both O O
the O O
protein O O
and O O
messenger B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
accumulation O O
of O O
the O O
multilineage B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
granulocyte-macrophage B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

The O O
regulation O O
of O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression O O
is O O
seen O O
in O O
both O O
normal O O
human O O
mitogen-activated O O
T O O
lymphocytes O O
and O O
T O O
lymphocytes O O
from O O
a O O
line O O
( O O
S-LB1 O O
) O O
transformed O O
with O O
human O O
T O O
cell O O
lymphotropic O O
virus O O
1 O O
( O O
HTLV-1 O O
) O O
. O O

In O O
contrast O O
, O O
cells O O
from O O
a O O
HTLV-1 O O
transformed O O
T O O
lymphocyte O O
line O O
( O O
Ab-VDR O O
) O O
established O O
from O O
a O O
patient O O
with O O
vitamin O O
D-resistant O O
rickets O O
type O O
II O O
with O O
undetectable O O
1 B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
25 I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OH I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2D3 I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cellular I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
resistant O O
to O O
the O O
action O O
of O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
. O O

Inhibition O O
of O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
can O O
occur O O
independently O O
of O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulation O O
and O O
is O O
probably O O
mediated O O
through O O
cellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
25 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
OH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2D3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
conclude O O
that O O
1 O B_MEASURE
, O O
25 O B_MEASURE
( O O
OH O O
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
may O O
be O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
physiology O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hematopoiesis O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

Altered O O
interaction O O
between O O
triiodothyronine O O
and O O
its O O
nuclear B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
absence O O
of O O
cortisol O O
: O O
a O O
proposed O O
mechanism O O
for O O
increased O O
thyrotropin O O
secretion O O
in O O
corticosteroid O O
deficiency O O
states O O
. O O

Thyroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
occasionally O O
appear O O
less O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
when O O
administered O O
alone O O
to O O
patients O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
panhypopituitarism O B_DISEASE
, O O
and O O
manifestations O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggestive O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hypothyroidism O B_DISEASE
have O O
been O O
reported O O
in O O
patients O B_PERSON
suffering O O
from O O
untreated O B_DISEASE
Addison O I_DISEASE
's O I_DISEASE
disease O I_DISEASE
. O O

In O O
the O O
latter O B_PERSON/B_DISEASE
condition O I_PERSON/I_DISEASE
, O O
thyrotropin O B_DISEASE
secretion O I_DISEASE
is O O
increased O O
: O O
this O O
occurs O O
already O O
after O O
as O O
little O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O O
2 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
of O O
temporary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
withdrawal O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
substitution O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
corticosteroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
while O O
circulating O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
thyroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
remain O O
within O O
normal O B_MEASURE/B_PERSON
limits O B_MEASURE/I_PERSON
. O O

Therefore O O
, O O
a O O
possible O O
role O O
of O O
cortisol O O
in O O
interaction O O
between O O
triiodothyronine O O
and O O
its O O
nuclear B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
examined O O
at O O
the O O
level O O
of O O
circulating O O
lymphocytes O O
obtained O O
from O O
patients O O
with O O
primary O O
or O O
secondary O O
adrenocortical O O
failure O O
. O O

The O O
affinity O B_GENE/B_MEASURE
of O O
these O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
to O O
be O O
decreased O O
, O O
by O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
on O O
average O B_MEASURE/B_SOCIAL_CIRCUMSTANCES
, O O
in O O
the O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
change O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
promptly O O
corrected O O
upon O O
resumption O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
. O O

The O O
number O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
binding O O
sites O B_LOCATION/B_ENT
was O O
not O O
significantly O O
modified O O
. O O

The O O
influence O O
of O O
cortisol O O
on O O
thyroid B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discussed O O
here O O
might O O
account O O
for O O
the O O
clinical O O
observations O O
mentioned O O
above O O
. O O

Inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
natural O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
killer O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NK O B_LOCATION/B_PERSON
) O O
cell O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
natural O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
killer O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
NK O B_PROTEIN[GENE]/B_LOCATION
) O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peripheral O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mononuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PBM O B_LOCATION
) O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
studied O O
in O O
vitro O B_MEASURE/B_LOCATION
using O O
a O O
direct O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
4-h O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
51Cr-release O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
assay O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
K O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
562 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
line O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
as O O
a O O
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Preincubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O O
20 O B_MEASURE
h O O
of O O
PBM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
drawn O O
from O O
healthy O B_PERSON/B_BIO
donors O I_PERSON/I_BIO
with O O
1 O B_MEASURE/B_LOCATION
X O I_MEASURE/I_LOCATION
10 O I_MEASURE/I_LOCATION
( O O
-8 O O
) O O
to O O
1 O B_MEASURE/B_LOCATION
X O I_MEASURE/I_LOCATION
10 O I_MEASURE/I_LOCATION
( O O
-5 O O
) O O
M O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cortisol O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
resulted O O
in O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
NK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
magnitude O B_MEASURE
of O O
the O O
suppression O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
directly O O
related O O
to O O
the O O
steroid O B_MEASURE
concentration O I_MEASURE
and O O
inversely O O
related O O
to O O
the O O
number O B_MEASURE/B_LOCATION
of O O
effector O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
able O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
minimize O O
the O O
enhancement O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
NK O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cytotoxicity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
obtainable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
immune O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interferon O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
IFN-gamma O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

A O O
significantly O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suppression O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
achieved O O
after O O
sequential O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
exposure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
PBM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
to O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
equimolar O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
levels O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
prostaglandin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
PgE2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
. O O

The O O
concomitant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
incubation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
theophylline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
isobutyl-methylxanthine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
failed O O
to O O
enhance O O
the O O
cortisol-induced O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppression O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
PgE2-dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O O
increased O O
after O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
PBM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
methyl-xanthines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
inhibitory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
partially O O
or O O
totally O O
prevented O O
by O O
the O O
concomitant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incubation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
equimolar O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
11-deoxycortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
RU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
486 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
not O O
of O O
progesterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Treatment O O
of O O
NK O O
effectors O O
with O O
a O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
anti-human I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
corticosteroid-binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
globulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CBG I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
produced O O
an O O
enhancement O O
of O O
the O O
spontaneous O O
NK O O
activity O O
and O O
a O O
partial O O
suppression O O
of O O
cortisol-mediated O O
effects O O
. O O

Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
endogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
play O O
a O O
role O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
in O O
the O O
regulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
NK O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cell-mediated O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
cytotoxicity O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

Since O O
the O O
effect O O
of O O
cortisol O O
was O O
additive O O
to O O
that O O
of O O
PgE2 O O
and O O
was O O
not O O
changed O O
by O O
phosphodiesterase B B_ENZYME[GENE]
inhibitors O O
, O O
it O O
is O O
conceivable O O
that O O
the O O
hormone O O
acts O O
at O O
a O O
level O O
different O O
from O O
the O O
adenylate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cyclase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
phosphodiesterase B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O O
. O O

Data O O
obtained O O
with O O
the O O
use O O
of O O
antiglucocorticoids O O
and O O
the O O
anti-CBG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O
compatible O O
with O O
a O O
role O O
both O O
of O O
high-affinity O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
of O O
CBG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
mediating O O
cortisol O O
action O O
on O O
the O O
human O O
NK O O
cell O O
activity O O
. O O

Interaction O O
of O O
cell-type-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
immunoglobulin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
VH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

All O O
human B B_GENE/B_LOCATION
and I I_GENE/I_LOCATION
murine I I_GENE/I_LOCATION
immunoglobulin I I_GENE/I_LOCATION
heavy I I_GENE/I_LOCATION
chain I I_GENE/I_LOCATION
variable I I_GENE/I_LOCATION
region I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
VH I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
genes I I_GENE/I_LOCATION
contain O O
the O O
sequence O O
ATGCAAAT O O
approximately O O
70 O O
nucleotides O O
5 O O
' O O
from O O
the O O
site O O
of O O
transcription O O
initiation O O
. O O

This O O
octanucleotide O O
, O O
in O O
reverse O O
orientation O O
, O O
is O O
also O O
found O O
in O O
all O O
light B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
variable I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
VL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
in O O
the O O
immunoglobulin B B_GENE/B_BIO
heavy I I_GENE/I_BIO
chain I I_GENE/I_BIO
transcriptional I I_GENE/I_BIO
enhancer I I_GENE/I_BIO
. O O

Transfection O O
studies O O
have O O
established O O
that O O
this O O
octamer O O
is O O
involved O O
in O O
the O O
lymphoid-specific O O
transcription O O
of O O
immunoglobulin B B_GENE
genes I I_GENE
. O O

Octamer-containing B B_PERSON/B_LOCATION
fragments I I_PERSON/I_LOCATION
have O O
been O O
reported O O
to O O
bind O O
a O O
factor O O
present O O
in O O
nuclear O O
extracts O O
of O O
human O O
cell O O
lines O O
; O O
however O O
, O O
identical O O
binding O O
activity O O
was O O
detected O O
in O O
both O O
B O O
lymphoid O O
and O O
non-lymphoid O O
cells O O
. O O

Here O O
we O O
establish O O
that O O
nuclear O O
extracts O O
from O O
distinct O O
cell O O
types O O
differ O O
in O O
their O O
ability O O
to O O
interact O O
with O O
octamer-containing B B_GENE
fragments I I_GENE
. O O

We O O
have O O
also O O
detected O O
a O O
DNA-protein O O
interaction O O
that O O
may O O
be O O
involved O O
in O O
the O O
cell-type O O
specificity O O
of O O
immunoglobulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
, O O
and O O
we O O
have O O
determined O O
that O O
a O O
sequence O O
upstream O O
of O O
the O O
octamer O O
participates O O
in O O
an O O
interaction O O
with O O
a O O
nuclear B B_GENE/B_BIO
protein I I_GENE/I_BIO
( O O
s O O
) O O
. O O

Preferential O O
transcription O O
of O O
HTLV-I B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
cell-free O O
extracts O O
of O O
human O O
T O O
cells O O
producing O O
HTLV-I B B_DISEASE/B_GENE
viral I B_DISEASE/I_GENE
proteins I B_DISEASE/I_GENE
. O O

The O O
promoters B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
adenovirus B B_GENE/B_DISEASE
2 I I_GENE/I_DISEASE
major I I_GENE/I_DISEASE
late I I_GENE/I_DISEASE
gene I I_GENE/I_DISEASE
, O O
the O O
mouse B B_GENE
beta-globin I I_GENE
gene I I_GENE
, O O
the O O
mouse B B_GENE
immunoglobulin I I_GENE
VH I I_GENE
gene I I_GENE
and O O
the O O
LTR B B_GENE/B_BIO
of O O
the O O
human O O
T-lymphotropic O O
retrovirus O O
type O O
I O O
were O O
tested O O
for O O
their O O
transcription O O
activities O O
in O O
cell-free O O
extracts O O
of O O
four O O
cell O O
lines O O
; O O
HeLa O O
, O O
CESS O O
( O O
Epstein-Barr O O
virus-transformed O O
human O O
B O O
cell O O
line O O
) O O
, O O
MT-1 O O
( O O
HTLV-I-infected O O
human O O
T O O
cell O O
line O O
without O O
viral O O
protein O O
synthesis O O
) O O
, O O
and O O
MT-2 O O
( O O
HTLV-I-infected O O
human O O
T O O
cell O O
line O O
producing O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

LTR B B_GENE/B_DISEASE
was O O
preferentially O O
transcribed O O
in O O
the O O
extracts O O
of O O
MT-2 O O
although O O
the O O
other O O
three O O
genes O O
were O O
transcribed O O
with O O
relatively O O
constant O O
efficiencies O O
in O O
different O O
extracts O O
. O O

The O O
results O O
agree O O
well O O
with O O
the O O
previous O O
in O O
vivo O O
studies O O
on O O
the O O
promoter O O
activity O O
of O O
HTLV-I B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Mixing O O
of O O
HeLa O B_VIRUS[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
MT-2 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
extracts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
the O O
presence O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
LTR-specific O B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulating O I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
MT-2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
extracts O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

A O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
binds O O
to O O
a O O
conserved O O
sequence O O
motif O O
in O O
transcriptional B B_GENE/B_MEASURE
control I I_GENE/I_MEASURE
elements I I_GENE/I_MEASURE
of O O
immunoglobulin B B_GENE/B_SPECIES[BIO]
genes I B_GENE/I_SPECIES[BIO]
. O O

Trans-acting B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factors I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
mediate O O
B-cell O O
specific O O
transcription O O
of O O
immunoglobulin B B_GENE
genes I I_GENE
have O O
been O O
postulated O O
based O O
on O O
an O O
analysis O O
of O O
the O O
expression O O
of O O
exogenously O O
introduced O O
immunoglobulin B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recombinants I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
lymphoid O O
and O O
non-lymphoid O O
cells O O
. O O

Two O O
B-cell-specific O O
, O O
cis-acting B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transcriptional I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
regulatory I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
elements I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
have O O
been O O
identified O O
. O O

One O O
element O O
is O O
located O O
in O O
the O O
intron O O
between O O
the O O
variable O O
( O O
V O O
) O O
and O O
constant O O
( O O
C O O
) O O
regions O O
of O O
both O O
heavy B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light-chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
acts O O
as O O
a O O
transcriptional O O
enhancer O O
. O O

The O O
second O O
element B B_GENE/B_LOCATION
is O O
found O O
upstream O O
of O O
both O O
heavy B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light-chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
element O O
directs O O
lymphoid-specific O O
transcription O O
even O O
in O O
the O O
presence O O
of O O
viral B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
enhancers I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

We O O
have O O
sought O O
nuclear O O
factors O O
that O O
might O O
bind O O
specifically O O
to O O
these O O
two O O
regulatory B B_GENE/B_LOCATION
elements I I_GENE/I_LOCATION
by O O
application O O
of O O
a O O
modified O O
gel O O
electrophoresis O O
DNA O O
binding O O
assay O O
. O O

We O O
report O O
here O O
the O O
identification O O
of O O
a O O
human B B_PROTEIN[GENE]/B_MEASURE
B-cell I I_PROTEIN[GENE]/I_MEASURE
nuclear I I_PROTEIN[GENE]/I_MEASURE
factor I I_PROTEIN[GENE]/I_MEASURE
( O O
IgNF-A B B_GENE
) O O
that O O
binds O O
to O O
DNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
upstream B B_LOCATION/B_BIO
regions I I_LOCATION/I_BIO
of O O
both O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
heavy I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light-chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
also O O
to O O
the O O
mouse B B_GENE/B_BIO
heavy-chain I I_GENE/I_BIO
gene I I_GENE/I_BIO
enhancer I I_GENE/I_BIO
. O O

This O O
sequence-specific O O
binding O O
is O O
probably O O
mediated O O
by O O
a O O
highly O O
conserved O O
sequence O O
motif O O
, O O
ATTTGCAT O O
, O O
present O O
in O O
all O O
three O O
transcriptional B B_GENE/B_LOCATION
elements I I_GENE/I_LOCATION
. O O

Interestingly O O
, O O
a O O
factor O O
showing O O
similar O O
binding O O
specificity O O
to O O
IgNF-A B B_GENE
is O O
also O O
present O O
in O O
human O O
HeLa O O
cells O O
. O O

The O O
new O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
world O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
primates O O
as O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
glucocorticoid O B_DISEASE
resistance O I_DISEASE
. O O

Many O B_PERSON
New O I_PERSON
World O I_PERSON
primate O I_PERSON
species O I_PERSON
have O O
greatly O O
increased O O
plasma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
cortisol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
concentrations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O O
decreased O O
plasma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cortisol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding O O
globulin O B_MEASURE/B_LOCATION
capacity O I_MEASURE/I_LOCATION
and O O
affinity O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
marked O B_DISEASE
resistance O I_DISEASE
of O O
the O O
hypothalamic-pituitary-adrenal O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
axis O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
to O O
suppression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
no O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
glucocorticoid O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excess O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
primates O B_PERSON/B_BIO
also O O
have O O
high O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
circulating O O
progesterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
estrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
mineralocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
androgen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
vitamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
D O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
glucocorticoid O O
target O O
tissues O O
that O O
have O O
been O O
examined O O
( O O
circulating O O
mononuclear O O
lymphocytes O O
and O O
cultured O O
skin O O
fibroblasts O O
) O O
have O O
normal O O
concentrations O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
decreased O O
affinity O O
for O O
dexamethasone O O
. O O

Transformation O O
of O O
B-lymphocytes O O
with O O
the O O
Epstein-Barr O O
virus O O
leads O O
to O O
glucocorticoid B B_GENE/B_DISEASE
receptor I I_GENE/I_DISEASE
induction O O
that O O
is O O
less O O
than O O
that O O
observed O O
with O O
cells O O
from O O
Old O O
World O O
primates O O
. O O

The O O
receptor O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
cells O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
a O O
low O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
low O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affinity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
leads O O
to O O
an O O
increased O O
loss O B_MEASURE
of O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bound O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
thermal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Meroreceptor O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generation O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
molecular O B_MEASURE/B_LOCATION
weight O I_MEASURE/I_LOCATION
of O O
the O O
receptor O B_GENE
, O O
determined O O
by O O
SDS-PAGE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
that O O
of O O
Old O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
World O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
primates O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
approximately O O
92 O B_MEASURE
, O O
000 O B_MEASURE
) O O
and O O
the O O
activation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
per O O
se O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
examined O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
heating O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
performing O O
phosphocellulose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
appears O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
that O O
of O O
human O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
ratios O O
of O O
nuclear O O
to O O
cytosolic B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
hormone-receptor-complexes I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
of O O
cytosolic O O
activated O O
to O O
unactivated B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complexes I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O O
intact O O
cells O O
are O O
similar O O
to O O
Old O O
World O O
primates O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
mixing O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O O
not O O
support O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
a O O
binding O B_DISEASE_ADJECTIVE[DISEASE]
inhibitor O I_DISEASE_ADJECTIVE[DISEASE]
( O O
s O O
) O O
or O O
a O O
deficient O B_ENZYME[GENE]/B_MEASURE
cytosolic O I_ENZYME[GENE]/I_MEASURE
positive O I_ENZYME[GENE]/I_MEASURE
modifier O I_ENZYME[GENE]/I_MEASURE
( O O
s O B_DISEASE/B_PROTEIN[GENE]
) O O
of O O
binding O B_GENE/B_DISEASE
underlies O O
the O O
findings O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
primates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
New O B_PERSON/B_SPECIES[BIO]
World O I_PERSON/I_SPECIES[BIO]
primates O O
, O O
unlike O O
men O B_PERSON/B_BIO
with O O
the O O
syndrome O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
primary O B_DISEASE
cortisol O I_DISEASE
resistance O I_DISEASE
, O O
have O O
compensated O O
for O O
their O O
condition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
intra-adrenal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
mineralocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adaptations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Thus O O
, O O
unlike O O
Old O O
World O O
primates O O
, O O
cortisol O O
in O O
New O O
World O O
primates O O
has O O
only O O
weak O O
sodium-retaining O O
potency O O
because O O
the O O
aldosterone B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
a O O
low O O
affinity O O
for O O
cortisol O O
. O O

The O O
common O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
element O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
would O O
explain O O
the O O
apparent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resistance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
six O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steroid O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormones O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
New O B_SPECIES[BIO]/B_PERSON
World O I_SPECIES[BIO]/I_PERSON
primates O I_SPECIES[BIO]/I_PERSON

Acetylation O O
and O O
modulation O O
of O O
erythroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Kruppel-like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
activity O O
by O O
interaction O O
with O O
histone B B_GENE
acetyltransferases I I_GENE
. O O

Erythroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Kruppel-like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EKLF B B_LOCATION/B_DISEASE
) O O
is O O
a O O
red B B_GENE
cell-specific I I_GENE
transcriptional I I_GENE
activator I I_GENE
that O O
is O O
crucial O O
for O O
consolidating O O
the O O
switch O O
to O O
high O O
levels O O
of O O
adult O O
beta-globin O O
expression O O
during O O
erythroid O O
ontogeny O O
. O O

EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
required O O
for O O
integrity O O
of O O
the O O
chromatin O O
structure O O
at O O
the O O
beta-like B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
globin I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
locus I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
it O O
interacts O O
with O O
a O O
positive-acting B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O O
. O O

We O O
find O O
that O O
EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
an O O
acetylated B B_GENE
transcription I I_GENE
factor I I_GENE
, O O
and O O
that O O
it O O
interacts O O
in O O
vivo O O
with O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
P/CAF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
its O O
interactions O O
with O O
these O O
histone B B_GENE/B_LOCATION
acetyltransferases I I_GENE/I_LOCATION
are O O
not O O
equivalent O O
, O O
as O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
P/CAF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
utilize O O
EKLF B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
as O O
a O O
substrate O O
for O O
in O O
vitro O O
acetylation O O
within O O
its O O
trans-activation O O
region O O
. O O

The O O
functional O O
effects O O
of O O
these O O
interactions O O
are O O
that O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
p300 B B_GENE/B_LOCATION
, O O
but O O
not O O
P/CAF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
enhance O O
EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
's O O
transcriptional O O
activation O O
of O O
the O O
beta-globin B B_GENE
promoter I I_GENE
in O O
erythroid O O
cells O O
. O O

These O O
results O O
establish O O
EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
tissue-specific B B_GENE/B_MEASURE
transcription I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
that O O
undergoes O O
post-translational O O
acetylation O O
and O O
suggest O O
a O O
mechanism O O
by O O
which O O
EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
able O O
to O O
alter O O
chromatin O O
structure O O
and O O
induce O O
beta-globin O O
expression O O
within O O
the O O
beta-like B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
globin I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
cluster I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O O

Recognition O O
of O O
herpes B B_DISEASE
simplex I I_DISEASE
virus I I_DISEASE
type I I_DISEASE
2 I I_DISEASE
tegument I I_DISEASE
proteins I I_DISEASE
by O O
CD4 O O
T O O
cells O O
infiltrating O O
human O O
genital O O
herpes O O
lesions O O
. O O

The O O
local O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cellular O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
herpes O B_DISEASE/B_VIRUS[BIO]
simplex O B_DISEASE/I_VIRUS[BIO]
virus O B_DISEASE/I_VIRUS[BIO]
( O O
HSV O B_VIRUS[BIO]/B_DISEASE
) O O
is O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
recurrent O B_DISEASE
HSV O I_DISEASE
infection O I_DISEASE
. O O

The O O
antiviral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
functions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
infiltrating O O
CD4-bearing O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
include O O
cytotoxicity O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
viral O B_DISEASE_ADJECTIVE[DISEASE]
growth O I_DISEASE_ADJECTIVE[DISEASE]
, O O
lymphokine O B_DISEASE_ADJECTIVE[DISEASE]
secretion O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
support O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
humoral O B_GENE
and O O
CD8 O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
responses O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
antigens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
recognized O O
by O O
many O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
HSV-specific O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CD4 O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
localizing O O
to O O
genital O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
HSV-2 O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lesions O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]
. O O

T O O
cells O O
recognizing O O
antigens O O
encoded O O
within O O
map O O
units O O
0.67 O O
to O O
0.73 O O
of O O
HSV B B_GENE/B_VIRUS[BIO]
DNA I I_GENE/I_VIRUS[BIO]
are O O
frequently O O
recovered O O
from O O
herpetic O O
lesions O O
. O O

Expression O O
cloning O O
with O O
this O O
region O O
of O O
DNA O O
now O O
shows O O
that O O
tegument B B_GENE/B_VIRUS[BIO]
protein I B_GENE/I_VIRUS[BIO]
VP22 B B_GENE/I_VIRUS[BIO]
and O O
the O O
viral B B_GENE
dUTPase I I_GENE
, O O
encoded O O
by O O
genes B B_GENE/B_PERSON
UL49 I I_GENE/I_PERSON
and I I_GENE/I_PERSON
UL50 I I_GENE/I_PERSON
, O O
respectively O O
, O O
are O O
T-cell B B_DISEASE_ADJECTIVE[DISEASE]
antigens I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Separate O O
epitopes B B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
VP22 B B_GENE/B_BIO
were O O
defined O O
for O O
T-cell O O
clones O O
from O O
each O O
of O O
three O O
patients O O
. O O

Reactivity O O
with O O
the O O
tegument B B_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
encoded O O
by O O
UL21 B B_GENE
was O O
identified O O
for O O
an O O
additional O O
patient O O
. O O

Three O O
new O O
epitopes O O
were O O
identified O O
in O O
VP16 B B_GENE/B_SPECIES[BIO]
, O O
a O O
tegument B B_PROTEIN[GENE]/B_LOCATION
protein I I_PROTEIN[GENE]/I_LOCATION
associated O O
with O O
VP22 B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Some O O
tegument-specific O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CD4 O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
T-cell O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
clones O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exhibited O O
cytotoxic O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
against O O
HSV-infected O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O O
suggest O O
that O O
herpes B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simplex I I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tegument I I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
processed O O
for O O
antigen O O
presentation O O
in O O
vivo O O
and O O
are O O
possible O O
candidate O O
compounds O O
for O O
herpes O O
simplex O O
vaccines O O
. O O

Fibrinogen B B_GENE
activates O O
NF-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mononuclear O O
phagocytes O O
. O O

Adhesion O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
extracellular O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
matrices O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
known O O
to O O
modulate O O
leukocyte O B_DISEASE
activation O I_DISEASE
, O O
although O O
the O O
mechanisms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
not O O
fully O O
understood O O
. O O

Mononuclear O O
phagocytes O O
are O O
exposed O O
to O O
fibrinous O O
provisional O O
matrix O O
throughout O O
migration O O
into O O
inflammatory O O
foci O O
, O O
so O O
this O O
study O O
was O O
undertaken O O
to O O
determine O O
whether O O
fibrinogen O O
triggers O O
activation O O
of O O
NF-kappa B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
B I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

U937 O O
cells O O
differentiated O O
with O O
PMA O O
in O O
nonadherent O O
culture O O
were O O
shown O O
to O O
express O O
two O O
fibrinogen-binding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
integrins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
predominately O O
CD11b/CD18 B B_GENE
, O O
and O O
to O O
a O O
lesser O O
extent O O
, O O
CD11c/CD18 B B_GENE
. O O

Cells O O
stimulated O O
with O O
fibrinogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
10-100 O O
microg/ml O O
) O O
/Mn2+ O O
( O O
50 O O
microM O O
) O O
for O O
2 O O
h O O
were O O
examined O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

NF-kappa B B_GENE
B I I_GENE
activation O O
, O O
minimal O O
in O O
unstimulated O O
cells O O
, O O
was O O
substantially O O
up-regulated O O
by O O
fibrinogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O

Fibrinogen B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
caused O O
activation O O
of O O
AP-1 B B_GENE
, O O
but O O
not O O
SP1 B B_GENE
or O O
cAMP B B_GENE
response I I_GENE
element-binding I I_GENE
protein I I_GENE
( I I_GENE
CREB I I_GENE
) I I_GENE
factors I I_GENE
. O O

Blocking O O
mAbs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
against O O
CD18 B B_GENE
and O O
CD11b B B_GENE
abrogated O O
fibrinogen B B_GENE
-induced O O
NF-kappa B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
B I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
activation O O
. O O

To O O
determine O O
the O O
effects O O
on O O
transcriptional O O
regulation O O
, O O
U937 O O
cells O O
were O O
transfected O O
with O O
a O O
plasmid O O
containing O O
the O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
bearing O O
two O O
NF-kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
) O O
coupled O O
to O O
a O O
chloramphenicol B B_GENE
acetyltransferase I I_GENE
( I I_GENE
CAT I I_GENE
) I I_GENE
reporter I I_GENE
. O O

Cells O O
were O O
subsequently O O
stimulated O O
with O O
1 O O
) O O
PMA O O
for O O
24 O O
h O O
, O O
inducing O O
CAT O O
activity O O
by O O
2.6-fold O O
, O O
2 O O
) O O
fibrinogen B B_GENE
/Mn2+ O O
for O O
2 O O
h O O
, O O
inducing O O
CAT O O
activity O O
by O O
3.2-fold O O
, O O
or O O
3 O O
) O O
costimulation O O
with O O
fibrinogen B B_GENE
and O O
PMA O O
, O O
inducing O O
5.7-fold O O
the O O
CAT O O
activity O O
induced O O
by O O
PMA O O
alone O O
. O O

We O O
conclude O O
that O O
contact O O
with O O
fibrinogen-derived B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
contribute O O
to O O
mononuclear O O
phagocyte O O
activation O O
by O O
signaling O O
through O O
CD11b/CD18 B B_GENE
, O O
resulting O O
in O O
selective O O
activation O O
of O O
transcriptional B B_GENE
regulatory I I_GENE
factors I I_GENE
, O O
including O O
NF-kappa B B_GENE
B I I_GENE
. O O

Peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
derived O O
from O O
patients O B_PERSON/B_DISEASE
with O O
lupus O B_DISEASE/B_LOCATION
express O I_DISEASE/I_LOCATION
estrogen O I_DISEASE/I_LOCATION
receptor O I_DISEASE/I_LOCATION
transcripts O I_DISEASE/I_LOCATION
similar O I_DISEASE/I_LOCATION
to O O
those O O
of O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

OBJECTIVE O O
: O O
To O O
identify O O
and O O
characterize O O
estrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ER I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expressed O O
in O O
immune O O
cells O O
of O O
patients O O
with O O
systemic O O
lupus O O
erythematosus O O
( O O
SLE O O
) O O
and O O
healthy O O
donors O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O O
prepared O O
from O O
patients O B_PERSON/B_BIO
with O O
SLE O B_DISEASE/B_LOCATION
( O O
n O B_OTHER/B_MEASURE
= O O
6 O B_MEASURE
) O O
and O O
healthy O B_DISEASE
donors O I_DISEASE
( O O
n O B_OTHER/B_MEASURE
= O O
8 O B_MEASURE
) O O
. O O

T O B_PERSON/B_LOCATION
cells O I_PERSON/I_LOCATION
were O O
separated O O
into O O
CD4 O B_GENE
and O O
CD8 O B_GENE
. O O

Some O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O O
stimulated O O
with O O
estradiol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
PMA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
ionomycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Epstein-Barr O B_PERSON/B_DISEASE
virus-transformed O O
B O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lines O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
n O B_MEASURE/B_LOCATION
= O O
7 O B_MEASURE
) O O
and O O
B O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hybridomas O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
n O B_MEASURE/B_LOCATION
= O O
2 O B_MEASURE
) O O
established O O
from O O
patients O B_PERSON
with O O
SLE O B_DISEASE/B_LOCATION
and O O
a O O
healthy O B_DISEASE/B_PERSON
individual O I_DISEASE/I_PERSON
were O O
used O O
as O O
a O O
B O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
source O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
cells O O
were O O
examined O O
for O O
ER B B_GENE
mRNA I I_GENE
by O O
reverse O O
transcription O O
nested O O
polymerase O O
chain O O
reaction O O
. O O

Amplified O O
cDNA B B_GENE/B_LOCATION
were O O
sequenced O O
by O O
standard O O
methods O O
. O O

RESULTS O O
: O O
In O O
all O O
cells O O
tested O O
, O O
ER B B_GENE
mRNA I I_GENE
was O O
expressed O O
without O O
prior O O
in O O
vitro O O
stimulation O O
. O O

Partial O O
sequences O O
from O O
exons B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
1-8 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
nearly O O
identical O O
to O O
the O O
published O O
sequence O O
of O O
the O O
human B B_GENE/B_BIO
ER I I_GENE/I_BIO
mRNA I I_GENE/I_BIO
. O O

There O O
were O O
no O O
notable O O
differences O O
in O O
the O O
ER B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transcripts I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O O
patients O O
and O O
healthy O O
controls O O
. O O

Variant O O
receptor O O
transcripts O O
lacking O O
exon B B_GENE
5 I I_GENE
or O O
exon B B_MEASURE/B_LOCATION
7 I I_MEASURE/I_LOCATION
, O O
which O O
encodes O O
the O O
hormone B B_GENE
binding I I_GENE
domain I I_GENE
, O O
were O O
identified O O
in O O
the O O
majority O O
of O O
the O O
cells O O
. O O

Precise O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
deletion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O O
the O O
exons O B_GENE
suggests O O
that O O
they O O
are O O
alternatively O O
spliced O O
transcripts O B_LOCATION/B_GENE
. O O

Whether O O
the O O
detected O O
transcripts O O
are O O
translated O O
into O O
functional B B_GENE
receptor I I_GENE
proteins I I_GENE
remains O O
to O O
be O O
determined O O
. O O

In O O
vitro O O
stimulation O O
did O O
not O O
affect O O
ER B B_GENE
mRNA I I_GENE
expression O O
. O O

The O O
presence O B_MEASURE/B_DISEASE
of O O
variants O B_DISEASE
did O O
not O O
correlate O O
with O O
disease O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
medication O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

CONCLUSION O O
: O O
Monocytes O O
, O O
T O O
cells O O
, O O
and O O
B O O
cells O O
in O O
patients O O
express O O
transcripts O O
of O O
the O O
normal O O
wild B B_GENE
type I I_GENE
ER I I_GENE
and O O
the O O
hormone B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
binding I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
domain I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variants I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
vivo O O
. O O

DNA O O
damaging O O
agents O O
induce O O
expression O O
of O O
Fas B B_GENE
ligand I I_GENE
and O O
subsequent O O
apoptosis O O
in O O
T O O
lymphocytes O O
via O O
the O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
and O O
AP-1 B B_GENE
. O O

Apoptosis O O
induced O O
by O O
DNA O O
damage O O
and O O
other O O
stresses O O
can O O
proceed O O
via O O
expression O O
of O O
Fas B B_GENE
ligand I I_GENE
( O O
FasL B B_GENE/B_LOCATION
) O O
and O O
ligation O O
of O O
its O O
receptor O O
, O O
Fas O O
( O O
CD95 O O
) O O
. O O

We O O
report O O
that O O
activation O O
of O O
the O O
two O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
crucially O O
involved O O
in O O
FasL B B_GENE
expression O O
induced O O
by O O
etoposide O O
, O O
teniposide O O
, O O
and O O
UV O O
irradiation O O
. O O

A O O
nondegradable B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mutant I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
I B B_GENE
kappa I I_GENE
B I I_GENE
blocked O O
both O O
FasL B B_GENE
expression O O
and O O
apoptosis O O
induced O O
by O O
DNA O O
damage O O
but O O
not O O
Fas O O
ligation O O
. O O

These O O
stimuli O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
induced O O
the O O
stress-activated O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SAPK/JNK O B_GENE/B_LOCATION
) O O
, O O
which O O
was O O
required O O
for O O
the O O
maximal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
apoptosis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
1.2 O O
kb O O
FasL B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
responded O O
to O O
DNA O O
damage O O
, O O
as O O
well O O
as O O
coexpression O O
with O O
p65 B B_GENE
Rel I I_GENE
or O O
Fos/Jun B B_GENE
. O O

Mutations O O
in O O
the O O
relevant O O
NF-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
eliminated O O
these O O
responses O O
. O O

Thus O O
, O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
and O O
AP-1 B B_GENE
contributes O O
to O O
stress-induced O O
apoptosis O O
via O O
the O O
expression O O
of O O
FasL B B_GENE
. O O

A O O
small O O
, O O
nonpeptidyl O O
mimic O O
of O O
granulocyte-colony-stimulating B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O O
see O O
commetns O O
] O O

A O O
nonpeptidyl O O
small O O
molecule O O
SB O O
247464 O O
, O O
capable O O
of O O
activating O O
granulocyte-colony-stimulating B B_GENE
factor I I_GENE
( O O
G-CSF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
signal O O
transduction O O
pathways O O
, O O
was O O
identified O O
in O O
a O O
high-throughput O O
assay O O
in O O
cultured O O
cells O O
. O O

Like O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
SB O O
247464 O O
induced O O
tyrosine O O
phosphorylation O O
of O O
multiple B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
stimulated O O
primary O O
murine O O
bone O O
marrow O O
cells O O
to O O
form O O
granulocytic O O
colonies O O
in O O
vitro O O
. O O

It O O
also O O
elevated O O
peripheral O B_DISEASE/B_GENE
blood O I_DISEASE/I_GENE
neutrophil O I_DISEASE/I_GENE
counts O I_DISEASE/I_GENE
in O O
mice O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
extracellular O O
domain O O
of O O
the O O
murine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G-CSF I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
required O O
for O O
the O O
activity O O
of O O
SB O O
247464 O O
, O O
suggesting O O
that O O
the O O
compound O O
acts O O
by O O
oligomerizing B B_MEASURE/B_GENE
receptor I I_MEASURE/I_GENE
chains I I_MEASURE/I_GENE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
a O O
small O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
molecule O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
can O O
activate O O
a O O
receptor O B_ENZYME[GENE]/B_LOCATION
that O O
normally O O
binds O O
a O O
relatively O O
large O B_DISEASE_ADJECTIVE[DISEASE]
protein O I_DISEASE_ADJECTIVE[DISEASE]
ligand O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Minimal O O
residual O O
disease O O
in O O
acute O O
myelogenous O O
leukemia O O
with O O
PML/RAR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
AML1/ETO B B_GENE/B_DISEASE
mRNA I I_GENE/I_DISEASE
and O O
phenotypic O O
analysis O O
of O O
possible O O
T O O
and O O
natural O O
killer O O
cells O O
in O O
bone O O
marrow O O
. O O

Here O O
we O O
studied O O
minimal O O
residual O O
disease O O
( O O
MRD O O
) O O
of O O
patients O O
with O O
acute O O
myeloid O O
leukemia O O
( O O
AML O O
) O O
who O O
have O O
PML/RAR B B_DISEASE/B_GENE
alpha I I_DISEASE/I_GENE
or O O
AML1/ETO B B_DISEASE/B_GENE
as O O
well O O
as O O
the O O
phenotypic O O
analysis O O
of O O
lymphocyte O O
subsets O O
involved O O
in O O
antitumor O O
immunity O O
. O O

Eight O B_TIME[MEASURE]/B_PERSON
patients O B_TIME[MEASURE]/I_PERSON
in O O
long-term O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
LT O B_PERSON/B_LOCATION
; O O
3 O B_NUMBER[MEASURE]/B_LOCATION
to O O
15 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
) O O
and O O
15 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
in O O
short-term O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
ST O B_PROTEIN[GENE]/B_DISEASE
; O O
up O O
to O O
3 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
) O O
remission O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
were O O
studied O O
. O O

Using O O
the O O
reverse O O
transcription-polymerase O O
chain O O
reaction O O
( O O
RT O O
) O O
assay O O
, O O
the O O
limit O O
of O O
detection O O
was O O
10 O O
( O O
-5 O O
) O O
to O O
10 O O
( O O
-6 O O
) O O
for O O
PML/RAR B B_GENE
alpha I I_GENE
transcript I I_GENE
and O O
10 O O
( O O
-4 O O
) O O
to O O
10 O O
( O O
-5 O O
) O O
for O O
the O O
AML1/ETO B B_GENE/B_MEASURE
transcript I I_GENE/I_MEASURE
. O O

Simultaneously O O
, O O
T O B_LOCATION/B_GENE
lymphocyte O I_LOCATION/I_GENE
subsets O I_LOCATION/I_GENE
and O O
NK O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
peripheral O B_BODY_PART_OR_ORGAN_COMPONENT
blood O I_BODY_PART_OR_ORGAN_COMPONENT
( O O
PB O B_LOCATION
) O O
and O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
marrow O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
BM O B_LOCATION
) O O
were O O
investigated O O
by O O
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytometric O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Four O B_NUMBER[MEASURE]
of O O
the O O
eight O B_PERSON
patients O I_PERSON
in O O
LT O B_DISEASE/B_PROTEIN[GENE]
and O O
7 O B_NUMBER[MEASURE]
of O O
the O O
15 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
in O O
ST O B_MEASURE/B_DISEASE
remission O I_MEASURE/I_DISEASE
were O O
MRD-positive O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

Although O O
all O O
MRD-positive O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
in O O
LT O B_DISEASE/B_LOCATION
remission O B_DISEASE/I_LOCATION
are O O
still O O
until O O
now O O
event-free O B_DISEASE_ADJECTIVE[DISEASE]
, O O
3 O B_NUMBER[MEASURE]
of O O
the O O
7 O B_NUMBER[MEASURE]
MRD-positive O I_NUMBER[MEASURE]
( O O
MRD+ O B_PROTEIN[GENE]/B_LOCATION
) O O
patients O B_PERSON/B_LOCATION
in O O
ST O B_MEASURE/B_DISEASE
remission O I_MEASURE/I_DISEASE
soon O O
relapsed O O
. O O

The O O
total O O
populations O O
of O O
CD4 B B_GENE
+ O O
, O O
CD8 B B_GENE
+ O O
and O O
CD56 B B_GENE
+ O O
[ O O
possible O O
T-cell O O
and O O
natural O O
killer O O
( O O
T/NK O O
) O O
populations O O
] O O
in O O
the O O
BM O O
of O O
ST O O
patients O O
and O O
MRD+/LT O O
patients O O
were O O
significantly O O
( O O
p O O
< O O
.01 O O
) O O
low O O
. O O

The O O
CD8+ O B_PERSON/B_GENE
CD28+ O I_PERSON/I_GENE
population O I_PERSON/I_GENE
showed O O
the O O
same O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
tendency O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
p O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
.01-.02 O O
) O O
. O O

The O O
T/NK O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
subsets O O
in O O
the O O
BM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
MRD-negative O B_DISEASE
( O O
MRD- O B_LOCATION
) O O
LT O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
MRD-/LT O B_LOCATION/B_DISEASE
) O O
patients O B_PERSON/B_BIO
showed O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numbers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
as O O
normal O B_PERSON/B_ORGANIZATION
volunteers O I_PERSON/I_ORGANIZATION
. O O

Basically O O
, O O
the O O
total O B_MEASURE/B_PERSON
percentage O I_MEASURE/I_PERSON
of O O
the O O
CD4+ O B_GENE
, O O
CD8+ O B_GENE
and O O
CD56+ O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
populations O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
BM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
was O O
increased O O
and O O
in O O
the O O
following O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
order O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
: O O
MRD-/LT O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
, O O
normal O B_PERSON/B_PROTEIN[GENE]
volunteers O B_PERSON/I_PROTEIN[GENE]
, O O
MRD+/LT O B_DISEASE/B_PROTEIN[GENE]
patients O B_DISEASE/I_PROTEIN[GENE]
and O O
MRD+ O B_PROTEIN[GENE]/B_LOCATION
or O O
-/ST O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
patients O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

The O O
percentages O B_MEASURE/B_LOCATION
of O O
the O O
T/NK-cell O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subsets O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
PB O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
not O O
significantly O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
these O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thus O O
, O O
the O O
difference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
possible O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T/NK-cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
BM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
may O O
strongly O O
influence O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
molecular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
remission O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
still O O
remain O O
to O O
be O O
confirmed O O
by O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
functional O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anti-tumor O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
immunity O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
T/NK O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O O
AML O B_DISEASE/B_PERSON
in O O
remission O B_DISEASE/B_BIO
. O O

Mycobacterium O O
tuberculosis O O
mannose-capped O O
lipoarabinomannan O O
can O O
induce O O
NF-kappaB B B_GENE
-dependent O O
activation O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
long I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeat I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
T O O
cells O O
. O O

Tuberculosis O B_DISEASE/B_LOCATION
has O O
emerged O O
as O O
an O O
epidemic O B_DISEASE/B_LOCATION
, O O
extended O O
by O O
the O O
large O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
individuals O B_PERSON/B_BIO
infected O O
with O O
human O B_DISEASE
immunodeficiency O I_DISEASE
virus O I_DISEASE
type O I_DISEASE
1 O I_DISEASE
( O O
HIV-1 O B_DISEASE
) O O
. O O

The O O
major O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
goal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
determine O O
whether O O
the O O
mycobacterial O B_DISEASE_ADJECTIVE[DISEASE]
cell O I_DISEASE_ADJECTIVE[DISEASE]
wall O I_DISEASE_ADJECTIVE[DISEASE]
component O I_DISEASE_ADJECTIVE[DISEASE]
mannose-capped O O
lipoarabinomannan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ManLAM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
of O O
Mycobacterium O B_DISEASE
tuberculosis O I_DISEASE
( O O
M. O B_OTHER/B_PROTEIN[GENE]
tuberculosis O O
) O B_DISEASE/B_PROTEIN[GENE]
could O O
activate O O
transcription O O
of O B_GENE
HIV-1 O O
in O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
with O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
the O O
use O O
of O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
an O O
in O O
vitro O O
cell O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

These O O
experiments O O
are O O
of O O
prime O O
importance O O
considering O O
that O O
CD4 B B_GENE
-expressing O O
T O O
lymphocytes O O
represent O O
the O O
major O O
virus O O
reservoir O O
in O O
the O O
peripheral O O
blood O O
of O O
infected O O
individuals O O
. O O

Using O O
the O O
1G5 O O
cell O O
line O O
harbouring O O
the O O
luciferase O O
reporter O O
gene O O
under O O
the O O
control O O
of O O
the O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
was O O
first O O
found O O
that O O
culture O O
protein O O
filtrates O O
( O O
CFP O O
) O O
from O O
M. O O
tuberculosis O O
or O O
purified O O
ManLAM O O
could O O
activate O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR-dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
unlike O O
similarly O O
prepared O O
CFP O O
extracts O O
devoid O O
of O O
ManLAM O O
. O O

The O O
implication O O
of O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
s I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
and/or O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
highlighted O O
by O O
the O O
abrogation O O
of O O
the O O
ManLAM-mediated O O
activation O O
of O O
HIV-1 O O
LTR-driven O O
gene O O
expression O O
using O O
herbimycin O O
A O O
and O O
H7 O O
. O O

It O O
was O O
also O O
determined O O
, O O
using O O
electrophoresis O O
mobility O O
shift O O
assays O O
, O O
that O O
M. O O
tuberculosis O O
ManLAM O O
led O O
to O O
the O O
nuclear O O
translocation O O
of O O
the O O
transcription B B_ENZYME[GENE]/B_BIO
factor I I_ENZYME[GENE]/I_BIO
NF-kappaB I I_ENZYME[GENE]/I_BIO
. O O

M. O O
tuberculosis O O
ManLAM O O
resulted O O
in O O
clear O O
induction O O
of O O
the O O
luciferase B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
placed O O
under O O
the O O
control O O
of O O
the O O
wild-type B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
but I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
not I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
the I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
kappaB-mutated I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
HIV-1 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
LTR I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Finally O O
, O O
the O O
ManLAM-mediated O O
activation O O
of O O
HIV-1 O O
LTR O O
transcription O O
was O O
found O O
to O O
be O O
independent O O
of O O
the O O
autocrine O O
or O O
paracrine O O
action O O
of O O
endogenous B B_GENE
TNF-alpha I I_GENE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
M. O B_OTHER/B_PROTEIN[GENE]
tuberculosis O O
can O B_DISEASE/B_BACTERIUM[BIO]
upregulate O O
HIV-1 O O
expression O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
could O O
thus O O
have O O
the O O
potential O O
to O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
influence O O
the O O
pathogenesis O O
of O B_DISEASE_ADJECTIVE[DISEASE]
HIV-1 O O
infection O B_DISEASE
. O I_DISEASE

Human B B_PERSON
immunodeficiency I I_PERSON
virus I I_PERSON
type I I_PERSON
1 I I_PERSON
long I I_PERSON
terminal I I_PERSON
repeat I I_PERSON
quasispecies O O
differ O O
in O O
basal O O
transcription O O
and O O
nuclear O O
factor O O
recruitment O O
in O O
human O O
glial O O
cells O O
and O O
lymphocytes O O
. O O

The O O
generation O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
genomic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
diversity O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
the O O
course O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
infection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O O
the O O
potential O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
affect O O
all O O
aspects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
HIV-1 O O
replication O B_TIME[MEASURE]/B_DISEASE
, O O
including O O
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
the O O
proviral O B_GENE
genome O I_GENE
. O O

To O O
gain O O
a O O
better O O
understanding O O
of O O
the O O
impact O O
of O O
long B B_GENE
terminal I I_GENE
repeat I I_GENE
( O O
LTR B B_PROTEIN[GENE]/B_DISEASE
) O O
sequence O O
diversity O O
on O O
LTR-directed B B_GENE
gene I I_GENE
expression O O
in O O
cells O O
of O O
the O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
and O O
immune O O
system O O
, O O
we O O
amplified O O
and O O
cloned O O
LTRs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
from O O
proviral O O
DNA O O
in O O
HIV-1-infected O O
peripheral O O
blood O O
. O O

Sequence O O
analysis O O
of O O
nineteen O O
LTRs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cloned O O
from O O
2 O O
adult O O
and O O
3 O O
pediatric O O
patients O O
revealed O O
an O O
average O O
of O O
33 O O
nucleotide O O
changes O O
( O O
with O O
respect O O
to O O
the O O
sequence O O
of O O
the O O
LAI B B_LOCATION/B_GENE
LTR I I_LOCATION/I_GENE
) O O
within O O
the O O
455-bp B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
U3 I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Transient O O
expression O O
analyses O O
in O O
cells O O
of O O
neuroglial O O
and O O
lymphocytic O O
origin O O
demonstrated O O
that O O
some O O
of O O
these O O
LTRs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
had O O
activities O O
which O O
varied O O
significantly O O
from O O
the O O
LAI B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
LTR I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
U-373 O O
MG O O
cells O O
( O O
an O O
astrocytoma O O
cell O O
line O O
) O O
as O O
well O O
as O O
in O O
Jurkat O O
cells O O
( O O
a O O
CD4-positive O O
lymphocyte O O
cell O O
line O O
) O O
. O O

While O O
LTRs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O O
demonstrated O O
the O O
highest O O
activities O O
in O O
U-373 O O
MG O O
cells O O
also O O
yielded O O
high O O
activities O O
in O O
Jurkat O O
cells O O
, O O
the O O
LTRs B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
were O O
generally O O
more O O
active O O
in O O
Jurkat O O
cells O O
when O O
compared O O
to O O
the O O
LAI B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LTR I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Differences O O
in O O
LTR B B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
also O O
resulted O O
in O O
differences O O
in O O
transcription O O
factor O O
recruitment O O
to O O
cis-acting B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sites I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
within O O
the O O
U3 B B_LOCATION/B_MEASURE
region I I_LOCATION/I_MEASURE
of O O
the O O
LTR B B_GENE/B_DISEASE
, O O
as O O
demonstrated O O
by O O
electrophoretic O O
mobility O O
shift O O
assays O O
. O O

In O O
particular O O
, O O
naturally O O
occurring O O
sequence O O
variation O O
impacted O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
binding O O
to O O
an O O
activating B B_GENE
transcription I I_GENE
factor I I_GENE
/ O O
cAMP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
CREB B B_LOCATION/B_ORGANIZATION
) O O
binding O O
site O O
( O O
located O O
between O O
the O O
LEF-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
distal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappaB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
that O O
we O O
identified O O
in O O
previous O O
studies O O
of O O
the O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
findings O O
suggest O O
that O O
LTR B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequence I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
changes O O
can O O
significantly O O
affect O O
basal O O
LTR O O
function O O
and O O
transcription O O
factor O O
recruitment O O
, O O
which O O
may O O
, O O
in O O
turn O O
, O O
alter O O
the O O
course O O
of O O
viral O O
replication O O
in O O
cells O O
of O O
CNS O O
and O O
immune O O
system O O
origin O O
. O O

HMG B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
box I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcription I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
lymphocyte O O
differentiation O O
. O O

The O O
identification O O
of O O
the O O
mammalian B B_GENE/B_BIO
sex-determining I I_GENE/I_BIO
gene I I_GENE/I_BIO
Sry I I_GENE/I_BIO
has O O
led O O
to O O
the O O
discovery O O
of O O
a O O
large O O
family O O
of O O
related O O
( O O
' O O
HMG B B_GENE/B_PERSON
box I I_GENE/I_PERSON
' O O
) O O
transcription B B_GENE/B_BIO
factors I I_GENE/I_BIO
that O O
control O O
developmental O O
events O O
in O O
yeast O O
, O O
C. O O
elegans O O
, O O
Drosophila O O
and O O
vertebrates O O
. O O

In O O
lymphocyte O O
differentiation O O
, O O
several O O
HMG B B_GENE
box I I_GENE
proteins I I_GENE
play O O
a O O
decisive O O
role O O
. O O

Sox-4 B B_GENE
is O O
important O O
for O O
very O O
early O O
B-cell O O
differentiation O O
, O O
while O O
TCF-1 B B_LOCATION/B_ORGANIZATION
/ O O
LEF-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
play O O
a O O
crucial O O
role O O
in O O
early O O
thymocyte O O
development O O
. O O

TCF/LEF B B_PERSON
proteins I I_PERSON
have O O
recently O O
been O O
found O O
to O O
constitute O O
a O O
downstream O O
component O O
of O O
the O O
Wingless/Wnt O O
signal O O
transduction O O
pathway O O
. O O

In O O
flies O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
this O O
pathway O B_LOCATION
controls O O
segment O B_MEASURE/B_ORGANISM_FUNCTION
polarity O I_MEASURE/I_ORGANISM_FUNCTION
; O O
in O O
Xenopus O B_SPECIES[BIO]
it O O
controls O O
the O O
definition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
body O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
axis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Deregulation O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
pathway O B_GENE/B_DISEASE
occurs O O
in O O
several O B_DISEASE
human O I_DISEASE
tumors O I_DISEASE
. O O

These O O
insights O O
in O O
the O O
molecular O O
events O O
that O O
are O O
involved O O
in O O
TCF/LEF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
function O O
in O O
these O O
organisms O O
may O O
eventually O O
lead O O
to O O
the O O
understanding O O
of O O
the O O
function O O
of O O
these O O
HMG B B_GENE
box I I_GENE
proteins I I_GENE
in O O
lymphoid O O
development O O

Transcriptional O O
regulation O O
by O O
C/EBP B B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DISEASE_ADJECTIVE[DISEASE]
and I I_DISEASE_ADJECTIVE[DISEASE]
-beta I I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
expression O O
of O O
the O O
gene O O
for O O
the O O
MRP14 B B_GENE
myeloid I I_GENE
calcium I I_GENE
binding I I_GENE
protein I I_GENE
. O O

Transcriptional O O
regulation O O
of O O
the O O
gene O O
for O O
the O O
myeloid B B_GENE
calcium I I_GENE
binding I I_GENE
protein I I_GENE
, O O
MRP14 B B_GENE
, O O
was O O
investigated O O
in O O
human O O
monocytic O O
leukemia O O
cell O O
lines O O
. O O

The O O
MRP14 B B_GENE/B_MEASURE
gene I I_GENE/I_MEASURE
was O O
not O O
expressed O O
in O O
monoblastic O O
ML-1 O O
cells O O
, O O
promonocytic O O
U-937 O O
cells O O
, O O
or O O
promyelocytic O O
HL-60 O O
cells O O
. O O

On O O
the O O
other O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
hand O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
gene O B_GENE/B_MEASURE
was O O
expressed O O
in O O
monocytic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
THP-1 O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
in O O
the O O
HL-60 O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
treated O O
with O O
1 O B_MEASURE
, O O
25-dihydroxyvitamin O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D3 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VD3 O B_PROTEIN[GENE]/B_MEASURE
) O O
. O O

The O O
level O O
of O O
MRP14 B B_GENE
in O O
VD3-treated O O
HL-60 O O
cells O O
was O O
two-fold O O
higher O O
than O O
that O O
in O O
THP-1 O O
cells O O
. O O

Among O O
several O O
known O O
transcription B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
motifs I I_GENE/I_MEASURE
, O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
s I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
VD3-treated O O
HL-60 O O
cells O O
and O O
THP-1 O O
cells O O
bound O O
to O O
the O O
CCAAT/enhancer B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
C/EBP I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
-binding I I_GENE/I_LOCATION
motif I I_GENE/I_LOCATION
that O O
was O O
located O O
in O O
the O O
upstream B B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
region I I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
MRP14 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
( O O
-81 O O
) O O
, O O
as O O
evidenced O O
by O O
the O O
competitive O O
gel O O
mobility-shift O O
assay O O
. O O

An O O
antibody O O
for O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
super-shifted O O
the O O
nucleoprotein B B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
THP-1 O O
cells O O
but O O
not O O
in O O
the O O
VD3-treated O O
HL-60 O O
cells O O
, O O
whereas O O
an O O
antibody O O
for O O
C/EBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocked O O
the O O
formation O O
of O O
the O O
complex O O
with O O
the O O
nuclear B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
HL-60 O O
cells O O
but O O
not O O
with O O
that O O
of O O
THP-1 O O
cells O O
. O O

An O O
anti-C/EBP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
delta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
had O O
no O O
effect O O
on O O
the O O
complex O O
in O O
either O O
cell O O
. O O

Thus O O
, O O
it O O
was O O
concluded O O
that O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
able O O
to O O
bind O O
to O O
the O O
C/EBP B B_GENE
motif I I_GENE
, O O
and O O
that O O
C/EBP B B_GENE/B_MEASURE
alpha I I_GENE/I_MEASURE
bound O O
to O O
the O O
motif O O
in O O
THP-1 O O
cells O O
and O O
C/EBP B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O O
to O O
that O O
in O O
the O O
VD3-treated O O
HL-60 O O
cells O O
. O O

Furthermore O O
, O O
to O O
examine O O
the O O
transcriptional O O
activity O O
of O O
the O O
C/EBP B B_GENE
motif I I_GENE
, O O
we O O
transfected O O
several O O
constructed O O
luciferase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
into O O
HL-60 O O
cells O O
and O O
THP-1 O O
cells O O
. O O

The O O
luciferase O O
activity O O
of O O
the O O
C/EBP B B_GENE
motif I I_GENE
in O O
HL-60 O O
cells O O
was O O
increased O O
by O O
VD3 O O
treatment O O
. O O

The O O
C/EBP B B_GENE/B_LOCATION
motif I I_GENE/I_LOCATION
in O O
the O O
MRP14 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
was O O
confirmed O O
to O O
function O O
as O O
a O O
regulatory O O
region O O
in O O
VD3-treated O O
HL-60 O O
cells O O
and O O
THP-1 O O
cells O O
by O O
the O O
assay O O
. O O

Since O O
C/EBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
also O O
detected O O
in O O
VD3-untreated O O
HL-60 O O
cells O O
by O O
immunoblotting O O
, O O
VD3 O O
activated O O
C/EBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
bind O O
to O O
the O O
motif O O
, O O
probably O O
through O O
post-translational O O
modification O O
. O O

Patients O B_PERSON/B_BIO
with O O
high-risk O B_DISEASE/B_LOCATION
myelodysplastic O I_DISEASE/I_LOCATION
syndrome O I_DISEASE/I_LOCATION
can O O
have O O
polyclonal O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
clonal O B_DISEASE
haemopoiesis O I_DISEASE
in O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
haematological O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
remission O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

The O O
clonality O O
of O O
mature O O
peripheral O O
blood-derived O O
myeloid O O
and O O
lymphoid O O
cells O O
and O O
bone O O
marrow O O
haemopoietic O O
progenitors O O
from O O
18 O O
females O O
with O O
myelodysplasia O O
( O O
MDS O O
) O O
( O O
five O O
refractory O O
anaemia O O
, O O
RA O O
; O O
one O O
RA O O
with O O
ringed O O
sideroblasts O O
, O O
RARS O O
; O O
three O O
chronic O O
myelomonocytic O O
leukaemia O O
, O O
CMML O O
; O O
four O O
RA O O
with O O
excess O O
of O O
blasts O O
, O O
RAEB O O
; O O
five O O
RAEB O O
in O O
transformation O O
, O O
RAEB-t O O
) O O
was O O
studied O O
by O O
X-chromosome B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inactivation O O
analysis O O
. O O

Using O O
the O O
human O B_GENE
androgen-receptor O I_GENE
( O O
HUMARA O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
assay O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
we O O
analysed O O
the O O
clonal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
patterns O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
highly O O
purified O B_TIME[MEASURE]/B_GENE
immature O I_TIME[MEASURE]/I_GENE
CD34+ O I_TIME[MEASURE]/I_GENE
38- O I_TIME[MEASURE]/I_GENE
and O O
committed O O
CD34+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
38+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
marrow-derived O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
CD16+ O B_GENE/B_TIME[MEASURE]
14- O I_GENE/I_TIME[MEASURE]
granulocytes O I_GENE/I_TIME[MEASURE]
, O O
CD14+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
CD3+ O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
CD19+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
B O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O O
peripheral O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
high-risk O B_DISEASE/B_MEASURE
patients O I_DISEASE/I_MEASURE
( O O
RAEB O B_DISEASE
, O O
RAEB-t O B_DISEASE/B_LOCATION
) O O
, O O
clonality O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
performed O O
before O O
and O O
after O O
intensive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
remission-induction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

All O O
patients O B_PERSON/B_BIO
, O O
except O O
one O B_NUMBER[MEASURE]/B_PERSON
with O O
RA O B_DISEASE/B_LOCATION
, O O
had O O
predominance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
a O O
single O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
clone O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
their O O
granulocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

The O O
same O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
clonal O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
pattern O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O O
found O O
in O O
CD34+ O B_BIO/B_DISEASE
progenitor O I_BIO/I_DISEASE
cells O I_BIO/I_DISEASE
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
CD3+ O B_PERSON/B_GENE
T O I_PERSON/I_GENE
lymphocytes O I_PERSON/I_GENE
were O O
polyclonal O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
oligoclonal O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
14/18 O B_PERSON/B_MEASURE
patients O B_PERSON/I_MEASURE
. O O

X-chromosome B B_GENE/B_DISEASE
inactivation O O
patterns O O
of O O
CD19+ O O
B O O
cells O O
were O O
highly O O
concordant O O
with O O
CD3+ O O
T O O
cells O O
except O O
for O O
two O O
patients O O
( O O
one O O
RA O O
, O O
one O O
CMML O O
) O O
with O O
monoclonal O O
B O O
and O O
polyclonal O O
T O O
lymphocytes O O
, O O
therefore O O
suggesting O O
a O O
clonal O O
mutation O O
in O O
a O O
progenitor O O
common O O
to O O
the O O
myeloid O O
and O O
B-lymphoid O O
lineages O O
or O O
the O O
coexistence O O
of O O
MDS O O
and O O
a O O
B-cell O O
disorder O O
in O O
these O O
particular O O
patients O O
. O O

After O O
high-dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
non-myeloablative O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
polyclonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
haemopoiesis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
reinstalled O O
in O O
the O O
mature O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
myeloid O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
immature O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
and O O
committed O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
marrow O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
three O B_NUMBER[MEASURE]/B_PERSON
of O O
four O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
achieving O O
complete O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
haematological O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
remission O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Therefore O O
we O O
conclude O O
that O O
most O O
haematological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remissions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
MDS O B_DISEASE/B_PERSON
are O O
associated O O
with O O
restoration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
polyclonal O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
haemopoiesis O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Prominent O B_PERSON
sex O I_PERSON
steroid O O
metabolism O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
in O O
human O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Steroid O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
metabolism O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
investigated O O
in O O
cultured O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
B-lymphoblastoid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
B-LCL O B_DISEASE
) O O
, O O
and O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Gene O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
examined O O
by O O
reverse-transcription O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
amplification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
RT-PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Appropriate O O
sized O O
transcripts B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
detected O O
in O O
both O O
cultured O O
and O O
fresh O O
peripheral O O
lymphocytes O O
for O O
CYP11A B B_GENE/B_LOCATION
, O O
CYP17 B B_GENE
, O O
HSD11L B B_GENE/B_DISEASE
( O O
11beta-hydroxysteroid B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
I I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
HSD17B1 B B_GENE/B_DISEASE
( O O
17beta-hydroxysteroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
SRD5A1 B B_GENE/B_DISEASE
( O O
5alpha-reductase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

B-LCL O O
, O O
but O O
not O O
T O O
and O O
B O O
cells O O
, O O
expressed O O
CYP11B B B_GENE
. O O

There O O
was O O
minimal O O
expression O O
of O O
HSD3B1 B B_GENE/B_LOCATION
and O O
HSD3B2 B B_GENE/B_DISEASE
( O O
3beta-hydroxysteroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
B-LCL O O
and O O
T O O
cells O O
. O O

Transcripts O O
for O O
CYP19 B B_GENE/B_DISEASE
and O O
HSD11K B B_GENE
were O O
not O O
detected O O
. O O

Corresponding O O
enzymatic O O
activity O O
was O O
detectable O O
only O O
for O O
17-hydroxysteroid B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
5alpha-reductase B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
producing O O
testosterone O O
and O O
5alpha-dihydrotestosterone O O
. O O

Steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
identities O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
confirmed O O
by O O
gas O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography/mass O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectrometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GC/MS O B_MEASURE/B_DISEASE
) O O
. O O

One O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
metabolite O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
thought O O
to O O
be O O
deoxycorticosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
identified O O
by O O
GC/MS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
6alpha-hydroxypregnanolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

It O O
was O O
concluded O O
that O O
sex O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolism O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
androgen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
occurs O O
in O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O O
and O O
may O O
modulate O O
immune O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Human O O
white O O
blood O O
cells O O
and O O
hair O O
follicles O O
are O O
good O O
sources O O
of O O
mRNA B B_GENE
for O O
the O O
pterin B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carbinolamine I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydratase/dimerization I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cofactor I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
HNF1 B B_GENE
for O O
mutation O O
detection O O
. O O

Pterin B B_PROTEIN[GENE]/B_TIME[MEASURE]
carbinolamine I I_PROTEIN[GENE]/I_TIME[MEASURE]
dehydratase/dimerization I I_PROTEIN[GENE]/I_TIME[MEASURE]
cofactor I I_PROTEIN[GENE]/I_TIME[MEASURE]
of O O
HNF1 B B_GENE/B_DISEASE
( O O
PCD/DCoH B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
a O O
protein O O
that O O
has O O
a O O
dual O O
function O O
. O O

It O O
is O O
a O O
pterin B B_ENZYME[GENE]
4alpha-carbinolamine I I_ENZYME[GENE]
dehydratase I I_ENZYME[GENE]
that O O
is O O
involved O O
in O O
the O O
regeneration O O
of O O
the O O
cofactor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetrahydrobiopterin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
the O O
phenylalanine O O
hydroxylase- O O
catalyzed O O
hydroxylation O O
of O O
phenylalanine O O
. O O

In O O
addition O O
, O O
it O O
is O O
the O O
dimerization O O
cofactor O O
of O O
HNF1 B B_GENE
that O O
is O O
able O O
to O O
activate O O
the O O
transcriptional O O
activity O O
of O O
HNF1 B B_GENE
. O O

Deficiencies O O
in O O
the O O
gene O O
for O O
this O O
dual B B_GENE
functional I I_GENE
protein I I_GENE
result O O
in O O
hyperphenylalaninemia O O
. O O

Here O O
we O O
report O O
for O O
the O O
first O O
time O O
that O O
the O O
PCD/DCoH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
present O O
in O O
human O O
white O O
blood O O
cells O O
and O O
hair O O
follicles O O
. O O

Taking O O
advantage O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
, O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
convenient O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
screening O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
mutations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
occurring O O
in O O
the O O
coding O B_LOCATION/B_PERSON
region O I_LOCATION/I_PERSON
of O O
this O O
gene O B_GENE/B_LOCATION
has O O
been O O
described O O
. O O

Copyright O B_LOCATION/B_PERSON
1998 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Biochemical O O
characterization O O
of O O
the O O
NF-Y B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
transcription I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
factor I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
complex I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
during O O
B O O
lymphocyte O O
development O O
. O O

The O O
transcription B B_GENE
factor I I_GENE
, O O
NF-Y B B_GENE
, O O
plays O O
a O O
critical O O
role O O
in O O
tissue-specific O O
major B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O O
. O O

In O O
this O O
report O O
the O O
biochemical O O
properties O O
of O O
the O O
heterotrimeric B B_GENE
NF-Y I I_GENE
complex I I_GENE
have O O
been O O
characterized O O
during O O
stage-specific O O
B-cell O O
development O O
, O O
and O O
in O O
several O O
class O O
II- O O
mutant O O
B-cell O O
lines O O
, O O
which O O
represent O O
distinct O O
bare O O
lymphocyte O O
syndrome O O
class O O
II O O
genetic O O
complementation O O
groups O O
. O O

The O O
NF-Y B B_GENE
complex I I_GENE
derived O O
from O O
class O O
II+ O O
mature O O
B-cells O O
bound O O
with O O
high O O
affinity O O
to O O
anion B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
exchangers I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
eluted O O
as O O
an O O
intact O O
trimeric B B_LOCATION
complex I I_LOCATION
, O O
whereas O O
, O O
NF-Y B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derived O O
from O O
class O O
II- O O
plasma O O
B-cells O O
, O O
and O O
from O O
bare O O
lymphocyte O O
syndrome O O
group O O
II O O
cell O O
lines O O
, O O
RJ2.2.5 O O
and O O
RM3 O O
, O O
dissociated O O
into O O
discrete O O
NF-YA B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
NF-YB B B_PROTEIN[GENE]
: I I_PROTEIN[GENE]
C I I_PROTEIN[GENE]
subunit B I_PROTEIN[GENE]
fractions I I_PROTEIN[GENE]
. O O

Recombination O O
of O O
the O O
MPC11 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B-cell I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derived I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NF-Y I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
low O O
molecular O O
mass O O
protein O O
fraction O O
, O O
NF-Y-associated B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
YAFs B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
derived O O
from O O
mature O O
A20 O O
B-cell O O
nuclei O O
, O O
conferred O O
high O O
affinity O O
anion O O
exchange O O
binding O O
to O O
NF-Y B B_GENE
as O O
an O O
intact B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trimeric I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
complex I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Recombination O O
of O O
the O O
native B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NF-YA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
transcriptional B B_GENE/B_PERSON
cofactor I I_GENE/I_PERSON
, O O
PC4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
likewise O O
conferred O O
high B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
affinity I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
NF-Y I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
binding O O
to O O
anion B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exchangers I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
stabilized O O
NF-Y B B_GENE/B_PERSON
interaction O O
with O O
CCAAT-box B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O O
. O O

Interaction O O
between O O
PC4 B B_GENE
and O O
NF-Y B B_GENE
was O O
mapped O O
to O O
the O O
C-terminal B B_LOCATION/B_BIO
region I I_LOCATION/I_BIO
of O O
PC4 B B_GENE
, O O
and O O
the O O
subunit B B_LOCATION/B_MEASURE
interaction I I_LOCATION/I_MEASURE
subdomain I I_LOCATION/I_MEASURE
of O O
the O O
highly B B_PROTEIN[GENE]
conserved I I_PROTEIN[GENE]
DNA I I_PROTEIN[GENE]
binding-subunit I I_PROTEIN[GENE]
interaction I I_PROTEIN[GENE]
domain I I_PROTEIN[GENE]
( O O
DBD B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
of O O
NF-YA B B_GENE
. O O

These O O
results O O
suggest O O
that O O
in O O
class O O
II+ O O
mature O O
B-cells O O
NF-Y B B_GENE
is O O
associated O O
with O O
the O O
protein O O
cofactor O O
, O O
PC4 B B_GENE
, O O
which O O
may O O
play O O
an O O
important O O
role O O
in O O
NF-Y-mediated O O
transcriptional O O
control O O
of O O
class B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Arrest O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
B O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocyte O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
terminal O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
differentiation O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
CD40 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
mechanism O B_DISEASE_ADJECTIVE[DISEASE]
for O O
lack O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
antibody-secreting O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
germinal O B_BIO/B_DISEASE
centers O I_BIO/I_DISEASE
. O O

Despite O O
extensive O O
research O O
, O O
the O O
role O O
of O O
CD40 B B_GENE
signaling O O
in O O
B O O
cell O O
terminal O O
differentiation O O
remains O O
controversial O O
. O O

Here O O
we O O
show O O
that O O
CD40 B B_GENE/B_LOCATION
engagement O O
arrests O O
B O O
cell O O
differentiation O O
prior O O
to O O
plasma O O
cell O O
formation O O
. O O

This O O
arrest O O
is O O
manifested O O
at O O
a O O
molecular O O
level O O
as O O
a O O
reduction O O
in O O
mRNA O O
levels O O
of O O
secretory O O
immunoglobulin O O
gene O O
products O O
such O O
as O O
mu O O
( O O
s O O
) O O
and O O
J O O
chain O O
as O O
well O O
as O O
the O O
loss O O
of O O
the O O
transcriptional B B_GENE
regulator I I_GENE
BLIMP-1 B I_GENE
. O O

Furthermore O O
, O O
the O O
inhibition O O
of O O
B O O
cell O O
differentiation O O
by O O
CD40 B B_GENE
engagement O O
could O O
not O O
be O O
overcome O O
by O O
either O O
mitogens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
could O O
be O O
reversed O O
by O O
antibodies O O
that O O
interfere O O
with O O
the O O
CD40 B B_GENE
/ O O
gp39 B B_GENE/B_LOCATION
interaction O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
secretory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunoglobulin O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
not O O
produced O O
by O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
are O O
actively O O
engaged O O
by O O
gp39-expressing O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

A O O
positively O O
charged O O
alpha-lipoic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analogue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
increased O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uptake O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
more O O
potent O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
immunomodulatory O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activity O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

alpha-Lipoic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
LA O B_LOCATION/B_ORGANIZATION
) O O
is O O
taken O O
up O O
by O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O O
reduced O O
to O O
its O O
potent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
dithiol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
form O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
dihydrolipoate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DHLA O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
, O O
much O B_MEASURE/B_LOCATION
of O O
which O O
is O O
rapidly O O
effluxed O O
out O O
from O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

To O O
improve O O
retention O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
the O O
LA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
molecule O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
modified O O
to O O
confer O O
a O O
positive O B_MEASURE/B_LOCATION
charge O I_MEASURE/I_LOCATION
at O O
physiological O B_LOCATION/B_PROTEIN[GENE]
pH O B_LOCATION/I_PROTEIN[GENE]
. O O

N O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
N-dimethyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
N'-2-amidoethyl-lipoate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
synthesized O O
. O O

The O O
protonated O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
form O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
new O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecule O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
referred O O
to O O
as O O
LA-Plus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
uptake O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
LA-Plus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Wurzburg O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
compared O O
to O O
that O O
of O O
LA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Several-fold O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
amounts O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
DHLA-Plus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
the O O
corresponding O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduced O O
form O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
LA-Plus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
were O O
detected O O
in O O
LA-Plus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
treated O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
compared O O
to O O
the O O
amount O B_MEASURE/B_LOCATION
of O O
DHLA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
found O O
in O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
treated O O
with O O
LA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

At O O
100 O O
microM O O
, O O
LA O O
did O O
not O O
but O O
LA-Plus O O
inhibited O O
H2O2 O O
induced O O
NF-kappaB B B_GENE
activation O O
and O O
NF-kappaB B B_GENE
directed O O
IL-2 B B_GENE
receptor I I_GENE
expression O O
. O O

Both O O
LA O O
and O O
LA-Plus O O
synergised O O
with O O
selenium O O
in O O
inhibiting O O
H2O2 O O
induced O O
NF-kappaB B B_GENE
activation O O
. O O

At O O
150 O O
microM O O
LA-Plus O O
, O O
but O O
not O O
LA O O
, O O
inhibited O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
NF-kappaB B B_GENE
activation O O
. O O

At O O
5 O B_GENE
microM O I_GENE
LA-Plus O I_GENE
, O O
but O O
not O O
LA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
protected O O
against O O
both O O
spontaneous O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
etoposide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
apoptosis O B_DISEASE
in O O
rat O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
thymocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

LA-Plus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
thus O O
an O O
improved O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
form O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
of O O
LA O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
increased O O
therapeutic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
potential O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Copyright O B_LOCATION/B_PERSON
1998 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Carrier O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identification O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
X-linked O B_LOCATION
immunodeficiency O I_LOCATION
diseases O I_LOCATION
. O O

OBJECTIVE O O
: O O
Carrier O O
identification O O
in O O
X-linked O O
immunodeficiency O O
disorders O O
can O O
be O O
based O O
on O O
the O O
demonstration O O
of O O
non-random O O
X O O
inactivation O O
( O O
NRXI O O
) O O
in O O
affected O O
blood O O
cell O O
lineages O O
when O O
growth O O
is O O
impaired O O
in O O
cells O O
expressing O O
the O O
abnormal B B_GENE
gene I I_GENE
. O O

We O O
examined O O
the O O
utility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
seeking O O
evidence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
NRXI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
test O O
the O O
carrier O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
status O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
women O B_PERSON
in O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
affected O O
by O O
X-linked O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
severe O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
combined O O
immunodeficiency O B_DISEASE
( O O
XSCID O B_LOCATION/B_DISEASE
) O O
and O O
X-linked O B_DISEASE/B_MEASURE
hypogammaglobulinaemia O I_DISEASE/I_MEASURE
( O O
XLH O B_DISEASE/B_LOCATION
) O O
, O O
to O O
identify O O
as O O
carriers O B_PERSON
the O O
mothers O B_PERSON/B_DISEASE
of O O
boys O B_PERSON
with O O
SCID O B_DISEASE
or O O
hypogammaglobulinaemia O B_DISEASE
whose O O
phenotype O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggested O O
X-linkage O B_DISEASE/B_GENE
and O O
to O O
infer O O
X-linkage O B_PERSON/B_GENE
in O O
boys O B_PERSON
with O O
SCID O B_DISEASE
or O O
hypogammaglobulinaemia O B_PERSON
whose O O
disease O B_DISEASE/B_GENE
was O O
not O O
clearly O O
X-linked O O
on O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
either O O
of O O
family O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
history O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
or O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
immunological O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHODOLOGY O O
: O O
A O O
polymerase O O
chain O O
reaction-based O O
method O O
was O O
used O O
to O O
amplify O O
a O O
polymorphic O O
CAG B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
repeat I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
first B B_GENE/B_LOCATION
exon I I_GENE/I_LOCATION
of O O
the O O
androgen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
after O O
selective O O
digestion O O
of O O
the O O
active B B_GENE
X I I_GENE
chromosome I I_GENE
with O O
a O O
methylation-sensitive B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
HpaII B B_TIME[MEASURE]/B_BACTERIUM[BIO]
to O O
distinguish O O
between O O
the O O
paternal B B_GENE/B_PERSON
and I I_GENE/I_PERSON
maternal I I_GENE/I_PERSON
alleles I I_GENE/I_PERSON
and O O
to O O
identify O O
their O O
methylation O O
status O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
Heterozygosity O B_DISEASE/B_LOCATION
was O O
found O O
in O O
24 O B_NUMBER[MEASURE]
of O O
31 O B_NUMBER[MEASURE]/B_PERSON
female O I_NUMBER[MEASURE]/I_PERSON
subjects O I_NUMBER[MEASURE]/I_PERSON
( O O
77 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
. O O

As O O
anticipated O O
, O O
NRXI O O
could O O
be O O
demonstrated O O
in O O
all O O
lymphoid O O
cells O O
studied O O
from O O
obligate O O
carriers O O
of O O
XSCID O O
and O O
an O O
obligate O O
carrier O O
of O O
XLH O O
but O O
not O O
on O O
a O O
carrier O O
of O O
X-linked O O
immunodeficiency O O
with O O
hyper-IgM B B_DISEASE
. O O

The O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
NRXI O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
mother O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
a O O
boy O B_PERSON
with O O
a O O
SCID O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
variant O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
showed O O
her O O
to O O
be O O
a O O
carrier O B_PERSON/B_MEASURE
of O O
XSCID O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
establishes O O
that O O
her O O
son O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
has O O
XSCID O O
, O O
not O O
otherwise O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
This O O
PCR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
provides O O
a O O
rapid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
carrier O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
X-linked O B_DISEASE/B_GENE
immunodeficiencies O B_DISEASE/I_GENE
, O O
and O O
has O O
allowed O O
us O O
to O O
expand O O
the O O
phenotype O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
XSCID O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Leukocyte-endothelial O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
interaction O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O O
augmented O O
by O O
high O B_DISEASE
glucose O I_DISEASE
concentrations O I_DISEASE
and O O
hyperglycemia O B_DISEASE
in O O
a O O
NF-kB-dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
fashion O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

We O O
addressed O O
the O O
role O O
of O O
hyperglycemia O O
in O O
leukocyte-endothelium O O
interaction O O
under O O
flow O O
conditions O O
by O O
exposing O O
human O O
umbilical O O
vein O O
endothelial O O
cells O O
for O O
24 O O
h O O
to O O
normal O O
( O O
5 O O
mM O O
) O O
, O O
high O O
concentration O O
of O O
glucose O O
( O O
30 O O
mM O O
) O O
, O O
advanced O O
glycosylation O O
end O O
product-albumin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
100 O O
microg/ml O O
) O O
, O O
or O O
hyperglycemic O O
( O O
174-316 O O
mg/dl O O
) O O
sera O O
from O O
patients O O
with O O
diabetes O O
and O O
abnormal O O
hemoglobin O O
A1c O O
( O O
8.1+/-1.4 O O
% O O
) O O
. O O

At O O
the O O
end O B_LOCATION/B_TIME[MEASURE]
of O O
incubation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
endothelial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
cells O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
were O O
perfused O O
with O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leukocyte O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suspension O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
parallel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
plate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
flow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
chamber O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
under O O
laminar O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
flow O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
1.5 O B_LOCATION/B_PROTEIN[GENE]
dyn/cm2 O I_LOCATION/I_PROTEIN[GENE]
) O O
. O O

Rolling O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
adherent O B_TIME[MEASURE]/B_PERSON
cells O I_TIME[MEASURE]/I_PERSON
were O O
evaluated O O
by O O
digital O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
image O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O O
that O O
30 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
glucose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
significantly O O
( O O
P O B_MEASURE
< O I_MEASURE
0.01 O I_MEASURE
) O O
increased O O
the O O
number O B_MEASURE/B_PERSON
of O O
adherent O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leukocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
endothelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
respect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
control O O
( O O
5 O B_MEASURE/B_LOCATION
mM O I_MEASURE/I_LOCATION
glucose O I_MEASURE/I_LOCATION
; O O
151+/-19 O B_MEASURE/B_LOCATION
versus O I_MEASURE/I_LOCATION
33+/-8 O I_MEASURE/I_LOCATION
cells/mm2 O I_MEASURE/I_LOCATION
) O O
. O O

A O O
similar O O
response O O
was O O
induced O O
by O O
endothelial O O
stimulation O O
with O O
IL-1beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
here O O
used O O
as O O
positive O O
control O O
( O O
195+/-20 O O
cells/mm2 O O
) O O
. O O

The O O
number O B_MEASURE/B_LOCATION
of O O
rolling O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
endothelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
surface O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
not O O
affected O O
by O O
high O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Stable O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adhesion O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
glucose-treated O O
as O O
well O O
as O O
to O O
IL-1beta-stimulated O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
endothelial O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
preceded O O
by O O
short O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
with O O
the O O
endothelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
surface O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

The O O
distance O B_MEASURE/B_LOCATION
travelled O O
by O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
before O O
arrest O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
30 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
on O O
IL-1beta-treated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
endothelial O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
significantly O O
( O O
P O B_TIME[MEASURE]/B_LOCATION
< O I_TIME[MEASURE]/I_LOCATION
0.01 O I_TIME[MEASURE]/I_LOCATION
) O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
observed O O
for O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
adhering O O
on O O
control O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
endothelium O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
30 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
glucose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
: O O
76.7+/-3.5 O B_MEASURE
; O O
IL1beta O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
69.7+/-4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
21.5+/-5 O B_MEASURE
microm O I_MEASURE
) O O
. O O

Functional O O
blocking O O
of O O
E-selectin B B_GENE
, O O
intercellular B B_GENE
cell I I_GENE
adhesion I I_GENE
molecule-1 I I_GENE
, O O
and O O
vascular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecule-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
endothelial O O
cells O O
with O O
the O O
corresponding O O
mouse B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mAb I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
significantly O O
inhibited O O
glucose-induced O O
increase O O
in O O
leukocyte O O
adhesion O O
( O O
67+/-16 O O
, O O
83+/-12 O O
, O O
62+/-8 O O
versus O O
144+/-21 O O
cells/ O O
mm2 O O
) O O
. O O

Confocal O O
fluorescence O O
microscopy O O
studies O O
showed O O
that O O
30 O O
mM O O
glucose O O
induced O O
an O O
increase O O
in O O
endothelial O O
surface O O
expression O O
of O O
E-selectin B B_GENE
, O O
intercellular B B_GENE
cell I I_GENE
adhesion I I_GENE
molecule-1 I I_GENE
, O O
and O O
vascular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecule-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Electrophoretic O O
mobility O O
shift O O
assay O O
of O O
nuclear O O
extracts O O
of O O
human O O
umbilical O O
vein O O
endothelial O O
cells O O
( O O
HUVEC O O
) O O
exposed O O
for O O
1 O O
h O O
to O O
30 O O
mM O O
glucose O O
revealed O O
an O O
intense O O
NF-kB B B_GENE
activation O O
. O O

Treatment O O
of O O
HUVEC O O
exposed O O
to O O
high O O
glucose O O
with O O
the O O
NF-kB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pyrrolidinedithiocarbamate O O
( O O
100 O O
microM O O
) O O
and O O
tosyl-phe-chloromethylketone O O
( O O
25 O O
microM O O
) O O
significantly O O
reduced O O
( O O
P O O
< O O
0.05 O O
) O O
leukocyte O O
adhesion O O
in O O
respect O O
to O O
HUVEC O O
treated O O
with O O
glucose O O
alone O O
. O O

A O O
significant O O
( O O
P O O
< O O
0.01 O O
) O O
inhibitory O O
effect O O
on O O
glucose-induced O O
leukocyte O O
adhesion O O
was O O
observed O O
after O O
blocking O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
with O O
staurosporine O O
( O O
5 O O
nM O O
) O O
. O O

When O O
HUVEC O O
were O O
treated O O
with O O
specific O O
antisense O O
oligodesoxynucleotides O O
against O O
PKCalpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PKCepsilon I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
before O O
the O O
addition O O
of O O
30 O O
mM O O
glucose O O
, O O
a O O
significant O O
( O O
P O O
< O O
0.05 O O
) O O
reduction O O
in O O
the O O
adhesion O O
was O O
also O O
seen O O
. O O

Advanced O O
glycosylation O O
end O O
product-albumin B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
significantly O O
increased O O
the O O
number O O
of O O
adhering O O
leukocytes O O
in O O
respect O O
to O O
native B B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
albumin I I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
used O O
as O O
control O O
( O O
110+/-16 O O
versus O O
66+/-7 O O
, O O
P O O
< O O
0.01 O O
) O O
. O O

Sera O O
from O O
diabetic O O
patients O O
significantly O O
( O O
P O O
< O O
0.01 O O
) O O
enhanced O O
leukocyte O O
adhesion O O
as O O
compared O O
with O O
controls O O
, O O
despite O O
normal O O
levels O O
of O O
IL-1beta B B_GENE
and O O
TNFalpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
sera O O
. O O

These O O
data O O
indicate O O
that O O
high O O
glucose O O
concentration O O
and O O
hyperglycemia O O
promote O O
leukocyte O O
adhesion O O
to O O
the O O
endothelium O O
through O O
upregulation O O
of O O
cell O O
surface O O
expression O O
of O O
adhesive O O
proteins O O
, O O
possibly O O
depending O O
on O O
NF-kB B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
. O O

Ikaros B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O O
hemopoietic O O
lineage O O
determination O O
and O O
homeostasis O O
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
the O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
control O O
hemopoietic O B_DISEASE/B_ORGANISM_FUNCTION
differentiation O B_DISEASE/I_ORGANISM_FUNCTION
have O O
focused O O
on O O
signaling O O
cascades O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O O
nuclear O B_LOCATION/B_ORGANIZATION
effectors O I_LOCATION/I_ORGANIZATION
that O O
drive O O
this O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developmental O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
regulated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fashion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Here O O
we O O
review O O
the O O
role O O
of O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
founding O O
member O O
of O O
a O O
unique O O
family O O
of O O
zinc B B_GENE/B_BIO
finger I I_GENE/I_BIO
transcription I I_GENE/I_BIO
factors I I_GENE/I_BIO
in O O
this O O
developmental O O
process O O
. O O

Studies O O
on O O
an O O
Ikaros B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
null O O
mutation O O
have O O
revealed O O
an O O
essential O O
role O O
for O O
this O O
factor O O
in O O
lymphoid O O
cell O O
fate O O
determination O O
and O O
at O O
subsequent O O
branch O O
points O O
of O O
the O O
T O O
cell O O
differentiation O O
pathway O O
. O O

Differences O O
in O O
the O O
phenotypes O O
of O O
a O O
null O O
and O O
a O O
dominant B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
negative I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DN I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Ikaros I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
provide O O
insight O O
into O O
a O O
regulatory O O
network O O
through O O
which O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exert O O
their O O
effects O O
in O O
development O O
. O O

In O O
addition O O
a O O
comparative O O
analysis O O
of O O
the O O
hemopoietic O O
stem O O
cell O O
and O O
precursor O O
compartment O O
resulting O O
from O O
the O O
two O O
Ikaros B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O O
a O O
profound O O
yet O O
not O O
absolute O O
requirement O O
for O O
Ikaros B B_DISEASE/B_GENE

Induction O O
of O O
early B B_DISEASE/B_VIRUS[BIO]
B I B_DISEASE/I_VIRUS[BIO]
cell I B_DISEASE/I_VIRUS[BIO]
factor I B_DISEASE/I_VIRUS[BIO]
( O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
multiple B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lineage I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
basic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
helix-loop-helix I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transcription I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
E12 B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
transcription B B_GENE
factors I I_GENE
encoded O O
by O O
the O O
E2A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
early B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
B I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
cell I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EBF B B_PROTEIN[GENE]/B_LOCATION
) O O
genes O O
are O O
required O O
for O O
the O O
proper O O
development O O
of O O
B O O
lymphocytes O O
. O O

However O O
, O O
the O O
absence O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
B O B_DISEASE/B_GENE
lineage O I_DISEASE/I_GENE
cells O I_DISEASE/I_GENE
in O O
E2A- O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
EBF-deficient O B_DISEASE/B_LOCATION
mice O I_DISEASE/I_LOCATION
has O O
made O O
it O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
determine O O
the O O
function O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
or O O
relationship O B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
these O O
proteins O B_LOCATION/B_GENE
. O O

We O O
report O O
the O O
identification O O
of O O
a O O
novel O O
model O O
system O O
in O O
which O O
the O O
role O O
of O O
E2A B B_LOCATION/B_GENE
and O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
regulation O O
of O O
multiple O O
B O O
lineage O O
traits O O
can O O
be O O
studied O O
. O O

We O O
found O O
that O O
the O O
conversion O O
of O O
70Z/3 O O
pre-B O O
lymphocytes O O
to O O
cells O O
with O O
a O O
macrophage-like O O
phenotype O O
is O O
associated O O
with O O
the O O
loss O O
of O O
E2A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Moreover O O
, O O
we O O
show O O
that O O
ectopic O O
expression O O
of O O
the O O
E2A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein O O
E12 B B_GENE/B_MEASURE
in O O
this O O
macrophage O O
line O O
results O O
in O O
the O O
induction O O
of O O
many B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lineage I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL7Ralpha B B_GENE
, O O
lambda5 B B_GENE
, O O
and O O
Rag-1 O O
, O O
and O O
the O O
ability O O
to O O
induce O O
kappa B B_GENE/B_DISEASE
light I I_GENE/I_DISEASE
chain I I_GENE/I_DISEASE
in O O
response O O
to O O
mitogen O O
. O O

Activation O O
of O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
one O O
of O O
the O O
critical O O
functions O O
of O O
E12 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
regulating O O
the O O
B O O
lineage O O
phenotype O O
since O O
expression O O
of O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
leads O O
to O O
the O O
activation O O
of O O
a O O
subset O O
of O O
E12 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-inducible O O
traits O O
. O O

Our O O
data O O
demonstrate O O
that O O
, O O
in O O
the O O
context O O
of O O
this O O
macrophage O O
line O O
, O O
E12 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
expression O O
of O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
together O O
these O O
transcription B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coordinately O O
regulate O O
numerous O O
B B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lineage-associated I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Activation-induced O O
down-regulation O O
of O O
retinoid B B_GENE
receptor I I_GENE
RXRalpha I I_GENE
expression O O
in O O
human O O
T O O
lymphocytes O O
. O O

Role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
cell O B_ORGANIZATION/B_PERSON
cycle O I_ORGANIZATION/I_PERSON
regulation O I_ORGANIZATION/I_PERSON
. O O

A O O
5.4-kilobase B B_GENE
mRNA I I_GENE
, O O
the O O
expression O O
of O O
which O O
is O O
down-regulated O O
after O O
treatment O O
of O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMCs O O
) O O
with O O
various O O
T O O
cell-activating O O
agents O O
, O O
was O O
isolated O O
using O O
an O O
mRNA O O
differential O O
display O O
method O O
. O O

Nucleotide O O
sequence O O
analysis O O
identified O O
the O O
5 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
end I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
this O O
RNA B B_GENE/B_BIO
as O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
retinoid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RXRalpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Here O O
, O O
we O O
report O O
the O O
nucleotide O O
sequence O O
of O O
3.6 B B_DISEASE/B_GENE
kilobases I B_DISEASE/I_GENE
of O O
this O O
RNA O O
, O O
which O O
represents O O
the O O
3 B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
RXRalpha B B_GENE
mRNA I I_GENE
, O O
the O O
sequence O O
of O O
which O O
has O O
not O O
been O O
previously O O
described O O
. O O

Activated O O
PBMCs O O
also O O
expressed O O
lower O O
levels O O
of O O
RXRalpha B B_GENE/B_LOCATION
protein O O
, O O
and O O
a O O
DNA O O
binding O O
assay O O
showed O O
that O O
the O O
activation-induced O O
loss O O
of O O
RXRalpha B B_GENE
mRNA I I_GENE
and O O
protein O O
expression O O
correlated O O
with O O
the O O
loss O O
of O O
DNA O O
binding O O
activity O O
of O O
this O O
protein O O
. O O

We O O
present O O
evidence O O
that O O
the O O
transition O O
from O O
G0/G1 O O
to O O
S O O
phase O O
of O O
the O O
cell O O
cycle O O
results O O
in O O
the O O
down-regulation O O
of O O
RXRalpha B B_GENE
expression O O
and O O
that O O
cell O O
cycle O O
inhibitors O O
, O O
which O O
block O O
the O O
cells O O
in O O
G1 O O
phase O O
, O O
prevent O O
this O O
down-regulation O O
. O O

The O O
decrease O O
in O O
the O O
levels O O
of O O
RXRalpha B B_GENE
mRNA I I_GENE
was O O
found O O
to O O
be O O
regulated O O
at O O
the O O
post-transcriptional O O
level O O
and O O
involved O O
new O O
protein O O
synthesis O O
. O O

These O O
observations O O
indicate O O
that O O
the O O
levels O O
of O O
RXRalpha B B_GENE/B_LOCATION
expression O O
in O O
T O O
lymphocytes O O
are O O
coupled O O
to O O
cell O O
cycle O O
progression O O
, O O
and O O
there O O
is O O
tight O O
regulatory O O
control O O
of O O
RXRalpha B B_GENE/B_BIO
expression O O
during O O
the O O
transition O O
from O O
G0/G1 O O
to O O
S O O
phase O O
of O O
the O O
cell O O
cycle O O
. O O

Epidemiology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pathogenesis O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
AIDS-related O B_DISEASE
lymphomas O I_DISEASE
. O O

Among O O
patients O B_PERSON/B_BIO
with O O
congenital O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O O
acquired O O
immunodeficiencies O B_DISEASE
, O O
non-Hodgkin O B_DISEASE
's O I_DISEASE
lymphoma O I_DISEASE
( O O
NHLs O B_DISEASE
) O O
are O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
tumors O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
the O O
immune O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
setting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
human O B_DISEASE
immunodeficiency O I_DISEASE
virus O I_DISEASE
( O O
HIV O B_DISEASE/B_VIRUS[BIO]
) O O
infection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
as O O
many O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
10 O B_NUMBER[MEASURE]
% O I_NUMBER[MEASURE]
to O O
20 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
people O B_PERSON
ultimately O O
developed O O
NHLs O B_DISEASE
. O O

These O O
tumors O B_DISEASE/B_PERSON
are O O
clinically O O
aggressive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
frequently O O
involve O O
extranodal O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sites O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
and O O
often O O
exhibit O O
unique O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
distinguish O O
them O O
from O O
NHL O B_DISEASE/B_ORGANIZATION
arising O O
in O O
individuals O B_PERSON/B_ORGANIZATION
with O O
other O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
forms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
immunosuppression O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Important O O
in O O
the O O
development O O
of O O
HIV-associated O O
NHL O O
are O O
cytokines B B_DISEASE
and O O
other O O
factors O O
that O O
induce O O
B-cell O O
proliferation O O
and O O
increase O O
the O O
likelihood O O
of O O
mutations O O
of O O
c-myc B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
bcl-6 B B_GENE
, O O
and O O
other O O
tumor-suppressor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
carcinogenic O O
potential O O
. O O

Specific O O
forms O O
of O O
HIV-associated O O
NHL O O
are O O
linked O O
to O O
expression O O
of O O
Epstein-Barr B B_DISEASE/B_VIRUS[BIO]
virus I B_DISEASE/I_VIRUS[BIO]
( I B_DISEASE/I_VIRUS[BIO]
EBV I B_DISEASE/I_VIRUS[BIO]
) I B_DISEASE/I_VIRUS[BIO]
-latent I B_DISEASE/I_VIRUS[BIO]
proteins I B_DISEASE/I_VIRUS[BIO]
; O O
the O O
newly O O
described O O
DNA O O
virus O O
, O O
Karposi O O
's O O
sarcoma-associated O O
herpesvirus/human O O
herpesvirus-8 O O
( O O
KSHV/HHV-8 O O
) O O
; O O
and O O
perhaps O O
HIV O O
. O O

Elucidation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
contribute O O
to O O
the O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
incidence O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
NHL O B_DISEASE
among O O
patients O B_PERSON/B_BIO
infected O O
with O O
HIV O B_DISEASE/B_VIRUS[BIO]
provides O O
insights O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
important O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
elements O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
lymphomagenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Matrix B B_GENE/B_PERSON
metalloproteinase I I_GENE/I_PERSON
expression O O
in O O
human O O
breast O O
cancer O O
: O O
an O O
immunohistochemical O O
study O O
including O O
correlation O O
with O O
cathepsin B B_GENE
D I I_GENE
, O O
type B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
collagen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
laminin B B_GENE
, O O
fibronectin B B_GENE
, O O
EGFR B B_GENE
, O O
c-erbB-2 B B_GENE/B_LOCATION
oncoprotein I I_GENE/I_LOCATION
, O O
p53 B B_GENE
, O O
steroid O O
receptors O O
status O O
and O O
proliferative O O
indices O O
. O O

Matrix B B_GENE/B_PERSON
metalloproteinase I I_GENE/I_PERSON
s O O
( O O
MMPs B B_GENE/B_BACTERIUM[BIO]
) O O
are O O
a O O
group O O
of O O
enzymes O O
thought O O
to O O
be O O
responsible O O
for O O
both O O
normal O O
connective O O
tissue O O
matrix O O
remodelling O O
and O O
accelerated O O
breakdown O O
associated O O
with O O
tumour O O
development O O
. O O

The O O
current O O
study O O
aimed O O
to O O
investigate O O
the O O
immunohistochemical O O
expression O O
of O O
matrix B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
metalloproteinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MMP-3 B B_GENE/B_LOCATION
, O O
stromelysin-1 B B_GENE/B_MEASURE
) O O
in O O
correlation O O
with O O
the O O
expression O O
of O O
Basement B B_GENE
Membrane I I_GENE
( I I_GENE
BM I I_GENE
) I I_GENE
antigen I I_GENE
( O O
type B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
collagen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
laminin B B_GENE
) O O
, O O
fibronectin B B_GENE
, O O
cathepsin B B_GENE
D I I_GENE
, O O
p53 B B_GENE
, O O
c-erbB-2 B B_GENE
, O O
proliferative O O
activity O O
( O O
Ki-67 B B_GENE/B_LOCATION
, O O
PCNA B B_GENE/B_MEASURE
) O O
, O O
steroid O O
receptor O O
content O O
as O O
well O O
as O O
to O O
the O O
other O O
conventional O O
clinicopathological O O
parameters O O
in O O
breast O O
cancer O O
. O O

This O O
study O O
was O O
performed O O
on O O
a O O
series O O
of O O
frozen O O
and O O
paraffin O O
sections O O
from O O
84 O O
breast O O
cancer O O
specimens O O
by O O
immunohistochemistry O O
using O O
the O O
monoclonal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibody I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MMP-3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Ab-1 B B_GENE/B_MEASURE
) O O
. O O

Stromelysin-1 B B_GENE/B_DISEASE
( O O
ST1 B B_GENE/B_DISEASE
) O O
was O O
observed O O
in O O
about O O
10 O O
% O O
of O O
epithelial O O
cells O O
in O O
the O O
control O O
groups O O
( O O
cases O O
of O O
fibrocystic O O
and O O
benign O O
proliferative O O
breast O O
disease O O
) O O
, O O
while O O
expression O O
( O O
> O O
10 O O
% O O
of O O
expression O O
) O O
was O O
detected O O
in O O
89.7 O O
% O O
of O O
tumours O O
. O O

The O O
expression O O
of O O
ST1 B B_GENE
in O O
carcinoma O O
cells O O
was O O
strongly O O
associated O O
with O O
its O O
presence O O
in O O
the O O
stroma O O
( O O
p O O
< O O
0.001 O O
) O O
. O O

A O O
significantly O O
positive O O
correlation O O
was O O
found O O
between O O
ST1 B B_GENE
expression O O
, O O
and O O
p53 B B_GENE/B_PERSON
tumour O O
suppressor O O
gene O O
product O O
( O O
p O O
= O O
0.004 O O
) O O
, O O
and O O
a O O
relationship O O
with O O
c-erbB-2 B B_GENE
protein O O
and O O
progesterone O O
receptor O O
status O O
was O O
also O O
indicated O O
. O O

These O O
findings O O
suggest O O
that O O
ST1 B B_GENE
expression O O
in O O
breast O O
cancer O O
tissue O O
is O O
irrespective O O
of O O
the O O
expression O O
of O O
the O O
extracellular O O
matrix O O
component O O
, O O
the O O
proteolytic B B_ENZYME[GENE]/B_MEASURE
enzyme I B_ENZYME[GENE]/I_MEASURE
cathepsin B B_ENZYME[GENE]/I_MEASURE
D I B_ENZYME[GENE]/I_MEASURE
and O O
the O O
growth O O
fraction O O
of O O
the O O
tumour O O
, O O
and O O
that O O
it O O
could O O
be O O
a O O
potential O O
new O O
prognostic O O
marker O O
in O O
breast O O
cancer O O
. O O

Use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
transfected O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
liver O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
cells O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
to O O
evaluate O O
potential O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
alcohol-induced O B_DISEASE_ADJECTIVE[DISEASE]
liver O I_DISEASE_ADJECTIVE[DISEASE]
injury O I_DISEASE_ADJECTIVE[DISEASE]
[ O O
see O O
comments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O O

There O O
is O O
increased O O
activity O O
of O O
the O O
proinflammatory B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
alcoholic O O
liver O O
disease O O
( O O
ALD O O
) O O
. O O

Hepatic O B_DISEASE
neutrophil O I_DISEASE
infiltration O I_DISEASE
is O O
a O O
principal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injurious O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manifestation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ALD O B_DISEASE
. O O

TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O O
induce O O
cellular O O
oxidative O O
injury O O
directly O O
, O O
and O O
indirectly O O
by O O
inducing O O
neutrophil O O
chemotactic O O
factor O O
( O O
IL-8 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
production O O
by O O
hepatocytes O O
. O O

IL-8 B B_DISEASE/B_GENE
activates O O
and O O
chemotactically O O
attracts O O
neutrophils O O
to O O
the O O
liver O O
where O O
they O O
release O O
oxidizing O O
substances O O
. O O

Patients O O
with O O
ALD O O
also O O
have O O
decreased O O
protective B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
cellular O O
oxidative O O
injury O O
. O O

Manganous B B_ENZYME[GENE]
superoxide I I_ENZYME[GENE]
dismutase I I_ENZYME[GENE]
( O O
MnSOD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
is O O
an O O
antioxidant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
protective I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
. O O

The O O
objectives O O
of O O
these O O
studies O O
were O O
to O O
investigate O O
mechanisms O O
for O O
induction O O
of O O
an O O
injurious B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-8 B B_GENE/B_LOCATION
) O O
and O O
a O O
protective B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
( O O
MnSOD B B_GENE/B_LOCATION
) O O
in O O
the O O
HepG2 O O
human O O
hepatoma O O
cell O O
line O O
. O O

In O O
the O O
first O O
set O O
of O O
experiments O O
, O O
IL-8 B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
constructs I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
were O O
used O O
to O O
transiently O O
transfect O O
a O O
derivative O O
( O O
MVh2E1-9 O O
) O O
of O O
the O O
HepG2 O O
cell O O
line O O
which O O
expresses O O
P-4502E1 B B_GENE/B_DISEASE
and O O
metabolizes O O
ethanol O O
. O O

Inactivation O O
of O O
the O O
NF-kappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3'NF-IL-6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
decreased O O
IL-8 B B_GENE/B_PERSON
gene I I_GENE/I_PERSON
transcriptional O O
activation O O
in O O
response O O
to O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
while O O
inactivation O O
of O O
the O O
5'NF-IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
increased O O
IL-8 B B_GENE/B_BIO
gene I I_GENE/I_BIO
transcriptional O O
activity O O
in O O
response O O
to O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

This O O
system O O
may O O
be O O
useful O O
to O O
assess O O
the O O
effects O O
of O O
ethanol O O
on O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
hepatocyte O O
IL-8 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O O
. O O

In O O
the O O
second O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
set O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
HepG2 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
cultured O O
in O O
25 O B_MEASURE
to O O
100 O B_MEASURE
mmol O I_MEASURE
concentrations O I_MEASURE
of O O
ethanol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Both O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ethanol O O
increased O O
HepG2 O O
cell O O
MnSOD B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
in O O
short-term O O
( O O
72 O O
hr O O
) O O
cultures O O
with O O
ethanol O O
. O O

However O O
, O O
after O O
long-term O O
( O O
10 O O
weeks O O
) O O
culture O O
with O O
ethanol O O
, O O
there O O
was O O
no O O
induction O O
of O O
MnSOD B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
ethanol O O
and O O
there O O
was O O
a O O
diminished O O
induction O O
of O O
MnSOD B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
response O O
to O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Further O O
studies O O
are O O
needed O O
to O O
assess O O
the O O
effect O O
of O O
this O O
diminished O O
induction O O
of O O
MnSOD B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
chronic O O
ethanol O O
culture O O
on O O
HepG2 O O
cell O O
susceptibility O O
to O O
TNF O O
cytotoxicity O O
. O O

We O O
conclude O O
that O O
transfected O O
liver O O
cell O O
lines O O
can O O
be O O
used O O
to O O
evaluate O O
mechanisms O O
for O O
increased O O
injurious B B_DISEASE/B_GENE
factors I I_DISEASE/I_GENE
and O O
decreased O O
protective B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
alcoholic O O
liver O O
injury O O
. O O

Tissue O O
factor O O
transcription O O
driven O O
by O O
Egr-1 B B_GENE
is O O
a O O
critical O O
mechanism O O
of O O
murine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pulmonary I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibrin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
deposition O O
in O O
hypoxia O O
. O O

Local O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hypoxemia O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
stasis O B_DISEASE
trigger O I_DISEASE
thrombosis O I_DISEASE
. O O

We O O
have O O
demonstrated O O
previously O O
that O O
in O O
a O O
murine O O
model O O
of O O
normobaric O O
hypoxia O O
pulmonary O O
fibrin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
deposition O O
is O O
a O O
result O O
of O O
expression O O
of O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
especially O O
in O O
oxygen-deprived B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mononuclear I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
phagocytes I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MPs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

We O O
now O O
show O O
that O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
early-growth-response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
product I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Egr-1 B B_GENE/B_DISEASE
) O O
is O O
rapidly O O
activated O O
in O O
hypoxia O O
, O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
, O O
and O O
is O O
responsible O O
for O O
transcription O O
and O O
expression O O
of O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
hypoxic O O
lung O O
. O O

MPs B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
HeLa O O
cells O O
subjected O O
to O O
hypoxia O O
( O O
pO2 O O
approximately O O
13 O O
torr O O
) O O
had O O
increased O O
levels O O
of O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
approximately O O
18-fold O O
) O O
and O O
an O O
increased O O
rate O O
of O O
transcription O O
( O O
approximately O O
15-fold O O
) O O
, O O
based O O
on O O
nuclear O O
run-on O O
analysis O O
. O O

Gel-shift O O
analysis O O
of O O
nuclear O O
extracts O O
from O O
hypoxic B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MPs I B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
HeLa O O
cells O O
demonstrated O O
increased O O
DNA-binding O O
activity O O
at O O
the O O
serum B B_LOCATION
response I I_LOCATION
region I I_LOCATION
( O O
SRR O O
; O O
-111/+14 O O
bp O O
) O O
of O O
the O O
tissue B B_GENE
factor I I_GENE
promoter I I_GENE
at O O
Egr-1 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
motifs I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Using O O
32P-labeled O O
Egr O O
consensus O O
oligonucleotide O O
, O O
we O O
observed O O
induction O O
of O O
DNA-binding O O
activity O O
in O O
nuclear O O
extracts O O
from O O
hypoxic O O
lung O O
and O O
HeLa O O
cells O O
because O O
of O O
activation O O
of O O
Egr-1 B B_GENE
, O O
by O O
means O O
of O O
supershift O O
analysis O O
. O O

Transient O O
transfection O O
of O O
HeLa O O
cells O O
with O O
chimeric B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plasmids I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
wild-type B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SRR I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
tissue B B_GENE/B_BIO
factor I I_GENE/I_BIO
promoter I I_GENE/I_BIO
showed O O
that O O
intact B B_GENE/B_MEASURE
Sp1 I I_GENE/I_MEASURE
sites I I_GENE/I_MEASURE
are O O
necessary O O
for O O
basal O O
promoter O O
activity O O
, O O
whereas O O
the O O
integrity O O
of O O
Egr-1 B B_GENE/B_MEASURE
sites I I_GENE/I_MEASURE
was O O
required O O
for O O
hypoxia-enhanced O O
expression O O
. O O

A O O
central O O
role O O
for O O
Egr-1 B B_GENE
in O O
hypoxia-mediated O O
tissue O O
factor O O
expression O O
was O O
confirmed O O
by O O
experiments O O
with O O
homozygous O O
Egr-1 B B_GENE/B_DISEASE
null O O
mice O O
; O O
wild-type O O
mice O O
subjected O O
to O O
oxygen B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
deprivation I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
expressed I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tissue I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
factor I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
showed O O
fibrin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
deposition O O
, O O
but O O
hypoxic O O
homozygous O O
Egr-1 B B_GENE/B_DISEASE
null O O
mice O O
displayed O O
neither O O
tissue B B_DISEASE/B_GENE
factor I B_DISEASE/I_GENE
nor O O
fibrin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

These O O
data O O
delineate O O
a O O
novel O O
biology O O
for O O
hypoxia-induced O O
fibrin B B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deposition O O
, O O
in O O
which O O
oxygen O O
deprivation-induced O O
activation O O
of O O
Egr-1 B B_GENE
, O O
resulting O O
in O O
expression O O
of O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
has O O
an O O
unexpected O O
and O O
central O O
role O O
. O O

Kinetics O O
of O O
cytokine O O
and O O
NFAT O O
gene O O
expression O O
in O O
human O O
interleukin-2-dependent O O
T O O
lymphoblasts O O
stimulated O O
via O O
T-cell B B_GENE
receptor I I_GENE
. O O

T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
respond O O
to O O
mitogenic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
antigenic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
proliferation O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
by O O
turning O O
on O O
cytokine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
gene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

Here O O
we O O
have O O
analysed O O
the O O
kinetics O O
and O O
nature O O
of O O
cytokine O O
production O O
in O O
human O O
peripheral O O
blood-derived O O
T O O
lymphoblasts O O
stimulated O O
with O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
Lens B B_GENE/B_SPECIES[BIO]
culinaris I I_GENE/I_SPECIES[BIO]
lectin I I_GENE/I_SPECIES[BIO]
( O O
LCL B B_DISEASE/B_PROTEIN[GENE]
) O O
. O O

T O O
cells O O
were O O
purified O O
from O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMC O O
) O O
and O O
primarily O O
activated O O
with O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
cultured O O
in O O
the O O
presence O O
of O O
interleukin-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IL-2 B B_GENE
) O O
. O O

Anti-CD3-restimulated O O
T O O
cells O O
( O O
mainly O O
CD8+ O O
) O O
produced O O
IL-2 B B_GENE
, O O
interferon-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IFN-gamma B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
tumour B B_GENE
necrosis I I_GENE
factor-alpha I I_GENE
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
low O O
levels O O
of O O
IL-4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-10 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
proteins O O
. O O

No O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
was O O
observed O O
. O O

In O O
LCL-stimulated O B_PERSON/B_BIO
cells O I_PERSON/I_BIO
the O O
cytokine O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
production O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pattern O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
very O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Steady-state O O
mRNA O O
levels O O
of O O
IL-2 B B_GENE
, O O
IL-10 B B_GENE
and O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
peaked O O
at O O
3 O O
hr O O
after O O
anti-CD3 O O
stimulation O O
and O O
declined O O
rapidly O O
thereafter O O
. O O

The O O
kinetics O O
of O O
TNF-alpha B B_GENE
mRNA I I_GENE
expression O O
was O O
faster O O
, O O
being O O
at O O
its O O
peak O O
level O O
1 O O
hr O O
after O O
stimulation O O
. O O

Anti-CD3-stimulated O O
IL-2 B B_GENE
gene I I_GENE
expression O O
was O O
down-regulated O O
by O O
protein O O
synthesis O O
inhibitor O O
, O O
whereas O O
IL-10 B B_GENE/B_PERSON
, I I_GENE/I_PERSON
IFN-gamma I I_GENE/I_PERSON
and I I_GENE/I_PERSON
TNF-alpha I I_GENE/I_PERSON
genes I I_GENE/I_PERSON
were O O
readily O O
induced O O
independent O O
of O O
ongoing O O
protein O O
synthesis O O
. O O

T-cell B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O O
also O O
induced O O
a O O
very O O
rapid O O
expression O O
of O O
c-jun B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-fos I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NFATc1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NFATc I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
gene O O
products O O
of O O
which O O
are O O
involved O O
in O O
cytokine O O
gene O O
expression O O
. O O

In O O
conclusion O O
, O O
the O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesized O O
by O O
IL-2-dependent O O
T O O
cells O O
were O O
predominantly O O
IL-2 B B_GENE
, O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

An O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O O
study O O
local O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
oxidation O I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
LDL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
its O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
arterial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wall O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Oxidized O B_LOCATION/B_ORGANIZATION
LDL O I_LOCATION/I_ORGANIZATION
( O O
oxLDL O B_GENE
) O O
is O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
atherosclerotic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lesions O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
is O O
believed O O
to O O
play O O
a O O
key O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
atherogenesis O B_DISEASE
. O O

Mainly O O
on O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
culture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
oxLDL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
has O O
been O O
shown O O
to O O
produce O O
many O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
biological O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
influence O O
the O O
atherosclerotic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
process O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

To O O
study O O
LDL O B_DISEASE/B_GENE
oxidation O I_DISEASE/I_GENE
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O O
we O O
have O O
established O O
a O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
which O O
Sprague-Dawley O B_SPECIES[BIO]/B_PERSON
rats O I_SPECIES[BIO]/I_PERSON
are O O
given O O
a O O
single O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
unmodified O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LDL O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
> O B_MEASURE/B_OTHER
or O O
= O O
4 O B_MEASURE
mg/kg O O
body O B_MEASURE
weight O I_MEASURE
) O O
. O O

Within O O
6 O O
hours O O
, O O
an O O
accumulation O O
of O O
apolipoprotein O O
B O O
and O O
epitopes B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
present O O
on O O
oxLDL O O
are O O
detected O O
in O O
the O O
arterial O O
endothelium O O
and O O
media O O
. O O

The O O
presence O O
of O O
oxLDL O O
is O O
associated O O
with O O
activation O O
of O O
the O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
nuclear B I_GENE/I_LOCATION
factor-kappaB I I_GENE/I_LOCATION
in O O
the O O
endothelium O O
as O O
well O O
as O O
endothelial O O
expression O O
of O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
. O O

Injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
LDL O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
enriched O O
with O O
the O O
antioxidant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probucol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
arterial O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
accumulation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
apolipoprotein O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
the O O
expression O B_GENE/B_MEASURE
of O O
oxLDL-specific O B_GENE
epitopes O I_GENE
was O O
reduced O O
at O O
24 O B_TIME[MEASURE]/B_SPORT[ENT]
hours O I_TIME[MEASURE]/I_SPORT[ENT]
. O O

Thus O O
, O O
this O O
simple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
has O O
the O O
potential O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
analyze O O
the O O
mechanisms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behind O O
and O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
LDL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Molecular O O
mechanisms O O
of O O
promoter O O
regulation O O
of O O
the O O
gp34 B B_GENE
gene I I_GENE
that O O
is O O
trans-activated O O
by O O
an O O
oncoprotein B B_GENE/B_DISEASE
Tax I I_GENE/I_DISEASE
of O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
I O O
. O O

We O O
investigated O O
the O O
molecular O O
mechanism O O
of O O
transcriptional O O
activation O O
of O O
the O O
gp34 B B_GENE
gene I I_GENE
by O O
the O O
Tax B B_GENE
oncoprotein I I_GENE
of O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV-I O O
) O O
. O O

gp34 B B_GENE
is O O
a O O
type B B_GENE
II I I_GENE
transmembrane I I_GENE
molecule I I_GENE
belonging O O
to O O
the O O
tumor O O
necrosis O O
factor O O
family O O
and O O
is O O
constitutively O O
expressed O O
on O O
HTLV-I-producing O O
cells O O
but O O
not O O
normal O O
resting O O
T O O
cells O O
. O O

The O O
transcriptional O O
regulatory O O
region O O
of O O
the O O
gp34 B B_GENE
gene I I_GENE
was O O
activated O O
by O O
HTLV-I O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
human O O
T O O
cell O O
line O O
Jurkat O O
, O O
in O O
which O O
endogenous O O
gp34 B B_GENE
is O O
induced O O
by O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Sequence O O
analysis O O
demonstrated O O
that O O
two O O
NF-kappaB-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
1 O O
and O O
2 O O
) O O
were O O
present O O
in O O
the O O
regulatory B B_LOCATION/B_BIO
region I B_LOCATION/I_BIO
. O O

Both O O
NF-kappaB-like B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elements I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
able O O
to O O
bind O O
to O O
NF-kappaB B B_GENE/B_DISEASE
or O O
its O O
related O O
factor O O
( O O
s O O
) O O
in O O
a O O
Tax B B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O O
manner O O
. O O

Chloramphenicol B B_GENE
acetyltransferase I I_GENE
assays O O
indicated O O
that O O
NF-kappaB-like B B_GENE
element I I_GENE
1 I I_GENE
was O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
-responsive O O
, O O
although O O
the O O
activity O O
was O O
lower O O
than O O
that O O
the O O
native B B_GENE/B_MEASURE
promoter I I_GENE/I_MEASURE
. O O

NF-kappaB B B_GENE/B_LOCATION
-like O O
element O O
2 O O
elevated O O
promoter O O
activity O O
when O O
combined O O
with O O
NF-kappaB-like B B_GENE
element I I_GENE
1 I I_GENE
, O O
indicating O O
cooperative O O
function O O
of O O
the O O
elements O O
for O O
maximum O O
promoter O O
function O O
. O O

Unlike O O
typical O O
NF-kappaB B B_GENE/B_BIO
elements I I_GENE/I_BIO
, O O
the O O
NF-kappaB-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
gp34 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
not O O
activated O O
by O O
treatment O O
of O O
Jurkat O O
cells O O
with O O
phorbol O O
ester O O
despite O O
induction O O
of O O
the O O
NF-kappaB B B_GENE
-like O O
binding O O
activity O O
. O O

Chloramphenicol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acetyltransferase I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter O O
assays O O
using O O
the O O
region O O
upstream O O
of O O
the O O
NF-kappaB-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
identified O O
an O O
upstream O O
region O O
that O O
reduced O O
transcription O O
from O O
cognate B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
noncognate I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
core I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
promoters I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
a O O
Tax-independent O O
manner O O
. O O

Our O O
results O O
imply O O
complex O O
regulation O O
of O O
expression O O
of O O
the O O
gp34 B B_GENE
gene I I_GENE
and O O
suggest O O
implication O O
of O O
gp34 B B_GENE
in O O
proliferation O O
of O O
HTLV-I O O
infected O O
T O O
cells O O
. O O

beta-Amyloid B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
fibrils I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
activate O O
parallel O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways O O
in O O
microglia O O
and O O
THP1 O O
monocytes O O
. O O

The O O
senile O O
plaques O O
of O O
Alzheimer O O
's O O
disease O O
are O O
foci O O
of O O
local O O
inflammatory O O
responses O O
, O O
as O O
evidenced O O
by O O
the O O
presence O O
of O O
acute B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phase I B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
proteins I B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
oxidative O O
damage O O
. O O

Fibrillar B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
forms I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
beta-amyloid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Abeta B B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
which O O
are O O
the O O
primary O O
constituents O O
of O O
senile O O
plaques O O
, O O
have O O
been O O
shown O O
to O O
activate O O
tyrosine O O
kinase-dependent O O
signal O O
transduction O O
cascades O O
, O O
resulting O O
in O O
inflammatory O O
responses O O
in O O
microglia O O
. O O

However O O
, O O
the O O
downstream O O
signaling O O
pathways O O
mediating O O
Abeta B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
inflammatory O O
events O O
are O O
not O O
well O O
characterized O O
. O O

We O O
report O O
that O O
exposure O O
of O O
primary O O
rat O O
microglia O O
and O O
human O O
THP1 O O
monocytes O O
to O O
fibrillar B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Abeta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
results O O
in O O
the O O
tyrosine B B_GENE
kinase I I_GENE
-dependent O O
activation O O
of O O
two O O
parallel O O
signal O O
transduction O O
cascades O O
involving O O
members O O
of O O
the O O
mitogen-activated B B_GENE/B_PERSON
protein I I_GENE/I_PERSON
kinase I I_GENE/I_PERSON
( I I_GENE/I_PERSON
MAPK I I_GENE/I_PERSON
) I I_GENE/I_PERSON
superfamily I I_GENE/I_PERSON
. O O

Abeta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O O
the O O
rapid O O
, O O
transient O O
activation O O
of O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ERK1 B B_GENE
) O O
and O O
ERK2 B B_GENE
in O O
microglia O O
and O O
ERK2 B B_GENE
in O O
THP1 O O
monocytes O O
. O O

A O O
second O O
superfamily B B_GENE/B_PERSON
member I I_GENE/I_PERSON
, O O
p38 B B_GENE
MAPK I I_GENE
, O O
was O O
also O O
activated O O
with O O
similar O O
kinetics O O
. O O

Scavenger B B_GENE
receptor I I_GENE
and O O
receptor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
for I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
advanced I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
end I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
RAGE B B_GENE/B_DISEASE
) O O
ligands O O
failed O O
to O O
activate O O
ERK B B_GENE
and O O
p38 B B_GENE
MAPK I I_GENE
in O O
the O O
absence O O
of O O
significant O O
increases O O
in O O
protein O O
tyrosine O O
phosphorylation O O
, O O
demonstrating O O
that O O
scavenger B B_GENE
receptors I I_GENE
and O O
RAGE B B_GENE
are O O
not O O
linked O O
to O O
these O O
pathways O O
. O O

Importantly O O
, O O
the O O
stress-activated B B_GENE/B_BIO
protein I I_GENE/I_BIO
kinases I I_GENE/I_BIO
( O O
SAPKs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
not O O
significantly O O
activated O O
in O O
response O O
to O O
Abeta B B_DISEASE/B_GENE
. O O

Downstream O O
effectors O O
of O O
the O O
MAPK O O
signal O O
transduction O O
cascades O O
include O O
MAPKAP B B_ENZYME[GENE]/B_BIO
kinases I I_ENZYME[GENE]/I_BIO
, O O
such O O
as O O
RSK1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
RSK2 B B_GENE
, O O
as O O
well O O
as O O
transcription B B_GENE
factors I I_GENE
. O O

Exposure O O
of O O
microglia O O
and O O
THP1 O O
monocytes O O
to O O
Abeta B B_GENE
resulted O O
in O O
the O O
activation O O
of O O
RSK1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
RSK2 B B_GENE
and O O
phosphorylation O O
of O O
cAMP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
at O O
Ser133 O O
, O O
providing O O
a O O
mechanism O O
for O O
Abeta B B_GENE/B_DISEASE
-induced O O
changes O O
in O O
gene O O
expression O O

Regulation O O
of O O
cellular B B_GENE/B_DISEASE
retinoic I I_GENE/I_DISEASE
acid I I_GENE/I_DISEASE
binding I I_GENE/I_DISEASE
protein I I_GENE/I_DISEASE
( O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
during O O
human O O
monocyte O O
differentiation O O
in O O
vitro O O
. O O

Cellular B B_GENE/B_PERSON
retinoic I I_GENE/I_PERSON
acid I I_GENE/I_PERSON
binding I I_GENE/I_PERSON
proteins I I_GENE/I_PERSON
( O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
are O O
low B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecular I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
weight I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
whose O O
precise O O
function O O
remains O O
unknown O O
. O O

They O O
bind O O
retinoids O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
may O O
thereby O O
modulate O O
the O O
intracellular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steady-state O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
retinoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Whereas O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
ubiquitously O O
expressed O O
, O O
CRABP B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
II I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
mainly O O
detected O O
in O O
various O O
cell O O
types O O
of O O
the O O
skin O O
. O O

By O O
representative O O
difference O O
analysis O O
we O O
found O O
that O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
also O O
strongly O O
expressed O O
in O O
human O O
monocyte-derived O O
macrophages O O
( O O
MAC O O
) O O
but O O
not O O
in O O
freshly O O
isolated O O
monocytes O O
( O O
MO O O
) O O
. O O

The O O
CRABP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
gradually O O
upregulated O O
during O O
differentiation O O
from O O
MO O O
to O O
MAC O O
in O O
the O O
presence O O
of O O
2 O O
% O O
serum O O
. O O

Adherence O O
, O O
which O O
is O O
important O O
for O O
MO O O
differentiation O O
, O O
induced O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
, O O
but O O
the O O
addition O O
of O O
10 O O
( O O
-7 O O
) O O
M O O
retinoic O O
acid O O
inhibited O O
the O O
upregulation O O
of O O
CRABP B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
II I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
expression O O
during O O
MO/MAC O O
differentiation O O
. O O

As O O
MO O O
can O O
differentiate O O
along O O
the O O
classical O O
pathway O O
not O O
only O O
to O O
MAC O O
but O O
also O O
to O O
dendritic O O
cells O O
we O O
analyzed O O
the O O
expression O O
of O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
MO-derived O O
dendritic O O
cells O O
cultured O O
with O O
10 O O
% O O
FCS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
IL-4 B B_GENE/B_LOCATION
, O O
and O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
contrast O O
to O O
MAC O O
, O O
MO-derived O O
dendritic O O
cells O O
showed O O
an O O
extremely O O
low O O
expression O O
of O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

From O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
conclude O O
( O O
1 O B_SEQUENCE[MEASURE]
) O O
that O O
the O O
availability O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O O
the O O
metabolism O B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
retinoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
MAC O B_DISEASE/B_PROTEIN[GENE]
compared O O
to O O
MO O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O O
dendritic O B_LOCATION/B_PERSON
cells O I_LOCATION/I_PERSON
and O O
( O O
2 O B_SEQUENCE[MEASURE]
) O O
that O O
this O O
may O O
influence O O
differentiation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
activation O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
those O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O O

Transcription B B_GENE
factor I I_GENE
B-cell-specific I I_GENE
activator I I_GENE
protein I I_GENE
( O O
BSAP B B_LOCATION/B_ORGANIZATION
) O O
is O O
differentially O O
expressed O O
in O O
B O O
cells O O
and O O
in O O
subsets O O
of O O
B-cell O O
lymphomas O O
. O O

The O O
paired B B_GENE
box I I_GENE
containing I I_GENE
gene I I_GENE
PAX-5 B I_GENE
encodes O O
the O O
transcription B B_GENE/B_DISEASE
factor I I_GENE/I_DISEASE
BSAP B I_GENE/I_DISEASE
( O O
B-cell-specific B B_PROTEIN[GENE]/B_DISEASE
activator I I_PROTEIN[GENE]/I_DISEASE
protein I I_PROTEIN[GENE]/I_DISEASE
) O O
, O O
which O O
plays O O
a O O
key O O
role O O
in O O
B-lymphocyte O O
development O O
. O O

Despite O O
its O O
known O O
involvement O O
in O O
a O O
rare O O
subtype O O
of O O
non-Hodgkin O O
's O O
lymphoma O O
( O O
NHL O O
) O O
, O O
a O O
detailed O O
examination O O
of O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
in O O
NHL O O
has O O
not O O
been O O
previously O O
reported O O
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
we O O
analyzed O O
normal O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
malignant O B_DISEASE/B_PERSON
lymphoid O I_DISEASE/I_PERSON
tissues O I_DISEASE/I_PERSON
and O O
cell O B_DISEASE
lines O I_DISEASE
, O O
including O O
102 O B_MEASURE/B_PERSON
cases O B_MEASURE/I_PERSON
of O O
B-cell O B_DISEASE
NHL O I_DISEASE
, O O
23 O B_MEASURE
cases O I_MEASURE
of O O
T- O O
and O O
null-cell O B_DISEASE
NHL O I_DISEASE
, O O
and O O
18 O B_NUMBER[MEASURE]/B_PERSON
cases O I_NUMBER[MEASURE]/I_PERSON
of O O
Hodgkin O B_DISEASE
's O I_DISEASE
disease O I_DISEASE
. O O

Normal O O
lymphoid O O
tissues O O
showed O O
strong O O
nuclear O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
in O O
mantle O O
zone O O
B O O
cells O O
, O O
less O O
intense O O
reactivity O O
in O O
follicular O O
center O O
B O O
cells O O
, O O
and O O
no O O
expression O O
in O O
cells O O
of O O
the O O
T-cell-rich O O
zones O O
. O O

Monocytoid O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
showed O O
weak O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
expression O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
whereas O O
plasma O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
extrafollicular O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
large O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
transformed O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Of O O
the O O
102 O O
B-cell O O
NHLs O O
, O O
83 O O
( O O
81 O O
% O O
) O O
demonstrated O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
. O O

All O O
of O O
the O O
13 O B_MEASURE
( O O
100 O B_MEASURE
% O I_MEASURE
) O O
B-cell O B_DISEASE_ADJECTIVE[DISEASE]
chronic O I_DISEASE_ADJECTIVE[DISEASE]
lymphocytic O I_DISEASE_ADJECTIVE[DISEASE]
leukemias O I_DISEASE_ADJECTIVE[DISEASE]
( O O
B-CLLs O B_DISEASE/B_LOCATION
) O O
, O O
21 O B_MEASURE
of O O
( O O
100 O B_MEASURE
% O I_MEASURE
) O O
mantle O B_DISEASE
cells O I_DISEASE
( O O
MCLs O B_DISEASE/B_PROTEIN[GENE]
) O O
, O O
and O O
20 O B_NUMBER[MEASURE]
of O O
21 O B_NUMBER[MEASURE]
( O O
95 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
follicular O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphomas O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
FLs O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
positive O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Moderate O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
staining O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intensities O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
found O O
in O O
most O B_DISEASE/B_PROTEIN[GENE]
B-CLL O B_DISEASE/I_PROTEIN[GENE]
and O O
FL O B_LOCATION/B_ORGANIZATION
cases O I_LOCATION/I_ORGANIZATION
, O O
whereas O O
most O B_NUMBER[MEASURE]/B_PERSON
MCLs O B_NUMBER[MEASURE]/I_PERSON
showed O O
strong O B_DISEASE_ADJECTIVE[DISEASE]
reactions O I_DISEASE_ADJECTIVE[DISEASE]
, O O
paralleling O O
the O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactivity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nonmalignant O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mantle O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Eight O O
of O O
12 O O
( O O
67 O O
% O O
) O O
marginal O O
zone O O
lymphoma O O
cases O O
showed O O
negative O O
or O O
low O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
, O O
and O O
17 O O
of O O
24 O O
( O O
71 O O
% O O
) O O
large O O
B-cell O O
lymphomas O O
displayed O O
moderate O O
to O O
strong O O
expression O O
. O O

None O O
of O O
the O O
23 O O
T- O O
and O O
null-cell O O
lymphomas O O
reacted O O
with O O
the O O
BSAP B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
antisera O O
, O O
whereas O O
in O O
Hodgkin O O
's O O
disease O O
, O O
2 O O
of O O
4 O O
( O O
50 O O
% O O
) O O
nodular O O
lymphocytic O O
predominance O O
and O O
5 O O
of O O
14 O O
( O O
36 O O
% O O
) O O
classical O O
cases O O
showed O O
weak O O
nuclear O O
or O O
nucleolar O O
BSAP B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions O O
in O O
a O O
fraction O O
of O O
the O O
tumor O O
cells O O
. O O

Western O O
blot O O
analysis O O
showed O O
a O O
52-kD O O
BSAP B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
band O O
in O O
B-cell O O
lines O O
, O O
but O O
not O O
in O O
non-B-cell O O
or O O
plasma O O
cell O O
lines O O
. O O

We O O
conclude O O
that O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
is O O
largely O O
restricted O O
to O O
lymphomas O O
of O O
B-cell O O
lineage O O
and O O
that O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
varies O O
in O O
B-cell O O
subsets O O
and O O
subtypes O O
of O O
B-cell O O
NHL O O
. O O

The O O
high O O
levels O O
of O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
especially O O
those O O
found O O
in O O
large-cell O O
lymphomas O O
and O O
in O O
some O O
follicular O O
lymphomas O O
, O O
may O O
be O O
a O O
consequence O O
of O O
deregulated O O
gene O O
expression O O
and O O
suggest O O
a O O
possible O O
involvement O O
of O O
PAX-5 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
certain O O
B-cell O O
malignancies O O
. O O

This O O
is O O
a O O
US O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
government O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
work O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

There O O
are O O
no O O
restrictions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
its O O
use O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

Mitogen O O
and O O
growth O O
factor-induced O O
activation O O
of O O
a O O
STAT-like B B_GENE/B_LOCATION
molecule I I_GENE/I_LOCATION
in O O
channel O O
catfish O O
lymphoid O O
cells O O
. O O

This O O
article O O
describes O O
the O O
identification O O
of O O
a O O
putative B B_GENE
STAT I I_GENE
molecule I I_GENE
in O O
the O O
channel O O
catfish O O
( O O
Ictalurus O O
punctatus O O
) O O
, O O
the O O
first O O
report O O
of O O
such O O
a O O
molecule O O
in O O
a O O
'lower O O
' O O
vertebrate O O
. O O

A O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
human B B_GENE
STAT6 I I_GENE
recognizes O O
an O O
approximately O O
100 B B_PROTEIN[GENE]/B_LOCATION
kDa I I_PROTEIN[GENE]/I_LOCATION
molecule I I_PROTEIN[GENE]/I_LOCATION
that O O
becomes O O
activated O O
and O O
translocates O O
to O O
the O O
nucleus O O
upon O O
both O O
growth O O
factor O O
and O O
mitogen O O
stimulation O O
of O O
catfish O O
leukocytes O O
. O O

This O O
presumed O O
catfish B B_LOCATION
STAT I I_LOCATION
binds O O
the O O
mammalian B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon-gamma I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
known O O
motif O O
of O O
mammalian O O
STAT O O
binding O O
, O O
as O O
shown O O
by O O
electromobility O O
shift O O
assays O O
. O O

Purification O O
of O O
the O O
proteins O O
present O O
in O O
these O O
DNA B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
confirms O O
that O O
the O O
catfish O O
reactive O O
molecule O O
binds O O
to O O
the O O
interferon-gamma B B_GENE
activation I I_GENE
site I I_GENE
sequence I I_GENE
. O O

These O O
results O O
suggest O O
that O O
STAT B B_GENE/B_BIO
molecules I I_GENE/I_BIO
have O O
been O O
highly O O
conserved O O
in O O
vertebrate O O
evolution O O
. O O

Isolation O O
and O O
analysis O O
of O O
a O O
T O O
cell O O
clone O O
variant O O
exhibiting O O
constitutively O O
phosphorylated B B_GENE
Ser133 I I_GENE
cAMP I I_GENE
response I I_GENE
element-binding I I_GENE
protein I I_GENE
. O O

In O O
driving O O
T O O
cell O O
proliferation O O
, O O
IL-2 B B_GENE
stimulates O O
a O O
new O O
program O O
of O O
gene O O
expression O O
that O O
includes O O
proliferating B B_GENE/B_DISEASE
cell I I_GENE/I_DISEASE
nuclear I I_GENE/I_DISEASE
antigen I I_GENE/I_DISEASE
( O O
PCNA B B_GENE
) O O
, O O
a O O
requisite O O
processivity O O
factor O O
for O O
DNA B B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
polymerase I B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
delta I B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

PCNA B B_GENE
transcription O O
is O O
regulated O O
in O O
part O O
through O O
tandem O O
CRE B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
promoter B B_GENE
and I I_GENE
CRE I I_GENE
binding I I_GENE
proteins I I_GENE
; O O
IL-2 B B_GENE
stimulates O O
CREB O O
phosphorylation O O
in O O
the O O
resting O O
cloned O O
T O O
lymphocyte O O
, O O
L2 O O
. O O

After O O
culturing O O
L2 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
greater O B_MEASURE
than O O
91 O B_NUMBER[MEASURE]/B_ENT
days O I_NUMBER[MEASURE]/I_ENT
, O O
we O O
consistently O O
isolate O O
a O O
stable O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variant O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
exhibits O O
constitutive O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
CREB O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
phosphorylation O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

L2 O O
and O O
L2 O O
variant O O
cells O O
were O O
tested O O
for O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
responsiveness O O
and O O
rapamycin O O
sensitivity O O
with O O
respect O O
to O O
specific O O
kinase O O
activity O O
, O O
PCNA O O
expression O O
and O O
proliferation O O
. O O

In O O
L2 O O
cells O O
, O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulated O O
and O O
rapamycin O O
inhibited O O
the O O
following O O
: O O
cAMP-independent O O
CREB B B_GENE/B_LOCATION
kinase I I_GENE/I_LOCATION
activity O O
, O O
PCNA O O
expression O O
and O O
proliferation O O
. O O

In O O
L2 O O
variant O O
cells O O
, O O
CREB B B_GENE
kinase I I_GENE
activity O O
was O O
constitutively O O
high O O
; O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulated O O
and O O
rapamycin O O
blocked O O
PCNA O O
expression O O
and O O
proliferation O O
. O O

These O O
results O O
indicate O O
that O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
a O O
rapamycin-sensitive O O
, O O
cAMP-independent O O
CREB B B_GENE/B_DISEASE
kinase I I_GENE/I_DISEASE
activity O O
in O O
L2 O O
cells O O
. O O

However O O
, O O
phosphorylation O O
of O O
CREB B B_GENE
alone O O
is O O
not O O
sufficient O O
to O O
drive O O
PCNA B B_GENE
expression O O
and O O
L2 O O
cell O O
proliferation O O
in O O
the O O
absence O O
of O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Serotonin O O
derivative O O
, O O
N- O O
( O O
p-coumaroyl O O
) O O
serotonin O O
, O O
inhibits O O
the O O
production O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
IL-1alpha B B_GENE
, O O
IL-1beta B B_GENE
, O O
and O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
by O O
endotoxin-stimulated O O
human O O
blood O O
monocytes O O
. O O

We O O
have O O
reported O O
that O O
N- O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p-coumaroyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
serotonin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CS O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
its O O
derivatives O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
antioxidative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
safflower O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
seeds O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

As O O
reactive O O
oxygen O O
species O O
( O O
ROS O O
) O O
are O O
implicated O O
in O O
the O O
signaling O O
of O O
lipopolysaccharide O O
( O O
LPS O O
) O O
, O O
we O O
examined O O
whether O O
CS O O
has O O
a O O
suppressive O O
effect O O
on O O
inflammatory B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytokine I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generation O O
from O O
human O O
monocyte O O
s O O
in O O
vitro O O
. O O

CS O O
at O O
50-200 O O
microM O O
reduced O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
necrosis I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factor I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
TNF B B_GENE/B_LOCATION
) O O
, O O
interleukin-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-1 B B_GENE
) O O
, O O
and O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activities O O
in O O
the O O
culture O O
supernatants O O
from O O
LPS-stimulated O O
human O O
blood O O
monocytes O O
without O O
cytotoxicity O O
. O O

ELISA O O
assay O O
revealed O O
that O O
the O O
production O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
IL-1alpha B B_GENE
, O O
IL-1beta B B_GENE
, O O
and O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
inhibited O O
by O O
CS O O
. O O

Northern O O
blot O O
analysis O O
showed O O
that O O
LPS-induced O O
expression O O
of O O
these O O
cytokine B B_GENE
mRNA I I_GENE
in O O
monocytes O O
was O O
suppressed O O
by O O
CS O O
. O O

NF-kappaB O B_GENE/B_PERSON
activation O I_GENE/I_PERSON
was O O
also O O
inhibited O O
by O O
CS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

These O O
findings O O
indicate O O
that O O
CS O O
has O O
a O O
suppressive O O
effect O O
on O O
proinflammatory O O
cytokine O O
production O O
from O O
monocytes O O
, O O
and O O
this O O
effect O O
is O O
based O O
in O O
part O O
on O O
the O O
suppression O O
of O O
cytokine B B_GENE
mRNA I I_GENE
expression O O
through O O
inhibition O O
of O O
NF-kappaB B B_GENE
activation O O
. O O

Elevated O O
expression O O
of O O
differentiation B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nm23 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
monoblastic O O
crisis O O
of O O
a O O
patient O O
with O O
chronic O O
myelogenous O O
leukemia O O
. O O

Differentiation B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nm23 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
found O O
to O O
be O O
expressed O O
in O O
high O O
quantities O O
in O O
acute O O
myelogenous O O
leukemia O O
( O O
AML O O
) O O
, O O
especially O O
in O O
acute O O
monocytic O O
leukemia O O
( O O
AML-M5 O O
) O O
and O O
is O O
suggested O O
as O O
a O O
new O O
prognostic O O
factor O O
in O O
AML-M5 O O
. O O

We O O
report O O
an O O
example O O
of O O
elevated O O
expression O O
of O O
nm23 B B_GENE
mRNA I I_GENE
in O O
a O O
patient O O
with O O
chronic O O
myelogenous O O
leukemia O O
( O O
CML O O
) O O
who O O
developed O O
monoblastic O O
crisis O O
. O O

Relative O O
levels O O
of O O
nm23-H1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-H2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
extracted O O
from O O
the O O
patient O O
's O O
peripheral O O
blood O O
mononuclear O O
cells O O
and O O
bone O O
marrow O O
mononuclear O O
cells O O
were O O
measured O O
by O O
quantitative O O
reverse O O
transcriptase O O
polymerase O O
chain O O
reaction O O
. O O

The O O
level O O
of O O
nm23-H1 B B_GENE
mRNA I I_GENE
in O O
CML O O
cells O O
at O O
the O O
chronic O O
phase O O
was O O
as O O
high O O
as O O
that O O
in O O
bone O O
marrow O O
cells O O
from O O
healthy O O
volunteers O O
. O O

The O O
mRNA O O
level O O
of O O
nm23-H2 B B_GENE
was O O
slightly O O
below O O
the O O
normal O O
level O O
. O O

At O O
blastic O O
crisis O O
, O O
however O O
, O O
expression O O
of O O
both O O
nm23-H1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-H2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
elevated O O
to O O
about O O
three O O
to O O
nine O O
times O O
of O O
that O O
at O O
the O O
chronic O O
phase O O
. O O

Proliferated O O
blastic O O
cells O O
were O O
positive O O
for O O
non-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
esterase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
the O O
serum O O
lysozyme O O
level O O
was O O
elevated O O
and O O
diagnosed O O
as O O
monoblastic O O
crisis O O
. O O

The O O
patient O B_PERSON/B_ORGANIZATION
received O O
combined O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
but O O
response O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
was O O
partial O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

These O O
findings O O
are O O
compatible O O
with O O
our O O
previous O O
report O O
that O O
nm23 B B_GENE
gene I I_GENE
is O O
overexpressed O O
in O O
monocytic O O
leukemia O O
. O O

Increased O O
transcription O O
decreases O O
the O O
spontaneous O O
mutation O O
rate O O
at O O
the O O
thymidine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
cells O O
. O O

Transcription O B_GENE
increases O I_MEASURE
DNA O I_MEASURE
repair O I_MEASURE
efficiency O I_MEASURE
and O O
modulates O O
the O O
distribution O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
certain O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
types O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
DNA O B_DISEASE/B_GENE
damage O I_DISEASE/I_GENE
. O O

Furthermore O O
, O O
increased O O
transcription O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulates O O
spontaneous O B_MEASURE
mutation O I_MEASURE
rate O I_MEASURE
in O O
yeast O B_BIO/B_DISEASE
. O O

We O O
explored O O
whether O O
transcription O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
affects O O
spontaneous O B_MEASURE
mutation O I_MEASURE
rate O I_MEASURE
in O O
human O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
first O O
developed O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
thymidine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
tk O B_PROTEIN[GENE]/B_DISEASE
) O O
inducible O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
human O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O O
the O O
Gal4-Estrogen O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
system O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
our O O
TK6i-G3 O O
and O O
G9 O O
tk O O
heterozygous O O
cell O O
lines O O
, O O
the O O
active O O
tk B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
allele I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
linked O O
to O O
an O O
inducible O O
promoter B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
. O O

Tk B B_DISEASE/B_ORGANISM_FUNCTION
mRNA I I_DISEASE/I_ORGANISM_FUNCTION
is O O
induced O O
following O O
treatment O O
with O O
estrogen O O
. O O

Spontaneous O B_GENE
mutation O I_GENE
rate O I_GENE
was O O
significantly O O
decreased O O
in O O
human O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
after O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
in O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
report O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
yeast O B_SPECIES[BIO]
. O O

Thus O O
, O O
humans O B_PERSON/B_BIO
may O O
have O O
evolved O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
or O O
additional O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
to O O
deal O O
with O O
transcription O B_GENE/B_DISEASE
related O O
spontaneous O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutagenesis O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Copyright O B_LOCATION/B_ORGANIZATION
1998 O I_LOCATION/I_ORGANIZATION
Elsevier O I_LOCATION/I_ORGANIZATION
Science O I_LOCATION/I_ORGANIZATION
B.V O I_LOCATION/I_ORGANIZATION
. O O

All O O
rights O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reserved O O
. O O

Mutation O O
of O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
normal O O
B O O
cells O O
by O O
the O O
process O O
of O O
somatic O O
hypermutation O O
of O O
Ig B B_GENE
genes I I_GENE
. O O

Immunoglobulin B B_PERSON/B_GENE
( I I_PERSON/I_GENE
Ig I I_PERSON/I_GENE
) I I_PERSON/I_GENE
genes I I_PERSON/I_GENE
are O O
hypermutated O O
in O O
B O O
lymphocytes O O
that O O
are O O
the O O
precursors O O
to O O
memory O O
B O O
cells O O
. O O

The O O
mutations O O
are O O
linked O O
to O O
transcription O O
initiation O O
, O O
but O O
non-Ig B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
promoters I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
permissible O O
for O O
the O O
mutation O O
process O O
; O O
thus O O
, O O
other O O
genes O O
expressed O O
in O O
mutating O O
B O O
cells O O
may O O
also O O
be O O
subject O O
to O O
somatic O O
hypermutation O O
. O O

Significant O O
mutations O O
were O O
not O O
observed O O
in O O
c-MYC B B_DISEASE/B_GENE
, I I_DISEASE/I_GENE
S14 I I_DISEASE/I_GENE
, I I_DISEASE/I_GENE
or I I_DISEASE/I_GENE
alpha-fetoprotein I I_DISEASE/I_GENE
( I I_DISEASE/I_GENE
AFP I I_DISEASE/I_GENE
) I I_DISEASE/I_GENE
genes I I_DISEASE/I_GENE
, O O
but O O
BCL-6 B B_GENE
was O O
highly O O
mutated O O
in O O
a O O
large O O
proportion O O
of O O
memory O O
B O O
cells O O
of O O
normal O O
individuals O O
. O O

The O O
mutation O O
pattern O O
was O O
similar O O
to O O
that O O
of O O
Ig B B_GENE/B_BIO
genes I I_GENE/I_BIO
. O O

CD28-mediated O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
activation O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
CD45RA+ O B_GENE
and O O
CD45RO+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
: O O
enhanced O O
levels O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
reactive O B_GENE/B_BACTERIUM[BIO]
oxygen O I_GENE/I_BACTERIUM[BIO]
intermediates O I_GENE/I_BACTERIUM[BIO]
and O O
c-Rel O B_DISEASE/B_GENE
nuclear O I_DISEASE/I_GENE
translocation O I_DISEASE/I_GENE
in O O
CD45RA+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

We O O
have O O
analyzed O O
the O O
effect O O
of O O
complete O O
T O O
cell O O
activation O O
( O O
anti-CD3 O O
plus O O
anti-CD28 O O
) O O
on O O
the O O
activation O O
of O O
NF-kappaB B B_GENE
in O O
CD45RA+ O O
( O O
naive O O
) O O
and O O
CD45RO+ O O
( O O
memory/effector O O
) O O
T O O
cells O O
. O O

Long O O
exposure O O
( O O
24 O O
h O O
) O O
induced O O
stronger O O
NF-kappaB B B_GENE
DNA O O
binding O O
in O O
CD45RA+ O O
cells O O
than O O
in O O
CD45RO+ O O
cells O O
. O O

Analysis O O
of O O
the O O
nuclear B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
c-Rel I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
after O O
anti-CD3+anti-CD28 O O
stimulation O O
the O O
level O O
of O O
c-Rel B B_GENE
was O O
higher O O
in O O
CD45RA+ O O
cells O O
. O O

Analysis O O
of O O
the O O
cytoplasmic B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
inhibitor I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
IkappaBalpha B I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
indicated O O
that O O
anti-CD3+anti-CD28 O O
stimulation O O
induced O O
a O O
long-lasting O O
degradation O O
in O O
CD45RA+ O O
cells O O
but O O
in O O
CD45RO+ O O
cells O O
the O O
degradation O O
process O O
was O O
more O O
rapid O O
. O O

Because O O
the O O
CD28 B B_GENE
costimulus O O
is O O
known O O
to O O
induce O O
the O O
production O O
of O O
reactive O O
oxygen O O
intermediates O O
( O O
ROIs O O
) O O
, O O
the O O
intracellular O O
ROI O O
levels O O
in O O
CD45RA+ O O
and O O
CD45RO+ O O
cells O O
were O O
compared O O
by O O
flow O O
cytometry O O
. O O

ROIs O B_MEASURE/B_GENE
were O O
produced O O
in O O
both O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
types O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
but O O
more O O
strongly O O
in O O
CD45RA+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
further O O
emphasize O O
the O O
differences O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O O
CD45RA+ O B_GENE
and O O
CD45RO+ O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
ROI-dependent O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O O
pathways O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Non-Hodgkin O B_DISEASE
's O I_DISEASE
lymphoma O I_DISEASE
involving O O
bilateral O B_DISEASE/B_PERSON
breasts O B_DISEASE/I_PERSON
[ O B_DISEASE/I_PERSON
see O O
comments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE

We O O
describe O O
here O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
diffuse O B_DISEASE/B_GENE
large O I_DISEASE/I_GENE
cell O I_DISEASE/I_GENE
type O I_DISEASE/I_GENE
non-Hodgkin O I_DISEASE/I_GENE
's O I_DISEASE/I_GENE
lymphoma O I_DISEASE/I_GENE
affecting O O
the O O
bilateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
breasts O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
contralateral O B_DISEASE
tumor O I_DISEASE
in O O
one O B_PERSON
case O I_PERSON
appeared O O
17 O B_TIME[MEASURE]/B_LOCATION
months O I_TIME[MEASURE]/I_LOCATION
after O O
the O O
first O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
mastectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
whereas O O
the O O
bilateral O B_DISEASE_ADJECTIVE[DISEASE]
tumors O I_DISEASE_ADJECTIVE[DISEASE]
occurred O O
concurrently O O
in O O
the O O
other O B_PERSON
patient O I_PERSON
who O O
was O O
pregnant O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
showed O O
widespread O B_DISEASE
dissemination O I_DISEASE
at O O
initial O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
presentation O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Lymphoma O O
cells O O
from O O
both O O
cases O O
showed O O
the O O
mature O O
B-cell O O
immunophenotype O O
and O O
had O O
rearrangements O O
of O O
the O O
BCL6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Both O O
patients O B_PERSON
developed O O
progressive O B_DISEASE
disease O I_DISEASE
despite O O
chemo-radiotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
died O O
of O O
leukemic O B_DISEASE
manifestations O I_DISEASE
. O O

There O O
were O O
no O O
apparent O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathological O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
lymphomas O B_DISEASE
of O O
mucosa-associated O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
lymphoid O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
tissue O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
origin O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]

Biochemical O O
characterization O O
of O O
MIP-1 B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
alpha I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
nuclear I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

A O O
family O O
of O O
hematopoietic B B_GENE/B_NUMBER[MEASURE]
specific I I_GENE/I_NUMBER[MEASURE]
transcription I I_GENE/I_NUMBER[MEASURE]
factors I I_GENE/I_NUMBER[MEASURE]
, O O
MIP-1 B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
nuclear I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
MNP I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
family I I_GENE/I_LOCATION
, O O
has O O
recently O O
been O O
identified O O
. O O

They O O
are O O
intimately O O
involved O O
in O O
regulating O O
the O O
transcription O O
of O O
the O O
huMIP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
monocytes O O
, O O
T-cells O O
, O O
and O O
transformed O O
B-cells O O
. O O

One O O
member O O
of O O
the O O
family O O
( O O
MNP-1 B B_GENE/B_DISEASE
) O O
is O O
essential O O
for O O
promoter O O
activity O O
in O O
monocytes O O
and O O
B-cells O O
, O O
while O O
another O O
( O O
MNP-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
required O O
for O O
full O O
promotor O O
activity O O
in O O
T-cells O O
. O O

A O O
third O O
member O O
of O O
the O O
family O O
( O O
MNP-3 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
expressed O O
in O O
PMA O O
induced O O
HL60 O O
cells O O
and O O
probably O O
has O O
a O O
role O O
in O O
monocyte O O
differentiation O O
. O O

In O O
this O O
communication O O
we O O
demonstrate O O
by O O
two O O
techniques O O
that O O
MNP-1 B B_GENE
and O O
MNP-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
distinct O O
but O O
related O O
factors O O
, O O
and O O
we O O
present O O
further O O
evidence O O
to O O
show O O
that O O
MNP-1 B B_GENE/B_PERSON
acts O O
as O O
a O O
heterodimer B B_GENE
. O O

Bcl-3 B B_GENE
expression O O
and O O
nuclear O O
translocation O O
are O O
induced O O
by O O
granulocyte-macrophage B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
erythropoietin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
proliferating O O
human O O
erythroid O O
precursors O O
. O O

Bcl-3 B B_GENE
is O O
a O O
proto-oncogene B B_GENE/B_BIO
involved O O
in O O
the O O
chromosomal O O
translocation O O
t B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
14 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
; I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
19 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
found O O
in O O
some O O
patients O O
with O O
chronic O O
lymphocytic O O
leukemia O O
. O O

It O O
shares O O
structural O O
similarities O O
with O O
and O O
is O O
a O O
member O O
of O O
the O O
IkappaB B B_GENE/B_PERSON
family I I_GENE/I_PERSON
of O O
proteins O O
. O O

In O O
this O O
report O O
, O O
involvement O O
of O O
Bcl-3 B B_GENE
in O O
hematopoietic O O
growth O O
factor-stimulated O O
erythroid O O
proliferation O O
and O O
differentiation O O
was O O
examined O O
. O O

In O O
TF-1 O O
cells O O
, O O
an O O
erythroleukemia O O
cell O O
line O O
, O O
granulocyte-macrophage B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GM-CSF B B_GENE/B_LOCATION
) O O
and O O
erythropoietin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Epo B B_GENE/B_LOCATION
) O O
greatly O O
enhanced O O
Bcl-3 B B_GENE
expression O O
at O O
both O O
the O O
protein O O
and O O
mRNA O O
levels O O
in O O
association O O
with O O
stimulation O O
of O O
proliferation O O
. O O

Bcl-3 B B_GENE
protein O O
was O O
also O O
highly O O
expressed O O
in O O
early O O
burst-forming O O
unit-erythroid O O
( O O
BFU-E O O
) O O
-derived O O
erythroid O O
precursors O O
( O O
day O O
7 O O
) O O
and O O
decreased O O
during O O
maturation O O
( O O
days O O
10 O O
and O O
14 O O
) O O
, O O
suggesting O O
that O O
Bcl-3 B B_GENE
is O O
involved O O
in O O
normal O O
erythroid O O
proliferation O O
. O O

In O O
these O O
hematopoietic O O
cells O O
, O O
Bcl-3 B B_GENE
was O O
hyperphosphorylated O O
. O O

GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
Epo B B_GENE
modulated O O
the O O
subcellular O O
localization O O
of O O
Bcl-3 B B_GENE
. O O

Upon O O
stimulation O O
of O O
TF-1 O O
cells O O
with O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
Epo B B_GENE
, O O
the O O
nuclear O O
translocation O O
of O O
Bcl-3 B B_GENE
was O O
dramatically O O
enhanced O O
. O O

Overexpression O O
of O O
Bcl-3 B B_GENE
in O O
TF-1 O O
cells O O
by O O
transient O O
transfection O O
along O O
with O O
the O O
NF-kappaB B B_GENE
factors I I_GENE
p50 I I_GENE
or I I_GENE
p52 I I_GENE
resulted O O
in O O
significant O O
induction O O
of O O
an O O
human B B_GENE
immunodeficiency I I_GENE
virus-type I I_GENE
1 I I_GENE
( I I_GENE
HIV-1 I I_GENE
) I I_GENE
kappaB-TATA-luceriferase I I_GENE
reporter I I_GENE
plasmid I I_GENE
, O O
demonstrating O O
that O O
Bcl-3 B B_GENE
has O O
a O O
positive O O
role O O
in O O
transactivation O O
of O O
kappaB-containing B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
erythroid O O
cells O O
. O O

Stimulation O O
with O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
enhanced O O
c-myb B B_GENE
mRNA I I_GENE
expression O O
in O O
these O O
cells O O
. O O

Bcl-3 B B_GENE
in O O
nuclear O O
extracts O O
of O O
TF-1 O O
cells O O
bound O O
to O O
a O O
kappaB B B_GENE/B_LOCATION
enhancer I B_GENE/I_LOCATION
in O O
the O O
c-myb B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
together O O
with O O
NF-kappaB2/p52 B B_GENE
and O O
this O O
binding O O
activity O O
was O O
enhanced O O
by O O
GM-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stimulation O O
. O O

Furthermore O O
, O O
cotransfection O O
of O O
Bcl-3 B B_GENE
with O O
p52 B B_GENE
or O O
p50 B B_GENE
in O O
TF-1 O O
cells O O
resulted O O
in O O
significant O O
activation O O
of O O
a O O
c-myb B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappaB-TATA-luceriferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
findings O O
suggest O O
that O O
Bcl-3 B B_GENE
may O O
participate O O
in O O
the O O
transcriptional O O
regulation O O
of O O
certain O O
kappaB-containing B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
involved O O
in O O
hematopoiesis O O
, O O
including O O
c-myb B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Copyright O B_LOCATION/B_PERSON
1998 O I_LOCATION/I_PERSON
by O O
The O O
American O B_ORGANIZATION/B_LOCATION
Society O I_ORGANIZATION/I_LOCATION
of O O
Hematology O B_PERSON
. O O

5-Lipoxygenase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
compartmentalization O O
in O O
granulocytic O O
cells O O
is O O
modulated O O
by O O
an O O
internal B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bipartite I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclear I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localizing I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
nuclear B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
factor I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
kappa I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
B I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
complex I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
formation O O
. O O

A O O
region O O
of O O
basic O O
amino O O
acids O O
spanning O O
residues B B_NUMBER[MEASURE]/B_GENE
639-656 I I_NUMBER[MEASURE]/I_GENE
in O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
5-lipoxygenase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resembles O O
a O O
consensus B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bipartite I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclear I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localizing I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
synthetic O O
peptide O O
consisting O O
of O O
the O O
Kaposi B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
fibroblast I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
signal I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
fused O O
to O O
the O O
5-lipoxygenase639-656 B B_GENE
bipartite I I_GENE
nuclear I I_GENE
localizing I I_GENE
sequence I I_GENE
has O O
a O O
prominent O O
inhibitory O O
effect O O
on O O
5-lipoxygenase B B_GENE
catalysis O O
in O O
granulocytic O O
HL-60 O O
cells O O
activated O O
by O O
calcium O O
ionophor O O
A23187 O O
. O O

Recombinant O O
5-lipoxygenase B B_GENE
was O O
not O O
affected O O
by O O
the O O
peptide O O
. O O

The O O
peptide O O
also O O
inhibited O O
redistribution O O
of O O
5-lipoxygenase B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
cytosol O O
to O O
the O O
nuclear O O
membrane O O
of O O
HL-60 O O
cells O O
stimulated O O
by O O
A23187 O O
. O O

5-Lipoxygenase B B_GENE
protein I I_GENE
was O O
detected O O
in O O
nuclear B B_GENE/B_NUMBER[MEASURE]
factor I B_GENE/I_NUMBER[MEASURE]
kappaB I B_GENE/I_NUMBER[MEASURE]
( I B_GENE/I_NUMBER[MEASURE]
NF-kappaB I B_GENE/I_NUMBER[MEASURE]
) I B_GENE/I_NUMBER[MEASURE]
p65 I B_GENE/I_NUMBER[MEASURE]
subunit I B_GENE/I_NUMBER[MEASURE]
immunoprecipitate O O
fractions O O
prepared O O
from O O
HL-60 O O
cell O O
lysates O O
. O O

The O O
amount O O
of O O
5-lipoxygenase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coimmunoprecipitated O O
by O O
NF-kappaB O O
antiserum O O
was O O
increased O O
following O O
A23187 O O
stimulation O O
. O O

In O O
cells O O
treated O O
with O O
agents O O
that O O
block O O
5-lipoxygenase B B_GENE
translocation O O
to O O
the O O
nucleus O O
, O O
5-lipoxygenase B B_GENE
protein O O
appearing O O
in O O
the O O
NF-kappaB B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
immunoprecipitate O O
was O O
diminished O O
. O O

Our O O
results O O
implicate O O
an O O
internal B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
bipartite I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
localizing I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
regulatory O O
domain O O
that O O
modulates O O
5-lipoxygenase B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
redistribution O O
and O O
catalysis O O
in O O
granulocytic O O
cells O O
. O O

Additionally O O
, O O
our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
molecular O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determinants O B_LOCATION/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
govern O O
5-lipoxygenase O B_GENE
and O O
NF-kappaB O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
redistribution O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
the O O
nucleus O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
may O O
be O O
coordinately O O
controlled O O
in O O
granulocytic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Copyright O B_LOCATION/B_PERSON
1998 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Inhibition O O
of O O
CD28/CD3-mediated O O
costimulation O O
of O O
naive O O
and O O
memory O O
human O O
T O O
lymphocytes O O
by O O
intracellular O O
incorporation O O
of O O
polyclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
specific O O
for O O
the O O
activator B B_GENE
protein-1 I I_GENE
transcriptional I I_GENE
complex I I_GENE
. O O

A O O
number O O
of O O
indirect O O
methods O O
have O O
been O O
utilized O O
in O O
demonstrating O O
activator B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein-1 I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O O
factor O O
function O O
in O O
IL-2 O O
promoter O O
activity O O
. O O

However O O
, O O
there O O
has O O
been O O
no O O
direct O O
demonstration O O
that O O
activator B B_GENE
protein-1 I I_GENE
is O O
involved O O
in O O
CD28-dependent O O
costimulation O O
of O O
IL-2 B B_GENE
gene I I_GENE
transcription O O
in O O
freshly O O
isolated O O
naive O O
and O O
memory O O
human O O
T O O
lymphocytes O O
. O O

To O O
address O O
this O O
issue O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
scrape O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
loading O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
applied O O
to O O
purified O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blood O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
T O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Since O O
scrape O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loading O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
relies O O
on O O
adherent O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
( O O
PB-T O B_PROTEIN[GENE]/B_MEASURE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
immobilized O O
on O O
the O O
nonspecific O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
cell O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
attachment O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
factor O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
poly-L-lysine O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
. O O

Cells O O
scraped O O
off O O
poly-L-lysine O O
in O O
the O O
presence O O
of O O
Ig B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
FITC I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
efficiently O O
incorporated O O
Ig O O
, O O
with O O
relatively O O
uniform O O
fluorescence O O
. O O

T O O
cells O O
retained O O
their O O
physical O O
parameters O O
as O O
measured O O
by O O
forward O O
and O O
side O O
light O O
scatter O O
, O O
and O O
functional O O
activity O O
as O O
measured O O
by O O
costimulation O O
of O O
proliferation O O
and O O
IL-2 B B_GENE
production O O
after O O
being O O
scraped O O
off O O
this O O
substrate O O
. O O

CD28/CD3-costimulated O O
T O O
cells O O
produced O O
intracellular O O
IL-2 B B_GENE
from O O
all O O
subsets O O
measured O O
( O O
CD4+ O O
, O O
CD4- O O
, O O
CD45RO+ O O
, O O
and O O
CD45RO- O O
) O O
. O O

IL-2 B B_GENE
production O O
and O O
intracellular O O
accumulation O O
in O O
nonscraped O O
PB-T O O
cells O O
activated O O
with O O
CD28/CD3 O O
coligation O O
were O O
skewed O O
favoring O O
CD45RO+ O O
and O O
CD4+ O O
subsets O O
, O O
as O O
was O O
IL-2 B B_GENE
production O O
in O O
scraped O O
PB-T O O
cells O O
. O O

The O O
intracellular O O
incorporation O O
of O O
Abs O O
specific O O
for O O
c-Fos B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
members I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
scrape O O
loading O O
inhibited O O
the O O
production O O
and O O
intracellular O O
accumulation O O
of O O
IL-2 B B_GENE
within O O
6 O O
h O O
of O O
costimulation O O
with O O
PMA/ionomycin O O
, O O
or O O
costimulation O O
by O O
CD28 O O
and O O
CD3 O O
ligation O O
. O O

Scrape O O
loading O O
thus O O
provides O O
an O O
efficient O O
mechanism O O
for O O
intracellular O O
incorporation O O
of O O
macromolecules O O
, O O
and O O
the O O
first O O
direct O O
evidence O O
that O O
c-Fos B B_GENE
and O O
c-Jun B B_GENE
are O O
involved O O
in O O
transcription O O
of O O
the O O
IL-2 B B_GENE
gene I I_GENE
within O O
its O O
correct O O
chromosomal O O
context O O
, O O
in O O
resting O O
human O O
T O O
lymphocyte O O
subpopulations O O
. O O

Differential O O
expression O O
of O O
Nur77 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O O
T-lymphotropic O O
virus O O
type O O
1-infected O O
cells O O
: O O
transactivation O O
of O O
the O O
TR3/nur77 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
Tax B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
analyzed O O
the O O
differential O O
expression O O
and O O
regulation O O
of O O
three O O
members O O
of O O
the O O
Nur77 B B_GENE/B_BIO
transcription I I_GENE/I_BIO
factor I I_GENE/I_BIO
family I I_GENE/I_BIO
by O O
the O O
human O O
T-lymphotropic O O
virus O O
type O O
1 O O
( O O
HTLV-1 O O
) O O
Tax B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
demonstrated O O
that O O
in O O
both O O
HTLV-1-infected O O
cells O O
and O O
Tax-expressing O O
JPX-9 O O
cells O O
, O O
TR3/nur77 B B_GENE
is O O
highly O O
expressed O O
, O O
whereas O O
neither O O
NOR-1 O O
nor O O
NOT O O
expression O O
is O O
detectable O O
. O O

Transient O O
transfection O O
analysis O O
further O O
confirmed O O
the O O
Tax B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transactivation O O
of O O
the O O
TR3/nur77 B B_GENE/B_LOCATION
promoter O O
but O O
not O O
the O O
NOR-1 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoter I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
different O O
cell O O
types O O
. O O

Furthermore O O
, O O
expression O O
of O O
a O O
luciferase B B_GENE
reporter I I_GENE
gene I I_GENE
driven O O
by O O
the O O
NGFI-B B B_GENE
( I I_GENE
rat I I_GENE
homolog I I_GENE
of I I_GENE
TR3/Nur77 I I_GENE
) I I_GENE
response I I_GENE
element I I_GENE
( O O
NBRE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
provided O O
evidence O O
that O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-mediated O O
transactivation O O
resulted O O
in O O
the O O
induction O O
of O O
a O O
functional O O
protein O O
. O O

Cotransfection O O
assays O O
with O O
the O O
TR3/nur77 B B_GENE
promoter I I_GENE
sequence I I_GENE
or O O
the O O
NBRE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O O
motif O O
together O O
with O O
a O O
series O O
of O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants O O
have O O
shown O O
that O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
TR3/nur77 B B_GENE
expression O O
is O O
mediated O O
by O O
CREB/ATF-related B B_GENE
transcription I I_GENE
factors I I_GENE
. O O

Negative O O
regulation O O
of O O
the O O
heat O O
shock O O
transcriptional O O
response O O
by O O
HSBP1 B B_GENE
. O O

In O O
response O O
to O O
stress O O
, O O
heat B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
shock I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HSF1 B B_GENE
) O O
acquires O O
rapid O O
DNA O O
binding O O
and O O
transient O O
transcriptional O O
activity O O
while O O
undergoing O O
conformational O O
transition O O
from O O
an O O
inert O O
non-DNA-binding B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monomer I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
active O O
functional O O
trimers O O
. O O

Attenuation O O
of O O
the O O
inducible O O
transcriptional O O
response O O
occurs O O
during O O
heat O O
shock O O
or O O
upon O O
recovery O O
at O O
non-stress O O
conditions O O
and O O
involves O O
dissociation O O
of O O
the O O
HSF1 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trimer I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
loss O O
of O O
activity O O
. O O

We O O
have O O
used O O
the O O
hydrophobic B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
repeats I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
the O O
HSF1 B B_GENE/B_DISEASE
trimerization O O
domain O O
in O O
the O O
yeast O O
two-hybrid O O
protein O O
interaction O O
assay O O
to O O
identify O O
heat B B_GENE
shock I I_GENE
factor I I_GENE
binding I I_GENE
protein I I_GENE
1 I I_GENE
( O O
HSBP1 B B_GENE
) O O
, O O
a O O
novel O O
, O O
conserved O O
, O O
76-amino-acid B B_PROTEIN[GENE]/B_PERSON
protein I I_PROTEIN[GENE]/I_PERSON
that O O
contains O O
two O O
extended O O
arrays O O
of O O
hydrophobic B B_PROTEIN[GENE]/B_LOCATION
repeats I I_PROTEIN[GENE]/I_LOCATION
that O O
interact O O
with O O
the O O
HSF1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
heptad I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeats I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

HSBP1 B B_GENE/B_DISEASE
is O O
nuclear-localized O O
and O O
interacts O O
in O O
vivo O O
with O O
the O O
active O O
trimeric O O
state O O
of O O
HSF1 B B_GENE
that O O
appears O O
during O O
heat O O
shock O O
. O O

During O O
attenuation O O
of O O
HSF1 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
inert O O
monomer O O
, O O
HSBP1 B B_GENE
associates O O
with O O
Hsp70 O O
. O O

HSBP1 B B_GENE/B_DISEASE
negatively O O
affects O O
HSF1 B B_GENE/B_BIO
DNA-binding O O
activity O O
, O O
and O O
overexpression O O
of O O
HSBP1 B B_GENE
in O O
mammalian O O
cells O O
represses O O
the O O
transactivation O O
activity O O
of O O
HSF1 B B_GENE
. O O

To O O
establish O O
a O O
biological O O
role O O
for O O
HSBP1 B B_GENE
, O O
the O O
homologous O O
Caenorhabditis B B_GENE/B_LOCATION
elegans I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
was O O
overexpressed O O
in O O
body O O
wall O O
muscle O O
cells O O
and O O
was O O
shown O O
to O O
block O O
activation O O
of O O
the O O
heat O O
shock O O
response O O
from O O
a O O
heat B B_GENE/B_DISEASE
shock I I_GENE/I_DISEASE
promoter-reporter I I_GENE/I_DISEASE
construct I I_GENE/I_DISEASE
. O O

Alteration O O
in O O
the O O
level O O
of O O
HSBP1 B B_GENE
expression O O
in O O
C. O O
elegans O O
has O O
severe O O
effects O O
on O O
survival O O
of O O
the O O
animals O O
after O O
thermal O O
and O O
chemical O O
stress O O
, O O
consistent O O
with O O
a O O
role O O
for O O
HSBP1 B B_GENE
as O O
a O O
negative O O
regulator O O
of O O
the O O
heat O O
shock O O
response O O
. O O

Long-range O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transcriptional O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
regulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cytokine O B_GENE
gene O I_GENE
expression O I_GENE
. O O

Most O O
studies O O
on O O
the O O
control O O
of O O
cytokine O O
gene O O
expression O O
have O O
involved O O
the O O
functional O O
analysis O O
of O O
proximal B B_GENE
promoters I I_GENE
. O O

Recent O O
work O O
has O O
identified O O
distal B B_LOCATION/B_BIO
elements I I_LOCATION/I_BIO
that O O
mediate O O
long-range O O
cytokine O O
gene O O
regulation O O
and O O
has O O
implicated O O
chromatin O O
reorganization O O
in O O
regulation O O
of O O
cytokine B B_GENE
gene I I_GENE
loci I I_GENE
. O O

These O O
studies O O
have O O
begun O O
to O O
elucidate O O
the O O
basis O O
for O O
cell-specificity O O
and O O
high-level O O
expression O O
of O O
cytokine B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
. O O

A O O
signaling O O
complex O O
of O O
Ca2+-calmodulin-dependent B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
see O O
comments O O
] O O

Stimulation O O
of O O
T O O
lymphocytes O O
results O O
in O O
a O O
rapid O O
increase O O
in O O
intracellular O O
calcium O O
concentration O O
( O O
[ O O
Ca2+ O O
] O O
i O O
) O O
that O O
parallels O O
the O O
activation O O
of O O
Ca2+-calmodulin-dependent B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CaMKIV B B_GENE
) O O
, O O
a O O
nuclear B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
can O O
phosphorylate O O
and O O
activate O O
the O O
cyclic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adenosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
monophosphate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cAMP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CREB B B_GENE/B_DISEASE
) O O
. O O

However O O
, O O
inactivation O O
of O O
CaMKIV B B_GENE
occurs O O
despite O O
the O O
sustained O O
increase O O
in O O
[ O O
Ca2+ O O
] O O
i O O
that O O
is O O
required O O
for O O
T O O
cell O O
activation O O
. O O

A O O
stable O O
and O O
stoichiometric O O
complex O O
of O O
CaMKIV B B_GENE
with O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serine-threonine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PP2A B B_GENE
) O O
was O O
identified O O
in O O
which O O
PP2A B B_GENE
dephosphorylates O O
CaMKIV B B_GENE
and O O
functions O O
as O O
a O O
negative O O
regulator O O
of O O
CaMKIV B B_GENE
signaling O O
. O O

In O O
Jurkat O O
T O O
cells O O
, O O
inhibition O O
of O O
PP2A B B_GENE
activity O O
by O O
small O O
t O O
antigen O O
enhanced O O
activation O O
of O O
CREB B B_GENE
-mediated O O
transcription O O
by O O
CaMKIV B B_GENE
. O O

These O O
findings O O
reveal O O
an O O
intracellular O O
signaling O O
mechanism O O
whereby O O
a O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serine-threonine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CaMKIV B B_GENE/B_LOCATION
) O O
is O O
regulated O O
by O O
a O O
tightly O O
associated O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
serine-threonine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PP2A B B_GENE/B_LOCATION
) O O
. O O

Hypoxia O O
down-regulates O O
MCP-1 B B_GENE
expression O O
: O O
implications O O
for O O
macrophage O O
distribution O O
in O O
tumors O O
. O O

Monocyte B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chemoattractant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MCP-1 B B_GENE
) O O
is O O
likely O O
to O O
contribute O O
to O O
the O O
macrophage O O
infiltrate O O
in O O
human O O
ovarian O O
carcinomas O O
. O O

Although O O
MCP-1 B B_GENE
is O O
predominantly O O
expressed O O
by O O
the O O
tumor O O
parenchyma O O
, O O
macrophages O O
accumulate O O
at O O
highest O O
density O O
in O O
necrotic O O
regions O O
, O O
which O O
are O O
associated O O
with O O
low O O
oxygen O O
tensions O O
. O O

Tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
can O O
stimulate O O
MCP-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
and O O
is O O
also O O
present O O
within O O
ovarian O O
carcinomas O O
. O O

We O O
have O O
investigated O O
the O O
effect O O
of O O
hypoxia O O
both O O
on O O
MCP-1 B B_GENE
expression O O
in O O
ovarian O O
cancer O O
cell O O
lines O O
and O O
monocyte O O
migration O O
. O O

Hypoxia O O
down-regulated O O
TNF-alpha-induced B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MCP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
protein O O
production O O
by O O
ovarian O O
cancer O O
cells O O
. O O

The O O
effect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
mimicked O O
by O O
cobalt O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
desferrioxamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
a O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
oxygen-sensing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
mechanism O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Unlike O O
antioxidants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
hypoxia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
did O O
not O O
inhibit O O
nuclear O B_GENE
factor O I_GENE
KB O I_GENE
mobilization O I_GENE
. O O

Monocyte O O
migration O O
in O O
response O O
to O O
MCP-1 B B_GENE
was O O
also O O
diminished O O
under O O
hypoxic O O
conditions O O
. O O

Down-regulation O O
of O O
MCP-1 B B_GENE
expression O O
and O O
the O O
inhibition O O
of O O
monocyte O O
migration O O
are O O
independent O O
effects O O
of O O
hypoxia O O
that O O
may O O
contribute O O
to O O
the O O
distribution O O
of O O
macrophages O O
within O O
ovarian O O
tumors O O
. O O

Activation O O
of O O
nuclear B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
factor I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
kappa I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
B I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
inflammatory O O
bowel O O
disease O O
[ O O
see O O
comments O O
] O O

BACKGROUND O O
: O O
Expression O O
of O O
pro-inflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
increased O O
in O O
the O O
intestinal O O
lamina O O
propria O O
of O O
patients O O
with O O
inflammatory O O
bowel O O
disease O O
( O O
IBD O O
) O O
. O O

Nuclear B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
kappa I I_GENE/I_MEASURE
B I I_GENE/I_MEASURE
( O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
) O O
controls O O
transcription O O
of O O
inflammation B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
. O O

On O O
activation O O
, O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
is O O
rapidly O O
released O O
from O O
its O O
cytoplasmic B B_ENZYME[GENE]/B_PERSON
inhibitor I I_ENZYME[GENE]/I_PERSON
( O O
I B B_GENE/B_DISEASE
kappa I I_GENE/I_DISEASE
B I I_GENE/I_DISEASE
) O O
, O O
transmigrates O O
into O O
the O O
nucleus O O
, O O
and O O
binds O O
to O O
DNA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elements I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
gene O O
promoter O O
regions O O
. O O

AIMS O O
: O O
To O O
investigate O O
whether O O
increased O O
activation O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
is O O
important O O
in O O
IBD O O
and O O
may O O
be O O
down-regulated O O
by O O
anti-inflammatory O O
treatment O O
. O O

METHODS O O
: O O
Activation O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
was O O
determined O O
by O O
western O O
blot O O
assessment O O
and O O
electrophoretic O O
mobility O O
shift O O
assay O O
in O O
nuclear O O
extracts O O
of O O
colonic O O
biopsy O O
samples O O
as O O
well O O
as O O
lamina O O
propria O O
mononuclear O O
cells O O
. O O

RESULTS O O
: O O
Nuclear O O
levels O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
p65 B I_GENE
are O O
increased O O
in O O
lamina O O
propria O O
biopsy O O
specimens O O
from O O
patients O O
with O O
Crohn O O
's O O
disease O O
in O O
comparison O O
with O O
patients O O
with O O
ulcerative O O
colitis O O
and O O
controls O O
. O O

Increased O O
activation O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
was O O
detected O O
in O O
lamina O O
propria O O
mononuclear O O
cells O O
from O O
patients O O
with O O
active O O
IBD O O
. O O

Corticosteroids O O
strongly O O
inhibit O O
intestinal O O
NF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kappa I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
in O O
IBD O O
in O O
vivo O O
and O O
in O O
vitro O O
by O O
stabilising O O
the O O
cytosolic B B_GENE
inhibitor I I_GENE
I B I_GENE
kappa I I_GENE
B I I_GENE
alpha O O
against O O
activation O O
induced O O
degradation O O
. O O

CONCLUSIONS O O
: O O
In O O
both O O
IBDs O O
, O O
but O O
particularly O O
Crohn O O
's O O
disease O O
, O O
increased O O
activation O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
may O O
be O O
involved O O
in O O
the O O
regulation O O
of O O
the O O
inflammatory O O
response O O
. O O

Inhibition O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
activation O O
may O O
represent O O
a O O
mechanism O O
by O O
which O O
steroids O O
exert O O
an O O
anti-inflammatory O O
effect O O
in O O
IBD O O

Insufficient O O
glycemic O O
control O O
increases O O
nuclear B B_GENE
factor-kappa I I_GENE
B I I_GENE
binding O O
activity O O
in O O
peripheral O O
blood O O
mononuclear O O
cells O O
isolated O O
from O O
patients O O
with O O
type O O
1 O O
diabetes O O
. O O

OBJECTIVE O O
: O O
The O O
redox-sensitive B B_GENE
transcription I I_GENE
factor I I_GENE
nuclear I I_GENE
factor-kappa I I_GENE
B I I_GENE
( O O
NF-kappa B B_GENE
B I I_GENE
) O O
is O O
believed O O
to O O
contribute O O
to O O
late O O
diabetic O O
complications O O
. O O

It O O
is O O
unknown O O
whether O O
NF-kappa B B_GENE/B_DISEASE
B I B_GENE/I_DISEASE
is O O
influenced O O
by O O
glycemic O O
control O O
. O O

RESEARCH O O
DESIGN O O
AND O O
METHODS O O
: O O
To O O
determine O O
whether O O
NF-kappa B B_GENE
B I I_GENE
is O O
activated O O
in O O
patients O O
with O O
insufficient O O
glycemic O O
control O O
( O O
HbA1c O O
> O O
10 O O
% O O
) O O
, O O
we O O
developed O O
a O O
tissue O O
culture-independent O O
electrophoretic O O
mobility O O
shift O O
assay O O
( O O
EMSA O O
) O O
-based O O
semiquantitative O O
detection O O
system O O
that O O
allowed O O
us O O
to O O
determine O O
NF-kappa B B_GENE
B I I_GENE
activation O O
in O O
ex O O
vivo-isolated O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMCs O O
) O O
. O O

We O O
included O O
43 O B_PERSON
patients O I_PERSON
with O O
type O B_DISEASE/B_LOCATION
1 O I_DISEASE/I_LOCATION
diabetes O I_DISEASE/I_LOCATION
in O O
this O O
cross-sectional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

10 O B_NUMBER[MEASURE]/B_PERSON
of O O
those O O
received O O
the O O
antioxidant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
thioctic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
600 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mg/day O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
p.o. O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
for O O
2 O O
weeks O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE

RESULTS O O
: O O
Monocytes O O
of O O
patients O O
with O O
HbA1c O O
levels O O
> O O
10 O O
% O O
demonstrated O O
significantly O O
higher O O
NF-kappa B B_GENE
B I I_GENE
binding O O
activity O O
in O O
an O O
EMSA O O
and O O
a O O
stronger O O
NF-kappa B B_GENE
B I I_GENE
staining O O
in O O
immunohistochemistry O O
than O O
monocytes O O
of O O
patients O O
with O O
HbA1c O O
levels O O
of O O
6-8 O O
% O O
. O O

The O O
increase O O
in O O
NF-kappa B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
correlated O O
with O O
an O O
increase O O
in O O
plasmatic O O
markers O O
of O O
lipid O O
peroxidation O O
. O O

Treatment O O
with O O
the O O
antioxidant O O
thioctic O O
acid O O
decreased O O
NF-kappa B B_GENE
B I I_GENE
binding O O
activity O O
. O O

CONCLUSIONS O O
: O O
Hyperglycemia O O
induces O O
activation O O
of O O
the O O
transcription O O
factor O O
NF-kappa B B_GENE
B I I_GENE
in O O
ex O O
vivo-isolated O O
PBMCs O O
of O O
patients O O
with O O
type O O
1 O O
diabetes O O
. O O

NF-kappa B B_GENE
B I I_GENE
activation O O
is O O
at O O
least O O
partially O O
dependent O O
on O O
oxidative O O
stress O O
, O O
since O O
the O O
antioxidant O O
thioctic O O
acid O O
significantly O O
lowered O O
the O O
extent O O
of O O
NF-kappa B B_GENE
B I I_GENE
binding O O
activity O O
. O O

Synergistic O O
activation O O
of O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ERK1/2 B B_GENE/B_LOCATION
) O O
by O O
erythropoietin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
stem B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
essential O O
for O O
expanded O O
erythropoiesis O O
. O O

Stem B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SCF B B_GENE/B_LOCATION
) O O
and O O
erythropoietin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
EPO B B_LOCATION/B_ORGANIZATION
) O O
work O O
synergistically O O
to O O
support O O
erythropoiesis O O
, O O
but O O
the O O
mechanism O O
for O O
this O O
synergism O O
is O O
unknown O O
. O O

By O O
using O O
purified O O
human O O
erythroid O O
colony-forming O O
cells O O
( O O
ECFC O O
) O O
, O O
we O O
have O O
found O O
that O O
SCF B B_GENE/B_BIO
and O O
EPO B B_LOCATION/B_ORGANIZATION
synergistically O O
activate O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MAPK B B_GENE
, O O
ERK1/2 B B_GENE
) O O
, O O
which O O
correlates O O
with O O
the O O
cell O O
growth O O
and O O
thus O O
may O O
be O O
responsible O O
for O O
the O O
synergistic O O
effects O O
. O O

Treatment O O
of O O
the O O
cells O O
with O O
PD98059 O O
and O O
wortmannin O O
, O O
inhibitors O O
of O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
PI-3 B B_GENE
kinase I I_GENE
, O O
respectively O O
, O O
inhibited O O
the O O
synergistic O O
activation O O
of O O
MAPK B B_GENE
and O O
also O O
the O O
cell O O
growth O O
, O O
further O O
supporting O O
this O O
conclusion O O
. O O

Wortmannin O O
only O O
inhibits O O
MAPK B B_GENE
activation O O
induced O O
by O O
EPO B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
not O O
that O O
by O O
SCF B B_GENE/B_BIO
, O O
suggesting O O
that O O
SCF B B_GENE/B_BIO
and O O
EPO B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
activate O O
MAPK B B_GENE
through O O
different O O
pathways O O
, O O
which O O
would O O
facilitate O O
synergy O O
. O O

Furthermore O O
, O O
EPO B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
SCF B B_GENE/B_BIO
, O O
led O O
to O O
activation O O
of O O
STAT5 B B_GENE
, O O
whereas O O
SCF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
wortmannin O O
had O O
no O O
effect O O
on O O
the O O
EPO B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
STAT5 B B_GENE
activation O O
, O O
suggesting O O
that O O
STAT5 B B_GENE
is O O
not O O
involved O O
in O O
the O O
synergistic O O
action O O
of O O
SCF B B_GENE/B_LOCATION
and O O
EPO B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Together O O
, O O
the O O
data O O
suggest O O
that O O
synergistic O O
activation O O
of O O
MAPK B B_GENE
by O O
SCF B B_GENE/B_BIO
and O O
EPO B B_GENE/B_LOCATION
is O O
essential O O
for O O
expanded O O
erythropoiesis O O
. O O

Copyright O B_LOCATION/B_PERSON
1998 O I_LOCATION/I_PERSON
by O O
The O O
American O B_ORGANIZATION/B_LOCATION
Society O I_ORGANIZATION/I_LOCATION
of O O
Hematology O B_PERSON
. O O

The O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
phenotypic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
primary O B_DISEASE/B_LOCATION
central O I_DISEASE/I_LOCATION
nervous O I_DISEASE/I_LOCATION
system O I_DISEASE/I_LOCATION
lymphoma O I_DISEASE/I_LOCATION
identifies O O
distinct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
categories O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
disease O B_DISEASE
and O O
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
histogenetic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivation O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
germinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
center-related O O
B O B_DISEASE
cells O I_DISEASE
. O O

Primary O B_DISEASE
central O I_DISEASE
nervous O I_DISEASE
system O I_DISEASE
lymphoma O I_DISEASE
( O O
PCNSL O B_DISEASE
) O O
is O O
a O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cause O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
morbidity O B_DISEASE
and O O
mortality O B_DISEASE
among O O
human O B_DISEASE
immunodeficiency O I_DISEASE
virus O I_DISEASE
( O O
HIV O B_DISEASE/B_VIRUS[BIO]
) O O
-infected O O
individuals O B_PERSON/B_BIO
. O O

The O O
precise O B_DISEASE
histogenetic O I_DISEASE
derivation O I_DISEASE
and O O
the O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathogenesis O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PCNSL O B_DISEASE
is O O
poorly O O
understood O O
. O O

In O O
an O O
attempt O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O O
clarify O O
the O O
histogenesis O B_DISEASE_ADJECTIVE[DISEASE]
and O O
pathogenesis O B_DISEASE
of O O
these O O
lymphomas O B_DISEASE/B_PERSON
, O O
49 O B_NUMBER[MEASURE]/B_BIO
PCNSL O I_NUMBER[MEASURE]/I_BIO
( O O
26 O B_MEASURE
acquired O O
immunodeficiency O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ O O
AIDS O B_DISEASE
] O I_DISEASE
-related O O
and O O
23 O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
AIDS-unrelated O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
analyzed O O
for O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
biologic O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
markers O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
which O O
are O O
known O O
to O O
bear O O
histogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
pathogenetic O B_DISEASE_ADJECTIVE[DISEASE]
significance O I_DISEASE_ADJECTIVE[DISEASE]
for O O
mature O B_DISEASE/B_PERSON
B-cell O I_DISEASE/I_PERSON
neoplasms O I_DISEASE/I_PERSON
. O O

PCNSL O O
associated O O
frequently O O
( O O
50.0 O O
% O O
) O O
with O O
mutations O O
of O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
noncoding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
are O O
regarded O O
as O O
a O O
marker O O
of O O
B-cell O O
transition O O
through O O
the O O
germinal O O
center O O
( O O
GC O O
) O O
. O O

Expression O O
of O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
is O O
restricted O O
to O O
GC O O
B O O
cells O O
throughout O O
physiologic O O
B-cell O O
maturation O O
, O O
was O O
detected O O
in O O
100 O O
% O O
AIDS-unrelated O O
PCNSL O O
and O O
in O O
56.2 O O
% O O
AIDS-related O O
cases O O
. O O

Notably O O
, O O
among O O
AIDS-related O O
PCNSL O O
, O O
expression O O
of O O
BCL-6 B B_GENE
was O O
mutually O O
exclusive O O
with O O
expression O O
of O O
Epstein-Barr B B_GENE
virus I I_GENE
( I I_GENE
EBV I I_GENE
) I I_GENE
-encoded I I_GENE
latent I I_GENE
membrane I I_GENE
protein I I_GENE
( I I_GENE
LMP I I_GENE
) I I_GENE
-1 I I_GENE
and O O
, O O
with O O
few O O
exceptions O O
, O O
also O O
of O O
BCL-2 B B_GENE
. O O

All O O
but O O
one O B_NUMBER[MEASURE]/B_PERSON
PCNSL O I_NUMBER[MEASURE]/I_PERSON
expressed O O
hMSH2 O B_GENE
, O O
which O O
among O O
mature O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
selectively O O
stains O O
GC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
data O O
suggest O O
that O O
PCNSL O O
may O O
be O O
frequently O O
related O O
to O O
GC O O
B O O
cells O O
and O O
may O O
be O O
segregated O O
into O O
two O O
major O O
biologic O O
categories O O
based O O
on O O
the O O
expression O O
pattern O O
of O O
BCL-6 B B_GENE
, O O
LMP-1 B B_GENE/B_DISEASE
, O O
and O O
BCL-2 B B_GENE
. O O

BCL-6 B B_GENE/B_DISEASE
( O O
+ O O
) O O
/ O O
LMP-1 B B_GENE
( O O
- O O
) O O
/ O O
BCL-2 B B_GENE
( O O
- O O
) O O
PCNSL O O
occur O O
both O O
in O O
the O O
presence O O
and O O
in O O
the O O
absence O O
of O O
HIV O O
infection O O
and O O
consistently O O
display O O
a O O
large O O
noncleaved O O
cell O O
morphology O O
. O O

Conversely O O
, O O
BCL-6 B B_GENE
( O O
- O O
) O O
/ O O
LMP-1 B B_GENE
( O O
+ O O
) O O
/ O O
BCL-2 B B_GENE
( O O
+ O O
) O O
PCNSL O O
are O O
restricted O O
to O O
HIV-infected O O
hosts O O
and O O
are O O
represented O O
by O O
lymphomas O O
with O O
immunoblastic O O
features O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
pathogenesis O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
histogenesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
PCNSL O B_DISEASE
and O O
may O O
be O O
helpful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
to O O
segregate O O
distinct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
biologic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
prognostic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
categories O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
lymphomas O B_DISEASE/B_PERSON
. O O

Copyright O B_LOCATION/B_PERSON
1998 O I_LOCATION/I_PERSON
by O O
The O O
American O B_ORGANIZATION/B_LOCATION
Society O I_ORGANIZATION/I_LOCATION
of O O
Hematology O B_PERSON
. O O

Antioxidant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
phorbol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ester-induced O O
adhesion O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
Jurkat O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
T-cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
to O O
endothelial O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Regulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
adhesion O B_GENE/B_ORGANISM_FUNCTION
molecule O B_GENE/I_ORGANISM_FUNCTION
expression O B_GENE/I_ORGANISM_FUNCTION
and O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
reactive O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxygen O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
redox O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sensitive O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
have O O
been O O
reported O O
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O O
clinically O O
safe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antioxidants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
regulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
adhesion O B_GENE
molecule O I_GENE
expression O I_GENE
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
endothelial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ECV O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
, O O
and O O
adherence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Jurkat O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
ECV O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
investigated O O
. O O

The O O
thiol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antioxidant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
alpha-lipoate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
at O O
clinically O O
relevant O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
doses O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
down-regulated O O
phorbol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12-myristate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
13-acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PMA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
-induced O O
adhesion O B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
molecule O B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
expression O B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
cell-cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
adhesion O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

Inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
PMA-induced O B_GENE/B_LOCATION
ICAM-1 O I_GENE/I_LOCATION
and O O
VCAM-1 O O
expression O B_GENE
as O O
well O O
as O O
PMA-induced O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adhesion O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Jurkat O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
T-cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
to O O
ECV O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
alpha-lipoate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
dose O B_DISEASE_ADJECTIVE[DISEASE]
dependent O I_DISEASE_ADJECTIVE[DISEASE]
( O O
50-250 O B_MEASURE
microM O I_MEASURE
) O O
. O O

The O O
effect O O
was O O
significant O O
for O O
ICAM-1 B B_GENE
( O O
p O O
< O O
.01 O O
) O O
and O O
VCAM-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
p O O
< O O
.01 O O
) O O
expression O O
in O O
cells O O
pretreated O O
with O O
100 O O
microM O O
alpha-lipoate O O
compared O O
to O O
PMA-activated O O
untreated O O
cells O O
. O O

Inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
PMA-induced O B_DISEASE_ADJECTIVE[DISEASE]
adhesion O I_DISEASE_ADJECTIVE[DISEASE]
molecule O I_DISEASE_ADJECTIVE[DISEASE]
expression O I_DISEASE_ADJECTIVE[DISEASE]
and O O
cell-cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
adhesion O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
was O O
more O O
pronounced O O
when O O
a O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
antioxidants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
alpha-lipoate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
alpha-tocopherol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
were O O
used O O
compared O O
to O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
either O O
of O O
these O O
antioxidant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
. O O

The O O
regulation O O
of O O
adhesion O O
molecule O O
expression O O
and O O
function O O
by O O
low O O
concentration O O
of O O
antioxidants O O
investigated O O
does O O
not O O
appear O O
to O O
be O O
NF-kappaB B B_GENE
regulated O O
or O O
transcription O O
dependent O O
because O O
no O O
change O O
in O O
the O O
mRNA O O
response O O
was O O
observed O O
. O O

Protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PKC B B_GENE
) O O
has O O
been O O
suggested O O
to O O
regulate O O
PMA-induced O O
adhesion O O
molecule O O
expression O O
by O O
post-transcriptional O O
stabilization O O
of O O
adhesion B B_GENE
molecule I I_GENE
mRNA I I_GENE
. O O

Alpha-lipoate O O
pretreatment O O
did O O
not O O
influence O O
the O O
response O O
of O O
PKC B B_GENE
activity O O
to O O
PMA O O
. O O

Oxidants O B_PERSON/B_GENE
are O O
known O O
to O O
be O O
involved O O
in O O
the O O
regulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cell O B_DISEASE
adhesion O I_DISEASE
processes O I_DISEASE
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
ECV O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
PMA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
generation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
intracellular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oxidants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Alpha-lipoate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
100 O B_MEASURE
or O O
250 O B_MEASURE
microM O I_MEASURE
) O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
decreased O O
PMA-induced O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
generation O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
intracellular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
inhibitory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
low O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
concentration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
alpha-lipaote O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alone O O
or O O
in O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O O
alpha-tocopherol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
agonist-induced O B_DISEASE/B_GENE
adhesion O I_DISEASE/I_GENE
processes O I_DISEASE/I_GENE
observed O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O O
be O O
of O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therapeutic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
value O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Binding O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
to O O
CD4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CXCR4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
differentially O O
regulates O O
expression O O
of O O
inflammatory B B_GENE
genes I I_GENE
and O O
activates O O
the O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ERK O O
signaling O O
pathway O O
. O O

We O O
have O O
previously O O
shown O O
that O O
binding O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
virions O O
to O O
CD4 B B_GENE
receptors I I_GENE
stimulates O O
association O O
of O O
Lck B B_GENE/B_BACTERIUM[BIO]
with O O
Raf-1 B B_GENE
and O O
results O O
in O O
the O O
activation O O
of O O
Raf-1 B B_GENE
kinase O O
in O O
a O O
Ras-independent O O
manner O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
demonstrate O O
that O O
HIV-1 B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
envelope I B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
glycoproteins I B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
both O O
T-cell-tropic O O
and O O
macrophagetropic O O
strains O O
rapidly O O
activate O O
the O O
ERK/mitogen-activated O O
protein O O
( O O
MAP O O
) O O
kinase O O
pathway O O
and O O
the O O
binding O O
of O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AP-1 B B_GENE
, O O
NF-kappaB B B_GENE
, O O
and O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
stimulate O O
expression O O
of O O
cytokine B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemokine I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
activation O O
of O O
this O O
signaling O O
pathway O O
requires O O
functional O O
CD4 B B_GENE
receptors I I_GENE
and O O
is O O
independent O O
of O O
binding O O
to O O
CXCR4 B B_GENE
. O O

Binding O O
of O O
the O O
natural O O
ligand O O
stromal B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell-derived I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
SDF-1 B B_GENE
) O O
to O O
CXCR4 B B_GENE
, O O
which O O
inhibits O O
entry O O
of O O
T-cell-tropic O O
HIV-1 O O
, O O
activates O O
also O O
the O O
ERK/ O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathway O O
. O O

However O O
, O O
SDF-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
did O O
not O O
affect O O
the O O
CD4-mediated O O
expression O O
of O O
cytokine B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemokine I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
results O O
provide O O
firm O O
molecular O O
evidence O O
that O O
binding O O
of O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
envelope I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycoproteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
CD4 B B_GENE
receptor I I_GENE
initiates O O
a O O
signaling O O
pathway O O
( O O
s O O
) O O
independent O O
of O O
the O O
binding O O
to O O
the O O
chemokine B B_GENE
receptor I I_GENE
that O O
leads O O
to O O
the O O
aberrant O O
expression O O
of O O
inflammatory B B_GENE
genes I I_GENE
and O O
may O O
contribute O O
significantly O O
to O O
HIV-1 O O
replication O O
as O O
well O O
as O O
to O O
deregulation O O
of O O
the O O
immune O O
system O O
. O O

Antigen O O
receptor O O
signaling O O
induces O O
MAP O O
kinase-mediated O O
phosphorylation O O
and O O
degradation O O
of O O
the O O
BCL-6 B B_GENE
transcription B I_GENE
factor I I_GENE
. O O

The O O
bcl-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proto-oncogene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O O
a O O
POZ/zinc B B_GENE/B_MEASURE
finger I I_GENE/I_MEASURE
transcriptional I I_GENE/I_MEASURE
repressor I I_GENE/I_MEASURE
expressed O O
in O O
germinal O O
center O O
( O O
GC O O
) O O
B O O
and O O
T O O
cells O O
and O O
required O O
for O O
GC O O
formation O O
and O O
antibody O O
affinity O O
maturation O O
. O O

Deregulation O O
of O O
bcl-6 B B_GENE
expression O O
by O O
chromosomal O O
rearrangements O O
and O O
point O O
mutations O O
of O O
the O O
bcl-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
B-cell O O
lymphoma O O
. O O

The O O
signals O O
regulating O O
bcl-6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
are O O
not O O
known O O
. O O

Here O O
we O O
show O O
that O O
antigen O O
receptor O O
activation O O
leads O O
to O O
BCL-6 B B_GENE
phosphorylation O O
by O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE
) O O
. O O

Phosphorylation O O
, O O
in O O
turn O O
, O O
targets O O
BCL-6 B B_GENE
for O O
rapid O O
degradation O O
by O O
the O O
ubiquitin B B_GENE
/ O O
proteasome B B_GENE
pathway O O
. O O

These O O
findings O O
indicate O O
that O O
BCL-6 B B_GENE
expression O O
is O O
directly O O
controlled O O
by O O
the O O
antigen O O
receptor O O
via O O
MAPK B B_GENE
activation O O
. O O

This O O
signaling O O
pathway O O
may O O
be O O
crucial O O
for O O
the O O
control O O
of O O
B-cell O O
differentiation O O
and O O
antibody O O
response O O
and O O
has O O
implications O O
for O O
the O O
regulation O O
of O O
other O O
POZ/zinc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finger I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcription I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
other O O
tissues O O
. O O

Glucocorticoid B B_PERSON/B_GENE
receptors I I_PERSON/I_GENE
are O O
differentially O O
expressed O O
in O O
the O O
cells O O
and O O
tissues O O
of O O
the O O
immune O O
system O O
. O O

Cytosolic B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GR B B_LOCATION/B_ORGANIZATION
) O O
binding O O
studies O O
on O O
immune O O
tissues O O
demonstrate O O
that O O
the O O
thymus O O
exhibits O O
three O O
to O O
four O O
times O O
higher O O
levels O O
of O O
GR B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
spleen O O
. O O

High O O
levels O O
of O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
consistent O O
with O O
the O O
exquisite O O
sensitivity O O
of O O
the O O
thymus O O
to O O
glucocorticoid O O
exposure O O
. O O

Nevertheless O O
, O O
whole O O
cell O O
binding O O
studies O O
reveal O O
similar O O
levels O O
of O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
immature O O
thymic O O
T O O
lymphocytes O O
and O O
more O O
mature O O
, O O
splenic O O
T O O
lymphocytes O O
. O O

Moreover O O
, O O
whole O O
cell O O
binding O O
techniques O O
indicate O O
that O O
neutrophils O O
( O O
which O O
represent O O
roughly O O
30 O O
% O O
of O O
splenic O O
leukocytes O O
) O O
exhibit O O
higher O O
GR B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
than O O
both O O
T O O
and O O
B O O
lymphocytes O O
, O O
further O O
contradicting O O
results O O
from O O
cytosolic O O
binding O O
studies O O
. O O

To O O
address O O
these O O
inconsistencies O O
, O O
GR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
assessed O O
in O O
immune O O
cells O O
and O O
tissues O O
using O O
cytosolic O O
radioligand O O
binding O O
. O O

Western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
immunocytochemistry O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Consistent O O
with O O
previous O O
cytosolic O O
receptor O O
binding O O
studies O O
on O O
immune O O
tissue O O
homogenates O O
, O O
thymic O O
T O O
cells O O
were O O
found O O
to O O
have O O
higher O O
levels O O
of O O
GR B B_GENE/B_DISEASE
than O O
T O O
cells O O
isolated O O
from O O
the O O
spleen O O
. O O

In O O
addition O O
, O O
neutrophils O O
were O O
found O O
to O O
have O O
fewer O O
GR B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
than O O
lymphocytes O O
and O O
monocytes O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
indicate O O
a O O
meaningful O B_MEASURE/B_PERSON
relationship O I_MEASURE/I_PERSON
between O O
receptor O B_DISEASE/B_GENE
expression O I_DISEASE/I_GENE
and O O
known O O
sensitivity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Functional O O
replacement O O
of O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
E2A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
HEB I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
mammalian B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
E2A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HEB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E2-2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encode O O
a O O
unique O O
class O O
of O O
basic B B_GENE
helix-loop-helix I I_GENE
( I I_GENE
bHLH I I_GENE
) I I_GENE
transcription I I_GENE
factors I I_GENE
that O O
are O O
evolutionarily O O
conserved O O
and O O
essential O O
for O O
embryonic O O
and O O
postnatal O O
development O O
. O O

While O O
the O O
structural O O
and O O
functional O O
similarities O O
among O O
the O O
gene B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
products I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O O
well O O
demonstrated O O
, O O
it O O
is O O
not O O
clear O O
why O O
deletion O O
of O O
E2A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
HEB B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
E2-2 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
leads O O
to O O
a O O
complete O O
arrest O O
in O O
B-lymphocyte O O
development O O
. O O

To O O
understand O O
the O O
molecular O O
basis O O
of O O
the O O
functional O O
specificity O O
between O O
E2A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
HEB B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
E2-2 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mammalian O O
development O O
, O O
we O O
generated O O
and O O
tested O O
a O O
panel O O
of O O
E2A B B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
knockin O O
mutations O O
including O O
subtle O O
mutations O O
in O O
the O O
E12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E47 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exons I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
substitution O O
of O O
both O O
E12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E47 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exons I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HEB I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
find O O
that O O
the O O
alternatively O O
spliced O O
E12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E47 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
E2A B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
gene I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
play O O
similar O O
and O O
additive O O
roles O O
in O O
supporting O O
B O O
lymphopoiesis O O
. O O

Further O O
, O O
we O O
find O O
that O O
HEB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
driven O O
by O O
the O O
endogenous B B_GENE/B_LOCATION
E2A I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
can O O
functionally O O
replace O O
E2A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
supporting O O
B-cell O O
commitment O O
and O O
differentiation O O
toward O O
completion O O
. O O

Finally O O
, O O
the O O
postnatal O O
lethality O O
associated O O
with O O
E2A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
disruption O O
is O O
fully O O
rescued O O
by O O
the O O
addition O O
of O O
HEB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
study O O
suggests O O
that O O
the O O
functional O O
divergence O O
among O O
E12 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
E47 B B_GENE
, O O
and O O
HEB B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
different O O
cell O O
types O O
is O O
partially O O
defined O O
by O O
the O O
context O O
of O O
gene O O
expression O O
. O O

Biased O O
dependency O O
of O O
CD80 B B_GENE
versus O O
CD86 B B_GENE
in O O
the O O
induction O O
of O O
transcription B B_GENE
factors I I_GENE
regulating O O
the O O
human B B_GENE/B_DISEASE
IL-2 I I_GENE/I_DISEASE
promoter I I_GENE/I_DISEASE
. O O

In O O
addition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
signals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O O
by O O
ligation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
TCR O B_GENE
, O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
need O O
additional O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O O
co-stimulatory O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
be O O
activated O O
. O O

One O O
such O O
co-stimulatory O O
signal O O
is O O
delivered O O
when O O
CD28 B B_GENE
on O O
T O O
cells O O
binds O O
to O O
CD80 B B_GENE
or O O
CD86 B B_GENE
on O O
antigen-presenting O O
cells O O
( O O
APC O O
) O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
analyzed O O
the O O
ability O O
of O O
CD80 B B_GENE
and O O
CD86 B B_GENE
to O O
co-stimulate O O
human O O
T O O
cells O O
activated O O
by O O
superantigen O O
. O O

Using O O
the O O
Raji O O
B O O
cell O O
lymphoma O O
, O O
which O O
express O O
similar O O
levels O O
of O O
CD80 B B_GENE
and O O
CD86 B B_GENE
, O O
it O O
was O O
found O O
that O O
T O O
cell O O
proliferation O O
was O O
mainly O O
co-stimulated O O
by O O
CD80 B B_GENE
. O O

To O O
further O O
characterize O O
the O O
consequences O O
of O O
this O O
biased O O
co-stimulatory O O
dependency O O
, O O
we O O
employed O O
a O O
well-defined O O
system O O
of O O
transfected O O
CHO O O
cells O O
expressing O O
human B B_GENE
MHC I I_GENE
class I I_GENE
II I I_GENE
together O O
with O O
CD80 B B_GENE
, O O
CD86 B B_GENE
or O O
CD80 B B_GENE
and O O
CD86 B B_GENE
. O O

Proliferation O O
of O O
freshly O O
prepared O O
CD4+ O O
T O O
cells O O
required O O
the O O
presence O O
of O O
either O O
CD80 B B_GENE
or O O
CD86 B B_GENE
. O O

However O O
, O O
IL-2 B B_GENE
production O O
reached O O
only O O
suboptimal O O
levels O O
in O O
the O O
presence O O
of O O
CD86 B B_GENE
but O O
optimal O O
levels O O
with O O
CD80 B B_GENE
. O O

To O O
analyze O O
IL-2 B B_GENE
transcriptional O O
activity O O
in O O
CD80 B B_GENE
and O O
CD86 B B_GENE
co-stimulated O O
T O O
cells O O
we O O
used O O
Jurkat O O
T O O
cells O O
transfected O O
with O O
luciferase B B_GENE
reporter I I_GENE
gene I I_GENE
constructs I I_GENE
. O O

CD80 B B_GENE
induced O O
higher O O
levels O O
of O O
IL-2 B B_GENE/B_DISEASE
promoter I I_GENE/I_DISEASE
-enhancer O O
activity O O
compared O O
to O O
CD86 B B_GENE
. O O

Furthermore O O
, O O
the O O
activity O O
of O O
transcription B B_GENE
factors I I_GENE
regulating O O
the O O
IL-2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
promoter-enhancer I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
including O O
activation B B_GENE
protein-1 I I_GENE
, O O
CD28 B B_GENE
response I I_GENE
element I I_GENE
and O O
nuclear B B_GENE
factor I I_GENE
kappaB I I_GENE
were O O
4-8 O O
times O O
higher O O
after O O
CD80 B B_GENE
compared O O
to O O
CD86 B B_GENE
ligation O O
. O O

Our O O
results O O
suggest O O
that O O
the O O
eventual O O
appearance O O
of O O
CD80 B B_GENE
on O O
recently O O
activated O O
CD86+ O O
APC O O
is O O
important O O
for O O
the O O
superinduction O O
of O O
IL-2 B B_GENE
production O O
and O O
to O O
support O O
vigorous O O
T O O
cell O O
proliferation O O
. O O

Duplication O O
of O O
the O O
DR3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
human B B_GENE/B_MEASURE
chromosome I B_GENE/I_MEASURE
1p36 I B_GENE/I_MEASURE
and O O
its O O
deletion O O
in O O
human O O
neuroblastoma O O
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DR3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
whose O O
product O O
is O O
also O O
known O O
as O O
Wsl-1/APO-3/TRAMP/LARD B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
encodes O O
a O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
is O O
expressed O O
primarily O O
on O O
the O O
surface O O
of O O
thymocytes O O
and O O
lymphocytes O O
. O O

DR3 B B_GENE
is O O
capable O O
of O O
inducing O O
both O O
NF-kappa B B_GENE
B I I_GENE
activation O O
and O O
apoptosis O O
when O O
overexpressed O O
in O O
mammalian O O
cells O O
, O O
although O O
its O O
ligand O O
has O O
not O O
yet O O
been O O
identified O O
. O O

We O O
report O O
here O O
that O O
the O O
DR3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
tandemly O O
duplicated O O
on O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chromosome I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
band I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1p36.2-p36.3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
that O O
these O O
genes O O
are O O
hemizygously O O
deleted O O
and/or O O
translocated O O
to O O
another O O
chromosome O O
in O O
neuroblastoma O O
( O O
NB O O
) O O
cell O O
lines O O
with O O
amplified O O
MYCN O O
. O O

Duplication O O
of O O
at O O
least O O
a O O
portion O O
of O O
the O O
DR3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
the O O
extracellular B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
transmembrane I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
regions I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
but O O
not O O
the O O
cytoplasmic B B_GENE
domain I I_GENE
, O O
was O O
demonstrated O O
by O O
both O O
fluorescence O O
in O O
situ O O
hybridization O O
and O O
genomic O O
Southern O O
blotting O O
. O O

In O O
most O O
NB O O
cell O O
lines O O
, O O
both O O
the O O
DR3 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
the I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DR3L I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequences I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O O
simultaneously O O
deleted O O
and/or O O
translocated O O
to O O
another O O
chromosome B B_GENE/B_LOCATION
. O O

Finally O O
, O O
DR3/ B B_GENE
Wsl-1 I I_GENE
protein I I_GENE
expression O O
is O O
quite O O
variable O O
among O O
these O O
NB O O
cell O O
lines O O
, O O
with O O
very O O
low O O
or O O
undetectable O O
levels O O
in O O
7 O O
of O O
17 O O
NB O O
cell O O
lines O O

Differential O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
protection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
normal O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
malignant O B_DISEASE
human O I_DISEASE
myeloid O I_DISEASE
progenitors O I_DISEASE
( O O
CFU-GM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
from O O
Ara-C O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
toxicity O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
using O O
cycloheximide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Cycloheximide O O
, O O
a O O
reversible O O
protein O O
synthesis O O
inhibitor O O
, O O
is O O
thought O O
to O O
block O O
DNA O O
replication O O
in O O
normal O O
cells O O
by O O
preventing O O
synthesis O O
of O O
a O O
labile B B_GENE
protein I I_GENE
. O O

In O O
animal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
systems O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
cycloheximide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protects O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
from O O
cytotoxic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
S-phase O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
cytosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arabinoside O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Ara-C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
. O O

Malignant O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cells O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
appear O O
not O O
to O O
be O O
susceptible O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
cycloheximide-induced O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arrest O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
, O O
subsequently O O
, O O
may O O
not O O
be O O
protected O O
from O O
Ara-C O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cytotoxicity O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cycloheximide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
granulocyte/macrophage O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
progenitors O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
CFU-GM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
) O O
after O O
in O O
vitro O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
Ara-C O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
exposure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
was O O
examined O O
using O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
bone O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
marrow O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
, O O
malignant O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
patients O B_PERSON/B_BIO
with O O
chronic O B_DISEASE
myelogenous O I_DISEASE
leukemia O I_DISEASE
( O O
CML O B_LOCATION/B_ORGANIZATION
) O O
, O O
and O O
clonogenic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
human O B_DISEASE/B_BIO
acute O I_DISEASE/I_BIO
nonlymphocytic O I_DISEASE/I_BIO
leukemia O I_DISEASE/I_BIO
cell O I_DISEASE/I_BIO
lines O I_DISEASE/I_BIO
HL-60 O O
and O O
KG-1 O B_GENE/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Mononuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
clonogenic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
incubated O O
for O O
one O B_TIME[MEASURE]/B_ENT
hour O I_TIME[MEASURE]/I_ENT
with O O
cycloheximide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
followed O O
by O O
the O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
for O O
three O B_NUMBER[MEASURE]
or O O
17 O B_NUMBER[MEASURE]/B_ENT
hours O I_NUMBER[MEASURE]/I_ENT
, O O
of O O
Ara-C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
before O O
being O O
plated O O
in O O
a O O
methylcellulose O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
culture O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

CFU-GM O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
survival O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O O
significantly O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
if O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O O
treated O O
with O O
cycloheximide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
before O O
Ara-C O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
exposure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Similar O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
cycloheximide O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
pretreatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
CML O B_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_DISEASE_ADJECTIVE[DISEASE]
and O O
clonogenic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
HL-60 O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
KG-1 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O O
to O O
protect O O
CFU-GM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
from O O
Ara-C-induced O B_DISEASE_ADJECTIVE[DISEASE]
cytotoxicity O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Primary O O
cortisol O O
resistance O O
accompanied O O
by O O
a O O
reduction O O
in O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
two O O
members O O
of O O
the O O
same O O
family O O
. O O

This O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
describes O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
a O O
man O B_PERSON/B_BIO
suspected O O
of O O
having O O
primary O B_DISEASE/B_LOCATION
cortisol O I_DISEASE/I_LOCATION
resistance O I_DISEASE/I_LOCATION
. O O

This O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
based O O
on O O
his O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
plasma O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cortisol O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
levels O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
24-h O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urinary O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
17-hydroxycorticosteroid O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excretion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
plus O O
the O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
he O O
had O O
no O O
manifestations O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Cushing O B_DISEASE
's O I_DISEASE
syndrome O I_DISEASE
. O O

Among O O
family O B_PERSON
members O I_PERSON
tested O O
, O O
his O O
mother O B_PERSON
also O O
had O O
hypercortisolemia O B_DISEASE/B_PERSON
. O O

Both O O
mother O B_PERSON
and O O
son O B_PERSON
had O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
unbound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plasma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
but O O
their O O
plasma O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ACTH O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
concentrations O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
within O O
the O O
normal O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
range O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Both O O
were O O
partially O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
dexamethasone O O
adrenal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suppression O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
both O O
had O O
mild O B_DISEASE
hypertension O I_DISEASE
without O O
hypokalemia O B_DISEASE
. O O

To O O
study O O
this O O
apparent O O
end-organ O O
resistance O O
to O O
cortisol O O
, O O
we O O
examined O O
the O O
glucocorticoid B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
peripheral O O
mononuclear O O
cells O O
. O O

Using O O
whole O O
cell O O
assays O O
, O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
patients O O
were O O
found O O
to O O
have O O
reduced O O
total O O
binding O O
capacity O O
. O O

We O O
conclude O O
that O O
these O O
two O O
patients O O
, O O
members O O
of O O
the O O
same O O
family O O
, O O
have O O
primary O O
cortisol O O
resistance O O
accompanied O O
by O O
a O O
reduced O O
number O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

[ O O
Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
response O O
to O O
polychemotherapy O O
in O O
acute O O
lymphatic O O
leukemia O O
] O O

Glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GR B B_LOCATION/B_ORGANIZATION
) O O
levels O O
were O O
quantified O O
in O O
leukemic O O
blasts O O
from O O
peripheral O O
blood O O
of O O
86 O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
. O O

The O O
subsequent O B_MEASURE
achievement O I_MEASURE
of O O
complete O B_DISEASE_ADJECTIVE[DISEASE]
remission O I_DISEASE_ADJECTIVE[DISEASE]
after O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O O
correlated O O
with O O
high O B_DISEASE
receptor O I_DISEASE
levels O I_DISEASE
. O O

Forty-seven O B_MEASURE
of O O
50 O B_PERSON
patients O I_PERSON
with O O
leukemic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
more O B_MEASURE/B_PERSON
than O O
6 O B_MEASURE
, O O
000 O B_MEASURE
receptor O I_MEASURE
sites O I_MEASURE
and O O
22 O B_NUMBER[MEASURE]
of O O
36 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
with O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
containing O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
6 O B_MEASURE
, O O
000 O B_MEASURE
receptor O I_MEASURE
sites O I_MEASURE
achieved O O
remission O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
study O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
leukemic O O
cells O O
may O O
predict O O
response O O
to O O
combination O O
chemotherapy O O
in O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
. O O

Specific O B_MEASURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
uptake O I_MEASURE/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
1 O B_MEASURE
, O O
25-dihydroxycholecalciferol O B_TIME[MEASURE]
by O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
chronic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
myeloid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukemia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
examined O O
mononuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
patients O B_PERSON/B_BIO
with O O
chronic O B_DISEASE
myeloid O I_DISEASE
leukemia O I_DISEASE
[ O I_DISEASE
CML O I_DISEASE
] O O
for O O
binding O O
of O O
and O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
1 O B_NUMBER[MEASURE]
, O O
25-dihydroxycholecalciferol O B_MEASURE
[ O I_MEASURE
1 O I_MEASURE
, O O
25- O B_MEASURE
( O O
OH O B_LOCATION/B_MEASURE
) O O
2D3 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Whole O B_PERSON
cells O I_PERSON
specifically O O
took O O
up O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
3H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
-1 O O
, O O
25- O B_MEASURE
( O O
OH O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
with O O
high O B_MEASURE/B_LOCATION
affinity O I_MEASURE/I_LOCATION
( O O
Kd O B_MEASURE/B_LOCATION
3.6 O I_MEASURE/I_LOCATION
X O I_MEASURE/I_LOCATION
10 O I_MEASURE/I_LOCATION
( O O
-11 O O
) O O
M O B_MEASURE
) O O
and O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Subcellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fractionation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
labeled O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
showed O O
that O O
binding O O
was O O
restricted O O
to O O
cytosols O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
nuclei O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Sucrose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gradient O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
centrifugation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
preincubated O O
with O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
3H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
-1 O O
, O O
25- O B_MEASURE
( O O
OH O O
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
revealed O O
a O O
single O B_MEASURE/B_BIO
3.6S O B_MEASURE/I_BIO
peak O B_MEASURE/I_BIO
which O O
was O O
totally O O
displaced O O
with O O
100-fold O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excess O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nonradioactive O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
we O O
were O O
unable O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
demonstrate O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O O
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
by O O
postlabeling O O
standard O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytosol O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
preparations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
cytosols O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
prepared O O
from O O
a O O
mixture O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
CML O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
and O O
1 O B_NUMBER[MEASURE]
, O O
25- O B_MEASURE
( O O
OH O B_MEASURE/B_PROTEIN[GENE]
) O O
2D3 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor-positive O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
T47D O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
human O B_DISEASE/B_LOCATION
breast O I_DISEASE/I_LOCATION
cancer O I_DISEASE/I_LOCATION
) O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
had O O
less O B_MEASURE
than O O
10 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
the O O
binding O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
measured O O
in O O
T47D O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytosol O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
alone O O
. O O

However O O
, O O
the O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
binding O O
in O O
T47D O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytosols O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
not O O
reduced O O
if O O
the O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
occupied O O
with O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
3H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
-1 O O
, O O
25- O B_MEASURE
( O O
OH O O
) O O
2D3 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
prior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PROTEIN[GENE]
to O O
the O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
CML O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytosols O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Thus O O
, O O
CML O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
appear O O
to O O
contain O O
both O O
the O O
receptor O B_GENE
for O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
an O O
unknown O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
substance O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
which O O
prevents O O
its O O
detection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
following O O
the O O
preparation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

Cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
patients O B_PERSON/B_BIO
with O O
CML O B_DISEASE/B_LOCATION
in O O
the O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
phase O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
specifically O O
bound O O
more O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
, O O
25- O B_MEASURE
( O O
OH O O
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
[ O O
18.0 O B_MEASURE
+/- O O
3.2 O B_MEASURE
( O O
S.E. O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
fmol/10 O O
( O B_MEASURE/B_LOCATION
7 O O
) O B_MEASURE/B_LOCATION
cells O O
] O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
than O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
did O O
those O O
in O O
acute O O
myeloid O B_DISEASE/B_PERSON
transformation O I_DISEASE/I_PERSON
[ O I_DISEASE/I_PERSON
7.2 O I_DISEASE/I_PERSON
+/- O I_DISEASE/I_PERSON
1.5 O I_DISEASE/I_PERSON
] O I_DISEASE/I_PERSON
or O I_DISEASE/I_PERSON
than O O
did O O
cells O O
from O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
patients O O
with O B_PERSON/B_LOCATION
acute O O
myeloid O B_DISEASE
leukemia O I_DISEASE
[ O I_DISEASE
2.6 O I_DISEASE
+/- O I_DISEASE
0.8 O I_DISEASE
] O I_DISEASE
. O I_DISEASE

Only O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
from O O
the O O
first O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_BIO
responded O O
to O O
the O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O O
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
by O O
differentiating O O
along O O
the O O
monocyte-macrophage O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
conclude O O
that O O
the O O
differentiation-induction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
is O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
depend O O
on O O
adequate O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
receptor O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
that O O
intact O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
rather O O
than O O
cytosol O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
preparations O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
should O O
be O O
studied O O
before O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
a O O
particular O B_DISEASE/B_MEASURE
tissue O I_DISEASE/I_MEASURE
are O O
designated O O
as O O
receptor O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
negative O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cell O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cycle O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
position O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
dexamethasone O B_MEASURE/B_DISEASE
binding O B_MEASURE/I_DISEASE
by O O
mouse O B_SPECIES[BIO]/B_DISEASE
and O O
human O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoid O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
dexamethasone O B_MEASURE
binding O I_MEASURE
during O O
S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dexamethasone O B_DISEASE_ADJECTIVE[DISEASE]
sensitivity O I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
determined O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cell O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
position O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
amount O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
was O O
specifically O O
bound O O
by O O
mouse O B_SPECIES[BIO]/B_DISEASE
and O O
human O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoid O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cell O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
lines O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
that O O
were O O
either O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
or O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]
to O O
growth O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
inhibition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
compared O O
. O O

Exponentially O O
growing O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
separated O O
by O O
centrifugal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
elutriation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
into O O
fractions O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
that O O
corresponded O O
to O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
positions O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
the O O
cell O B_TIME[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cycle O B_TIME[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
cell O B_MEASURE
cycle O I_MEASURE
phase O I_MEASURE
distribution O I_MEASURE
of O O
each O O
fraction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
estimated O O
by O O
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
autoradiography O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
amount O B_MEASURE/B_LOCATION
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bound O O
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
each O O
fraction O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
measured O O
by O O
a O O
whole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
assay O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
dexamethasone-sensitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lines O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
two O B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
mouse O I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
and O O
one O B_PERSON/B_BIO
human O B_PERSON/I_BIO
) O O
, O O
we O O
found O O
that O O
the O O
amount O B_MEASURE/B_LOCATION
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bound O O
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
increased O O
2-4-fold O B_DISEASE_ADJECTIVE[DISEASE]
between O O
G1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
and O O
S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
and O O
then O O
decreased O O
during O O
G2/M O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Results O O
were O O
the O O
same O O
when O O
the O O
amount O O
of O O
dexamethasone O O
bound O O
per O O
milligram O O
of O O
cell B B_PROTEIN[GENE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
protein I B_PROTEIN[GENE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
was O O
measured O O
. O O

Binding O B_TIME[MEASURE]/B_LOCATION
affinity O I_TIME[MEASURE]/I_LOCATION
was O O
the O O
same O B_MEASURE/B_LOCATION
during O O
G1 O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
but O O
the O O
proportion O B_MEASURE
of O O
bound O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
translocated O O
to O O
the O O
nucleus O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
was O O
greater O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
during O O
S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O O

In O O
contrast O B_MEASURE
, O O
we O O
found O O
that O O
the O O
amount O B_MEASURE/B_LOCATION
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bound O O
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
by O O
three O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
dexamethasone-resistant O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
two O B_SPECIES[BIO]/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
mouse O B_SPECIES[BIO]/I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
and O O
one O B_BIO/B_PERSON
human O I_BIO/I_PERSON
) O O
did O O
not O O
increase O O
during O O
S O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
phase O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O O

Our O O
results O O
indicate O O
that O O
cell O O
cycle O O
changes O O
in O O
dexamethasone O O
binding O O
are O O
not O O
simply O O
related O O
to O O
changes O O
in O O
cell B B_GENE/B_MEASURE
protein I B_GENE/I_MEASURE
or O O
cell O O
volume O O
during O O
the O O
cell O O
cycle O O
. O O

An O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
dexamethasone O B_MEASURE/B_DISEASE
binding O I_MEASURE/I_DISEASE
during O O
S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
may O O
be O O
required O O
for O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
inhibit O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
growth O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
and O O
a O O
failure O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
dexamethasone O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
increase O O
during O O
S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
might O O
represent O O
a O O
new O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mechanism O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
dexamethasone O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resistance O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
lymphoid O B_DISEASE/B_BIO
cells O I_DISEASE/I_BIO
. O O

Presence O O
and O O
steroid O O
inducibility O O
of O O
glutamine B B_GENE/B_LOCATION
synthetase I I_GENE/I_LOCATION
in O O
human O O
leukemic O O
cells O O
. O O

Glutamine B B_GENE
synthetase I I_GENE
( O O
EC O O
6.3.1.2 O O
; O O
GS O O
) O O
is O O
present O O
in O O
lymphoblasts O O
from O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
( O O
ALL O O
) O O
as O O
well O O
as O O
in O O
normal O O
peripheral O O
blood O O
lymphocytes O O
. O O

In O O
16 O O
out O O
of O O
20 O O
ALL O O
patients O O
studied O O
exposure O O
of O O
the O O
cells O O
to O O
physiological O O
concentrations O O
of O O
dexamethasone O O
in O O
vitro O O
increased O O
enzyme B B_GENE
activity O O
above O O
the O O
control O O
levels O O
. O O

The O O
increase O O
was O O
specific O O
for O O
glucocorticoid B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
receptor I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
ligands O O
. O O

A O O
direct O O
correlation O O
was O O
found O O
between O O
the O O
magnitude O O
of O O
glucocorticoid-mediated O O
increase O O
of O O
GS O O
activity O O
and O O
the O O
cellular O O
levels O O
of O O
specific O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assayed O O
in O O
the O O
same O O
cell O O
specimen O O
. O O

Moreover O O
, O O
the O O
basal O O
levels O O
of O O
the O O
enzyme B B_GENE
measured O O
in O O
cells O O
prior O O
to O O
exposure O O
to O O
dexamethasone O O
correlated O O
negatively O O
with O O
receptor O O
density O O
. O O

It O O
is O O
suggested O O
that O O
the O O
presence O O
of O O
steroid-inducible B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GS I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
ALL O O
cells O O
may O O
prove O O
to O O
be O O
a O O
marker O O
for O O
functional B B_DISEASE/B_GENE
receptor I I_DISEASE/I_GENE
sites I I_DISEASE/I_GENE
. O O

Binding O O
of O O
progestins O O
to O O
the O O
glucocorticoid B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
receptor I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O O

Correlation O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
their O O
glucocorticoid-like O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
functions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
mononuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
leukocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

A O O
number O O
of O O
physiological O O
and O O
synthetic O O
progestins O O
were O O
tested O O
for O O
their O O
ability O O
to O O
compete O O
with O O
[ O O
3H O O
] O O
dexamethasone O O
for O O
the O O
binding O O
to O O
the O O
glucocorticoid B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
of O O
human O O
mononuclear O O
leukocytes O O
and O O
their O O
ability O O
to O O
elicit O O
glucocorticoid-like O O
effects O O
on O O
the O O
same O O
cells O O
. O O

As O O
compared O O
to O O
the O O
reference O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
compound O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
dexamethasone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
relative O B_TIME[MEASURE]/B_LOCATION
receptor O I_TIME[MEASURE]/I_LOCATION
binding O I_TIME[MEASURE]/I_LOCATION
affinity O I_TIME[MEASURE]/I_LOCATION
defined O O
as O O
100 O B_MEASURE
% O I_MEASURE
) O O
, O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthetic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
progestins O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
a O O
pregnane-type O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
megestrol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
medroxyprogesterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
were O O
found O O
to O O
display O O
a O O
considerable O B_MEASURE
binding O I_MEASURE
affinity O I_MEASURE
towards O O
the O O
receptor O B_GENE
( O O
46 O B_MEASURE
and O O
42 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
respectively O O
) O O
. O O

The O O
relative O B_MEASURE/B_DISEASE
binding O I_MEASURE/I_DISEASE
affinity O I_MEASURE/I_DISEASE
of O O
the O O
naturally O O
occurring O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
to O O
the O O
receptor O B_GENE
was O O
clearly O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
. O O

The O O
effective O O
binding O O
of O O
medroxyprogesterone O O
acetate O O
to O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
was O O
confirmed O O
by O O
direct O O
binding O O
studies O O
utilizing O O
a O O
tritiated O O
derivative O O
of O O
this O O
steroid O O
. O O

No O O
evidence O O
for O O
the O O
existence O O
of O O
a O O
specific O O
progesterone B B_PROTEIN[GENE]
receptor I I_PROTEIN[GENE]
in O O
human O O
mononuclear O O
leukocytes O O
was O O
obtained O O
as O O
judged O O
by O O
the O O
results O O
of O O
competition O O
experiments O O
where O O
a O O
progesterone O O
receptor-specific O O
ligand O O
[ O O
3H O O
] O O
Org O O
2058 O O
was O O
used O O
. O O

Medroxyprogesterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
megestrol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
induced O O
glucocorticoid-like O B_DISEASE_ADJECTIVE[DISEASE]
effects O I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
lymphocyte O B_BODY_PART_OR_ORGAN_COMPONENT
functions O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

These O O
included O O
inhibition O O
of O O
the O O
proliferative O O
responses O O
to O O
the O O
T-cell B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mitogens I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concanavalin B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
phytohaemagglutinin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O O
an O O
enhanced O O
accumulation O O
of O O
immunoglobulin O O
secreting O O
cells O O
in O O
pokeweed O O
mitogen-stimulated O O
cultures O O
. O O

The O O
progestin O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
appears O O
to O O
be O O
mediated O O
through O O
a O O
radiosensitive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
suppressor O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
) O O
subpopulation O B_MEASURE
of O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O O
, O O
the O O
synthetic O O
progestins O O
related O O
structurally O O
to O O
19-nortestosterone O O
, O O
norethisterone O O
and O O
d-norgestrel O O
, O O
were O O
virtually O O
devoid O O
of O O
binding O O
affinity O O
towards O O
the O O
glucocorticoid B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
nor O O
did O O
they O O
measurably O O
influence O O
the O O
in O O
vitro O O
lymphocyte O O
functions O O
. O O

These O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrate O O
that O O
certain O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
progestins O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
common O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
probably O O
possess O O
inherent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
glucocorticoid O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
suggest O O
that O O
side O B_DISEASE_ADJECTIVE[DISEASE]
effects O I_DISEASE_ADJECTIVE[DISEASE]
attributable O I_DISEASE_ADJECTIVE[DISEASE]
to O O
this O O
character O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
e.g. O B_DISEASE/B_PROTEIN[GENE]
suppression O O
of O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
the O O
pituitary-adrenal O O
axis O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
) O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
might O O
be O O
expected O O
when O O
these O O
compounds O O
are O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
in O O
pharmacological O O
doses O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Metabolic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
ultrastructural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
in O O
vitro O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lysis O I_ORGANIZATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chronic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukemia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Human O O
chronic O O
lymphocytic O O
leukemia O O
( O O
CLL O O
) O O
cells O O
like O O
prothymocytes O O
and O O
immunoactivated O O
T-lymphocytes O O
are O O
readily O O
lysed O O
in O O
vitro O O
by O O
pharmacological O O
concentrations O O
of O O
glucocorticoids O O
such O O
as O O
cortisol O O
, O O
whereas O O
peripheral O O
blood O O
lymphocytes O O
and O O
thymocytes O O
are O O
unaffected O O
by O O
the O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
metabolic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
ultrastructural O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
cortisol-induced O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
killing O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
process O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O O
CLL O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
are O O
recorded O O
. O O

In O O
vitro O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
lysis O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
found O O
to O O
be O O
temperature O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dependent O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
was O O
detected O O
only O O
after O O
6 O B_NUMBER[MEASURE]/B_LOCATION
to O O
8 O B_MEASURE
hr O I_MEASURE
incubation O I_MEASURE
with O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
means O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
trypan O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blue O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exclusion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
30 O O
min O O
of O O
incubation O O
with O O
cortisol O O
at O O
either O O
37 O O
degrees O O
or O O
4 O O
degrees O O
followed O O
by O O
the O O
removal O O
of O O
the O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
still O O
sufficient O O
to O O
induce O O
the O O
lytic O O
process O O
. O O

Ultrastructural O O
studies O O
demonstrated O O
sequential O O
changes O O
in O O
the O O
cytoplasm O O
, O O
including O O
swelling O O
of O O
mitochondria O O
and O O
cytoplasmic O O
decompartmentalization O O
, O O
followed O O
by O O
loss O O
of O O
surface O O
microvilli O O
with O O
the O O
appearance O O
of O O
`` O O
holes O O
'' O O
in O O
the O O
cell O O
membrane O O
, O O
and O O
subsequent O O
condensation O O
of O O
nuclear B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
chromatin I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
large O O
holes O O
in O O
the O O
membrane O O
appearing O O
after O O
6 O O
hr O O
of O O
incubation O O
with O O
the O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
the O O
cause O O
for O O
the O O
penetration O O
of O O
the O O
viable O O
stain O O
into O O
the O O
dead O O
cells O O
, O O
as O O
seen O O
by O O
light O O
microscopy O O
. O O

Addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
metabolic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O O
actinomycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
D O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
puromycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
and O O
cycloheximide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
following O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lysis O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

An O O
excess O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
an O O
antagonist O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
such O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
as O O
cortexolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
to O O
inhibit O O
the O O
cortisol-induced O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cytolysis O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
the O O
CLL O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

It O O
is O O
suggested O O
that O O
the O O
glucocorticoid-induced O O
lysis O O
of O O
human O O
CLL O O
cells O O
is O O
similar O O
to O O
the O O
phenomenon O O
observed O O
in O O
rat O O
or O O
murine O O
lymphocytes O O
and O O
is O O
mediated O O
by O O
interaction O O
of O O
the O O
steroid O O
molecule O O
with O O
the O O
cytoplasmic B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
resulting O O
complex O O
appears O O
to O O
activate O O
specific O O
gene B B_GENE
( O O
s O O
) O O
the O O
products O O
of O O
which O O
eventually O O
cause O O
cytolysis O O
. O O

Glucocorticoid B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
lymphoid O O
tumors O O
. O O

There O O
is O O
a O O
range O O
of O O
levels O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
numbers O O
seen O O
in O O
the O O
various O O
subclasses O O
of O O
acute O O
lymphatic O O
leukemia O O
( O O
ALL O O
) O O
. O O

This O O
variability O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
not O O
be O O
explained O O
by O O
the O O
known O O
correlation O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
active O B_DISEASE/B_ORGANISM_FUNCTION
cell O I_DISEASE/I_ORGANISM_FUNCTION
proliferation O I_DISEASE/I_ORGANISM_FUNCTION
and O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
number O B_MEASURE
of O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
since O O
the O O
tumors O B_DISEASE/B_PERSON
with O O
the O O
highest O B_MEASURE/B_DISEASE
growth O I_MEASURE/I_DISEASE
fraction O I_MEASURE/I_DISEASE
( O O
i.e. O O
, O O
Burkitt O O
's O B_DISEASE
lymphoma O I_DISEASE
and O I_DISEASE
T-cell O O
leukemia O B_DISEASE/B_GENE
) O I_DISEASE/I_GENE
tend O O
to O O
have O O
lower O O
average O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
receptor O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
numbers O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
do O O
tumors O O
with O B_DISEASE/B_PERSON
lower O O
growth O B_DISEASE/B_MEASURE
fractions O I_DISEASE/I_MEASURE
such O I_DISEASE/I_MEASURE
as O I_DISEASE/I_MEASURE
common O O
ALL O B_LOCATION/B_MEASURE
. O O

All O O
clinical O O
specimens O O
from O O
patients O O
with O O
lymphatic O O
leukemia O O
have O O
some O O
measurable O O
level O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
; O O
therefore O O
, O O
the O O
resistance O O
seen O O
in O O
vivo O O
can O O
not O O
be O O
explained O O
by O O
the O O
lack O O
of O O
receptors O O
. O O

However O O
, O O
there O O
has O O
been O O
a O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
our O O
hands O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
receptor O B_MEASURE/B_DISEASE
level O B_MEASURE/I_DISEASE
and O O
prognosis O B_MEASURE/B_DISEASE
. O O

On O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
it O O
is O O
proposed O O
that O O
perhaps O O
the O O
high O B_DISEASE/B_PERSON
receptor O I_DISEASE/I_PERSON
cell O I_DISEASE/I_PERSON
lines O I_DISEASE/I_PERSON
( O O
i.e. O O
, O O
common O B_LOCATION/B_MEASURE
ALL O O
of O O
childhood O B_PERSON/B_DISEASE
) O O
have O O
relative O B_MEASURE
stability O I_MEASURE
of O O
their O O
genetic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
material O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
making O O
glucocorticoid-resistant O B_DISEASE
mutations O I_DISEASE
less O O
likely O B_DISEASE_ADJECTIVE[DISEASE]
to O O
occur O O
in O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
these O O
cells O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
than O O
in O O
low-receptor O B_DISEASE/B_PERSON
cell O I_DISEASE/I_PERSON
lines O I_DISEASE/I_PERSON
( O O
i.e. O O
, O O
T-cell O B_DISEASE/B_PERSON
leukemia O I_DISEASE/I_PERSON
) O O
. O O

This O O
greater O B_DISEASE_ADJECTIVE[DISEASE]
genetic O I_DISEASE_ADJECTIVE[DISEASE]
variability O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
low-receptor O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
lines O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
could O O
account O O
for O O
the O O
earlier O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
emergence O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
clinical O B_DISEASE
glucocorticoid O I_DISEASE
resistance O I_DISEASE
in O O
these O O
patients O B_PERSON/B_BIO
. O O

[ O O
Tumor O O
histology O O
and O O
steroid B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
receptors I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
breast O O
carcinoma O O
] O O

In O O
Specimens O O
of O O
115 O O
patients O O
with O O
breast O O
cancer O O
4 O O
tumorparameters O O
( O O
tumorsize O O
, O O
tumorboder O O
, O O
nucleargrade O O
, O O
lymphocytic O O
stromal O O
reaction O O
) O O
3 O O
features O O
of O O
regional O O
lymphnodes O O
( O O
sinushistiocytosis O O
, O O
T-cellreaction O O
, O O
lymphnode O O
metastases O O
) O O
and O O
estrogen B B_DISEASE
and I I_DISEASE
progesteron I I_DISEASE
receptors I I_DISEASE
were O O
determined O O
. O O

A O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sinushistiocytosis O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
T-cellreaction O B_DISEASE
could O O
be O O
verified O O
mainly O O
in O O
metastases O B_DISEASE/B_BIO
in O O
free O B_DISEASE/B_BIO
lymphnodes O I_DISEASE/I_BIO
. O O

The O O
steroid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O O
does O O
not O O
correlate O O
with O O
histological O O
parameters O O

Aldosterone-receptor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deficiency O O
in O O
pseudohypoaldosteronism O O
. O O

Pseudohypoaldosteronism O B_DISEASE
, O O
a O O
syndrome O B_DISEASE
characterized O O
by O O
salt O B_DISEASE
wasting O I_DISEASE
and O O
failure O B_DISEASE_ADJECTIVE[DISEASE]
to O O
thrive O O
, O O
usually O O
presents O O
in O O
infancy O B_TIME[MEASURE]/B_PERSON
as O O
high O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
urinary O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
levels O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
despite O O
hyponatremia O B_DISEASE
, O O
hyperkalemia O B_DISEASE
, O O
hyperreninemia O B_DISEASE
, O O
and O O
elevated O O
aldosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

We O O
have O O
investigated O O
this O O
syndrome O O
for O O
the O O
possibility O O
of O O
abnormal B B_DISEASE_ADJECTIVE[DISEASE]
Type I I_DISEASE_ADJECTIVE[DISEASE]
I I I_DISEASE_ADJECTIVE[DISEASE]
or O O
`` B B_MEASURE/B_PROTEIN[GENE]
mineralocorticoid-like I I_MEASURE/I_PROTEIN[GENE]
'' I I_MEASURE/I_PROTEIN[GENE]
receptors I I_MEASURE/I_PROTEIN[GENE]
, O O
which O O
have O O
intrinsic O O
steroid O O
specificity O O
indistinguishable O O
from O O
that O O
of O O
renal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mineralocorticoid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
are O O
found O O
in O O
many O O
tissues O O
and O O
cells O O
, O O
including O O
mononuclear O O
leukocytes O O
. O O

We O O
have O O
studied O O
three O B_PERSON
patients O I_PERSON
with O O
pseudohypoaldosteronism O B_DISEASE/B_LOCATION
: O O
the O O
28-year-old O B_PERSON
index O I_PERSON
case O I_PERSON
in O O
Melbourne O B_LOCATION
( O O
Patient O B_LOCATION/B_MEASURE
1 O I_LOCATION/I_MEASURE
) O O
and O O
two O B_PERSON/B_NUMBER[MEASURE]
siblings O B_PERSON/I_NUMBER[MEASURE]
in O O
Munich O B_LOCATION/B_NUMBER[MEASURE]
, O O
eight O B_NUMBER[MEASURE]/B_LOCATION
and O O
two O B_NUMBER[MEASURE]
years O I_NUMBER[MEASURE]
of O O
age O B_TIME[MEASURE]
( O O
Patients O B_NUMBER[MEASURE]
2 O I_NUMBER[MEASURE]
and O O
3 O B_NUMBER[MEASURE]
) O O
; O O
clinically O O
, O O
Patient O B_PERSON
3 O I_PERSON
had O O
a O O
less O O
severe O B_DISEASE/B_PERSON
case O I_DISEASE/I_PERSON
than O O
his O O
sister O B_PERSON
. O O

Percoll-separated O B_MEASURE/B_GENE
control O I_MEASURE/I_GENE
monocytes O I_MEASURE/I_GENE
bound O O
[ O O
3H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
aldosterone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
affinity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
Kd O B_PROTEIN[GENE]/B_MEASURE
approximately O O
3 O B_MEASURE/B_COLOR
nM O I_MEASURE/I_COLOR
) O O
and O O
limited O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
capacity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
150 O B_MEASURE/B_LOCATION
to O O
600 O B_MEASURE/B_ENT
sites O I_MEASURE/I_ENT
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
) O O
. O O

On O O
repeated O O
examination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
no O O
[ O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O O
aldosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
found O O
in O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O O
Patients O B_NUMBER[MEASURE]/B_PERSON
1 O I_NUMBER[MEASURE]/I_PERSON
and O O
2 O B_NUMBER[MEASURE]
; O O
in O O
Patient O B_PERSON/B_MEASURE
3 O B_PERSON/I_MEASURE
, O O
the O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
62 O B_MEASURE
sites O I_MEASURE
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
, O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
2 O B_MEASURE/B_LOCATION
S.D. O I_MEASURE/I_LOCATION
below O O
those O O
of O O
the O O
control O O
. O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON

Levels O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
parents O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
Munich O B_PERSON/B_ORGANIZATION
patients O I_PERSON/I_ORGANIZATION
( O O
first O B_PERSON/B_MEASURE
cousins O B_PERSON/I_MEASURE
) O O
were O O
normal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
appears O O
that O O
pseudohypoaldosteronism O O
is O O
caused O O
by O O
a O O
Type O O
I O O
receptor O O
defect O O
, O O
that O O
the O O
defect O O
may O O
be O O
complete O O
or O O
partial O O
, O O
that O O
transmission O O
may O O
be O O
autosomal O O
recessive O O
, O O
and O O
that O O
the O O
study O O
of O O
patients O O
with O O
pseudohypoaldosteronism O O
may O O
indicate O O
physiologic O O
roles O O
for O O
Type B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
nonepithelial O O
tissues O O
. O O

Glucocorticoid O O
inhibition O O
of O O
urokinase-like B B_DISEASE/B_GENE
plasminogen I B_DISEASE/I_GENE
activators I B_DISEASE/I_GENE
in O O
cultured O O
human O O
lymphoblasts O O
. O O

Two O B_MEASURE/B_LOCATION
human O I_MEASURE/I_LOCATION
lymphoblast O I_MEASURE/I_LOCATION
cell O I_MEASURE/I_LOCATION
lines O I_MEASURE/I_LOCATION
, O O
LICR-LON-HMy2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
( O O
HMy2 O B_GENE
cells O I_GENE
) O O
and O O
GM4672A O B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
are O O
moderately O O
growth O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibited O O
by O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
1 O B_MEASURE
, O O
4-pregnadien-9-fluoro-16 O B_TIME[MEASURE]
alpha-methyl-11 O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
17 O B_MEASURE/B_PERSON
alpha O I_MEASURE/I_PERSON
, O O
21-triol-3 O B_MEASURE
, O O
20-dione O B_MEASURE
) O O
( O O
Dex O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Both O O
cell O O
types O O
secrete O O
a O O
urokinase B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
UK I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
-like I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
plasminogen I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PA B B_LOCATION/B_ORGANIZATION
) O O
. O O

Treatment O O
of O O
both O O
HMy2 O O
and O O
GM4672A O O
cells O O
with O O
Dex O O
for O O
1-4 O O
days O O
inhibits O O
extracellular O O
PA B B_GENE/B_DISEASE
activity O O
in O O
a O O
concentration-dependent O O
manner O O
, O O
being O O
half-maximal O O
at O O
approximately O O
1 O O
X O O
10 O O
( O O
-9 O O
) O O
M O O
. O O

Inhibition O O
of O O
PA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
both O O
cell O O
types O O
is O O
specific O O
for O O
active O O
glucocorticoids O O
, O O
and O O
this O O
specificity O O
parallels O O
the O O
ability O O
of O O
various O O
steroids O O
to O O
bind O O
to O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

HMy2 O O
cell O O
PA B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
is O O
fully O O
suppressible O O
by O O
Dex O O
, O O
whereas O O
up O O
to O O
one O O
third O O
of O O
the O O
activator O O
expressed O O
by O O
GM4672A O O
cells O O
is O O
resistant O O
to O O
glucocorticoid O O
inhibition O O
. O O

Mixing O O
experiments O O
using O O
a O O
UK O O
standard O O
and O O
conditioned O O
media O O
from O O
Dex-treated O O
cells O O
suggest O O
an O O
absence O O
of O O
glucocorticoid-inducible B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
UK B B_GENE
or O O
plasmin B B_LOCATION
in O O
both O O
cell O O
types O O
. O O

However O O
, O O
conditioned O O
media O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
from O O
Dex-treated O B_DISEASE/B_BIO
GM4672A O I_DISEASE/I_BIO
cells O I_DISEASE/I_BIO
inhibits O O
a O O
portion O B_MEASURE
of O O
the O O
homologous O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cellular O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
activator O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
conditioned O O
media O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
from O O
control O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
GM4672A O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

Thus O O
, O O
low O O
levels O O
of O O
glucocorticoid-inducible B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
contribute O O
to O O
, O O
but O O
can O O
not O O
fully O O
account O O
for O O
, O O
Dex O O
inhibition O O
of O O
GM4672A B B_GENE
PA I I_GENE
activity O O
. O O

Glucocorticoid-inducible B B_GENE/B_TIME[MEASURE]
inhibitors I I_GENE/I_TIME[MEASURE]
in O O
HMy2 O O
cells O O
are O O
either O O
totally O O
absent O O
or O O
are O O
present O O
at O O
undetectable O O
levels O O
. O O

Thus O O
, O O
regulation O O
of O O
UK-like B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PAs I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
HMy2 O O
and O O
GM4672A O O
cells O O
differs O O
with O O
respect O O
to O O
the O O
extent O O
to O O
which O O
glucocorticoids O O
inhibit O O
constitutively B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expressed I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
, O O
as O O
well O O
as O O
the O O
possible O O
contribution O O
of O O
glucocorticoid-inducible B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
regulatory O O
process O O
in O O
GM4672A O O
cells O O
. O O

Characterization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
aldosterone O B_GENE
binding O I_GENE
sites O I_GENE
in O O
circulating O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
mononuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
leukocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

Aldosterone O B_GENE/B_PERSON
binding O I_GENE
sites O B_LOCATION/B_ENT
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
mononuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
leukocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O O
characterized O O
after O O
separation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
blood O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
a O O
Percoll O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gradient O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

After O O
washing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
resuspension O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
RPMI-1640 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
incubated O O
at O O
37 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
for O O
1 O B_MEASURE
h O O
with O O
different O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
concentrations O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
aldosterone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
plus O O
a O O
100-fold O B_MEASURE
concentration O I_MEASURE
of O O
RU-26988 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
11 O B_MEASURE/B_PERSON
alpha O I_MEASURE/I_PERSON
, O O
17 O B_NUMBER[MEASURE]
alpha-dihydroxy-17 O I_NUMBER[MEASURE]
beta-propynylandrost-1 O I_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
, O O
6-trien-3-one O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
with O O
or O O
without O O
an O O
excess O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
unlabeled O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aldosterone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Aldosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
binds O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
a O O
single O B_MEASURE/B_LOCATION
class O B_MEASURE/I_LOCATION
of O O
receptors O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
an O O
affinity O B_MEASURE
of O O
2.7 O B_MEASURE
+/- O I_MEASURE
0.5 O I_MEASURE
nM O I_MEASURE
( O O
means O B_MEASURE/B_LOCATION
+/- O O
SD O B_MEASURE/B_DISEASE
, O O
n O O
= O O
14 O B_MEASURE
) O O
and O O
a O O
capacity O B_MEASURE/B_LOCATION
of O O
290 O B_MEASURE
+/- O O
108 O B_MEASURE
sites/cell O I_MEASURE
( O O
n O B_MEASURE/B_LOCATION
= O O
14 O B_MEASURE
) O O
. O O

The O O
specificity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
show O O
a O O
hierarchy O B_PERSON/B_MEASURE
of O O
affinity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
desoxycorticosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
= O O
corticosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
= O O
aldosterone O B_MEASURE
greater O I_MEASURE
than O O
hydrocortisone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
greater O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
results O O
indicate O O
that O O
mononuclear O O
leukocytes O O
could O O
be O O
useful O O
for O O
studying O O
the O O
physiological O O
significance O O
of O O
these O O
mineralocorticoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
their O O
regulation O O
in O O
humans O O
. O O

Mineralocorticoid B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
circulating O O
mononuclear O O
leukocytes O O
of O O
patients O O
with O O
primary O O
hyperaldosteronism O O
. O O

Mineralocorticoid B B_GENE/B_PERSON
and I I_GENE/I_PERSON
glucocorticoid I I_GENE/I_PERSON
receptors I I_GENE/I_PERSON
were O O
measured O O
in O O
circulating O O
mononuclear O O
leukocytes O O
in O O
5 O O
patients O O
affected O O
by O O
Conn O O
's O O
syndrome O O
( O O
3 O O
cases O O
of O O
bilateral O O
adrenal O O
hyperplasia O O
and O O
2 O O
cases O O
of O O
adenoma O O
plus O O
unilateral O O
hyperplasia O O
) O O
. O O

The O O
number O B_MEASURE
of O O
the O O
binding O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
sites O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
resulted O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
189 O B_MEASURE
+/- O O
114 O B_MEASURE
, O O
mean O B_MEASURE
+/- O O
SD O B_MEASURE/B_DISEASE
) O O
, O O
as O O
compared O O
with O O
the O O
normal O B_MEASURE/B_PERSON
controls O I_MEASURE/I_PERSON
( O O
298 O B_MEASURE/B_PROTEIN[GENE]
+/- O I_MEASURE/I_PROTEIN[GENE]
105 O I_MEASURE/I_PROTEIN[GENE]
) O O
. O O

The O O
affinity O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
aldosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
the O O
receptor O B_GENE
was O O
found O O
to O O
be O O
not O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
that O O
of O O
healthy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
control O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
subjects O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
capacity O O
and O O
the O O
affinity O O
of O O
dexamethasone O O
for O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ranged O O
in O O
the O O
normal O O
values O O
. O O

These O O
data O O
suggest O O
a O O
possible O O
down-regulation O O
of O O
mineralocorticoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
humans O O
. O O

Short-term O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
long-term O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
estrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
lymphoid O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
lymphoid O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
some O O
remarks O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
significance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
carcinogenesis O B_DISEASE/B_ORGANISM_FUNCTION
. O O

Estrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O O
long O O
been O O
thought O O
to O O
play O O
a O O
role O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
regulating O O
the O O
immune O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
difference O B_MEASURE
in O O
some O O
types O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
immune O B_DISEASE
responses O I_DISEASE
between O O
males O B_PERSON
and O O
females O B_PERSON/B_BIO
is O O
well-known O B_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
is O O
the O O
pronounced O B_DISEASE_ADJECTIVE[DISEASE]
thymic O I_DISEASE_ADJECTIVE[DISEASE]
involution O I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
exogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
estrogens O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Estrogens O O
stimulate O O
some O O
aspects O O
of O O
macrophage O O
activity O O
and O O
, O O
depending O O
on O O
dose O O
and O O
mitogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
inhibit O O
or O O
stimulate O O
lymphocyte O O
proliferative O O
response O O
in O O
vitro O O
. O O

Another O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
the O O
estrogen O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
delayed O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
type O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
hypersensitivity O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
response O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
broad O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
review O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
given O O
of O O
such O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
estrogen O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
lymphoid O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
immune O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Most O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
published O O
so O O
far O O
are O O
phenomenological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
the O O
recent O O
description O O
of O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
thymus O O
and O O
in O O
some O O
lymphocyte O O
subpopulations O O
, O O
as O O
well O O
as O O
a O O
deeper O O
understanding O O
of O O
regulating O O
factors O O
in O O
the O O
immune O O
system O O
, O O
open O O
the O O
possibility O O
of O O
a O O
more O O
detailed O O
understanding O O
of O O
the O O
estrogen O O
mechanism O O
of O O
interference O O
. O O

Estrogen O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
adults O B_PERSON/B_BIO
are O O
reversible O B_DISEASE_ADJECTIVE[DISEASE]
. O O

After O O
treating O O
neonatal O B_PERSON/B_DISEASE
mice O I_PERSON/I_DISEASE
with O O
the O O
synthetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
estrogen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diethylstilbestrol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DES O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
disturbances O B_DISEASE_ADJECTIVE[DISEASE]
are O O
induced O O
in O O
lymphocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
populations O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
lymphocyte O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
are O O
permanent O B_DISEASE_ADJECTIVE[DISEASE]
and O O
irreversible O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Lymphocytes O O
from O O
adult O O
, O O
neonatally O O
DES-treated O O
female O O
mice O O
have O O
a O O
reduced O O
mitogen O O
response O O
to O O
ConA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
LPS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
T B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mitogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
the O O
delayed O O
type O O
hypersensitivity O O
response O O
is O O
depressed O O
. O O

A O O
detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrated O O
a O O
decreased O O
T O B_DISEASE/B_MEASURE
helper O I_DISEASE/I_MEASURE
cell O I_DISEASE/I_MEASURE
population O I_DISEASE/I_MEASURE
. O O

The O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Natural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Killer O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
permanently O O
reduced O O
and O O
this O O
functional O B_DISEASE_ADJECTIVE[DISEASE]
impairment O I_DISEASE_ADJECTIVE[DISEASE]
is O O
related O O
to O O
a O O
decreased O O
number O B_MEASURE
of O O
these O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
in O O
turn O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determined O O
at O O
the O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
marrow O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
level O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O O

The O O
same O B_PERSON/B_ENT
animals O I_PERSON/I_ENT
have O O
an O O
increased O O
sensitivity O B_DISEASE/B_MEASURE
to O O
chemical O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carcinogens O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
methylcholanthrene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
) O O
and O O
they O O
spontaneously O O
develop O O
epithelial O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
uterine O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cervix O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
which O O
morphologically O O
are O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
adenocarcinoma O B_DISEASE
. O O

The O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
estrogen-associated O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
malignancy O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
estrogen O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
lymphocyte O B_PERSON/B_DISEASE
functions O I_PERSON/I_DISEASE
deserves O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
affecting O O
the O O
hormonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
normal O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
leukaemic O B_DISEASE/B_PERSON
peripheral O I_DISEASE/I_PERSON
leucocytes O I_DISEASE/I_PERSON
. O O

The O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigated O O
the O O
behaviour O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
uptake O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
leukaemic O B_DISEASE
cells O I_DISEASE
( O O
CML O B_DISEASE/B_LOCATION
, O O
CLL O B_DISEASE/B_LOCATION
, O O
AML O B_DISEASE
, O O
ALL O O
) O O
, O O
in O O
basal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conditions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
after O O
incubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
modify O O
the O O
cellular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cAMP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
PGE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
PGF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
leukaemic O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
cells O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O O
an O O
alteration O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
incorporation O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

This O O
alteration O O
was O O
scarcely O O
modified O O
by O O
incubation O O
with O O
theophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
which O O
increases O O
cellular O O
concentration O O
of O O
cAMP O O
. O O

On O O
the O O
other O B_PERSON/B_MEASURE
hand O I_PERSON/I_MEASURE
, O O
it O O
was O O
moderately O O
counteracted O O
by O O
thioproline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
was O O
evidently O O
inhibited O O
by O O
flurbiprofen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
also O O
reduced O O
cellular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
prostaglandins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
particularly O O
PGE2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
with O O
the O O
exception O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
PGF2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
which O O
showed O O
a O O
poor O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
in O O
the O O
behavior O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
hormonal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uptake O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CML O B_DISEASE
, O O
in O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
that O O
of O O
AML O B_DISEASE/B_LOCATION
, O O
CLL O B_DISEASE
and O O
ALL O O
peripheral O B_LOCATION
leucocytes O I_LOCATION
. O O

Human O B_DISEASE
breast O I_DISEASE
cancer O I_DISEASE
and O O
impaired O B_DISEASE
NK O I_DISEASE
cell O I_DISEASE
function O I_DISEASE
. O O

Recent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
advances O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
tumor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunology O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
led O O
to O O
the O O
discovery O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
a O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphoid O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
unique O B_DISEASE
antitumor O I_DISEASE
activity O I_DISEASE
. O O

Natural O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
killer O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O O
NK O B_PROTEIN[GENE]/B_LOCATION
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
form O O
an O O
antitumor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
surveillance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
appear O O
to O O
be O O
vital O B_DISEASE_ADJECTIVE[DISEASE]
in O O
preventing O O
tumor O B_DISEASE
growth O I_DISEASE
and O O
metastasis O B_DISEASE/B_ORGANISM_FUNCTION
in O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

We O O
studied O O
NK O B_DISEASE_ADJECTIVE[DISEASE]
activity O I_DISEASE_ADJECTIVE[DISEASE]
in O O
patients O B_PERSON/B_BIO
with O O
benign O B_DISEASE_ADJECTIVE[DISEASE]
and O O
malignant O B_DISEASE
breast O I_DISEASE
disease O I_DISEASE
, O O
using O O
a O O
chromium-51 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
release O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
microtiter O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cytotoxicity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
K562 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
targets O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Compared O O
with O O
benign O B_PERSON/B_BIO
controls O I_PERSON/I_BIO
, O O
patients O B_PERSON/B_BIO
with O O
malignancies O B_DISEASE
had O O
significantly O O
depressed O O
NK O B_DISEASE_ADJECTIVE[DISEASE]
-mediated O I_DISEASE_ADJECTIVE[DISEASE]
lysis O I_DISEASE_ADJECTIVE[DISEASE]
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0.01 O B_MEASURE
) O O
. O O

Furthermore O O
, O O
lysis O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
those O O
with O O
advanced O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
disease O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O O
stages O B_TIME[MEASURE]/B_PROTEIN[GENE]
II O I_TIME[MEASURE]/I_PROTEIN[GENE]
, O O
III O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
, O O
and O O
IV O B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
) O O
was O O
significantly O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
in O O
those O O
with O O
limited O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
disease O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
stage O B_LOCATION
I O I_LOCATION
) O O
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0.01 O B_MEASURE
) O O
. O O

NK O B_DISEASE_ADJECTIVE[DISEASE]
activity O I_DISEASE_ADJECTIVE[DISEASE]
was O O
not O O
correlated O O
to O O
estrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
progesterone O O
receptor O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
states O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O O

Positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
correlation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
depressed O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
natural O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
killer O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activity O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
with O O
the O O
extent O B_DISEASE/B_MEASURE
of O O
tumor O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
spread O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
supports O O
the O O
concept O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
an O O
NK O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
immune O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
surveillance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
breast O B_DISEASE
cancer O I_DISEASE
and O O
emphasizes O O
its O O
importance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
malignancy O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Immunosuppressive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
progesterone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O O
pregnancy O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
depends O O
on O O
the O O
progesterone O B_MEASURE/B_LOCATION
binding O I_MEASURE/I_LOCATION
capacity O I_MEASURE/I_LOCATION
of O O
the O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Cytotoxic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
progesterone O B_MEASURE/B_LOCATION
binding O I_MEASURE/I_LOCATION
capacity O I_MEASURE/I_LOCATION
of O O
the O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
together O O
with O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
progesterone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
concentrations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
were O O
determined O O
in O O
women O B_PERSON/B_ORGANIZATION
with O O
normal O B_DISEASE/B_ORGANISM_FUNCTION
pregnancy O I_DISEASE/I_ORGANISM_FUNCTION
or O O
with O O
a O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
threatened O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
abortion O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
or O O
threatened O O
premature O B_ORGANISM_FUNCTION/B_DISEASE
labour O I_ORGANISM_FUNCTION/I_DISEASE
. O O

The O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
women O B_PERSON
with O O
threatened O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
abortion O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
or O O
threatened O O
premature O B_ORGANISM_FUNCTION/B_DISEASE
labour O I_ORGANISM_FUNCTION/I_DISEASE
showed O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
cytotoxic O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
activity O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0.001 O B_MEASURE
) O O
and O O
significantly O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
progesterone O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
binding O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
capacity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0.001 O B_MEASURE
) O O
than O O
did O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O O
from O O
the O O
healthy O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
pregnant O B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
women O B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Significant O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inverse O I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation O I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
between O O
progesterone O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cytotoxic O B_MEASURE
activity O I_MEASURE
of O O
the O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0.001 O B_MEASURE
) O O
, O O
but O O
the O O
progesterone O B_MEASURE/B_LOCATION
concentration O I_MEASURE/I_LOCATION
of O O
the O O
pregnancy O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O O
to O O
have O O
no O O
influence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
two O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicate O O
that O O
intact O B_MEASURE/B_DISEASE
progesterone O B_MEASURE/I_DISEASE
binding O B_MEASURE/I_DISEASE
capacity O B_MEASURE/I_DISEASE
of O O
the O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
an O O
essential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
factor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
for O O
the O O
manifestation O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
blocking O O
effect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
exerted O O
by O O
pregnancy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
serum O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
lymphocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
cytotoxicity O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_ORGANISM_FUNCTION
in O O
vitro O B_SPECIES[BIO]/B_LOCATION
. O O

Serum O O
sex O O
steroid O O
and O O
peptide O O
hormone O O
concentrations O O
, O O
and O O
endometrial O O
estrogen O O
and O O
progestin O O
receptor O O
levels O O
during O O
administration O O
of O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leukocyte I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interferon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Five O O
normally O O
cycling O O
healthy O O
women O O
were O O
given O O
daily O O
subcutaneous O O
injections O O
of O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leukocyte I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interferon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
3 O O
X O O
10 O O
( O O
6 O O
) O O
units/day O O
) O O
from O O
the O O
3rd O O
through O O
23rd O O
day O O
of O O
the O O
menstrual O O
cycle O O
, O O
and O O
serum O O
steroid O O
and O O
peptide O O
hormone O O
concentrations O O
monitored O O
at O O
3-day O O
intervals O O
during O O
the O O
treatment O O
and O O
the O O
preceding O O
control O O
cycle O O
. O O

Concentrations O O
of O O
cytosol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nuclear I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
estrogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
ERC B B_LOCATION/B_ORGANIZATION
and O O
ERN B B_LOCATION/B_ORGANIZATION
, O O
respectively O O
) O O
and O O
progestin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PRC B B_LOCATION
and O O
PRN B B_LOCATION/B_ORGANIZATION
) O O
were O O
also O O
measured O O
from O O
endometrial O O
biopsies O O
taken O O
on O O
the O O
24th O O
day O O
of O O
the O O
control O O
and O O
treatment O O
cycle O O
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
an O O
extensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monitoring O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
chemical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
hematological O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
blood O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
performed O O
. O O

Serum O O
estradiol O O
and O O
progesterone O O
concentrations O O
were O O
significantly O O
decreased O O
during O O
the O O
treatment O O
cycle O O
, O O
suggesting O O
that O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interacts O O
in O O
vivo O O
with O O
the O O
function O O
of O O
both O O
FSH O O
and O O
LH O O
. O O

No O O
significant O O
changes O O
were O O
observed O O
in O O
the O O
serum O O
peptide O O
hormone O O
concentrations O O
measured O O
( O O
FSH O O
, O O
LH O O
, O O
prolactin O O
, O O
insulin O O
, O O
growth O O
hormone O O
and O O
TSH O O
) O O
; O O
neither O O
were O O
the O O
levels O O
of O O
endometrial B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ERC I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ERN I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
PRC I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
PRN I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
affected O O
by O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O O
. O O

As O O
expected O O
, O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
resulted O O
in O O
decreased O O
leukocyte O O
counts O O
. O O

Moreover O O
, O O
an O O
increasing O O
tendency O O
in O O
the O O
activities O O
of O O
serum B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
alkaline I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
gamma-glutamyltransferase B B_GENE
during O O
the O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
shows O O
that O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
may O O
slightly O O
interfere O O
with O O
the O O
liver O O
function O O
. O O

These O O
results O O
suggest O O
that O O
one O O
of O O
the O O
mechanisms O O
by O O
which O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O O
may O O
affect O O
the O O
growth O O
of O O
hormone-dependent O O
neoplasms O O
could O O
be O O
the O O
interaction O O
with O O
production O O
and/or O O
function O O
of O O
circulating O O
hormonal O O
compounds O O
. O O

[ O O
Glucocorticoid B B_GENE
receptor I I_GENE
level O O
in O O
the O O
blood O O
leukocytes O O
in O O
different O O
acute O O
diseases O O
] O O

Content O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
cytosol O O
of O O
blood O O
leukocytes O O
, O O
concentration O O
of O O
cortisol O O
and O O
amount O O
of O O
leukocytes O O
in O O
blood O O
were O O
studied O O
in O O
20 O O
patients O O
with O O
acute O O
impairments O O
within O O
the O O
second O O
day O O
of O O
the O O
disease O O
. O O

Content O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
blood O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
leukocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
studied O O
using O O
3H-triamcinolone O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Distinct O O
increase O O
in O O
amount O O
of O O
the O O
leukocyte B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
in O O
patients O O
with O O
poisoning O O
by O O
dichlorethane O O
and O O
hypnotic O O
drugs O O
under O O
conditions O O
of O O
acute O O
myocardial O O
infarction O O
. O O

In O O
acute O O
pancreatitis O O
content O O
of O O
the O O
leukocyte B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
receptors I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
not O O
altered O O
as O O
compared O O
with O O
controls O O
. O O

Concentration O B_MEASURE/B_ENT
of O O
endogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cortisol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
increased O O
in O O
blood O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
all O O
the O O
patients O B_PERSON/B_BIO
, O O
except O O
of O O
the O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
acetate O B_DISEASE/B_PERSON
intoxication O I_DISEASE/I_PERSON
. O O

Reverse O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
observed O O
between O O
concentration O B_MEASURE/B_LOCATION
of O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
blood O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
content O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
leukocytes O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

But O O
in O O
the O O
patients O O
with O O
acute O O
pancreatitis O O
the O O
decrease O O
in O O
content O O
of O O
leukocyte B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
not O O
observed O O
although O O
there O O
was O O
an O O
increase O O
in O O
cortisol O O
concentration O O
in O O
blood O O
. O O

The O O
role O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
immunological O O
processes O O
under O O
conditions O O
of O O
purulent O O
complications O O
and O O
possibility O O
to O O
regulate O O
the O O
metabolism O O
in O O
leukocytes O O

Therapeutic O O
concentrations O O
of O O
glucocorticoids O O
suppress O O
the O O
antimicrobial O O
activity O O
of O O
human O O
macrophages O O
without O O
impairing O O
their O O
responsiveness O O
to O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

By O O
exposing O O
human O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
blood-derived O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
alveolar O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
to O O
dexamethasone O O
, O O
we O O
showed O O
in O O
these O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
that O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
markedly O O
suppress O O
the O O
antimicrobial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
but O O
not O O
macrophage O O
activation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
by O O
lymphokines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
little O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O O
2.5 O B_MEASURE
X O I_MEASURE
10 O I_MEASURE
( O O
-8 O O
) O O
mol/liter O B_MEASURE/B_LOCATION
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
prevented O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
from O O
inhibiting O O
germination O B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_BIO
of O O
Aspergillus O B_BIO
spores O I_BIO
or O O
from O O
eliminating O O
ingested O B_BIO/B_DISEASE
bacteria O I_BIO/I_DISEASE
such O I_BIO/I_DISEASE
as O O
Listeria O B_BACTERIUM[BIO]
, O O
Nocardia O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
or O O
Salmonella O B_BACTERIUM[BIO]
. O O

Damage O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
macrophage O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
inhibited O O
by O O
progesterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
appeared O O
to O O
be O O
receptor-mediated O O
. O O

In O O
accordance O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
observations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
required O O
24-36 O B_MEASURE
h O O
to O O
suppress O O
antimicrobial O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

While O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interfered O O
with O O
base-line O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
comparable O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
drug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
patients O B_PERSON/B_BIO
had O O
no O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
macrophage O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Proliferating O O
lymphocytes O O
and O O
gamma-interferon B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thus O O
increased O O
the O O
antimicrobial O O
activity O O
of O O
phagocytes O O
exposed O O
to O O
glucocorticoids O O
over O O
that O O
of O O
control O O
cells O O
. O O

Macrophage O O
activation O O
and O O
correction O O
of O O
the O O
dexamethasone O O
effect O O
by O O
gamma-interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
however O O
, O O
was O O
dependent O O
on O O
the O O
pathogen O O
. O O

The O O
lymphokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enhanced O O
the O O
antimicrobial O O
activity O O
of O O
dexamethasone-treated O O
macrophages O O
against O O
Listeria O O
and O O
Salmonella O O
but O O
not O O
against O O
Aspergillus O O
or O O
Nocardia O O
. O O

Dexamethasone-induced O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
damage O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
antimicrobial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parallels O O
observations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
glucocorticoids O O
render O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
laboratory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
susceptible O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
listeriosis O B_DISEASE/B_BACTERIUM[BIO]
and O O
aspergillosis O B_DISEASE
by O O
damaging O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resident O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
macrophages O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Suppression O O
of O O
macrophage O O
antimicrobial O O
activity O O
should O O
thus O O
be O O
considered O O
when O O
treating O O
patients O O
with O O
glucocorticoids O O
; O O
its O O
prevention O O
by O O
gamma-interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O O
be O O
beneficial O O
for O O
some O O
but O O
not O O
all O O
pathogens O O
. O O

Interleukin B B_GENE
2 I I_GENE
receptor I I_GENE
( O O
Tac B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
expression O O
in O O
HTLV-I-associated O O
adult O O
T-cell O O
leukemia O O
. O O

Interleukin-2 B B_GENE
( O O
IL-2 B B_GENE
) O O
is O O
a O O
lymphokine B B_GENE
synthesized O O
by O O
some O O
T-cells O O
following O O
activation O O
. O O

Resting O O
T-cells O O
do O O
not O O
express O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
receptors O O
are O O
rapidly O O
expressed O O
on O O
T-cells O O
following O O
interaction O O
of O O
antigens O O
, O O
mitogens O O
, O O
or O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O O
the O O
antigen-specific B B_GENE
T-cell I I_GENE
receptor I I_GENE
complex I I_GENE
. O O

Using O O
anti-Tac B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
recognizes O O
the O O
IL-2 B B_GENE
receptor I I_GENE
, O O
the O O
receptor O O
has O O
been O O
purified O O
and O O
shown O O
to O O
be O O
a O O
Mr O O
33 O O
, O O
000 O O
peptide O O
that O O
is O O
posttranslationally O O
glycosylated O O
to O O
a O O
Mr O O
55 O O
, O O
000 O O
mature O O
form O O
. O O

Normal O O
resting O O
T-cells O O
and O O
most O O
leukemic O O
T-cell O O
populations O O
do O O
not O O
express O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
however O O
, O O
the O O
leukemic O O
cells O O
of O O
the O O
11 O O
patients O O
examined O O
who O O
had O O
human O O
T-cell O O
lymphotropic O O
virus-associated O O
adult O O
T-cell O O
leukemia O O
expressed O O
the O O
Tac B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
human O O
T-cell O O
lymphotropic O O
virus-I O O
infected O O
cells O O
, O O
the O O
Mr O O
42 O O
, O O
000 O O
long O O
open B B_GENE
reading I I_GENE
frame I I_GENE
protein I I_GENE
encoded O O
in O O
part O O
by O O
the O O
pX B B_GENE
region I I_GENE
of O O
this O O
virus O O
may O O
act O O
as O O
a O O
transacting B B_GENE
transcriptional I I_GENE
activator I I_GENE
that O O
induces O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O O
, O O
thus O O
providing O O
an O O
explanation O O
for O O
the O O
constant O O
association O O
of O O
IL-2 B B_GENE
receptor I I_GENE
expression O O
with O O
adult O O
T-cell O O
lymphotropic O O
virus-I O O
infection O O
of O O
lymphoid O O
cells O O
. O O

The O O
constant O O
expression O O
of O O
large O O
numbers O O
of O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
may O O
be O O
aberrant O O
may O O
play O O
a O O
role O O
in O O
the O O
uncontrolled O O
growth O O
of O O
adult O O
T-cell O O
leukemia O O
cells O O
. O O

Two O O
patients O O
with O O
Tac-positive O O
adult O O
T-cell O O
leukemia O O
have O O
been O O
treated O O
with O O
the O O
anti-Tac B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

One O O
of O O
the O O
patients O O
had O O
6- O O
and O O
3-mo O O
remissions O O
of O O
his O O
leukemia O O
following O O
two O O
courses O O
of O O
therapy O O
with O O
this O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
directed O O
toward O O
this O O
growth B B_PROTEIN[GENE]/B_DISEASE
factor I I_PROTEIN[GENE]/I_DISEASE
receptor I I_PROTEIN[GENE]/I_DISEASE
. O O

Lymphocyte O O
glucocorticoid B B_GENE
receptor I I_GENE
binding O O
in O O
depressed O O
patients O O
with O O
hypercortisolemia O O
. O O

Despite O O
elevated O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
serum O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
urinary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
patients O B_PERSON
with O O
depressive O B_DISEASE/B_LOCATION
illness O I_DISEASE/I_LOCATION
manifest O O
none O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stigmata O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
glucocorticoid O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excess O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
hypercortisolemia O O
in O O
the O O
absence O O
of O O
clinical O O
effects O O
suggests O O
a O O
state O O
of O O
hormone O O
resistance O O
and O O
could O O
be O O
mediated O O
by O O
alterations O O
in O O
the O O
glucocorticoid B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
receptor I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O O

Earlier O O
studies O O
have O O
shown O O
that O O
small O O
doses O O
of O O
glucocorticoids O O
cause O O
a O O
decrease O O
in O O
glucocorticoid B B_GENE
receptor I I_GENE
binding O O
in O O
normal O O
human O O
lymphocytes O O
. O O

White O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
depressed O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
significant O B_DISEASE/B_LOCATION
hypercortisolemia O I_DISEASE/I_LOCATION
would O O
be O O
expected O O
to O O
show O O
a O O
similar O B_MEASURE
change O I_MEASURE
in O O
receptor O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
if O O
peripheral O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tissues O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
adequately O O
exposed O O
to O O
and O O
sensitive O B_DISEASE
to O O
the O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
we O O
compared O O
the O O
binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dexamethasone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
normal O B_PERSON/B_MEASURE
subjects O I_PERSON/I_MEASURE
and O O
depressed O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
hypercortisolemia O B_DISEASE/B_LOCATION
. O O

Lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
normal O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
had O O
a O O
mean O B_MEASURE
receptor O I_MEASURE
concentration O I_MEASURE
of O O
10.2 O B_NUMBER[MEASURE]
+/- O I_NUMBER[MEASURE]
0.66 O I_NUMBER[MEASURE]
fm/10 O I_NUMBER[MEASURE]
( O O
6 O B_MEASURE/B_LOCATION
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
S.E.M. O B_MEASURE/B_PERSON
) O O
and O O
a O O
dissociation O O
constant O B_MEASURE
of O I_MEASURE
4.8 O O
+/- O B_MEASURE
0.47 O I_MEASURE
nM O I_MEASURE
. O I_MEASURE

Lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
from O O
depressed O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
abnormal O B_MEASURE
0800 O I_MEASURE
h O O
serum O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cortisol O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
had O O
a O O
mean O B_MEASURE/B_PERSON
receptor O I_MEASURE/I_PERSON
concentration O I_MEASURE/I_PERSON
of O O
8.8 O B_MEASURE
+/- O I_MEASURE
0.75 O I_MEASURE
fm/10 O I_MEASURE
( O O
6 O B_NUMBER[MEASURE]
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
which O O
was O O
not O O
significantly O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
that O O
in O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
from O O
normal O B_PERSON/B_MEASURE
subjects O I_PERSON/I_MEASURE
or O O
from O O
depressed O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
with O O
normal O B_DISEASE
post-dexamethasone O I_DISEASE
cortisol O I_DISEASE
levels O I_DISEASE
( O O
9.4 O B_MEASURE
+/- O I_MEASURE
0.95 O I_MEASURE
fm/10 O I_MEASURE
( O O
6 O B_NUMBER[MEASURE]
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
) O O
. O O

Lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
depressed O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
elevated O B_DISEASE/B_LOCATION
urinary O I_DISEASE/I_LOCATION
free O I_DISEASE/I_LOCATION
cortisol O I_DISEASE/I_LOCATION
excretion O I_DISEASE/I_LOCATION
( O O
UFC O B_ORGANIZATION/B_LOCATION
) O O
also O O
had O O
normal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concentration O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
binding O B_MEASURE
affinity O I_MEASURE
for O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
lack O O
of O O
a O O
change O O
in O O
lymphocyte O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
concentration O O
in O O
the O O
presence O O
of O O
cortisol O O
excess O O
suggests O O
the O O
possibility O O
that O O
hypercortisolemia O O
in O O
depressive O O
illness O O
represents O O
a O O
state O O
of O O
peripheral O O
glucocorticoid O O
resistance O O
. O O

Structure O O
and O O
regulation O O
of O O
the O O
glucocorticoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hormone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
glucocorticoid B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
is O O
an O O
intracellular B B_PROTEIN[GENE]/B_BIO
protein I I_PROTEIN[GENE]/I_BIO
which O O
possesses O O
three O O
distinct O O
domains O O
, O O
one O O
that O O
binds O O
agonist O O
and O O
antagonist O O
steroids O O
, O O
one O O
that O O
binds O O
DNA O O
, O O
and O O
one O O
that O O
binds O O
anti-receptor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
is O O
required O O
for O O
glucocorticoid O O
modulation O O
of O O
gene O O
expression O O
. O O

In O O
intact O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
receptor O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
, O O
affinity O B_GENE/B_MEASURE
and O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
can O O
change O O
in O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
factors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
bind O O
to O O
the O O
receptor O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
or O O
that O O
act O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indirectly O O
through O O
ill-defined O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
may O O
include O O
resumption O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
arrest O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
cycling O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
variations O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
intracellular O B_MEASURE/B_DISEASE
calcium O I_MEASURE/I_DISEASE
ion O I_MEASURE/I_DISEASE
concentrations O I_MEASURE/I_DISEASE
. O O

Some O O
of O O
these O O
factors O O
appear O O
to O O
exert O O
their O O
effect O O
by O O
controlling O O
critical O O
receptor O O
properties O O
such O O
as O O
ATP-dependent O O
phosphorylation O O
, O O
integrity O O
of O O
thiol B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
exposure O O
of O O
key B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amino I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
residues I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
agonists O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
promote O O
the O O
'transformation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O O
of O O
the O O
receptor O B_GENE
into O O
the O O
DNA-binding O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
state O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
which O O
is O O
competent O B_DISEASE_ADJECTIVE[DISEASE]
for O O
modulating O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Glucocorticoid O O
antagonists O O
are O O
steroids O O
that O O
interact O O
with O O
the O O
receptor O O
but O O
either O O
fail O O
to O O
produce O O
a O O
stable B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
complex I B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
or O O
produce O O
a O O
stable B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
but I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inefficient I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
substituent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O O
confer O O
agonist O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
antagonist O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
identified O O
, O O
the O O
molecular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
determinants O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
this O O
difference O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
receptor O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
remain O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

Most O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
receptor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
accommodated O O
by O O
postulating O O
the O O
existence O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
an O O
intracellular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
involves O O
five O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
states O I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
the O O
receptor O B_GENE
. O O

The O O
active O B_GENE
free O I_GENE
receptor O I_GENE
is O O
phosphorylated O O
, O O
reduced O O
, O O
and O O
presumably O O
oligomeric O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
( O O
state O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Following O O
binding O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
an O O
agonist O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
state O B_LOCATION/B_MEASURE
B O I_LOCATION/I_MEASURE
) O O
, O O
it O O
can O O
become O O
transformed O O
by O O
dissociation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
into O O
its O O
subunits O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
dephosphorylation O B_ENZYME[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
state O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
transformed B B_GENE
receptor I I_GENE
then O O
interacts O O
with O O
chromatin B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
state O O
D O O
) O O
. O O

Dissociation O O
of O O
the O O
steroid O O
and O O
oxidation O O
of O O
receptor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thiol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
s O O
) O O
lead O O
to O O
the O O
inactive O O
receptor O O
form O O
( O O
state O O
E O O
) O O
. O O

Reduction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
rephosphorylation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
the O O
receptor O B_GENE
enable O O
it O O
to O O
bind O O
steroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
again O O
so O O
that O O
the O O
cycle O B_TIME[MEASURE]/B_LOCATION
is O O
closed O O
. O O

Thermodynamics O O
of O O
steroid O O
binding O O
to O O
the O O
human B B_GENE
glucocorticoid I I_GENE
receptor I I_GENE
. O O

The O O
thermodynamics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O O
their O O
receptor O B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
in O O
cytosol O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoblastoid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
rate O B_MEASURE
and O O
affinity O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constants O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
0 O B_MEASURE
degree O I_MEASURE
and O O
25 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
were O O
calculated O O
by O O
curve-fitting O O
from O O
time-course O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
equilibrium O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
kinetics O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
with O O
a O O
simple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reversible O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
bimolecular O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interaction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Arrhenius O B_PERSON/B_LOCATION
and O O
Va O B_DISEASE/B_MEASURE
n't O O
Hoff O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
plots O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
curvilinear O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
both O O
steroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

At O O
equilibrium O B_MEASURE/B_LOCATION
, O O
the O O
solution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
the O O
equation O B_MEASURE/B_PROTEIN[GENE]
delta O B_MEASURE/I_PROTEIN[GENE]
G O B_MEASURE/I_PROTEIN[GENE]
= O O
delta O B_MEASURE/B_PROTEIN[GENE]
H O I_MEASURE/I_PROTEIN[GENE]
- O O
T O B_MEASURE/B_GENE
X O I_MEASURE/I_GENE
delta O I_MEASURE/I_GENE
S O I_MEASURE/I_GENE
( O O
eqn. O B_MEASURE/B_LOCATION
1 O O
) O B_MEASURE/B_LOCATION
was O O
( O O
in O O
kJ O O
X O B_MEASURE
mol-1 O I_MEASURE
) O I_MEASURE
-47 O O
= O O
36 O O
- O B_MEASURE
83 O O
( O B_MEASURE
dexamethasone O O
) O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
-42 O O
= O O
-9 O O
- O O
33 O O
( O B_MEASURE
cortisol O O
) O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
0 O O
degree O B_MEASURE/B_LOCATION
C O I_MEASURE/I_LOCATION
. O I_MEASURE/I_LOCATION

Enthalpy O B_MEASURE/B_LOCATION
and O O
entropy O B_MEASURE
changes O I_MEASURE
decreased O O
quasi-linearly O O
with O O
temperature O B_MEASURE
such O I_MEASURE
that O O
, O O
at O O
25 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
, O O
the O O
respective O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
-50 O B_MEASURE
= O O
-75 O O
+ O B_MEASURE
25 O I_MEASURE
and O O
-43 O B_MEASURE
= O O
-48 O O
+ O O
5 O B_MEASURE
. O O

Thus O O
, O O
for O O
both O O
steroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
entropy-driven O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
at O O
low O B_MEASURE
temperature O I_MEASURE
and O O
became O O
entirely O O
enthalpy-driven O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
at O O
20 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
. O O

Thermodynamic O B_MEASURE/B_LOCATION
values O B_MEASURE/I_LOCATION
for O O
the O O
transition O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
state O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
calculated O O
from O O
the O O
rate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constants O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
the O O
forward O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reaction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
eqn. O O
( O O
1 O O
) O B_MEASURE
gave O O
45 O O
= O B_MEASURE
84 O O
- O B_MEASURE
39 O O
( O B_MEASURE
dexamethasone O O
) O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
46 O O
= O B_MEASURE
60 O O
- O B_MEASURE
14 O O
( O B_MEASURE
cortisol O O
) O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
0 O O
degree O B_MEASURE/B_LOCATION
C O I_MEASURE/I_LOCATION
, O I_MEASURE/I_LOCATION
and O O
44 O O
= O B_MEASURE
24 O O
+ O B_MEASURE
20 O I_MEASURE
( O I_MEASURE
dexamethasone O O
) O O
and O O
46 O O
= O B_MEASURE
28 O O
+ O B_MEASURE
18 O I_MEASURE
( O I_MEASURE
cortisol O O
) O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
25 O O
degrees O B_MEASURE/B_LOCATION
C O I_MEASURE/I_LOCATION
. O I_MEASURE/I_LOCATION

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fit O O
quite O O
well O O
with O O
a O O
two-step O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ross O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
& O O
Subramanian O B_PERSON
( O O
1981 O B_MEASURE
) O O
Biochemistry O B_MEASURE
20 O I_MEASURE
, O O
3096-3102 O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
proposed O O
for O O
ligand-protein O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
involves O O
a O O
partial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
immobilization O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
reacting O O
species O B_BIO/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
governed O O
by O O
hydrophobic O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
forces O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
followed O O
by O O
stabilization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
complex O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
short-range O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

On O O
the O O
basis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
this O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
an O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
transition-state O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
thermodynamics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
led O O
to O O
the O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
no O O
more O B_MEASURE
than O O
half O B_MEASURE/B_LOCATION
of O O
the O O
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
area O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
engaged O O
in O O
the O O
binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
process O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cell O O
cycle-related O O
changes O O
in O O
number O O
of O O
T-lymphocyte B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
glucocorticoids O O
and O O
insulin O O
. O O

Enriched O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T-lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
stimulated O O
with O O
PHA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
examined O O
for O O
variations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
insulin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
receptor O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numbers O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
the O O
early O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
phases O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cycle O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Cells O O
in O O
G0 O O
, O O
G1a O O
and O O
G1b O O
phases O O
, O O
where O O
the O O
G1a O O
- O O
G1b O O
transition O O
is O O
an O O
Interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependent O O
event O O
, O O
were O O
quantitated O O
by O O
flow O O
cytometry O O
. O O

Few O O
but O O
significant O O
numbers O O
of O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2700/cell O O
) O O
and O O
no O O
insulin B B_GENE
receptors I I_GENE
( O O
-1/cell O O
) O O
were O O
found O O
in O O
the O O
resting O O
( O O
G0 O O
) O O
phase O O
. O O

As O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
entered O O
the O O
G1a O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
the O O
specific O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
increased O O
and O O
of O O
insulin O B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
took O O
place O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Although O O
the O O
specific O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
binding O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
further O O
increased O O
as O O
T-cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
entered O O
the O O
G1b O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
as O O
measured O O
at O O
44 O B_MEASURE
h O O
of O O
incubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
and O O
using O O
hydroxyurea-treated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
the O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
specific O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
binding O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
took O O
place O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
during O O
the O O
period O B_TIME[MEASURE]
16 O I_TIME[MEASURE]
- O O
20 O B_MEASURE
h O I_MEASURE
after O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O O

Based O O
on O O
these O O
findings O O
, O O
it O O
is O O
concluded O O
that O O
both O O
receptor O O
types O O
( O O
cell B B_PROTEIN[GENE]/B_LOCATION
membrane I I_PROTEIN[GENE]/I_LOCATION
and I I_PROTEIN[GENE]/I_LOCATION
cytoplasmic I I_PROTEIN[GENE]/I_LOCATION
receptors I I_PROTEIN[GENE]/I_LOCATION
) O O
are O O
being O O
formed O O
and O O
increased O O
at O O
G1 O O
phase O O
prior O O
to O O
cell O O
proliferation O O
, O O
indicating O O
the O O
importance O O
of O O
G1 O O
phase O O
in O O
immunoregulation O O
. O O

Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
cortico-sensitivity O O
in O O
a O O
human O O
clonal O O
monocytic O O
cell O O
line O O
, O O
CM-SM O O
. O O

CM-SM O B_DISEASE/B_PROTEIN[GENE]
is O O
a O O
clonal O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
line O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
precursor O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
mononuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
phagocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
inducible O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
to O O
macrophage O O
differentiation O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
tumor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
promoter O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phorbol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ester O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
12-O-tetradecanoyl-phorbol-13-acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TPA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
. O O

Untreated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
CM-SM O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
contain O O
single O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
high-affinity O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
( O O
KD O B_DISEASE/B_PROTEIN[GENE]
= O O
4.0 O B_MEASURE/B_LOCATION
X O I_MEASURE/I_LOCATION
10 O I_MEASURE/I_LOCATION
( O O
-9 O O
) O O
M O B_OTHER/B_MEASURE
) O O
glucocorticoid-specific O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
approximately O O
60 O B_MEASURE
, O O
000 O B_MEASURE
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
) O O
, O O
as O O
measured O O
by O O
a O O
whole O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
at O O
37 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
, O O
using O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triamcinolone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
CM-SM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
dexamethasone O O
( O O
DEX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
produced O O
a O O
progressive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
dose- O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
time-related O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
series O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
CM-SM O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
growth O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
saturation O B_MEASURE
density O I_MEASURE
, O O
morphology O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O O
with O O
half-maximal O B_MEASURE/B_LOCATION
effects O I_MEASURE/I_LOCATION
at O O
about O O
10 O B_MEASURE
( O O
-9 O O
) O O
M O B_MEASURE/B_OTHER
for O O
DEX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

TA-receptor O B_GENE
sites O I_GENE
rapidly O O
decreased O O
( O O
about O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
after O O
DEX O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
without O O
any O O
apparent O B_DISEASE_ADJECTIVE[DISEASE]
change O I_DISEASE_ADJECTIVE[DISEASE]
in O O
steroid O B_MEASURE/B_LOCATION
specificity O I_MEASURE/I_LOCATION
and O O
affinity O B_GENE/B_MEASURE
. O O

After O O
5 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
culture O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
with O O
a O O
saturating O B_MEASURE
concentration O I_MEASURE
( O O
3.6 O B_MEASURE/B_LOCATION
X O I_MEASURE/I_LOCATION
10 O I_MEASURE/I_LOCATION
( O O
-8 O O
) O O
M O B_MEASURE
) O O
of O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
reached O O
a O O
saturation O B_MEASURE/B_LOCATION
density O I_MEASURE/I_LOCATION
of O O
about O O
9.0 O B_NUMBER[MEASURE]
X O I_NUMBER[MEASURE]
10 O I_NUMBER[MEASURE]
( O O
6 O B_MEASURE
) O O
viable O B_MEASURE/B_LOCATION
cells/ml O I_MEASURE/I_LOCATION
( O O
about O O
4.0 O B_NUMBER[MEASURE]
X O I_NUMBER[MEASURE]
10 O I_NUMBER[MEASURE]
( O O
6 O B_MEASURE
) O O
viable O B_MEASURE/B_LOCATION
cells/ml O I_MEASURE/I_LOCATION
in O O
the O O
controls O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
while O O
the O O
modal O B_MEASURE/B_LOCATION
volume O I_MEASURE/I_LOCATION
of O O
the O O
resulting O O
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
approximately O O
60 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
, O O
as O O
compared O O
to O O
the O O
volume O B_MEASURE
of O O
untreated O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

DEX-treated O B_PERSON/B_BIO
cells O I_PERSON/I_BIO
appeared O O
less O O
differentiated O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
than O O
controls O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
assessed O O
by O O
combined O O
morphologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
antigenic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
cytoenzymatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analyses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

DEX O O
almost O O
completely O O
inhibited O O
TPA O O
activation O O
of O O
the O O
following O O
macrophage O O
functions O O
: O O
adherency O O
to O O
the O O
culture O O
plate O O
, O O
expression O O
of O O
lysosomal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzymes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
Fc B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
C3 I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
receptors I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
and O O
stimulation O O
of O O
phagocytosis O O
. O O

After O O
removal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
DEX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O O
within O O
a O O
few O B_TIME[MEASURE]/B_LOCATION
passages O I_TIME[MEASURE]/I_LOCATION
, O O
returned O O
to O O
a O O
state O B_MEASURE
apparently O O
identical O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
untreated O B_PERSON/B_MEASURE
controls O I_PERSON/I_MEASURE
and O O
could O O
be O O
induced O O
to O O
macrophage O O
differentiation O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
TPA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Acute O B_DISEASE
lymphoblastic O I_DISEASE
leukemia O I_DISEASE
in O O
children O B_PERSON/B_LOCATION
: O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
controversies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
future O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perspective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Disease-free O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
survival O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
DFS O B_DISEASE
) O O
in O O
childhood O B_PERSON/B_MEASURE
ALL O O
is O O
60 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
and O O
survival O B_MEASURE/B_DISEASE
in O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
average O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
poor O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
prognostic O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
groups O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
defined O O
by O O
initial O B_MEASURE/B_PERSON
WBC O B_MEASURE/I_PERSON
and O O
age O B_GENE
is O O
90 O B_MEASURE
, O O
60 O B_MEASURE
, O O
and O O
45 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
respectively O O
. O O

Additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
immunological O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
morphological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
cytokinetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
cytogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
have O O
been O O
identified O O
, O O
illustrating O O
the O O
heterogeneity O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
ALL O O
and O O
its O O
derivation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
from O O
malignant O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
clones O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O O
various O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
stages O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
differentiation O B_ORGANISM_FUNCTION/B_DISEASE
and O O
with O O
varying O O
rates O B_MEASURE/B_LOCATION
of O O
proliferation O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Of O O
biologic O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
importance O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
these O O
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
may O O
refine O O
further O B_LOCATION
the O O
characteristic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
features O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
clinically-determined O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prognostic O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Multivariate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
large O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
prospective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
trials O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
homogeneous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
will O O
be O O
required O O
to O O
determine O O
the O O
independent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prognostic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
importance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
strategies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
in O O
ALL O O
include O O
( O O
1 O B_SEQUENCE[MEASURE]/B_PERSON
) O O
tailoring O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
its O O
intensity O B_MEASURE/B_PERSON
to O O
prognostic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
groups O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
; O O
( O O
2 O O
) O O
multiple-drug O O
combinations O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
induction O B_PERSON
; O O
( O O
3 O B_NUMBER[MEASURE]/B_LOCATION
) O O
early O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
use O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
intrathecal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
IT O O
) O O
methotrexate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MTX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
; O O
( O O
4 O B_NUMBER[MEASURE]
) O O
CNS O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
prophylaxis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
IT O O
MTX O O
alone O O
in O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
prognosis O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
patients O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
combined O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cranial O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
radiation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
CXRT O B_LOCATION
) O O
, O O
1800 O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
rads O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
plus O O
IT O O
MTX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
average O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
poor O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
prognosis O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
patients O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
show O O
a O O
CNS O B_MEASURE
relapse O I_MEASURE
rate O I_MEASURE
of O O
5 O B_MEASURE/B_DISEASE
% O B_MEASURE/I_DISEASE
in O O
all O O
prognostic O B_PERSON/B_LOCATION
groups O I_PERSON/I_LOCATION
. O O

Late O B_DISEASE_ADJECTIVE[DISEASE]
neuropsychological O I_DISEASE_ADJECTIVE[DISEASE]
defects O I_DISEASE_ADJECTIVE[DISEASE]
caused O O
by O O
cranial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
XRT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PROTEIN[GENE]
and O O
IT O O
MTX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
prompted O O
programs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
designed O O
to O O
reduce O O
the O O
potential O B_MEASURE
late O I_MEASURE
toxicity O I_MEASURE
of O O
CNS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
prophylaxis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

More O O
pronounced O O
in O O
younger O B_PERSON/B_ENT
children O I_PERSON/I_ENT
, O O
these O O
abnormalities O B_DISEASE_ADJECTIVE[DISEASE]
include O O
decreased O O
IQ O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
visual-motor O B_DISEASE
incoordination O I_DISEASE
, O O
poor O B_DISEASE_ADJECTIVE[DISEASE]
performance O I_DISEASE_ADJECTIVE[DISEASE]
in O O
mathematics O B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
memory O B_DISEASE
dysfunction O I_DISEASE
. O O

Until O O
1980 O B_TIME[MEASURE]
, O O
more O O
intensive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
consolidation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
and O O
maintenance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
had O O
failed O O
to O O
prolong O O
DFS O B_DISEASE
in O O
children O B_PERSON/B_BIO
with O O
a O O
poor O B_DISEASE
prognosis O I_DISEASE
. O O

In O O
West O B_LOCATION/B_MEASURE
Germany O I_LOCATION/I_MEASURE
( O O
Berlin-Frankfurt-Muenster O B_MEASURE/B_LOCATION
protocol O I_MEASURE/I_LOCATION
) O O
a O O
70 O B_MEASURE/B_LOCATION
to O O
75 O B_MEASURE
% O I_MEASURE
DFS O I_MEASURE
is O O
seen O O
in O O
all O O
patients O B_PERSON
regardless O O
of O O
initial O B_MEASURE/B_DISEASE
WBC O B_MEASURE/I_DISEASE
, O O
suggesting O O
that O O
effective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
will O O
override O O
prognostic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Ultra-high-dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
MTX O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
without O O
cranial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
radiation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
is O O
also O O
showing O O
promise O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
poor O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prognosis O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
issues O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
include O O
the O O
optimal O B_MEASURE
duration O I_MEASURE
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
the O O
role O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
testicular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biopsies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
prophylactic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
testicular O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
radiation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggest O O
that O O
prognostic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
lose O O
their O O
significance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
2 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
of O O
continuous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
complete O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
remission O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
that O O
2 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
years O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
maintenance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
adequate O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Bilateral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
open-wedge O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
testicular O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
biopsies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
identified O O
occult O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
testicular O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
8 O B_NUMBER[MEASURE]/B_LOCATION
to O O
10 O B_MEASURE
% O I_MEASURE
of O O
males O B_PERSON
. O O

A O O
unified O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
children O B_PERSON
with O O
leukemia/lymphoma O B_DISEASE/B_GENE
, O O
a O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
a O O
particularly O O
poor O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
prognosis O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
utilizing O O
NHL-type O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
may O O
be O O
more O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
conventional O B_LOCATION/B_RELIGION[SOCIAL_CIRCUMSTANCES]
ALL O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

( O O
ABSTRACT O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRUNCATED O I_MEASURE
AT O O
400 O B_LOCATION/B_PERSON
WORDS O I_LOCATION/I_PERSON
) O O

Glucocorticoid B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
vitro O O
sensitivity O O
to O O
steroid O O
hormones O O
in O O
human O O
lymphoproliferative O O
diseases O O
and O O
myeloid O O
leukemia O O
. O O

The O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GR B B_PROTEIN[GENE]/B_DISEASE
) O O
quantitation O O
by O O
a O O
whole-cell O O
assay O O
and/or O O
cytosol O O
technique O O
and O O
the O O
in O O
vitro O O
sensitivity O O
to O O
steroids O O
have O O
been O O
assessed O O
in O O
peripheral O O
blood O O
cells O O
from O O
normal O O
donors O O
and O O
patients O O
with O O
chronic O O
lymphatic O O
leukemia O O
( O O
CLL O O
) O O
, O O
acute O O
lymphoblastic O O
leukemia O O
( O O
ALL O O
) O O
, O O
lymphosarcoma O O
cell O O
leukemia O O
( O O
LSCL O O
) O O
, O O
acute O O
nonlymphatic O O
leukemia O O
( O O
ANLL O O
) O O
, O O
and O O
chronic O O
myeloid O O
leukemia O O
( O O
CML O O
) O O
. O O

Within O O
the O O
lymphoproliferative O O
diseases O O
, O O
ALL O O
cells O O
exhibited O O
the O O
highest O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration O O
( O O
regardless O O
of O O
the O O
method O O
used O O
) O O
and O O
the O O
highest O O
in O O
vitro O O
inhibition O O
of O O
spontaneous O O
[ O O
3H O O
] O O
thymidine O O
( O O
[ O O
3H O O
] O O
TdR O O
) O O
uptake O O
by O O
glucocorticoids O O
. O O

A O O
significant O O
relationship O O
between O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration O O
( O O
whole-cell O O
assay O O
) O O
and O O
in O O
vitro O O
sensitivity O O
to O O
dexamethasone O O
was O O
also O O
found O O
. O O

On O O
the O O
contrary O B_PERSON/B_MEASURE
, O O
CLL O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
presented O O
the O O
highest O B_MEASURE/B_PERSON
sensitivity O B_MEASURE/I_PERSON
to O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
PHA-stimulated O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
cultures O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
from O O
the O O
only O B_NUMBER[MEASURE]
two O I_NUMBER[MEASURE]
ALL O O
patients O B_PERSON
who O O
did O O
not O O
undergo O O
a O O
remission O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
after O O
glucocorticoid-inclusive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
had O O
both O O
the O O
lowest O B_MEASURE
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sensitivity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
the O O
lowest O B_MEASURE
GR O I_MEASURE
concentration O I_MEASURE
with O O
whole-cell O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Concerning O O
myeloid O O
leukemia O O
, O O
ANLL O O
patients O O
had O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentrations O O
slightly O O
higher O O
than O O
those O O
found O O
in O O
the O O
ALL O O
group O O
but O O
exhibited O O
the O O
lowest O O
degree O O
of O O
inhibition O O
of O O
spontaneous O O
[ O O
3H O O
] O O
TdR O O
uptake O O
by O O
dexamethasone O O
( O O
stimulatory O O
effects O O
occurred O O
in O O
some O O
cases O O
) O O
. O O

CML O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
exhibited O O
an O O
inhibition O B_MEASURE/B_DISEASE
degree O B_MEASURE/I_DISEASE
by O O
in O O
vitro O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
of O O
ANLL O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
but O O
not O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
from O O
that O O
of O O
lymphoproliferative O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
diseases O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

No O O
clear O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationship O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
GR O B_DISEASE_ADJECTIVE[DISEASE]
pattern O I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cell O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
sensitivity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
clinicohematologic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
in O O
myeloid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
leukemia-bearing O O
patients O B_PERSON/B_BIO
. O O

Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
vitro O O
corticosensitivity O O
of O O
peanut-positive O O
and O O
peanut-negative O O
human O O
thymocyte O O
subpopulations O O
. O O

In O O
6 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thymus O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glands O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
immature O B_MEASURE/B_GENE
subset O I_MEASURE/I_GENE
of O O
thymocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
was O O
separated O O
from O O
the O O
more O O
mature O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
one O B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
, O O
by O O
differential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peanut O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lectin O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agglutination O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
2 O O
cell O O
subpopulations O O
were O O
analyzed O O
for O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O O
by O O
using O O
a O O
whole O O
cell O O
assay O O
, O O
with O O
( O O
3H O O
) O O
-triamcinolone O O
acetonide O O
as O O
tracer O O
. O O

The O O
unagglutinated O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
thymocytes O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O O
peanut O B_DISEASE_ADJECTIVE[DISEASE]
negative O I_DISEASE_ADJECTIVE[DISEASE]
) O O
contained O O
about O O
2 O B_MEASURE/B_ORGANIZATION
times O I_MEASURE/I_ORGANIZATION
more O I_MEASURE/I_ORGANIZATION
receptor O I_MEASURE/I_ORGANIZATION
sites O I_MEASURE/I_ORGANIZATION
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
than O O
agglutinated O O
( O O
peanut O B_DISEASE_ADJECTIVE[DISEASE]
positive O I_DISEASE_ADJECTIVE[DISEASE]
) O O
ones O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
7650 O B_PROTEIN[GENE]/B_LOCATION
+/- O I_PROTEIN[GENE]/I_LOCATION
1550 O I_PROTEIN[GENE]/I_LOCATION
S.D. O O
verus O B_MEASURE/B_PERSON
3195 O I_MEASURE/I_PERSON
+/- O O
896 O B_MEASURE
S.D. O O
) O O
. O O

The O O
affinity O B_GENE/B_MEASURE
for O O
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subsets O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
as O O
was O O
the O O
stereospecificity O B_MEASURE
for O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
time-course O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
steroid-receptor O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
association O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
cytoplasmic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
to O O
nuclear O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
translocation O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Despite O O
the O O
greater O O
number O O
of O O
glucocorticoid B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
receptor I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
sites O O
, O O
the O O
peanut-negative O O
thymocyte O O
subpopulation O O
did O O
not O O
differ O O
from O O
the O O
peanut-positive O O
one O O
in O O
its O O
sensitivity O O
to O O
the O O
inhibitory O O
effects O O
of O O
triamcinolone O O
acetonide O O
, O O
as O O
determined O O
by O O
measurements O O
of O O
the O O
incorporation O O
of O O
radiolabeled O O
precursors O O
of O O
protein O O
and O O
DNA O O
. O O

Moreover O O
, O O
the O O
peanut-negative O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subset O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
appeared O O
more O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
steroid-induced O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lysis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
compared O O
to O O
the O O
peanut-positive O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
one O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thus O O
, O O
our O O
data O O
suggest O O
that O O
glucocorticoid O O
receptor O O
density O O
and O O
corticosensitivity O O
are O O
not O O
directly O O
correlated O O
and O O
that O O
the O O
number O O
of O O
glucocorticoid B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O O
may O O
be O O
dependent O O
on O O
the O O
degree O O
of O O
immunologic O O
maturation O O

Defective O O
binding O O
and O O
function O O
of O O
1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
25-dihydroxyvitamin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
D3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
peripheral O O
mononuclear O O
cells O O
of O O
patients O O
with O O
end-organ O O
resistance O O
to O O
1 O O
, O O
25-dihydroxyvitamin O O
D O O
. O O

Lectin-induced O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
DNA O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
synthesis O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mononuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
17 O B_PERSON/B_MEASURE
normal O I_PERSON/I_MEASURE
donors O I_PERSON/I_MEASURE
was O O
inhibited O O
( O O
40-60 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O O
by O O
1 O B_NUMBER[MEASURE]
, O O
25-dihydroxyvitamin O B_MEASURE
D3 O I_MEASURE
( O O
1 O B_MEASURE/B_LOCATION
, O O
25 O B_MEASURE
[ O I_MEASURE
OH O I_MEASURE
] O I_MEASURE
2D3 O I_MEASURE
) O O
at O O
physiological O B_MEASURE/B_LOCATION
concentrations O B_MEASURE/I_LOCATION
( O O
10 O B_MEASURE
( O O
-10 O B_MEASURE
) O O
-10 O B_MEASURE/B_LOCATION
( O O
-9 O B_MEASURE
) O O
M O B_MEASURE/B_LOCATION
) O O
. O O

The O O
lymphocytes O O
acquire O O
specific O O
receptors O O
for O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
upon O O
activation O O
by O O
the O O
lectins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

This O O
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
precedes O O
the O O
inhibitory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
1 O B_TIME[MEASURE]
, O O
25 O B_MEASURE
( O O
OH O B_LOCATION/B_PROTEIN[GENE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O

We O O
studied O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
six O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
from O O
four O B_LOCATION/B_ENT
different O I_LOCATION/I_ENT
kindreds O I_LOCATION/I_ENT
with O O
the O O
syndrome O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hereditary O B_DISEASE
end-organ O I_DISEASE
resistance O I_DISEASE
to O O
1 O B_MEASURE
, O O
25 O B_MEASURE
( O O
OH O O
) O O
2D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
the O O
so-called O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
vitamin O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
D-dependent O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
rickets O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
type O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
II O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
) O O
. O O

In O O
five O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
( O O
three O B_MEASURE/B_ENT
kindreds O I_MEASURE/I_ENT
) O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
mononuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
did O O
not O O
acquire O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
1 O B_MEASURE
, O O
25 O B_MEASURE
( O O
OH O O
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
upon O O
phytohemagglutinin-induced O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Moreover O O
, O O
in O O
contrast O O
to O O
normal O O
lymphocytes O O
, O O
the O O
mitogenic O O
stimulation O O
of O O
these O O
patients O O
' O O
lymphocytes O O
by O O
phytohemagglutinin B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
concanavalin O O
A O O
was O O
not O O
inhibited O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
. O O

Activated O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
of O O
the O O
sixth O B_PERSON/B_BIO
patient O B_PERSON/I_BIO
from O O
a O O
fourth O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
kindred O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
exhibited O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
normal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
binding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] O O
1 O B_MEASURE
, O O
25 O B_MEASURE
( O O
OH O O
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
but O O
the O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O O
to O O
inhibit O O
the O O
mitogenic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
vitamin O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effector O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
previously O O
observed O O
in O O
fibroblasts O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cultured O O
from O O
skin O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
biopsies O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
of O O
the O O
same O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_BIO
. O O

The O O
conclusions O O
from O O
these O O
findings O O
are O O
: O O
( O O
a O O
) O O
the O O
inhibition O O
of O O
mitogenic O O
stimulation O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
is O O
mediated O O
by O O
specific B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
functional I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
the O O
hormone O O
; O O
and O O
( O O
b O O
) O O
the O O
receptors O O
for O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
in O O
mononuclear O O
cells O O
are O O
probably O O
controlled O O
genetically O O
by O O
the O O
same O O
mechanisms O O
as O O
the O O
effector O O
system O O
in O O
well-characterized O O
target O O
organs O O
of O O
the O O
hormone O O
, O O
such O O
as O O
intestine O O
and O O
kidney O O
. O O

Glucocorticoid B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
receptors I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
mononuclear O O
leukocytes O O
from O O
myasthenia O O
gravis O O
patients O O
. O O

The O O
present O O
study O O
was O O
performed O O
to O O
analyse O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
GR B B_LOCATION/B_ORGANIZATION
) O O
binding O O
in O O
peripheral O O
blood O O
mononuclear O O
leukocytes O O
( O O
MNL O O
) O O
from O O
39 O O
myasthenia O O
gravis O O
( O O
MG O O
) O O
patients O O
( O O
unoperated O O
patients O O
( O O
n O O
= O O
13 O O
) O O
, O O
thymectomized O O
patients O O
( O O
n O O
= O O
14 O O
) O O
and O O
patients O O
receiving O O
glucocorticoids O O
: O O
thymectomized O O
( O O
n O O
= O O
11 O O
) O O
and O O
unoperated O O
( O O
n O O
= O O
6 O O
] O O
. O O

A O O
whole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
assay O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O O
3 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
H O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
used O O
. O O

GR B B_PERSON
mean O O
values O O
were O O
significantly O O
higher O O
in O O
the O O
MNL O O
of O O
MG O O
patients O O
( O O
thymectomized O O
or O O
not O O
) O O
not O O
receiving O O
glucocorticoid O O
than O O
in O O
the O O
MNL O O
of O O
healthy O O
donors O O
. O O

Affinity O B_GENE/B_TIME[MEASURE]
was O O
within O O
the O O
normal O B_MEASURE/B_LOCATION
range O B_MEASURE/I_LOCATION
. O O

Sex O B_PERSON/B_MEASURE
, O O
age O B_TIME[MEASURE]/B_PERSON
or O O
clinical O B_MEASURE/B_LOCATION
forms O I_MEASURE/I_LOCATION
of O O
illness O B_DISEASE
did O O
not O O
influence O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
patients O O
receiving O O
prednisone O O
( O O
Pd O O
) O O
the O O
GR B B_GENE/B_DISEASE
values O O
were O O
significantly O O
lower O O
than O O
in O O
MG O O
patients O O
without O O
Pd O O
therapy O O
, O O
independent O O
of O O
Pd O O
dose O O
or O O
time O O
of O O
administration O O
. O O

No O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
receptor O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O O
normal O B_PERSON/B_LOCATION
subjects O B_PERSON/I_LOCATION
and O O
MG O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
receiving O O
Pd O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
found O O
. O O

Immunological O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
interference O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
high O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dose O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
corticosteroids O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

High-dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
corticosteroids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HDC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
will O O
influence O O
cellular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
as O O
well O O
as O O
humoral O B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
participants O B_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
immune O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
lymphoid O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
will O O
decrease O O
in O O
size O B_MEASURE
and O O
weight O B_MEASURE/B_LOCATION
after O O
prolonged O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
HDC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Lymphocyte O B_PERSON
functions O I_PERSON
will O O
be O O
impaired O O
. O O

Reduced O O
synthesis O B_MEASURE/B_GENE
of O O
B- O O
as O O
well O O
as O O
T-lymphocytes O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
seen O O
. O O

The O O
inhibitory O O
effect O O
on O O
B-cell O O
function O O
can O O
be O O
observed O O
both O O
as O O
decreased O O
serum O O
levels O O
of O O
immunoglobulins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
as O O
impaired O O
binding O O
of O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
complement O O
to O O
the O O
cellular O O
surface O O
. O O

Reduced O O
T-cell O O
function O O
indicated O O
by O O
impaired O O
stimulation O O
by O O
PHA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
porkweed B B_DISEASE/B_GENE
as O O
well O O
as O O
by O O
impaired O O
lymphokinin O O
effects O O
on O O
leukocyte O O
migration O O
inhibition O O
has O O
been O O
reported O O
. O O

Reduced O O
lymphocyte O B_MEASURE/B_DISEASE
adherence O B_MEASURE/I_DISEASE
to O O
antigen O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
suppressed O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lymphocyte O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reaction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
have O O
also O O
been O O
observed O O
. O O

Humoral O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factors O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
involved O O
in O O
chemotaxis O B_DISEASE
, O O
opsonisation O B_DISEASE_ADJECTIVE[DISEASE]
, O O
phagocytosis O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
vascular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
permeability O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leading O O
to O O
leakage O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
fluid O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
factors O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involved O O
in O O
lysis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
antigens O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
are O O
impaired O O
. O O

This O O
can O O
be O O
explained O O
partly O O
by O O
the O O
observed O O
reduced O O
complement O B_DISEASE_ADJECTIVE[DISEASE]
activation O I_DISEASE_ADJECTIVE[DISEASE]
via O O
the O O
alternative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
well O O
as O O
the O O
classical O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pathway O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
HDC O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Acute O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processes O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
increased O O
vascular O B_DISEASE_ADJECTIVE[DISEASE]
permeability O I_DISEASE_ADJECTIVE[DISEASE]
and O O
accumulation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
impairing O O
factors O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
could O O
be O O
influenced O O
beneficially O O
by O O
HDC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

This O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
can O O
be O O
seen O O
in O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O O
septic O B_DISEASE
shock O I_DISEASE
or O O
rejection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
transplant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

However O O
, O O
if O O
sepsis O B_DISEASE
or O O
rejection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
not O O
rapidly O O
reversed O O
, O O
complications O B_DISEASE_ADJECTIVE[DISEASE]
such O I_DISEASE_ADJECTIVE[DISEASE]
as O O
multisystem O B_DISEASE
organ O I_DISEASE
failure O I_DISEASE
and O O
bacteremia O B_DISEASE
are O O
prone O B_DISEASE_ADJECTIVE[DISEASE]
to O O
appear O O
. O O

Identification O O
of O O
human B B_GENE/B_LOCATION
leukemic I I_GENE/I_LOCATION
glucocorticoid I I_GENE/I_LOCATION
receptors I I_GENE/I_LOCATION
using O O
affinity O O
labeling O O
and O O
anti-human B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Antisera O O
raised O O
against O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lymphoid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
glucocorticoid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
used O O
in O O
combination O O
with O O
the O O
glucocorticoid O O
receptor O O
affinity O O
label O O
[ O O
3H O O
] O O
dexamethasone O O
21-mesylate O O
[ O O
( O O
3H O O
] O O
DM O O
) O O
to O O
identify O O
the O O
glucocorticoid B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
human O O
B-lymphoblastoid O O
cell O O
line O O
IM-9 O O
and O O
the O O
human O O
T-cell O O
leukemic O O
cell O O
line O O
CEM-C7 O O
. O O

Antisera O O
were O O
obtained O O
following O O
immunization O O
of O O
New O O
Zealand O O
White O O
rabbits O O
with O O
[ B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3H I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
triamcinolone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acetonide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3H I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-glucocorticoid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
partially O O
purified O O
by O O
two-stage O O
DNA-cellulose O O
chromatography O O
. O O

The O O
presence O O
of O O
anti-human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
verified O O
by O O
: O O
( O O
a O O
) O O
adsorption O O
of O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
3H I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
TA-receptor-antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
Protein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
( O O
b O O
) O O
a O O
shift O O
to O O
higher O O
apparent O O
molecular O O
weight O O
in O O
the O O
elution O O
position O O
from O O
Sephacryl O O
S300 O O
of O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
3H I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
] I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
TA-receptor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complexes I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
incubated O O
with O O
immune O O
serum O O
; O O
and O O
( O O
c O O
) O O
the O O
ability O O
of O O
immune O O
serum O O
to O O
displace O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
3H I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
] I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
TA-receptor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
complexes I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
on O O
sucrose O O
gradients O O
. O O

These O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
recognized O O
rat O O
liver O O
and O O
murine B B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
S49 I I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
cell I I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
glucocorticoid I I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
receptors I I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
. O O

Sodium O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dodecyl O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sulfate-polyacrylamide O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gel O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
electrophoresis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
[ O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DM-labeled O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IM-9 O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytosol O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identified O O
a O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
competable O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
band O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
with O O
a O O
molecular O B_MEASURE/B_PERSON
weight O I_MEASURE/I_PERSON
of O O
approximately O O
90 O B_MEASURE
, O O
000 O B_MEASURE
, O O
three O B_NUMBER[MEASURE]/B_PERSON
minor O I_NUMBER[MEASURE]/I_PERSON
competable O I_NUMBER[MEASURE]/I_PERSON
components O I_NUMBER[MEASURE]/I_PERSON
with O O
molecular O B_MEASURE/B_LOCATION
weights O I_MEASURE/I_LOCATION
of O O
approximately O O
78 O B_MEASURE
, O O
000 O B_MEASURE
, O O
approximately O O
51 O B_MEASURE
, O O
000 O B_MEASURE
, O O
and O O
approximately O O
38 O B_MEASURE
, O O
500 O B_MEASURE
, O O
and O O
at O O
least O O
21 O B_NUMBER[MEASURE]/B_LOCATION
other O I_NUMBER[MEASURE]/I_LOCATION
noncompetable O I_NUMBER[MEASURE]/I_LOCATION
components O I_NUMBER[MEASURE]/I_LOCATION
. O O

Following O O
immunoprecipitation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
[ O O
3H O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
] O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
DM-labeled O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
cytosol O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
with O O
immune O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
serum O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
only O O
the O O
Mr O B_MEASURE/B_PERSON
90 O I_MEASURE/I_PERSON
, O O
000 O B_MEASURE
and O O
78 O B_MEASURE
, O O
000 O B_MEASURE
components O I_MEASURE
were O O
seen O O
. O O

Sodium O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dodecyl O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sulfate-polyacrylamide O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gel O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
electrophoresis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
3H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
DM-labeled O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
CEM-C7 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
cytosol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
revealed O O
a O O
larger O B_MEASURE/B_LOCATION
number O B_MEASURE/I_LOCATION
of O O
[ O O
3H O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DM-labeled O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
components O I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
after O O
immunoprecipitation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
DM-labeled O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CEM-C7 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cytosol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
a O O
predominant O B_DISEASE/B_PROTEIN[GENE]
competable O B_DISEASE/I_PROTEIN[GENE]
component O B_DISEASE/I_PROTEIN[GENE]
with O O
a O O
molecular O B_MEASURE/B_PERSON
weight O I_MEASURE/I_PERSON
of O O
90 O B_MEASURE
, O O
000 O B_MEASURE
was O O
easily O O
identified O O
. O O

This O O
component O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
markedly O O
diminished O O
when O O
cytosols O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
glucocorticoid O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
receptor-deficient O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
cell O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
line O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
ICR-27 O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
were O O
used O O
. O O

Thus O O
, O O
the O O
combination O O
of O O
affinity O O
labeling O O
and O O
anti-human B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
capable O O
of O O
providing O O
direct O O
physical O O
identification O O
of O O
human B B_GENE
lymphoid I I_GENE
glucocorticoid I I_GENE
receptors I I_GENE
. O O

Effect O O
of O O
thymosin O O
on O O
glucocorticoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
and O O
glucocorticoid O O
sensitivity O O
of O O
human O O
thymocytes O O
. O O

Incubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O O
thymosin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fraction O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
( O O
TMS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
F5 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
300 O B_MEASURE/B_LOCATION
micrograms/ml O I_MEASURE/I_LOCATION
) O O
a O O
partially O O
purified O O
thymic O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
reduced O O
the O O
steroid O B_MEASURE/B_DISEASE
binding O I_MEASURE/I_DISEASE
activity O I_MEASURE/I_DISEASE
of O O
human O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
infant O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
thymocytes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
9.6 O B_MEASURE
+/- O O
2.1 O B_MEASURE
fmole/ml O I_MEASURE
to O O
5.0 O B_MEASURE
+/- O I_MEASURE
2.0 O I_MEASURE
fmole/ml O I_MEASURE
. O O

The O O
glucocorticoid B B_PROTEIN[GENE]/B_MEASURE
receptor I I_PROTEIN[GENE]/I_MEASURE
activity O O
in O O
normal O O
infant O O
thymocytes O O
was O O
found O O
to O O
be O O
2 O O
, O O
146 O O
+/- O O
726 O O
( O O
s.d. O O
) O O
sites O O
per O O
cell O O
with O O
dissociation O O
constant O O
of O O
1.4 O O
+/- O O
0.6 O O
X O O
10 O O
( O O
-8 O O
) O O
M O O
. O O

TMS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
F5 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O O
increased O O
the O O
resistance O B_DISEASE_ADJECTIVE[DISEASE]
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
thymocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
cytolytic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effect O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
2.5 O B_MEASURE/B_LOCATION
X O B_MEASURE/I_LOCATION
10 O B_MEASURE/I_LOCATION
( O O
-8 O O
) O O
M O B_OTHER/B_MEASURE
) O O
to O O
168.6 O B_MEASURE/B_LOCATION
+/- O O
30.2 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
P O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0.01 O B_MEASURE
) O O
. O O

In O O
animals O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
medullary O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
and O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
more O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]
to O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
than O O
immature O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
thymic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O O
that O O
thymosin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O O
induce O O
changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
consistent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O O
differentiation O B_PROTEIN[GENE]/B_DISEASE
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
thymocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
a O O
physiological O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
thymosin O B_GENE
in O O
intrathymic O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
T O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
maturation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
man O B_SPECIES[BIO]
. O O

Incubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
a O O
human O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
malignant O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
thymus O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
derived O O
T O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
line O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
MOLT O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
3 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
with O O
TMS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
F5 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O O
resulted O O
in O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
number O B_MEASURE/B_DISEASE
of O O
steroid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
binding O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
sites O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
to O O
44.2 O B_MEASURE/B_LOCATION
+/- O O
15.3 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0.05 O B_MEASURE
) O O
, O O
but O O
TMS O B_LOCATION/B_PERSON
F5 O I_LOCATION/I_PERSON
did O O
not O O
significantly O O
reduce O O
the O O
glucocorticoid O B_MEASURE
sensitivity O I_MEASURE
of O O
MOLT O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Specific B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
high-affinity I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
1 O O
, O O
25-dihydroxyvitamin O O
D3 O O
in O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
: O O
presence O O
in O O
monocytes O O
and O O
induction O O
in O O
T O O
lymphocytes O O
following O O
activation O O
. O O

Human O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
peripheral O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
have O O
high O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
Kd O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0.14 O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nM O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sedimentation O B_MEASURE/B_LOCATION
coefficient O I_MEASURE/I_LOCATION
3.7S O I_MEASURE/I_LOCATION
) O O
. O O

Resting O O
human O O
peripheral O O
blood O O
T O O
lymphocytes O O
, O O
however O O
, O O
do O O
not O O
have O O
a O O
demonstrable O O
1 B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
25- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
OH I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2D3 I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

After O O
activation O O
with O O
phytohemagglutinin B B_BIO/B_GENE
the O O
T O O
cells O O
exhibit O O
the O O
receptor O O
within O O
24 O O
h O O
, O O
and O O
this O O
expression O O
is O O
blocked O O
by O O
cycloheximide O O
. O O

The O O
receptor O B_GENE
in O O
activated O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
a O O
sedimentation O B_MEASURE/B_LOCATION
coefficient O I_MEASURE/I_LOCATION
of O O
3.7S O B_MEASURE
and O O
a O O
high O B_LOCATION/B_MEASURE
affinity O B_LOCATION/I_MEASURE
( O O
Kd O B_LOCATION/B_MEASURE
0.10 O I_LOCATION/I_MEASURE
nM O I_LOCATION/I_MEASURE
) O O
for O O
the O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chronic O B_DISEASE
glucocorticoid O I_DISEASE
excess O I_DISEASE
in O O
man O B_PERSON/B_BIO
on O O
insulin O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
circulating O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
: O O
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
between O O
endogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
exogenous O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
hypercorticism O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
measured O O
[ O O
125I O B_MEASURE/B_DISEASE
] O B_MEASURE/I_DISEASE
insulin O B_MEASURE/I_DISEASE
binding O B_MEASURE/I_DISEASE
to O O
circulating O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
or O O
erythrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
16 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
with O O
chronic O B_DISEASE/B_LOCATION
glucocorticoid O I_DISEASE/I_LOCATION
excess O I_DISEASE/I_LOCATION
, O O
9 O B_NUMBER[MEASURE]
chronically O O
treated O O
with O O
prednisone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
7 O B_NUMBER[MEASURE]
with O O
adrenocortical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hyperfunction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

With O O
monocytes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
[ O O
125I O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
insulin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
binding O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
iincreased O O
in O O
all O O
patients O B_PERSON/B_BIO
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
binding O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicated O O
that O O
increased O O
binding O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O B_PERSON/B_BIO
treated O O
with O O
prednisone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
due O O
to O O
an O O
ncrease O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
receptor O B_MEASURE/B_BIO
concentration O B_MEASURE/I_BIO
, O O
whereas O O
in O O
patients O B_PERSON/B_BIO
with O O
adrenocortical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hyperfunction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
was O O
due O O
to O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
receptor O B_MEASURE
affinity O I_MEASURE
. O O

With O O
erythrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
patients O B_PERSON/B_BIO
with O O
adrenocortical O B_DISEASE
hyperfunction O I_DISEASE
there O O
was O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
receptor O B_MEASURE
affinity O I_MEASURE
and O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
receptor O B_MEASURE
concentration O I_MEASURE
, O O
so O O
that O O
the O O
binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
125I O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
insulin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
disparity O O
of O O
results O O
between O O
endogenous O O
and O O
exogenous O O
hypercorticism O O
, O O
between O O
the O O
two O O
cell O O
types O O
, O O
and O O
between O O
the O O
present O O
studies O O
and O O
previous O O
studies O O
suggest O O
that O O
the O O
effects O O
of O O
glucocorticoid O O
excess O O
on O O
the O O
insulin B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
receptor I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
are O O
extremely O O
complex O O
and O O
wide-ranging O O
and O O
that O O
in O O
this O O
condition O O
, O O
extrapolations O O
in O O
humans O O
from O O
data O O
with O O
circulating O O
cells O O
to O O
liver O O
and O O
muscle O O
may O O
not O O
be O O
appropriate O O
. O O

Reduced O O
level O O
of O O
cellular B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O O
with O O
anorexia O O
nervosa O O
. O O

Specific O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
measured O O
in O O
circulating O O
mononuclear O O
leukocytes O O
from O O
12 O O
patients O O
with O O
anorexia O O
nervosa O O
and O O
21 O O
healthy O O
control O O
subjects O O
. O O

Cells O O
from O O
patients O O
were O O
found O O
to O O
contain O O
a O O
significantly O O
( O O
p O O
less O O
than O O
0.01 O O
) O O
lower O O
level O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
( O O
3830 O O
+/- O O
210 O O
sites/cell O O
, O O
mean O O
+/- O O
SE O O
) O O
than O O
those O O
from O O
controls O O
( O O
4930 O O
+/- O O
250 O O
sites/cell O O
) O O
. O O

A O O
partial O O
glucocorticoid B B_GENE
receptor I I_GENE
defect O O
may O O
well O O
explain O O
the O O
abnormal O O
cortisol O O
metabolism O O
and O O
glucocorticoid O O
resistance O O
commonly O O
found O O
in O O
patients O O
with O O
anorexia O O
nervosa O O
. O O

Regulation O O
of O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
in O O
human O O
lymphocytes O O
. O O

The O O
presence O O
of O O
a O O
glucocorticoid B B_GENE
receptor I I_GENE
in O O
human O O
lymphocytes O O
is O O
well O O
established O O
, O O
but O O
factors O O
affecting O O
its O O
regulation O O
have O O
not O O
been O O
described O O
. O O

Using O O
a O O
competitive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
binding O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
whole O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
we O O
have O O
examined O O
the O O
binding O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-dexamethasone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O O
24 O B_MEASURE
and O O
37 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
in O O
untreated O B_PERSON/B_BIO
normal O I_PERSON/I_BIO
subjects O I_PERSON/I_BIO
and O O
in O O
healthy O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
taking O O
various O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
preparations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

At O O
24 O B_MEASURE
degrees O I_MEASURE
C O I_MEASURE
normal O I_MEASURE
human O I_MEASURE
lymphocytes O I_MEASURE
had O O
6000 O B_NUMBER[MEASURE]
binding O O
sites/cell O B_LOCATION
and O O
a O O
dissociation O B_MEASURE
constant O I_MEASURE
of O O
4 O B_MEASURE
x O O
10 O B_MEASURE
( O O
-9 O B_MEASURE
) O O
M O B_MEASURE
. O O

The O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_MEASURE/B_LOCATION
mg O I_MEASURE/I_LOCATION
of O O
prednisone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
37.5 O B_MEASURE/B_LOCATION
mg O I_MEASURE/I_LOCATION
of O O
cortisone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
resulted O O
in O O
a O O
30 O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
binding O O
sites O B_MEASURE
after O O
1 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
week O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
no O O
change O B_MEASURE
in O O
binding O O
affinity O B_TIME[MEASURE]/B_GENE
. O O

No O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
number O B_MEASURE/B_LOCATION
of O O
binding O O
sites O B_LOCATION/B_ENT
was O O
noted O O
before O O
1 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
week O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
diminished O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
persisted O O
for O O
1 O B_TIME[MEASURE]
week O I_TIME[MEASURE]
after O O
discontinuation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
hospitalized O O
patients O B_PERSON/B_BIO
taking O O
40-60 O B_MEASURE
mg O I_MEASURE
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O O
demonstrated O O
the O O
same O B_MEASURE
change O I_MEASURE
in O O
number O B_MEASURE/B_LOCATION
of O O
binding O O
sites O B_LOCATION/B_ENT
that O O
was O O
seen O O
in O O
normal O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
taking O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

When O O
binding O O
assays O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
carried O O
out O O
at O O
physiologic O B_MEASURE/B_LOCATION
temperature O B_MEASURE/I_LOCATION
there O O
was O O
the O O
same O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
number O B_MEASURE
of O O
binding O O
sites O B_LOCATION/B_ENT
after O O
dexamethasone O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
, O O
and O O
in O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
there O O
was O O
a O O
two-fold O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
binding O B_MEASURE/B_DISEASE
affinity O I_MEASURE/I_DISEASE
. O O

Glucocorticoid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
administration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O O
a O O
time-dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
number O B_MEASURE/B_LOCATION
of O O
lymphocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
glucocorticoid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
binding O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
sites O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
that O O
is O O
independent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
type O B_MEASURE
of O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administered O O
. O O

This O O
is O O
the O O
first O B_SEQUENCE[MEASURE]
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
demonstration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modulate O O
their O O
own O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
man O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O O

Immunoglobulin O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
localization O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
benign O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
malignant O B_DISEASE
lesions O I_DISEASE
of O O
the O O
human O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mammary O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gland O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Using O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imunofluorescence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lesions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
266 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
breast O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
for O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
IgA O B_GENE
, O O
IgM O B_GENE/B_DISEASE
, O O
or O O
IgG O B_GENE
localization O I_GENE
. O O

The O O
lesions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
included O O
benign O B_DISEASE/B_PERSON
elements O I_DISEASE/I_PERSON
from O O
66 O B_MEASURE/B_PERSON
subcutaneous O I_MEASURE/I_PERSON
mastectomy O I_MEASURE/I_PERSON
specimens O I_MEASURE/I_PERSON
in O O
which O O
the O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
simultaneous O B_DISEASE
breast O I_DISEASE
malignancy O I_DISEASE
was O O
documented O O
, O O
primary O B_DISEASE
breast O I_DISEASE
carcinomas O I_DISEASE
from O O
153 O B_MEASURE/B_PERSON
mastectomy O B_MEASURE/I_PERSON
specimens O B_MEASURE/I_PERSON
, O O
and O O
47 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
biopsies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
containing O O
metastatic O B_DISEASE
breast O I_DISEASE
cancer O I_DISEASE
. O O

A O O
statistically O O
significant O O
association O O
of O O
IgA B B_GENE/B_DISEASE
and O O
IgM B B_GENE
with O O
benign O O
lesions O O
was O O
contrasted O O
to O O
the O O
association O O
of O O
IgG B B_GENE
with O O
malignant O O
lesions O O
. O O

In O O
both O O
primary O O
and O O
metastatic O O
lesions O O
, O O
IgG B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
localization O O
was O O
associated O O
with O O
estrogen-receptor-poor O O
primary O O
cancers O O
as O O
compared O O
with O O
estrogen-receptor-rich O O
primary O O
cancers O O
. O O

Among O O
primary O O
breast O O
cancer O O
patients O O
, O O
IgG B B_GENE/B_DISEASE
localization O O
in O O
the O O
tumor O O
correlated O O
with O O
relative O O
lymphopenia O O
. O O

A O O
shorter O O
disease-free O O
interval O O
was O O
noted O O
in O O
association O O
with O O
IgG B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
localization O O
among O O
the O O
metastatic O O
breast O O
lesions O O
. O O

No O O
statistically O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
association O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
stage O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
disease O B_DISEASE
and O O
immunoglobulin O B_DISEASE
presence O I_DISEASE
was O O
demonstrable O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Moderate-to-severe O O
intraductal O O
epithelial O O
hyperplasias O O
were O O
more O O
often O O
associated O O
with O O
immunoglobulin B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
G I I_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
localization O O
that O O
were O O
other O O
benign O O
lesions O O

Correlation O O
of O O
steroid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
histologic O O
differentiation O O
in O O
mammary O O
carcinoma O O
. O O

A O O
Singapore O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experience O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Cancer O B_DISEASE/B_LOCATION
of O O
the O O
breast O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
is O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]
tumor O I_DISEASE_ADJECTIVE[DISEASE]
in O O
females O B_PERSON
in O O
Singapore O B_LOCATION
, O O
with O O
the O O
rate O B_MEASURE
of O O
20.7 O B_TIME[MEASURE]
per O O
100 O B_MEASURE
, O O
000 O B_MEASURE
per O O
year O B_TIME[MEASURE]/B_PERSON
( O O
1977 O B_MEASURE
estimate O I_MEASURE
) O O
, O O
which O O
is O O
predicted O O
to O O
increase O O
to O O
29.8 O B_TIME[MEASURE]
per O O
100 O B_MEASURE
, O O
000 O B_TIME[MEASURE]
women O I_TIME[MEASURE]
per O O
year O B_TIME[MEASURE]/B_PERSON
by O O
1995 O B_TIME[MEASURE]
. O O

A O O
detailed O O
histopathologic O O
review O O
of O O
50 O O
primary O O
breast O O
cancer O O
tumors O O
analyzed O O
for O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ER B B_PROTEIN[GENE]/B_LOCATION
) O O
level O O
was O O
carried O O
out O O
and O O
a O O
variety O O
of O O
morphologic O O
features O O
correlated O O
with O O
ER B B_LOCATION/B_GENE
results O O
to O O
identify O O
any O O
factors O O
that O O
will O O
improve O O
the O O
management O O
and O O
prognosis O O
for O O
breast O O
cancer O O
. O O

Cytosol O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
was O O
incubated O O
with O O
3H-estradiol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
absence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
cold O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diethylstilbestrol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
bound O O
and O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
separated O O
by O O
Dextran-coated O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
charcoal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Tumors O O
binding O O
more O O
than O O
5 O O
fmol/mg O O
cytosol B B_GENE
protein I I_GENE
were O O
classified O O
as O O
ER B B_GENE
-positive O O
. O O

Progesterone B B_GENE
receptor I I_GENE
( O O
PR B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
level O O
was O O
analyzed O O
in O O
some O O
specimens O O
with O O
the O O
use O O
of O O
a O O
similar O O
method O O
. O O

Most O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
patients O B_PERSON
were O O
Chinese O B_LOCATION/B_PERSON
( O O
90 O B_LOCATION/B_PERSON
% O I_LOCATION/I_PERSON
) O O
. O O

Three O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
were O O
Malays O B_LOCATION/B_PERSON
, O O
one O B_NUMBER[MEASURE]/B_PERSON
was O O
Indian O B_PERSON/B_LOCATION
, O O
and O O
one O B_NUMBER[MEASURE]/B_PERSON
was O O
European O B_LOCATION/B_PERSON
in O O
this O O
series O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Results O O
indicated O O
that O O
there O O
was O O
strong O O
correlation O O
between O O
ER B B_GENE
level O O
, O O
age O O
, O O
and O O
histologic O O
grade O O
of O O
the O O
tumors O O
. O O

No O O
correlation O O
existed O O
between O O
absence O O
or O O
presence O O
of O O
lymph O O
node O O
metastases O O
and O O
ER B B_GENE/B_DISEASE
. O O

Although O O
there O O
was O O
a O O
trend O O
for O O
ER B B_GENE
-positive O O
tumors O O
to O O
have O O
a O O
low-grade O O
lymphocytic O O
infiltration O O
, O O
the O O
difference O O
was O O
not O O
statistically O O
significant O O
. O O

Mononuclear O O
cells O O
infiltrating O O
human O O
mammary O O
carcinomas O O
: O O
immunohistochemical O O
analysis O O
with O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Breast O O
carcinomas O O
were O O
examined O O
by O O
the O O
immunoperoxidase O O
technique O O
using O O
antisera O O
specific O O
for O O
lymphocyte O O
subsets O O
, O O
monocytes O O
, O O
NK O O
cells O O
and O O
major B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HLA-A B B_GENE
, O O
-B B B_PROTEIN[GENE]/B_LOCATION
, O O
-C O O
; O O
Ia-like B B_DISEASE/B_PERSON
) O O
. O O

Sixty-four O O
per O O
cent O B_SEQUENCE[MEASURE]
of O O
the O O
patients O B_PERSON
had O O
a O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]
or O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mononuclear O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cell O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
infiltration O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
77 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
of O O
the O O
patients O B_PERSON
without O O
mononuclear O B_DISEASE
cell O I_DISEASE
infiltration O I_DISEASE
had O O
receptors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
estrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O O
compared O O
to O O
51 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
patients O B_PERSON/B_LOCATION
with O O
infiltration O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
majority O B_PERSON/B_MEASURE
of O O
the O O
infiltrating O O
mononuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
were O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
; O O
generally O O
the O O
OKT8 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
predominant O B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
Leu O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3A/OKT8 O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratio O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
related O O
to O O
histological O B_MEASURE/B_PERSON
type O I_MEASURE/I_PERSON
, O O
tumor O B_MEASURE/B_PERSON
size O I_MEASURE/I_PERSON
, O O
age O B_MEASURE/B_LOCATION
of O O
the O O
patient O B_PERSON/B_DISEASE
or O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
metastases O B_DISEASE
. O O

Some O O
of O O
the O O
T O O
cells O O
had O O
the O O
Ia B B_GENE
antigen I I_GENE
and O O
were O O
thus O O
probably O O
activated O O
. O O

The O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
either O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
less O O
numerous O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
the O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
. O O

There O O
was O O
no O O
relation O B_PERSON/B_DISEASE
between O O
their O O
distribution O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
the O O
various O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
parameters O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
studied O O
. O O

A O O
few O O
monocytes O O
were O O
heterogeneous O O
according O O
to O O
their O O
markers O O
( O O
OKM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
acid O O
phosphatase O O
) O O
. O O

In O O
6 O O
cases O O
only O O
there O O
was O O
a O O
strong O O
infiltration O O
of O O
mononuclear O O
cells O O
positive O O
for O O
acid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
number O B_MEASURE
of O O
the O O
natural O B_PERSON
killer O I_PERSON
cells O I_PERSON
was O O
also O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Only O O
a O O
few O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
mononuclear O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
infiltrating O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
had O O
receptors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
transferrin O B_GENE
. O O

There O O
was O O
a O O
positive O O
correlation O O
between O O
the O O
inflammatory O O
infiltration O O
and O O
the O O
presence O O
of O O
HLA B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
class-I I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
antigens I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
on O O
tumor O O
cell O O
s O O
. O O

Some O O
of O O
the O O
antisera O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
specific O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
lymphocyte O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
subsets O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O O
stained O O
the O O
breast O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
carcinoma O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
great O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
subsets O B_MEASURE/B_LOCATION
of O O
mononuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
in O O
breast O B_DISEASE/B_BIO
carcinomas O I_DISEASE/I_BIO
may O O
correspond O O
to O O
various O B_DISEASE_ADJECTIVE[DISEASE]
systems O I_DISEASE_ADJECTIVE[DISEASE]
of O O
defense O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
against O O
neoplasm O B_DISEASE/B_BIO
. O O

A O O
case O O
of O O
male O O
pseudohermaphroditism O O
with O O
normal O O
androgen B B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
receptor I I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
binding O O
and O O
47 O O
, O O
XYY O O
karyotype O O
. O O

A O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
male O B_DISEASE/B_PERSON
pseudohermaphroditism O I_DISEASE/I_PERSON
with O O
47 O B_MEASURE/B_PERSON
, O O
XYY O B_MEASURE/B_GENE
karyotype O I_MEASURE/I_GENE
in O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
cutaneous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fibroblasts O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
described O O
. O O

The O O
plasma O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testosterone O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
HCG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
slightly O O
below O O
the O O
normal O B_MEASURE/B_LOCATION
range O I_MEASURE/I_LOCATION
on O O
two O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
occasions O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
suggesting O O
a O O
deficit O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
gonadal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
function O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O O

A O O
study O O
of O O
the O O
receptors O O
for O O
dihydrotestosterone O O
in O O
fibroblasts O O
of O O
genital O O
and O O
nongenital O O
skin O O
showed O O
a O O
normal O O
concentration O O
of O O
receptors O O
in O O
genital O O
skin O O
; O O
5-alpha-reductase B B_GENE/B_PERSON
activity O O
in O O
fibroblasts O O
of O O
the O O
genital O O
skin O O
was O O
low O O
, O O
but O O
the O O
plasma O O
relationship O O
testosterone/dihydrotestosterone O O
under O O
HCG O O
stimulation O O
was O O
normal O O
. O O

The O O
diagnostic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possibility O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
testicular O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
feminization O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
syndrome O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O O
normal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
dihydrotestosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
commented O O
on O O
. O O

1 O O
, O O
25-Dihydroxyvitamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D3 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibits O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen-induced O O
T O B_DISEASE
cell O I_DISEASE
activation O I_DISEASE
. O O

The O O
proliferative O O
response O O
of O O
murine O O
spleen O O
and O O
thymus O O
cells O O
to O O
antigen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
but O O
not O O
to O O
lectin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
inhibited O O
by O O
the O O
active O O
metabolite O O
of O O
vitamin O O
D3 O O
, O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
. O O

To O O
directly O O
examine O O
the O O
effect O O
of O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
on O O
T O O
cell O O
activation O O
in O O
the O O
absence O O
of O O
other O O
complicating O O
interactions O O
, O O
we O O
utilized O O
a O O
panel O O
of O O
cloned O O
Ia-restricted O O
T O O
cell O O
hybridomas O O
that O O
secrete O O
IL B B_GENE
2 I I_GENE
on O O
activation O O
by O O
cloned O O
Ia-bearing O O
stimulator O O
cells O O
( O O
TA3 O O
) O O
or O O
when O O
stimulated O O
by O O
mitogen O O
. O O

Physiologic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
concentrations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O O
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
0.01 O B_MEASURE/B_LOCATION
to O O
0.1 O B_MEASURE
nm O I_MEASURE
) O O
inhibited O O
the O O
antigen-induced O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
secretion O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
IL O B_GENE
2 O I_GENE
by O O
several O B_NUMBER[MEASURE]/B_BIO
of O O
these O O
T O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hybridomas O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

This O O
inhibition O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
dependent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
concentration O B_MEASURE/B_LOCATION
of O O
the O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
could O O
be O O
overcome O O
by O O
increasing O O
the O O
number O B_MEASURE
of O O
Ia-bearing O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulator O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cells O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
used O O
. O O

Pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
T O B_DISEASE/B_PROTEIN[GENE]
hybridoma O B_DISEASE/I_PROTEIN[GENE]
but O O
not O O
the O O
TA3 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
stimulator O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
with O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
resulted O O
in O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
activation O B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

These O O
results O O
are O O
consistent O O
with O O
the O O
finding O O
that O O
specific O O
1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
25- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
OH I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2D3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
present O O
on O O
the O O
T O O
cell O O
hybridomas O O
but O O
are O O
lacking O O
in O O
TA3 O O
cells O O
. O O

1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
failed O O
, O O
however O O
, O O
to O O
inhibit O O
the O O
activation O O
of O O
the O O
T O O
cell O O
hybridomas O O
by O O
lectin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
by O O
an O O
anti-Thy-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O O
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
may O O
be O O
interfering O O
with O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
events O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
antigen-induced O B_DISEASE
T O I_DISEASE
cell O I_DISEASE
activation O I_DISEASE
, O O
perhaps O O
by O O
hindering O O
T O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
recognition O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
relevant O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
stimulator O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
surfaces O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

This O O
system O O
should O O
prove O O
useful O O
in O O
studying O O
the O O
molecular O O
mechanisms O O
by O O
which O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
acts O O
to O O
inhibit O O
T O O
cell O O
activation O O
and O O
subsequent O O
IL B B_GENE
2 I I_GENE
production O O
. O O

Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
steroid O O
sensitivity O O
in O O
normal O O
and O O
neoplastic O O
human O O
lymphoid O O
tissues O O
: O O
a O O
review O O
. O O

The O O
determination O O
of O O
estrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
progesterone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
breast O O
cancer O O
has O O
been O O
shown O O
to O O
be O O
useful O O
in O O
predicting O O
the O O
response O O
to O O
endocrine O O
therapy O O
. O O

Given O O
their O O
well-known O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitory O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
lymphoid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
tissue O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O O
been O O
used O O
widely O O
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
leukemia O B_DISEASE/B_LOCATION
. O O

Given O O
these O O
facts O O
, O O
over O O
the O O
last O O
10 O O
years O O
, O O
several O O
investigators O O
have O O
measured O O
the O O
number O O
of O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
normal O O
and O O
neoplastic O O
lymphoid O O
tissue O O
to O O
see O O
whether O O
their O O
number O O
correlated O O
with O O
glucocorticoid O O
responsiveness O O
in O O
vitro O O
or O O
in O O
vivo O O
. O O

No O O
clear O O
correlation O O
could O O
be O O
established O O
between O O
the O O
level O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
and O O
the O O
in O O
vitro O O
action O O
of O O
steroids O O
in O O
normal O O
and O O
neoplastic O O
lymphoid O O
tissue O O
. O O

In O O
contrast O O
, O O
attempts O O
to O O
correlate O O
glucocorticoid B B_GENE
receptor I I_GENE
levels O O
in O O
acute O O
lymphocytic O O
leukemia O O
to O O
in O O
vivo O O
steroid O O
responsiveness O O
and O O
immunological O O
type O O
using O O
the O O
whole-cell-binding O O
assay O O
for O O
receptor O O
determination O O
and O O
selecting O O
the O O
patients O O
according O O
to O O
age O O
and O O
immunological O O
criteria O O
have O O
been O O
more O O
successful O O
. O O

[ O O
Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
normal O O
human O O
lymphocytes O O
] O O

Glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
GC O B_PROTEIN[GENE]/B_DISEASE
) O O
receptors O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
in O O
intact O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
11 O B_PERSON/B_BIO
donors O B_PERSON/I_BIO
. O O

GC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
binding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
found O O
to O O
be O O
highly O O
reproducible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
repeated O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O O

It O O
was O O
shown O O
that O O
GC B B_GENE
receptors I I_GENE
in O O
donors O O
' O O
lymphocytes O O
could O O
be O O
distributed O O
into O O
two O O
different O O
classes O O
similarly O O
to O O
the O O
pattern O O
seen O O
in O O
skin O O
fibroblasts O O
. O O

Human O O
lymphocytes O O
are O O
an O O
adequate O O
object O O
for O O
studying O O
genetically O O
determined O O
variability O O
of O O
GC B B_DISEASE/B_GENE
receptors I I_DISEASE/I_GENE
and O O
its O O
clinical O O
importance O O
. O O

Specific O O
estrogen B B_GENE
binding I I_GENE
sites I I_GENE
in O O
human O O
lymphoid O O
cells O O
and O O
thymic O O
cells O O
. O O

The O O
binding O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
estrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
preparations O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
mononuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
well O O
as O O
by O O
splenic O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
thymic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
demonstrated O O
by O O
three O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
approaches O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Dextran-coated O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
charcoal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whole O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
gel O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
filtration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
a O O
sepharose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
4B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
column O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Scatchard O O
's O O
analysis O O
of O O
[ O O
3H O O
] O O
-moxestrol O O
( O O
R2858 O O
) O O
and O O
[ O O
3H O O
] O O
-estradiol O O
binding O O
proves O O
the O O
existence O O
of O O
a O O
single O O
class O O
of O O
receptor B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O O
a O O
dissociation O O
constant O O
of O O
0.18-2.4 O O
X O O
10 O O
( O O
-9 O O
) O O
M O O
. O O

Physicochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
properties O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
binder O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
binding O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
steroid O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
specificity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
are O O
quite O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
those O O
reported O O
for O O
the O O
thymus O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
small O B_SPECIES[BIO]
mammalian O I_SPECIES[BIO]
species O I_SPECIES[BIO]
or O O
human O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
thymoma O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Administration O O
of O O
fibroblast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
patients O O
with O O
advanced O O
breast O O
cancer O O
: O O
possible O O
effects O O
on O O
skin O O
metastasis O O
and O O
on O O
hormone B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Eleven O O
patients O O
with O O
metastasized O O
breast O O
cancer O O
received O O
8 O O
intramuscular O O
injections O O
of O O
6 O O
x O O
10 O O
( O O
6 O O
) O O
units O O
of O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fibroblast I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interferon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
over O O
a O O
period O O
of O O
40 O O
days O O
. O O

The O O
injections O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
cause O O
local O B_DISEASE
irritation O I_DISEASE
or O O
inflammation O B_DISEASE/B_BACTERIUM[BIO]
. O O

Fever O B_DISEASE
occurred O O
in O O
only O O
1 O B_NUMBER[MEASURE]
of O O
the O O
11 O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
. O O

Although O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
types O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
metastases O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
monitored O O
, O O
only O O
skin O B_NUMBER[MEASURE]
nodules O I_NUMBER[MEASURE]
consistently O O
( O O
10 O B_NUMBER[MEASURE]
out O O
of O O
11 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
) O O
exhibited O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
were O O
suggestive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
therapeutic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
either O O
a O O
simple O B_DISEASE_ADJECTIVE[DISEASE]
decrease O I_DISEASE_ADJECTIVE[DISEASE]
in O O
size O B_MEASURE
of O O
some O O
nodules O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
or O O
central O B_DISEASE_ADJECTIVE[DISEASE]
necrosis O I_DISEASE_ADJECTIVE[DISEASE]
accompanied O O
by O O
an O O
inflammatory O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reaction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

NK-activity O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
significantly O O
increased O O
after O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
first O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
the O O
effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
subsequent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
injections O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
less O O
clear O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Receptors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
for O O
estrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
progestogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
increased O O
in O O
the O O
tumor O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
biopsies O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
2 O B_NUMBER[MEASURE]
out O O
of O O
2 O B_NUMBER[MEASURE]
and O O
5 O B_NUMBER[MEASURE]
out O O
of O O
6 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
tested O O
respectively O O
. O O

Decreased O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
in O O
adrenal O O
insufficiency O O
. O O

To O O
examine O O
the O O
effect O O
of O O
glucocorticoid O O
deficiency O O
on O O
the O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
we O O
examine O O
the O O
binding O O
of O O
[ O O
3H O O
] O O
dexamethasone O O
to O O
lymphocytes O O
in O O
normal O O
subjects O O
and O O
patients O O
with O O
adrenal O O
insufficiency O O
before O O
and O O
after O O
glucocorticoid O O
replacement O O
therapy O O
. O O

Using O O
a O O
whole O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
competitive O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
normal O B_PERSON/B_GENE
human O I_PERSON/I_GENE
lymphocytes O I_PERSON/I_GENE
had O O
5977 O B_MEASURE
+/- O O
1487 O B_MEASURE/B_LOCATION
( O O
mean O B_MEASURE
+/- O O
SD O B_LOCATION/B_DISEASE
) O O
binding O O
sites/cell O B_LOCATION/B_MEASURE
and O O
a O O
dissociation O B_MEASURE/B_LOCATION
constant O I_MEASURE/I_LOCATION
of O O
10 O B_MEASURE
+/- O I_MEASURE
2 O I_MEASURE
nM O I_MEASURE
. O O

Lymphocytes O O
from O O
patients O O
with O O
untreated O O
adrenal O O
insufficiency O O
had O O
fewer O O
binding B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
3364 O O
+/-322 O O
) O O
and O O
a O O
2-fold O O
increase O O
in O O
binding O O
affinity O O
( O O
5.4 O O
+/- O O
0.9 O O
mM O O
) O O
. O O

The O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
conventional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
replacement O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
cortisone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
6 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
months O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
caused O O
no O O
change O B_MEASURE
in O O
receptor O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
was O O
associated O O
with O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
binding O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toward O O
normal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

After O O
long O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
term O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
glucocorticoid O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
replacement O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
binding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
those O O
in O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

The O O
physiological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
implications O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
decreased O O
receptor O B_MEASURE/B_DISEASE
number O I_MEASURE/I_DISEASE
and O O
increased O O
binding O B_MEASURE
affinity O I_MEASURE
in O O
adrenal O B_DISEASE
insufficiency O I_DISEASE
remain O O
to O O
be O O
elucidated O O
. O O

Glucocorticoid B B_GENE
receptor I I_GENE
concentrations O O
and O O
terminal O O
transferase B B_ENZYME[GENE]/B_DISEASE
activity O O
as O O
indicators O O
of O O
prognosis O O
in O O
acute O O
non-lymphocytic O O
leukaemia O O
. O O

Activity O O
of O O
terminal B B_ENZYME[GENE]
deoxynucleotidyl I I_ENZYME[GENE]
transferase I I_ENZYME[GENE]
( O O
TdT B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
adenosine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deaminase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
5'nucleotidase B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
cellular O O
concentration O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dexamethasone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
determined O O
in O O
25 O O
patients O O
with O O
acute O O
non-lymphocytic O O
leukaemia O O
. O O

All O O
patients O B_PERSON
were O O
treated O O
according O O
to O O
a O O
common O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Increased O O
activity O O
of O O
TdT B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
greater O O
than O O
0.1 O O
unit/microgram O O
DNA O O
) O O
was O O
found O O
in O O
11 O O
patients O O
. O O

This O O
group O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_BIO
was O O
shown O O
to O O
have O O
higher O B_DISEASE_ADJECTIVE[DISEASE]
remission O I_DISEASE_ADJECTIVE[DISEASE]
and O O
survival O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O B_OTHER/B_MEASURE
= O O
0.06 O B_MEASURE
) O O
compared O O
with O O
patients O B_PERSON/B_ORGANIZATION
with O O
low O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
TdT O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
glucocorticoid B B_MEASURE/B_GENE
receptor I I_MEASURE/I_GENE
concentration O O
of O O
the O O
leukaemic O O
blast O O
cells O O
ranged O O
from O O
0 O O
to O O
0.94 O O
fmol/microgram O O
DNA O O
. O O

Thirteen O O
patients O O
had O O
blast O O
cells O O
with O O
a O O
glucocorticoid B B_MEASURE/B_GENE
receptor I I_MEASURE/I_GENE
concentration O O
over O O
0.22 O O
fmol/microgram O O
DNA O O
. O O

These O O
patients O B_PERSON/B_BIO
had O O
significantly O O
increased O O
remission O B_DISEASE
and O O
survival O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O B_OTHER/B_MEASURE
= O O
0.006 O B_MEASURE
) O O
compared O O
with O O
those O O
with O O
a O O
low O B_DISEASE/B_LOCATION
receptor O I_DISEASE/I_LOCATION
concentration O I_DISEASE/I_LOCATION
. O O

This O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
not O O
be O O
explained O O
by O O
a O O
difference O B_MEASURE
in O O
sensitivity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O O
these O O
were O O
not O O
used O O
as O O
therapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Adenosine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deaminase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
5'nucleotidase B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
activities O O
both O O
varied O O
within O O
two O O
orders O O
of O O
magnitude O O
. O O

No O O
correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
found O O
between O O
activities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
enzymes O B_ENZYME[GENE]
and O O
remission O B_DISEASE
or O O
survival O B_DISEASE_ADJECTIVE[DISEASE]
rate O I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O O
show O O
that O O
measurements O O
of O O
TdT B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
and O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
concentration O O
yield O O
valuable O O
prognostic O O
information O O
in O O
acute O O
non-lymphocytic O O
leukaemia O O

[ O O
3H O O
] O O
cortivazol O O
: O O
a O O
unique O O
high O O
affinity O O
ligand O O
for O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
. O O

Cortivazol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CVZ O B_LOCATION
) O O
and O O
deacylcortivazol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DAC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
are O O
pyrazolosteroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

In O O
previous O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
work O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
showed O O
that O O
DAC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
40-fold O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
more O O
potent O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
DEX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
lysing O O
leukemic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
lymphoblasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O O

To O O
assess O O
the O O
interaction O O
between O O
these O O
atypical O O
steroids O O
and O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
, O O
we O O
examined O O
the O O
binding O O
of O O
[ O O
3H O O
] O O
CVZ O O
to O O
cytosol O O
from O O
glucocorticoid-sensitive O O
and O O
-resistant O O
variants O O
of O O
the O O
human O O
leukemic O O
cell O O
line O O
CEM O O
C7 O O
. O O

In O O
glucocorticoid-sensitive O O
cells O O
[ O O
3H O O
] O O
CVZ O O
causes O O
a O O
2-fold O O
induction O O
of O O
glutamine B B_ENZYME[GENE]
synthetase I I_ENZYME[GENE]
and O O
binds O O
to O O
a O O
protein O O
in O O
the O O
4.6 O O
S O O
region O O
of O O
high O O
salt O O
sucrose O O
gradients O O
. O O

On O O
DEAE-cellulose O O
chromatography O O
, O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CVZ-receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
a O O
shift O O
from O O
high O O
( O O
0.25 O O
M O O
KP O O
) O O
to O O
low O O
salt O O
( O O
0.09 O O
M O O
KP O O
) O O
eluting O O
forms O O
upon O O
activation O O
. O O

CVZ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
competes O O
for O O
a O O
97 O B_MEASURE
, O O
000-dalton O B_MEASURE/B_PROTEIN[GENE]
protein O I_MEASURE/I_PROTEIN[GENE]
labeled O O
by O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dexamethasone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mesylate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Scatchard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CVZ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
glucocorticoid-sensitive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
a O O
curvilinear O B_MEASURE
plot O I_MEASURE
which O O
resolved O O
into O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O O
0.4 O B_MEASURE/B_COLOR
nM O I_MEASURE/I_COLOR
) O O
and O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
11 O B_MEASURE
nM O I_MEASURE
) O O
affinity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
components O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
receptor O O
concentration O O
of O O
the O O
low O O
affinity O O
site O O
( O O
0.30 O O
pmol/mg O O
protein O O
) O O
was O O
approximately O O
twice O O
that O O
of O O
the O O
high B B_GENE/B_MEASURE
affinity I I_GENE/I_MEASURE
site I I_GENE/I_MEASURE
( O O
0.14 O O
pmol/mg O O
protein O O
) O O
. O O

Dissociation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
dilution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and/or O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
excess O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
unlabeled O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CVZ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
supported O O
the O O
presence O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
independent O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sites O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O B_MEASURE
, O O
the O O
binding O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
DEX O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
C7 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cytosol O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
revealed O O
a O O
single O B_MEASURE
class O I_MEASURE
of O O
binding O O
sites O B_LOCATION/B_ENT
( O O
Kd O B_PROTEIN[GENE]/B_LOCATION
= O O
1.9 O B_MEASURE/B_COLOR
nM O I_MEASURE/I_COLOR
; O O
receptor O B_MEASURE/B_LOCATION
concentration O I_MEASURE/I_LOCATION
, O O
0.46 O B_MEASURE/B_LOCATION
pmol/mg O I_MEASURE/I_LOCATION
protein O I_MEASURE/I_LOCATION
) O O
. O O

Examination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CVZ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
using O O
10 O B_NUMBER[MEASURE]/B_LOCATION
( O O
-5 O O
) O O
M O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DEX O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
the O O
competing O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
DEX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binds O O
only O O
to O O
the O O
low O B_PROTEIN[GENE]/B_LOCATION
affinity O I_PROTEIN[GENE]/I_LOCATION
site O I_PROTEIN[GENE]/I_LOCATION
detected O O
by O O
[ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CVZ O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

In O O
cytosol O O
from O O
a O O
glucocorticoid-resistant O O
cell O O
line O O
with O O
virtually O O
no O O
[ O O
3H O O
] O O
DEX O O
binding O O
, O O
[ O O
3H O O
] O O
CVZ O O
detected O O
a O O
single O O
high B B_PROTEIN[GENE]/B_LOCATION
affinity I I_PROTEIN[GENE]/I_LOCATION
binding I I_PROTEIN[GENE]/I_LOCATION
site I I_PROTEIN[GENE]/I_LOCATION
that O O
was O O
similar O O
in O O
dissociation O O
constant O O
( O O
0.8 O O
nM O O
) O O
and O O
receptor O O
concentration O O
( O O
0.13 O O
pmol/mg O O
protein O O
) O O
to O O
the O O
high B B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity I B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O O
in O O
the O O
glucocorticoid-sensitive O O
cell O O
line O O
C7 O O
. O O

A O O
controlled O O
pore O O
glass O O
bead O O
assay O O
for O O
the O O
measurement O O
of O O
cytoplasmic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

An O O
assay O O
for O O
the O O
quantitation O O
of O O
cytoplasmic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
lymphoid O O
tissue O O
has O O
been O O
developed O O
using O O
controlled O O
pore O O
glass O O
( O O
CPG O O
) O O
beads O O
. O O

Soluble O O
receptor B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
-- I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
3H-steroid I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
cytosol O O
or O O
nuclear O O
extract O O
) O O
is O O
adsorbed O O
quantitatively O O
within O O
the O O
crevasses O O
of O O
porous O O
glass O O
beads O O
. O O

Excess O O
labeled O O
steroid O O
as O O
well O O
as O O
most O O
non-specifically O O
bound O O
steroid O O
is O O
easily O O
washed O O
away O O
, O O
leaving O O
the O O
hormone-receptor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
complex I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
retained O O
by O O
the O O
beads O O
. O O

Bound O O
3H-steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
eluted O O
with O O
ethanol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
measured O O
for O O
radioactivity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
procedure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
is O O
simple O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
highly O O
reproducible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
carried O O
out O O
using O O
frozen O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
stable O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
many O B_TIME[MEASURE]
months O I_TIME[MEASURE]
) O O
containing O O
as O O
few O B_NUMBER[MEASURE]/B_PERSON
as O O
1 O B_MEASURE
X O O
10 O B_NUMBER[MEASURE]
( O O
7 O B_MEASURE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O O

A O O
comparison O O
of O O
the O O
CPG O O
assay O O
to O O
dextran O O
coated O O
charcoal O O
and O O
a O O
whole O O
cell O O
assay O O
demonstrates O O
that O O
CPG O O
and O O
dextran O O
coated O O
charcoal O O
give O O
equivalent O O
measurements O O
of O O
cytosolic B B_GENE
receptor I I_GENE
concentration O O
, O O
while O O
the O O
CPG O O
and O O
whole O O
cell O O
assays O O
provide O O
equivalent O O
values O O
for O O
total O O
receptor O O
content O O
. O O

Plasmacytoid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blast O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
crisis O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
B-cell O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
chronic O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
lymphocytic O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
leukemia O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
: O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
estradiol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
growth O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O O
differentiation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
vitro O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Evolution O O
of O O
a O O
case O O
of O O
chronic O O
lymphocytic O O
leukemia O O
( O O
CLL O O
) O O
into O O
blast O O
crisis O O
was O O
found O O
to O O
be O O
characterized O O
by O O
three O O
unusual O O
features O O
( O O
1 O O
) O O
the O O
phenotype O O
of O O
the O O
emerging O O
blast O O
cells O O
was O O
that O O
of O O
pre-plasmacytoid O O
cells O O
as O O
shown O O
by O O
plasma O O
cell O O
morphology O O
and O O
an O O
immunological O O
phenotype O O
corresponding O O
partially O O
with O O
CLL- O O
or O O
intermediate O O
B-cells O O
, O O
partially O O
with O O
plasma O O
cells O O
( O O
terminal B B_GENE/B_LOCATION
transferase I I_GENE/I_LOCATION
- O O
, O O
common O O
acute B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leukemia I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
, O O
Ia+ B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
surface B B_GENE
immunoglobulin I I_GENE
heavy I I_GENE
chains I I_GENE
- O O
, O O
surface B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ O O
, O O
intracytoplasmic B B_GENE/B_DISEASE
immunoglobulin I I_GENE/I_DISEASE
A+ I I_GENE/I_DISEASE
and I I_GENE/I_DISEASE
G+ I I_GENE/I_DISEASE
, O O
BA-1+ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
polyclonal O O
gammaglobulin O O
production O O
) O O
; O O
( O O
2 O O
) O O
cytogenetic O O
analysis O O
of O O
spontaneous O O
metaphases O O
revealed O O
that O O
in O O
addition O O
to O O
the O O
typical O O
CLL O O
abnormality O O
, O O
trisomy O O
12 O O
, O O
in O O
all O O
of O O
the O O
cells O O
, O O
an O O
additional O O
translocation O O
between O O
chromosomes B B_DISEASE/B_GENE
14 I I_DISEASE/I_GENE
and I I_DISEASE/I_GENE
17 I I_DISEASE/I_GENE
was O O
present O O
in O O
40 O O
% O O
with O O
a O O
presumptive O O
breakpoint O O
on O O
chromosome B B_GENE/B_MEASURE
14 I I_GENE/I_MEASURE
( O O
q12-3 O O
) O O
never O O
described O O
before O O
( O O
commonly O O
q32 O O
) O O
and O O
( O O
3 O O
) O O
the O O
progression O O
of O O
the O O
disease O O
was O O
associated O O
with O O
a O O
striking O O
increase O O
in O O
the O O
expression O O
by O O
the O O
transformed O O
cells O O
of O O
specific O O
binding O O
sites O O
for O O
estradiol O O
( O O
E2 O O
) O O
due O O
to O O
an O O
actual O O
increase O O
in O O
total O O
cellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
not O O
to O O
a O O
change O O
in O O
receptor O O
affinity O O
for O O
E2 O O
. O O

The O O
functional O O
status O O
of O O
the O O
steroid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
confirmed O O
by O O
nuclear O O
transfer O O
of O O
the O O
cytoplasmic B B_GENE
hormone-receptor I I_GENE
complex I I_GENE
upon O O
temperature O O
activation O O
. O O

Since O O
the O O
rise O O
in O O
E2-receptor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
display O O
paralleled O O
a O O
large O O
increase O O
in O O
the O O
proliferative O O
activity O O
of O O
the O O
cells O O
as O O
well O O
as O O
a O O
change O O
in O O
their O O
maturation O O
status O O
the O O
question O O
was O O
raised O O
as O O
to O O
whether O O
the O O
E2-receptor B B_PROTEIN[GENE]/B_MEASURE
should O O
be O O
considered O O
as O O
a O O
physiological O O
marker O O
of O O
growth O O
rate O O
or O O
of O O
cellular O O
differentiation O O
. O O

Exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
patient O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
's O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blast O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
E2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
resulted O O
in O O
cessation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O O
at O O
least O O
one O B_TIME[MEASURE]
mitosis O I_TIME[MEASURE]
after O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
inducer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
seen O O
from O O
the O O
replacement O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
the O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blasts O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
CLL-like O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
without O O
definite O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
signs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
alteration O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
differentiation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
status O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

This O O
suggests O O
the O O
association O O
of O O
E2-receptor B B_GENE
expression O O
with O O
control O O
of O O
growth O O
rather O O
than O O
cell O O
maturation O O
. O O

Multiple O O
forms O O
and O O
fragments O O
of O O
cytosolic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
human O O
leukemic O O
cells O O
and O O
normal O O
lymphocytes O O
. O O

Therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
generally O O
more O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
acute O B_DISEASE/B_LOCATION
lymphoblastic O I_DISEASE/I_LOCATION
leukemia O I_DISEASE/I_LOCATION
than O O
in O O
other O B_DISEASE/B_NUMBER[MEASURE]
types O I_DISEASE/I_NUMBER[MEASURE]
of O O
human O B_DISEASE
leukemia O I_DISEASE
. O O

Previous O O
studies O O
, O O
however O O
, O O
have O O
not O O
revealed O O
any O O
consistent O O
relationship O O
between O O
clinical O O
responsiveness O O
and O O
the O O
cellular O O
or O O
cytosolic O O
concentration O O
of O O
glucocorticoid-binding B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
objectives O O
of O O
this O O
study O O
were O O
to O O
determine O O
whether O O
there O O
are O O
intrinsic O O
structural O O
differences O O
among O O
the O O
glucocorticoid B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
various O O
types O O
of O O
leukemic O O
cells O O
and O O
normal O O
lymphocytes O O
and O O
to O O
investigate O O
the O O
role O O
of O O
endogenous B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptidases I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
receptor O O
degradation O O
. O O

Cytosols O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
were O O
prepared O O
from O O
fresh O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
rapidly O O
frozen O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leukocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
6 O B_MEASURE
healthy O I_MEASURE
adults O I_MEASURE
and O O
35 O B_PERSON/B_BIO
high-risk O I_PERSON/I_BIO
leukemia O I_PERSON/I_BIO
patients O I_PERSON/I_BIO
( O O
median O B_MEASURE/B_LOCATION
white O I_MEASURE/I_LOCATION
blood O I_MEASURE/I_LOCATION
cell O I_MEASURE/I_LOCATION
count O I_MEASURE/I_LOCATION
, O O
150 O B_MEASURE
, O O
000 O B_MEASURE
cells/microliter O I_MEASURE
; O O
median O B_MEASURE/B_PERSON
age O I_MEASURE/I_PERSON
, O O
13 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
) O O
. O O

Receptors O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
labeled O O
with O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triamcinolone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
quantitated O O
by O O
charcoal-dextran O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
Sephadex O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LH-20 O O
chromatography O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Mean O B_MEASURE/B_LOCATION
and O O
median O B_MEASURE
cytosolic O I_MEASURE
receptor O I_MEASURE
concentrations O I_MEASURE
in O O
12 O B_MEASURE/B_DISEASE
acute O I_MEASURE/I_DISEASE
lymphoblastic O I_MEASURE/I_DISEASE
leukemia O I_MEASURE/I_DISEASE
specimens O I_MEASURE/I_DISEASE
lacking O O
the O O
standard O B_GENE
B-cell O I_GENE
or O O
T-cell O B_GENE
markers O I_GENE
( O O
`` O B_PROTEIN[GENE]/B_LOCATION
null O I_PROTEIN[GENE]/I_LOCATION
cells O O
'' O O
) O O
were O O
approximately O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
4-fold O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
higher O O
than O O
in O B_PERSON/B_BIO
23 O I_PERSON/I_BIO
other O I_PERSON/I_BIO
leukemic O I_PERSON/I_BIO
cell O I_PERSON/I_BIO
specimens O O

No O O
other O B_DISEASE_ADJECTIVE[DISEASE]
consistent O I_DISEASE_ADJECTIVE[DISEASE]
differences O I_DISEASE_ADJECTIVE[DISEASE]
in O O
receptor O B_DISEASE/B_GENE
content O I_DISEASE/I_GENE
were O O
observed O O
. O O

Agarose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
filtration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
ultracentrifugation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
hypotonic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
buffers O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
20 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Na2MoO4 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O O
complexes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
similar O B_MEASURE/B_COLOR
size O I_MEASURE/I_COLOR
and O O
shape O B_MEASURE
in O O
all O O
clinical O B_NUMBER[MEASURE]
specimens O I_NUMBER[MEASURE]
tested O O
and O O
two O B_NUMBER[MEASURE]/B_LOCATION
established O O
leukemic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lines O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

They O O
had O O
Stokes O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radii O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Rs O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
of O O
8.1 O B_MEASURE
+/- O O
0.5 O B_MEASURE
( O O
S.D. O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
nm O O
( O B_MEASURE/B_LOCATION
n O O
= O B_OTHER/B_MEASURE
50 O O
) O B_MEASURE
, O O
sedimentation O O
coefficients O B_MEASURE
of O I_MEASURE
9.5 O O
+/- O B_MEASURE
0.3S O I_MEASURE
( O I_MEASURE
n O O
= O B_OTHER/B_MEASURE
40 O O
) O B_MEASURE
, O O
molecular O O
weights O B_MEASURE/B_LOCATION
of O I_MEASURE/I_LOCATION
approximately O O
330 O O
, O B_MEASURE
000 O O
, O B_MEASURE
and O O
axial O O
ratios O B_MEASURE
( O I_MEASURE
a/b O O
) O B_PROTEIN[GENE]/B_LOCATION
of O O
approximately O O
12 O O
. O B_NUMBER[MEASURE]/B_LOCATION

In O O
hypertonic O O
, O O
molybdate-free O O
buffer O O
, O O
these O O
oligomeric B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
dissociated O O
into O O
subunits O O
with O O
Rs O O
of O O
5.9 O O
+/- O O
0.3 O O
nm O O
( O O
n O O
= O O
12 O O
) O O
and O O
a/b O O
of O O
11 O O
to O O
12 O O
, O O
as O O
observed O O
previously O O
for O O
other O O
receptors O O
. O O

Fragmentation O O
of O O
the O O
oligomer B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
subunit B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
evident O O
in O O
some O O
cytosols O O
. O O

High O O
activities O O
of O O
peptidases B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
various O O
specificities O O
were O O
detected O O
in O O
leukemic O O
cell O O
cytosols O O
, O O
as O O
in O O
other O O
cytosols O O
, O O
by O O
fluorometric O O
assays O O
with O O
derivatives O O
of O O
7-amino-4-methylcoumarin O O
. O O

Receptor O O
cleavage O O
by O O
these O O
and O O
other O O
endogenous B B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzymes I I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
account O O
for O O
previous O O
observations O O
of O O
`` O O
abnormal O O
'' O O
receptors O O
in O O
cytosols O O
from O O
some O O
leukemic O O
specimens O O
. O O

We O O
conclude O O
that O O
intrinsic O B_DISEASE_ADJECTIVE[DISEASE]
structural O I_DISEASE_ADJECTIVE[DISEASE]
defects O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
receptors O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
unlikely O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
explanations O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
unresponsiveness O B_DISEASE_ADJECTIVE[DISEASE]
of O O
some O O
types O B_PERSON/B_LOCATION
of O O
leukemia O B_DISEASE
to O O
steroid O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
number O O
and O O
intracellular O O
water O O
space O O
. O O

In O O
order O O
to O O
elucidate O O
the O O
relationship O O
between O O
cell O O
water O O
content O O
and O O
number O O
of O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
eleven O O
normal O O
and O O
malignant O O
lymphoid O O
or O O
myelomonocytic O O
cell O O
types O O
originating O O
from O O
mouse O O
, O O
rat O O
and O O
man O O
were O O
investigated O O
. O O

The O O
cellular O O
water O O
space O O
was O O
measured O O
with O O
3H2O O O
, O O
and O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
number O O
was O O
measured O O
in O O
a O O
whole-cell O O
binding O O
assay O O
with O O
[ O O
3H O O
] O O
dexamethasone O O
at O O
30 O O
and O O
37 O O
degrees O O
C O O
. O O

The O O
intracellular O O
water O O
phase O O
concentration O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
around O O
40 O O
nmol/l O O
cell O O
water O O
) O O
, O O
and O O
the O O
dependence O O
of O O
receptor O O
affinity O O
on O O
temperature O O
were O O
similar O O
in O O
normal O O
and O O
malignant O O
rodent O O
and O O
human O O
cells O O
. O O

It O O
is O O
concluded O O
that O O
comparisons O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
are O O
best O O
made O O
on O O
the O O
basis O O
of O O
intracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
concentrations O O
. O O

Covalent O O
labeling O O
of O O
rat O O
thymocyte O O
and O O
human B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
lymphoid I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
glucocorticoid I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
receptor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

Lymphoid O O
cells O O
contain O O
specific O O
receptors B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
glucocorticoids O O
. O O

We O O
have O O
used O O
[ O O
3H O O
] O O
dexamethasone-21-mesylate O O
to O O
label O O
covalently O O
glucocorticoid B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rat O O
thymic O O
lymphocytes O O
and O O
in O O
neoplastic O O
cells O O
obtained O O
from O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
and O O
malignant O O
lymphoma O O
. O O

The O O
covalently O O
labeled O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
identified O O
by O O
polyacrylamide O O
gel O O
electrophoresis O O
( O O
in O O
the O O
presence O O
of O O
0.1 O O
% O O
sodium O O
dodecyl O O
sulfate O O
) O O
. O O

In O O
cytosolic O O
fractions O O
prepared O O
from O O
rat O O
thymic O O
lymphocytes O O
, O O
[ O O
3H O O
] O O
-dexamethasone-21-mesylate O O
labels O O
a O O
protein O O
( O O
Mr O O
approximately O O
equal O O
to O O
95 O O
, O O
000 O O
) O O
which O O
was O O
identified O O
as O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
by O O
the O O
following O O
criteria O O
: O O
( O O
a O O
) O O
labeling O O
of O O
this O O
moiety O O
is O O
inhibited O O
by O O
treatment O O
with O O
a O O
100-fold O O
molar O O
excess O O
of O O
glucocorticoids O O
, O O
such O O
as O O
dexamethasone O O
and O O
triamcinolone O O
acetonide O O
; O O
and O O
( O O
b O O
) O O
the O O
covalently O O
labeled O O
Mr O O
approximately O O
equal O O
to O O
95 O O
, O O
000 O O
protein O O
is O O
activated O O
( O O
by O O
heating O O
at O O
20 O O
degrees O O
for O O
30 O O
min O O
) O O
to O O
a O O
form O O
that O O
binds O O
to O O
DNA-cellulose O O
. O O

When O O
intact O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
thymocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
are O O
treated O O
with O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dexamethasone-21-mesylate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
an O O
Mr O B_PROTEIN[GENE]/B_MEASURE
approximately O O
equal O B_MEASURE
to O O
95 O B_MEASURE
, O O
000 O B_MEASURE/B_PERSON
moiety O I_MEASURE/I_PERSON
is O O
also O O
labeled O O
covalently O O
. O O

Approximately O O
35 O O
% O O
of O O
the O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
labeled O O
covalently O O
when O O
intact O O
thymocytes O O
are O O
treated O O
with O O
100 O O
nM O O
[ O O
3H O O
] O O
dexamethasone-21-mesylate O O
for O O
30 O O
min O O
at O O
4 O O
degrees O O
. O O

Neoplastic O B_PERSON/B_DISEASE
cells O I_PERSON/I_DISEASE
from O O
acute O B_DISEASE
lymphoblastic O I_DISEASE
leukemia O I_DISEASE
and O O
malignant O B_DISEASE
lymphoma O I_DISEASE
were O O
treated O O
with O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dexamethasone-21-mesylate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
all O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
Mr O B_PROTEIN[GENE]/B_MEASURE
approximately O O
equal O B_MEASURE
to O O
95 O B_MEASURE
, O O
000 O B_MEASURE/B_PERSON
moiety O I_MEASURE/I_PERSON
was O O
labeled O O
covalently O O
; O O
labeling O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
inhibited O O
by O O
excess O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Smaller B B_NUMBER[MEASURE]/B_PERSON
moieties I I_NUMBER[MEASURE]/I_PERSON
were O O
also O O
identified O O
by O O
competition O O
experiments O O
; O O
these O O
may O O
represent O O
proteolytic B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
fragments I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
Mr O O
approximately O O
equal O O
to O O
95 O O
, O O
000 O O
receptor O O
. O O

Thus O O
, O O
in O O
rat O O
and O O
human O O
lymphoid O O
cells O O
, O O
[ O O
3H O O
] O O
dexamethasone-21-mesylate O O
can O O
be O O
used O O
to O O
label O O
covalently O O
the O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
association O O
of O O
cytosol O O
oestrogen B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
progesterone I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
histological O O
features O O
of O O
breast O O
cancer O O
and O O
early O O
recurrence O O
of O O
disease O O
. O O

Two O O
hundred O O
and O O
eighty-eight O O
primary O O
breast O O
tumours O O
were O O
examined O O
for O O
the O O
presence O O
or O O
absence O O
of O O
oestrogen B B_DISEASE/B_GENE
( I I_DISEASE/I_GENE
REc I I_DISEASE/I_GENE
) I I_DISEASE/I_GENE
and I I_DISEASE/I_GENE
progesterone I I_DISEASE/I_GENE
( I I_DISEASE/I_GENE
RPc I I_DISEASE/I_GENE
) I I_DISEASE/I_GENE
receptors I I_DISEASE/I_GENE
. O O

Analysis O O
has O O
shown O O
a O O
relative O O
interdependence O O
between O O
the O O
steroid B B_GENE
receptor I I_GENE
status O O
of O O
primary O O
breast O O
cancer O O
and O O
other O O
prognostic O O
variables O O
such O O
as O O
histological O O
grade O O
, O O
lymphocytic O O
infiltration O O
and O O
tumour O O
elastosis O O
. O O

There O O
were O O
significant O O
associations O O
between O O
epithelial O O
cellularity O O
, O O
stromal O O
fibrosis O O
and O O
the O O
value O O
of O O
REc B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
those O O
tumours O O
in O O
which O O
the O O
receptor O O
was O O
present O O
. O O

Cellularity O O
and O O
fibrosis O O
were O O
unrelated O O
to O O
the O O
presence O O
or O O
absence O O
of O O
oestrogen B B_DISEASE/B_GENE
receptor I I_DISEASE/I_GENE
. O O

By O O
contrast O O
, O O
neither O O
the O O
presence O O
or O O
absence O O
nor O O
the O O
value O O
of O O
RPc B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
related O O
to O O
cellularity O O
or O O
fibrosis O O
. O O

The O O
value O O
of O O
REc B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
RPc B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O O
as O O
an O O
indicator O O
of O O
prognosis O O
was O O
examined O O
in O O
a O O
sub-group O O
of O O
175 O O
patients O O
receiving O O
no O O
additional O O
treatment O O
following O O
mastectomy O O
. O O

Overall O O
relapse-free O O
survival O O
( O O
RFS O O
) O O
was O O
no O O
different O O
for O O
those O O
patients O O
with O O
receptors O O
compared O O
to O O
those O O
without O O
them O O
( O O
REc B B_LOCATION
P O O
= O O
0.11 O O
, O O
RPc O O
P O O
= O O
0.7 O O
) O O
. O O

There O O
was O O
no O O
difference O B_MEASURE
in O O
RFS O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
receptor O B_DISEASE/B_GENE
positive O I_DISEASE/I_GENE
and O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
tumours O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
when O O
the O O
axillary O B_DISEASE/B_MEASURE
node O B_DISEASE/I_MEASURE
status O B_DISEASE/I_MEASURE
was O O
taken O O
into O O
account O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Clinical O O
implications O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O O
leukemia O O
. O O

Normal O O
lymphoid O O
cells O O
contain O O
glucocorticoid B B_GENE
receptor I I_GENE
. O O

A O O
variety O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
stimuli O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
activate O O
these O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
also O O
induce O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
in O O
receptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Similar O O
glucocorticoid B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
detected O O
in O O
lymphoid O O
cells O O
from O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
( O O
ALL O O
) O O
. O O

Absence O O
of O O
the O O
glucocorticoid B B_GENE/B_DISEASE
receptor I I_GENE/I_DISEASE
( O O
usually O O
found O O
in O O
treated O O
patients O O
) O O
predicts O O
lack O O
of O O
glucocorticoid O O
responsiveness O O
. O O

Furthermore O O
, O O
in O O
our O O
hands O O
, O O
glucocorticoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
correlate O O
with O O
the O O
duration O O
of O O
complete O O
remission O O
in O O
ALL O O
( O O
though O O
not O O
in O O
other O O
forms O O
of O O
leukemia O O
) O O
. O O

This O O
association O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
independent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
cell O B_MEASURE/B_DISEASE
type O I_MEASURE/I_DISEASE
, O O
age O B_MEASURE/B_LOCATION
, O O
sex O B_PERSON/B_MEASURE
, O O
or O O
initial O B_MEASURE/B_LOCATION
leukocyte O B_MEASURE/I_LOCATION
count O B_MEASURE/I_LOCATION
. O O

The O O
level O B_MEASURE/B_LOCATION
of O O
receptor O B_GENE
shows O O
a O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlation O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O O
increasing O O
aggressiveness O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
the O O
tumor O B_DISEASE/B_PERSON
( O O
null-cell O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
leukemia O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
greater O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O O
T-cell O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
leukemia O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
greater O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O O
Burkitt O B_DISEASE
's O I_DISEASE
lymphoma O I_DISEASE
) O O
. O O

Corticosteroid-mediated O B_PERSON/B_LOCATION
immunoregulation O I_PERSON/I_LOCATION
in O O
man O B_DISEASE
. O O

Glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O O
profound O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
human O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
the O O
precise O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
corticosteroid-induced O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoregulation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
man O B_DISEASE/B_BIO
have O O
not O O
been O O
precisely O O
defined O O
. O O

Intracytoplasmic B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
corticosteroid-specific I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
receptors I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
appear O O
to O O
be O O
an O O
important O O
common O O
pathway O O
for O O
steroid-induced O O
changes O O
, O O
but O O
variations O O
of O O
receptor O O
parameters O O
do O O
not O O
account O O
for O O
the O O
multifaceted O O
effects O O
on O O
the O O
immune O O
system O O
. O O

Human O B_PERSON/B_SPECIES[BIO]
circulating O O
mononuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
redistribute O O
out O O
of O O
the O O
intravascular O B_BODY_PART_OR_ORGAN_COMPONENT
compartment O I_BODY_PART_OR_ORGAN_COMPONENT
following O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
corticosteroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Although O O
certain O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
components O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
this O O
redistribution O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
phenomenon O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
well-characterized O O
, O O
the O O
importance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
compartmental O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cellular O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
shift O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O O
respect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
mechanisms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
corticosteroid-induced O B_DISEASE
immunoregulation O I_DISEASE
are O O
less O O
well-defined O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
observations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
activated O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
may O O
be O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
the O O
lytic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effects O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
under O O
certain O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
situations O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
elimination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
selected O O
subsets O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
may O O
be O O
a O O
relevant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanism O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
corticosteroid-mediated O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
immunoregulation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
man O B_PERSON/B_BIO
. O O

Corticosteroid-mediated O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
monocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanism O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
drug-induced O B_DISEASE_ADJECTIVE[DISEASE]
immunoregulation O I_DISEASE_ADJECTIVE[DISEASE]
in O O
monocyte-dependent O B_DISEASE/B_BIO
responses O I_DISEASE/I_BIO
. O O

In O O
some O O
experimental O O
conditions O O
, O O
corticosteroids O O
inhibit O O
Interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
by O O
monocytes O O
. O O

The O O
immunoregulatory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
corticosteroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
lymphocyte O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
complex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
vitro O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
corticosteroids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
appear O O
to O O
selectively O O
affect O O
early O B_DISEASE_ADJECTIVE[DISEASE]
immunoregulatory O I_DISEASE_ADJECTIVE[DISEASE]
events O I_DISEASE_ADJECTIVE[DISEASE]
as O O
opposed O O
to O O
altering O O
an O O
established O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Multiple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sites O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
steroid-induced O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
modulations O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
human O B_DISEASE/B_GENE
B O I_DISEASE/I_GENE
cell O I_DISEASE/I_GENE
responses O I_DISEASE/I_GENE
have O O
been O O
defined O O
. O O

Human O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
II O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Whole O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cytoplasmic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
properties O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
lymphoblastoid O B_DISEASE
, O O
leukaemia O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
lymphoma O B_DISEASE
lines O I_DISEASE
. O O

The O O
glucocorticoid O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
18 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
human O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
lymphoid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cell O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
lines O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
HLCL O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
have O O
been O O
investigated O O
. O O

The O O
specificity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
confirmed O O
with O O
various O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agonists O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
antagonists O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
gradation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
whole O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cytoplasmic O B_MEASURE/B_BIO
glucocorticoid O I_MEASURE/I_BIO
binding O I_MEASURE/I_BIO
capacity O I_MEASURE/I_BIO
was O O
observed O O
in O O
the O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cell O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
line O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
types O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
: O O
lymphoblastoid O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
greater O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O O
lymphoma O B_DISEASE
greater O I_DISEASE
than O O
leukaemia O B_DISEASE
. O O

The O O
cytoplasmic B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptors I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
of O O
leukaemia O O
and O O
lymphoblastoid O O
lines O O
appeared O O
to O O
contain O O
both O O
proteinaceous O O
and O O
phospholipid O O
components O O
. O O

Cytoplasmic B B_PERSON/B_GENE
steroid-receptor I I_PERSON/I_GENE
complexes I I_PERSON/I_GENE
exhibited O O
a O O
wide O O
range O O
of O O
sedimentation O O
coefficients O O
( O O
8.5-11.3S O O
) O O
in O O
low O O
ionic O O
strength O O
buffer O O
but O O
there O O
was O O
no O O
correlation O O
with O O
cell O O
line O O
type O O
or O O
glucocorticoid O O
sensitivity O O
. O O

Activation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
these O O
complexes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O O
heat O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
37 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
degrees O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
or O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
high O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ionic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strength O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
buffer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0.3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
M O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
NaCl O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
induced O O
nuclear O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
but O O
only O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
high O B_LOCATION/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
ionic O B_LOCATION/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
strength O B_LOCATION/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
buffer O B_LOCATION/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
manifested O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
sedimentation O B_MEASURE/B_DISEASE
coefficient O I_MEASURE/I_DISEASE
. O O

No O O
correlation O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
between O O
the O O
level O B_MEASURE/B_LOCATION
or O O
nature O B_MEASURE
of O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
the O O
cytolethal O B_BIO/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
cytostatic O B_DISEASE_ADJECTIVE[DISEASE]
responsiveness O I_DISEASE_ADJECTIVE[DISEASE]
of O O
HLCL O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
glucocorticoid O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
vitro O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
resistance O O
to O O
cytolethal O O
effects O O
can O O
not O O
be O O
ascribed O O
to O O
a O O
failure O O
of O O
cells O O
to O O
take O O
up O O
and O O
bind O O
steroid O O
or O O
to O O
significant O O
differences O O
in O O
the O O
molecular O O
species O O
of O O
cytoplasmic B B_PROTEIN[GENE]
receptors I I_PROTEIN[GENE]
present O O
. O O

The O O
molecular O B_LOCATION
mechanisms O I_LOCATION
by O O
which O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
achieve O O
cytolethal O B_DISEASE_ADJECTIVE[DISEASE]
responses O I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
lymphoid O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]

CD28 B B_GENE
-mediated O O
activation O O
in O O
CD45RA+ O O
and O O
CD45RO+ O O
T O O
cells O O
: O O
enhanced O O
levels O O
of O O
reactive O O
oxygen O O
intermediates O O
and O O
c-Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear O O
translocation O O
in O O
CD45RA+ O O
cells O O
. O O

We O O
have O O
analyzed O O
the O O
effect O O
of O O
complete O O
T O O
cell O O
activation O O
( O O
anti-CD3 B B_GENE
plus O O
anti-CD28 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
on O O
the O O
activation O O
of O O
NF-kappaB B B_GENE
in O O
CD45RA+ O O
( O O
naive O O
) O O
and O O
CD45RO+ O O
( O O
memory/effector O O
) O O
T O O
cells O O
. O O

Long O O
exposure O O
( O O
24 O O
h O O
) O O
induced O O
stronger O O
NF-kappaB B B_GENE
DNA O O
binding O O
in O O
CD45RA+ O O
cells O O
than O O
in O O
CD45RO+ O O
cells O O
. O O

Analysis O O
of O O
the O O
nuclear B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
c-Rel I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
after O O
anti-CD3+anti-CD28 O O
stimulation O O
the O O
level O O
of O O
c-Rel B B_GENE
was O O
higher O O
in O O
CD45RA+ O O
cells O O
. O O

Analysis O O
of O O
the O O
cytoplasmic O O
inhibitor O O
IkappaBalpha B B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
anti-CD3+anti-CD28 O O
stimulation O O
induced O O
a O O
long-lasting O O
degradation O O
in O O
CD45RA+ O O
cells O O
but O O
in O O
CD45RO+ O O
cells O O
the O O
degradation O O
process O O
was O O
more O O
rapid O O
. O O

Because O O
the O O
CD28 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
costimulus O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
to O O
induce O O
the O O
production O B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
reactive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
oxygen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
intermediates O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O O
ROIs O B_GENE/B_DISEASE
) O O
, O O
the O O
intracellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ROI O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
CD45RA+ O B_GENE/B_DISEASE
and O O
CD45RO+ O B_GENE/B_BIO
cells O I_GENE/I_BIO
were O O
compared O O
by O O
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

ROIs O B_MEASURE/B_GENE
were O O
produced O O
in O O
both O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
types O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
but O O
more O O
strongly O O
in O O
CD45RA+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
further O O
emphasize O O
the O O
differences O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O O
CD45RA+ O B_GENE
and O O
CD45RO+ O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
ROI-dependent O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O O
pathways O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Ikaros B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O O
hemopoietic O O
lineage O O
determination O O
and O O
homeostasis O O
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
the O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
control O O
hemopoietic O B_DISEASE/B_ORGANISM_FUNCTION
differentiation O B_DISEASE/I_ORGANISM_FUNCTION
have O O
focused O O
on O O
signaling O O
cascades O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O O
nuclear O B_LOCATION/B_ORGANIZATION
effectors O I_LOCATION/I_ORGANIZATION
that O O
drive O O
this O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developmental O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
regulated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fashion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Here O O
we O O
review O O
the O O
role O O
of O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
founding O O
member O O
of O O
a O O
unique O O
family O O
of O O
zinc B B_GENE/B_BIO
finger I I_GENE/I_BIO
transcription I I_GENE/I_BIO
factors I I_GENE/I_BIO
in O O
this O O
developmental O O
process O O
. O O

Studies O O
on O O
an O O
Ikaros B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
null O O
mutation O O
have O O
revealed O O
an O O
essential O O
role O O
for O O
this O O
factor O O
in O O
lymphoid O O
cell O O
fate O O
determination O O
and O O
at O O
subsequent O O
branch O O
points O O
of O O
the O O
T O O
cell O O
differentiation O O
pathway O O
. O O

Differences O O
in O O
the O O
phenotypes O O
of O O
a O O
null O O
and O O
a O O
dominant O O
negative O O
( O O
DN O O
) O O
Ikaros O O
mutation O O
provide O O
insight O O
into O O
a O O
regulatory O O
network O O
through O O
which O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exert O O
their O O
effects O O
in O O
development O O
. O O

In O O
addition O O
a O O
comparative O O
analysis O O
of O O
the O O
hemopoietic O O
stem O O
cell O O
and O O
precursor O O
compartment O O
resulting O O
from O O
the O O
two O O
Ikaros B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutations O O
reveals O O
a O O
profound O O
yet O O
not O O
absolute O O
requirement O O
for O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
production O O
and O O
differentiation O O
of O O
these O O
populations O O
. O O

Overexpression O O
of O O
p65 O O
and O O
c-Jun O O
substitutes O O
for O O
B7-1 O O
costimulation O O
by O O
targeting O O
the O O
CD28RE B B_GENE/B_LOCATION
within O O
the O O
IL-2 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
role O O
of O O
Rel B B_GENE/B_DISEASE
and O O
activation B B_GENE
protein-1 I I_GENE
( O O
AP-1 B B_GENE/B_DISEASE
) O O
in O O
IL-2 B B_GENE/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoter I B_GENE/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
in O O
B7-1- O O
and O O
leukocyte O O
function-associated O O
Ag-3 O O
( O O
LFA. O O
3 O O
) O O
-costimulated O O
T O O
cells O O
has O O
been O O
evaluated O O
. O O

We O O
demonstrate O O
that O O
overexpression O O
of O O
c-Jun B B_GENE
but O O
not O O
c-Fos B B_GENE
increases O O
IL-2 B B_GENE
promoter I I_GENE
activity O O
in O O
both O O
B7-1- O O
and O O
LFA-3-costimulated O O
Jurkat O O
T O O
cells O O
. O O

Cotransfection O O
of O O
both O O
c-Jun O O
and O O
c-Fos O O
substitutes O O
for O O
B7-1 O O
costimulation O O
in O O
driving O O
an O O
activation B B_GENE/B_LOCATION
protein-1 I I_GENE/I_LOCATION
response I I_GENE/I_LOCATION
element I I_GENE/I_LOCATION
but O O
not O O
for O O
the O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Overexpression O O
of O O
Rel B B_GENE
proteins I I_GENE
demonstrated O O
that O O
p65-expressing O O
Jurkat O O
cells O O
transcribed O O
equally O O
well O O
a O O
nuclear B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
kappabeta I I_GENE/I_MEASURE
reporter I I_GENE/I_MEASURE
construct I I_GENE/I_MEASURE
when O O
costimulated O O
with O O
B7-1 B B_GENE
or O O
LFA-3 B B_GENE
, O O
but O O
transcription O O
of O O
IL-2 B B_GENE
promoter I I_GENE
or O O
CD28 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CD28RE I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-driven I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
superior O O
in O O
B7-1-costimulated O O
cells O O
. O O

Combined O O
expression O O
of O O
c-Jun B B_GENE
and O O
p65 B B_GENE
induced O O
vigorous O O
transcription O O
of O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CD28RE-driven I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
both O O
LFA-3- O O
and O O
B7-1-costimulated O O
Jurkat O O
cells O O
. O O

Mutating O O
the O O
CD28RE B B_GENE/B_LOCATION
but O O
not O O
the O O
upstream B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappabeta-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
reduced O O
B7-1 B B_GENE
-driven O O
transcription O O
> O O
90 O O
% O O
. O O

The O O
results O O
implicates O O
a O O
major O O
role O O
of O O
the O O
CD28RE B B_GENE/B_LOCATION
in O O
the O O
integration O O
of O O
p65 B B_GENE
/ O O
c-Jun B B_GENE
-mediated O O
transcription O O
within O O
the O O
IL-2 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
suggest O O
that O O
the O O
transition O O
from O O
an O O
autocrine O O
LFA-3 B B_GENE
-driven O O
immune O O
response O O
to O O
a O O
B7 O O
-- O O
induced O O
paracrine O O
immune O O
response O O
involves O O
the O O
activation O O
of O O
c-Jun B B_GENE
and O O
p65 B B_GENE
, O O
which O O
target O O
the O O
CD28RE B B_GENE
region O O
of O O
the O O
IL-2 B B_GENE
promoter I I_GENE
. O O

Defects O B_DISEASE_ADJECTIVE[DISEASE]
in O O
actin-cap O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O O
Vav-deficient O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mice O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
implicate O O
an O O
actin O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requirement O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
lymphocyte O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
signal O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
transduction O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

BACKGROUND O O
: O O
Antigen-receptor O O
interactions O O
on O O
lymphocytes O O
result O O
in O O
local O O
clustering O O
of O O
actin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O O
receptors O O
and O O
signaling O O
molecules O O
into O O
an O O
asymmetric O O
membrane O O
structure O O
termed O O
a O O
cap O O
. O O

Although O O
actin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerization O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
to O O
be O O
required O O
, O O
the O O
mechanisms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
underlying O O
cap O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
formation O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
unclear O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
studied O O
the O O
events O O
underlying O O
cap O O
formation O O
using O O
mice O O
bearing O O
a O O
null O O
mutation O O
in O O
vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-/- O O
) O O
, O O
a O O
gene O O
that O O
encodes O O
a O O
guanine-nucleotide B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
exchange I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
GTPase B B_GENE
Rac I I_GENE
. O O

RESULTS O O
: O O
Lymphocytes O O
from O O
vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-/- O O
mice O O
failed O O
to O O
form O O
T-cell O O
receptor O O
caps O O
following O O
activation O O
and O O
had O O
a O O
defective O O
actin O O
cytoskeleton O O
. O O

The O O
vav-/- O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
deficient O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
interleukin-2 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IL-2 O B_GENE/B_MEASURE
) O O
production O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
proliferation O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
and O O
the O O
peak O B_MEASURE
of O O
Ca2+ O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mobilization O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reduced O O
although O O
of O O
normal O B_TIME[MEASURE]
duration O I_TIME[MEASURE]
. O O

Activation O O
of O O
Jun B B_GENE/B_DISEASE
N-terminal I I_GENE/I_DISEASE
kinase I I_GENE/I_DISEASE
or O O
stress-activated B B_GENE
kinase I I_GENE
( O O
JNK B B_GENE/B_LOCATION
or O O
SAPK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE/B_LOCATION
) O O
and O O
the O O
induction O O
of O O
the O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-ATc1 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
egr-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
normal O O
. O O

Despite O O
the O O
reduced O O
Ca2+ O O
mobilization O O
, O O
translocation O O
of O O
cytoplasmic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NF-ATc I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
nucleus O O
was O O
normal O O
, O O
reflecting O O
that O O
the O O
lower O O
levels O O
of O O
Ca2+ O O
in O O
vav-/- O O
cells O O
were O O
still O O
sufficient O O
to O O
activate O O
calcineurin B B_GENE
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
with O O
cytochalasin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
D O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
blocks O O
actin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerization O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
inhibited O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cap O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
produced O O
defects O B_DISEASE_ADJECTIVE[DISEASE]
in O O
signaling O O
and O O
IL-2 O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
transcriptional O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
induction O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O O
response O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
antigen-receptor O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
were O O
nearly O O
identical O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
those O O
seen O O
in O O
vav-/- O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
transfection O O
studies O O
, O O
either O O
constitutively O O
active O O
Vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
Rac B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
complement O O
constitutively O O
active O O
calcineurin B B_GENE
to O O
activate O O
NF-AT-dependent O O
transcription O O
. O O

CONCLUSIONS O O
: O O
These O O
results O O
indicate O O
that O O
Vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
required O O
for O O
cap O O
formation O O
in O O
lymphocytes O O
. O O

Furthermore O O
, O O
the O O
correlation O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
cap O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
IL-2 O O
production O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
proliferation O B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
supports O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
an O O
actin-dependent O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
source O B_LOCATION
of O O
specialized O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulatory O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CD14 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O O
activation O O
of O O
human O O
endothelial O O
cells O O
by O O
Bacteroides O O
fragilis O O
outer O O
membrane O O
. O O

We O O
studied O O
the O O
capacity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
isolated O B_BACTERIUM[BIO]
Bacteriodes O I_BACTERIUM[BIO]
fragilis O O
outer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
membrane O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
B. O O
fragilis O B_BACTERIUM[BIO]
NCTC9343 O I_BACTERIUM[BIO]
lipopolysaccharide O I_BACTERIUM[BIO]
( O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
; O O
endotoxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
B. O O
fragilis O B_BACTERIUM[BIO]/B_DISEASE
NCTC9343 O I_BACTERIUM[BIO]/I_DISEASE
capsular O I_BACTERIUM[BIO]/I_DISEASE
polysaccharides O I_BACTERIUM[BIO]/I_DISEASE
to O O
activate O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
umbilical O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
vein O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
endothelial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HUVEC O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
) O O
monolayers O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

To O O
assess O O
HUVEC O O
activation O O
, O O
E-selectin B B_GENE
expression O O
was O O
measured O O
by O O
enzyme-linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
, O O
Northern O O
blot O O
analysis O O
for O O
E-selectin-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
electrophoretic O O
gel O O
mobility O O
shift O O
assay O O
( O O
EMSA O O
) O O
for O O
NF-kappa B B_GENE
B I I_GENE
, O O
a O O
transcription B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
necessary O O
for O O
E-selectin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
gene I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
activation O O
. O O

Exposure O O
of O O
HUVECs O O
to O O
B. O O
fragilis O O
outer O O
membrane O O
fractions O O
, O O
separated O O
from O O
other O O
components O O
of O O
the O O
B. O O
fragilis O O
cell O O
wall O O
by O O
isopycnic O O
, O O
sucrose O O
gradient O O
centrifugation O O
, O O
significantly O O
increased O O
surface O O
expression O O
of O O
E-selectin B B_GENE
and O O
induced O O
functional O O
endothelial O O
cell O O
-dependent O O
leukocyte O O
adhesion O O
. O O

B. O O
fragilis O O
outer O O
membranes O O
induced O O
translocation O O
of O O
NF-kappa B B_GENE
B I I_GENE
to O O
HUVEC O O
nuclei O O
and O O
accumulation O O
of O O
E-selectin B B_GENE
mRNA I I_GENE
in O O
HUVEC O O
cytoplasm O O
. O O

E-selectin O B_DISEASE_ADJECTIVE[DISEASE]
expression O I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
B. O B_PROTEIN[GENE]/B_DISEASE
fragilis O O
outer O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
membranes O I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
was O I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
not O O
blocked O O
by O O
polymixin O O
B O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

In O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
E-selectin O B_DISEASE_ADJECTIVE[DISEASE]
expression O I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
outer O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
membrane O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
fractions O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
purified O O
from O O
E. O B_OTHER/B_PERSON
coli O O
was O B_BACTERIUM[BIO]/B_PERSON
competitively O O
inhibited O O
by O O
polymixin O O
B O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

Neither O O
purified O O
B. O O
fragilis O B_BACTERIUM[BIO]/B_GENE
LPS O I_BACTERIUM[BIO]/I_GENE
, O O
a O O
prominent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
constituent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
outer O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
membrane O B_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
nor O O
purified O O
B. O O
fragilis O B_BACTERIUM[BIO]
capsular O I_BACTERIUM[BIO]
polysaccharides O I_BACTERIUM[BIO]
induced O O
HUVEC O B_DISEASE_ADJECTIVE[DISEASE]
activation O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O O
different O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
directed O O
against O O
human B B_GENE
CD14 I I_GENE
completely O O
inhibited O O
B. O O
fragilis O O
outer O O
membrane-induced O O
NF-kappa B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
, O O
E-selectin O O
transcription O O
, O O
and O O
E-selectin O O
surface O O
expression O O
. O O

We O O
conclude O O
that O O
the O O
outer O O
membrane O O
component O O
of O O
the O O
B. O O
fragilis O O
cell O O
wall O O
contains O O
a O O
proinflammatory O O
factor O O
( O O
s O O
) O O
, O O
that O O
is O O
not O O
LPS O O
, O O
which O O
induces O O
human O O
endothelial O O
cell O O
activation O O
by O O
a O O
soluble O O
CD14 B B_GENE
-dependent O O
mechanism O O
. O O

NF-kappaB B B_GENE
protects O O
HIV-1-infected O O
myeloid O O
cells O O
from O O
apoptosis O O
. O O

HIV-1 O O
infection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
primary O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
myeloid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lines O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
sustained O O
NF-kappaB O B_DISEASE/B_GENE
activation O I_DISEASE/I_GENE
. O O

Recently O O
, O O
NF-kappaB O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
induction O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
shown O O
to O O
play O O
a O O
role O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
protecting O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
programmed O O
cell O B_DISEASE
death O I_DISEASE
. O O

In O O
the O O
present O O
study O O
, O O
we O O
sought O O
to O O
investigate O O
whether O O
constitutive O O
NF-kappaB B B_GENE
activity O O
in O O
chronically O O
HIV-1-infected O O
promonocytic O O
U937 O O
( O O
U9-IIIB O O
) O O
and O O
myeloblastic O O
PLB-985 O O
( O O
PLB-IIIB O O
) O O
cells O O
affects O O
apoptotic O O
signaling O O
. O O

TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
cycloheximide O O
caused O O
infected O O
cells O O
to O O
undergo O O
apoptosis O O
more O O
rapidly O O
than O O
parental O O
U937 O O
and O O
PLB-985 O O
cells O O
. O O

Inhibition O O
of O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
NF-kappaB O O
activation O O
using O O
the O O
antioxidant O O
N-acetylcysteine O O
( O O
NAC O O
) O O
resulted O O
in O O
increased O O
apoptosis O O
in O O
both O O
U937 O O
and O O
U9-IIIB O O
cells O O
, O O
while O O
preactivation O O
of O O
NF-kappaB B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
the O O
non-apoptotic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inducer I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IL-1beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
caused O O
a O O
relative O O
decrease O O
in O O
apoptosis O O
. O O

Inhibition O O
of O O
constitutive O O
NF-kappaB B B_GENE
activity O O
in O O
U9-IIIB O O
and O O
PLB-IIIB O O
cells O O
also O O
induced O O
apoptosis O O
, O O
suggesting O O
that O O
NF-kappaB O O
protects O O
cells O O
from O O
a O O
persistent O O
apoptotic O O
signal O O
. O O

TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O O
NAC O O
treatment O O
resulted O O
in O O
a O O
marked O O
decrease O O
in O O
Bcl-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
in O O
HIV-1-infected O O
cells O O
, O O
coupled O O
with O O
an O O
increase O O
in O O
Bax B B_GENE/B_DISEASE
protein I I_GENE/I_DISEASE
compared O O
to O O
uninfected O O
cells O O
, O O
suggesting O O
that O O
the O O
difference O O
in O O
susceptibility O O
to O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
apoptosis O O
may O O
relate O O
to O O
the O O
differences O O
in O O
relative O O
levels O O
of O O
Bcl-2 B B_GENE
and O O
Bax B B_GENE
. O O

The O O
protective O O
role O O
of O O
NF-kappaB B B_GENE
in O O
blocking O O
TNFalpha- O O
and O O
HIV-1-induced O O
apoptosis O O
was O O
supported O O
by O O
studies O O
in O O
Jurkat O O
T O O
cells O O
engineered O O
to O O
express O O
IkappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repressor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutants I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TD-IkappaB B B_PROTEIN[GENE]/B_LOCATION
) O O
under O O
the O O
control O O
of O O
a O O
tetracycline-responsive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cells O O
underwent O O
apoptosis O O
in O O
response O O
to O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
only O O
when O O
NF-kappaB O O
activation O O
was O O
inhibited O O
by O O
TD-IkappaB B B_GENE
expression O O
. O O

As O O
was O O
observed O O
for O O
the O O
U9-IIIB O O
cells O O
, O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
treatment O O
also O O
induced O O
a O O
marked O O
decrease O O
in O O
Bcl-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
in O O
TD-IkappaB O O
expressing O O
cells O O
. O O

These O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O O
that O O
apoptotic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
perturbed O O
in O O
HIV-1-infected O B_DISEASE
U9-IIIB O I_DISEASE
cells O I_DISEASE
and O O
indicate O O
that O O
NF-kappaB O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
play O O
an O O
additional O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protective O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
HIV-1-induced O B_DISEASE/B_GENE
apoptosis O I_DISEASE/I_GENE
in O O
myeloid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O O

Human O O
normal O O
peripheral O O
blood O O
B-lymphocytes O O
are O O
deficient O O
in O O
DNA-dependent O O
protein O O
kinase O O
activity O O
due O O
to O O
the O O
expression O O
of O O
a O O
variant O O
form O O
of O O
the O O
Ku86 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
heterodimeric O O
Ku B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
comprises O O
a O O
86 B B_MEASURE/B_PROTEIN[GENE]
kDa I I_MEASURE/I_PROTEIN[GENE]
( I I_MEASURE/I_PROTEIN[GENE]
Ku86 I I_MEASURE/I_PROTEIN[GENE]
) I I_MEASURE/I_PROTEIN[GENE]
amd O O
a O O
70 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kDa I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ku70 I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunits I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
an O O
abundant O O
nuclear B B_GENE
DNA-binding I I_GENE
protein I I_GENE
which O O
binds O O
in O O
vitro O O
to O O
DNA B B_GENE
termini I I_GENE
without O O
sequence O O
specificity O O
. O O

Ku B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
DNA-targeting B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
component I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
large O O
catalytic B B_LOCATION/B_PERSON
sub-unit I I_LOCATION/I_PERSON
of O O
the O O
DNA-dependent B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DNA-PK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CS I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
that O O
plays O O
a O O
critical O O
role O O
in O O
mammalian O O
double-strand O O
break O O
repair O O
and O O
lymphoid O O
V O O
( O O
D O O
) O O
J O O
recombination O O
. O O

By O O
using O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
we O O
demonstrated O O
that O O
in O O
addition O O
to O O
the O O
major B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ku I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
x I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usually O O
detected O O
in O O
cell O O
line O O
extracts O O
, O O
a O O
second O O
complex O O
with O O
faster O O
electrophoretic O O
mobility O O
was O O
observed O O
in O O
normal O O
peripheral O O
blood O O
lymphocytes O O
( O O
PBL O O
) O O
extracts O O
. O O

The O O
presence O O
of O O
this O O
faster B B_GENE
migrating I I_GENE
complex I I_GENE
was O O
restricted O O
to O O
B O O
cells O O
among O O
the O O
circulating O O
lymphocyte O O
population O O
. O O

Western O O
blot O O
analysis O O
revealed O O
that O O
B O O
cells O O
express O O
a O O
variant O O
form O O
of O O
the O O
Ku86 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
an O O
apparent O O
molecular O O
weight O O
of O O
69 O O
kDa O O
, O O
and O O
not O O
the O O
86 B B_GENE/B_MEASURE
kDa- I I_GENE/I_MEASURE
full-length I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
. O O

Although O O
the O O
heterodimer B B_GENE
Ku70/variant-Ku86 I I_GENE
binds O O
to O O
DNA-ends B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
this O O
altered O O
form O O
of O O
the O O
Ku B B_GENE
heterodimer I I_GENE
has O O
a O O
decreased O O
ability O O
to O O
recruit O O
the O O
catalytic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
component I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
complex O O
, O O
DNA-PK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CS I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
contributes O O
to O O
an O O
absence O O
of O O
detectable O O
DNA-PK O O
activity O O
in O O
B O O
cells O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O O
a O O
molecular O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basis O B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
increased O O
sensitivity O B_DISEASE
of O O
B O B_DISEASE
cells O I_DISEASE
to O O
ionizing O O
radiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
identify O O
a O O
new O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
regulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
DNA-PK O B_DISEASE/B_GENE
activity O B_DISEASE/I_GENE
that O O
operates O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Co-stimulation O O
of O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
with O O
IL-2 B B_GENE
and O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
monoclonal I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibodies I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
induces O O
phosphorylation O O
of O O
CREB B B_GENE
. O O

Phosphorylation O O
of O O
the O O
cAMP-response B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CREB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
within O O
1 O O
h O O
of O O
CD2 B B_GENE
but O O
not O O
CD3 B B_GENE/B_MEASURE
cross-linking O O
of O O
human O O
PBMC O O
was O O
recently O O
demonstrated O O
. O O

The O O
absence O O
of O O
P-CREB B B_GENE
following O O
CD3 O O
cross-linking O O
was O O
unexpected O O
, O O
as O O
other O O
laboratories O O
reported O O
increased O O
phosphorylation O O
of O O
CREB B B_GENE
following O O
CD3 O O
cross-linking O O
of O O
the O O
Jurkat O O
lymphocyte O O
cell O O
line O O
. O O

Due O O
to O O
Jurkat O O
T-cells O O
being O O
IL-2-independent O O
, O O
it O O
was O O
postulated O O
that O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O O
provide O O
a O O
necessary O O
co-stimulus O O
for O O
phosphorylation O O
of O O
CREB B B_GENE
in O O
primary O O
lymphocytes O O
. O O

Therefore O O
, O O
P-CREB B B_GENE/B_DISEASE
was O O
evaluated O O
following O O
co-stimulation O O
of O O
human O O
PBMC O O
through O O
the O O
IL-2 B B_GENE
and I I_GENE
CD2 I I_GENE
or I I_GENE
CD3 I I_GENE
receptors I I_GENE
. O O

IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
further O O
augment O O
phosphorylation O O
of O O
CREB B B_GENE
following O O
CD2 O O
cross-linking O O
. O O

However O O
, O O
while O O
neither O O
IL-2 B B_GENE
nor O O
CD3 O O
cross-linking O O
alone O O
induced O O
P-CREB B B_GENE/B_DISEASE
, O O
a O O
4.5-fold O O
increase O O
in O O
phosphorylation O O
of O O
CREB B B_GENE
within O O
1 O O
h O O
of O O
IL-2/CD3 O O
co-stimulation O O
was O O
observed O O
. O O

Phosphorylation O O
was O O
not O O
associated O O
with O O
the O O
induction O O
of O O
cAMP O O
, O O
and O O
inhibition O O
of O O
PKA O O
signaling O O
had O O
no O O
effect O O
on O O
P-CREB B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Consistent O O
with O O
signal O O
transduction O O
through O O
p56lck B B_GENE
or O O
p59fyn B B_GENE
, O O
inhibition O O
of O O
PTK O O
signaling O O
reduced O O
phosphorylation O O
50 O O
% O O
. O O

Interestingly O O
, O O
inhibiting O O
PKC O B_GENE
signaling O O
with O O
calphostin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
further O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
increased O O
P-CREB O B_DISEASE/B_GENE
levels O I_DISEASE/I_GENE
3-fold O I_DISEASE/I_GENE
over O O
that O O
observed O O
in O O
IL-2/CD3 O B_GENE/B_PERSON
co-stimulated O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
not O O
pretreated O O
with O O
a O O
PKC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O O
to O O
previous O O
studies O O
performed O O
in O O
the O O
absence O O
of O O
exogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
IL-2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
no O O
increase O O
in O O
binding O O
of O O
CREB B B_GENE
to O O
a O O
32P-labeled O O
oligonucleotide O O
probe O O
was O O
observed O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

These O O
data O O
suggest O O
that O O
the O O
IL-2 B B_GENE
and O O
CD3 B B_GENE
signaling O O
pathways O O
provide O O
a O O
necessary O O
and O O
co-operative O O
stimulus O O
promoting O O
phosphorylation O O
of O O
CREB B B_GENE
following O O
receptor O O
cross-linking O O
. O O

HIV-1 O O
infection O B_GENE/B_DISEASE
induces O O
a O O
selective O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
STAT5 O B_DISEASE/B_GENE
protein O B_DISEASE/I_GENE
expression O B_DISEASE/I_GENE
. O O

HIV-1 O O
infection O B_DISEASE/B_GENE
is O O
accompanied O O
by O O
qualitative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
quantitative O B_DISEASE_ADJECTIVE[DISEASE]
defects O I_DISEASE_ADJECTIVE[DISEASE]
in O O
CD4+ O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Loss O O
of O O
immune O O
function O O
in O O
HIV O O
patients O O
is O O
usually O O
associated O O
with O O
a O O
profound O O
dysregulation O O
of O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
. O O

To O O
investigate O O
whether O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
defects O O
occur O O
during O O
HIV O O
infection O O
, O O
PHA O O
blasts O O
from O O
healthy O O
human O O
donors O O
were O O
infected O O
with O O
two O O
strains O O
of O O
HIV-1 O O
and O O
screened O O
for O O
the O O
expression O O
of O O
STAT B B_GENE/B_BIO
proteins I I_GENE/I_BIO
used O O
in O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
. O O

A O O
selective O O
decrease O O
in O O
STAT5B B B_GENE/B_DISEASE
was O O
seen O O
8 O O
days O O
after O O
infection O O
with O O
the O O
BZ167 O O
dual-tropic O O
HIV O O
isolate O O
, O O
but O O
not O O
with O O
the O O
Ba-L O O
, O O
M-tropic O O
strain O O
. O O

Based O O
on O O
these O O
findings O O
, O O
purified O O
T O O
cells O O
from O O
HIV-infected O O
patients O O
in O O
different O O
stages O O
of O O
disease O O
were O O
also O O
tested O O
for O O
STAT O O
expression O O
; O O
decreases O O
in O O
STAT5A B B_GENE
, O O
STAT5B B B_GENE
, O O
and O O
STAT1alpha B B_GENE
were O O
observed O O
in O O
all O O
patients O O
. O O

The O O
reduction O O
in O O
STATs B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
seen O O
in O O
vivo O O
and O O
in O O
vitro O O
after O O
HIV O O
infection O O
may O O
contribute O O
to O O
the O O
loss O O
of O O
T O O
cell O O
function O O
in O O
HIV O O
disease O O
. O O

Transcription B B_GENE/B_LOCATION
factors I I_GENE/I_LOCATION
that O O
regulate O O
monocyte O O
/ O O
macrophage O O
differentiation O O
. O O

Although O O
all O O
the O O
cells O O
in O O
an O O
organism O O
contain O O
the O O
same O O
genetic O O
information O O
, O O
differences O O
in O O
the O O
cell O O
phenotype O O
arise O O
from O O
the O O
expression O O
of O O
lineage-specific B B_GENE/B_MEASURE
genes I I_GENE/I_MEASURE
. O O

During O O
myelopoiesis O O
, O O
external O O
differentiating O O
signals O O
regulate O O
the O O
expression O O
of O O
a O O
set O O
of O O
transcription B B_GENE
factors I I_GENE
. O O

The O O
combined O O
action O O
of O O
these O O
transcription B B_GENE
factors I I_GENE
subsequently O O
determines O O
the O O
expression O O
of O O
myeloid-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
generation O O
of O O
monocytes O O
and O O
macrophages O O
. O O

In O O
particular O O
, O O
the O O
transcription B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
factor I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
PU.1 I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
has O O
a O O
critical O O
role O O
in O O
this O O
process O O
. O O

We O O
review O O
the O O
contribution O O
of O O
several O O
transcription B B_GENE
factors I I_GENE
to O O
the O O
control O O
of O O
macrophage O O
development O O

Transcription B B_GENE
factor I I_GENE
LKLF I I_GENE
is O O
sufficient O O
to O O
program O O
T O O
cell O O
quiescence O O
via O O
a O O
c-Myc O O
-- O O
dependent O O
pathway O O
. O O

T O O
lymphocytes O O
circulate O O
in O O
a O O
quiescent O O
state O O
until O O
they O O
encounter O O
cognate B B_PROTEIN[GENE]
antigen I I_PROTEIN[GENE]
bound O O
to O O
the O O
surface O O
of O O
an O O
antigen-presenting O O
cell O O
. O O

The O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
pathways O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
regulate O O
T O B_DISEASE
cell O I_DISEASE
quiescence O I_DISEASE
remain O O
largely O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Here O O
we O O
show O O
that O O
forced O O
expression O O
of O O
the O O
lung B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Kruppel-like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
Jurkat O O
T O O
cells O O
is O O
sufficient O O
to O O
program O O
a O O
quiescent O O
phenotype O O
characterized O O
by O O
decreased O O
proliferation O O
, O O
reduced O O
cell O O
size O O
and O O
protein O O
synthesis O O
and O O
decreased O O
surface O O
expression O O
of O O
activation O O
markers O O
. O O

Conversely O O
, O O
LKLF-deficient O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
produced O O
by O O
gene O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
targeting O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
showed O O
increased O O
proliferation O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
increased O O
cell O B_MEASURE
size O I_MEASURE
and O O
enhanced O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
surface O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
markers O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

LKLF B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O O
to O O
function O O
, O O
at O O
least O O
in O O
part O O
, O O
by O O
decreasing O O
expression O O
of O O
the O O
proto-oncogene B B_GENE
encoding O O
c-Myc B B_GENE
. O O

Forced O O
expression O O
of O O
LKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
associated O O
with O O
markedly O O
decreased O O
c-Myc B B_GENE
expression O O
. O O

In O O
addition O O
, O O
many O O
effects O O
of O O
LKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
were O O
mimicked O O
by O O
expression O O
of O O
the O O
dominant-negative B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MadMyc I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
rescued O O
by O O
overexpression O O
of O O
c-Myc B B_GENE
. O O

Thus O O
, O O
LKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
both O O
necessary O O
and O O
sufficient O O
to O O
program O O
quiescence O O
in O O
T O O
cells O O
and O O
functions O O
, O O
in O O
part O O
, O O
by O O
negatively O O
regulating O O
a O O
c-Myc O O
-- O O
dependent O O
pathway O O
. O O

HTLV-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p12 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhances O O
STAT5 O O
activation O O
and O O
decreases O O
the O O
interleukin-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
requirement O O
for O O
proliferation O O
of O O
primary O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
. O O

The O O
p12 B B_GENE
( I I_GENE
I I I_GENE
) I I_GENE
protein I I_GENE
, O O
encoded O O
by O O
the O O
pX B B_GENE
open I I_GENE
reading I I_GENE
frame I I_GENE
I I I_GENE
of O O
the O O
human O O
T-lymphotropic O O
virus O O
type O O
1 O O
( O O
HTLV-1 O O
) O O
, O O
is O O
a O O
hydrophobic B B_ENZYME[GENE]/B_MEASURE
protein I I_ENZYME[GENE]/I_MEASURE
that O O
localizes O O
to O O
the O O
endoplasmic O O
reticulum O O
and O O
the O O
Golgi O O
. O O

Although O O
p12 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
I I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
contains O O
4 O O
minimal O O
proline-rich O O
, O O
src B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
homology I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
3-binding I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
motifs I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PXXP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
a O O
characteristic O O
commonly O O
found O O
in O O
proteins O O
involved O O
in O O
signaling O O
pathways O O
, O O
it O O
has O O
not O O
been O O
known O O
whether O O
p12 B B_GENE/B_MEASURE
( I I_GENE/I_MEASURE
I I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
has O O
a O O
role O O
in O O
modulating O O
intracellular O O
signaling O O
pathways O O
. O O

This O O
study O O
demonstrated O O
that O O
p12 B B_GENE
( I I_GENE
I I I_GENE
) I I_GENE
binds O O
to O O
the O O
cytoplasmic B B_LOCATION/B_PERSON
domain I I_LOCATION/I_PERSON
of O O
the O O
interleukin-2 B B_GENE
receptor I I_GENE
( I I_GENE
IL-2R I I_GENE
) I I_GENE
beta I I_GENE
chain I I_GENE
that O O
is O O
involved O O
in O O
the O O
recruitment O O
of O O
the O O
Jak1 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
Jak3 I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kinases I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

As O O
a O O
result O O
of O O
this O O
interaction O O
, O O
p12 B B_GENE
( I I_GENE
I I I_GENE
) I I_GENE
increases O O
signal B B_GENE
transducers I I_GENE
and I I_GENE
activators I I_GENE
of I I_GENE
transcription I I_GENE
5 I I_GENE
( O O
STAT5 B B_GENE
) O O
DNA O O
binding O O
and O O
transcriptional O O
activity O O
and O O
this O O
effect O O
depends O O
on O O
the O O
presence O O
of O O
both O O
IL-2R B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Jak3 B B_GENE
. O O

Transduction O O
of O O
primary O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMCs O O
) O O
with O O
a O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
immunodeficiency I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
virus I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
type I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1-based I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
retroviral I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
vector I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
expressing O O
p12 B B_GENE/B_DISEASE
( I I_GENE/I_DISEASE
I I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
also O O
resulted O O
in O O
increased O O
STAT5 B B_GENE
phosphorylation O O
and O O
DNA O O
binding O O
. O O

However O O
, O O
p12 B B_GENE/B_PERSON
( I I_GENE/I_PERSON
I I I_GENE/I_PERSON
) I I_GENE/I_PERSON
could O O
increase O O
proliferation O O
of O O
human O O
PBMCs O O
only O O
after O O
stimulation O O
of O O
T-cell B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
treatment O O
of O O
cells O O
with O O
low O O
concentrations O O
of O O
alphaCD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alphaCD28 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

In O O
addition O O
, O O
the O O
proliferative O O
advantage O O
of O O
p12 O O
( O O
I O O
) O O
-transduced O O
PBMCs O O
was O O
evident O O
mainly O O
at O O
low O O
concentrations O O
of O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Together O O
, O O
these O O
data O O
indicate O O
that O O
p12 B B_GENE
( I I_GENE
I I I_GENE
) I I_GENE
may O O
confer O O
a O O
proliferative O O
advantage O O
on O O
HTLV-1-infected O O
cells O O
in O O
the O O
presence O O
of O O
suboptimal O O
antigen O O
stimulation O O
and O O
that O O
this O O
event O O
may O O
account O O
for O O
the O O
clonal O O
proliferation O O
of O O
infected O O
T O O
cells O O
in O O
vivo O O
. O O

( O O
Blood. O O
2001 O B_MEASURE
; O O
98 O B_MEASURE
: O O
823-829 O B_MEASURE
) O O

Single O O
dose O O
intranasal O O
administration O O
of O O
retinal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
autoantigen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
generates O O
a O O
rapid O O
accumulation O O
and O O
cell O O
activation O O
in O O
draining O O
lymph O O
node O O
and O O
spleen O O
: O O
implications O O
for O O
tolerance O O
therapy O O
. O O

BACKGROUND/AIMS O O
: O O
A O O
single O O
intranasal O O
delivery O O
of O O
retinal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
autoantigen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suppresses O O
effectively O O
experimental O O
autoimmune O O
uveoretinitis O O
( O O
EAU O O
) O O
. O O

To O O
further O O
unravel O O
underlying O O
mechanisms O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wished O O
to O O
determine O O
, O O
firstly O O
, O O
the O O
kinetics O B_MEASURE/B_DISEASE
of O O
antigen O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
delivery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O O
, O O
secondly O O
, O O
the O O
early O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cellular O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
responses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
involved O O
in O O
the O O
initial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nasal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mucosal O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tolerance O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

METHODS O O
: O O
Flow O O
cytometry O O
, O O
cell O O
proliferation O O
assays O O
, O O
and O O
microscopy O O
were O O
used O O
to O O
track O O
antigen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
following O O
a O O
single O O
, O O
intranasal O O
dose O O
of O O
Alexa-488 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
labelled I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
retinal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antigen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

RESULTS O O
: O O
A O O
rapid O O
accumulation O O
of O O
antigen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O O
both O O
superficial O O
cervical O O
lymph O O
nodes O O
( O O
SCLN O O
) O O
and O O
spleen O O
was O O
observed O O
after O O
30 O O
minutes O O
. O O

Significant O O
proliferative O O
responses O O
to O O
IRBP O O
were O O
elicited O O
by O O
48 O O
hours O O
indicating O O
that O O
systemic O O
priming O O
of O O
naive O O
T O O
cells O O
to O O
retinal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
had O O
occurred O O
. O O

Cell O O
activation O O
was O O
further O O
confirmed O O
by O O
immunoprecipitation O O
studies O O
, O O
which O O
demonstrated O O
phosphorylation O O
of O O
STAT4 B B_GENE
but O O
not O O
STAT6 B B_GENE
in O O
both O O
lymph O O
nodes O O
and O O
spleen O O
. O O

However O O
, O O
at O O
24 O O
hours O O
, O O
STAT4 O O
heterodimerisation O O
with O O
STAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
only O O
observed O O
in O O
spleen O O
. O O

CONCLUSIONS O O
: O O
The O O
results O O
provide O O
novel O O
evidence O O
that O O
following O O
a O O
single O O
intranasal O O
application O O
rapid O O
transfer O O
of O O
antigen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
occurs O O
. O O

Resulting O O
T O B_DISEASE
cell O I_DISEASE
proliferation O I_DISEASE
develops O O
consequent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
differential O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
signalling O O
in O O
SCLN O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
spleen O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
understanding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
underlying O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cellular O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
is O O
inferred O O
by O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
the O O
contribution O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
local O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
versus O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
systemic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tolerance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
may O O
assist O O
in O O
strategies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
clinically O O
apply O O
mucosal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tolerance O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
successfully O O
. O O

Regulation O O
of O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-18 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
on O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
during O O
T O O
helper O O
( O O
Th O O
) O O
1/Th2 O O
differentiation O O
. O O

Critical O O
downregulatory O O
role O O
of O O
IL-4 B B_PERSON/B_ENT
. O O

Interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-18 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
well O O
characterized O O
as O O
a O O
costimulatory B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
induction O O
of O O
IL-12-mediated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
interferon I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IFN I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
production O O
by O O
T O O
helper O O
( O O
Th O O
) O O
1 O O
cells O O
, O O
but O O
also O O
can O O
induce O O
IL-4 O O
production O O
and O O
thus O O
facilitate O O
the O O
differentiation O O
of O O
Th2 O O
cells O O
. O O

To O O
determine O O
the O O
mechanisms O O
by O O
which O O
IL-18 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
might O O
regulate O O
these O O
diametrically O O
distinct O O
immune O O
responses O O
, O O
we O O
have O O
analyzed O O
the O O
role O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
regulation O O
of O O
IL-18 B B_GENE
receptor I I_GENE
alpha I I_GENE
chain I I_GENE
( O O
IL-18Ralpha B B_PROTEIN[GENE]/B_LOCATION
) O O
expression O O
. O O

The O O
majority O O
of O O
peripheral O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
constitutively O O
expressed O O
the O O
IL-18Ralpha B B_GENE
. O O

Upon O O
antigen O O
stimulation O O
in O O
the O O
presence O O
of O O
IL-12 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
marked O O
enhancement O O
of O O
IL-18Ralpha B B_GENE
expression O O
was O O
observed O O
. O O

IL-12 B B_GENE
-mediated O O
upregulation O O
of O O
IL-18Ralpha B B_GENE
required O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Activated O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
that O O
expressed O O
low O O
levels O O
of O O
IL-18Ralpha B B_GENE
could O O
produce O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
when O O
stimulated O O
with O O
the O O
combination O O
of O O
IL-12 B B_GENE
and O O
IL-18 B B_GENE
, O O
while O O
CD4 O O
( O O
+ O O
) O O
cells O O
which O O
expressed O O
high O O
levels O O
of O O
IL-18Ralpha B B_GENE
could O O
respond O O
to O O
IL-18 B B_GENE
alone O O
. O O

In O O
contrast O O
, O O
T O O
cell O O
stimulation O O
in O O
the O O
presence O O
of O O
IL-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
a O O
downregulation O O
of O O
IL-18Ralpha B B_GENE
expression O O
. O O

Both O O
IL-4 O O
( O O
-/ O O
) O O
- O O
and O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
( O O
Stat O O
) O O
6 O O
( O O
-/ O O
) O O
- O O
T O O
cells O O
expressed O O
higher O O
levels O O
of O O
IL-18Ralpha B B_GENE
after O O
TCR O O
stimulation O O
. O O

Furthermore O O
, O O
activated O O
T O O
cells O O
from O O
Stat6 O O
( O O
-/ O O
) O O
- O O
mice O O
produced O O
more O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
response O O
to O O
IL-18 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
wild-type O O
controls O O
. O O

Thus O O
, O O
positive/negative O O
regulation O O
of O O
the O O
IL-18Ralpha B B_GENE
by O O
the O O
major O O
inductive O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-12 B B_GENE
and O O
IL-4 B B_GENE
) O O
determines O O
the O O
capacity O O
of O O
IL-18 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
to O O
polarize O O
an O O
immune O O
response O O
. O O

Glucocorticoid-regulated B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
transcription I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factors I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Glucocorticoids O B_PERSON
are O O
the O O
most O O
effective O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antiinflammatory O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drugs O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
used O O
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
asthma O B_DISEASE/B_LOCATION
. O O

They O O
act O O
by O O
binding O O
to O O
a O O
specific O O
receptor O O
( O O
GR B B_GENE/B_DISEASE
) O O
that O O
, O O
upon O O
activation O O
, O O
translocates O O
to O O
the O O
nucleus O O
and O O
either O O
increases O O
( O O
transactivates O O
) O O
or O O
decreases O O
( O O
transrepresses O O
) O O
gene O O
expression O O
. O O

Inhibition O O
of O O
pro-inflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
such O O
as O O
activator B B_GENE
protein I I_GENE
( I I_GENE
AP I I_GENE
) I I_GENE
-1 I I_GENE
, O O
signal B B_GENE
transducers I I_GENE
and I I_GENE
activators I I_GENE
of I I_GENE
transcription I I_GENE
( O O
STATs B B_GENE/B_LOCATION
) O O
, O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NFAT B B_GENE/B_ORGANIZATION
) O O
and O O
nuclear B B_GENE
factor I I_GENE
( I I_GENE
NF I I_GENE
) I I_GENE
-kappa I I_GENE
B I I_GENE
is O O
thought O O
to O O
be O O
a O O
major O O
action O O
of O O
glucocorticoids O O
. O O

Acetylation O O
of O O
histones B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allows O O
unwinding O O
of O O
the O O
local B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
structure I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
enables O O
RNA B B_GENE
polymerase I I_GENE
II I I_GENE
to O O
enhance O O
gene O O
transcription O O
. O O

Histone O O
acetylation O O
is O O
regulated O O
by O O
a O O
balance O O
between O O
the O O
activity O O
of O O
histone B B_ENZYME[GENE]
acetyltransferases I I_ENZYME[GENE]
( O O
HATs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
and O O
histone B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deacetylases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HDACs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acts O O
as O O
a O O
direct O O
inhibitor O O
of O O
NF-kappa O O
B-induced O O
HAT O O
activity O O
and O O
also O O
by O O
recruiting O O
HDAC2 B B_GENE
to O O
the O O
NF-kappa B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
B/HAT I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complex I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

A O O
sub-group O O
of O O
patients O O
with O O
glucocorticoid-insensitive O O
asthma O O
have O O
an O O
inability O O
to O O
induce O O
histone O O
acetylation O O
in O O
response O O
to O O
dexamethasone O O
suggesting O O
reduced O O
expression O O
of O O
a O O
GR-specific B B_GENE/B_MEASURE
HAT I I_GENE/I_MEASURE
. O O

This O O
suggests O O
that O O
pharmacological O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
manipulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
specific O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histone O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetylation O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
potentially O O
useful O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
approach O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
inflammatory O B_DISEASE
diseases O I_DISEASE
. O O

Identification O O
of O O
the O O
precise O O
mechanism O O
by O O
which O O
activated B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GR I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recruits O O
HDAC2 B B_GENE
may O O
reveal O O
new O O
targets O O
for O O
the O O
development O O
of O O
drugs O O
that O O
may O O
dissociate O O
the O O
antiinflammatory O O
actions O O
of O O
glucocorticoids O O
from O O
their O O
side O O
effects O O
that O O
are O O
largely O O
due O O
to O O
gene O O
induction O O
. O O

Copyright O B_LOCATION/B_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Differential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
ultraviolet-B-induced O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
immunomodulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
XPA O B_DISEASE/B_GENE
, O O
XPC O B_LOCATION/B_PERSON
, O O
and O O
CSB O B_LOCATION/B_DISEASE
DNA O I_LOCATION/I_DISEASE
repair-deficient O I_LOCATION/I_DISEASE
mice O I_LOCATION/I_DISEASE
. O O

Ultraviolet O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
B O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
irradiation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
has O O
serious O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequences O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
cellular O B_DISEASE/B_PERSON
immunity O I_DISEASE/I_PERSON
and O O
can O O
suppress O O
the O O
rejection O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
skin O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tumors O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
the O O
resistance O B_DISEASE_ADJECTIVE[DISEASE]
to O O
infectious O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diseases O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
damage O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
plays O O
a O O
crucial O B_PERSON/B_MEASURE
role O I_PERSON/I_MEASURE
in O O
these O O
immunomodulatory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
ultraviolet O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
impaired O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
ultraviolet-B-induced O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
DNA O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
damage O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
has O O
been O O
shown O O
to O O
cause O O
suppression O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cellular O B_DISEASE
immunity O I_DISEASE
. O O

Ultraviolet-B-induced O B_DISEASE/B_GENE
DNA O B_DISEASE/I_GENE
damage O B_DISEASE/I_GENE
is O O
repaired O O
by O O
the O O
nucleotide O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
excision O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
repair O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mechanism O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
very O O
efficiently O O
. O O

Nucleotide O B_DISEASE/B_GENE
excision O B_DISEASE/I_GENE
repair O B_DISEASE/I_GENE
comprises O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
subpathways O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O O
transcription-coupled O B_GENE/B_LOCATION
and O O
global O B_GENE
genome O I_GENE
repair O I_GENE
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
immunologic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequences O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
specific O B_DISEASE
nucleotide O I_DISEASE
excision O I_DISEASE
repair O I_DISEASE
defects O I_DISEASE
in O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mouse O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
XPA O B_DISEASE/B_PROTEIN[GENE]
, O O
XPC O B_DISEASE/B_LOCATION
, O O
and O O
CSB O B_DISEASE
mutant O I_DISEASE
mice O I_DISEASE
, O O
were O O
investigated O O
. O O

XPA O B_PERSON/B_BIO
mice O I_PERSON/I_BIO
carry O O
a O O
total O B_DISEASE/B_GENE
nucleotide O I_DISEASE/I_GENE
excision O I_DISEASE/I_GENE
repair O I_DISEASE/I_GENE
defect O I_DISEASE/I_GENE
, O O
whereas O O
XPC O B_LOCATION/B_PERSON
and O O
CSB O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
mice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
only O O
lack O O
global O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genome O B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
transcription-coupled O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
excision O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repair O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
. O O

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O O
that O O
cellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
immune O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
XPA O B_DISEASE/B_PROTEIN[GENE]
, O O
XPC O B_LOCATION/B_PERSON
, O O
and O O
CSB O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
mice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
are O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
with O O
their O O
wild-type O B_GENE/B_PERSON
( O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
littermates O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
may O O
indicate O O
that O O
the O O
reported O B_DISEASE_ADJECTIVE[DISEASE]
altered O O
cellular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responses O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
xeroderma O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pigmentosum O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
not O O
constitutive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
but O O
could O O
be O O
due O B_DISEASE_ADJECTIVE[DISEASE]
to O O
external O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
factors O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O O
ultraviolet O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
B O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Upon O O
exposure O O
to O O
ultraviolet O O
B O O
, O O
only O O
XPA O O
mice O O
are O O
very O O
sensitive O O
to O O
ultraviolet-B-induced O O
inhibition O O
of O O
Th1-mediated O O
contact O O
hypersensitivity O O
responses O O
and O O
interferon-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O O
in O O
skin O O
draining O O
lymph O O
nodes O O
. O O

Lipopolysaccharide-stimulated O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
necrosis I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factor I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
alpha I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
interleukin-10 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
are O O
significantly O O
augmented O O
in O O
both O O
XPA O O
and O O
CSB O O
mice O O
after O O
ultraviolet O O
B O O
exposure O O
. O O

Lymph O B_MEASURE/B_PERSON
node O I_MEASURE/I_PERSON
cell O I_MEASURE/I_PERSON
numbers O I_MEASURE/I_PERSON
were O O
increased O O
very O O
significantly O O
in O O
XPA O B_DISEASE/B_PROTEIN[GENE]
, O O
mildly O O
increased O O
in O O
CSB O B_DISEASE/B_PROTEIN[GENE]
, O O
and O O
not O O
in O O
XPC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
mice O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

In O O
general O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
XPC O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O O
not O O
exhibit O O
any O O
indication O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
enhanced O B_DISEASE_ADJECTIVE[DISEASE]
ultraviolet O I_DISEASE_ADJECTIVE[DISEASE]
B O I_DISEASE_ADJECTIVE[DISEASE]
susceptibility O I_DISEASE_ADJECTIVE[DISEASE]
with O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
immune O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
parameters O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analyzed O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
both O O
global O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
genome O I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair O I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
transcription-coupled O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
repair O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O O
needed O O
to O O
prevent O O
immunomodulation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
ultraviolet O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
transcription-coupled O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repair O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
the O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
DNA O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
repair O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
subpathway O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
nucleotide O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
excision O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O O
prevents O O
the O O
acute O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ultraviolet-B-induced O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
erythema O B_DISEASE
. O O

Biomechanical O O
strain O O
induces O O
class O O
a O O
scavenger B B_GENE
receptor I I_GENE
expression O O
in O O
human O O
monocyte/macrophages O O
and O O
THP-1 O O
cells O O
: O O
a O O
potential O O
mechanism O O
of O O
increased O O
atherosclerosis O O
in O O
hypertension O O
. O O

BACKGROUND O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Although O O
hypertension O B_DISEASE
is O O
an O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]
of O O
atherosclerosis O B_DISEASE/B_LOCATION
, O O
the O O
mechanisms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
this O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O O
incompletely O O
described O O
. O O

Previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
suggested O O
that O O
biomechanical O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strain O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulates O O
macrophage O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phenotype O I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
tested O O
the O O
hypothesis O O
that O O
biomechanical O O
strain O O
can O O
induce O O
expression O O
of O O
the O O
class B B_GENE
A I I_GENE
scavenger I I_GENE
receptor I I_GENE
( O O
SRA B B_LOCATION/B_ORGANIZATION
) O O
, O O
an O O
important O O
lipoprotein B B_GENE/B_PERSON
receptor I I_GENE/I_PERSON
in O O
atherogenesis O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Human O O
monocyte/macrophages O O
or O O
THP-1 O O
cells O O
were O O
cultured O O
in O O
a O O
device O O
that O O
imposes O O
uniform O O
biaxial O O
cyclic O O
1-Hz O O
strains O O
of O O
0 O O
% O O
, O O
1 O O
% O O
, O O
2 O O
% O O
, O O
or O O
3 O O
% O O
, O O
and O O
SRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
was O O
analyzed O O
. O O

Mechanical O O
strains O O
induced O O
SRA B B_GENE
mRNA I I_GENE
( O O
3.5+/-0.6-fold O O
at O O
3 O O
% O O
strain O O
for O O
48 O O
hours O O
, O O
P O O
< O O
0.01 O O
) O O
and O O
SRA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
THP-1 O O
cells O O
in O O
an O O
amplitude-dependent O O
manner O O
. O O

This O O
induction O O
was O O
accompanied O O
by O O
augmented O O
expression O O
of O O
the O O
class B B_GENE
B I I_GENE
scavenger I I_GENE
receptor I I_GENE
CD36 I I_GENE
( O O
2.8+/-0.3-fold O O
, O O
P O O
< O O
0.001 O O
) O O
but O O
not O O
by O O
increased O O
peroxisome B B_GENE
proliferator-activated I I_GENE
receptor-gamma I I_GENE
expression O O
. O O

To O O
evaluate O O
this O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
apolipoprotein O B_GENE
E O I_GENE
( O O
-/- O B_PERSON/B_PROTEIN[GENE]
) O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
randomly O O
assigned O O
to O O
receive O O
standard O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
chow O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
a O O
high-cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
diet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
or O O
a O O
high-cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
hypertension O B_DISEASE
induced O O
by O O
angiotensin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
II O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
infusion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O O
8 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Immunohistochemistry O O
revealed O O
that O O
among O O
macrophages O O
in O O
atherosclerotic O O
lesions O O
of O O
the O O
aorta O O
, O O
the O O
proportion O O
of O O
macrophages O O
with O O
SRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
was O O
highest O O
in O O
hypertensive O O
animals O O
on O O
a O O
high-cholesterol O O
diet O O
( O O
43.9+/-0.7 O O
% O O
, O O
versus O O
12.0+/-2.0 O O
% O O
for O O
normotensive O O
animals O O
on O O
a O O
high-cholesterol O O
diet O O
and O O
4.7+/-4.7 O O
% O O
for O O
animals O O
on O O
standard O O
chow O O
; O O
P O O
< O O
0.001 O O
) O O
. O O

CONCLUSIONS O O
: O O
Biomechanical O O
strain O O
induces O O
SRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
by O O
monocyte/macrophages O O
, O O
suggesting O O
a O O
novel O O
mechanism O O
for O O
promotion O O
of O O
atherosclerosis O O
in O O
hypertensive O O
patients O O
. O O

High O B_DISEASE/B_GENE
glucose O B_DISEASE/I_GENE
induces O O
MCP-1 O O
expression O B_GENE
partly O O
via O O
tyrosine O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase-AP-1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
peritoneal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mesothelial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
High O B_DISEASE_ADJECTIVE[DISEASE]
glucose O I_DISEASE_ADJECTIVE[DISEASE]
in O O
peritoneal O B_DISEASE/B_PERSON
dialysis O I_DISEASE/I_PERSON
solutions O I_DISEASE/I_PERSON
has O O
been O O
implicated O O
in O O
the O O
pathogenesis O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
peritoneal O B_DISEASE
fibrosis O I_DISEASE
in O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ambulatory O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
peritoneal O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dialysis O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
CAPD O B_DISEASE/B_GENE
) O O
patients O B_PERSON/B_DISEASE
. O O

However O O
, O O
the O O
mechanisms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
not O O
very O O
clear O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Peritoneal O O
macrophages O O
seem O O
to O O
participate O O
in O O
the O O
process O O
of O O
peritoneal O O
fibrosis O O
and O O
monocyte B B_GENE
chemoattractant I I_GENE
protein-1 I I_GENE
( O O
MCP-1 B B_GENE/B_DISEASE
) O O
plays O O
a O O
key O O
role O O
in O O
the O O
recruitment O O
of O O
monocytes O O
toward O O
the O O
peritoneal O O
cavity O O
. O O

However O O
, O O
little O O
is O O
known O O
about O O
the O O
effect O O
of O O
high O O
glucose O O
on O O
MCP-1 B B_GENE
expression O O
and O O
its O O
signal O O
transduction O O
pathway O O
in O O
human O O
peritoneal O O
mesothelial O O
cells O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Mesothelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O O
cultured O O
with O O
glucose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
5 O B_MEASURE/B_LOCATION
to O O
100 O B_MEASURE
mmol/L O I_MEASURE
) O O
or O O
mannitol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chronically O O
for O O
up O O
to O O
seven O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
. O O

MCP-1 B B_GENE/B_MEASURE
expression O O
of O O
mRNA O O
and O O
protein O O
was O O
measured O O
by O O
Northern O O
blot O O
analysis O O
and O O
enzyme-linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
. O O

Chemotactic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
high-glucose-conditioned O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
culture O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
supernatant O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
measured O O
by O O
chemotactic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
examine O O
the O O
roles O O
of O O
the O O
transcription B B_GENE
factors I I_GENE
activator B I_GENE
protein-1 I I_GENE
( O O
AP-1 B B_GENE/B_DISEASE
) O O
and O O
nuclear B B_GENE
factor-kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
, O O
electrophoretic O O
mobility O O
shift O O
assay O O
( O O
EMSA O O
) O O
was O O
performed O O
. O O

RESULTS O O
: O O
Glucose O O
induced O O
MCP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
a O O
time- O O
and O O
dose-dependent O O
manner O O
. O O

MCP-1 B B_DISEASE_ADJECTIVE[DISEASE]
protein I I_DISEASE_ADJECTIVE[DISEASE]
in O O
cell O O
culture O O
supernant O O
was O O
also O O
increased O O
. O O

Equivalent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
concentrations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
mannitol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
no O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

High-glucose-conditioned O O
supernatant O O
possessed O O
an O O
increased O O
chemotactic O O
activity O O
for O O
monocytes O O
, O O
which O O
was O O
neutralized O O
by O O
anti-MCP-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

EMSA O O
revealed O O
that O O
glucose O O
increased O O
the O O
AP-1 B B_GENE
binding O O
activity O O
in O O
a O O
time- O O
and O O
dose-dependent O O
manner O O
, O O
but O O
not O O
NF-kappaB B B_GENE
. O O

Curcumin O O
, O O
an O O
inhibitor O O
of O O
AP-1 B B_GENE
, O O
dose-dependently O O
suppressed O O
the O O
induction O O
of O O
MCP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
high O O
glucose O O
. O O

Tyrosine O O
kinase O O
inhibitors O O
such O O
as O O
genistein O O
( O O
12.5 O O
to O O
50 O O
micromol/L O O
) O O
and O O
herbimycin O O
A O O
( O O
0.1 O O
to O O
1 O O
micromol/L O O
) O O
inhibited O O
the O O
high-glucose-induced O O
MCP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
a O O
dose-dependent O O
manner O O
, O O
and O O
also O O
suppressed O O
the O O
high-glucose-induced O O
AP-1 B B_GENE
binding O O
activity O O
. O O

CONCLUSIONS O O
: O O
: O O
High O O
glucose O O
induced O O
mesothelial O O
MCP-1 B B_GENE
expression O O
partly O O
via O O
the O O
tyrosine O O
kinase- O O
AP-1 B B_GENE
pathway O O
. O O

Signal O B_ORGANIZATION/B_TIME[MEASURE]
thresholds O B_ORGANIZATION/I_TIME[MEASURE]
and O O
modular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
synergy O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O O
expression O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
costimulatory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
B O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
analyzed O O
intracellular O O
pathways O O
modulating O O
surface O O
densities O O
of O O
CD80 B B_GENE
and O O
CD86 B B_GENE
in O O
B O O
cells O O
activated O O
through O O
ligation O O
of O O
the O O
Ag B B_GENE
receptor I I_GENE
, O O
and O O
the O O
adhesion B B_GENE
molecule I I_GENE
CD54 B I_GENE
. O O

Whereas O O
B B B_GENE
cell I I_GENE
Ag I I_GENE
receptor I I_GENE
( O O
BCR B B_GENE/B_LOCATION
) O O
cross-linking O O
alone O O
stimulated O O
increased O O
expression O O
of O O
CD86 B B_GENE
, O O
up-regulation O O
of O O
CD80 B B_GENE
required O O
dual O O
stimulation O O
with O O
anti-IgM B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
anti-CD54 B B_GENE
. O O

The O O
principal O O
downstream O O
component O O
contributed O O
by O O
BCR B B_GENE
signaling O O
, O O
toward O O
both O O
CD80 B B_GENE
and O O
CD86 B B_GENE
induction O O
, O O
was O O
the O O
elevated O O
concentration O O
of O O
free O O
cytoplasmic O O
Ca O O
( O O
2+ O O
) O O
, O O
recruited O O
by O O
way O O
of O O
capacitative O O
influx O O
. O O

This O O
alone O O
was O O
sufficient O O
to O O
generate O O
an O O
increase O O
in O O
CD86 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
. O O

However O O
, O O
CD80 B B_GENE/B_LOCATION
enhancement O O
required O O
the O O
concerted O O
action O O
of O O
both O O
intracellular O O
Ca O O
( O O
2+ O O
) O O
concentration O O
and O O
CD54-initiated O O
pathways O O
. O O

The O O
nexus O O
between O O
anti-IgM O O
and O O
anti-CD54 O O
stimulation O O
, O O
in O O
the O O
context O O
of O O
CD80 B B_GENE
regulation O O
, O O
was O O
identified O O
to O O
involve O O
a O O
self-propagating O O
process O O
of O O
sequential O O
synergy O O
. O O

The O O
first O O
step O O
involved O O
amplified O O
accumulation O O
of O O
intracellular O O
cAMP O O
, O O
as O O
a O O
result O O
of O O
cross-talk O O
between O O
BCR B B_GENE
-mobilized O O
Ca O O
( O O
2+ O O
) O O
and O O
CD54-derived O O
signals O O
. O O

This O O
then O O
facilitated O O
a O O
second O O
synergistic O O
interaction O O
between O O
Ca O O
( O O
2+ O O
) O O
and O O
cAMP O O
, O O
culminating O O
in O O
CD80 B B_GENE
expression O O
. O O

Our O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
distinct O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
signal O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
transducer O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
requirements O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
the O O
added O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequences O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cross-talk O B_DISEASE/B_GENE
, O O
offers O O
an O O
explanation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
variable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
costimulatory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecule O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
diverse O B_DISEASE
physiological O I_DISEASE
stimuli O I_DISEASE
. O O

Importantly O O
, O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
also O O
reveal O O
how O O
concentration O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
threshold O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
barriers O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
recruitment O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
second O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
messengers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
can O O
be O O
overcome O O
by O O
constructive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
convergence O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
signaling O O
modules O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Epstein-Barr O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
virus O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
neoplastic O B_DISEASE/B_LOCATION
transformation O I_DISEASE/I_LOCATION
. O O

In O O
this O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
we O O
focus O O
on O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O O
basic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O O
translational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
relating O O
to O O
the O O
Epstein-Barr O B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
virus O I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EBV O B_VIRUS[BIO]/B_DISEASE
) O O
. O O

Beside O O
its O O
well-known O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tropism O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
epithelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
EBV O B_VIRUS[BIO]/B_DISEASE
also O O
infects O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
granulocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

After O O
primary O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
EBV O B_VIRUS[BIO]/B_DISEASE
persists O O
throughout O O
the O O
life O B_BODY_PART_OR_ORGAN_COMPONENT
span O I_BODY_PART_OR_ORGAN_COMPONENT
in O O
resting O O
memory O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
B O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
, O O
from O O
where O O
it O O
is O O
reactivated O O
upon O O
breakdown O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
immunity O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

In O O
the O O
process O O
of O O
neoplastic O O
transformation O O
, O O
the O O
EBV-encoded B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
latent I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
membrane I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
LMP1 I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
oncogene I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
represents O O
the O O
major O O
driving O O
force O O
. O O

LMP1 B B_GENE
acts O O
like O O
a O O
constitutively B B_GENE/B_PERSON
activated I I_GENE/I_PERSON
receptor I I_GENE/I_PERSON
of O O
the O O
tumor B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
necrosis I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
family I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
allows O O
the O O
amplification O O
or O O
bypassing O O
of O O
physiological O O
regulatory O O
signals O O
through O O
direct O O
and O O
indirect O O
interactions O O
with O O
proteins O O
of O O
the O O
tumor B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
necrosis I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
factor I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
receptor-associated I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
factor I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
( I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
TRAF I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
) I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
family I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
. O O

TRAF2 B B_GENE
-mediated O O
NF-kappaB B B_GENE
activation O O
, O O
AP-1 B B_GENE
induction O O
and O O
JAK3 B B_GENE/B_LOCATION
/ O O
STAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O O
may O O
result O O
in O O
sustained O O
proliferation O O
leading O O
to O O
lymphoma O O
. O O

The O O
ability O O
of O O
LMP1 B B_GENE
to O O
suppress O O
germinal O O
center O O
formation O O
and O O
its O O
capacity O O
to O O
mediate O O
its O O
own O O
transcriptional O O
activation O O
shed O O
new O O
light O O
on O O
the O O
pathogenesis O O
of O O
EBV-associated O O
latency O O
type O O
II O O
lymphoproliferations O O
like O O
Hodgkin O O
's O O
disease O O
and O O
angioimmunoblastic O O
lymphadenopathy O O
. O O

The O O
carboxy B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
terminus I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
LMP1 B B_GENE
is O O
also O O
a O O
reliable O O
marker O O
for O O
individual O O
EBV O O
strain O O
identification O O
and O O
thus O O
offers O O
new O O
possibilities O O
in O O
tracing O O
the O O
molecular O O
events O O
leading O O
to O O
posttransplant O O
lymphoproliferative O O
disorders O O
( O O
PTLDs O O
) O O
. O O

Cytotoxic O O
T O O
lymphocytes O O
directed O O
against O O
well-characterized O O
epitopes O O
of O O
EBV B B_DISEASE/B_VIRUS[BIO]
latency I B_DISEASE/I_VIRUS[BIO]
genes I B_DISEASE/I_VIRUS[BIO]
represent O O
an O O
already O O
successful O O
and O O
promising O O
therapeutic O O
approach O O
to O O
EBV-associated O O
lymphomas O O
, O O
in O O
particular O O
PTLDs O O

Interferon-alpha B B_DISEASE/B_GENE
drives O O
T O O
cell-mediated O O
immunopathology O O
in O O
the O O
intestine O O
. O O

The O O
ability O O
of O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
IFN I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
-alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
to O O
induce O O
autoimmunity O O
and O O
exacerbate O O
Th1 O O
diseases O O
is O O
well O O
known O O
. O O

We O O
have O O
recently O O
described O O
enhanced O O
expression O O
of O O
IFN-alpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
mucosa O O
of O O
patients O O
with O O
celiac O O
disease O O
( O O
CD O O
) O O
, O O
a O O
gluten-sensitive O O
Th1-mediated O O
enteropathy O O
, O O
characterized O O
by O O
villous O O
atrophy O O
and O O
crypt O O
cell O O
hyperplasia O O
. O O

Previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O O
this O O
laboratory O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
shown O O
that O O
T O B_DISEASE
cell O I_DISEASE
activation O I_DISEASE
in O O
explant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cultures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
human O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
fetal O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
gut O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
can O O
also O O
result O O
in O O
villous O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
atrophy O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
crypt O O
cell O B_DISEASE/B_ORGANIZATION
hyperplasia O I_DISEASE/I_ORGANIZATION
. O O

We O O
have O O
, O O
therefore O O
, O O
examined O O
changes O O
that O O
take O O
place O O
in O O
explant O O
cultures O O
of O O
human O O
fetal O O
gut O O
after O O
activation O O
of O O
T O O
cells O O
with O O
anti-CD3 B B_GENE
and/or O O
IFN-alpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
show O O
that O O
activation O O
of O O
T O O
cells O O
with O O
anti-CD3 B B_GENE
alone O O
elicits O O
a O O
small O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response O O
with O O
no O O
tissue O O
injury O O
. O O

Similarly O O
, O O
no O O
changes O O
are O O
seen O O
in O O
explants O O
cultured O O
with O O
IFN-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alone O O
. O O

However O O
, O O
addition O O
of O O
IFN-alpha B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
results O O
in O O
enhanced O O
Th1 O O
response O O
and O O
crypt O O
cell O O
hyperplasia O O
. O O

This O O
is O O
associated O O
with O O
enhanced O O
phosphorylation O O
of O O
STAT1 B B_GENE
, O O
STAT3 B B_GENE
, O O
and O O
Fyn B B_GENE
, I I_GENE
a I I_GENE
Src I I_GENE
homology I I_GENE
tyrosine I I_GENE
kinase I I_GENE
, O O
which O O
interacts O O
with O O
both O O
TCR O O
and O O
IFN-alpha O O
signal O O
components O O
. O O

Together O O
these O O
data O O
indicate O O
that O O
IFN-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
facilitate O O
activation O O
of O O
Th1-reactive O O
cells O O
in O O
the O O
gut O O
and O O
drive O O
immunopathology O O
. O O

Suppression O O
of O O
tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
necrosis I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
production O O
by O O
cAMP O O
in O O
human O O
monocytes O O
: O O
dissociation O O
with O O
mRNA O O
level O O
and O O
independent O O
of O O
interleukin-10 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BACKGROUND O O
: O O
Elevation O O
of O O
cellular O O
cAMP O O
inhibits O O
lipopolysaccharide O O
( O O
LPS O O
) O O
-stimulated O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF-alpha B B_GENE/B_LOCATION
) O O
production O O
and O O
increases O O
the O O
expression O O
of O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-10 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mononuclear O O
cells O O
. O O

TNF-alpha B B_GENE
gene I I_GENE
expression O O
obligates O O
activation O O
of O O
the O O
transcription B B_GENE
factor I I_GENE
nuclear B I_GENE
factor I I_GENE
kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
. O O

Exogenous O O
IL-10 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibits O O
NF-kappaB B B_GENE
in O O
monocytes O O
and O O
thus O O
attenuates O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O O
. O O

We O O
examined O O
the O O
role O O
of O O
endogenous O O
IL-10 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
regulation O O
of O O
NF-kappaB B B_GENE
activation O O
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O O
in O O
human O O
monocytes O O
by O O
cAMP O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
stimulated O O
with O O
Escherichia O B_GENE/B_BACTERIUM[BIO]
coli O I_GENE/I_BACTERIUM[BIO]
LPS O I_GENE/I_BACTERIUM[BIO]
( O O
100 O B_LOCATION/B_MEASURE
ng/ml O I_LOCATION/I_MEASURE
) O O
with O O
and O O
without O O
forskolin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FSK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
50 O B_NUMBER[MEASURE]/B_LOCATION
microM O I_NUMBER[MEASURE]/I_LOCATION
) O O
or O O
dibutyryl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cyclic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
AMP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
dbcAMP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
100 O B_NUMBER[MEASURE]/B_LOCATION
microM O I_NUMBER[MEASURE]/I_LOCATION
) O O
. O O

Cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
IL-10 B B_GENE
) O O
release O O
was O O
measured O O
by O O
immunoassay O O
. O O

TNF-alpha B B_GENE
mRNA I I_GENE
was O O
measured O O
by O O
reverse O O
transcription O O
polymerase O O
chain O O
reaction O O
, O O
and O O
NF-kappaB B B_GENE
DNA O O
binding O O
activity O O
was O O
assessed O O
by O O
gel O O
mobility O O
shift O O
assay O O
. O O

RESULTS O O
: O O
cAMP-elevating O O
agents O O
inhibited O O
LPS-stimulated O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
release O O
( O O
0.77 O O
+/- O O
0.13 O O
ng/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
+ O O
dbcAMP O O
and O O
0.68 O O
+/- O O
0.19 O O
ng/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
+ O O
FSK O O
, O O
both O O
P O O
< O O
0.05 O O
vs O O
1.61 O O
+/- O O
0.34 O O
ng/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
alone O O
) O O
. O O

Conversely O O
, O O
cAMP O O
enhanced O O
LPS-stimulated O O
IL-10 B B_GENE
release O O
( O O
100 O O
+/- O O
21.5 O O
pg/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
+ O O
dbcAMP O O
and O O
110 O O
+/- O O
25.2 O O
pg/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
+ O O
FSK O O
, O O
both O O
P O O
< O O
0.05 O O
vs O O
53.3 O O
+/- O O
12.8 O O
pg/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
alone O O
) O O
. O O

Neither O O
TNF-alpha B B_GENE
mRNA I I_GENE
expression O O
nor O O
NF-kappaB B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
stimulated O O
by O O
LPS O O
was O O
inhibited O O
by O O
the O O
cAMP-elevating O O
agents O O
. O O

Neutralization O O
of O O
IL-10 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
a O O
specific O O
antibody B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
attenuate O O
the O O
effect O O
of O O
cAMP-elevating O O
agents O O
on O O
TNF-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
production O O
. O O

CONCLUSION O O
: O O
The O O
results O O
indicate O O
that O O
cAMP O O
inhibits O O
LPS-stimulated O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O O
through O O
a O O
posttranscriptional O O
mechanism O O
that O O
is O O
independent O O
of O O
endogenous O O
IL-10 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Copyright O B_LOCATION/B_PERSON
2001 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Activation O O
of O O
the O O
p21 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
CIP1/WAF1 I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
by O O
bone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
morphogenetic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein-2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mouse O O
B O O
lineage O O
cells O O
. O O

BMPs B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exert O O
a O O
negative O O
growth O O
effect O O
on O O
various O O
types O O
of O O
cells O O
. O O

We O O
have O O
previously O O
reported O O
that O O
BMP-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O O
the O O
growth O O
of O O
HS-72 O O
mouse O O
hybridoma O O
cells O O
by O O
inducing O O
p21 O O
( O O
CIP1/WAF1 O O
) O O
expression O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
demonstrated O O
that O O
BMP-2 B B_GENE
activated O O
the O O
mouse O O
p21 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
CIP1/WAF1 I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
in O O
HS-72 O O
cells O O
, O O
and O O
that O O
a O O
29-base B B_MEASURE/B_LOCATION
pair I I_MEASURE/I_LOCATION
( I I_MEASURE/I_LOCATION
b I I_MEASURE/I_LOCATION
) I I_MEASURE/I_LOCATION
region I I_MEASURE/I_LOCATION
of O O
the O O
promoter O O
( O O
-1928/-1900 O O
relative O O
to O O
the O O
TATA B B_GENE/B_MEASURE
box I I_GENE/I_MEASURE
) O O
, O O
conserved O O
between O O
mice O O
and O O
humans O O
, O O
was O O
responsive O O
to O O
BMP-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O O
well O O
as O O
expression O O
of O O
Smad1 B B_GENE
, O O
Smad4 B B_GENE
, O O
and O O
constitutively O O
active O O
mutants O O
of O O
BMP B B_GENE
type I I_GENE
I I I_GENE
receptors I I_GENE
. O O

Furthermore O O
, O O
an O O
oligonucleotide O O
containing O O
the O O
29-b B B_GENE/B_LOCATION
region I I_GENE/I_LOCATION
was O O
found O O
to O O
be O O
associated O O
with O O
Smad4 B B_GENE
and O O
phosphorylated B B_GENE/B_MEASURE
Smad1 I I_GENE/I_MEASURE
in O O
the O O
nuclear O O
extract O O
of O O
BMP-2 B B_GENE
-stimulated O O
HS-72 O O
cells O O
. O O

These O O
results O O
suggested O O
that O O
BMP-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
might O O
activate O O
p21 O O
( O O
CIP1/WAF1 O O
) O O
transcription O O
by O O
inducing O O
a O O
binding O O
of O O
Smad4 B B_GENE
and O O
Smad1 B B_GENE/B_MEASURE
to O O
the O O
29-b B B_LOCATION/B_BIO
region I B_LOCATION/I_BIO
in O O
HS-72 O O
cells O O
. O O

Dendritic O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
cell O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
development O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
from O O
common O B_BIO/B_DISEASE
myeloid O I_BIO/I_DISEASE
progenitors O I_BIO/I_DISEASE
. O O

Dendritic O O
cells O O
( O O
DCs O O
) O O
are O O
professional O O
antigen-presenting O O
cells O O
which O O
both O O
initiate O O
adaptive O O
immune O O
responses O O
and O O
control O O
tolerance O O
to O O
self-antigens B B_DISEASE/B_BIO
. O O

It O O
has O O
been O O
suggested O O
that O O
these O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O O
responder O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
depend O O
on O O
subsets O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
DCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
arising O O
from O O
either O O
myeloid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
lymphoid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
hematopoietic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
origins O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
CD8 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
alpha+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
Mac-1- O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
DCs O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
supposed O O
to O O
be O O
of O O
lymphoid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
while O O
CD8 O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
alpha- O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
Mac-1+ O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
DCs O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
supposed O O
to O O
be O O
of O O
myeloid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
origin O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O O

Here O O
we O O
summarize O O
our O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
both O O
CD8 O B_GENE
alpha+ O I_GENE
and O O
CD8 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
alpha- O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
DCs O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
can O O
arise O O
from O O
clonogenic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
common O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
myeloid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CMPs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
in O O
both O O
thymus O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
spleen O O
. O O

Therefore O O
CD8 B B_GENE/B_MEASURE
alpha I I_GENE/I_MEASURE
expression O O
DCs O O
does O O
not O O
indicate O O
a O O
lymphoid O O
origin O O
and O O
differences O O
among O O
CD8 O O
alpha+ O O
and O O
CD8 O O
alpha- O O
DCs O O
might O O
rather O O
reflect O O
maturation O O
status O O
than O O
ontogeny O O
. O O

On O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
transplantation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
it O O
seems O O
likely O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
that O O
most O B_MEASURE/B_DISEASE
of O O
the O O
DCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
in O O
secondary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lymphoid O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
organs O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
substantial O B_MEASURE/B_PERSON
fraction O I_MEASURE/I_PERSON
of O O
thymic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
DCs O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
are O O
myeloid-derived O O
. O O

Macrophage O O
stimulation O O
with O O
Murabutide O O
, O O
an O O
HIV-suppressive O O
muramyl O O
peptide O O
derivative O O
, O O
selectively O O
activates O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
C/EBPbeta B B_GENE
and O O
STAT1 B B_GENE
: O O
role O O
of O O
CD14 B B_GENE
and O O
Toll-like B B_GENE
receptors I I_GENE
2 I I_GENE
and I I_GENE
4 I I_GENE
. O O

The O O
smallest O B_MEASURE/B_PERSON
unit O I_MEASURE/I_PERSON
of O O
bacterial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
peptidoglycans O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
known O O
to O O
be O O
endowed O O
with O O
biological O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activities O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
muramyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dipeptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
MDP O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

A O O
clinically O O
acceptable O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
synthetic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
derivative O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
MDP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
namely O O
murabutide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MB O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
has O O
been O O
found O O
to O O
present O O
interesting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pharmacological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
properties O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
to O O
suppress O O
HIV-1 O B_DISEASE_ADJECTIVE[DISEASE]
replication O I_DISEASE_ADJECTIVE[DISEASE]
in O O
monocyte-derived O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MDM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

We O O
have O O
addressed O O
the O O
signaling O O
events O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activated O O
in O O
MDM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
either O O
MB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
the O O
potent O B_LOCATION/B_ORGANIZATION
immunostimulant O I_LOCATION/I_ORGANIZATION
LPS O I_LOCATION/I_ORGANIZATION
. O O

We O O
also O O
examined O O
whether O O
signaling O O
by O O
muramyl O O
peptides O O
involves O O
the O O
use O O
of O O
cell B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
surface I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
CD14 B B_GENE
and O O
Toll-like B B_GENE/B_MEASURE
receptor I I_GENE/I_MEASURE
2 I I_GENE/I_MEASURE
( O O
TLR2 B B_GENE
) O O
or O O
TLR4 B B_GENE/B_PERSON
that O O
are O O
known O O
to O O
be O O
signal-transducing B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
other O O
bacterial O O
cell O O
wall O O
components O O
. O O

We O O
demonstrate O O
that O O
, O O
unlike O O
LPS O O
, O O
the O O
safe O O
immunomodulator O O
MB O O
selectively O O
activates O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Erk I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1/2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
the O O
absence O O
of O O
detectable O O
Jun B B_GENE
N-terminal I I_GENE
kinase I I_GENE
( O O
JNK B B_GENE/B_LOCATION
) O O
or O O
p38 B B_GENE
mitogen-activated I I_GENE
kinase I I_GENE
activation O O
. O O

Furthermore O O
, O O
STAT1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation O O
but O O
weak O O
or O O
no O O
activation O O
of O O
STAT3 B B_GENE
or O O
STAT5 B B_GENE
respectively O O
, O O
could O O
be O O
detected O O
in O O
MB-stimulated O O
MDM O O
. O O

Using O O
MonoMac6 O O
cells O O
, O O
we O O
observed O O
high O O
C/EBPbeta B B_GENE
and O O
AP-1 B B_GENE
but O O
weaker O O
and O O
transient O O
NF-kappaB B B_GENE
activation O O
by O O
MB O O
. O O

Moreover O O
, O O
the O O
truncated O O
form O O
of O O
C/EBPbeta B B_GENE/B_LOCATION
, O O
known O O
to O O
repress O O
HIV-1 O O
transcription O O
, O O
was O O
detected O O
in O O
extracts O O
from O O
MB-treated O O
THP-1 O O
cells O O
. O O

Surprisingly O O
, O O
neither O O
MB O O
nor O O
MDP O O
were O O
able O O
to O O
transduce O O
signals O O
via O O
CD14 B B_GENE/B_LOCATION
and O O
TLR2 B B_GENE
or I I_GENE
4 I I_GENE
. O O

These O O
findings O O
present O O
major O O
differences O O
in O O
the O O
early O O
cell O O
activation O O
process O O
between O O
LPS O O
and O O
muramyl O O
peptides O O
, O O
and O O
strongly O O
argue O O
for O O
the O O
implication O O
of O O
co-receptors B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
other O O
than O O
TLR2 B B_GENE
and O O
TLR4 B B_GENE
in O O
mediating O O
the O O
signaling O O
events O O
induced O O
by O O
defined O O
subunits O O
of O O
bacterial O O
peptidoglycans O O
. O O

Nuclear B B_PERSON/B_GENE
peroxisome I I_PERSON/I_GENE
proliferator-activated I I_PERSON/I_GENE
receptors I I_PERSON/I_GENE
alpha I I_PERSON/I_GENE
and I I_PERSON/I_GENE
gamma I I_PERSON/I_GENE
have O O
opposing O O
effects O O
on O O
monocyte O O
chemotaxis O O
in O O
endometriosis O O
. O O

The O O
peroxisome B B_GENE
proliferator-activated I I_GENE
receptors I I_GENE
( I I_GENE
PPARs I I_GENE
) I I_GENE
alpha I I_GENE
and I I_GENE
gamma I I_GENE
are O O
nuclear B B_GENE
receptors I I_GENE
that O O
play O O
important O O
roles O O
in O O
inflammatory O O
diseases O O
like O O
ulcerative O O
colitis O O
and O O
arthritis O O
. O O

In O O
this O O
study O O
, O O
we O O
examined O O
the O O
possible O O
role O O
of O O
PPARs B B_GENE
in O O
macrophage O O
attraction O O
into O O
the O O
peritoneal O O
cavity O O
of O O
patients O O
with O O
endometriosis O O
. O O

We O O
identified O O
PPAR-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
messenger O O
RNA O O
by O O
RT-PCR O O
and O O
protein O O
by O O
immunoblotting O O
of O O
lysates O O
of O O
peritoneal O O
macrophages O O
and O O
monocytic O O
U937 O O
cells O O
. O O

Using O O
immunocytochemistry O O
, O O
we O O
localized O O
PPAR-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
within O O
the O O
nuclei O O
of O O
both O O
cell O O
types O O
. O O

Monocyte O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
chemotactic O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
activity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
peritoneal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fluid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
patients O B_PERSON
with O O
endometriosis O B_DISEASE
was O O
quantified O O
in O O
Boyden O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
chambers O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Migration O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
U937 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
increased O O
by O O
WY O B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
14643 O B_LOCATION/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
reduced O O
by O O
rosiglitazone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Peritoneal O O
fluid O O
from O O
patients O O
with O O
endometriosis O O
activated O O
U937 O O
cells O O
transiently O O
transfected O O
with O O
a O O
PPAR-alpha/GAL4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
luciferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

By O O
contrast O O
, O O
peritoneal O O
fluid O O
did O O
not O O
cause O O
significant O O
activation O O
of O O
PPAR-gamma/GAL4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
constructs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
U937 O O
cells O O
transiently O O
transfected O O
with O O
a O O
PPAR B B_GENE
response I I_GENE
element I I_GENE
luciferase I I_GENE
reporter I I_GENE
showed O O
disease O O
stage-dependent O O
up-regulation O O
when O O
treated O O
with O O
peritoneal O O
fluid O O
from O O
patients O O
with O O
endometriosis O O
. O O

Treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
peritoneal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
fluid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O O
healthy O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
down-regulated O O
PPAR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transactivation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
conclude O O
that O O
peritoneal O O
fluid O O
of O O
endometriosis O O
patients O O
contains O O
activators O O
of O O
PPAR-alpha B B_GENE
that O O
stimulate O O
macrophage O O
chemotaxis O O
. O O

Inhibitors O O
of O O
PPAR-alpha B B_GENE/B_DISEASE
or O O
activators O O
of O O
PPAR-gamma B B_GENE
could O O
be O O
developed O O
for O O
the O O
treatment O O
of O O
inflammation O O
associated O O
with O O
endometriosis O O
. O O

Long-term-impaired O O
expression O O
of O O
nuclear B B_GENE
factor-kappa I I_GENE
B I I_GENE
and O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
peripheral O O
blood O O
mononuclear O O
cells O O
of O O
trauma O O
patients O O
. O O

Nuclear B B_GENE
factor I I_GENE
( I I_GENE
NF I I_GENE
) I I_GENE
-kappa I I_GENE
B I I_GENE
expression O O
and O O
dimer O O
characteristics O O
were O O
studied O O
in O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMCs O O
) O O
of O O
major-trauma O O
patients O O
and O O
healthy O O
controls O O
. O O

Analysis O O
of O O
PBMCs O O
on O O
days O O
1 O O
, O O
3 O O
, O O
5 O O
, O O
and O O
10 O O
after O O
trauma O O
revealed O O
that O O
expression O O
of O O
both O O
p65p50 B B_GENE
heterodimers I I_GENE
and O O
p50p50 B B_GENE
homodimers I I_GENE
was O O
significantly O O
reduced O O
compared O O
with O O
that O O
in O O
controls O O
. O O

In O O
vitro O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
lipopolysaccharide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O O
LPS O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
PBMCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
induced O O
NF-kappa O B_DISEASE/B_GENE
B O B_DISEASE/I_GENE
translocation O B_DISEASE/I_GENE
. O O

However O O
, O O
throughout O O
the O O
survey O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
p65p50 O B_DISEASE_ADJECTIVE[DISEASE]
activation O I_DISEASE_ADJECTIVE[DISEASE]
remained O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
trauma O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
than O O
in O O
controls O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

After O O
LPS O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
vitro O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
p65p50/p50p50 O B_MEASURE
ratio O I_MEASURE
was O O
significantly O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
PBMCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
trauma O B_DISEASE/B_PERSON
patients O I_DISEASE/I_PERSON
than O O
from O O
healthy O B_PERSON/B_BIO
controls O I_PERSON/I_BIO
. O O

The O O
ex O O
vivo O O
expression O O
of O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
higher O O
in O O
PBMCs O O
of O O
controls O O
than O O
of O O
trauma O O
patients O O
. O O

LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
did O O
not O O
induce O O
I O O
kappa O B_TIME[MEASURE]/B_LOCATION
B O I_TIME[MEASURE]/I_LOCATION
expression O I_TIME[MEASURE]/I_LOCATION
in O O
PBMCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
trauma O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
, O O
but O O
strong O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
obtained O O
with O O
staphylococci O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
suggesting O O
that O O
this O O
defect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
not O O
universal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
depends O O
on O O
the O O
nature O B_MEASURE/B_DISEASE
of O O
the O O
activating O O
signal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Although O O
no O O
direct O O
correlation O O
was O O
found O O
between O O
levels O O
of O O
interleukin-10 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
transforming B B_GENE/B_MEASURE
growth I B_GENE/I_MEASURE
factor-beta I B_GENE/I_MEASURE
and O O
NF-kappa B B_GENE/B_DISEASE
B I B_GENE/I_DISEASE
, O O
these O O
immunosuppressive B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokines I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
significantly O O
elevated O O
in O O
trauma O O
patients O O
by O O
10 O O
days O O
after O O
admission O O
. O O

The O O
long-term O O
low-basal O O
and O O
LPS-induced O O
nuclear O O
translocation O O
of O O
NF-kappa B B_GENE
B I I_GENE
recalled O O
long-term O O
immunoparalysis O O
observed O O
in O O
patients O O
with O O
severe O O
inflammatory O O
stress O O
such O O
as O O
trauma O O
. O O

Hepatic O B_DISEASE_ADJECTIVE[DISEASE]
ischemia-reperfusion O I_DISEASE_ADJECTIVE[DISEASE]
injury O I_DISEASE_ADJECTIVE[DISEASE]
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
morbidity O B_DISEASE
associated O O
with O O
liver O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
major O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
hepatic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
resections O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
partly O O
a O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
ischemia-reperfusion O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

DATA O B_MEASURE/B_ORGANIZATION
SOURCES O I_MEASURE/I_ORGANIZATION
: O O
The O O
entire O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
world O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
literature O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
the O O
subject O B_PERSON
was O O
searched O O
via O O
Medline O B_LOCATION/B_ORGANIZATION
. O O

Keywords O O
included O O
reperfusion O O
injury O O
, O O
transplantation O O
, O O
liver O O
resection O O
, O O
nitric O O
oxide O O
, O O
endothelin O O
, O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
Kupffer O O
cells O O
, O O
ischemic/ischaemic O O
preconditioning O O
, O O
and O O
nuclear B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factor-kappa I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
An O O
imbalance O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
endothelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
nitric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
results O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
failure O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
hepatic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
microcirculation O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
at O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
of O O
reperfusion O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Activation O O
of O O
nuclear B B_GENE
factor-kappa I I_GENE
B I I_GENE
in O O
the O O
liver O O
promotes O O
proinflammatory B B_DISEASE/B_GENE
cytokine I I_DISEASE/I_GENE
and O O
adhesion B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
molecule I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
synthesis O O
. O O

These O O
result O O
in O O
oxygen-derived O O
free O B_DISEASE_ADJECTIVE[DISEASE]
radical O I_DISEASE_ADJECTIVE[DISEASE]
production O I_DISEASE_ADJECTIVE[DISEASE]
and O O
neutrophil O B_DISEASE_ADJECTIVE[DISEASE]
recruitment O I_DISEASE_ADJECTIVE[DISEASE]
, O O
further O O
contributing O O
to O O
cellular O B_DISEASE
injury O I_DISEASE
. O O

Various O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapeutic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
modalities O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acting O O
on O O
the O O
above O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mediators O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
successfully O O
used O O
to O O
attenuate O O
reperfusion O B_DISEASE/B_GENE
injury O I_DISEASE/I_GENE
in O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
hepatic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
resection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Application O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
the O O
knowledge O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gained O O
from O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hepatic O B_DISEASE/B_GENE
ischemia-reperfusion O I_DISEASE/I_GENE
to O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
setting O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
will O O
improve O O
the O O
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
hepatic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O O

Down-regulation O O
of O O
IL-12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p40 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Plasmodium O O
berghei-infected O O
mice O O
. O O

We O O
analyzed O O
the O O
mechanism O O
that O O
causes O O
suppression O O
of O O
IL-12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p40 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induction O O
during O O
Plasmodium O O
berghei O O
infection O O
. O O

Although O O
IL-12 B B_GENE
together O O
with O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plays O O
an O O
important O O
role O O
in O O
protection O O
against O O
pathogenic O O
infection O O
, O O
the O O
IL-12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p70 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
production O O
of O O
infected O O
macrophages O O
is O O
lower O O
than O O
that O O
by O O
the O O
uninfected O O
macrophages O O
. O O

We O O
showed O O
in O O
the O O
present O O
study O O
that O O
the O O
induction O O
of O O
IL-12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p40 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
but O O
not O O
IL-12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p35 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
macrophages O O
of O O
P. O O
berghei-infected O O
mice O O
was O O
profoundly O O
inhibited O O
. O O

The O O
inhibition O O
was O O
induced O O
by O O
interaction O O
with O O
macrophages O O
that O O
had O O
contacted O O
with O O
P. O O
berghei-infected O O
erythrocytes O O
and O O
was O O
mediated O O
by O O
a O O
soluble O O
factor O O
, O O
IL-10 B B_GENE
. O O

There O O
was O O
comparable O O
activation O O
of O O
NF-kappaB B B_GENE
in O O
uninfected O O
and O O
infected O O
cells O O
. O O

The O O
induction O O
of O O
IFN-regulatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
comparable O O
in O O
transcription O O
level O O
in O O
uninfected O O
and O O
infected O O
cells O O
, O O
while O O
the O O
unidentified O O
complex O O
formation O O
of O O
IFN-regulatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
observed O O
in O O
infected O O
cells O O
. O O

Therefore O O
, O O
the O O
inhibition O O
of O O
the O O
IL-12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p40 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induction O O
appeared O O
to O O
be O O
regulated O O
at O O
transcriptional O O
regulation O O
level O O
of O O
the O O
gene O O
. O O

The O O
Friend B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GATA I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
U-shaped O O
, O O
FOG-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
FOG-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O O
as O O
negative O O
regulators O O
of O O
blood O O
, O O
heart O O
, O O
and O O
eye O O
development O O
in O O
Drosophila O O
. O O

Friend B B_PERSON/B_GENE
of I I_PERSON/I_GENE
GATA I I_PERSON/I_GENE
( I I_PERSON/I_GENE
FOG I I_PERSON/I_GENE
) I I_PERSON/I_GENE
proteins I I_PERSON/I_GENE
regulate O O
GATA O O
factor-activated O O
gene O O
transcription O O
. O O

During O O
vertebrate O O
hematopoiesis O O
, O O
FOG B B_BIO/B_GENE
and I I_BIO/I_GENE
GATA I I_BIO/I_GENE
proteins I I_BIO/I_GENE
cooperate O O
to O O
promote O O
erythrocyte O O
and O O
megakaryocyte O O
differentiation O O
. O O

The O O
Drosophila B B_GENE
FOG I I_GENE
homologue I I_GENE
U-shaped I I_GENE
( O O
Ush B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
expressed O O
similarly O O
in O O
the O O
blood O O
cell O O
anlage O O
during O O
embryogenesis O O
. O O

During O O
hematopoiesis O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
the O O
acute O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myeloid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leukemia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homologue O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Lozenge O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Glial O B_DISEASE/B_GENE
cells O B_DISEASE/I_GENE
missing O O
are O O
required O O
for O O
the O O
production O B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
crystal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
plasmatocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
. O O

However O O
, O O
additional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
factors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
been O O
predicted O O
to O O
control O O
crystal O B_DISEASE
cell O I_DISEASE
proliferation O I_DISEASE
. O O

In O O
this O O
report O O
, O O
we O O
show O O
that O O
Ush B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
expressed O O
in O O
hemocyte O O
precursors O O
and O O
plasmatocytes O O
throughout O O
embryogenesis O O
and O O
larval O O
development O O
, O O
and O O
the O O
GATA B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
Serpent I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
essential O O
for O O
Ush B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
embryonic O O
expression O O
. O O

Furthermore O O
, O O
loss O O
of O O
ush O O
function O O
results O O
in O O
an O O
overproduction O O
of O O
crystal O O
cells O O
, O O
whereas O O
forced O O
expression O O
of O O
Ush B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O O
this O O
cell O O
population O O
. O O

Murine B B_PERSON/B_GENE
FOG-1 I I_PERSON/I_GENE
and I I_PERSON/I_GENE
FOG-2 I I_PERSON/I_GENE
also O O
can O O
repress O O
crystal O O
cell O O
production O O
, O O
but O O
a O O
mutant O O
version O O
of O O
FOG-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacking O O
a O O
conserved O O
motif O O
that O O
binds O O
the O O
corepressor B B_GENE/B_LOCATION
C-terminal I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
fails O O
to O O
affect O O
the O O
cell O O
lineage O O
. O O

The O O
GATA B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Pannier I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Pnr B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
required O O
for O O
eye O O
and O O
heart O O
development O O
in O O
Drosophila O O
. O O

When O O
Ush B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O O
FOG-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
FOG-2 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
or O O
mutant B B_GENE/B_PERSON
FOG-2 I I_GENE/I_PERSON
is O O
coexpressed O O
with O O
Pnr B B_GENE/B_PERSON
during O O
these O O
developmental O O
processes O O
, O O
severe O O
eye O O
and O O
heart O O
phenotypes O O
result O O
, O O
consistent O O
with O O
a O O
conserved O O
negative O O
regulation O O
of O O
Pnr B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
function O O
. O O

These O O
results O O
indicate O O
that O O
the O O
fly O O
and O O
mouse O O
FOG B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
function O O
similarly O O
in O O
three O O
distinct O O
cellular O O
contexts O O
in O O
Drosophila O O
, O O
but O O
may O O
use O O
different O O
mechanisms O O
to O O
regulate O O
genetic O O
events O O
in O O
blood O O
vs O O
. O O
cardial O O
or O O
eye O O
cell O O
lineages O O

The O O
RING B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finger I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Siah-1 B I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulates O O
the O O
level O O
of O O
the O O
transcriptional B B_GENE
coactivator I I_GENE
OBF-1 B I_GENE
. O O

The O O
transcriptional B B_GENE/B_MEASURE
coactivator I I_GENE/I_MEASURE
OBF-1 B I_GENE/I_MEASURE
, O O
which O O
interacts O O
with O O
Oct-1 B B_GENE
and O O
Oct-2 B B_GENE
and O O
the O O
octamer B B_GENE/B_BIO
site I I_GENE/I_BIO
DNA I I_GENE/I_BIO
, O O
has O O
been O O
shown O O
to O O
be O O
critical O O
for O O
development O O
of O O
a O O
normal O O
immune O O
response O O
and O O
the O O
formation O O
of O O
germinal O O
centers O O
in O O
secondary O O
lymphoid O O
organs O O
. O O

Here O O
we O O
have O O
identified O O
the O O
RING B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finger I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Siah-1 B I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
protein O O
interacting O O
specifically O O
with O O
OBF-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
interaction O O
is O O
mediated O O
by O O
the O O
C-terminal B B_LOCATION/B_PROTEIN[GENE]
part O O
of O O
Siah-1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
by O O
residues O O
in O O
the O O
N-terminus B B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
OBF-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
partly O O
distinct O O
from O O
the O O
residues O O
required O O
for O O
formation O O
of O O
a O O
complex O O
with O O
the O O
Oct B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
POU I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
DNA O O
. O O

Interaction O O
between O O
Siah-1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
OBF-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leads O O
to O O
downregulation O O
of O O
OBF-1 O O
protein O O
level O O
but O O
not O O
mRNA O O
, O O
and O O
to O O
a O O
corresponding O O
reduction O O
in O O
octamer O O
site-dependent O O
transcription O O
activation O O
. O O

Inhibition O O
of O O
the O O
ubiquitin-proteasome O O
pathway O O
in O O
B O O
cells O O
leads O O
to O O
elevated O O
levels O O
of O O
OBF-1 B B_GENE
protein I I_GENE
. O O

Furthermore O O
, O O
in O O
immunized O O
mice O O
, O O
OBF-1 B B_GENE/B_MEASURE
protein I I_GENE/I_MEASURE
amounts O O
are O O
dramatically O O
increased O O
in O O
primary O O
activated O O
B O O
cells O O
, O O
without O O
concomitant O O
increase O O
in O O
OBF-1 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mRNA I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
data O O
suggest O O
that O O
Siah-1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
part O O
of O O
a O O
novel O O
regulatory O O
loop O O
controlling O O
the O O
level O O
of O O
OBF-1 B B_GENE
protein I I_GENE
in O O
B O O
cells O O
. O O

The O O
beta-catenin O B_GENE
-- O O
TCF-1 O O
pathway O B_LOCATION
ensures O O
CD4 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
CD8 O B_GENE
( O O
+ O B_DISEASE/B_PROTEIN[GENE]
) O O
thymocyte O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
survival O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

The O O
association O O
of O O
trans-acting B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TCFs B B_GENE/B_LOCATION
) O O
or O O
lymphoid B B_GENE/B_BIO
enhancer I I_GENE/I_BIO
factor I I_GENE/I_BIO
1 I I_GENE/I_BIO
( O O
LEF-1 B B_GENE/B_LOCATION
) O O
with O O
their O O
coactivator O O
beta-catenin O O
mediates O O
transient O O
transcriptional O O
responses O O
to O O
extracellular O O
Wnt O O
signals O O
. O O

We O O
show O O
here O O
that O O
T O O
cell O O
maturation O O
depends O O
on O O
the O O
presence O O
of O O
the O O
beta-catenin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
domain O B_LOCATION/B_GENE
is O O
necessary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
mediate O O
the O O
survival O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
immature O B_GENE
CD4 O I_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
CD8 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
double-positive O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
DP O B_PROTEIN[GENE]/B_DISEASE
) O O
thymocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

Accelerated O O
spontaneous O O
thymocyte O O
death O O
in O O
the O O
absence O O
of O O
TCF-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
correlates O O
with O O
aberrantly O O
low O O
expression O O
of O O
the O O
anti-apoptotic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Bcl-x B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
L I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Increasing O O
anti-apoptotic O O
effectors O O
in O O
thymocytes O O
by O O
the O O
use O O
of O O
a O O
Bcl-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transgene I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rescued O O
TCF-1-deficient O O
DP O O
thymocytes O O
from O O
apoptosis O O
. O O

Thus O O
, O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
upon O O
association O O
with O O
beta-catenin O O
, O O
transiently O O
ensures O O
the O O
survival O O
of O O
immature O O
T O O
cells O O
, O O
which O O
enables O O
them O O
to O O
generate O O
and O O
edit O O
T B B_GENE
cell I I_GENE
receptor I I_GENE
( I I_GENE
TCR I I_GENE
) I I_GENE
alpha I I_GENE
chains I I_GENE
and O O
attempt O O
TCR B B_GENE
-mediated O O
positive O O
selection O O
. O O

TRAIL/Apo2L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligand I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
selectively O O
induces O O
apoptosis O O
and O O
overcomes O O
drug O O
resistance O O
in O O
multiple O O
myeloma O O
: O O
therapeutic O O
applications O O
. O O

Multiple O B_DISEASE
myeloma O I_DISEASE
( O O
MM O B_LOCATION/B_DISEASE
) O O
remains O O
incurable O B_DISEASE_ADJECTIVE[DISEASE]
and O O
novel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
urgently O O
needed O O
. O O

Preclinical O O
in O O
vitro O O
and O O
in O O
vivo O O
evaluations O O
were O O
performed O O
to O O
assess O O
the O O
potential O O
therapeutic O O
applications O O
of O O
human O O
recombinant O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TNF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
apoptosis-inducing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ligand/Apo2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ligand I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TRAIL/Apo2L B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
MM O O
. O O

TRAIL/Apo2L B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
potently O O
induced O O
apoptosis O O
of O O
MM O O
cells O O
from O O
patients O O
and O O
the O O
majority O O
of O O
MM O O
cell O O
lines O O
, O O
including O O
cells O O
sensitive O O
or O O
resistant O O
to O O
dexamethasone O O
( O O
Dex O O
) O O
, O O
doxorubicin O O
( O O
Dox O O
) O O
, O O
melphalan O O
, O O
and O O
mitoxantrone O O
. O O

TRAIL/Apo2L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O O
overcame O O
the O O
survival O O
effect O O
of O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
6 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
MM O O
cells O O
and O O
did O O
not O O
affect O O
the O O
survival O O
of O O
peripheral O O
blood O O
and O O
bone O O
marrow O O
mononuclear O O
cells O O
and O O
purified O O
B O O
cells O O
from O O
healthy O O
donors O O
. O O

The O O
status O O
of O O
the O O
TRAIL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
assessed O O
by O O
immunoblotting O O
and O O
flow O O
cytometry O O
) O O
could O O
not O O
predict O O
TRAIL O O
sensitivity O O
of O O
MM O O
cells O O
. O O

The O O
anti-MM O O
activity O O
of O O
TRAIL/Apo2L B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
confirmed O O
in O O
nu/xid/bg O O
mice O O
xenografted O O
with O O
human O O
MM O O
cells O O
; O O
TRAIL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
500 O O
microg O O
intraperitoneally O O
daily O O
for O O
14 O O
days O O
) O O
was O O
well O O
tolerated O O
and O O
significantly O O
suppressed O O
the O O
growth O O
of O O
plasmacytomas O O
. O O

Dox O O
up-regulated O O
the O O
expression O O
of O O
the O O
TRAIL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
death B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DR5 B B_GENE
) O O
and O O
synergistically O O
enhanced O O
the O O
effect O O
of O O
TRAIL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
not O O
only O O
against O O
MM O O
cells O O
sensitive O O
to O O
, O O
but O O
also O O
against O O
those O O
resistant O O
to O O
, O O
Dex- O O
or O O
Dox-induced O O
apoptosis O O
. O O

Nuclear O O
factor O O
( O O
NF O O
) O O
-kappaB O O
inhibitors O O
, O O
such O O
as O O
SN50 O O
( O O
a O O
cell-permeable O O
inhibitor O O
of O O
the O O
nuclear O O
translocation O O
and O O
transcriptional O O
activity O O
of O O
NF-kappaB B B_GENE
) O O
or O O
the O O
proteasome O O
inhibitor O O
PS-341 O O
, O O
enhanced O O
the O O
proapoptotic O O
activity O O
of O O
TRAIL/Apo2L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
against O O
TRAIL-sensitive O O
MM O O
cells O O
, O O
whereas O O
SN50 O O
reversed O O
the O O
TRAIL O O
resistance O O
of O O
ARH-77 O O
and O O
IM-9 O O
MM O O
cells O O
. O O

Importantly O O
, O O
normal O O
B O O
lymphocytes O O
were O O
not O O
sensitized O O
to O O
TRAIL B B_GENE/B_DISEASE
by O O
either O O
Dox O O
, O O
SN50 O O
, O O
or O O
PS-341 O O
. O O

These O O
preclinical O O
studies O O
suggest O O
that O O
TRAIL/Apo2L B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
overcome O O
conventional O O
drug O O
resistance O O
and O O
provide O O
the O O
basis O O
for O O
clinical O O
trials O O
of O O
TRAIL B B_GENE
-based O O
treatment O O
regimens O O
to O O
improve O O
outcome O O
in O O
patients O O
with O O
MM O O
. O O

( O O
Blood. O O
2001 O B_MEASURE
; O O
98 O B_MEASURE
: O O
795-804 O B_TIME[MEASURE]
) O O

CD28 B B_GENE
costimulation O O
is O O
required O O
not O O
only O O
to O O
induce O O
IL-12 B B_GENE/B_DISEASE
receptor I I_GENE/I_DISEASE
but O O
also O O
to O O
render O O
janus B B_PERSON/B_GENE
kinases/STAT4 I I_PERSON/I_GENE
responsive O O
to O O
IL-12 B B_GENE
stimulation O O
in O O
TCR-triggered O O
T O O
cells O O
. O O

The O O
activation O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
resting O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
for O O
the O O
acquisition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
various O B_DISEASE_ADJECTIVE[DISEASE]
functions O I_DISEASE_ADJECTIVE[DISEASE]
depends O O
on O O
whether O O
CD28 O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
costimulatory O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
provided O O
upon O O
T O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
cell O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
receptor O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
. O O

Here O O
, O O
we O O
investigated O O
how O O
CD28 O O
costimulation O O
functions O O
to O O
allow O O
TCR B B_GENE/B_DISEASE
-triggered O O
resting O O
T O O
cells O O
to O O
acquire O O
IL-12 B B_GENE/B_MEASURE
responsiveness O O
. O O

When O O
T O O
cells O O
are O O
stimulated O O
with O O
low O O
doses O O
of O O
anti-CD3 B B_GENE
mAb I I_GENE
, O O
CD28 O O
costimulation O O
was O O
required O O
for O O
the O O
optimal O O
levels O O
of O O
IL-12 B B_GENE
receptor I I_GENE
( O O
IL-12R B B_PROTEIN[GENE]/B_LOCATION
) O O
expression O O
. O O

However O O
, O O
stimulation O O
of O O
T O O
cells O O
with O O
high O O
doses O O
of O O
anti-CD3 B B_GENE
alone O O
induced O O
comparable O O
levels O O
of O O
IL-12R B B_GENE
expression O O
to O O
those O O
induced O O
upon O O
CD28 O O
costimulation O O
. O O

Nevertheless O O
, O O
there O O
was O O
a O O
substantial O O
difference O O
in O O
IL-12 B B_GENE/B_PERSON
responsiveness O O
between O O
these O O
two O O
groups O O
of O O
T O O
cells O O
: O O
compared O O
to O O
anti-CD28-costimulated O O
T O O
cells O O
, O O
T O O
cells O O
that O O
were O O
not O O
costimulated O O
with O O
anti-CD28 B B_GENE
exhibited O O
decreased O O
levels O O
of O O
Janus B B_GENE
kinases I I_GENE
( O O
JAK B B_GENE
) O O
JAK2/TYK2 B B_GENE/B_MEASURE
and O O
STAT4 B B_GENE
phosphorylation O O
and O O
IFN-y O O
production O O
following O O
IL-12 B B_GENE
stimulation O O
. O O

Importantly O O
, O O
STAT6 O B_GENE/B_DISEASE
phosphorylation O I_GENE/I_DISEASE
following O O
IL-4 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
was O O
not O O
decreased O O
in O O
anti-CD28-uncostimulated O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
resutls O O
indicate O O
that O O
CD28 O O
costimulation O O
not O O
only O O
contributes O O
to O O
up-regulating O O
IL-12R B B_GENE
expression O O
but O O
is O O
also O O
required O O
to O O
render O O
JAKs/STAT4 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
responsive O O
to O O
IL-12 B B_GENE
stimulation O O
. O O

Constitutively O O
activated O O
Akt-1 B B_GENE
is O O
vital O O
for O O
the O O
survival O O
of O O
human O O
monocyte-differentiated O O
macrophages O O
. O O

Role O O
of O O
Mcl-1 B B_GENE
, O O
independent O O
of O O
nuclear B B_GENE
factor I I_GENE
( I I_GENE
NF I I_GENE
) I I_GENE
-kappaB I I_GENE
, O O
Bad B B_GENE
, O O
or O O
caspase O O
activation O O
. O O

Recent O O
data O O
from O O
mice O O
deficient O O
for O O
phosphatase B B_GENE/B_DISEASE
and O O
tensin B B_GENE/B_LOCATION
homologue I I_GENE/I_LOCATION
deleted O O
from O O
chromosome B B_GENE
10 I I_GENE
or O O
src B B_MEASURE
homology I I_MEASURE
2 I I_MEASURE
domain-containing I I_MEASURE
5 I I_MEASURE
' I I_MEASURE
inositol I I_MEASURE
phosphatase I I_MEASURE
, O O
phosphatases B B_ENZYME[GENE]/B_BIO
that O O
negatively O O
regulate O O
the O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3-kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI3K B B_GENE/B_LOCATION
) O O
pathway O O
, O O
revealed O O
an O O
increased O O
number O O
of O O
macrophages O O
in O O
these O O
animals O O
, O O
suggesting O O
an O O
essential O O
role O O
for O O
the O O
PI3K B B_GENE
pathway O O
for O O
macro-phage O O
survival O O
. O O

Here O O
, O O
we O O
focused O O
on O O
the O O
role O O
of O O
the O O
PI3K-regulated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serine/threonine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Akt-1 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
modulating O O
macrophage O O
survival O O
. O O

Akt-1 B B_GENE
was O O
constitutively O O
activated O O
in O O
human O O
macrophages O O
and O O
addition O O
of O O
the O O
PI3K B B_GENE
inhibitor O O
, O O
LY294002 O O
, O O
suppressed O O
the O O
activation O O
of O O
Akt-1 B B_GENE
and O O
induced O O
cell O O
death O O
. O O

Furthermore O O
, O O
suppression O O
of O O
Akt-1 B B_GENE
by O O
inhibition O O
of O O
PI3K B B_GENE
or O O
a O O
dominant B B_GENE
negative I I_GENE
( I I_GENE
DN I I_GENE
) I I_GENE
Akt-1 I I_GENE
resulted O O
in O O
loss O O
of O O
mitochondrial O O
transmembrane O O
potential O O
, O O
activation O O
of O O
caspases-9 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
DNA O O
fragmentation O O
. O O

The O O
effects O O
of O O
PI3K B B_GENE
inhibition O O
were O O
reversed O O
by O O
the O O
ectopic O O
expression O O
of O O
constitutively O O
activated O O
Akt-1 B B_GENE
or O O
Bcl-x B B_GENE
( I I_GENE
L I I_GENE
) I I_GENE
. O O

Inhibition O O
of O O
PI3K B B_GENE
/Akt-1 O O
pathway O O
either O O
by O O
LY294002 O O
or O O
DN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Akt-1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
had O O
no O O
effect O O
on O O
the O O
constitutive O O
or O O
inducible O O
activation O O
of O O
nuclear B B_GENE
factor I I_GENE
( I I_GENE
NF I I_GENE
) I I_GENE
-kappaB I I_GENE
in O O
human O O
macrophages O O
. O O

However O O
, O O
after O O
inhibition O O
of O O
the O O
PI3K B B_GENE
/ O O
Akt-1 B B_GENE
pathway O O
, O O
a O O
marked O O
decrease O O
in O O
the O O
expression O O
of O O
the O O
antiapoptotic B B_GENE
molecule I I_GENE
Mcl-1 B I_GENE
, O O
but O O
not O O
other O O
Bcl-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
members I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
observed O O
, O O
and O O
Mcl-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
rescued O O
macrophages O O
from O O
LY294002-induced O O
cell O O
death O O
. O O

Further O O
, O O
inhibition O O
of O O
Mcl-1 B B_GENE
by O O
antisense O O
oligonucleotides O O
, O O
also O O
resulted O O
in O O
macrophage O O
apoptosis O O
. O O

Thus O O
, O O
our O O
findings O O
demonstrate O O
that O O
the O O
constitutive O O
activation O O
of O O
Akt-1 B B_GENE
regulates O O
macrophage O O
survival O O
through O O
Mcl-1 B B_GENE/B_DISEASE
, O O
which O O
is O O
independent O O
of O O
caspases B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
NF-kappaB B B_GENE
, O O
or O O
Bad B B_GENE
. O O

GRbeta O B_GENE
expression O I_GENE
in O O
nasal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
polyp O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
inflammatory O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cells O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
its O O
relationship O B_PERSON
to O O
the O O
anti-inflammatory O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
intranasal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluticasone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Nasal O B_DISEASE
polyposis O I_DISEASE
disease O I_DISEASE
is O O
an O O
inflammatory O B_DISEASE/B_LOCATION
disorder O I_DISEASE/I_LOCATION
with O O
intense O B_DISEASE
eosinophilic O I_DISEASE
infiltration O I_DISEASE
of O O
respiratory O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mucosa O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O O
is O O
often O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
control O O
with O O
topical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
steroids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Recent O O
evidence O O
suggests O O
that O O
overexpression O O
of O O
the O O
glucocorticoid B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
splice I I_GENE/I_LOCATION
variant I I_GENE/I_LOCATION
GRbeta B I_GENE/I_LOCATION
in O O
inflammatory O O
cells O O
might O O
contribute O O
to O O
steroid O O
insensitivity O O
in O O
diseases O O
such O O
as O O
asthma O O
. O O

OBJECTIVE O O
: O O
The O O
purposes O O
of O O
this O O
investigation O O
were O O
to O O
determine O O
whether O O
nasal O O
polyp O O
( O O
NP O O
) O O
inflammatory O O
cells O O
overexpress O O
GRbeta B B_GENE
and O O
to O O
examine O O
whether O O
GRbeta B B_GENE/B_PERSON
overexpression O O
is O O
associated O O
with O O
insensitivity O O
to O O
the O O
potent O O
topical O O
steroid O O
fluticasone O O
propionate O O
( O O
FP O O
) O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Biopsies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
obtained O O
from O O
10 O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
with O O
NPs O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
and O O
4 O B_NUMBER[MEASURE]/B_ENT
weeks O I_NUMBER[MEASURE]/I_ENT
after O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
intranasal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Middle O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
turbinates O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biopsies O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
6 O B_PERSON
healthy O I_PERSON
, O O
nonallergic O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
served O O
as O O
normal O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Biopsies O O
were O O
immunostained O O
for O O
inflammatory O O
cell O O
markers O O
as O O
well O O
as O O
GRbeta B B_GENE
and O O
probed O O
for O O
various O O
cytokine B B_GENE
mRNA I I_GENE
. O O

The O O
anti-inflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
FP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
examined O O
in O O
relation O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
pretreatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
GRbeta O B_GENE
expression O I_GENE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O O
The O O
total O B_MEASURE
numbers O I_MEASURE
of O O
inflammatory O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O O
increased O O
in O O
NPs O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
percentage O O
of O O
inflammatory O O
cells O O
expressing O O
GRbeta B B_GENE
was O O
also O O
increased O O
( O O
40.5 O O
% O O
+/- O O
19.2 O O
% O O
vs O O
16.1 O O
% O O
+/- O O
4.0 O O
% O O
, O O
P O O
=.009 O O
) O O
. O O

GRbeta B B_GENE
expression O O
in O O
NPs O O
was O O
almost O O
exclusive O O
to O O
T O O
lymphocytes O O
, O O
eosinophils O O
, O O
and O O
macrophages O O
. O O

An O O
inverse O O
correlation O O
was O O
observed O O
between O O
the O O
baseline O O
inflammatory O O
cell O O
GRbeta B B_GENE/B_MEASURE
expression O O
and O O
the O O
reduction O O
after O O
FP O O
treatment O O
in O O
EG2-positive O O
eosinophils O O
, O O
CD4-positive O O
T O O
lymphocytes O O
, O O
endothelial O O
VCAM-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
, O O
and O O
IL-4 O O
mRNA-positive O O
cells O O
. O O

NPs O O
that O O
were O O
`` O O
FP-insensitive O O
'' O O
in O O
terms O O
of O O
suppression O O
of O O
eosinophil O O
numbers O O
( O O
major B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
basic I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
-positive O O
) O O
had O O
a O O
significantly O O
greater O O
percentage O O
of O O
GRbeta-positive O O
inflammatory O O
cells O O
, O O
a O O
higher O O
ratio O O
of O O
GRbeta-positive/GRalpha-positive O O
cells O O
, O O
and O O
increased O O
numbers O O
of O O
GRbeta-positive O O
eosinophils O O
and O O
macrophages O O
in O O
comparison O O
with O O
those O O
that O O
were O O
`` O O
FP-sensitive. O O
'' O O

`` O O
FP-insensitive O O
'' O O
NPs O O
also O O
demonstrated O O
a O O
higher O O
percentage O O
of O O
IL-5-positive O O
inflammatory O O
cells O O
expressing O O
GRbeta B B_GENE
before O O
and O O
after O O
FP O O
treatment O O
. O O

CONCLUSION O O
: O O
GRbeta B B_GENE/B_LOCATION
expression O O
appears O O
to O O
be O O
a O O
marker O O
of O O
steroid O O
insensitivity O O
in O O
NPs O O
. O O

Expression O O
of O O
GRbeta B B_GENE
by O O
NP O O
inflammatory O O
cells O O
, O O
particularly O O
T O O
cells O O
and O O
eosinophils O O
, O O
might O O
render O O
them O O
resistant O O
to O O
suppression O O
by O O
topical O O
steroids O O
and O O
thereby O O
contribute O O
to O O
persistent O O
NP O O
inflammation O O
. O O

Transcriptional O O
regulation O O
of O O
galectin-10 B B_GENE/B_DISEASE
( O O
eosinophil B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Charcot-Leyden I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
crystal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
: O O
a O O
GC B B_GENE/B_LOCATION
box I B_GENE/I_LOCATION
( O O
-44 O O
to O O
-50 O O
) O O
controls O O
butyric O O
acid O O
induction O O
of O O
gene O O
expression O O
. O O

Galectin-10 B B_GENE
( O O
gal-10 B B_GENE/B_DISEASE
, O O
also O O
known O O
as O O
Charcot-Leyden B B_GENE/B_DISEASE
crystal I I_GENE/I_DISEASE
protein I I_GENE/I_DISEASE
) O O
is O O
a O O
member O O
of O O
the O O
galectin B B_PERSON/B_BIO
family I I_PERSON/I_BIO
of O O
beta-galactoside B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
is O O
expressed O O
uniquely O O
in O O
eosinophilic O O
and O O
basophilic O O
leukocytes O O
. O O

To O O
gain O O
a O O
better O O
understanding O O
of O O
galectin O O
gene O O
expression O O
, O O
we O O
present O O
an O O
analysis O O
of O O
the O O
transcriptional O O
regulation O O
of O O
the O O
gene O O
encoding O O
gal-10 B B_GENE
. O O

Analysis O O
of O O
the O O
minimal B B_GENE/B_LOCATION
promoter I B_GENE/I_LOCATION
revealed O O
nine O O
consensus-binding B B_LOCATION/B_PERSON
sites I I_LOCATION/I_PERSON
for O O
transcription B B_GENE/B_MEASURE
factors I I_GENE/I_MEASURE
, O O
including O O
several O O
that O O
are O O
also O O
found O O
in O O
the O O
minimal B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
galectins B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
-1 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
-2 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
-3 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
decrease O O
in O O
gal-10 O O
promoter O O
activity O O
after O O
disruption O O
of O O
either O O
the O O
GC B B_GENE
box I I_GENE
( O O
-44 O O
to O O
-50 O O
) O O
or O O
the O O
Oct B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
-255 O O
to O O
-261 O O
) O O
suggests O O
that O O
these O O
sites O O
, O O
along O O
with O O
the O O
previously O O
characterized O O
GATA B B_LOCATION/B_ORGANIZATION
and I I_LOCATION/I_ORGANIZATION
EoTF I I_LOCATION/I_ORGANIZATION
sites I I_LOCATION/I_ORGANIZATION
, O O
are O O
necessary O O
for O O
full O O
promoter O O
activity O O
. O O

By O O
supershift O O
analysis O O
, O O
we O O
demonstrate O O
binding O O
of O O
the O O
transcription B B_GENE
factors I I_GENE
Sp1 B I_GENE
and O O
Oct1 B B_GENE/B_LOCATION
to O O
the O O
consensus B B_GENE/B_LOCATION
GC I I_GENE/I_LOCATION
box I I_GENE/I_LOCATION
and O O
the O O
Oct B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
. O O

Similar O O
to O O
gal-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
gal-10 O O
expression O O
is O O
induced O O
by O O
butyric O O
acid O O
, O O
an O O
effect O O
that O O
is O O
lost O O
upon O O
ablation O O
of O O
the O O
GC B B_GENE
box I I_GENE
. O O

Additionally O O
, O O
we O O
demonstrate O O
AML3 O O
binding O O
to O O
the O O
consensus B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AML I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
YY1 B B_TIME[MEASURE]/B_GENE
binding I I_TIME[MEASURE]/I_GENE
to O O
the O O
Inr B B_LOCATION/B_GENE
sequence I I_LOCATION/I_GENE
, O O
both O O
elements O O
functioning O O
as O O
silencers O O
in O O
the O O
gal-10 B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
promoter I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Tumour-stromal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interactions O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Role O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
stroma O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
in O O
mammary O B_DISEASE
development O I_DISEASE
. O O

Mammary O B_DISEASE_ADJECTIVE[DISEASE]
development O I_DISEASE_ADJECTIVE[DISEASE]
depends O O
on O O
branching O O
morphogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O O
namely O O
the O O
bifurcation O B_DISEASE/B_ORGANIZATION
and O O
extension O B_TIME[MEASURE]/B_DISEASE
of O O
ductal O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
points O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
end O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
buds O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
secretory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
lobules O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
into O O
a O O
more O O
or O O
less O O
fatty O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
stroma O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O O

Because O O
breast O B_DISEASE/B_PERSON
carcinomas O I_DISEASE/I_PERSON
are O O
overwhelmingly O O
ductal O B_BODY_PART_OR_ORGAN_COMPONENT
in O O
origin O B_DISEASE/B_LOCATION
, O O
this O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
focuses O O
on O O
stromal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
influences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
guiding O O
postnatal O B_DISEASE/B_ORGANISM_FUNCTION
ductal O I_DISEASE/I_ORGANISM_FUNCTION
development O I_DISEASE/I_ORGANISM_FUNCTION
and O O
there O O
is O O
only O O
the O O
briefest O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
account O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
embryonic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stroma O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
mesenchyme O B_MEASURE/B_PROTEIN[GENE]
) O O
. O O

The O O
stroma O B_BODY_PART_OR_ORGAN_COMPONENT
as O O
the O O
necessary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
target O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O O
endocrine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
mammogens O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O O
the O O
source O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
stimulatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
growth O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
described O O
and O O
the O O
importance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mammary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
epithelium-induced O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
modifications O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
periductal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
stroma O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
emphasized O O
. O O

Evidence O O
is O O
presented O O
that O O
if O O
they O O
are O O
to O O
grow O O
, O O
end O O
buds O O
must O O
condition O O
proximal O O
fatty O O
stroma O O
by O O
recruiting O O
white O O
blood O O
cells O O
as O O
well O O
as O O
inducing O O
stromal O O
cell O O
division O O
and O O
, O O
possibly O O
, O O
estrogen B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
induction O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
fibrous O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
stromal O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
tunic O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
around O O
the O O
end O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bud O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
described O O
and O O
its O O
likely O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ductal O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
morphogen O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
discussed O O
; O O
a O O
possible O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
growth O B_DISEASE/B_ORGANISM_FUNCTION
inhibition O B_DISEASE/I_ORGANISM_FUNCTION
is O O
also O O
considered O O
. O O

Although O O
the O O
signals O O
governing O O
fibrotic O O
induction O O
, O O
ductal O O
morphogenesis O O
, O O
and O O
growth O O
inhibition O O
are O O
unknown O O
, O O
a O O
role O O
for O O
transforming O O
growth B B_GENE
factor-beta I I_GENE
is O O
highly O O
likely O O
and O O
is O O
discussed O O
. O O

Finally O O
, O O
a O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
new O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conceptual O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
experimental O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
approaches O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
understanding O O
stromal-epithelial O B_DISEASE
signaling O I_DISEASE
is O O
discussed O O
. O O

Adipophilin B B_GENE
is O O
a O O
sensitive O O
marker O O
for O O
lipid O O
loading O O
in O O
human O O
blood O O
monocytes O O
. O O

Adipophilin B B_GENE
, O O
a O O
marker O O
of O O
lipid O O
accumulation O O
initially O O
described O O
in O O
adipocytes O O
, O O
was O O
recently O O
shown O O
to O O
be O O
induced O O
in O O
macrophage O O
foam O O
cells O O
. O O

We O O
found O O
that O O
even O O
freshly O O
isolated O O
blood O O
monocytes O O
express O O
adipophilin B B_GENE
and O O
that O O
the O O
amount O O
of O O
adipophilin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
variable O O
in O O
monocytes O O
from O O
different O O
healthy O O
individuals O O
. O O

However O O
, O O
the O O
physiological O O
expression O O
of O O
adipophilin B B_GENE/B_DISEASE
does O O
not O O
correlate O O
with O O
the O O
levels O O
of O O
free O O
fatty O O
acids O O
, O O
cholesterylesters O O
or O O
free O O
cholesterol O O
. O O

Enzymatically B B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
modified I I_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
low-density I I_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
lipoprotein I I_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
( O O
E-LDL B B_PROTEIN[GENE]/B_LOCATION
) O O
induces O O
rapid O O
foam O O
cell O O
formation O O
in O O
monocytes O O
and O O
upregulates O O
adipophilin B B_GENE
mRNA O O
and O O
protein O O
within O O
2 O O
h O O
of O O
incubation O O
. O O

This O O
rapid O O
induction O O
of O O
adipophilin B B_GENE
is O O
accompanied O O
by O O
a O O
significant O O
increase O O
of O O
free O O
fatty O O
acids O O
in O O
monocytes O O
incubated O O
with O O
E-LDL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Adipophilin B B_GENE/B_DISEASE
facilitates O O
the O O
uptake O O
of O O
free O O
fatty O O
acids O O
, O O
and O O
here O O
we O O
demonstrate O O
that O O
free O O
fatty O O
acids O O
increase O O
is O O
related O O
to O O
the O O
early O O
upregulation O O
of O O
adipophilin O O
expression O O
in O O
blood O O
monocytes O O
. O O

Fatty O O
acids O O
are O O
ligands O O
for O O
peroxisome B B_GENE/B_LOCATION
proliferator-activated I I_GENE/I_LOCATION
receptor-gamma I I_GENE/I_LOCATION
( O O
PPARgamma B B_GENE
) O O
, O O
and O O
the O O
upregulation O O
of O O
adipophilin B B_GENE
mRNA I I_GENE
by O O
PPARgamma B B_GENE
agonists O O
like O O
15d-PGJ O O
( O O
2 O O
) O O
and O O
ciglitazone O O
indicates O O
that O O
PPARgamma B B_GENE/B_PERSON
may O O
mediate O O
the O O
induction O O
of O O
adipophilin O O
expression O O
in O O
human O O
blood O O
monocytes O O
. O O

Constitutive O O
expression O O
of O O
MHC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
melanoma O O
cell O O
lines O O
results O O
from O O
the O O
transcription O O
of O O
class B B_GENE/B_LOCATION
II I I_GENE/I_LOCATION
transactivator I I_GENE/I_LOCATION
abnormally O O
initiated O O
from O O
its O O
B B B_GENE/B_PERSON
cell-specific I I_GENE/I_PERSON
promoter I I_GENE/I_PERSON
. O O

In O O
melanoma O O
cell O O
lines O O
, O O
two O O
different O O
patterns O O
of O O
MHC O O
class O O
II O O
expression O O
have O O
been O O
described O O
, O O
either O O
an O O
IFN O O
gamma-inducible O O
expression O O
of O O
HLA-DR B B_GENE
and O O
HLA-DP B B_PROTEIN[GENE]/B_LOCATION
, O O
with O O
a O O
faint O O
or O O
null O O
expression O O
of O O
HLA-DQ B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
resembling O O
that O O
described O O
for O O
melanocytes O O
, O O
or O O
a O O
constitutive O O
expression O O
, O O
i.e. O O
, O O
IFN-gamma O O
independent O O
, O O
of O O
all O O
three O O
HLA-D B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isotypes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
this O O
latter O B_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
associated O O
with O O
a O O
more O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
progression O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
melanoma O B_DISEASE
tumors O I_DISEASE
, O O
we O O
have O O
analyzed O O
in O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
melanoma O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
lines O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
the O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leading O O
to O O
this O O
abnormal O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
MHC O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
class O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
II O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

In O O
agreement O O
with O O
the O O
evidence O O
of O O
a O O
coordinate O O
transcription O O
of O O
the O O
HLA-D B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
these O O
cell O O
lines O O
, O O
we O O
have O O
shown O O
the O O
constitutive O O
expression O O
of O O
CIITA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transactivator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
CIITA B B_TIME[MEASURE]/B_LOCATION
being O O
known O O
as O O
the O O
master O O
switch O O
of O O
MHC O O
class O O
II O O
expression O O
. O O

Unexpectedly O O
, O O
these O O
transcripts O O
initiate O O
from O O
promoter B B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_LOCATION
III I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_LOCATION
of O O
the O O
CIITA B B_GENE
gene I I_GENE
, O O
a O O
promoter O O
that O O
is O O
mainly O O
used O O
constitutively O O
in O O
B O O
lymphocytes O O
. O O

This O O
expression O O
was O O
further O O
shown O O
to O O
occur O O
through O O
factor O O
( O O
s O O
) O O
acting O O
on O O
the O O
enhancer O O
located O O
upstream O O
of O O
CIITA B B_GENE
promoter I I_GENE
III I I_GENE
, O O
which O O
was O O
previously O O
described O O
in O O
epithelioid O O
cells O O
as O O
an O O
IFN-gamma-response O O
sequence O O
. O O

The O O
hypothesis O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
general O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
abnormality O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
IFN-gamma O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
transduction O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
dismissed O O
. O O

Constitutive O O
transcription O O
of O O
CIITA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
promoter B B_GENE
III I I_GENE
having O O
been O O
observed O O
in O O
unrelated O O
melanoma O O
cell O O
lines O O
, O O
we O O
propose O O
the O O
hypothesis O O
that O O
this O O
phenomenon O O
might O O
not O O
be O O
a O O
random O O
event O O
, O O
but O O
could O O
be O O
linked O O
to O O
the O O
neoplasic O O
state O O
of O O
the O O
melanoma O O
cells O O

Caspase B B_GENE
-mediated O O
calcineurin O O
activation O O
contributes O O
to O O
IL-2 B B_GENE
release O O
during O O
T O O
cell O O
activation O O
. O O

Calcineurin B B_GENE
, O O
a O O
Ca B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2+ I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/calmodulin-dependent I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Ser/Thr I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2B I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
plays O O
a O O
critical O O
role O O
in O O
IL-2 O O
production O O
during O O
T O O
cell O O
activation O O
. O O

It O O
has O O
been O O
previously O O
reported O O
that O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release O O
in O O
activated O O
Jurkat O O
T O O
requires O O
caspase-like O O
activity O O
( O O
Posmantur O O
et O O
al. O O
( O O
1998 O O
) O O
Exp. O O
Cell. O O
Res. O O
244 O O
, O O
302-309 O O
) O O
. O O

We O O
report O O
here O O
that O O
the O O
60-kDa B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
catalytic I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
calcineurin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Cn B B_LOCATION/B_PROTEIN[GENE]
A I I_LOCATION/I_PROTEIN[GENE]
) O O
was O O
partially O O
cleaved O O
to O O
a O O
45-kDa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
form O O
in O O
phytohemagglutinin O O
A O O
( O O
PHA O O
) O O
or O O
phorbol O O
ester O O
+ O O
ionomycin O O
( O O
P O O
+ O O
I O O
) O O
-activated O O
Jurkat O O
cells O O
. O O

In O O
parallel O O
, O O
proteolytic O O
activation O O
of O O
upstream O O
caspases B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
caspase-8 O O
and O O
-9 O O
) O O
as O O
well O O
as O O
effector B B_GENE
caspase-3 I I_GENE
was O O
also O O
observed O O
. O O

Cn B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cleavage O O
was O O
caspase O O
mediated O O
, O O
since O O
it O O
was O O
inhibitable O O
by O O
pan-caspase O O
inhibitor O O
Cbz-Asp-CH O O
( O O
2 O O
) O O
OC O O
( O O
O O O
) O O
-2 O O
, O O
6-dichlorobenzene O O
( O O
Z-D-DCB O O
) O O
. O O

Cn B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
A I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cleavage O O
was O O
also O O
observed O O
when O O
purified O O
calcineurin B B_GENE/B_DISEASE
was O O
digested O O
in O O
vitro O O
with O O
caspase-3 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Truncated B B_DISEASE/B_MEASURE
Cn I I_DISEASE/I_MEASURE
A I I_DISEASE/I_MEASURE
was O O
associated O O
with O O
enhanced O O
phosphatase O O
activity O O
and O O
reduced O O
calmodulin O O
sensitivity O O
. O O

Furthermore O O
, O O
in O O
PHA O O
or O O
P O O
+ O O
I-activated O O
Jurkat O O
cells O O
, O O
dephosphorylation O O
of O O
calcineurin B B_GENE
substrate O O
NFATc B B_GENE
( O O
a O O
transcription B B_ENZYME[GENE]/B_MEASURE
factor I I_ENZYME[GENE]/I_MEASURE
known O O
to O O
be O O
involved O O
in O O
transactivation O O
of O O
the O O
IL-2 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
) O O
, O O
was O O
also O O
suppressed O O
by O O
Z-D-DCB O O
. O O

Taken O O
together O O
, O O
our O O
results O O
suggest O O
that O O
caspase-mediated O O
cleavage O O
of O O
Cn B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contributes O O
to O O
IL-2 O O
production O O
during O O
T O O
cell O O
activation O O
. O O

Copyright O B_LOCATION/B_PERSON
2001 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Maturation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
human O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dendritic O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
sulfasalazine O B_DISEASE_ADJECTIVE[DISEASE]
target O I_DISEASE_ADJECTIVE[DISEASE]
. O O

AIM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Sulfasalazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
nonsteroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti-inflammatory O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
effective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
treating O O
some O O
autoimmune O B_DISEASE
diseases O I_DISEASE
, O O
but O O
its O O
mechanism O B_LOCATION
of O O
action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O O
unclear O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
determine O O
whether O O
dendritic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
could O O
be O O
a O O
possible O B_PERSON/B_LOCATION
target O I_PERSON/I_LOCATION
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
studied O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sulfasalazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
metabolites O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
aminosalicylate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sulfapyridine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
on O O
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
maturation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
( O O
terminal O B_DISEASE/B_LOCATION
differentiation O B_DISEASE/I_LOCATION
) O O
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
myeloid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
dendritic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

METHODS O O
: O O
We O O
prepared O O
immature O O
dendritic O O
cells O O
by O O
incubating O O
CD14-positive O O
cells O O
in O O
the O O
presence O O
of O O
granulocyte- B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
macrophage I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IL I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
cells O O
were O O
matured O O
by O O
addition O O
of O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TNF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-a I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
IL-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
presence O O
of O O
sulfasalazine O O
or O O
its O O
metabolites O O
-- O O
aminosalicylate O O
and O O
sulfapyridine O O
, O O
or O O
their O O
combinations O O
. O O

We O O
quantified O O
the O O
effect O O
of O O
drugs O O
on O O
the O O
dendritic O O
cell O O
characteristics O O
, O O
such O O
as O O
stimulation O O
of O O
autologous O O
and O O
allogeneic O O
pan-T O O
cell O O
proliferation O O
, O O
surface O O
marker O O
phenotype O O
, O O
IL-12 O O
p40 O O
subunit O O
secretion O O
, O O
and O O
activation O O
of O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O O
Dendritic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
treated O O
with O O
sulfasalazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
1.25 O B_MEASURE
micromol/L O I_MEASURE
or O O
2.5 O B_MEASURE
micromol/L O I_MEASURE
) O O
could O O
not O O
stimulate O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
( O O
p O B_MEASURE
< O I_MEASURE
0.028 O I_MEASURE
, O O
two-sided O O
paired O O
t-test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

In O O
distinction O O
to O O
drug-free O O
maturing O O
dendritic O O
cells O O
, O O
2.5 O O
micromol/L O O
sulfasalazine O O
upregulated O O
the O O
levels O O
of O O
CD14 B B_GENE
and O O
CD68 B B_GENE
and O O
downregulated O O
the O O
levels O O
of O O
CD40 B B_GENE
, O O
CD80 B B_GENE
, O O
and O O
CD83 B B_GENE
( O O
for O O
all O O
CD O O
markers O O
, O O
p O O
< O O
0.03 O O
for O O
difference O O
between O O
measurements O O
in O O
the O O
absence O O
and O O
the O O
presence O O
of O O
sulfasalazine O O
) O O
. O O

From O O
concentration-dependent O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
CD83 O B_GENE/B_MEASURE
expression O B_GENE/I_MEASURE
, O O
we O O
found O O
an O O
apparent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ID50 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1.5 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
micromol/L O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfasalazine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
apparent O B_MEASURE
ID50 O I_MEASURE
value O I_MEASURE
for O O
aminosalicylate-inhibited O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
maturation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
4 O B_MEASURE
micromol/L O I_MEASURE
. O O

Sulfapyridine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O O
no O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

At O O
1.25 O B_TIME[MEASURE]/B_PERSON
micromol/L O I_TIME[MEASURE]/I_PERSON
, O O
sulfasalazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
largely O O
inhibited O O
NF-kB O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O O
dendritic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Maturing O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
dendritic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
are O O
hundred-fold O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
more O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
to O O
sulfasalazine O O
than O O
T O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
NK O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
most O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
described O O
so O O
far O O
. O O

Thus O O
, O O
dendritic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
maturation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sulfasalazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Because O O
of O O
the O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
dendritic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
( O O
auto O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
immunity O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
inhibition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
their O O
maturation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
might O O
provide O O
a O O
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
for O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
optimization O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sulfasalazine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Defective O O
function O O
of O O
the O O
proteasome B B_GENE
in O O
autoimmunity O O
: O O
involvement O O
of O O
impaired O O
NF-kappaB O O
activation O O
. O O

Type O O
1 O O
diabetes O O
( O O
also O O
known O O
as O O
insulin-dependent O O
diabetes O O
mellitus O O
or O O
juvenile-onset O O
diabetes O O
) O O
is O O
usually O O
caused O O
by O O
T O O
cell-mediated O O
autoimmunity O O
, O O
with O O
a O O
prediabetic O O
state O O
characterized O O
by O O
the O O
production O O
of O O
autoantibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
specific O O
for O O
proteins O O
expressed O O
by O O
pancreatic O O
beta O O
cells O O
. O O

The O O
nonobese O O
patient O O
with O O
diabetes O O
( O O
NOD O O
) O O
mouse O O
is O O
a O O
spontaneous O O
model O O
of O O
type O O
1 O O
diabetes O O
with O O
a O O
strong O O
genetic O O
component O O
that O O
maps O O
to O O
the O O
major B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
histocompatibility I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
complex I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
MHC I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
the O O
genome B B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

A O O
specific O O
proteasome B B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
defect O O
has O O
been O O
identified O O
in O O
NOD O O
mouse O O
in O O
select O O
lymphocytic O O
and O O
monocytic O O
lineages O O
that O O
results O O
from O O
down-regulation O O
of O O
expression O O
of O O
the O O
proteasome B B_GENE/B_MEASURE
subunit I I_GENE/I_MEASURE
LMP2 I I_GENE/I_MEASURE
, O O
which O O
is O O
encoded O O
by O O
a O O
gene O O
in O O
the O O
MHC B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
genomic I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
region I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
defect O O
prevents O O
the O O
proteolytic O O
processing O O
required O O
for O O
the O O
production O O
and O O
activation O O
of O O
the O O
transcription B B_GENE
factor I I_GENE
nuclear I I_GENE
factor-kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
, O O
which O O
plays O O
important O O
roles O O
in O O
immune O O
and O O
inflammatory O O
responses O O
, O O
as O O
well O O
as O O
increases O O
the O O
susceptibility O O
of O O
the O O
affected O O
cells O O
to O O
apoptosis O O
induced O O
by O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necrosis I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor-alpha I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
novel O O
role O O
of O O
the O O
proteasome B B_BODY_PART_OR_ORGAN_COMPONENT/B_ENZYME[GENE]
in O O
dysfunction O O
in O O
autoimmunity O O
is O O
presented O O
and O O
documented O O
to O O
be O O
both O O
tissue O O
and O O
developmental O O
stage O O
specific O O
. O O

We O O
propose O O
a O O
role O O
of O O
the O O
proteasome B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
as O O
a O O
step O O
in O O
disease O O
pathogenesis O O
and O O
tissue O O
targeting O O
. O O

Down-regulation O O
of O O
TDT O O
transcription O O
in O O
CD4 O O
( O O
+ O O
) O O
CD8 O O
( O O
+ O O
) O O
thymocytes O O
by O O
Ikaros B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
direct O O
competition O O
with O O
an O O
Ets B B_GENE/B_LOCATION
activator I I_GENE/I_LOCATION
. O O

Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
unique O O
regulator O O
of O O
lymphopoiesis O O
that O O
associates O O
with O O
pericentromeric B B_GENE
heterochromatin I I_GENE
and O O
has O O
been O O
implicated O O
in O O
heritable O O
gene O O
inactivation O O
. O O

Binding O O
and O O
competition O O
experiments O O
demonstrate O O
that O O
Ikaros B B_PERSON/B_GENE
dimers I I_PERSON/I_GENE
compete O O
with O O
an O O
Ets B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
occupancy O O
of O O
the O O
lymphocyte-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
TdT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Mutations O O
that O O
selectively O O
disrupt O O
Ikaros O O
binding O O
to O O
an O O
integrated B B_GENE/B_MEASURE
TdT I I_GENE/I_MEASURE
promoter I I_GENE/I_MEASURE
had O O
no O O
effect O O
on O O
promoter O O
function O O
in O O
a O O
CD4 O O
( O O
+ O O
) O O
CD8 O O
( O O
+ O O
) O O
thymocyte O O
line O O
. O O

However O O
, O O
these O O
mutations O O
abolished O O
down-regulation O O
on O O
differentiation O O
, O O
providing O O
evidence O O
that O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plays O O
a O O
direct O O
role O O
in O O
repression O O
. O O

Reduced O O
access O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
restriction O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzyme O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cleavage O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
suggested O O
that O O
chromatin O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alterations O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accompany O O
down-regulation O B_DISEASE
. O O

The O O
Ikaros-dependent O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
down-regulation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
event O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
and O O
the O O
observed O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatin O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alterations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
appear O O
to O O
precede O O
pericentromeric O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repositioning O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Current O O
models O O
propose O O
that O O
the O O
functions O O
of O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
should O O
be O O
disrupted O O
by O O
a O O
small O O
isoform B B_GENE/B_LOCATION
that O O
retains O O
the O O
dimerization B B_GENE
domain I I_GENE
and O O
lacks O O
the O O
DNA-binding B B_GENE
domain I I_GENE
. O O

Surprisingly O O
, O O
in O O
the O O
CD4 O O
( O O
+ O O
) O O
CD8 O O
( O O
+ O O
) O O
thymocyte O O
line O O
, O O
overexpression O O
of O O
a O O
small B B_GENE
Ikaros I I_GENE
isoform I I_GENE
had O O
no O O
effect O O
on O O
differentiation O O
or O O
on O O
the O O
pericentromeric O O
targeting O O
and O O
DNA-binding O O
properties O O
of O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Rather O O
, O O
the O O
small O O
isoform B B_GENE
assembled O O
into O O
multimeric B B_LOCATION/B_BIO
complexes I I_LOCATION/I_BIO
with O O
DNA-bound B B_GENE
Ikaros I I_GENE
at O O
the O O
pericentromeric O O
foci O O
. O O

The O O
capacity O O
for O O
in O O
vivo O O
multimer O O
formation O O
suggests O O
that O O
interactions O O
between O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bound O O
to O O
the O O
TdT B B_GENE
promoter I I_GENE
and O O
those O O
bound O O
to O O
pericentromeric B B_GENE/B_MEASURE
repeat I I_GENE/I_MEASURE
sequences I I_GENE/I_MEASURE
may O O
contribute O O
to O O
the O O
pericentromeric O O
repositioning O O
of O O
the O O
inactive B B_GENE
gene I I_GENE
. O O

Type B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferons I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IL-12 B B_GENE/B_BIO
: O O
convergence O O
and O O
cross-regulation O O
among O O
mediators O O
of O O
cellular O O
immunity O O
. O O

Therapeutic O O
use O O
of O O
type B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IFN I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IFN-alpha/beta B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
has O O
become O O
common O O
. O O

Many O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
diverse O B_DISEASE
diseases O I_DISEASE
targeted O O
are O O
marked O O
by O O
pathogenetic O B_DISEASE_ADJECTIVE[DISEASE]
abnormalities O I_DISEASE_ADJECTIVE[DISEASE]
in O O
cell-mediated O B_DISEASE
immunity O I_DISEASE
( O O
CMI O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
these O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
either O O
causing O O
injury O B_DISEASE
to O O
the O O
host O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O O
lacking O O
sufficient O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
vigor O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
virus O B_DISEASE/B_BIO
or O O
tumor O B_DISEASE/B_BIO
clearance O B_DISEASE/I_BIO
, O O
or O O
both O O
. O O

In O O
general O B_PERSON/B_LOCATION
, O O
therapeutic O B_MEASURE/B_PERSON
efficacy O B_MEASURE/I_PERSON
is O O
limited O O
. O O

It O O
is O O
thus O O
notable O O
that O O
the O O
pleiotropic O O
effects O O
of O O
type B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IFN I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
CMI O O
remain O O
poorly O O
understood O O
. O O

We O O
characterized O O
the O O
effects O O
of O O
type B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IFN I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
production O O
of O O
IL-12 B B_GENE
, O O
the O O
central B B_PERSON/B_GENE
immunoregulatory I I_PERSON/I_GENE
cytokine I I_PERSON/I_GENE
of O O
the O O
CD4 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
+ I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
T I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cell I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
arm I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O O
CMI O O
. O O

We O O
show O O
that O O
type B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
IFN I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
potent O O
inhibitors O O
of O O
IL-12 O O
production O O
by O O
human O O
monocytes/macrophages O O
. O O

The O O
underlying O O
mechanism O O
involves O O
transcriptional O O
inhibition O O
of O O
the O O
IL-12p40 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
marked O O
by O O
down-regulation O O
of O O
PU.1 O O
binding O O
activity O O
at O O
the O O
upstream B B_LOCATION/B_MEASURE
Ets I I_LOCATION/I_MEASURE
site I I_LOCATION/I_MEASURE
of O O
the O O
IL-12p40 B B_GENE
promoter I I_GENE
. O O

Type B B_PERSON/B_GENE
I I I_PERSON/I_GENE
IFN I I_PERSON/I_GENE
have O O
previously O O
been O O
shown O O
to O O
be O O
able O O
to O O
substitute O O
for O O
IL-12 B B_GENE
in O O
driving O O
IFN-gamma O O
production O O
from O O
T O O
and O O
NK O O
cells O O
. O O

The O O
ability O O
of O O
IFN-alpha/beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
suppress O O
IL-12 O O
production O O
while O O
up-regulating O O
IFN-gamma O O
production O O
suggests O O
a O O
possible O O
mechanistic O O
basis O O
for O O
the O O
difficulties O O
of O O
employing O O
these O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
diseases O O
involving O O
abnormalities O O
of O O
CMI O O
. O O

Nuclear B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
factor-kappaB I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
suppressive O O
and O O
inhibitor-kappaB B B_GENE
stimulatory O O
effects O O
of O O
troglitazone O O
in O O
obese O O
patients O O
with O O
type O O
2 O O
diabetes O O
: O O
evidence O O
of O O
an O O
antiinflammatory O O
action O O
? O O

It O O
has O O
been O O
shown O O
recently O O
that O O
troglitazone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exerts O O
an O O
anti-inflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
vitro O B_BIO/B_LOCATION
, O O
and O O
in O O
experimental O B_SPECIES[BIO]/B_ORGANIZATION
animals O I_SPECIES[BIO]/I_ORGANIZATION
. O O

To O O
test O O
these O O
properties O O
in O O
humans O O
, O O
we O O
investigated O O
the O O
effect O O
of O O
troglitazone O O
on O O
the O O
proinflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-kappaB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
inhibitory B B_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
IkappaB I I_PROTEIN[GENE]
in O O
mononuclear O O
cells O O
( O O
MNC O O
) O O
and O O
plasma B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
soluble I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
intracellular I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
adhesion I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
molecule-1 I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
monocyte B B_GENE
chemoattractant I I_GENE
protein-1 I I_GENE
, O O
plasminogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
C-reactive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
also O O
examined O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
troglitazone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
reactive O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygen O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
species O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
generation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
p47 O B_GENE
( O O
phox O B_GENE
) O O
subunit O B_GENE
expression O I_GENE
, O O
9-hydroxyoctadecadienoic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
9-HODE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
, O O
13-HODE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
o-tyrosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
m-tyrosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
obese O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
type O B_DISEASE
2 O I_DISEASE
diabetes O I_DISEASE
. O O

Seven O B_PERSON/B_BIO
obese O I_PERSON/I_BIO
patients O I_PERSON/I_BIO
with O O
type O B_DISEASE/B_LOCATION
2 O I_DISEASE/I_LOCATION
diabetes O I_DISEASE/I_LOCATION
were O O
treated O O
with O O
troglitazone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
400 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg/day O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
for O O
4 O B_DISEASE
weeks O I_DISEASE
. O O

Blood O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
obtained O O
at O O
weekly O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
intervals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Nuclear B B_GENE
factor-kappaB I I_GENE
binding O O
activity O O
in O O
MNC O O
nuclear O O
extracts O O
was O O
significantly O O
inhibited O O
after O O
troglitazone O O
treatment O O
at O O
week O O
1 O O
and O O
continued O O
to O O
be O O
inhibited O O
up O O
to O O
week O O
4 O O
. O O

On O O
the O O
other O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
hand O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
IkappaB O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protein O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
increased O O
significantly O O
after O O
troglitazone O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
at O O
week O B_TIME[MEASURE]/B_LOCATION
1 O B_TIME[MEASURE]/I_LOCATION
, O O
and O O
this O O
increase O B_DISEASE_ADJECTIVE[DISEASE]
persisted O O
throughout O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Plasma B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocyte I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
chemoattractant I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
protein-1 I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
soluble B B_GENE
intracellular I I_GENE
adhesion I I_GENE
molecule-1 I I_GENE
concentrations O O
did O O
not O O
decrease O O
significantly O O
after O O
troglitazone O O
treatment O O
, O O
although O O
there O O
was O O
a O O
trend O O
toward O O
inhibition O O
. O O

Reactive O O
oxygen O O
species O O
generation O O
by O O
polymorphonuclear O O
cells O O
and O O
MNC O O
, O O
p47 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phox I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subunit I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
quantities O O
, O O
plasminogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activator I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibitor-1 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
C-reactive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
decreased O O
significantly O O
after O O
troglitazone O O
intake O O
. O O

13-HODE/linoleic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
9-HODE/linoleic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratios O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
decreased O O
after O O
troglitazone O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intake O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

However O O
, O O
o-tyrosine/phenylalanine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
m-tyrosine/phenylalanine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratios O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
change O O
significantly O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O O
that O O
troglitazone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
has O O
profound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiinflammatory O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
antioxidant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
obese O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
type O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2 O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
diabetics O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O O
these O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
recently O O
described O O
beneficial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiatherosclerotic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
troglitazone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O O
the O O
vascular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
level O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

OX40 O O
stimulation O O
by O O
gp34/OX40 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ligand I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhances O O
productive O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
infection O O
. O O

OX40 B B_GENE
is O O
a O O
member O O
of O O
the O O
tumor B B_GENE/B_PERSON
necrosis I I_GENE/I_PERSON
factor I I_GENE/I_PERSON
( I I_GENE/I_PERSON
TNF I I_GENE/I_PERSON
) I I_GENE/I_PERSON
receptor I I_GENE/I_PERSON
superfamily I I_GENE/I_PERSON
and O O
known O O
to O O
be O O
an O O
important O O
costimulatory B B_GENE
molecule I I_GENE
expressed O O
on O O
activated O O
T O O
cells O O
. O O

To O O
investigate O O
the O O
role O O
of O O
costimulation O O
of O O
OX40 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
infection O O
by O O
its O O
natural O O
ligand O O
, O O
gp34 B B_GENE
, O O
the O O
OX40-transfected O O
ACH-2 O O
cell O O
line O O
, O O
ACH-2/OX40 O O
, O O
chronically O O
infected O O
with O O
HIV-1 O O
, O O
was O O
cocultured O O
with O O
paraformaldehyde O O
( O O
PFA O O
) O O
-fixed O O
gp34-transfected O O
mouse O O
cell O O
line O O
, O O
SV-T2/gp34 O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
HIV-1 O O
production O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
strongly O O
induced O O
. O O

This O O
was O O
followed O O
by O O
apparent O O
apoptosis O O
, O O
and O O
both O O
processes O O
were O O
specifically O O
inhibited O O
by O O
the O O
gp34 B B_GENE
-specific O O
neutralizing B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
monoclonal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5A8 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Endogenous O O
TNF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TNF-alpha B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
TNF-beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O O
were O O
not O O
involved O O
in O O
the O O
enhanced O O
HIV-1 O O
production O O
. O O

Furthermore O O
, O O
enhanced O O
HIV-1 O O
transcription O O
in O O
gp34 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-stimulated O O
ACH-2/OX40 O O
cells O O
was O O
dependent O O
on O O
the O O
kappa B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
long I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeat I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
the O O
OX40-gp34 O O
interaction O O
activated O O
NF-kappa B B_GENE
B I I_GENE
consisting O O
of O O
p50 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p65 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

When O O
primary O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
activated O O
CD4 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
acutely O O
infected O O
with O O
HIV-1 O B_DISEASE/B_GENE
( O O
NL4-3 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
( O O
CXCR4-using O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
T-cell-line-tropic O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
) O O
were O O
cocultured O O
with O O
PFA-fixed O B_GENE
gp34 O I_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T-cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukemia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
virus O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
type O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
1-bearing O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
MT-2 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
SV-T2/gp34 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
HIV-1 O O
production O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
also O O
markedly O O
enhanced O O
. O O

The O O
enhancement O O
was O O
again O O
significantly O O
inhibited O O
by O O
5A8 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
present O O
study O O
first O O
shows O O
that O O
OX40-gp34 O O
interaction O O
stimulates O O
HIV-1 O O
expression O O
and O O
suggests O O
that O O
OX40 O O
triggering O O
by O O
gp34 B B_GENE
may O O
play O O
an O O
important O O
role O O
in O O
enhancing O O
HIV-1 O O
production O O
in O O
both O O
acutely O O
and O O
latently O O
infected O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
in O O
vivo O O
. O O

Troglitazone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
PPARgamma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligand O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
inhibits O O
osteopontin O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
gene O B_DISEASE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
expression O B_DISEASE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytes/macrophage O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
THP-1 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Peroxizome B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proliferator-activated I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor-gamma I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PPARgamma B B_GENE
) O O
is O O
a O O
member O O
of O O
the O O
nuclear B B_GENE/B_PERSON
receptor I I_GENE/I_PERSON
family I I_GENE/I_PERSON
of O O
transcription B B_GENE/B_BIO
factors I I_GENE/I_BIO
that O O
regulate O O
adipocyte O O
differentiation O O
. O O

Recent O O
studies O O
indicate O O
that O O
liganded B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PPARgamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
not O O
only O O
promotes O O
differentiation O O
but O O
also O O
inhibits O O
the O O
activation O O
of O O
macrophages O O
. O O

Osteopontin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
component O O
of O O
extracellular O O
matrix O O
, O O
is O O
synthesized O O
by O O
macrophages O O
in O O
atherosclerotic O O
plaques O O
. O O

In O O
this O O
study O O
, O O
we O O
examined O O
whether O O
PPARgamma B B_GENE
ligand O O
regulates O O
osteopontin O O
gene O O
expression O O
in O O
THP-1 O O
cells O O
, O O
a O O
cell O O
line O O
derived O O
from O O
human O O
monocytic O O
leukemia O O
cells O O
which O O
can O O
differentiate O O
to O O
macrophage O O
upon O O
stimulation O O
with O O
phorbol O O
ester O O
PMA O O
. O O

Northern O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
that O O
osteopontin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
markedly O O
induced O O
in O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
PMA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Troglitazone O O
, O O
a O O
PPARgamma B B_GENE/B_DISEASE
ligand O O
, O O
dramatically O O
attenuated O O
the O O
PMA-induced O O
osteopontin O O
expression O O
. O O

Transient O O
transfection O O
assays O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
osteopontin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter/luciferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
construct I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
contains O O
a O O
5'-flanking B B_LOCATION/B_MEASURE
region I I_LOCATION/I_MEASURE
between O O
-1500 O O
and O O
+87 O O
relative O O
to O O
the O O
transcription B B_GENE/B_MEASURE
start I I_GENE/I_MEASURE
site I I_GENE/I_MEASURE
demonstrate O O
that O O
either O O
treatment O O
with O O
troglitazone O O
or O O
cotransfection O O
of O O
PPARgamma B B_GENE
expression I I_GENE
vector I I_GENE
inhibits O O
osteopontin O O
promoter O O
activity O O
. O O

These O O
data O O
indicate O O
that O O
troglitazone O O
reduces O O
osteopontin O O
gene O O
expression O O
at O O
transcriptional O O
level O O
through O O
PPARgamma B B_GENE
activation O O
, O O
and O O
suggest O O
the O O
role O O
of O O
troglitazone O O
in O O
inhibiting O O
the O O
ability O O
of O O
macrophages O O
to O O
produce O O
extracellular O O
matrix O O
, O O
which O O
is O O
particularly O O
relevant O O
to O O
atherosclerotic O O
plaque O O
formation O O
. O O

Transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulates O O
Ig B B_GENE
lambda I I_GENE
light O O
chain O O
gene O O
rearrangement O O
. O O

The O O
tissue- O O
and O O
stage-specific O O
assembly O O
of O O
Ig B B_GENE
and I I_GENE
TCR I I_GENE
genes I I_GENE
is O O
mediated O O
by O O
a O O
common O O
V B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
D I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
J I I_GENE/I_LOCATION
recombinase I I_GENE/I_LOCATION
complex I I_GENE/I_LOCATION
in O O
precursor O O
lymphocytes O O
. O O

Directed O O
alterations O O
in O O
the O O
accessibility O O
of O O
V B B_GENE/B_LOCATION
, I I_GENE/I_LOCATION
D I I_GENE/I_LOCATION
, I I_GENE/I_LOCATION
and I I_GENE/I_LOCATION
J I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
segments I I_GENE/I_LOCATION
target O O
the O O
recombinase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
specific O O
Ag B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
loci I I_GENE/I_LOCATION
. O O

Accessibility O O
within O O
a O O
given O O
locus B B_GENE/B_LOCATION
is O O
regulated O O
by O O
the O O
functional O O
interaction O O
of O O
transcription B B_GENE
factors I I_GENE
with O O
cognate B B_GENE
enhancer I I_GENE
elements I I_GENE
and O O
correlates O O
with O O
the O O
transcriptional O O
activity O O
of O O
unrearranged O O
gene B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
segments I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
demonstrated O O
in O O
our O O
prior O O
studies O O
, O O
rearrangement O O
of O O
the O O
Igkappa B B_GENE
locus I I_GENE
is O O
regulated O O
by O O
the O O
inducible B B_GENE
transcription I I_GENE
factor I I_GENE
NF-kappaB B I_GENE
. O O

In O O
contrast O O
to O O
the O O
Igkappa B B_GENE/B_BIO
locus I I_GENE/I_BIO
, O O
known O O
transcriptional B B_GENE
control I I_GENE
elements I I_GENE
in O O
the O O
Iglambda B B_GENE/B_LOCATION
locus I I_GENE/I_LOCATION
lack O O
functional O O
NF-kappaB B B_GENE/B_MEASURE
binding I I_GENE/I_MEASURE
sites I I_GENE/I_MEASURE
. O O

Consistent O O
with O O
this O O
observation O O
, O O
the O O
expression O O
of O O
assembled O O
Iglambda B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mature O O
B O O
cells O O
has O O
been O O
shown O O
to O O
be O O
NF-kappaB B B_GENE
independent O O
. O O

Nonetheless O O
, O O
we O O
now O O
show O O
that O O
specific O O
repression O O
of O O
NF-kappaB B B_GENE
inhibits O O
germline O O
transcription O O
and O O
recombination O O
of O O
Iglambda B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
segments I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
precursor O O
B O O
cells O O
. O O

Molecular O O
analyses O O
indicate O O
that O O
the O O
block O O
in O O
NF-kappaB B B_GENE
impairs O O
Iglambda O O
rearrangement O O
at O O
the O O
level O O
of O O
recombinase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
accessibility O O
. O O

In O O
contrast O O
, O O
the O O
activities O O
of O O
known O O
Iglambda B B_GENE/B_BIO
promoter I I_GENE/I_BIO
and O O
enhancer B B_GENE
elements I I_GENE
are O O
unaffected O O
in O O
the O O
same O O
cellular O O
background O O
. O O

These O O
findings O O
expand O O
the O O
range O O
of O O
NF-kappaB B B_GENE
action O O
in O O
precursor O O
B O O
cells O O
beyond O O
Igkappa B B_GENE/B_DISEASE
to O O
include O O
the O O
control O O
of O O
recombinational O O
accessibility O O
at O O
both O O
L B B_GENE/B_LOCATION
chain I I_GENE/I_LOCATION
loci I I_GENE/I_LOCATION
. O O

Moreover O O
, O O
our O O
results O O
strongly O O
suggest O O
the O O
existence O O
of O O
a O O
novel O O
Iglambda B B_GENE/B_LOCATION
regulatory I I_GENE/I_LOCATION
element I I_GENE/I_LOCATION
that O O
is O O
either O O
directly O O
or O O
indirectly O O
activated O O
by O O
NF-kappaB B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
the O O
early O O
stages O O
of O O
B O O
cell O O
development O O
. O O

Transcription B B_GENE
factor I I_GENE
STAT5A B I_GENE
is O O
a O O
substrate O O
of O O
Bruton B B_GENE
's I I_GENE
tyrosine I I_GENE
kinase I I_GENE
in O O
B O O
cells O O
. O O

STAT5A B B_GENE
is O O
a O O
molecular O O
regulator O O
of O O
proliferation O O
, O O
differentiation O O
, O O
and O O
apoptosis O O
in O O
lymphohematopoietic O O
cells O O
. O O

Here O O
we O O
show O O
that O O
STAT5A B B_GENE
can O O
serve O O
as O O
a O O
functional O O
substrate O O
of O O
Bruton B B_GENE
's I I_GENE
tyrosine I I_GENE
kinase I I_GENE
( O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Purified B B_GENE/B_PERSON
recombinant I I_GENE/I_PERSON
BTK I I_GENE/I_PERSON
was O O
capable O O
of O O
directly O O
binding O O
purified B B_GENE
recombinant I I_GENE
STAT5A I I_GENE
with O O
high O O
affinity O O
( O O
K O O
( O O
d O O
) O O
= O O
44 O O
nm O O
) O O
, O O
as O O
determined O O
by O O
surface O O
plasmon O O
resonance O O
using O O
a O O
BIAcore O O
biosensor O O
system O O
. O O

BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
also O O
capable O O
of O O
tyrosine-phosphorylating O O
ectopically O O
expressed O O
recombinant B B_GENE
STAT5A I I_GENE
on O O
Tyr O O
( O O
694 O O
) O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
in O O
a O O
Janus B B_GENE
kinase I I_GENE
3 I I_GENE
-independent O O
fashion O O
. O O

BTK B B_PERSON/B_GENE
phosphorylated O O
the O O
Y665F B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
, I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
Y668F I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
, I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
Y682F I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
, I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
Y683F I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
but O O
not O O
the O O
Y694F B B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutant I I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
of O O
STAT5A B B_GENE
. O O

STAT5A O O
mutations O O
in O O
the O O
Src B B_GENE/B_BIO
homology I I_GENE/I_BIO
2 I I_GENE/I_BIO
( I I_GENE/I_BIO
SH2 I I_GENE/I_BIO
) I I_GENE/I_BIO
and I I_GENE/I_BIO
SH3 I I_GENE/I_BIO
domains I I_GENE/I_BIO
did O O
not O O
alter O O
the O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-mediated O O
tyrosine O O
phosphorylation O O
. O O

Recombinant B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
BTK I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
proteins I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
mutant O O
pleckstrin O O
homology O O
, O O
SH2 B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
or I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
SH3 I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
domains I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
were O O
capable O O
of O O
phosphorylating O O
STAT5A B B_GENE
, O O
whereas O O
recombinant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
BTK I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
with O O
SH1/kinase O O
domain O O
mutations O O
were O O
not O O
. O O

In O O
pull-down O O
experiments O O
, O O
only O O
full-length B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
BTK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
SH1/kinase B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
( O O
but O O
not O O
the O O
pleckstrin O O
homology O O
, O O
SH2 B B_PROTEIN[GENE]/B_LOCATION
, I I_PROTEIN[GENE]/I_LOCATION
or I I_PROTEIN[GENE]/I_LOCATION
SH3 I I_PROTEIN[GENE]/I_LOCATION
domains I I_PROTEIN[GENE]/I_LOCATION
) O O
were O O
capable O O
of O O
binding O O
STAT5A B B_GENE
. O O

Ectopically O O
expressed O O
BTK B B_GENE
kinase I I_GENE
domain I I_GENE
was O O
capable O O
of O O
tyrosine-phosphorylating O O
STAT5A B B_GENE
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-mediated O O
tyrosine O O
phosphorylation O O
of O O
ectopically O O
expressed O O
wild O O
type O O
( O O
but O O
not O O
Tyr B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
694 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) O O
STAT5A B B_GENE/B_LOCATION
enhanced O O
its O O
DNA O O
binding O O
activity O O
. O O

In O O
BTK B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
-competent O O
chicken O O
B O O
cells O O
, O O
anti-IgM-stimulated O O
tyrosine O O
phosphorylation O O
of O O
STAT5 B B_GENE
protein I I_GENE
was O O
prevented O O
by O O
pretreatment O O
with O O
the O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
LFM-A13 O O
but O O
not O O
by O O
pretreatment O O
with O O
the O O
JAK3 O O
inhibitor O O
HI-P131 O O
. O O

B O O
cell O O
antigen O O
receptor O O
ligation O O
resulted O O
in O O
enhanced O O
tyrosine O O
phosphorylation O O
of O O
STAT5 B B_GENE
in O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-deficient O O
chicken O O
B O O
cells O O
reconstituted O O
with O O
wild B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
type I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
human I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
BTK I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
but O O
not O O
in O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-deficient O O
chicken O O
B O O
cells O O
reconstituted O O
with O O
kinase-inactive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BTK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Similarly O O
, O O
anti-IgM O O
stimulation O O
resulted O O
in O O
enhanced O O
tyrosine O O
phosphorylation O O
of O O
STAT5A B B_GENE
in O O
BTK B B_DISEASE/B_GENE
-competent O O
B O O
cells O O
from O O
wild O O
type O O
mice O O
but O O
not O O
in O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-deficient O O
B O O
cells O O
from O O
XID O O
mice O O
. O O

In O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
from O O
XID O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
from O O
JAK3 O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
knockout O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mice O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
showed O O
a O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
STAT5A O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
phosphorylation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
response O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
anti-IgM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

These O O
findings O O
provide O O
unprecedented O O
experimental O O
evidence O O
that O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plays O O
a O O
nonredundant O O
and O O
pivotal O O
role O O
in O O
B O O
cell O O
antigen O O
receptor-mediated O O
STAT5A O O
activation O O
in O O
B O O
cells O O

Role O O
of O O
T-bet B B_GENE
in O O
commitment O O
of O O
TH1 O O
cells O O
before O O
IL-12 B B_GENE
-dependent O O
selection O O
. O O

How O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
control O O
differentiation O O
of O O
helper O O
T O O
( O O
TH O O
) O O
cells O O
is O O
controversial O O
. O O

We O O
show O O
that O O
T-bet B B_GENE
, O O
without O O
apparent O O
assistance O O
from O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
12 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-12 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
STAT4 B B_GENE/B_MEASURE
, O O
specifies O O
TH1 O O
effector O O
fate O O
by O O
targeting O O
chromatin O O
remodeling O O
to O O
individual O O
interferon-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IFN-gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alleles I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
inducing O O
IL-12 B B_GENE
receptor I I_GENE
beta2 I I_GENE
expression O O
. O O

Subsequently O O
, O O
it O O
appears O O
that O O
IL-12 B B_GENE/B_LOCATION
/ O O
STAT4 B B_MEASURE/B_GENE
serves O O
two O O
essential O O
functions O O
in O O
the O O
development O O
of O O
TH1 O O
cells O O
: O O
as O O
growth B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
inducing O O
survival O O
and O O
cell O O
division O O
; O O
and O O
as O O
trans-activator B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
prolonging O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthesis O O
through O O
a O O
genetic O O
interaction O O
with O O
the O O
coactivator B B_GENE/B_PERSON
, O O
CREB-binding B B_GENE
protein I I_GENE
. O O

These O O
results O O
suggest O O
that O O
a O O
cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O O
not O O
simply O O
induce O O
TH O O
fate O O
choice O O
but O O
instead O O
may O O
act O O
as O O
an O O
essential O O
secondary O O
stimulus O O
that O O
mediates O O
selective O O
survival O O
of O O
a O O
lineage O O
. O O

Stat6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
necessary O O
and O O
sufficient O O
for O O
IL-4 O O
's O O
role O O
in O O
Th2 O O
differentiation O O
and O O
cell O O
expansion O O
. O O

IL-4 B B_GENE
plays O O
a O O
critical O O
role O O
in O O
the O O
differentiation O O
of O O
T O O
CR-stimulated O O
naive O O
CD4 O O
T O O
cells O O
to O O
the O O
Th2 O O
phenotype O O
. O O

In O O
response O O
to O O
IL-4 B B_GENE/B_DISEASE
, O O
the O O
IL-4R B B_GENE
activates O O
a O O
set O O
of O O
phosphotyrosine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain-containing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
insulin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
substrate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1/2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
IL-4R B B_GENE
interacting I I_GENE
protein I I_GENE
, O O
as O O
well O O
as O O
Stat6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Stat6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
shown O O
to O O
be O O
required O O
for O O
Th2 O O
differentiation O O
. O O

To O O
determine O O
the O O
roles O O
of O O
the O O
phosphotyrosine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adaptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Th2 O O
differentiation O O
, O O
we O O
prepared O O
a O O
retrovirus O O
containing O O
a O O
mutant O O
of O O
the O O
human B B_GENE
( I I_GENE
h I I_GENE
) I I_GENE
IL-4R I I_GENE
alpha-chain I I_GENE
, O O
Y497F B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
unable O O
to O O
recruit O O
these O O
adaptors O O
. O O

The O O
mutant B B_GENE
hIL-4Ralpha I I_GENE
, O O
as O O
well O O
as O O
the O O
wild-type B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
WT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hIL-4Ralpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
introduced O O
into O O
naive O O
CD4 O O
T O O
cells O O
. O O

Upon O O
hIL-4 O O
stimulation O O
, O O
Y497F B B_GENE/B_PERSON
worked O O
as O O
well O O
as O O
the O O
WT B B_GENE
hIL-4Ralpha I I_GENE
in O O
driving O O
Th2 O O
differentiation O O
, O O
as O O
measured O O
by O O
Gata3 O O
up-regulation O O
and O O
IL-4 O O
production O O
. O O

Furthermore O O
, O O
IL-4-driven O O
cell O O
expansion O O
was O O
also O O
normal O O
in O O
the O O
cells O O
infected O O
with O O
Y497F B B_DISEASE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
although O O
cells O O
infected O O
with O O
Y497F B B_DISEASE/B_VIRUS[BIO]
were O O
not O O
capable O O
of O O
phosphorylating O O
insulin B B_GENE
receptor I I_GENE
substrate I I_GENE
2 I I_GENE
. O O

These O O
results O O
suggest O O
that O O
the O O
signal O O
pathway O O
mediated O O
by O O
Y497 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
dispensable O O
for O O
both O O
IL-4 B B_GENE
-driven O O
Th2 O O
differentiation O O
and O O
cell O O
expansion O O
. O O

Both O O
WT B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Y497F I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hIL-4Ralpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lose O O
the O O
ability O O
to O O
drive O O
Th2 O O
differentiation O O
and O O
cell O O
expansion O O
in O O
Stat6-knockout O O
CD4 O O
T O O
cells O O
. O O

A O O
constitutively O O
activated O O
form O O
of O O
Stat6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
introduced O O
into O O
CD4 O O
T O O
cells O O
resulted O O
in O O
both O O
Th2 O O
differentiation O O
and O O
enhanced O O
cell O O
expansion O O
. O O

Thus O O
, O O
activated B B_GENE
Stat6 I I_GENE
is O O
necessary O O
and O O
sufficient O O
to O O
mediate O O
both O O
IL-4 B B_GENE
-driven O O
Th2 O O
differentiation O O
and O O
cell O O
expansion O O
in O O
CD4 O O
T O O
cells O O
. O O

The O O
effect O O
of O O
HIV-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulatory I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
cellular O O
genes O O
: O O
derepression O O
of O O
the O O
IL-2 B B_GENE
promoter I I_GENE
by O O
Tat B B_GENE
. O O

In O O
HIV-infected O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
individuals O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
dysregulation O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
the O O
immune O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
characterized O O
by O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
disorders O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
cytokine O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
network O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Increase O O
secretion O O
of O O
IL-2 B B_GENE
, O O
the O O
major O O
T O O
cell O O
growth O O
and O O
differentiation O O
cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
may O O
play O O
a O O
decisive O O
role O O
in O O
sensitization O O
of O O
T O O
cells O O
for O O
activation O O
induced O O
apoptosis O O
and O O
indirect O O
death O O
of O O
activated O O
T O O
cells O O
through O O
augmented O O
virus O O
replication O O
. O O

We O O
investigated O O
the O O
cause O O
of O O
enhanced O O
IL-2 O O
secretion O O
and O O
found O O
that O O
the O O
HIV B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tat I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
this O O
effect O O
. O O

We O O
demonstrate O O
that O O
increased O O
IL-2 O O
secretion O O
is O O
due O O
to O O
Tat B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-enhanced O O
IL-2 B B_GENE
promoter I I_GENE
activation O O
. O O

Tat B B_GENE
derepresses O O
and O O
activates O O
the O O
distal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
AP-1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
position B B_LOCATION/B_PROTEIN[GENE]
-185 I I_LOCATION/I_PROTEIN[GENE]
to I I_LOCATION/I_PROTEIN[GENE]
-177 I I_LOCATION/I_PROTEIN[GENE]
) O O
in O O
the O O
IL-2 B B_GENE
promoter I I_GENE
. O O

In O O
nonstimulated O O
T O O
cells O O
a O O
repressor O O
complex O O
containing O O
NF-IL6 B B_GENE
, O O
JunB B B_GENE/B_BACTERIUM[BIO]
, O O
c-Fos B B_GENE
and O O
Fra-1 B B_GENE
is O O
formed O O
on O O
the O O
AP-1 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
( I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
IL-2/d I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
) I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
site I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
represses O O
IL-2 B B_GENE
promoter I I_GENE
activity O O
. O O

After O O
T O O
cell O O
activation O O
, O O
a O O
heterodimeric B B_LOCATION
activator I I_LOCATION
containing O O
p65 B B_GENE
and O O
c-Jun B B_GENE
binds O O
to O O
the O O
AP-1 B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
IL-2/d I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
site I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

HIV B B_GENE/B_DISEASE
Tat I I_GENE/I_DISEASE
enhances O O
activation O O
of O O
NF-kappaB B B_GENE
and O O
consequently O O
, O O
activates O O
the O O
AP-1 B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
IL-2/d I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
site I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Our O O
data O O
provide O O
evidence O O
for O O
a O O
novel O O
mechanism O O
by O O
which O O
HIV B B_DISEASE
Tat I I_DISEASE
dysregulates O O
IL-2 O O
production O O
and O O
therefore O O
may O O
contribute O O
to O O
the O O
HIV-1 O O
infection O O
in O O
a O O
way O O
yet O O
to O O
be O O
clarified O O
. O O

Transforming B B_GENE
growth I I_GENE
factor-beta1 I I_GENE
interferes O O
with O O
thrombopoietin-induced O O
signal O O
transduction O O
in O O
megakaryoblastic O O
and O O
erythroleukemic O O
cells O O
. O O

OBJECTIVE O O
: O O
Thrombopoietin B B_GENE
( O O
TPO B B_PROTEIN[GENE]/B_DISEASE
) O O
and O O
transforming B B_GENE
growth I I_GENE
factor-beta I I_GENE
( I I_GENE
1 I I_GENE
) I I_GENE
( O O
TGF-beta B B_GENE/B_MEASURE
( I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
) O O
have O O
been O O
shown O O
to O O
exert O O
opposite O O
effects O O
on O O
proliferation O O
and O O
megakaryocytic O O
differentiation O O
of O O
hematopoietic O O
cells O O
. O O

To O O
determine O O
whether O O
TGF-beta B B_GENE
( I I_GENE
1 I I_GENE
) I I_GENE
interferes O O
directly O O
with O O
TPO B B_GENE
-induced O O
signal O O
transduction O O
in O O
hematopoietic O O
cells O O
, O O
we O O
compared O O
the O O
regulatory O O
effects O O
in O O
the O O
TPO B B_GENE
-responsive O O
cell O O
lines O O
Mo-7e O O
and O O
HEL O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
The O O
cells O O
were O O
stimulated O O
by O O
100 O O
ng/mL O O
TPO B B_GENE
and/or O O
100 O O
ng/mL O O
TGF-beta1 B B_GENE
and O O
analyzed O O
for O O
proliferation O O
( O O
3H O O
thymidine O O
incorporation O O
) O O
, O O
viability O O
( O O
trypan O O
blue O O
exclusion O O
) O O
, O O
and O O
protein O O
expression O O
and O O
phosphorylation O O
( O O
Western O O
blot O O
) O O
. O O

RESULTS O O
: O O
TPO B B_GENE/B_DISEASE
enhanced O O
the O O
proliferation O O
of O O
Mo-7e O O
cells O O
as O O
determined O O
by O O
3H-thymidine O O
incorporation O O
, O O
whereas O O
TGF-beta1 B B_GENE
suppressed O O
baseline O O
cell O O
growth O O
and O O
antagonized O O
the O O
proliferative O O
effect O O
of O O
TPO B B_GENE
. O O

TPO B B_PROTEIN[GENE]/B_DISEASE
-induced O O
proliferation O O
also O O
was O O
reduced O O
by O O
a O O
specific O O
inhibitor O O
of O O
the O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE
) O O
pathway O O
( O O
PD098059 O O
) O O
, O O
which O O
inhibits O O
activation O O
of O O
the O O
MAPK B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
extracellular I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
signal-regulated I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
kinases I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
ERK B B_GENE/B_LOCATION
) O O
ERK1 B B_GENE
and O O
ERK2 B B_GENE/B_LOCATION
, O O
and O O
AG490 O O
, O O
an O O
inhibitor O O
of O O
Janus B B_GENE
kinase-2 I I_GENE
, O O
which O O
completely O O
blocked O O
TPO B B_GENE
-induced O O
proliferation O O
. O O

As O O
demonstrated O O
by O O
Western O O
blotting O O
, O O
TGF-beta1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduced O O
the O O
TPO B B_GENE
-stimulated O O
ERK1 B B_GENE
/ O O
ERK2 B B_GENE
and O O
STAT5 O O
phosphorylation O O
in O O
Mo-7e O O
and O O
HEL O O
cells O O
. O O

This O O
effect O O
was O O
completely O O
reversed O O
by O O
preincubation O O
with O O
a O O
tyrosine O O
phosphatase O O
inhibitor O O
( O O
Na3VO4 O O
) O O
, O O
which O O
suggests O O
that O O
TGF-beta1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activated O O
a O O
phosphatase B B_GENE/B_LOCATION
. O O

Although O O
STAT3 B B_GENE
also O O
was O O
activated O O
by O O
TPO B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
STAT3 B B_GENE/B_MEASURE
activation O O
remained O O
unaltered O O
by O O
TGF-beta1 B B_GENE
. O O

CONCLUSION O O
: O O
Taken O O
together O O
, O O
these O O
data O O
suggest O O
that O O
TGF-beta1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
modulates O O
TPO B B_GENE
-mediated O O
effects O O
on O O
megakaryocytic O O
proliferation O O
by O O
interfering O O
with O O
TPO B B_GENE
-induced O O
signal O O
transduction O O
, O O
particularly O O
by O O
reducing O O
the O O
activities O O
of O O
MAPK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ERK1/ERK2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
STAT5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Invariant B B_GENE
chain I I_GENE
induces O O
B O O
cell O O
maturation O O
by O O
activating O O
a O O
TAF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
105-NF-kappaB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-dependent O O
transcription O O
program O O
. O O

Early O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stages O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
B O B_DISEASE/B_ORGANISM_FUNCTION
cell O I_DISEASE/I_ORGANISM_FUNCTION
development O I_DISEASE/I_ORGANISM_FUNCTION
occur O O
in O O
the O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
marrow O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
resulting O O
in O O
formation O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
immature O B_DISEASE/B_GENE
B O I_DISEASE/I_GENE
cells O I_DISEASE/I_GENE
. O O

From O O
there O O
these O O
immature O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
migrate O O
to O O
the O O
spleen O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
where O O
they O O
differentiate O O
to O O
mature O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

This O O
final O O
maturation O O
step O O
is O O
crucial O O
for O O
the O O
B O O
cells O O
to O O
become O O
responsive O O
to O O
antigens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
to O O
participate O O
in O O
the O O
immune O O
response O O
. O O

Recently O O
, O O
invariant B B_GENE
chain I I_GENE
( O O
Ii B B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
a O O
major B B_GENE
histocompatibility I I_GENE
complex I I_GENE
class I I_GENE
II I I_GENE
chaperone I I_GENE
, O O
as O O
well O O
as O O
the O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Rel B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
p65/RelA B B_GENE
, O O
were O O
found O O
to O O
play O O
a O O
role O O
in O O
the O O
final O O
antigen-independent O O
differentiation O O
stage O O
of O O
B O O
cells O O
in O O
the O O
spleen O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
a O O
possible O O
link O O
between O O
Ii B B_GENE/B_DISEASE
-dependent O O
B O O
cell O O
maturation O O
and O O
the O O
NF-kappaB O O
pathway O O
. O O

Our O O
studies O O
indicate O O
that O O
Ii B B_DISEASE/B_GENE
-induced O O
B O O
cell O O
maturation O O
involves O O
activation O O
of O O
transcription O O
mediated O O
by O O
the O O
NF-kappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p65/RelA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homodimer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
requires O O
the O O
B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell-enriched I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coactivator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TBP-associated B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
105 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Androgens O B_PERSON/B_LOCATION
indirectly O O
accelerate O O
thymocyte O B_DISEASE/B_ORGANISM_FUNCTION
apoptosis O I_DISEASE/I_ORGANISM_FUNCTION
. O O

Apoptotic O B_DISEASE
processes O I_DISEASE
, O O
or O O
the O O
disturbance O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
natural O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
processes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
may O O
be O O
involved O O
in O O
the O O
pathogenesis O B_DISEASE
of O O
autoimmune O B_DISEASE/B_LOCATION
diseases O I_DISEASE/I_LOCATION
( O O
AID O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Women O B_PERSON/B_BIO
are O O
, O O
in O O
general O B_PERSON/B_TIME[MEASURE]
, O O
more O O
susceptible O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
men O B_PERSON
to O O
develop O O
AID O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like O O
rheumatoid O B_DISEASE
arthritis O I_DISEASE
. O O

Androgens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
in O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
oestrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
have O O
favourable O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
AID O B_PERSON/B_BIO
models O B_PERSON/I_BIO
as O O
well O O
as O O
in O O
human O B_PERSON/B_ORGANIZATION
AID O I_PERSON/I_ORGANIZATION
. O O

It O O
is O O
known O O
that O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
, O O
used O O
for O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
AID O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
increase O O
apoptosis O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
thymus O B_BODY_PART_OR_ORGAN_COMPONENT
resulting O O
in O O
decreased O O
numbers O B_MEASURE
of O O
CD4+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
CD8+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
thymocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

It O O
was O O
asked O O
whether O O
androgens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
in O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
oestrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
exert O O
their O O
favourable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
AID O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O O
a O O
mechanism O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comparable O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
that O O
described O O
for O O
GC O B_DISEASE
by O O
eliminating O O
the O O
apoptosis O B_DISEASE_ADJECTIVE[DISEASE]
prone O I_DISEASE_ADJECTIVE[DISEASE]
CD4+ O I_DISEASE_ADJECTIVE[DISEASE]
CD8+ O I_DISEASE_ADJECTIVE[DISEASE]
population O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
thymus O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

Although O O
both O O
androgens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
oestrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proved O O
thymolytic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
significantly O O
decreased O B_MEASURE
percentage O I_MEASURE
of O O
CD4+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
CD8+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
thymocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
was O O
observed O O
by O O
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
mice O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
androgen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyltestosterone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
with O O
the O O
oestrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ethinylestradiol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
investigate O O
whether O O
the O O
observed O O
thymolytic O O
effects O O
were O O
due O O
to O O
the O O
presence O O
of O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
thymocytes O O
, O O
cells O O
were O O
isolated O O
from O O
the O O
thymus O O
and O O
incubated O O
with O O
androgens O O
or O O
oestrogens O O
to O O
measure O O
apoptosis O O
. O O

Several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
used O O
to O O
determine O O
thymocyte O B_DISEASE/B_GENE
apoptosis O I_DISEASE/I_GENE
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
but O O
no O O
enhanced O B_DISEASE_ADJECTIVE[DISEASE]
apoptotic O I_DISEASE_ADJECTIVE[DISEASE]
signal O I_DISEASE_ADJECTIVE[DISEASE]
was O O
observed O O
. O O

Using O O
the O O
very O O
sensitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
TUNEL O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
assay O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
no O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
androgens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
thymocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
could O O
be O O
observed O O
. O O

This O O
is O O
in O O
sharp O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
contrast O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
the O O
high O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
signal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
observed O O
with O O
GC O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Therefore O O
, O O
upon O O
in O O
vivo O O
androgen O O
treatment O O
, O O
other O O
cells O O
containing O O
androgen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
than O O
thymocytes O O
are O O
probably O O
involved O O
in O O
inducing O O
the O O
increase O O
in O O
thymic O O
apoptosis O O
. O O

To O O
study O O
the O O
role O O
of O O
the O O
androgen B B_GENE
receptor I I_GENE
on O O
thymocyte O O
apoptosis O O
, O O
androgen B B_NUMBER[MEASURE]
receptor I I_NUMBER[MEASURE]
mutant O O
( O O
Tfm/Y O O
) O O
mice O O
were O O
treated O O
with O O
androgens O O
. O O

No O O
alterations O O
of O O
thymocyte O O
subpopulations O O
were O O
seen O O
, O O
suggesting O O
that O O
changes O O
in O O
the O O
percentage O O
of O O
CD4+ O O
CD8+ O O
thymocytes O O
after O O
administration O O
of O O
androgens O O
depend O O
on O O
the O O
presence O O
of O O
functional O O
androgen B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Thus O O
, O O
it O O
is O O
concluded O O
that O O
androgens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indirectly O O
accelerate O O
thymocyte O B_DISEASE/B_ORGAN_OR_TISSUE_FUNCTION[ORGANISM_FUNCTION]
apoptosis O B_DISEASE/I_ORGAN_OR_TISSUE_FUNCTION[ORGANISM_FUNCTION]
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Inhibition O O
of O O
the O O
transcription B B_GENE/B_LOCATION
factors I I_GENE/I_LOCATION
AP-1 B I_GENE/I_LOCATION
and O O
NF-kappaB B B_GENE
in O O
CD4 O O
T O O
cells O O
by O O
peroxisome B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proliferator-activated I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ligands I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
peroxisome B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PPARgamma B B_GENE
) O O
, O O
a O O
member O O
of O O
the O O
nuclear B B_GENE/B_BIO
hormone I I_GENE/I_BIO
receptor I I_GENE/I_BIO
superfamily I I_GENE/I_BIO
, O O
is O O
essential O O
for O O
adipocyte O O
differentiation O O
and O O
glucose O O
homeostasis O O
. O O

PPARgamma B B_GENE
has O O
been O O
found O O
recently O O
to O O
regulate O O
macrophage O O
activation O O
in O O
response O O
to O O
mitogens B B_DISEASE
and O O
inflammation O O
. O O

Our O O
study O O
shows O O
PPARgamma B B_GENE
to O O
be O O
preferentially O O
expressed O O
in O O
the O O
nuclei O O
of O O
resting O O
T O O
cells O O
and O O
to O O
increase O O
upon O O
activation O O
of O O
T O O
cells O O
by O O
either O O
anti-CD3 B B_GENE
and O O
anti-CD28 B B_GENE
or O O
phorbol O O
myristyl O O
acetate O O
( O O
PMA O O
) O O
. O O

We O O
also O O
found O O
the O O
PPARgamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligand I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ciglitizone O O
to O O
attenuate O O
the O O
activation O O
of O O
T O O
cells O O
by O O
inhibiting O O
cytokine O O
gene O O
expression O O
and O O
anti-CD3 B B_GENE
and O O
anti-CD28 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
PMA-induced O O
proliferative O O
responses O O
. O O

Inhibition O O
of O O
both O O
the O O
proliferative O O
response O O
and O O
inflammatory O O
cytokine O O
expression O O
in O O
CD4 O O
T O O
cells O O
was O O
correlated O O
with O O
suppression O O
of O O
the O O
activated O O
transcription B B_GENE/B_LOCATION
factors I I_GENE/I_LOCATION
AP1 B I_GENE/I_LOCATION
and O O
NF-kappaB B B_GENE
. O O

PPARgamma B B_PERSON/B_DISEASE
ligands I I_PERSON/I_DISEASE
also O O
strongly O O
inhibited O O
SEA-induced O O
Vbeta3 O O
T O O
cell O O
activation O O
in O O
vivo O O
. O O

These O O
results O O
, O O
together O O
with O O
previous O O
findings O O
of O O
the O O
inhibitory O O
effect O O
of O O
PPARgamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligands I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
activated O O
macrophages O O
, O O
provide O O
clear O O
evidence O O
for O O
PPARgamma B B_GENE
as O O
a O O
negative B B_GENE/B_PERSON
regulator I I_GENE/I_PERSON
of O O
the O O
inflammatory O O
activation O O
of O O
both O O
macrophage O O
and O O
T O O
cells O O
. O O

PPARgamma B B_GENE
may O O
thus O O
be O O
a O O
potential O O
therapeutic O O
target O O
for O O
the O O
treatment O O
of O O
autoimmunity O O
. O O

A O O
prominent O O
role O O
for O O
activator B B_GENE
protein-1 I I_GENE
in O O
the O O
transcription O O
of O O
the O O
human B B_GENE
2B4 I I_GENE
( I I_GENE
CD244 I I_GENE
) I I_GENE
gene I I_GENE
in O O
NK O O
cells O O
. O O

The O O
cell B B_GENE/B_PERSON
surface I I_GENE/I_PERSON
glycoprotein I I_GENE/I_PERSON
2B4 I I_GENE/I_PERSON
( O O
CD244 B B_GENE
) O O
of O O
the O O
Ig B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
superfamily I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
is O O
involved O O
in O O
the O O
regulation O O
of O O
NK O O
and O O
T O O
lymphocyte O O
functions O O
. O O

We O O
have O O
recently O O
identified O O
CD48 B B_GENE
as O O
the O O
high B B_GENE/B_PERSON
affinity I I_GENE/I_PERSON
counterreceptor I I_GENE/I_PERSON
for O O
2B4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
both O O
mice O O
and O O
humans O O
. O O

The O O
cytoplasmic B B_GENE
domain I I_GENE
of O O
2B4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associates O O
with O O
src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homology I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain-containing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
signaling B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphocyte I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecule-associated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
whose O O
mutation O O
is O O
the O O
underlying O O
genetic O O
defect O O
in O O
the O O
X-linked O O
lymphoproliferative O O
syndrome O O
. O O

In O O
this O O
study O O
, O O
we O O
report O O
the O O
molecular O O
cloning O O
and O O
characterization O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2B4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
h2B4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Through O O
primer O O
extension O O
analysis O O
, O O
we O O
found O O
that O O
the O O
transcription O O
of O O
the O O
h2B4 B B_GENE
gene I I_GENE
initiates O O
at O O
multiple O O
start O O
sites O O
. O O

We O O
isolated O O
h2B4 B B_GENE
genomic I I_GENE
clones I I_GENE
and O O
PCR O O
amplified O O
the O O
5 B B_GENE/B_LOCATION
' I I_GENE/I_LOCATION
untranslated I I_GENE/I_LOCATION
region I I_GENE/I_LOCATION
containing O O
the O O
promoter B B_GENE
elements I I_GENE
. O O

We O O
have O O
identified O O
a O O
functional O O
AP-1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O O
lies O O
between O O
( O O
-106 O O
to O O
-100 O O
) O O
through O O
transient O O
transfection O O
analysis O O
in O O
YT O O
cells O O
, O O
a O O
human O O
NK O O
cell O O
line O O
. O O

EMSAs O O
with O O
Abs B B_GENE
specific O O
for O O
various O O
protein B B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
AP-1 B B_GENE/B_LOCATION
family I I_GENE/I_LOCATION
revealed O O
that O O
multiple O O
members O O
of O O
the O O
Jun B B_PERSON/B_ORGANIZATION
family I I_PERSON/I_ORGANIZATION
are O O
involved O O
in O O
the O O
regulation O O
of O O
the O O
h2B4 B B_GENE
gene I I_GENE
. O O

Mutation O O
of O O
the O O
AP-1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
not O O
only O O
abolishes O O
protein/DNA O O
interactions O O
but O O
also O O
promoter O O
activity O O
. O O

These O O
results O O
demonstrate O O
a O O
significant O O
role O O
for O O
AP-1 B B_GENE
in O O
the O O
transcriptional O O
regulation O O
of O O
the O O
h2B4 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
. O O

Functional O O
correction O O
of O O
FA-C O O
cells O O
with O O
FANCC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
suppresses O O
the O O
expression O O
of O O
interferon B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gamma-inducible I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Because O O
hematopoietic O O
cells O O
derived O O
from O O
Fanconi O O
anemia O O
( O O
FA O O
) O O
patients O O
of O O
the O O
C-complementation O O
group O O
( O O
FA-C O O
) O O
are O O
hypersensitive O O
to O O
the O O
inhibitory O O
effects O O
of O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IFNgamma B B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
the O O
products O O
of O O
certain O O
IFNgamma-inducible B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
known O O
to O O
influence O O
hematopoietic O O
cell O O
survival O O
were O O
quantified O O
. O O

High O O
constitutive O O
expression O O
of O O
the O O
IFNgamma-inducible B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
IFN-stimulated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunit I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ISGF3gamma B B_GENE/B_DISEASE
) O O
, O O
IFN B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IRF-1 B B_GENE/B_DISEASE
) O O
, O O
and O O
the O O
cyclin-dependent B B_GENE/B_PERSON
kinase I I_GENE/I_PERSON
inhibitor I I_GENE/I_PERSON
p21 I I_GENE/I_PERSON
( O O
WAF1 B B_GENE/B_DISEASE
) O O
was O O
found O O
in O O
FANCC B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
mutant O O
B O O
lymphoblasts O O
, O O
low-density O O
bone O O
marrow O O
cells O O
, O O
and O O
murine O O
embryonic O O
fibroblasts O O
. O O

Paradoxically O O
, O O
these O O
cells O O
do O O
not O O
activate B B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
signal I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
transducer I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
of I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
STAT I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
properly O O
. O O

In O O
an O O
attempt O O
to O O
clarify O O
mechanisms O O
by O O
which O O
FA-C O O
cells O O
overexpress O O
IFNgamma-inducible B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
face O O
of O O
defective O O
STAT1 O O
phosphorylation O O
, O O
it O O
was O O
reasoned O O
that O O
decreased O O
levels O O
of O O
activated B B_GENE
STAT1 I I_GENE
might O O
result O O
in O O
reduced O O
expression O O
of O O
a O O
hematopoietic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IFNgamma-responsive I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
normally O O
modulates O O
expression O O
of O O
other O O
IFNgamma-responsive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Levels O O
of O O
the O O
IFNgamma B B_GENE
-inducible O O
factor O O
IFN B B_PROTEIN[GENE]/B_MEASURE
consensus I I_PROTEIN[GENE]/I_MEASURE
sequence I I_PROTEIN[GENE]/I_MEASURE
binding I I_PROTEIN[GENE]/I_MEASURE
protein I I_PROTEIN[GENE]/I_MEASURE
( O O
ICSBP B B_DISEASE/B_GENE
) O O
, O O
a O O
negative B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
trans-acting I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
some O O
IFNgamma-inducible B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
were O O
quantified O O
. O O

ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
levels O O
were O O
reduced O O
in O O
FA-C O O
B O O
lymphoblasts O O
and O O
MEFs O O
. O O

However O O
, O O
enforced O O
expression O O
of O O
ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
failed O O
to O O
down-regulate O O
IRF-1 B B_GENE
, O O
ISGF3gamma B B_GENE
, O O
and O O
p21 B B_GENE
( I I_GENE
WAF1 I I_GENE
) I I_GENE
. O O

Thus O O
, O O
the O O
FANCC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
functions O O
to O O
modulate O O
expression O O
of O O
a O O
family O O
of O O
genes O O
that O O
in O O
normal O O
cells O O
are O O
inducible O O
only O O
by O O
specific O O
environmental O O
cues O O
for O O
apoptosis O O
or O O
mitogenic O O
inhibition O O
, O O
but O O
it O O
does O O
so O O
independently O O
of O O
the O O
classic O O
IFN-STAT1 O O
pathway O O
and O O
is O O
not O O
the O O
direct O O
result O O
of O O
reduced O O
ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
. O O

A O O
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
investigation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
E2A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
function O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
lymphocyte O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
development O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
are O O
derived O O
from O O
hematopoietic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stem O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
HSC O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
) O O
following O O
a O O
series O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
regulated O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
differentiation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
events O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Multipotent O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
HSCs O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
become O O
committed O O
to O O
the O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lineage O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
bone O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
marrow O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
lineage O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
in O O
the O O
thymus O B_BODY_PART_OR_ORGAN_COMPONENT
after O O
receiving O O
appropriate O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
signals O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
corresponding O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
microenvironment O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O O

These O O
committed O O
lymphoid O O
cells O O
must O O
then O O
undergo O O
V O O
( O O
D O O
) O O
J O O
recombination O O
at O O
the O O
immunoglobulin B B_GENE
gene I I_GENE
or O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resulting O O
in O O
clonal O O
production O O
of O O
functional O O
B O O
or O O
T O O
lymphocytes O O
, O O
respectively O O
. O O

Lymphocyte O O
commitment O O
and O O
differentiation O O
are O O
accompanied O O
by O O
programmed O O
gene O O
expression O O
or O O
repression O O
events O O
which O O
are O O
driven O O
by O O
lineage B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stage I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
basic-helix-loop-helix B B_GENE
( I I_GENE
bHLH I I_GENE
) I I_GENE
transcription I I_GENE
factors I I_GENE
encoded O O
by O O
the O O
E2A B B_GENE
gene I I_GENE
are O O
involved O O
in O O
several O O
differentiation O O
events O O
during O O
B O O
and O O
T O O
cell O O
development O O
, O O
including O O
lineage O O
commitment O O
, O O
initiation O O
of O O
V O O
( O O
D O O
) O O
J O O
recombination O O
, O O
and O O
antigen O O
receptor O O
mediated O O
proliferation O O
and O O
differentiation O O
. O O

Several O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recent O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviews O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
provided O O
a O O
comprehensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
discussion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
E2A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
lymphocyte O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
development O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O O
1 O B_MEASURE
, O O
2 O B_MEASURE
) O O
. O O

Here O O
, O O
we O O
only O O
discuss O O
some O O
of O O
the O O
genetic O O
approaches O O
our O O
laboratory O O
( O O
except O O
where O O
it O O
is O O
noted O O
) O O
has O O
undertaken O O
to O O
investigate O O
the O O
molecular O O
pathways O O
mediated O O
by O O
E2A B B_GENE
transcription I I_GENE
factors I I_GENE
in O O
lymphocyte O O
development O O

D609 O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibits O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ionizing O O
radiation-induced O O
oxidative O B_DISEASE/B_GENE
damage O I_DISEASE/I_GENE
by O O
acting O O
as O O
a O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antioxidant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Tricyclodecan-9-yl-xanthogenate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
D609 O B_LOCATION/B_PROTEIN[GENE]
) O O
has O O
been O O
extensively O O
studied O O
in O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
systems O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O O
exhibits O O
a O O
variety O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
biological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
functions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
antiviral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
antitumor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
anti-inflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activities O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Most O O
of O O
these O O
activities O O
have O O
been O O
largely O O
attributed O O
to O O
the O O
inhibitory O O
effect O O
of O O
D609 O O
on O O
phosphatidylcholine-specific O O
phospholipase B B_ENZYME[GENE]
C I I_ENZYME[GENE]
. O O

However O O
, O O
as O O
a O O
xanthate O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivative O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
D609 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
strong O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrolyte O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
readily O O
dissociates O O
to O O
xanthate O O
anions O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cations O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
alkali O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
metals O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
solution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Xanthate O B_PERSON/B_LOCATION
anions O I_PERSON/I_LOCATION
and O O
protonated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
xanthic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contain O O
a O O
free O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
thiol O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
moiety O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
are O O
highly O O
reductive O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
implies O O
that O O
D609 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
xanthate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derivatives O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
function O O
as O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antioxidants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Indeed O O
, O O
we O O
found O O
that O O
D609 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O O
the O O
Fenton O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
reaction-induced O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
oxidation O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
dihydrorhodamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
123 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
a O O
dose-dependent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manner O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
similar O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
that O O
of O O
pyrrolidinedithiocarbamate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
well O O
known O O
antioxidant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
D609 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
inhibited O O
the O O
formation O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
alpha-phenyl-tert-butylnitrone-free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
radical O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
spin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
adducts O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
lipid O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
peroxidation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
synaptosomal O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
membranes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
the O O
Fenton O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
reagents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Furthermore O O
, O O
preincubation O O
of O O
lymphocytes O O
with O O
D609 O O
resulted O O
in O O
a O O
significant O O
diminution O O
of O O
ionizing O O
radiation O O
( O O
IR O O
) O O
-induced O O
1 O O
) O O
production O O
of O O
reactive O O
oxygen O O
species O O
; O O
2 O O
) O O
decrease O O
in O O
intracellular O O
reduced O O
glutathione O O
; O O
3 O O
) O O
oxidative O O
damage O O
to O O
proteins O O
and O O
lipids O O
; O O
and O O
4 O O
) O O
activation O O
of O O
nuclear B B_GENE
factor-kappaB I I_GENE
. O O

Moreover O O
, O O
when O O
D609 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
50 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mg/kg O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
i.v. O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
was O O
administered O O
to O O
mice O O
10 O O
min O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
prior O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
to O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
total O O
body O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
IR O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
6.5 O O
and O B_MEASURE
8.5 O O
Gy O B_MEASURE/B_LOCATION
) O I_MEASURE/I_LOCATION
, O O
it O O
protected O O
the O O
mice O O
from O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IR-induced O O
lethality O B_DISEASE
. O I_DISEASE

Thus O O
, O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
D609 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
a O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antioxidant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
has O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
inhibit O O
IR-induced O B_DISEASE/B_GENE
cellular O B_DISEASE/I_GENE
oxidative O B_DISEASE/I_GENE
stress O B_DISEASE/I_GENE
. O O

Inhibition O O
of O O
AP-1 B B_GENE
by O O
the O O
glucocorticoid-inducible O O
protein B B_GENE/B_LOCATION
GILZ I I_GENE/I_LOCATION
. O O

The O O
immunosuppressive O O
effects O O
of O O
glucocorticoids O O
arise O O
largely O O
by O O
inhibition O O
of O O
cytokine O O
gene O O
expression O O
, O O
which O O
has O O
been O O
ascribed O O
to O O
interference O O
between O O
the O O
glucocorticoid B B_GENE
receptor I I_GENE
and O O
transcription B B_GENE
factors I I_GENE
such O O
as O O
AP-1 B B_GENE
and O O
NF-kappa B B_GENE
B I I_GENE
as O O
well O O
as O O
by O O
competition O O
for O O
common O O
coactivators O O
. O O

Here O O
we O O
show O O
that O O
glucocorticoid-induced O O
inhibition O O
of O O
interleukin-2 O O
mRNA O O
expression O O
in O O
activated O O
normal O O
T O O
cells O O
required O O
new O O
protein O O
synthesis O O
, O O
suggesting O O
that O O
this O O
phenomenon O O
is O O
secondary O O
to O O
expression O O
of O O
glucocorticoid-regulated O O
genes B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

One O O
of O O
the O O
most O O
prominent O O
glucocorticoid-induced O O
genes B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
glucocorticoid-induced B B_GENE
leucine I I_GENE
zipper I I_GENE
( O O
GILZ B B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
which O O
has O O
been O O
reported O O
to O O
inhibit O O
activation-induced O O
up-regulation O O
of O O
Fas B B_GENE
ligand I I_GENE
( I I_GENE
FasL I I_GENE
) I I_GENE
mRNA I I_GENE
. O O

Indeed O O
, O O
transient O O
expression O O
of O O
GILZ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Jurkat O O
T O O
cells O O
blocked O O
induction O O
of O O
a O O
reporter B B_GENE/B_LOCATION
construct I I_GENE/I_LOCATION
driven O O
by O O
the O O
FasL B B_GENE
promoter I I_GENE
. O O

This O O
could O O
be O O
accounted O O
for O O
by O O
GILZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-mediated O O
inhibition O O
of O O
Egr-2 B B_GENE
and O O
Egr-3 B B_GENE
, O O
NFAT/AP-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-inducible O O
transcription B B_GENE
factors I I_GENE
that O O
bind O O
a O O
regulatory B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
in O O
the O O
FasL B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
and O O
up-regulate O O
FasL O O
expression O O
. O O

GILZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O O
potently O O
inhibited O O
AP-1-driven B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter-driven I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
recombinant O O
GILZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
specifically O O
interacted O O
with O O
c-Fos B B_GENE
and O O
c-Jun B B_GENE/B_LOCATION
in O O
vitro O O
and O O
inhibited O O
the O O
binding O O
of O O
active B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
its O O
target O O
DNA O O
. O O

Whereas O O
homodimerization O O
of O O
GILZ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O O
the O O
presence O O
of O O
its O O
leucine B B_GENE/B_PERSON
zipper I I_GENE/I_PERSON
, O O
the O O
interaction O O
with O O
c-Fos B B_GENE
and O O
c-Jun B B_GENE
occurred O O
through O O
the O O
N-terminal B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
60-amino B B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
GILZ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thus O O
, O O
GILZ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represents O O
a O O
glucocorticoid-induced O O
gene O O
product O O
that O O
can O O
inhibit O O
a O O
variety O O
of O O
activation-induced O O
events O O
, O O
at O O
least O O
in O O
part O O
by O O
direct O O
interference O O
with O O
AP-1 B B_GENE
, O O
and O O
is O O
therefore O O
a O O
candidate O O
for O O
a O O
mediator O O
of O O
glucocorticoid-induced O O
immunosuppression O O
. O O

Pharmacokinetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
a O O
T O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell-tolerizing O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
T O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell-activating O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
peptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Vaccination O O
with O O
a O O
peptide O O
representing O O
a O O
CTL O O
epitope O O
from O O
the O O
human O O
papillomavirus O O
( O O
HPV O O
) O O
16 O O
E7 B B_GENE
protein I I_GENE
induces O O
a O O
specific O O
CTL O O
response O O
that O O
prevents O O
the O O
outgrowth O O
of O O
HPV16 O O
E7-expressing O O
tumors O O
. O O

In O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O O
vaccination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
a O O
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
encoding O O
an O O
adenovirus O B_VIRUS[BIO]/B_DISEASE
type O I_VIRUS[BIO]/I_DISEASE
5 O I_VIRUS[BIO]/I_DISEASE
( O O
Ad5 O B_PROTEIN[GENE]/B_SPECIES[BIO]
) O O
E1A O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CTL O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epitope O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
CTL O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tolerance O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
enhanced O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
growth O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
an O O
Ad5 O B_DISEASE
E1A-expressing O I_DISEASE
tumor O I_DISEASE
. O O

It O O
is O O
unclear O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
why O O
these O O
peptides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induce O O
such O B_DISEASE
opposite O I_DISEASE
effects O I_DISEASE
. O O

To O O
determine O O
whether O O
a O O
difference O B_MEASURE
in O O
pharmacokinetics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O O
explain O O
the O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contrasts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
tritiated O O
Ad5 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
E1A O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
HPV16 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
E7 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
peptides O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
injected O O
into O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O O
that O O
the O O
tolerizing O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
peptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
spread O O
through O O
the O O
body O B_BODY_PART_OR_ORGAN_COMPONENT
16 O I_BODY_PART_OR_ORGAN_COMPONENT
times O I_BODY_PART_OR_ORGAN_COMPONENT
faster O O
than O O
the O O
activating O O
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
was O O
cleared O O
at O O
least O O
2 O B_TIME[MEASURE]
times O I_TIME[MEASURE]
faster O O
. O O

The O O
HPV16 O O
E7 O O
peptide O O
kinetics O O
correlated O O
with O O
the O O
kinetics O O
of O O
HPV16 B B_VIRUS[BIO]/B_PROTEIN[GENE]
E7 I B_VIRUS[BIO]/I_PROTEIN[GENE]
-specific O O
CTL O O
induction O O
. O O

In O O
contrast O O
, O O
Ad5 O O
E1A O O
peptide O O
injection O O
resulted O O
in O O
physical O O
deletion O O
of O O
preexisting O O
Ad5 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
E1A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-specific O O
CTLs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
within O O
24 O O
h O O
after O O
injection O O
. O O

This O O
tolerization O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
occurred O O
at O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
when O O
the O O
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reached O O
its O O
maximum O B_MEASURE/B_LOCATION
peptide O B_MEASURE/I_LOCATION
concentration O B_MEASURE/I_LOCATION
in O O
the O O
organs O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

These O O
data O O
suggest O O
that O O
ubiquitous O O
expression O O
of O O
the O O
tolerizing O O
Ad5 O O
E1A O O
peptide O O
within O O
a O O
short O O
period O O
of O O
time O O
causes O O
activation-induced O O
cell O O
death O O
of O O
Ad5 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
E1A I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
-specific O O
CTLs B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Therefore O O
, O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
the O O
pharmacokinetics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
peptides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
vital O B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
peptide-based O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vaccines O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Smad3 B B_GENE
and O O
Smad4 B B_GENE
mediate O O
transforming B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor-beta1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
IgA O O
expression O O
in O O
murine O O
B O O
lymphocytes O O
. O O

Transforming B B_GENE/B_DISEASE
growth I I_GENE/I_DISEASE
factor I I_GENE/I_DISEASE
( I I_GENE/I_DISEASE
TGF I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
-beta1 I I_GENE/I_DISEASE
is O O
well O O
established O O
as O O
a O O
critical O O
IgA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isotype I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
switching I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Smad B B_GENE/B_MEASURE
molecules I I_GENE/I_MEASURE
have O O
been O O
reported O O
to O O
act O O
as O O
transducers B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
transcriptional B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
the O O
expression O O
of O O
TGF-beta1 B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
-targeted O O
genes B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

We O O
examined O O
the O O
involvement O O
of O O
Smad B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
TGF-beta1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
IgA O O
expression O O
. O O

First O O
, O O
we O O
found O O
that O O
TGF-beta1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O O
increases O O
endogenous B B_DISEASE_ADJECTIVE[DISEASE]
germ-line I I_DISEASE_ADJECTIVE[DISEASE]
( I I_DISEASE_ADJECTIVE[DISEASE]
GL I I_DISEASE_ADJECTIVE[DISEASE]
) I I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_DISEASE_ADJECTIVE[DISEASE]
by O O
LPS-stimulated O O
CH12.LX.4933 O O
( O O
mu O O
( O O
+ O O
) O O
) O O
B O O
lymphoma O O
cells O O
. O O

To O O
investigate O O
its O O
signaling O O
mechanisms O O
, O O
the O O
lymphoma O O
cell O O
line O O
was O O
transfected O O
with O O
pFL3 B B_GENE
that O O
contains O O
the O O
TGF-beta-responsive B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
of O O
the O O
GLalpha B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
and O O
stimulated O O
with O O
TGF-beta1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Similar O O
to O O
endogenous B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GLalpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
TGF-beta1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
GLalpha B B_GENE/B_MEASURE
promoter I I_GENE/I_MEASURE
activity O O
and O O
overexpression O O
of O O
Smad3 B B_GENE
markedly O O
enhances O O
the O O
promoter O O
activity O O
. O O

This O O
activity O O
is O O
further O O
augmented O O
by O O
cotransfected B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Smad4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

On O O
the O O
other O O
hand O O
, O O
Smad7 B B_GENE
substantially O O
abrogates O O
the O O
synergistic O O
effect O O
of O O
Smad3/4 B B_GENE
on O O
GLalpha B B_GENE
promoter I I_GENE
activity O O
. O O

In O O
addition O O
, O O
overexpression O O
of O O
Smad3/4 B B_GENE
enhances O O
TGF-beta1 B B_GENE
-induced O O
endogenous B B_DISEASE/B_GENE
GLalpha I I_DISEASE/I_GENE
transcripts I I_DISEASE/I_GENE
in O O
normal O O
spleen O O
B O O
cell O O
s O O
. O O

Finally O O
, O O
in O O
the O O
presence O O
of O O
TGF-beta1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
overexpression O O
of O O
Smad3/4 B B_GENE
selectively O O
increases O O
both O O
surface O O
IgA O O
expression O O
and O O
IgA O O
production O O
. O O

The O O
results O O
from O O
the O O
present O O
study O O
indicate O O
that O O
Smad3 B B_GENE
, O O
Smad4 B B_GENE
, O O
and O O
Smad7 B B_GENE
, O O
at O O
least O O
in O O
part O O
, O O
serve O O
as O O
mediators O O
linking O O
TGF-beta1 B B_GENE/B_LOCATION
to O O
transcriptional O O
regulation O O
of O O
IgA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
switching I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
regulation O O
of O O
IgA O O
class O O
switching O O
. O O

The O O
translesion B B_GENE
DNA I I_GENE
polymerase I I_GENE
zeta I I_GENE
plays O O
a O O
major O O
role O O
in O O
Ig O O
and O O
bcl-6 O O
somatic O O
hypermutation O O
. O O

Ig O O
somatic O O
mutations O O
would O O
be O O
introduced O O
by O O
a O O
polymerase B B_GENE
( O O
pol B B_PROTEIN[GENE]/B_DISEASE
) O O
while O O
repairing O O
DNA O O
outside O O
main O O
DNA O O
replication O O
. O O

We O O
show O O
that O O
human O O
B O O
cells O O
constitutively O O
express O O
the O O
translesion B B_GENE/B_DISEASE
pol I I_GENE/I_DISEASE
zeta I I_GENE/I_DISEASE
, O O
which O O
effectively O O
extends O O
DNA O O
past O O
mismatched O O
bases O O
( O O
mispair O O
extender O O
) O O
, O O
and O O
pol B B_PROTEIN[GENE]
eta I I_PROTEIN[GENE]
, O O
which O O
bypasses O O
DNA O O
lesions O O
in O O
an O O
error-free O O
fashion O O
. O O

Upon O O
B B B_GENE
cell I I_GENE
receptor I I_GENE
( O O
BCR B B_PROTEIN[GENE]/B_LOCATION
) O O
engagement O O
and O O
coculture O O
with O O
activated O O
CD4+ O O
T O O
cells O O
, O O
these O O
lymphocytes O O
upregulated O O
pol B B_GENE
zeta I I_GENE
, O O
downregulated O O
pol B B_GENE
eta I I_GENE
, O O
and O O
mutated O O
the O O
Ig B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bcl-6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Inhibition O O
of O O
the O O
pol B B_GENE
zeta I I_GENE
REV3 B I_GENE
catalytic I I_GENE
subunit I I_GENE
by O O
specific O O
phosphorothioate-modified O O
oligonucleotides O O
impaired O O
Ig O O
and O O
bcl-6 O O
hypermutation O O
and O O
UV O O
damage-induced O O
DNA O O
mutagenesis O O
, O O
without O O
affecting O O
cell O O
cycle O O
or O O
viability O O
. O O

Thus O O
, O O
pol B B_GENE
zeta I I_GENE
plays O O
a O O
critical O O
role O O
in O O
Ig O O
and O O
bcl-6 O O
hypermutation O O
, O O
perhaps O O
facilitated O O
by O O
the O O
downregulation O O
of O O
pol B B_GENE
eta I I_GENE
. O O

Molecular O O
mechanism O O
of O O
cell O O
cycle O O
progression O O
induced O O
by O O
the O O
oncogene B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
product I B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Tax I B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
human O O
T-cell O O
leukemia O O
virus O O
type O O
I O O
. O O

The O O
trans-activator B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Tax I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
human O O
T-cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV-I O O
) O O
plays O O
an O O
important O O
role O O
in O O
the O O
development O O
of O O
adult O O
T-cell O O
leukemia O O
through O O
, O O
at O O
least O O
in O O
part O O
, O O
its O O
ability O O
to O O
stimulate O O
cell O O
growth O O
. O O

We O O
previously O O
reported O O
that O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
cell O O
cycle O O
progression O O
from O O
G0/G1 O O
phase O O
to O O
S O O
and O O
G2/M O O
phases O O
in O O
human O O
T-cell O O
line O O
Kit O O
225 O O
cells O O
. O O

To O O
elucidate O O
molecular O O
mechanism O O
of O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
-induced O O
cell O O
cycle O O
progression O O
, O O
we O O
systematically O O
examined O O
the O O
effects O O
of O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
biochemical O O
events O O
associated O O
with O O
cell O O
cycle O O
progression O O
. O O

Introduction O O
of O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
into O O
resting O O
Kit O O
225 O O
cells O O
induced O O
activation O O
of O O
the O O
G1/S O O
transition O O
regulation O O
cascade O O
consisting O O
of O O
activation O O
of O O
cyclin B B_GENE
dependent I I_GENE
kinase I I_GENE
2 I I_GENE
( O O
CDK2 B B_GENE
) O O
and O O
CDK4 B B_GENE
, O O
phosphorylation O O
of O O
the O O
Rb B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
an O O
increase O O
in O O
free O O
E2F B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
kinase O O
activation O O
was O O
found O O
to O O
result O O
from O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
expression O O
of O O
genes O O
for O O
cell B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cycle I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
regulatory I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
molecules I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
including O O
cyclin B B_GENE
D2 I I_GENE
, O O
cyclin B B_GENE
E I I_GENE
, O O
E2F1 B B_GENE
, O O
CDK2 B B_GENE
, O O
CDK4 B B_GENE
and O O
CDK6 B B_GENE/B_MEASURE
, O O
and O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
reduction O O
of O O
CDK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p19 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
INK4d B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
p27 B B_GENE
( I I_GENE
Kip1 I I_GENE
) I I_GENE
. O O

These O O
modulations O O
by O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
always O O
paralleled O O
the O O
ability O O
of O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
activate O O
the O O
NF-kappaB O O
transcription O O
pathway O O
. O O

These O O
results O O
indicate O O
the O O
important O O
role O O
of O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-mediated O O
trans-activation O O
of O O
the O O
genes O O
for O O
cell B B_GENE/B_ORGANIZATION
cycle I I_GENE/I_ORGANIZATION
regulatory I I_GENE/I_ORGANIZATION
molecules I I_GENE/I_ORGANIZATION
in O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O O
cell O O
cycle O O
progression O O
. O O

Cot B B_GENE
kinase I I_GENE
induces O O
cyclooxygenase-2 O O
expression O O
in O O
T O O
cells O O
through O O
activation O O
of O O
the O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cyclooxygenase-2 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
COX-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
induced O O
in O O
human O O
T O O
lymphocytes O O
upon O O
T B B_GENE/B_DISEASE
cell I I_GENE/I_DISEASE
receptor I I_GENE/I_DISEASE
triggering O O
. O O

Here O O
we O O
report O O
that O O
Cot B B_GENE
kinase I I_GENE
, O O
a O O
mitogen-activated B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
involved O O
in O O
T O O
cell O O
activation O O
, O O
up-regulates O O
COX-2 B B_GENE
gene I I_GENE
expression O O
in O O
Jurkat O O
T O O
cells O O
. O O

Induction O O
of O O
COX-2 O O
promoter O O
activity O O
by O O
Cot B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
kinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
occurred O O
mainly O O
through O O
activation O O
of O O
the O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NFAT B B_GENE/B_LOCATION
) O O
. O O

Mutation O O
of O O
the O O
distal B B_LOCATION
( I I_LOCATION
-105/-97 I I_LOCATION
) I I_LOCATION
and O O
proximal B B_LOCATION/B_GENE
( I B_LOCATION/I_GENE
-76/-61 I B_LOCATION/I_GENE
) I B_LOCATION/I_GENE
NFAT B B_LOCATION/I_GENE
response I B_LOCATION/I_GENE
elements I B_LOCATION/I_GENE
in O O
the O O
COX-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
abolished O O
the O O
activation O O
induced O O
by O O
Cot B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Even O O
more O O
, O O
coexpression O O
of O O
a O O
dominant O O
negative O O
version O O
of O O
NFAT B B_GENE
inhibited O O
Cot B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-mediated O O
COX-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O O
, O O
whereas O O
cotransfection O O
of O O
a O O
constitutively O O
active O O
version O O
of O O
the O O
calcium-dependent B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
calcineurin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synergizes O O
with O O
Cot B B_GENE
kinase I I_GENE
in O O
the O O
up-regulation O O
of O O
COX-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-driven O O
transcription O O
. O O

Strikingly O O
, O O
Cot B B_GENE/B_PERSON
kinase I I_GENE/I_PERSON
increased O O
transactivation O O
mediated O O
by O O
a O O
GAL4-NFAT B B_GENE/B_LOCATION
fusion I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
containing O O
the O O
N-terminal B B_GENE/B_LOCATION
transactivation I I_GENE/I_LOCATION
domain I I_GENE/I_LOCATION
of O O
NFATp B B_GENE
. O O

In O O
contrast O O
to O O
phorbol O O
ester O O
plus O O
calcium O O
ionophore O O
A23187 O O
, O O
Cot B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
kinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
increases O O
both O O
COX-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
and O O
NFAT B B_GENE
-mediated O O
transactivation O O
in O O
a O O
cyclosporin O O
A-independent O O
manner O O
. O O

These O O
data O O
indicate O O
that O O
Cot B B_GENE
kinase I I_GENE
up-regulates O O
COX-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-driven O O
transcription O O
through O O
the O O
NFAT B B_GENE/B_LOCATION
response I I_GENE/I_LOCATION
elements I I_GENE/I_LOCATION
, O O
being O O
the O O
Cot B B_GENE
kinase I I_GENE
-induced O O
NFAT B B_GENE
-dependent O O
transactivation O O
presumably O O
implicated O O
in O O
this O O
up-regulation O O
. O O

Positive O O
and O O
negative O O
roles O O
of O O
the O O
trans-acting B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
T I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
cell I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
factor-1 I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
for O O
the O O
acquisition O O
of O O
distinct O O
Ly-49 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MHC I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
NK O O
cells O O
. O O

Members O O
of O O
the O O
Ly-49 B B_GENE/B_PERSON
gene I I_GENE/I_PERSON
family I I_GENE/I_PERSON
code O O
for O O
class B B_GENE
I I I_GENE
MHC-specific I I_GENE
receptors I I_GENE
that O O
regulate O O
NK O O
cell O O
function O O
. O O

Due O O
to O O
a O O
combinatorial O O
distribution O O
of O O
Ly-49 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
NK O O
cells O O
display O O
considerable O O
clonal O O
heterogeneity O O
. O O

The O O
acquisition O O
of O O
one O O
Ly-49 B B_GENE
receptor I I_GENE
, O O
Ly-49A B B_GENE/B_MEASURE
is O O
strictly O O
dependent O O
on O O
the O O
transcriptional B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
trans-acting I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cell-specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Indeed O O
, O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binds O O
to O O
two O O
sites O O
in O O
the O O
Ly-49a B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
and O O
regulates O O
its O O
activity O O
, O O
suggesting O O
that O O
the O O
Ly-49a B B_GENE/B_PERSON
gene I I_GENE/I_PERSON
is O O
a O O
direct O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O O
. O O

TCF-1 B B_MEASURE/B_PERSON
deficiency O O
resulted O O
in O O
the O O
altered O O
usage O O
of O O
additional O O
Ly-49 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
show O O
in O O
this O O
study O O
, O O
using O O
TCF-1 B B_GENE/B_NUMBER[MEASURE]
beta I I_GENE/I_NUMBER[MEASURE]
( I I_GENE/I_NUMBER[MEASURE]
2 I I_GENE/I_NUMBER[MEASURE]
) I I_GENE/I_NUMBER[MEASURE]
-microglobulin I I_GENE/I_NUMBER[MEASURE]
double-deficient O O
mice O O
, O O
that O O
these O O
repertoire O O
alterations O O
are O O
not O O
due O O
to O O
Ly-49/MHC O O
class O O
I O O
interactions O O
. O O

Our O O
findings O O
rather O O
suggest O O
a O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O O
, O O
cell O O
autonomous O O
effect O O
on O O
the O O
acquisition O O
of O O
multiple O O
Ly-49 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Besides O O
reduced O O
receptor O O
usage O O
( O O
Ly-49A B B_PROTEIN[GENE]/B_LOCATION
and I I_PROTEIN[GENE]/I_LOCATION
D I I_PROTEIN[GENE]/I_LOCATION
) O O
, O O
we O O
also O O
observed O O
no O O
effect O O
( O O
Ly-49C B B_PROTEIN[GENE]/B_LOCATION
) O O
and O O
significantly O O
expanded O O
( O O
Ly-49G B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
receptor O O
usage O O
in O O
the O O
absence O O
of O O
TCF-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

These O O
effects O O
did O O
not O O
in O O
all O O
cases O O
correlate O O
with O O
the O O
presence O O
of O O
TCF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
respective O O
proximal B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Therefore O O
, O O
besides O O
TCF-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O O
to O O
the O O
proximal B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
Ly-49 O O
acquisition O O
may O O
also O O
be O O
regulated O O
by O O
TCF-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O O
to O O
more O O
distant O O
cis-acting B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
elements I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and/or O O
by O O
regulating O O
the O O
expression O O
of O O
additional O O
trans-acting B B_GENE/B_LOCATION
factors I I_GENE/I_LOCATION
. O O

Consistent O O
with O O
the O O
observed O O
differential O O
, O O
positive O O
or O O
negative O O
role O O
of O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Ly-49 B B_GENE/B_DISEASE
receptor I I_GENE/I_DISEASE
acquisition O O
, O O
reporter O O
gene O O
assays O O
revealed O O
the O O
presence O O
of O O
an O O
inducing O O
as O O
well O O
as O O
a O O
repressing O O
TCF B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
certain O O
proximal O O
Ly-49 B B_GENE/B_LOCATION
promoters I I_GENE/I_LOCATION
. O O

These O O
findings O O
reveal O O
an O O
important O O
role O O
of O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
formation O O
of O O
the O O
NK B B_GENE
cell I I_GENE
receptor I I_GENE
repertoire O O
. O O

Ligation O O
of O O
CD11b B B_GENE
and O O
CD11c B B_GENE
beta I I_GENE
( I I_GENE
2 I I_GENE
) I I_GENE
integrins B I_GENE
by O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
soluble B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CD23 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
macrophage B B_GENE
inflammatory I I_GENE
protein I I_GENE
1alpha I I_GENE
( O O
MIP-1alpha B B_GENE
) O O
and O O
MIP-1beta B B_GENE
production O O
in O O
primary O O
human O O
monocytes O O
through O O
a O O
pathway O O
dependent O O
on O O
nuclear B B_GENE
factor-kappaB I I_GENE
. O O

Chemokines B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
adhesion B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
such O O
as O O
integrins B B_GENE/B_DISEASE
play O O
a O O
major O O
part O O
in O O
the O O
trafficking O O
, O O
extravasation O O
, O O
and O O
recruitment O O
of O O
leukocytes O O
to O O
inflammatory O O
sites O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
investigated O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O B_NUMBER[MEASURE]
) O O
integrin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
engagement O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
chemokine O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
production O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
by O O
freshly O O
isolated O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
found O O
that O O
ligation O O
of O O
CD11b B B_GENE
or O O
CD11c B B_GENE
but O O
not O O
CD11a B B_GENE/B_MEASURE
alpha I I_GENE/I_MEASURE
chains I I_GENE/I_MEASURE
of O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
integrins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
soluble B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CD23 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sCD23 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rapidly O O
induced O O
transcription O O
and O O
secretion O O
of O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
macrophage B B_MEASURE/B_GENE
inflammatory I I_MEASURE/I_GENE
protein I I_MEASURE/I_GENE
( I I_MEASURE/I_GENE
MIP I I_MEASURE/I_GENE
) I I_MEASURE/I_GENE
1alpha I I_MEASURE/I_GENE
, O O
and O O
MIP-1beta B B_GENE
. O O

Because O O
the O O
promoters B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
these O O
chemokine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contain O O
kappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
assessed O O
the O O
possible O O
role O O
of O O
nuclear B B_GENE
factor-kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
in O O
controlling O O
induction O O
of O O
the O O
genes O O
through O O
beta O O
( O O
2 O O
) O O
integrin O O
engagement O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
showed O O
that O O
sCD23 B B_GENE
or O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
CD11b B B_GENE
or O O
to O O
CD11c B B_GENE
up-regulated O O
DNA-binding O O
activity O O
of O O
NF-kappaB B B_GENE
. O O

Activation O O
of O O
NF-kappaB B B_GENE
was O O
accompanied O O
by O O
degradation O O
of O O
its O O
cytosolic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IkappaB-alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Blockade O O
of O O
depletion O O
of O O
IkappaB-alpha B B_GENE
by O O
proteasome O O
inhibitors O O
( O O
proteasome O O
inhibitor O O
I O O
or O O
acetyl-leucinyl-leucinyl-norleucinal O O
) O O
led O O
to O O
concomitant O O
inhibition O O
of O O
NF-kappaB O O
DNA-binding O O
activity O O
and O O
expression O O
of O O
MIP-1alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MIP-1beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
messenger I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
beta O O
( O O
2 O O
) O O
integrin O O
ligation O O
. O O

These O O
results O O
suggest O O
that O O
triggering O O
of O O
CD11b B B_GENE
or O O
CD11c B B_GENE
beta I I_GENE
( I I_GENE
2 I I_GENE
) I I_GENE
integrin O O
on O O
primary O O
human O O
monocytes O O
provides O O
activation O O
signals O O
leading O O
to O O
nuclear O O
translocation O O
of O O
NF-kappaB B B_GENE
and O O
subsequent O O
secretion O O
of O O
MIP-1alpha B B_GENE
and O O
MIP-1beta B B_GENE
that O O
may O O
have O O
an O O
important O O
role O O
in O O
recruitment O O
of O O
other O O
inflammatory O O
cells O O
during O O
initiation O O
of O O
an O O
inflammatory O O
response O O

Synergistic O O
transcriptional O O
activation O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Acyl-coenzyme I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cholesterol I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acyltransterase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
interferon-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
all-trans-retinoic O O
acid O O
THP-1 O O
cells O O
. O O

Acyl-coenzyme B B_GENE/B_ORGANIZATION
A I I_GENE/I_ORGANIZATION
: I I_GENE/I_ORGANIZATION
cholesterol I I_GENE/I_ORGANIZATION
acyltransferase I I_GENE/I_ORGANIZATION
( O O
ACAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
is O O
an O O
intracellular B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involved O O
in O O
cellular O O
cholesterol O O
homeostasis O O
and O O
in O O
atherosclerotic O O
foam O O
cell O O
formation O O
. O O

Human B B_GENE/B_LOCATION
ACAT-1 I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
contains O O
two O O
promoters B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
P1 B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
P7 B B_PROTEIN[GENE]
) O O
, O O
each O O
located O O
in O O
a O O
different O O
chromosome B B_LOCATION/B_PERSON
( I I_LOCATION/I_PERSON
1 I I_LOCATION/I_PERSON
and I I_LOCATION/I_PERSON
7 I I_LOCATION/I_PERSON
) I I_LOCATION/I_PERSON
( O O
Li O O
, O O
B. O O
L. O O
, O O
Li O O
, O O
X. O O
L. O O
, O O
Duan O O
, O O
Z. O O
J. O O
, O O
Lee O O
, O O
O. O O
, O O
Lin O O
, O O
S. O O
, O O
Ma O O
, O O
Z. O O
M. O O
, O O
Chang O O
, O O
C. O O
C. O O
, O O
Yang O O
, O O
X. O O
Y. O O
, O O
Park O O
, O O
J. O O
P. O O
, O O
Mohandas O O
, O O
T. O O
K. O O
, O O
Noll O O
, O O
W. O O
, O O
Chan O O
, O O
L. O O
, O O
and O O
Chang O O
, O O
T. O O
Y. O O
( O O
1999 O O
) O O
J. O O
Biol O O
Chem. O O
274 O O
, O O
11060-11071 O O
) O O
. O O

Interferon-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IFN-gamma B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
a O O
cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
exerts O O
many O O
pro-atherosclerotic O O
effects O O
in O O
vivo O O
, O O
causes O O
up-regulation O O
of O O
ACAT-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
blood O O
monocyte-derived O O
macrophages O O
and O O
macrophage-like O O
cells O O
but O O
not O O
in O O
other O O
cell O O
types O O
. O O

To O O
examine O O
the O O
molecular O O
nature O O
of O O
this O O
observation O O
, O O
we O O
identified O O
within O O
the O O
ACAT-1 B B_GENE/B_MEASURE
P1 I I_GENE/I_MEASURE
promoter I I_GENE/I_MEASURE
a O O
159-base B B_GENE/B_MEASURE
pair I I_GENE/I_MEASURE
core I I_GENE/I_MEASURE
region I I_GENE/I_MEASURE
. O O

This O O
region O O
contains O O
4 O O
Sp1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
an O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GAS B B_GENE/B_BACTERIUM[BIO]
) O O
that O O
overlaps O O
with O O
the O O
second O O
Sp1 B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
. O O

In O O
the O O
monocytic O O
cell O O
line O O
THP-1 O O
cell O O
, O O
the O O
combination O O
of O O
IFN-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
all-trans-retinoic O O
acid O O
( O O
a O O
known O O
differentiation O O
agent O O
) O O
enhances O O
the O O
ACAT-1 B B_GENE
P1 I I_GENE
promoter I I_GENE
but O O
not O O
the O O
P7 B B_GENE
promoter I I_GENE
. O O

Additional O O
experiments O O
showed O O
that O O
all-trans-retinoic O O
acid O O
causes O O
large O O
induction O O
of O O
the O O
transcription B B_GENE
factor I I_GENE
STAT1 I I_GENE
, O O
while O O
IFN-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
causes O O
activation O O
of O O
STAT1 B B_GENE
such O O
that O O
it O O
binds O O
to O O
the O O
GAS/Sp1 B B_GENE/B_MEASURE
site I I_GENE/I_MEASURE
in O O
the O O
ACAT-1 B B_GENE
P1 I I_GENE
promoter I I_GENE
. O O

Our O O
work O O
provides O O
a O O
molecular O O
mechanism O O
to O O
account O O
for O O
the O O
effect O O
of O O
IFN-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
causing O O
transcriptional O O
activation O O
of O O
ACAT-1 B B_GENE
in O O
macrophage-like O O
cells O O
. O O

Inhaled O O
nitric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
down-regulates O O
intrapulmonary O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
nitric O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
oxide O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
production O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
lipopolysaccharide-induced O B_DISEASE/B_BIO
acute O I_DISEASE/I_BIO
lung O I_DISEASE/I_BIO
injury O I_DISEASE/I_BIO
. O O

OBJECTIVE O O
: O O
To O O
examine O O
whether O O
inhaled O O
nitric O O
oxide O O
( O O
NO O O
) O O
affected O O
the O O
intrapulmonary O O
production O O
of O O
NO O O
, O O
reactive O O
oxygen O O
species O O
, O O
and O O
nuclear B B_GENE
factor-kappaB I I_GENE
in O O
a O O
lipopolysaccharide O O
( O O
LPS O O
) O O
-induced O O
model O O
of O O
acute O O
lung O O
injury O O
. O O

DESIGN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
randomized O O
, O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

SETTING O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Experimental O B_LOCATION/B_PERSON
laboratory O I_LOCATION/I_PERSON
at O O
a O O
biomedical O B_LOCATION/B_MEASURE
institute O I_LOCATION/I_MEASURE
. O O

SUBJECTS O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Twenty O B_PERSON
male O I_PERSON
rabbits O I_PERSON
weighing O O
2.5-3.5 O B_NUMBER[MEASURE]/B_LOCATION
kg O I_NUMBER[MEASURE]/I_LOCATION
. O O

INTERVENTIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
or O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
5 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg/kg O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
body O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
was O O
administered O O
intravenously O O
with O O
or O O
without O O
NO O O
inhalation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ppm O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
in O O
each O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
five O B_PERSON/B_SPECIES[BIO]
rabbits O I_PERSON/I_SPECIES[BIO]
. O O

MEASUREMENTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
AND O O
MAIN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
RESULTS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increased O O
the O O
lung O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leak O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
index O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
the O O
neutrophils O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
NO O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
bronchoalveolar O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lavage O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fluid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
NO O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
produced O O
by O O
resting O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
stimulated O O
alveolar O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Inhaled O O
NO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
decreased O O
the O O
lung O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leak O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
index O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
the O O
neutrophils O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
NO O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O O
measured O O
by O O
nitrite O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
lavage O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluid O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
NO O O
produced O O
by O O
the O O
resting O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
stimulated O O
alveolar O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Inhaled O O
NO O O
also O O
blocked O O
the O O
activities O O
of O O
reactive O O
oxygen O O
species O O
and O O
nuclear B B_GENE
factor-kappaB I I_GENE
binding O O
to O O
DNA O O
in O O
lavage O O
cells O O
and O O
in O O
alveolar O O
macrophages O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Inhaled O O
NO O O
attenuates O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
LPS-induced O O
acute O B_DISEASE/B_GENE
lung O I_DISEASE/I_GENE
injury O I_DISEASE/I_GENE
, O O
possibly O O
by O O
decreasing O O
NO O O
production O B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
lungs O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

The O O
mechanism O O
of O O
reducing O O
NO O O
production O O
resulting O O
from O O
inhaled O O
NO O O
may O O
involve O O
, O O
in O O
part O O
, O O
the O O
activities O O
of O O
reactive O O
oxygen O O
species O O
and/or O O
nuclear B B_GENE
factor-kappaB I I_GENE
. O O

Treatment O O
of O O
allergic O O
airway O O
inflammation O O
and O O
hyperresponsiveness O O
by O O
antisense-induced O O
local O O
blockade O O
of O O
GATA-3 B B_GENE
expression O O
. O O

Recent O O
studies O O
in O O
transgenic O O
mice O O
have O O
revealed O O
that O O
expression O O
of O O
a O O
dominant O O
negative O O
form O O
of O O
the O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
GATA-3 I I_GENE/I_LOCATION
in O O
T O O
cells O O
can O O
prevent O O
T O O
helper O O
cell O O
type O O
2 O O
( O O
Th2 O O
) O O
-mediated O O
allergic O O
airway O O
inflammation O O
in O O
mice O O
. O O

However O O
, O O
it O O
remains O O
unclear O O
whether O O
GATA-3 B B_GENE
plays O O
a O O
role O O
in O O
the O O
effector O O
phase O O
of O O
allergic O O
airway O O
inflammation O O
and O O
whether O O
antagonizing O O
the O O
expression O O
and/or O O
function O O
of O O
GATA-3 B B_GENE
can O O
be O O
used O O
for O O
the O O
therapy O O
of O O
allergic O O
airway O O
inflammation O O
and O O
hyperresponsiveness O O
. O O

Here O O
, O O
we O O
analyzed O O
the O O
effects O O
of O O
locally O O
antagonizing O O
GATA-3 B B_GENE
function O O
in O O
a O O
murine O O
model O O
of O O
asthma O O
. O O

We O O
could O O
suppress O O
GATA-3 O O
expression O O
in O O
interleukin B B_GENE
( I I_GENE
IL I I_GENE
) I I_GENE
-4 I I_GENE
-producing O O
T O O
cells O O
in O O
vitro O O
and O O
in O O
vivo O O
by O O
an O O
antisense O O
phosphorothioate O O
oligonucleotide O O
overlapping O O
the O O
translation B B_LOCATION/B_ORGANIZATION
start I I_LOCATION/I_ORGANIZATION
site I I_LOCATION/I_ORGANIZATION
of O O
GATA-3 B B_GENE
, O O
whereas O O
nonsense O O
control O O
oligonucleotides O O
were O O
virtually O O
inactive O O
. O O

In O O
a O O
murine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
asthma O B_DISEASE/B_LOCATION
associated O O
with O O
allergic O B_DISEASE
pulmonary O I_DISEASE
inflammation O I_DISEASE
and O O
hyperresponsiveness O B_DISEASE
in O O
ovalbumin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
OVA O B_DISEASE/B_LOCATION
) O O
-sensitized O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
local O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intranasal O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
fluorescein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isothiocyanate-labeled O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
GATA-3 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antisense O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oligonucleotides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
led O O
to O O
DNA O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
uptake O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
lung O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
a O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
intracellular O B_DISEASE/B_GENE
GATA-3 O I_DISEASE/I_GENE
expression O I_DISEASE/I_GENE
. O O

Such O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intrapulmonary O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
blockade O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
GATA-3 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
caused O O
an O O
abrogation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
signs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
lung O B_DISEASE/B_GENE
inflammation O I_DISEASE/I_GENE
including O O
infiltration O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
eosinophils O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
Th2 O B_DISEASE
cytokine O I_DISEASE
production O I_DISEASE
. O O

Furthermore O O
, O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
antisense O B_GENE
but O O
not O O
nonsense O B_GENE
oligonucleotides O I_GENE
induced O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
airway O B_DISEASE
hyperresponsiveness O I_DISEASE
in O O
OVA-sensitized O B_DISEASE/B_BIO
mice O I_DISEASE/I_BIO
to O O
levels O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparable O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
saline-treated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mice O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
as O O
assessed O O
by O O
both O O
enhanced O O
pause O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
PenH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
responses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]
resistance O I_DISEASE_ADJECTIVE[DISEASE]
determined O O
by O O
body O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
plethysmography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

These O O
data O O
indicate O O
a O O
critical O O
role O O
for O O
GATA-3 B B_GENE
in O O
the O O
effector O O
phase O O
of O O
a O O
murine O O
asthma O O
model O O
and O O
suggest O O
that O O
local O O
delivery O O
of O O
GATA-3 O O
antisense O O
oligonucleotides O O
may O O
be O O
a O O
novel O O
approach O O
for O O
the O O
treatment O O
of O O
airway O O
hyperresponsiveness O O
such O O
as O O
in O O
asthma O O
. O O

This O O
approach O O
has O O
the O O
potential O O
advantage O O
of O O
suppressing O O
the O O
expression O O
of O O
various O O
proinflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Th2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
simultaneously O O
rather O O
than O O
suppressing O O
the O O
activity O O
of O O
a O O
single O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

T O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
helper-cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulates O O
atherosclerosis O B_DISEASE/B_GENE
in O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O O
conditions O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
mild O B_DISEASE
hypercholesterolemia O I_DISEASE
. O O

BACKGROUND O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
T O B_GENE
cells O I_GENE
are O O
implicated O O
in O O
atherosclerosis O B_DISEASE/B_LOCATION
, O O
but O O
little O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
about O O
the O O
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
especially O O
under O O
conditions O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
mild O B_DISEASE
hypercholesterolemia O I_DISEASE
. O O

METHODS O O
AND O O
RESULTS O O
: O O
BALB/c O O
mice O O
, O O
making O O
a O O
CD4+ O O
Th2 O O
( O O
IL-4+ O O
) O O
cell O O
response O O
, O O
express O O
both O O
MHC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
d I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
IE B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
d I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
are O O
atherosclerosis-resistant O O
. O O

C57Bl/6 O O
mice O O
produce O O
a O O
CD4+ O O
Th1 O O
( O O
interferon O O
[ O O
IFN O O
] O O
gamma+ O O
) O O
response O O
, O O
express O O
IA B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
b I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
no O O
IE B B_DISEASE/B_GENE
, O O
and O O
are O O
atherosclerosis-prone O O
. O O

To O O
evaluate O O
T O B_DISEASE_ADJECTIVE[DISEASE]
helper-cell O I_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_DISEASE_ADJECTIVE[DISEASE]
in O O
fatty O B_DISEASE
streak O I_DISEASE
formation O I_DISEASE
, O O
wild-type O O
C57Bl/6 O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
mice O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IA O B_PROTEIN[GENE]/B_DISEASE
( O O
b O O
) O O
+IE- O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
transgenic O B_BIO/B_GENE
mice O I_BIO/I_GENE
, O O
either O O
AB O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
o O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
IA O B_DISEASE/B_PROTEIN[GENE]
( O O
b O O
) O O
-IE- O O
; O O
ABEalpha O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IA-IE O B_LOCATION/B_PROTEIN[GENE]
( O O
k O B_MEASURE/B_PROTEIN[GENE]
) O O
+ O B_PROTEIN[GENE]/B_DISEASE
; O O
or O O
BL O B_LOCATION
: O O
TG O B_PROTEIN[GENE]/B_MEASURE
: O O
Ealpha O B_PROTEIN[GENE]/B_LOCATION
, O O
IA O B_PROTEIN[GENE]/B_DISEASE
( O O
b O O
) O O
+IE O B_LOCATION/B_PROTEIN[GENE]
( O O
k O B_MEASURE/B_PROTEIN[GENE]
) O O
+ O B_PROTEIN[GENE]/B_DISEASE
, O O
were O O
fed O O
a O O
high-cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
16 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
and O O
evaluated O O
histomorphometrically O O
for O O
aortic O B_DISEASE
lesions O I_DISEASE
. O O

Lesion O B_MEASURE/B_PERSON
size O B_MEASURE/I_PERSON
in O O
AB O B_LOCATION/B_PERSON
( O O
o O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
ABEalpha O B_LOCATION
, O O
and O O
BL O B_LOCATION
: O O
TG O B_LOCATION
: O O
Ealpha O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
strains O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
decreased O O
by O O
54 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
79 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
and O O
82 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
respectively O O
, O O
compared O O
with O O
wild-type O B_GENE
, O O
correlating O O
with O O
decreased O O
Th1 O B_GENE
and O O
increased O O
Th2 O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
suggesting O O
that O O
T O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
helper-cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
fatty O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesion O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Decreasing O O
Th1 O O
cells O O
by O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
alpha-CD4 B B_GENE
) O O
or O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-4 B B_GENE
) O O
also O O
caused O O
> O O
/=80 O O
% O O
reductions O O
in O O
lesion O O
size O O
. O O

Immunohistology O O
revealed O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
IL-4 B B_GENE
, O O
colocalized O O
with O O
activated O O
macrophages O O
. O O

Confirming O O
these O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mouse O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
strain O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
BALB/c O B_PERSON/B_GENE
Stat O I_PERSON/I_GENE
6 O I_PERSON/I_GENE
knockout O I_PERSON/I_GENE
mice O I_PERSON/I_GENE
( O O
Th2 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell-deficient O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
developed O O
aortic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesions O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparable O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
C57Bl/6 O B_PERSON/B_BIO
mice O I_PERSON/I_BIO
on O O
the O O
same O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diet O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O O
: O O
In O O
mildly O O
hypercholesterolemic O O
C57Bl/6 O O
mice O O
, O O
presence O O
of O O
IA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
b I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O O
absence O O
of O O
IE B B_DISEASE/B_GENE
regulated O O
CD4+ O O
T O O
helper-cell O O
phenotype O O
; O O
fatty O O
lesions O O
were O O
proportional O O
to O O
IFNgamma+ O O
Th1 O O
cells O O
in O O
both O O
C57Bl/6 O O
and O O
BALB/c O O
strains O O
. O O

IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
may O O
participate O O
through O O
macrophage O O
activation O O
, O O
whereas O O
IL-4 B B_GENE
may O O
act O O
to O O
limit O O
Th1-cell O O
response O O
. O O

Requirement O O
for O O
p38 B B_GENE
and O O
p44/p42 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
RAGE B B_GENE
-mediated O O
nuclear B B_GENE
factor-kappaB I I_GENE
transcriptional O O
activation O O
and O O
cytokine O O
secretion O O
. O O

Advanced O O
glycation O O
end O O
product O O
( O O
AGE O O
) O O
activation O O
of O O
the O O
signal-transducing B B_GENE/B_DISEASE
receptor I I_GENE/I_DISEASE
for I I_GENE/I_DISEASE
AGE I I_GENE/I_DISEASE
( O O
RAGE B B_GENE/B_DISEASE
) O O
has O O
been O O
linked O O
to O O
a O O
proinflammatory O O
phenotypic O O
change O O
within O O
cells O O
. O O

However O O
, O O
the O O
precise O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intracellular O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
pathways O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
involved O O
have O O
not O O
been O O
elucidated O O
. O O

We O O
demonstrate O O
here O O
that O O
human O O
serum O O
albumin O O
modified O O
with O O
N O O
( O O
varepsilon O O
) O O
- O O
( O O
carboxymethyl O O
) O O
lysine O O
( O O
CML O O
) O O
, O O
a O O
major O O
AGE O O
adduct O O
that O O
progressively O O
accumulates O O
with O O
aging O O
, O O
diabetes O O
, O O
and O O
renal O O
failure O O
, O O
induced O O
nuclear B B_GENE/B_DISEASE
factor I I_GENE/I_DISEASE
( I I_GENE/I_DISEASE
NF I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
-kappaB I I_GENE/I_DISEASE
-driven O O
reporter O O
gene O O
expression O O
in O O
human O O
monocytic O O
THP-1 O O
cells O O
. O O

The O O
NF-kappaB O O
response O O
was O O
blocked O O
with O O
a O O
synthetic O O
peptide O O
corresponding O O
to O O
the O O
putative B B_LOCATION
ligand-binding I I_LOCATION
domain I I_LOCATION
of O O
RAGE B B_GENE
, O O
with O O
anti- O O
RAGE B B_GENE
antiserum O O
, O O
and O O
by O O
coexpression O O
of O O
truncated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lacking O O
the O O
intracellular B B_LOCATION/B_PERSON
domain I B_LOCATION/I_PERSON
. O O

Signal O O
transduction O O
from O O
RAGE B B_GENE
to O O
NF-kappaB B B_GENE
involved O O
the O O
generation O O
of O O
reactive O O
oxygen O O
species O O
, O O
since O O
reporter O O
gene O O
expression O O
was O O
blocked O O
with O O
the O O
antioxidant O O
N-acetyl-L-cysteine O O
. O O

CML-modified B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
albumin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
produced O O
rapid O O
transient O O
activation O O
of O O
tyrosine O O
phosphorylation O O
, O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE
) O O
, O O
but O O
not O O
c-Jun B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RAGE B B_GENE
-mediated O O
NF-kappaB O O
activation O O
was O O
suppressed O O
by O O
the O O
selective O O
p38 B B_GENE
MAPK I I_GENE
inhibitor O O
SB203580 O O
and O O
by O O
coexpression O O
of O O
a O O
kinase-dead O O
p38 O O
dominant-negative O O
mutant O O
. O O

Activation O O
of O O
NF-kappaB B B_GENE
by O O
CML-modified B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
albumin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
increased O O
secretion O O
of O O
proinflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
interleukin-1beta B B_GENE
, O O
and O O
monocyte B B_GENE
chemoattractant I I_GENE
protein-1 I I_GENE
) O O
severalfold O O
, O O
and O O
inhibition O O
of O O
p38 B B_GENE
MAPK I I_GENE
blocked O O
these O O
increases O O
. O O

These O O
results O O
indicate O O
that O O
p38 B B_GENE
MAPK I I_GENE
activation O O
mediates O O
RAGE B B_GENE
-induced O O
NF-kappaB B B_GENE
-dependent O O
secretion O O
of O O
proinflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
suggest O O
that O O
accelerated O O
inflammation O O
may O O
be O O
a O O
consequence O O
of O O
cellular O O
activation O O
induced O O
by O O
this O O
receptor O O
. O O

Antigen-receptor O O
cross-linking O O
and O O
lipopolysaccharide O O
trigger O O
distinct O O
phosphoinositide B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3-kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-dependent O O
pathways O O
to O O
NF-kappa O O
B O O
activation O O
in O O
primary O O
B O O
cells O O
. O O

The O O
NF-kappaB/Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
play O O
an O O
important O O
role O O
in O O
the O O
expression O O
of O O
genes O O
involved O O
in O O
B O O
cell O O
development O O
, O O
differentiation O O
and O O
function O O
. O O

Nuclear B B_GENE
NF-kappaB I I_GENE
is O O
induced O O
in O O
B O O
cells O O
by O O
engagement O O
of O O
either O O
the O O
BCR B B_GENE
or O O
CD40 B B_GENE/B_LOCATION
or O O
by O O
stimulation O O
with O O
lipopolysaccharide O O
( O O
LPS O O
) O O
. O O

Despite O O
the O O
importance O O
of O O
NF-kappaB B B_GENE
to O O
B O O
cell O O
function O O
, O O
little O O
is O O
known O O
about O O
the O O
signaling O O
pathways O O
leading O O
to O O
NF-kappaB O O
activation O O
. O O

In O O
this O O
report O O
we O O
address O O
the O O
role O O
of O O
phosphoinositide B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3'-kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI B B_GENE/B_LOCATION
3-kinase I I_GENE/I_LOCATION
) O O
in O O
BCR B B_GENE
- O O
and O O
LPS-induced O O
NF-kappaB O O
activation O O
using O O
populations O O
of O O
primary O O
murine O O
resting O O
B O O
cells O O
. O O

Using O O
the O O
specific O O
pharmacological O O
inhibitors O O
of O O
PI B B_GENE
3-kinase I I_GENE
, O O
Wortmannin O O
and O O
LY294002 O O
, O O
we O O
demonstrate O O
that O O
PI B B_GENE
3-kinase I I_GENE
activity O O
is O O
vital O O
for O O
BCR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
NF-kappaB B B_GENE
DNA-binding O O
activity O O
. O O

Furthermore O O
, O O
we O O
show O O
that O O
this O O
is O O
achieved O O
via O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-dependent O O
degradation O O
of O O
IkappaBalpha B B_GENE
. O O

Similar O O
analyses O O
reveal O O
that O O
PI B B_GENE
3-kinase I I_GENE
is O O
also O O
critical O O
in O O
triggering O O
NF-kappaB B B_GENE
DNA-binding O O
activity O O
and O O
IkappaBalpha B B_GENE
degradation O O
following O O
LPS O O
stimulation O O
. O O

Interestingly O O
, O O
a O O
PKC O O
inhibitor O O
which O O
blocked O O
the O O
BCR B B_GENE
-induced O O
IkappaBalpha B B_GENE
degradation O O
had O O
no O O
effect O O
on O O
the O O
degradation O O
of O O
IkappaBalpha B B_GENE
after O O
LPS O O
stimulation O O
. O O

Taken O O
together O O
, O O
our O O
results O O
indicate O O
the O O
involvement O O
of O O
PI B B_GENE
3-kinase I I_GENE
in O O
at O O
least O O
two O O
distinct O O
signaling O O
pathways O O
leading O O
to O O
activation O O
of O O
NF-kappaB B B_GENE
in O O
B O O
cells O O
. O O

Tetramer-guided O O
epitope O O
mapping O O
: O O
rapid O O
identification O O
and O O
characterization O O
of O O
immunodominant O O
CD4+ O O
T O O
cell O O
epitopes O O
from O O
complex O O
antigens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

T O O
cell O O
responses O O
to O O
Ags B B_DISEASE/B_VIRUS[BIO]
involve O O
recognition O O
of O O
selected O O
peptide B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
epitopes I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
contained O O
within O O
the O O
antigenic B B_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
. O O

In O O
this O O
report O O
, O O
we O O
describe O O
a O O
new O O
approach O O
for O O
direct O O
identification O O
of O O
CD4+ O O
T O O
cell O O
epitopes O O
of O O
complex O O
Ags B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O O
uses O O
human B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
class I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
II I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tetramers I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
identify O O
reactive O O
cells O O
. O O

With O O
a O O
panel O O
of O O
60 O O
overlapping O O
peptides O O
covering O O
the O O
entire O O
sequence O O
of O O
the O O
VP16 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
major O O
Ag B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
HSV-2 O O
, O O
we O O
generated O O
a O O
panel O O
of O O
class B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MHC I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetramers I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loaded O O
with O O
peptide O O
pools O O
that O O
were O O
used O O
to O O
stain O O
peripheral O O
lymphocytes O O
of O O
an O O
HSV-2 O O
infected O O
individual O O
. O O

With O O
this O O
approach O O
, O O
we O O
identified O O
four O O
new O O
DRA1*0101/DRB1*0401- O O
and O O
two O O
DRA1*0101/DRB1*0404-restricted O O
, O O
VP16-specific B B_LOCATION/B_PERSON
epitopes I I_LOCATION/I_PERSON
. O O

By O O
using O O
tetramers B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
sort O O
individual O O
cells O O
, O O
we O O
easily O O
obtained O O
a O O
large O O
number O O
of O O
clones O O
specific O O
to O O
these O O
epitopes B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
DRA1*0101/DRB1*0401 O O
and O O
DRA1*0101/DRB1*0404 O O
are O O
structurally O O
very O O
similar O O
, O O
nonoverlapping O O
VP16 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
epitopes I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O O
identified O O
, O O
illustrating O O
high O O
selectivity O O
of O O
individual O O
allele O O
polymorphisms O O
within O O
common O O
MHC O O
variants O O
. O O

This O O
rapid O O
approach O O
to O O
detecting O O
CD4+ O O
T O O
cell O O
epitopes O O
from O O
complex O O
Ags B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
be O O
applied O O
to O O
any O O
known O O
Ag B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
gives O O
a O O
T O O
cell O O
response O O
. O O

Localized O O
pancreatic O B_DISEASE
NF-kappaB O I_DISEASE
activation O I_DISEASE
and O O
inflammatory O B_DISEASE/B_GENE
response O I_DISEASE/I_GENE
in O O
taurocholate-induced O B_DISEASE
pancreatitis O I_DISEASE
. O O

Transcription B B_GENE
factor I I_GENE
nuclear I I_GENE
factor-kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
is O O
activated O O
in O O
cerulein O O
pancreatitis O O
and O O
mediates O O
cytokine O O
expression O O
. O O

The O O
role O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
transcription O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
pancreatitis O B_DISEASE
has O O
not O O
been O O
established O O
. O O

Here O O
we O O
report O O
upregulation O O
of O O
NF-kappaB B B_GENE
and O O
inflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
their O O
correlation O O
with O O
local O O
pancreatic O O
injury O O
, O O
in O O
a O O
model O O
of O O
severe O O
pancreatitis O O
. O O

Rats O B_BIO/B_PERSON
received O O
intraductal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infusion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
taurocholate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
pancreatic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
head O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
tail O B_BODY_PART_OR_ORGAN_COMPONENT
were O O
analyzed O O
separately O O
. O O

NF-kappaB B B_GENE
and O O
activator B B_GENE/B_LOCATION
protein-1 I I_GENE/I_LOCATION
( O O
AP-1 B B_GENE
) O O
activation O O
were O O
assessed O O
by O O
gel O O
shift O O
assay O O
, O O
and O O
mRNA O O
expression O O
of O O
interleukin-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
tumor B B_GENE/B_LOCATION
necrosis I I_GENE/I_LOCATION
factor-alpha I I_GENE/I_LOCATION
, O O
KC O O
, O O
monocyte B B_GENE/B_LOCATION
chemoattractant I I_GENE/I_LOCATION
protein-1 I I_GENE/I_LOCATION
, O O
and O O
inducible B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nitric I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oxide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
assessed O O
by O O
semiquantitative O O
RT-PCR O O
. O O

Morphological O O
damage O O
and O O
trypsin O O
activation O O
were O O
much O O
greater O O
in O O
the O O
pancreatic O O
head O O
than O O
tail O O
, O O
in O O
parallel O O
with O O
a O O
stronger O O
activation O O
of O O
NF-kappaB B B_GENE
and I I_GENE
cytokine I I_GENE
mRNA I I_GENE
. O O

Saline O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mildly O O
affected O O
these O O
parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

AP-1 B B_GENE
was O O
strongly O O
activated O O
in O O
both O O
pancreatic O O
segments O O
after O O
either O O
taurocholate O O
or O O
saline O O
infusion O O
. O O

NF-kappaB B B_GENE
inhibition O O
with O O
N-acetylcysteine O O
ameliorated O O
the O O
local O O
inflammatory O O
response O O
. O O

Correlation O O
between O O
localized O O
NF-kappaB B B_GENE
activation O O
, O O
cytokine O O
upregulation O O
, O O
and O O
tissue O O
damage O O
suggests O O
a O O
key O O
role O O
for O O
NF-kappaB B B_GENE
in O O
the O O
development O O
of O O
the O O
inflammatory O O
response O O
of O O
acute O O
pancreatitis O O
. O O

CD45 B B_GENE
tyrosine I I_GENE
phosphatase I I_GENE
controls O O
common O O
gamma-chain B B_GENE
cytokine I I_GENE
-mediated O O
STAT B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
extracellular O O
signal-related O O
kinase O O
phosphorylation O O
in O O
activated O O
human O O
lymphoblasts O O
: O O
inhibition O O
of O O
proliferation O O
without O O
induction O O
of O O
apoptosis O O
. O O

The O O
objective O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
test O O
whether O O
CD45 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
influence O O
signaling O O
processes O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
activated O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoblasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
this O O
end O O
, O O
we O O
generated O O
lymphoblasts O O
which O O
proliferate O O
in O O
response O O
to O O
common O O
gamma-chain B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytokines I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
readily O O
undergo O O
apoptosis O O
after O O
cytokine O O
withdrawal O O
. O O

In O O
experiments O O
with O O
the O O
CD45R0 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mAb I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
UCHL-1 I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
control B B_GENE/B_TIME[MEASURE]
CD45 I I_GENE/I_TIME[MEASURE]
mAbs I I_GENE/I_TIME[MEASURE]
, O O
we O O
found O O
significant O O
inhibition O O
of O O
proliferation O O
. O O

Interestingly O O
, O O
the O O
pan-CD45 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mAb I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GAP8.3 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
most O O
effective O O
in O O
inhibition O O
of O O
OKT-3-mediated O O
proliferation O O
in O O
quiescent O O
lymphocytes O O
, O O
was O O
ineffective O O
in O O
lymphoblasts O O
. O O

Addition O O
of O O
CD3 B B_GENE
mAb I I_GENE
OKT-3 I I_GENE
had O O
no O O
influence O O
on O O
IL-2-mediated O O
proliferation O O
( O O
with O O
or O O
without O O
UCHL-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
. O O

In O O
contrast O O
, O O
after O O
addition O O
of O O
OKT-3 B B_GENE
to O O
IL-4 B B_GENE
- O O
and O O
IL-7 B B_GENE
-stimulated O O
proliferation O O
assays O O
, O O
UCHL-1 B B_GENE/B_PERSON
signals O O
could O O
not O O
significantly O O
alter O O
cellular O O
proliferation O O
. O O

We O O
did O O
not O O
find O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
apoptosis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
following O O
CD45R0 O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
signaling O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
Western O O
blots O O
using O O
mAbs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
detecting O O
phosphorylated B B_GENE
STAT-3 I I_GENE
, I I_GENE
STAT-5 I I_GENE
, I I_GENE
STAT-6 I I_GENE
, O O
or O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1/2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
found O O
that O O
CD45R0 O O
signaling O O
could O O
effectively O O
diminish O O
phosphorylation O O
of O O
these O O
intracellular O O
signaling O O
components O O
. O O

Using O O
RT-PCR O O
, O O
we O O
found O O
that O O
CD45R0 O O
signaling O O
inhibited O O
IL-2 O O
mRNA O O
production O O
without O O
major O O
influence O O
on O O
IL-13 B B_GENE
, O O
IL-5 B B_GENE
, O O
or O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
. O O

Costimulation O O
with O O
OKT-3 B B_GENE
and O O
IL-2 B B_GENE/B_LOCATION
optimally O O
induced O O
secretion O O
of O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
IL-5 B B_GENE
, O O
which O O
was O O
not O O
decreased O O
by O O
CD45 O O
signals O O
. O O

In O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
we O O
illustrate O O
that O O
CD45R0 O B_GENE
signals O I_GENE
control O O
early O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokine O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor-associated O O
signaling O O
processes O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
mRNA O B_GENE
and O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
synthesis O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
activated O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoblasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
we O O
show O O
the O O
existence O O
of O O
CD45 B B_GENE/B_BIO
epitopes I I_GENE/I_BIO
( O O
GAP8.3 B B_GENE/B_LOCATION
) O O
, O O
which O O
are O O
active O O
and O O
critical O O
for O O
signaling O O
in O O
quiescent O O
lymphocytes O O
, O O
but O O
are O O
nonfunctional O O
in O O
activated O O
human O O
lymphoblasts O O
. O O

Pax5 B B_GENE/B_LOCATION
determines O O
the O O
identity O O
of O O
B O O
cells O O
from O O
the O O
beginning O O
to O O
the O O
end O O
of O O
B-lymphopoiesis O O
. O O

Despite O O
being O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
most O O
intensively O O
studied O O
cell O B_DISEASE
types O I_DISEASE
, O O
the O O
molecular O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
basis O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
B O B_DISEASE
cell O I_DISEASE
specification O I_DISEASE
is O O
largely O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
Pax5 B B_GENE
gene I I_GENE
encoding O O
the O O
transcription B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
BSAP I I_GENE/I_MEASURE
is O O
required O O
for O O
progression O O
of O O
B-lymphopoiesis O O
beyond O O
the O O
pro-B O O
cell O O
stage O O
. O O

Pax5-deficient O B_PERSON
pro-B O I_PERSON
cells O I_PERSON
are O O
, O O
however O O
, O O
not O O
yet O O
committed O B_PERSON
to O O
the O O
B-lymphoid O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lineage O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
instead O O
have O O
a O O
broad O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphomyeloid O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developmental O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pax5 B B_GENE
appears O O
to O O
mediate O O
B-lineage O O
commitment O O
by O O
repressing O O
the O O
transcription O O
of O O
non-B-lymphoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
simultaneously O O
activating O O
the O O
expression O O
of O O
B-lineage-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Pax5 B B_GENE
thus O O
functions O O
both O O
as O O
a O O
transcriptional O O
repressor O O
and O O
activator O O
, O O
depending O O
on O O
its O O
interactions O O
with O O
corepressors B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
Groucho B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
family I I_GENE/I_LOCATION
or O O
with O O
positive O O
regulators O O
such O O
as O O
the O O
TATA-binding B B_GENE
protein I I_GENE
. O O

Once O O
committed O O
to O O
the O O
B-lineage O O
, O O
B O O
cells O O
require O O
Pax5 B B_GENE/B_MEASURE
function O O
to O O
maintain O O
their O O
B-lymphoid O O
identity O O
throughout O O
B O O
cell O O
development O O

Partners O O
in O O
transcription O O
: O O
NFAT B B_GENE
and O O
AP-1 B B_GENE
. O O

Combinatorial O O
regulation O O
is O O
a O O
powerful O O
mechanism O O
that O O
enables O O
tight O O
control O O
of O O
gene O O
expression O O
, O O
via O O
integration O O
of O O
multiple O O
signaling O O
pathways O O
that O O
induce O O
different O O
transcription B B_GENE/B_LOCATION
factors I I_GENE/I_LOCATION
required O O
for O O
enhanceosome O O
assembly O O
. O O

The O O
four O O
calcium-regulated O O
transcription B B_GENE/B_BIO
factors I I_GENE/I_BIO
of O O
the O O
NFAT B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
family I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
act O O
synergistically O O
with O O
AP-1 B B_GENE/B_BIO
( I I_GENE/I_BIO
Fos/Jun I I_GENE/I_BIO
) I I_GENE/I_BIO
proteins I I_GENE/I_BIO
on O O
composite O O
DNA O O
elements O O
which O O
contain O O
adjacent O O
NFAT B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
where O O
they O O
form O O
highly O O
stable O O
ternary O O
complexes O O
to O O
regulate O O
the O O
expression O O
of O O
diverse O O
inducible O O
genes O O
. O O

Concomitant O O
induction O O
of O O
NFAT B B_GENE
and O O
AP-1 B B_GENE
requires O O
concerted O O
activation O O
of O O
two O O
different O O
signaling O O
pathways O O
: O O
calcium/calcineurin O O
, O O
which O O
promotes O O
NFAT O O
dephosphorylation O O
, O O
nuclear O O
translocation O O
and O O
activation O O
; O O
and O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PKC I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/Ras I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
promotes O O
the O O
synthesis O O
, O O
phosphorylation O O
and O O
activation O O
of O O
members O O
of O O
the O O
Fos B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Jun I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
families I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
transcription B B_GENE/B_DISEASE
factors I I_GENE/I_DISEASE
. O O

A O O
fifth O O
member O O
of O O
the O O
NFAT B B_GENE/B_BIO
family I I_GENE/I_BIO
, O O
NFAT5 B B_GENE/B_LOCATION
, O O
controls O O
the O O
cellular O O
response O O
to O O
osmotic O O
stress O O
, O O
by O O
a O O
mechanism O O
that O O
requires O O
dimer O O
formation O O
and O O
is O O
independent O O
of O O
calcineurin B B_GENE
or O O
of O O
interaction O O
with O O
AP-1 B B_GENE
. O O

Pharmacological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interference O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
theNFAT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
AP-1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
interaction O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
selective O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
manipulation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
immune O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Balanced O O
activation O O
of O O
NFAT B B_GENE
and O O
AP-1 B B_GENE
is O O
known O O
to O O
be O O
required O O
for O O
productive O O
immune O O
responses O O
, O O
but O O
the O O
role O O
of O O
NFAT O O
: O O
AP-1 O O
interactions O O
in O O
other O O
cell O O
types O O
and O O
biological O O
processes O O
remains O O
to O O
be O O
understood O O
. O O

Cytokine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
production O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
Vgamma O B_GENE
( O O
+ O B_PROTEIN[GENE]/B_DISEASE
) O O
-T-cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
subsets O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
is O O
an O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
determining O O
CD4 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
-Th-cell O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
phenotype O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O O
susceptibility O B_DISEASE
of O O
BALB/c O B_SPECIES[BIO]/B_PERSON
mice O I_SPECIES[BIO]/I_PERSON
to O O
coxsackievirus O O
B3-induced O B_DISEASE_ADJECTIVE[DISEASE]
myocarditis O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O O
coxsackievirus O O
B3 O O
( O O
CVB3 O O
) O O
variants O O
( O O
H3 O O
and O O
H310A1 O O
) O O
differ O O
by O O
a O O
single O O
amino O O
acid O O
mutation O O
in O O
the O O
VP2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
capsid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

H3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O O
severe O B_DISEASE/B_GENE
myocarditis O I_DISEASE/I_GENE
in O O
BALB/c O B_SPECIES[BIO]
mice O I_SPECIES[BIO]
, O O
but O O
H310A1 O B_DISEASE/B_GENE
is O O
amyocarditic O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Infection O O
with O O
H3 O O
, O O
but O O
not O O
H310A1 O O
, O O
preferentially O O
activates O O
Vgamma4 O O
Vdelta4 O O
cells O O
, O O
which O O
are O O
strongly O O
positive O O
for O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interferon I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
IFN-gamma B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
whereas O O
Vgamma1 O O
Vdelta4 O O
cells O O
are O O
increased O O
in O O
both O O
H3 O O
and O O
H310A1 O O
virus-infected O O
animals O O
. O O

Depletion O O
of O O
Vgamma1 O O
( O O
+ O O
) O O
cells O O
using O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
anti-Vgamma1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
enhanced O O
myocarditis O O
and O O
CD4 O O
( O O
+ O O
) O O
- O O
, O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
+ O O
) O O
-cell O O
responses O O
in O O
both O O
H3- O O
and O O
H310A1-infected O O
mice O O
yet O O
decreased O O
the O O
CD4 O O
( O O
+ O O
) O O
- O O
, O O
IL-4 O O
( O O
+ O O
) O O
-cell O O
response O O
. O O

Depleting O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Vgamma4 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
+ O B_GENE/B_DISEASE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
suppressed O O
myocarditis O B_DISEASE/B_GENE
and O O
reduced O O
CD4 O B_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
IFN-gamma O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
+ O B_DISEASE/B_GENE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
but O O
increased O O
CD4 O B_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
IL-4 O B_GENE
( O O
+ O B_OTHER/B_DISEASE
) O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

The O O
role O O
of O O
cytokine O O
production O O
by O O
Vgamma1 O O
( O O
+ O O
) O O
and O O
Vgamma4 O O
( O O
+ O O
) O O
T O O
cells O O
was O O
investigated O O
by O O
adoptively O O
transferring O O
these O O
cells O O
isolated O O
from O O
H3-infected O O
BALB/c O O
Stat4 O O
knockout O O
( O O
Stat4ko O O
) O O
( O O
defective O O
in O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
) O O
or O O
BALB/c O O
Stat6ko O O
( O O
defective O O
in O O
IL-4 O O
expression O O
) O O
mice O O
into O O
H3 O O
virus-infected O O
wild-type O O
BALB/c O O
recipients O O
. O O

Vgamma4 O O
and O O
Vgamma1 O O
( O O
+ O O
) O O
T O O
cells O O
from O O
Stat4ko O O
mice O O
expressed O O
IL-4 B B_GENE
but O O
no O O
or O O
minimal O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
these O O
cell O O
populations O O
derived O O
from O O
Stat6ko O O
mice O O
expressed O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
but O O
no O O
IL-4 B B_GENE
. O O

Stat4ko O B_GENE/B_MEASURE
Vgamma1 O I_GENE/I_MEASURE
( O O
+ O B_DISEASE/B_GENE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
IL-4 O B_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
) O O
suppress O O
myocarditis O B_DISEASE/B_GENE
. O O

Stat6ko O B_GENE
Vgamma1 O I_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
IFN-gamma O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
+ O B_DISEASE/B_PROTEIN[GENE]
) O O
) O O
were O O
not O O
inhibitory O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

Stat6ko O B_GENE/B_MEASURE
Vgamma4 O I_GENE/I_MEASURE
( O O
+ O B_GENE/B_DISEASE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
IFN-gamma O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
+ O B_DISEASE/B_GENE
) O O
) O O
significantly O O
enhanced O O
myocarditis O B_DISEASE
. O O

Stat4ko O B_GENE
Vgamma4 O I_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
IL-4 O B_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
) O O
neither O O
inhibited O O
nor O O
enhanced O B_DISEASE_ADJECTIVE[DISEASE]
disease O I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
that O O
distinct O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gammadelta-T-cell O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subsets O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
control O O
myocarditis O B_DISEASE
susceptibility O I_DISEASE
and O O
bias O O
the O O
CD4 O B_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
-Th-cell O B_MEASURE/B_LOCATION
response O I_MEASURE/I_LOCATION
. O O

The O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
produced O O
by O O
the O O
Vgamma O O
subpopulation O O
have O O
a O O
significant O O
influence O O
on O O
the O O
CD4 B B_GENE
( O O
+ O O
) O O
-Th-cell O O
phenotype O O
. O O

Plasmin B B_GENE
-induced O O
expression O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
monocytes O O
involves O O
AP-1 B B_GENE
and O O
IKKbeta B B_GENE
-mediated O O
NF-kappaB O O
activation O O
. O O

It O O
was O O
previously O O
shown O O
that O O
plasmin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activates O O
human O O
peripheral O O
monocytes O O
in O O
terms O O
of O O
lipid O O
mediator O O
release O O
and O O
chemotactic O O
migration O O
. O O

Here O O
it O O
is O O
demonstrated O O
that O O
plasmin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
proinflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
release O O
and O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TF B B_PROTEIN[GENE]
) O O
expression O O
by O O
monocytes O O
. O O

Plasmin B B_GENE/B_MEASURE
0.043 O O
to O O
1.43 O O
CTA O O
U/mL O O
, O O
but O O
not O O
active B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
site-blocked I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
triggered O O
concentration-dependent O O
expression O O
of O O
mRNA O O
for O O
interleukin-1alpha B B_GENE
( O O
IL-1alpha B B_GENE
) O O
, O O
IL-1beta B B_GENE
, O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
and O O
TF B B_GENE
with O O
maximum O O
responses O O
after O O
4 O O
hours O O
. O O

Plasmin B B_GENE
-mediated O O
mRNA O O
expression O O
was O O
inhibited O O
in O O
a O O
concentration-dependent O O
manner O O
by O O
the O O
lysine O O
analogue O O
trans-4- O O
( O O
aminomethyl O O
) O O
cyclohexane-1-carboxylic O O
acid O O
( O O
t-AMCA O O
) O O
. O O

Increases O O
in O O
mRNA O O
levels O O
were O O
followed O O
by O O
concentration- O O
and O O
time-dependent O O
release O O
of O O
IL-1alpha B B_GENE
, O O
IL-1beta B B_GENE
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
TF B B_GENE
expression O O
on O O
monocyte O O
surfaces O O
. O O

Neither O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nor O O
TF B B_GENE
could O O
be O O
detected O O
when O O
monocytes O O
were O O
preincubated O O
with O O
actinomycin O O
D O O
or O O
cycloheximide O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
indicated O O
plasmin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
activation O O
of O O
NF-kappaB B B_GENE
; O O
DNA-binding B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
complexes I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
composed O O
of O O
p50 B B_GENE
, O O
p65 B B_GENE
, O O
and O O
c-Rel B B_GENE
, O O
as O O
shown O O
by O O
supershift O O
experiments O O
. O O

Nuclear O O
translocation O O
of O O
NF-kappaB/Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coincided O O
with O O
IkappaBalpha O O
degradation O O
. O O

At O O
variance O O
with O O
endotoxic O O
lipopolysaccharide O O
, O O
plasmin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elicited O O
the O O
rapid O O
degradation O O
of O O
another O O
cytoplasmic B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
NF-kappaB I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
p105 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Proteolysis O O
of O O
NF-kappaB O O
inhibitors O O
was O O
apparently O O
due O O
to O O
transient O O
activation O O
of O O
IkappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IKK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
reached O O
maximum O O
activity O O
at O O
1 O O
hour O O
after O O
plasmin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O O
. O O

In O O
addition O O
, O O
AP-1 O O
binding O O
was O O
increased O O
in O O
plasmin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-treated O O
monocytes O O
, O O
with O O
most O O
complexes O O
composed O O
of O O
JunD B B_GENE/B_DISEASE
, O O
c-Fos B B_GENE/B_LOCATION
, O O
and O O
FosB B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
findings O O
further O O
substantiate O O
the O O
role O O
of O O
plasmin B B_GENE
as O O
a O O
proinflammatory O O
activator O O
of O O
human O O
monocytes O O
and O O
reveal O O
an O O
important O O
new O O
link O O
between O O
the O O
plasminogen-plasmin O O
system O O
and O O
inflammation O O
. O O

( O O
Blood. O O
2001 O B_MEASURE
; O O
97 O B_MEASURE
: O O
3941-3950 O B_MEASURE/B_LOCATION
) O O

STAT3 B B_GENE
is O O
constitutively O O
active O O
in O O
some O O
patients O O
with O O
Polycythemia O O
rubra O O
vera O O
. O O

OBJECTIVE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Polycythemia O B_DISEASE/B_GENE
vera O I_DISEASE/I_GENE
is O O
a O O
clonal O B_DISEASE
stem O I_DISEASE
cell O I_DISEASE
disorder O I_DISEASE
characterized O O
by O O
hyperproliferation O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
erythroid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O O
myeloid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
megakaryocytic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lineages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

While O O
it O O
has O O
been O O
shown O O
that O O
progenitor O O
cells O O
of O O
P. O O
vera O O
patients O O
are O O
hypersensitive O O
to O O
several O O
growth O O
factors O O
including O O
erythropoietin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
insulin-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
thrombopoietin B B_GENE
, O O
interleukin-3 B B_GENE
, O O
and O O
granulocyte/monocyte B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
molecular O O
pathogenesis O O
of O O
this O O
disease O O
remains O O
unknown O O
. O O

Growth O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
hypersensitivity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
could O O
be O O
mediated O O
by O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
signal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transduction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pathways O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
therefore O O
investigated O O
a O O
common O O
downstream O O
effector O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
signal B B_GENE
transducers I I_GENE
and I I_GENE
activators I I_GENE
of I I_GENE
transcription I I_GENE
( O O
STATs B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

A O O
constitutive O O
activation O O
of O O
STAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
explain O O
the O O
increased O O
proliferation O O
of O O
P. O O
vera O O
cells O O
even O O
in O O
the O O
absence O O
of O O
growth O O
factor O O
stimulation O O
. O O

METHODS O O
: O O
Peripheral O O
granulocytes O O
from O O
patients O O
with O O
P. O O
vera O O
and O O
from O O
healthy O O
volunteers O O
were O O
assayed O O
for O O
STAT1 B B_GENE
, I I_GENE
3 I I_GENE
, I I_GENE
and I I_GENE
5 I I_GENE
DNA O O
binding O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
Four O B_NUMBER[MEASURE]
of O O
14 O B_LOCATION/B_PERSON
P. O B_LOCATION/I_PERSON
vera O O
patients O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
analyzed O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
showed O O
constitutive O O
STAT3 O B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_DISEASE_ADJECTIVE[DISEASE]
binding O I_DISEASE_ADJECTIVE[DISEASE]
in O I_DISEASE_ADJECTIVE[DISEASE]
unstimulated O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
granulocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
, O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
while O O
none O O
of O B_PERSON/B_NUMBER[MEASURE]
the O O
17 O O
healthy O B_PERSON
volunteers O I_PERSON
tested O I_PERSON
did O O
. O O

None O O
of O O
the O O
subjects O O
showed O O
constitutive O O
STAT1 B B_GENE
or O O
STAT5 B B_GENE
activity O O
. O O

Western O O
blotting O O
demonstrated O O
that O O
, O O
in O O
the O O
three O O
patients O O
, O O
STAT3 B B_GENE
is O O
constitutively O O
phosphorylated O O
on O O
Tyr O O
705 O O
, O O
whereas O O
it O O
is O O
unphosphorylated O O
in O O
the O O
other O O
patients O O
and O O
in O O
controls O O
. O O

Interestingly O O
, O O
constitutive O O
STAT3 B B_GENE
activity O O
did O O
not O O
correlate O O
with O O
the O O
duration O O
of O O
disease O O
or O O
the O O
treatment O O
regimen O O
. O O

It O O
was O O
observed O O
in O O
a O O
recently O O
diagnosed O O
patient O B_PERSON/B_DISEASE
and O O
in O O
two O B_PERSON
patients O I_PERSON
treated O O
only O O
with O O
phlebotomy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

CONCLUSION O O
: O O
Our O O
data O O
suggest O O
that O O
constitutive O O
phosphorylation O O
and O O
activation O O
of O O
STAT3 B B_GENE
is O O
not O O
a O O
secondary O O
event O O
induced O O
by O O
mutagenizing O O
agents O O
or O O
by O O
prolonged O O
hyperproliferation O O
of O O
hematopoietic O O
cells O O
, O O
but O O
rather O O
represents O O
a O O
primary O O
molecular O O
aberration O O
. O O

Constitutively B B_GENE/B_PERSON
active I I_GENE/I_PERSON
STAT3 I I_GENE/I_PERSON
may O O
contribute O O
to O O
the O O
growth O O
factor O O
hypersensitivity O O
of O O
P. O O
vera O O
cells O O
. O O

Identification O O
of O O
phosphorylation B B_ENZYME[GENE]/B_LOCATION
sites I I_ENZYME[GENE]/I_LOCATION
for O O
Bruton B B_GENE
's I I_GENE
tyrosine I I_GENE
kinase I I_GENE
within O O
the O O
transcriptional B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
regulator I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
BAP/TFII-I I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

Bruton B B_GENE
's I I_GENE
tyrosine I I_GENE
kinase I I_GENE
( O O
Btk B B_LOCATION/B_ORGANIZATION
) O O
, O O
a O O
member O O
of O O
the O O
Tec B B_GENE/B_LOCATION
family I I_GENE/I_LOCATION
of I I_GENE/I_LOCATION
cytosolic I I_GENE/I_LOCATION
kinases I I_GENE/I_LOCATION
, O O
is O O
essential O O
for O O
B O O
cell O O
development O O
and O O
function O O
. O O

BAP/TFII-I B B_GENE
, O O
a O O
protein O O
implicated O O
in O O
transcriptional O O
regulation O O
, O O
is O O
associated O O
with O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
B O O
cells O O
and O O
is O O
transiently O O
phosphorylated O O
on O O
tyrosine O O
following O O
B O O
cell O O
receptor O O
engagement O O
. O O

BAP/TFII-I B B_GENE
is O O
a O O
substrate O O
for O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vitro O O
and O O
is O O
hyperphosphorylated O O
on O O
tyrosine O O
upon O O
coexpression O O
with O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mammalian O O
cells O O
. O O

In O O
an O O
effort O O
to O O
understand O O
the O O
physiologic O O
consequences O O
of O O
BAP/TFII-I B B_GENE
tyrosine O O
phosphorylation O O
following O O
B O O
cell O O
receptor O O
stimulation O O
, O O
site-directed O O
mutagenesis O O
and O O
phosphopeptide O O
mapping O O
were O O
used O O
to O O
locate O O
the O O
predominant O O
sites O O
of O O
BAP/TFII-I B B_GENE
phosphorylation O O
by O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vitro O O
. O O

These O O
residues O O
, O O
Tyr248 O O
, O O
Tyr357 O O
, O O
and O O
Tyr462 O O
, O O
were O O
also O O
found O O
to O O
be O O
the O O
major O O
sites O O
for O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O O
phosphorylation O O
of O O
BAP/TFII-I B B_GENE
in O O
vivo O O
. O O

Residues O O
Tyr357 O O
and O O
Tyr462 O O
are O O
contained O O
within O O
the O O
loop B B_LOCATION/B_ORGANIZATION
regions I I_LOCATION/I_ORGANIZATION
of O O
adjacent O O
helix-loop-helix-like B B_LOCATION/B_BIO
repeats I B_LOCATION/I_BIO
within O O
BAP/TFII-I B B_GENE
. O O

Mutation O O
of O O
either O O
Tyr248 O O
, O O
Tyr357 O O
, O O
or O O
Tyr462 O O
to O O
phenylalanine O O
reduced O O
transcription O O
from O O
a O O
c-fos B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
relative O O
to O O
wild-type B B_GENE/B_TIME[MEASURE]
BAP/TFII-I I I_GENE/I_TIME[MEASURE]
in O O
transfected O O
COS-7 O O
cells O O
, O O
consistent O O
with O O
the O O
interpretation O O
that O O
phosphorylation O O
at O O
these O O
sites O O
contributes O O
to O O
transcriptional O O
activation O O
. O O

Phosphorylation O O
of O O
BAP/TFII-I B B_GENE
by O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
link O O
engagement O O
of O O
receptors O O
such O O
as O O
surface O O
immunoglobulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
modulation O O
of O O
gene O O
expression O O
. O O

Expression O O
of O O
interferon B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
consensus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O O
potent O O
immunity O O
against O O
BCR/ABL-induced O O
leukemia O O
. O O

Mice O O
deficient O O
in O O
the O O
interferon B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
consensus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
develop O O
a O O
disease O O
resembling O O
chronic O O
myeloid O O
leukemia O O
( O O
CML O O
) O O
, O O
which O O
in O O
humans O O
is O O
caused O O
by O O
the O O
BCR/ABL B B_GENE/B_DISEASE
oncoprotein I I_GENE/I_DISEASE
. O O

Interferon-alpha B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IFN-alpha B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
induces O O
ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
and O O
is O O
an O O
effective O O
therapy O O
for O O
CML O O
. O O

This O O
study O O
examined O O
whether O O
enforced O O
expression O O
of O O
ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
might O O
antagonize O O
BCR/ABL-induced O O
leukemia O O
; O O
results O O
demonstrated O O
that O O
ICSBP-modified O O
cells O O
generated O O
a O O
protective O O
CD8 O O
( O O
+ O O
) O O
cytotoxic O O
T-cell O O
response O O
against O O
BCR/ABL-transformed O O
BaF3 O O
cells O O
in O O
a O O
murine O O
leukemia O O
model O O
. O O

ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
represents O O
a O O
novel O O
means O O
of O O
stimulating O O
a O O
host O O
immune O O
response O O
to O O
BCR/ABL O O
( O O
+ O O
) O O
leukemia O O
cells O O
and O O
a O O
potential O O
strategy O O
for O O
immunotherapy O O
of O O
CML O O
. O O

( O O
Blood. O O
2001 O B_MEASURE
; O O
97 O B_MEASURE
: O O
3491-3497 O B_MEASURE
) O O

A O O
transcriptional O O
block O O
in O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
at O O
the O O
-150 B B_GENE/B_MEASURE
AP-1 I I_GENE/I_MEASURE
site I I_GENE/I_MEASURE
in O O
effector O O
CD8+ O O
T O O
cells O O
. O O

Both O O
CD4+ O O
and O O
CD8+ O O
T O O
cells O O
that O O
produce O O
IL-2 B B_GENE
in O O
response O O
to O O
Ag O O
recognition O O
have O O
been O O
isolated O O
. O O

However O O
, O O
most O O
effector O O
CD8+ O O
T O O
cells O O
recovered O O
after O O
exposure O O
to O O
Ag B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O O
not O O
produce O O
sufficient O O
IL-2 B B_GENE
to O O
sustain O O
growth O O
, O O
and O O
depend O O
on O O
CD4+ O O
T O O
helper O O
cells O O
for O O
this O O
obligate O O
growth O O
factor O O
. O O

IL-2 O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
CD4+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
primarily O O
controlled O O
at O O
the O O
level O B_MEASURE/B_LOCATION
of O O
transcription O B_GENE
, O O
but O O
mechanisms O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
restricting O O
IL-2 O O
production O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
CD8+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
have O O
not O O
been O O
elucidated O O
. O O

To O O
evaluate O O
transcriptional O O
regulation O O
of O O
the O O
IL-2 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
in O O
CD8+ O O
T O O
cells O O
, O O
we O O
stably O O
transfected O O
reporter B B_GENE/B_PERSON
genes I I_GENE/I_PERSON
into O O
Ag B B_VIRUS[BIO]/B_GENE
-specific O O
CD8+ O O
T O O
cell O O
clones O O
. O O

CD28+ O O
CD8 O O
( O O
+ O O
) O O
T O O
cells O O
unable O O
to O O
transcribe O O
the O O
IL-2 B B_GENE
gene I I_GENE
in O O
response O O
to O O
antigenic O O
stimulation O O
had O O
a O O
block O O
in O O
transactivation O O
of O O
the O O
-150 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CD28 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CD28RE I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
IL-2 B B_GENE
promoter I I_GENE
, O O
but O O
did O O
transactivate O O
the O O
composite O O
NFAT/AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
OCT/AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
a O O
consensus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motif I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Mutation O O
of O O
the O O
nonconsensus B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-150 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AP-1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
a O O
consensus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
AP-1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
or O O
insertion O O
of O O
a O O
CD28RE/AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
consensus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
upstream O O
of O O
the O O
native O O
-150 B B_GENE/B_LOCATION
CD28RE/AP-1 I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
restored O O
transactivation O O
of O O
the O O
altered O O
promoter B B_GENE/B_LOCATION
. O O

These O O
results O O
suggest O O
that O O
the O O
defect O O
at O O
the O O
-150 B B_PERSON/B_GENE
site I B_PERSON/I_GENE
may O O
reflect O O
the O O
absence O O
or O O
inactivity O O
of O O
a O O
required O O
factor O O
rather O O
than O O
repression O O
of O O
the O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Stem B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
interleukin-3 B B_GENE
induce O O
stepwise O O
generation O O
of O O
erythroid O O
precursor O O
cells O O
from O O
a O O
basic O O
fibroblast B B_GENE
growth I I_GENE
factor I I_GENE
-dependent O O
hematopoietic O O
stem O O
cell O O
line O O
, O O
A-6 O O
. O O

A O O
m O O
ultipotent O O
immature O O
myeloid O O
cell O O
population O O
was O O
produced O O
from O O
a O O
basic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fibroblast I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
bFGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
-dependent O O
hematopoietic O O
stem O O
cell O O
line O O
, O O
A-6 O O
, O O
when O O
cultured O O
with O O
stem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SCF B B_GENE/B_LOCATION
) O O
replacing O O
bFGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Those O O
cells O O
were O O
positive O O
for O O
stem B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
markers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
c-kit B B_GENE
and O O
CD34 B B_GENE
, O O
and O O
a O O
myeloid B B_GENE/B_MEASURE
cell I I_GENE/I_MEASURE
marker I I_GENE/I_MEASURE
, I I_GENE/I_MEASURE
F4/80 I I_GENE/I_MEASURE
. O O

Some O O
cell O O
fractions O O
were O O
also O O
positive O O
for O O
Mac-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
a I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
macrophage I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
marker I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
Gr-1 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
a I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
granulocytic I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
maker I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
but O O
negative O O
for O O
an O O
erythroid B B_GENE
marker I I_GENE
TER119 I I_GENE
. O O

They O O
also O O
showed O O
the O O
expression O O
of O O
mRNA O O
for O O
the O O
myeloid-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PU.1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
but O O
did O O
not O O
that O O
for O O
the O O
erythroid-specific B B_GENE
GATA-1 I I_GENE
. O O

Among O O
various O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
interleukin-3 B B_GENE
( O O
IL-3 B B_GENE
) O O
induced O O
erythroid O O
precursor O O
cells O O
that O O
expressed O O
the O O
erythroid-specific B B_GENE
GATA-1 I I_GENE
and O O
beta-major B B_GENE
globin I I_GENE
. O O

The O O
quantitative O O
analysis O O
showed O O
that O O
erythroid O O
precursor O O
cells O O
were O O
newly O O
produced O O
from O O
the O O
immature O O
myeloid O O
cells O O
by O O
cultivation O O
with O O
IL-3 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

SCF B B_GENE/B_BIO
and O O
IL-3 B B_GENE/B_LOCATION
induced O O
stepwise O O
generation O O
of O O
erythroid O O
precursor O O
cells O O
from O O
an O O
A-6 O O
hematopoietic O O
stem O O
cell O O
line O O
. O O

Copyright O B_LOCATION/B_PERSON
2001 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Distinct O O
BMI-1 B B_GENE
and O O
EZH2 B B_GENE
expression O O
patterns O O
in O O
thymocytes O O
and O O
mature O O
T O O
cells O O
suggest O O
a O O
role O O
for O O
Polycomb B B_GENE/B_MEASURE
genes I I_GENE/I_MEASURE
in O O
human O O
T O O
cell O O
differentiation O O
. O O

BMI-1 B B_GENE/B_DISEASE
and O O
EZH2 B B_GENE/B_DISEASE
Polycomb-group B I_GENE/I_DISEASE
( I I_GENE/I_DISEASE
PcG I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
proteins I I_GENE/I_DISEASE
belong O O
to O O
two O O
distinct O O
protein O O
complexes O O
involved O O
in O O
the O O
regulation O O
of O O
hematopoiesis O O
. O O

Using O O
unique O O
PcG-specific O O
antisera O O
and O O
triple O O
immunofluorescence O O
, O O
we O O
found O O
that O O
mature O O
resting O O
peripheral O O
T O O
cells O O
expressed O O
BMI-1 B B_GENE
, O O
whereas O O
dividing O O
blasts O O
were O O
EZH2 O O
( O O
+ O O
) O O
. O O

By O O
contrast O O
, O O
subcapsular O O
immature O O
double-negative O O
( O O
DN O O
) O O
( O O
CD4 O O
( O O
- O O
) O O
/CD8 O O
( O O
- O O
) O O
) O O
T O O
cells O O
in O O
the O O
thymus O O
coexpressed O O
BMI-1 B B_GENE
and O O
EZH2 B B_GENE
or O O
were O O
BMI-1 O O
single O O
positive O O
. O O

Their O O
descendants O O
, O O
double-positive O O
( O O
DP O O
; O O
CD4 O O
( O O
+ O O
) O O
/CD8 O O
( O O
+ O O
) O O
) O O
cortical O O
thymocytes O O
, O O
expressed O O
EZH2 B B_GENE
without O O
BMI-1 B B_TIME[MEASURE]
. O O

Most O B_GENE
EZH2 O I_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
DN O B_PROTEIN[GENE]/B_DISEASE
and O O
DP O B_LOCATION
thymocytes O I_LOCATION
were O O
dividing O O
, O O
while O O
DN O B_GENE/B_LOCATION
BMI-1 O I_GENE/I_LOCATION
( O O
+ O B_DISEASE/B_GENE
) O O
/EZH2 O B_GENE
( O O
- O O
) O O
thymocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
resting O O
and O O
proliferation O B_TIME[MEASURE]/B_DISEASE
was O O
occasionally O O
noted O O
in O O
DN O B_GENE
BMI-1 O I_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
/EZH2 O B_GENE
( O O
+ O B_DISEASE/B_PROTEIN[GENE]
) O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Maturation O O
of O O
DP O O
cortical O O
thymocytes O O
to O O
single-positive O O
( O O
CD4 O O
( O O
+ O O
) O O
/CD8 O O
( O O
- O O
) O O
or O O
CD8 O O
( O O
+ O O
) O O
/CD4 O O
( O O
- O O
) O O
) O O
medullar O O
thymocytes O O
correlated O O
with O O
decreased O O
detectability O O
of O O
EZH2 B B_GENE
and O O
continued O O
relative O O
absence O O
of O O
BMI-1 B B_GENE
. O O

Our O O
data O O
show O O
that O O
BMI-1 B B_GENE
and O O
EZH2 B B_GENE
expression O O
in O O
mature O O
peripheral O O
T O O
cells O O
is O O
mutually O O
exclusive O O
and O O
linked O O
to O O
proliferation O O
status O O
, O O
and O O
that O O
this O O
pattern O O
is O O
not O O
yet O O
established O O
in O O
thymocytes O O
of O O
the O O
cortex O O
and O O
medulla O O
. O O

T O O
cell O O
stage-specific O O
PcG O O
expression O O
profiles O O
suggest O O
that O O
PcG B B_GENE/B_BIO
genes I I_GENE/I_BIO
contribute O O
to O O
regulation O O
of O O
T O O
cell O O
differentiation O O
. O O

They O O
probably O O
reflect O O
stabilization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
type-specific O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gene O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
irreversibility O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
lineage O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
choice O I_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
difference O B_MEASURE
in O O
PcG O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O O
medullar O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
thymocytes O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
mature O O
interfollicular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
indicates O O
that O O
additional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
maturation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
processes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
occur O O
after O O
thymocyte O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transportation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
the O O
thymus O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

Stepwise O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lineage O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
restriction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
progenitors O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O O
lympho-myelopoiesis O B_DISEASE/B_BIO
. O O

It O O
has O O
long O O
been O O
controversial O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
whether O O
hematopoiesis O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
progresses O O
through O O
ordered O O
stages O B_DISEASE/B_LOCATION
of O O
determination O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
in O O
embryonic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
development O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

This O O
is O O
due O O
to O O
the O O
absence O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
methodology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
capable O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
exactly O O
determining O O
the O O
developmental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
hematopoietic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stem/progenitor O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
multilineage O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
progenitor O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MLP O B_LOCATION/B_ORGANIZATION
) O O
assay O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
enabled O O
us O O
to O O
discriminate O O
among O O
seven O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
types O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
hematopoietic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
are O O
multipotent O B_DISEASE_ADJECTIVE[DISEASE]
progenitor O I_DISEASE_ADJECTIVE[DISEASE]
p-MTB O I_DISEASE_ADJECTIVE[DISEASE]
( O O
capable O B_PERSON/B_LOCATION
of O O
generating O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
myeloid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
bipotent O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p-MT O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
p-MB O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
p-TB O B_DISEASE/B_PROTEIN[GENE]
, O O
and O O
unipotent O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
p-M O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
p-T O O
and O O
p-B O O
. O O

Among O O
these O O
seven O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
types O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
the O O
p-TB O B_SEQUENCE[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
type O I_SEQUENCE[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
progenitor O I_SEQUENCE[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
found O O
to O O
be O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
indicate O O
that O O
the O O
process O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
lineage O B_DISEASE/B_ORGANISM_FUNCTION
commitment O I_DISEASE/I_ORGANISM_FUNCTION
proceeds O I_DISEASE/I_ORGANISM_FUNCTION
through O O
an O O
ordered O O
but O O
not O O
random O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

By O O
extending O O
the O O
area O B_LOCATION/B_MEASURE
of O O
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
include O O
the O O
erythroid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lineage O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
more O O
convincing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
the O O
ordered O O
process O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
obtained O O
. O O

Detailed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
exact O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
illustration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
process O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
hematopoiesis O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGAN_OR_TISSUE_FUNCTION[ORGANISM_FUNCTION]
will O O
provide O O
an O O
opportunity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
revive O O
hematopoiesis O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
as O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
most O O
fascinating O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
targets O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O O
developmental O B_DISEASE/B_BIO
biology O I_DISEASE/I_BIO

Epstein-Barr O O
Virus O O
and O O
its O O
glycoprotein-350 B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
upregulate O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
B-lymphocytes O O
via O O
CD21 B B_GENE/B_LOCATION
, O O
involving O O
activation O O
of O O
NF-kappaB B B_GENE/B_DISEASE
and O O
different O O
signaling O O
pathways O O
. O O

Epstein-Barr O B_DISEASE/B_VIRUS[BIO]
virus O B_DISEASE/I_VIRUS[BIO]
( O O
EBV O B_VIRUS[BIO]/B_DISEASE
) O O
is O O
a O O
ubiquitous O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
highly O O
immunotropic O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
gamma O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
herpesvirus O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
that O O
infects O O
more O B_MEASURE/B_PERSON
than O O
90 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
humans O B_PERSON/B_BIO
worldwide O O
. O O

Its O O
pathogenicity O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
leads O O
to O O
a O O
number O B_MEASURE/B_LOCATION
of O O
diseases O B_DISEASE
including O O
tumors O B_DISEASE/B_PERSON
that O O
result O O
from O O
EBV O B_DISEASE
's O I_DISEASE
ability O I_DISEASE
to O O
readily O O
transform O O
B-lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
, O O
to O O
a O O
lesser O B_MEASURE/B_DISEASE
extent O I_MEASURE/I_DISEASE
, O O
epithelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

EBV O O
utilizes O O
CD21/CR2 B B_GENE
as O O
its O O
receptor O O
on O O
B O O
cells O O
to O O
initiate O O
the O O
infection O O
process O O
. O O

EBV O O
binds O O
to O O
CR2 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
its O O
major B B_GENE/B_BIO
envelope I I_GENE/I_BIO
glycoprotein-350 I I_GENE/I_BIO
( O O
gp350 B B_GENE
) O O
and O O
is O O
also O O
a O O
remarkable O O
immunomodulating O O
agent O O
. O O

We O O
had O O
previously O O
shown O O
that O O
EBV O O
is O O
capable O O
of O O
modulating O O
the O O
synthesis O O
of O O
a O O
number O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
now O O
show O O
that O O
while O O
both O O
purified O O
recombinant B B_GENE/B_VIRUS[BIO]
gp350 I B_GENE/I_VIRUS[BIO]
( O O
rgp350 B B_GENE
) O O
and O O
EBV O O
upregulate O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthesis O O
in O O
B O O
cells O O
, O O
EBV-induced O O
IL-6 O O
gene O O
activation O O
occurs O O
for O O
a O O
significantly O O
longer O O
period O O
of O O
time O O
( O O
i.e. O O
12 O O
hours O O
for O O
EBV O O
as O O
compared O O
to O O
6 O O
hours O O
for O O
rgp350 B B_GENE/B_VIRUS[BIO]
) O O
. O O

Moreover O O
, O O
the O O
half-life O O
of O O
EBV-induced O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
also O O
significantly O O
longer O O
( O O
10 O O
hours O O
) O O
than O O
that O O
of O O
mRNA O O
induced O O
by O O
rgp350 B B_GENE/B_VIRUS[BIO]
( O O
about O O
6 O O
hours O O
) O O
. O O

Both O O
EBV O O
and O O
gp350 B B_GENE/B_VIRUS[BIO]
enhance O O
the O O
binding O O
of O O
the O O
NF-kappaB B B_GENE
transcription I I_GENE
factor I I_GENE
, O O
as O O
determined O O
by O O
band-shift O O
and O O
augment O O
NF-kappaB B B_GENE/B_MEASURE
-mediated O O
activation O O
of O O
a O O
CAT B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
we O O
demonstrate O O
that O O
while O O
the O O
activation O O
of O O
IL-6 O O
gene O O
expression O O
by O O
gp350 B B_GENE/B_VIRUS[BIO]
is O O
mediated O O
primarily O O
by O O
the O O
protein O O
kinase O O
C O O
pathway O O
, O O
EBV O O
can O O
mediate O O
its O O
effects O O
through O O
multiple O O
signaling O O
pathways O O
. O O

To O O
our O O
knowledge O O
this O O
is O O
the O O
first O O
report O O
showing O O
that O O
the O O
binding O O
of O O
a O O
herpesvirus B B_GENE
envelope I I_GENE
glycoprotein I I_GENE
to O O
CR2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
human O O
B O O
cells O O
results O O
in O O
the O O
activation O O
of O O
the O O
NF-kappaB B B_GENE
transcription I I_GENE
factor I I_GENE
leading O O
to O O
the O O
upregulation O O
of O O
IL-6 O O
gene O O
expression O O
in O O
these O O
lymphocytes O O
. O O

Copyright O B_LOCATION/B_PERSON
2001 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Gene- O B_TIME[MEASURE]/B_PERSON
and O O
tissue-specificity O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
mutation O B_DISEASE/B_GENE
in O O
Big O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Blue O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
treated O O
with O O
the O O
hepatocarcinogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N-hydroxy-2-acetylaminofluorene O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
a O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
we O O
found O O
that O O
treating O O
transgenic O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Big O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blue O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
hepatocarcinogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N-hydroxy-2-acetylaminofluorene O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
N-OH-AAF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
produced O O
the O O
same O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
major O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adduct O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
target O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
liver O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
nontarget O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
spleen O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
bone O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
marrow O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
induced O O
lacI O B_DISEASE
mutants O I_DISEASE
in O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
and O O
induced O O
much O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
frequencies O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
l O B_GENE/B_DISEASE
acI O I_GENE/I_DISEASE
and O O
hprt O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutants O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
spleen O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

In O O
the O O
present O O
study O O
, O O
sequence O O
analysis O O
was O O
conducted O O
on O O
lacI B B_SPECIES[BIO]/B_GENE
DNA I B_SPECIES[BIO]/I_GENE
and O O
hprt B B_GENE
cDNA I I_GENE
from O O
the O O
mutants O O
, O O
to O O
determine O O
the O O
mutational O O
specificity O O
of O O
N-OH-AAF O O
in O O
the O O
rat O O
. O O

All O O
the O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectra O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
N-OH-AAF-treated O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
rats O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
differed O O
significantly O O
from O O
corresponding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mutation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
profiles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O O
untreated O B_PERSON/B_BIO
animals O I_PERSON/I_BIO
( O O
P O B_OTHER/B_LOCATION
= O O
0.02 O B_MEASURE
to O O
P O B_MEASURE
< O I_MEASURE
0.0001 O I_MEASURE
) O O
. O O

Although O O
there O O
were O O
similarities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
among O O
the O O
mutational O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
patterns O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
derived O O
from O O
N-OH-AAF-treated O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
rats O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
e.g. O B_DISEASE/B_PROTEIN[GENE]
, O O
G O O
: O B_OTHER/B_LOCATION
C O O
-- O B_MEASURE/B_GENE
> O O
T O B_MEASURE/B_LOCATION
: O I_MEASURE/I_LOCATION
A O O
transversion O O
was O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
the O O
most O O
common O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]
in O I_DISEASE_ADJECTIVE[DISEASE]
all O O
mutation O O
sets O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
) O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
there O O
were O O
significant O O
differences O B_MEASURE
in O I_MEASURE
the O O
patterns O O
of O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
basepair O O
substitution O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
frameshift O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O O
liver O O
and O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
spleen O O
lymphocyte O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lacI O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
mutants O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
P O O
= O B_PROTEIN[GENE]/B_LOCATION
0.02 O O
) O B_MEASURE
and O O
between O O
the O O
spleen O O
lymphocyte O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
lacI O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
and O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
hprt O O
mutants O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
( O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
P O O
= O B_PROTEIN[GENE]/B_LOCATION
0.04 O O
) O B_MEASURE
. O O

Also O O
, O O
multiplex O O
PCR O O
analysis O O
of O O
genomic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
hprt O O
mutants O O
indicated O O
that O O
12 O O
% O O
of O O
mutants O O
from O O
treated O O
rats O O
had O O
major O O
deletions O O
in O O
the O O
hprt B B_GENE
gene I I_GENE
; O O
no O O
corresponding O O
incidence O O
of O O
large O O
deletions O O
was O O
evident O O
among O O
lacI O O
mutations O O
. O O

All O O
the O O
mutation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
profiles O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reflect O O
the O O
general O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutational O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
specificity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
the O O
major O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adduct O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
formed O O
by O O
N-OH-AAF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
differences O O
between O O
N-OH-AAF O O
mutation O O
in O O
the O O
endogenous B B_GENE/B_BIO
gene I I_GENE/I_BIO
and O O
transgene B B_GENE
can O O
be O O
partially O O
explained O O
by O O
the O O
structures O O
of O O
the O O
two O O
genes O O
. O O

The O O
tissue-specificity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
mutation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectra O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
contribute O O
to O O
targeting O O
tumor O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

Environ. O O
Mol. O O
Mutagen. O O
37 O B_MEASURE
: O O
203-214 O B_MEASURE
, O O
2001 O B_MEASURE/B_LOCATION
. O O

Published O O
2001 O B_PERSON/B_ENT
Wiley-Liss O I_PERSON/I_ENT
, O O
Inc O B_ORGANIZATION/B_PERSON
. O O

Caspase B B_GENE
-dependent O O
cleavage O O
of O O
the O O
hematopoietic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adaptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Gads I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alters O O
signalling O O
from O O
the O O
T B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
cell I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Gads B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
SH2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
SH3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
domain I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-containing O O
, O O
hematopoietic-specific B B_GENE
adaptor I I_GENE
protein I I_GENE
that O O
functions O O
in O O
signalling O O
from O O
the O O
T B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
cell I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
receptor I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Gads B B_PERSON/B_GENE
acts O O
by O O
linking O O
SLP-76 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
bound O O
by O O
the O O
carboxy-terminal B B_GENE
Gads I I_GENE
SH3 I I_GENE
domain I I_GENE
, O O
to O O
tyrosine B B_GENE/B_LOCATION
phosphorylated I I_GENE/I_LOCATION
LAT I I_GENE/I_LOCATION
which O O
contains O O
binding O O
sites O O
for O O
the O O
Gads B B_PROTEIN[GENE]
SH2 I I_PROTEIN[GENE]
domain I I_PROTEIN[GENE]
. O O

Gads B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
distinguished O O
from O O
Grb2 B B_GENE/B_BIO
and O O
the O O
closely O O
related O O
Grap B B_GENE/B_BIO
protein I I_GENE/I_BIO
by O O
the O O
presence O O
of O O
a O O
120 B B_LOCATION/B_MEASURE
amino I I_LOCATION/I_MEASURE
acid I I_LOCATION/I_MEASURE
unique I I_LOCATION/I_MEASURE
region I I_LOCATION/I_MEASURE
between O O
the O O
SH2 B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
carboxy B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
terminal I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SH3 I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Here O O
we O O
demonstrate O O
that O O
the O O
unique O O
region O O
of O O
Gads B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
contains O O
a O O
capase B B_LOCATION/B_GENE
cleavage I I_LOCATION/I_GENE
site I I_LOCATION/I_GENE
. O O

Induction O O
of O O
apoptosis O O
in O O
lymphocytes O O
results O O
in O O
detectable O O
Gads B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cleavage O O
by O O
60 O O
min O O
. O O

Gads B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cleavage O O
is O O
blocked O O
in O O
vivo O O
by O O
treating O O
cells O O
with O O
a O O
caspase O O
3 O O
inhibitor O O
. O O

A O O
putative B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
caspase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cleavage I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
identified O O
within O O
the O O
unique O O
region O O
and O O
mutation O O
of O O
this O O
site O O
prevented O O
Gads B B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
cleavage O O
in O O
vitro O O
, O O
and O O
in O O
vivo O O
. O O

The O O
Gads B B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
cleavage O O
products O O
retained O O
the O O
predicted O O
binding O O
specificity O O
for O O
SLP-76 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
LAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Expression O O
of O O
the O O
Gads B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cleavage O O
products O O
in O O
Jurkat O O
T O O
cells O O
inhibited O O
NFAT O O
activation O O
following O O
TCR O O
cross O O
linking O O
. O O

These O O
findings O O
indicate O O
that O O
cleavage O O
of O O
Gads B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O O
could O O
function O O
to O O
alter O O
signalling O O
downstream O O
of O O
the O O
T B B_GENE/B_LOCATION
cell I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
by O O
disrupting O O
cross O O
talk O O
between O O
SLP-76 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
LAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Targeting O O
of O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
interleukin-2 B B_GENE
promoter I I_GENE
via O O
CREB-Rel O O
cross-talk O O
during O O
mitogen B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
oncogenic O O
molecular O O
signaling O O
in O O
activated O O
T-cells O O
. O O

In O O
this O O
report O O
, O O
we O O
explore O O
the O O
mechanisms O O
of O O
targeting O O
of O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
interleukin-2 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
( I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
IL-2 I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
) I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O O
response O O
to O O
mitogenic O O
and O O
oncogenic O O
molecular O O
signals O O
. O O

Recruitment O O
of O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
cAMP-responsive B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
element-binding I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
protein-Rel I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cross-talk O O
at O O
the O O
composite B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CD28 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CD28RE B B_GENE/B_LOCATION
) O O
- O O
TRE B B_MEASURE/B_LOCATION
element I B_MEASURE/I_LOCATION
of O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
is O O
essential O O
for O O
promoter O O
inducibility O O
during O O
T-cell O O
activation O O
, O O
and O O
CD28RE-TRE B B_GENE/B_LOCATION
is O O
the O O
exclusive O O
target O O
of O O
the O O
human O O
T-cell O O
lymphotropic O O
virus O O
type O O
I O O
oncoprotein B B_GENE/B_DISEASE
Tax I I_GENE/I_DISEASE
. O O

The O O
intrinsic O O
histone O O
acetyltransferase O O
activity O O
of O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
dispensable O O
for O O
activation O O
of O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
and O O
the O O
N-terminal B B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
743 I B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
residues I B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contain O O
the O O
minimal O O
structural O O
requirements O O
for O O
synergistic O O
transactivation O O
of O O
the O O
CD28RE-TRE B B_GENE/B_LOCATION
, O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
and O O
endogenous O O
IL-2 B B_GENE
gene I I_GENE
expression O O
. O O

Mutational O O
analysis O O
of O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O O
differential O O
structural O O
requirements O O
for O O
the O O
N-terminal O O
p300 O O
module O O
by O O
individual O O
cis-elements B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
within O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
. O O

These O O
findings O O
provide O O
evidence O O
that O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assembles O O
at O O
the O O
IL-2 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
to O O
form O O
an O O
enhanceosome-like O O
signal O O
transduction O O
target O O
that O O
is O O
centrally O O
integrated O O
at O O
the O O
CD28RE-TRE B B_LOCATION
element I I_LOCATION
of O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
through O O
specific O O
protein O O
module-targeted O O
associations O O
in O O
activated O O
T-cells O O
. O O

Regulation O O
of O O
cytokine O O
production O O
in O O
T-cell O O
responses O O
to O O
inhalant O O
allergen O O
: O O
GATA-3 B B_GENE/B_PERSON
expression O O
distinguishes O O
between O O
Th1- O O
and O O
Th2-polarized O O
immunity O O
. O O

BACKGROUND O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
The O O
precise O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
nature O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
allergen-specific O B_DISEASE
cytokine O I_DISEASE
responses O I_DISEASE
in O O
atopics O B_BIO/B_DISEASE
versus O I_BIO/I_DISEASE
non-atopics O I_BIO/I_DISEASE
, O O
in O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
'Th1 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
polarity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
' O O
of O O
responses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
non-atopics O B_DISEASE/B_BIO
, O O
remains O O
controversial O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
is O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
relative O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
insensitivity O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cytokine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
associated O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
kinetics O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
cytokine O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
production O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
catabolism O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
in O O
in O O
vitro O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

As O O
an O O
alternative O O
to O O
cytokine O O
measurement O O
, O O
this O O
study O O
focuses O O
on O O
expression O O
of O O
the O O
transcription B B_GENE
factor I I_GENE
GATA-3 I I_GENE
for O O
analysis O O
of O O
allergen-specific O O
Th O O
cell O O
responses O O
. O O

METHODS O O
: O O
Cord O O
blood O O
mononuclear O O
cells O O
were O O
Th1- O O
or O O
Th2-polarized O O
by O O
culture O O
in O O
IL-12- O O
or O O
IL-4-employing O O
established O O
methods O O
; O O
PBMC O O
from O O
house O O
dust O O
mite O O
( O O
HDM O O
) O O
-sensitive O O
atopics O O
and O O
controls O O
were O O
stimulated O O
overnight O O
with O O
HDM O O
; O O
cytokine O O
production O O
was O O
measured O O
by O O
ELISA O O
and O O
GATA-3 B B_GENE/B_DISEASE
mRNA I I_GENE/I_DISEASE
expression O O
by O O
PCR O O
. O O

RESULTS O O
: O O
Cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-driven O O
Th2 O O
polarization O O
of O O
naive O O
T O O
cells O O
is O O
associated O O
with O O
marked O O
upregulation O O
of O O
GATA-3 B B_GENE
expression O O
, O O
whereas O O
a O O
reciprocal O O
expression O O
pattern O O
accompanies O O
differentiation O O
towards O O
the O O
Th1 O O
cytokine O O
phenotype O O
. O O

In O O
T O O
cells O O
from O O
HDM O O
skin O O
prick O O
test-positive O O
( O O
HDM-SPT+/HDM-IgE+ O O
) O O
volunteers O O
, O O
overnight O O
stimulation O O
results O O
in O O
marked O O
upregulation O O
of O O
GATA-3 B B_GENE
expression O O
, O O
compared O O
to O O
an O O
equally O O
marked O O
downregulation O O
of O O
expression O O
in O O
T O O
cells O O
from O O
SPT-/IgE- O O
subjects O O
. O O

In O O
subjects O O
who O O
are O O
HDM-SPT+ O O
but O O
IgE- O O
, O O
GATA-3 B B_GENE/B_DISEASE
expression O O
levels O O
remained O O
relatively O O
stable O O
during O O
culture O O
with O O
HDM O O
. O O

CONCLUSIONS O O
: O O
Upregulation O O
of O O
GATA-3 B B_GENE
expression O O
in O O
PBMC O O
is O O
a O O
hallmark O O
of O O
the O O
early O O
phase O O
of O O
Th2 O O
recall O O
responses O O
to O O
specific O O
allergen O O
in O O
atopics O O
. O O

The O O
reciprocal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
expression O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
pattern O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
observed O O
in O O
HDM-specific O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
recall O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
responses O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
non-atopics O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
provides O O
independent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
confirmation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
underlying O O
Th1-like O B_DISEASE
immunity O I_DISEASE
in O O
these O O
subjects O B_PERSON/B_BIO
. O O

The O O
parallel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
neonatal O B_MEASURE/B_PERSON
T O I_MEASURE/I_PERSON
cells O I_MEASURE/I_PERSON
suggest O O
that O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
may O O
be O O
utilized O O
for O O
monitoring O O
the O O
progress O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
allergen-specific O B_DISEASE
Th1/Th2 O I_DISEASE
memory O I_DISEASE
development O I_DISEASE
during O O
early O B_DISEASE/B_ORGANISM_FUNCTION
childhood O B_DISEASE/I_ORGANISM_FUNCTION
, O O
and O O
hence O O
in O O
assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
risk O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O O
future O B_DISEASE
allergic O I_DISEASE
disease O I_DISEASE
. O O

Copyright O B_MEASURE/B_PERSON
2001 O I_MEASURE/I_PERSON
S. O O
Karger O B_PERSON
AG O I_PERSON
, O O
Basel O B_LOCATION/B_ORGANIZATION

The O O
heat O O
shock O O
response O O
reduces O O
myelin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
oligodendrocyte I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
glycoprotein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
-induced O O
experimental O O
autoimmune O O
encephalomyelitis O O
in O O
mice O O
. O O

The O O
stress O O
response O O
( O O
SR O O
) O O
can O O
block O O
inflammatory O O
gene O O
expression O O
by O O
preventing O O
activation O O
of O O
transcription B B_GENE
factor I I_GENE
nuclear B I_GENE
factor-kappa I I_GENE
B I I_GENE
( O O
NF-kappaB B B_GENE
) O O
. O O

As O O
inflammatory O B_DISEASE/B_LOCATION
gene O B_DISEASE/I_LOCATION
expression O B_DISEASE/I_LOCATION
contributes O O
to O O
the O O
pathogenesis O B_DISEASE_ADJECTIVE[DISEASE]
of O O
demyelinating O O
diseases O B_DISEASE/B_LOCATION
, O O
we O O
tested O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
SR O B_GENE/B_DISEASE
on O O
the O O
progression O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
demyelinating O O
disease O B_DISEASE
experimental O I_DISEASE
autoimmune O I_DISEASE
encephalomyelitis O I_DISEASE
( O O
EAE O B_DISEASE/B_LOCATION
) O O
. O O

EAE O O
was O O
actively O O
induced O O
in O O
C57BL/6 O O
mice O O
using O O
an O O
encephalitogenic O O
myelin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oligodendrocyte I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glycoprotein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MOG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
35-55 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
peptide O O
. O O

Whole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
body O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hyperthermia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
used O O
to O O
induce O O
a O O
heat O B_DISEASE
shock O I_DISEASE
response O I_DISEASE
( O O
HSR O B_DISEASE/B_PROTEIN[GENE]
) O O
in O O
immunized O O
mice O B_SPECIES[BIO]/B_PERSON
2 O I_SPECIES[BIO]/I_PERSON
days O I_SPECIES[BIO]/I_PERSON
after O O
the O O
booster O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
MOG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
35-55 O B_TIME[MEASURE]/B_LOCATION
) O O
peptide O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

The O O
HSR O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduced O O
the O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
EAE O B_DISEASE
by O O
70 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
, O O
delayed O O
disease O B_DISEASE_ADJECTIVE[DISEASE]
onset O I_DISEASE_ADJECTIVE[DISEASE]
by O O
6 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
, O O
and O O
attenuated O O
disease O B_DISEASE
severity O I_DISEASE
. O O

The O O
HSR O O
attenuated O O
leukocyte O O
infiltration O O
into O O
CNS O O
assessed O O
by O O
quantitation O O
of O O
perivascular O O
infiltrates O O
, O O
and O O
by O O
reduced O O
staining O O
for O O
CD4 B B_GENE
and O O
CD25 B B_GENE
immunopositive O O
T-cells O O
. O O

T-cell O O
activation O O
, O O
assessed O O
by O O
the O O
production O O
of O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IFNgamma B B_PROTEIN[GENE]/B_LOCATION
) O O
in O O
response O O
to O O
MOG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
35-55 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
was O O
also O O
decreased O O
by O O
the O O
HSR O O
. O O

The O O
HSR O O
reduced O O
inflammatory O O
gene O O
expression O O
in O O
the O O
brain O O
that O O
normally O O
occurs O O
during O O
EAE O O
, O O
including O O
the O O
early O O
increase O O
in O O
RANTES B B_GENE
( O O
regulated B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
on I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
activation I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
normal I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
T-cell I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
expressed I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
secreted I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
expression O O
, O O
and O O
the O O
later O O
expression O O
of O O
the O O
inducible O O
form O O
of O O
nitric B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
early O O
activation O O
of O O
transcription B B_GENE
factor I I_GENE
NF-kappaB B I_GENE
was O O
also O O
blocked O O
by O O
the O O
HSR O O
. O O

The O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
the O O
SR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reduces O O
inflammation O B_DISEASE/B_BACTERIUM[BIO]
in O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]
severity O I_DISEASE_ADJECTIVE[DISEASE]
of O O
EAE O B_DISEASE/B_LOCATION
opens O O
a O O
novel O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
therapeutic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
approach O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O O
prevention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
autoimmune O B_DISEASE
diseases O I_DISEASE
. O O

In O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intracellular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
developing O O
thymocytes O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

Information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
regarding O O
the O O
intracellular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processes O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
occur O O
during O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
T O B_DISEASE/B_GENE
cells O I_DISEASE/I_GENE
has O O
largely O O
been O O
obtained O O
with O O
the O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
transgenic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mouse O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
models O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
which O O
although O O
providing O O
invaluable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
information O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
time O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
consuming O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O O
costly O B_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
this O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
we O O
have O O
developed O O
a O O
novel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O O
facilitates O O
the O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
signal O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transduction O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
T-lymphocyte O B_DISEASE/B_ORGANISM_FUNCTION
development O I_DISEASE/I_ORGANISM_FUNCTION
. O O

This O O
approach O O
uses O O
reporter-plasmids B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
the O O
detection O O
of O O
intracellular O O
signals O O
mediated O O
by O O
the O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
cyclic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AMP-dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Reporter-plasmids B B_PERSON/B_GENE
are O O
transfected O O
into O O
thymocytes O O
in O O
fetal O O
thymic O O
organ O O
culture O O
by O O
accelerated O O
DNA/particle O O
bombardment O O
( O O
gene O O
gun O O
) O O
, O O
and O O
the O O
activation O O
of O O
a O O
signaling O O
pathway O O
is O O
determined O O
in O O
the O O
form O O
of O O
a O O
standard O O
luciferase O O
assay O O
. O O

Importantly O O
, O O
this O O
powerful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
technique O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
preserves O O
the O O
structural O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
integrity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
the O O
thymus O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
, O O
and O O
will O O
provide O O
an O O
invaluable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tool O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
study O O
how O O
thymocytes O O
respond O O
to O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
environmental O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimuli O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encountered O O
during O O
differentiation O B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
within O O
the O O
thymic O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
milieu O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O O

Thus O O
, O O
this O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
allows O O
for O O
the O O
monitoring O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
signals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
occur O O
in O O
a O O
biological O B_MEASURE/B_BIO
time O B_MEASURE/I_BIO
frame O B_MEASURE/I_BIO
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
during O O
differentiation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
within O O
the O O
natural O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
environment O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
differentiating O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Core-binding B B_GENE
factor I I_GENE
beta I I_GENE
( O O
CBFbeta B B_GENE
) O O
, O O
but O O
not O O
CBFbeta-smooth B B_GENE
muscle I I_GENE
myosin I I_GENE
heavy I I_GENE
chain I I_GENE
, O O
rescues O O
definitive O O
hematopoiesis O O
in O O
CBFbeta B B_GENE
-deficient O O
embryonic O O
stem O O
cells O O
. O O

Core-binding B B_PROTEIN[GENE]
factor I I_PROTEIN[GENE]
beta I I_PROTEIN[GENE]
( O O
CBFbeta B B_GENE/B_DISEASE
) O O
is O O
the O O
non-DNA-binding B B_GENE/B_MEASURE
subunit I I_GENE/I_MEASURE
of O O
the O O
heterodimeric B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
CBFs I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Genes B B_GENE/B_DISEASE
encoding I I_GENE/I_DISEASE
CBFbeta I I_GENE/I_DISEASE
( O O
CBFB B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
one O O
of O O
the O O
DNA-binding B B_GENE/B_NUMBER[MEASURE]
CBFalpha I I_GENE/I_NUMBER[MEASURE]
subunits I I_GENE/I_NUMBER[MEASURE]
, I I_GENE/I_NUMBER[MEASURE]
Runx1 I I_GENE/I_NUMBER[MEASURE]
( O O
also O O
known O O
as O O
CBFalpha2 B B_GENE/B_DISEASE
, O O
AML1 B B_GENE
, O O
and O O
PEBP2alphaB B B_GENE/B_DISEASE
) O O
, O O
are O O
required O O
for O O
normal O O
hematopoiesis O O
and O O
are O O
also O O
frequent O O
targets O O
of O O
chromosomal O O
translocations O O
in O O
acute O O
leukemias O O
in O O
humans O O
. O O

Homozygous O O
disruption O O
of O O
either O O
the O O
Runx1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Cbfb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mice O O
results O O
in O O
embryonic O O
lethality O O
at O O
midgestation O O
due O O
to O O
hemorrhaging O O
in O O
the O O
central O O
nervous O O
system O O
, O O
and O O
severely O O
impairs O O
fetal O O
liver O O
hematopoiesis O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
that O O
Cbfb-deficient O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mouse O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
embryonic O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stem O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
ES O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
can O O
differentiate O O
into O O
primitive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
erythroid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
colonies O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
but O O
are O O
impaired O O
in O O
their O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
produce O O
definitive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
erythroid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
and O O
myeloid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
colonies O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
mimicking O O
the O O
in O O
vivo O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defect O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Definitive O O
hematopoiesis O O
is O O
restored O O
by O O
ectopic O O
expression O O
of O O
full-length B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Cbfb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transgenes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
well O O
as O O
by O O
a O O
transgene O O
encoding O O
only O O
the O O
heterodimerization B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
of O O
CBFbeta B B_GENE
. O O

In O O
contrast O O
, O O
the O O
CBFbeta B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
smooth B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
muscle I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
myosin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heavy I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
SMMHC I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fusion I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
generated O O
by O O
the O O
inv B B_GENE/B_DISEASE
( I B_GENE/I_DISEASE
16 I B_GENE/I_DISEASE
) I B_GENE/I_DISEASE
associated O O
with O O
acute O O
myeloid O O
leukemias O O
( O O
M4Eo O O
) O O
can O O
not O O
rescue O O
definitive O O
hematopoiesis O O
by O O
Cbfb-deficient O O
ES O O
cells O O
. O O

Sequences O O
responsible O O
for O O
the O O
inability O O
of O O
CBFbeta B B_PROTEIN[GENE]/B_DISEASE
-SMMHC O O
to O O
rescue O O
definitive O O
hematopoiesis O O
reside O O
in O O
the O O
SMMHC B B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
portion I I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
fusion B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
. O O

Results O O
also O O
show O O
that O O
the O O
CBFbeta-SMMHC B B_GENE
fusion I I_GENE
protein I I_GENE
transdominantly O O
inhibits O O
definitive O O
hematopoiesis O O
, O O
but O O
not O O
to O O
the O O
same O O
extent O O
as O O
homozygous O O
loss O O
of O O
Runx1 B B_GENE
or O O
Cbfb B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CBFbeta-SMMHC B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preferentially O O
inhibits O O
the O O
differentiation O O
of O O
myeloid O O
lineage O O
cells O O
, O O
while O O
increasing O O
the O O
number O O
of O O
blastlike O O
cells O O
in O O
culture O O
. O O

The O O
latency O O
pattern O O
of O O
Epstein-Barr O O
virus O O
infection O O
and O O
viral O O
IL-10 B B_GENE
expression O O
in O O
cutaneous O O
natural O O
killer/T-cell O O
lymphomas O O
. O O

The O O
nasal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
type O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
extranodal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
natural O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
killer O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
T O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
NK/T O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
-cell O B_DISEASE
lymphoma O I_DISEASE
is O O
usually O O
associated O O
with O O
latent O B_DISEASE/B_VIRUS[BIO]
Epstein-Barr O B_DISEASE/I_VIRUS[BIO]
virus O B_DISEASE/I_VIRUS[BIO]
( O O
EBV O B_VIRUS[BIO]/B_DISEASE
) O O
infection O B_DISEASE
. O O

In O O
order O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
elucidate O O
the O O
EBV O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
examined O O
eight O B_PERSON
patients O I_PERSON
with O O
cutaneous O B_DISEASE/B_GENE
EBV-related O I_DISEASE/I_GENE
NK/T-cell O I_DISEASE/I_GENE
lymphomas O I_DISEASE/I_GENE
, O O
including O O
six O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
with O O
a O O
NK-cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phenotype O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
two O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
with O O
a O O
T-cell O B_DISEASE/B_GENE
phenotype O I_DISEASE/I_GENE
. O O

The O O
implication O O
of O O
EBV O O
in O O
the O O
skin O O
lesions O O
was O O
determined O O
by O O
the O O
presence O O
of O O
EBV-DNA B B_VIRUS[BIO]/B_GENE
, O O
EBV-encoded B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
nuclear I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
RNA I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
EBER B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
a O O
clonality O O
of O O
EBV-DNA B B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
fragments I I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
the O O
terminal B B_GENE/B_DISEASE
repeats I I_GENE/I_DISEASE
. O O

Transcripts O O
of O O
EBV-encoded B B_DISEASE/B_BIO
genes I I_DISEASE/I_BIO
were O O
screened O O
by O O
reverse O O
transcription- O O
polymerase O O
chain O O
reaction O O
( O O
RT-PCR O O
) O O
, O O
and O O
confirmed O O
by O O
Southern O O
blot O O
hybridization O O
. O O

The O O
expression O O
of O O
EBV-related B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
examined O O
by O O
immunostaining O O
using O O
paraffin-embedded O O
tissue O O
sections O O
and O O
cell O O
pellets O O
of O O
EBV-positive O O
cell O O
lines O O
. O O

Our O O
study O O
demonstrated O O
that O O
all O O
samples O O
from O O
the O O
patients O O
contained O O
EBV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
was O O
transcribed O O
using O O
the O O
Q B B_GENE
promoter I I_GENE
, O O
whereas O O
both O O
the O O
Q B B_PROTEIN[GENE]/B_LOCATION
promoter I I_PROTEIN[GENE]/I_LOCATION
and O O
another O O
upstream B B_GENE
promoter I I_GENE
( O O
Cp/Wp B B_PROTEIN[GENE]
) O O
were O O
used O O
in O O
EBV-positive O O
cell O O
lines O O
, O O
B95.8 O O
, O O
Raji O O
and O O
Jiyoye O O
. O O

Latent B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
membrane I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LMP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
detected O O
in O O
seven O O
of O O
eight O O
patients O O
and O O
all O O
cell O O
lines O O
, O O
whereas O O
EBNA-2 B B_GENE/B_PERSON
transcripts I I_GENE/I_PERSON
were O O
found O O
only O O
in O O
the O O
cell O O
lines O O
. O O

Immunostaining O O
showed O O
no O O
LMP-1 B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
EBNA-2 I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ZEBRA I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antigens I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
paraffin-embedded O O
tissue O O
sections O O
, O O
although O O
they O O
were O O
positive O O
in O O
the O O
cell O O
line O O
cells O O
. O O

Latent B B_GENE/B_PERSON
BHRF1 I I_GENE/I_PERSON
transcripts I I_GENE/I_PERSON
encoding O O
bcl-2 B B_GENE/B_VIRUS[BIO]
homologue I B_GENE/I_VIRUS[BIO]
and O O
BCRF1 B B_GENE/B_BIO
transcripts I I_GENE/I_BIO
encoding O O
viral B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interleukin I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vIL I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-10 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
detected O O
in O O
one O O
and O O
two O O
of O O
eight O O
patients O O
, O O
respectively O O
. O O

A O O
patient O B_PERSON/B_BIO
with O O
NK-cell O B_DISEASE
lymphoma O I_DISEASE
expressing O O
both O O
transcripts O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
died O O
of O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]
progression O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
illness O B_DISEASE
. O O

Our O O
results O O
indicate O O
that O O
the O O
restricted O O
expression O O
of O O
the O O
latency-associated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
EBV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
production O O
of O O
vIL-10 B B_GENE
and I I_GENE
bcl-2 I I_GENE
homologue I I_GENE
may O O
favour O O
tumour O O
growth O O
, O O
evading O O
the O O
host O O
immune O O
surveillance O O
. O O

Copyright O B_ENT/B_LOCATION
2001 O I_ENT/I_LOCATION
Cancer O I_ENT/I_LOCATION
Research O I_ENT/I_LOCATION
Campaign O I_ENT/I_LOCATION
. O O

Oxidized O B_NUMBER[MEASURE]/B_PERSON
alkyl O B_NUMBER[MEASURE]/I_PERSON
phospholipids O B_NUMBER[MEASURE]/I_PERSON
are O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
high O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affinity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
peroxisome O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
proliferator-activated O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ligands O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
agonists O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Synthetic O B_NUMBER[MEASURE]/B_GENE
high O I_NUMBER[MEASURE]/I_GENE
affinity O I_NUMBER[MEASURE]/I_GENE
peroxisome O I_NUMBER[MEASURE]/I_GENE
proliferator-activated O O
receptor O B_GENE
( O O
PPAR O B_LOCATION/B_ORGANIZATION
) O O
agonists O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
known O O
, O O
but O O
biologic O B_NUMBER[MEASURE]/B_ORGANIZATION
ligands O I_NUMBER[MEASURE]/I_ORGANIZATION
are O O
of O O
low O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
affinity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Oxidized B B_PROTEIN[GENE]
low I I_PROTEIN[GENE]
density I I_PROTEIN[GENE]
lipoprotein I I_PROTEIN[GENE]
( O O
oxLDL B B_GENE/B_LOCATION
) O O
is O O
inflammatory O O
and O O
signals O O
through O O
PPARs B B_GENE
. O O

We O O
showed O O
, O O
by O O
phospholipase O O
A O O
( O O
1 O O
) O O
digestion O O
, O O
that O O
PPARgamma O O
agonists O O
in O O
oxLDL B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
arise O O
from O O
the O O
small O O
pool O O
of O O
alkyl O O
phosphatidylcholines O O
in O O
LDL B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

We O O
identified O O
an O O
abundant O O
oxidatively O O
fragmented O O
alkyl O O
phospholipid O O
in O O
oxLDL B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
hexadecyl O O
azelaoyl O O
phosphatidylcholine O O
( O O
azPC O O
) O O
, O O
as O O
a O O
high O O
affinity O O
ligand O O
and O O
agonist O O
for O O
PPARgamma B B_GENE/B_LOCATION
. O O

[ O O
( O O
3 O O
) O O
H O O
] O O
azPC O O
bound O O
recombinant B B_GENE
PPARgamma I I_GENE
with O O
an O O
affinity O O
( O O
K O O
( O O
d O O
) O O
( O O
( O O
app O O
) O O
) O O
approximately O O
40 O O
nm O O
) O O
that O O
was O O
equivalent O O
to O O
rosiglitazone O O
( O O
BRL49653 O O
) O O
, O O
and O O
competition O O
with O O
rosiglitazone O O
showed O O
that O O
binding O O
occurred O O
in O O
the O O
ligand-binding B B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pocket I B_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

azPC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
PPRE O B_DISEASE/B_GENE
reporter O B_DISEASE/I_GENE
gene O B_DISEASE/I_GENE
expression O B_DISEASE/I_GENE
, O O
as O O
did O O
rosiglitazone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
a O O
half-maximal O B_MEASURE/B_LOCATION
effect O B_MEASURE/I_LOCATION
at O O
100 O B_TIME[MEASURE]/B_PERSON
nm O I_TIME[MEASURE]/I_PERSON
. O O

Overexpression O O
of O O
PPARalpha B B_GENE/B_LOCATION
or O O
PPARgamma B B_GENE
revealed O O
that O O
azPC O O
was O O
a O O
specific O O
PPARgamma O O
agonist O O
. O O

The O O
scavenger B B_GENE/B_MEASURE
receptor I I_GENE/I_MEASURE
CD36 I I_GENE/I_MEASURE
is O O
encoded O O
by O O
a O O
PPRE-responsive B B_GENE
gene I I_GENE
, O O
and O O
azPC O O
enhanced O O
expression O O
of O O
CD36 B B_GENE
in O O
primary O O
human O O
monocytes O O
. O O

We O O
found O O
that O O
anti-CD36 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O O
azPC O O
uptake O O
, O O
and O O
it O O
inhibited O O
PPRE O O
reporter O O
induction O O
. O O

Results O O
with O O
a O O
small O O
molecule O O
phospholipid B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flippase I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mimetic I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
azPC O O
acts O O
intracellularly O O
and O O
that O O
cellular O O
azPC O O
accumulation O O
was O O
efficient O O
. O O

Thus O O
, O O
certain O O
alkyl O O
phospholipid O O
oxidation O O
products O O
in O O
oxLDL B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
are O O
specific O O
, O O
high O O
affinity O O
extracellular O O
ligands O O
and O O
agonists O O
for O O
PPARgamma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
induce O O
PPAR-responsive B B_DISEASE/B_GENE
genes I B_DISEASE/I_GENE

Regulation O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MAT2B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O O
the O O
regulatory B B_PROTEIN[GENE]/B_PERSON
beta I I_PROTEIN[GENE]/I_PERSON
subunit I I_PROTEIN[GENE]/I_PERSON
of O O
methionine B B_GENE
adenosyltransferase I I_GENE
, O O
MAT B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
II I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Methionine B B_GENE
adenosyltransferase I I_GENE
( O O
MAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
catalyzes O O
the O O
biosynthesis O O
of O O
S-adenosylmethionine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
AdoMet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O O
, O O
a O O
key O O
molecule O O
in O O
transmethylation O O
reactions O O
and O O
polyamine O O
biosynthesis O O
. O O

The O O
MAT B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
II I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
isozyme I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
consists O O
of O O
a O O
catalytic B B_PROTEIN[GENE]
alpha2 I I_PROTEIN[GENE]
and I I_PROTEIN[GENE]
a I I_PROTEIN[GENE]
regulatory I I_PROTEIN[GENE]
beta I I_PROTEIN[GENE]
subunit I I_PROTEIN[GENE]
. O O

Down-regulation O O
of O O
the O O
MAT B B_GENE
II I I_GENE
beta I I_GENE
subunit I I_GENE
expression O O
causes O O
a O O
6-10-fold O O
increase O O
in O O
intracellular O O
AdoMet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
. O O

To O O
understand O O
the O O
mechanism O O
by O O
which O O
the O O
beta B B_GENE
subunit I I_GENE
expression O O
is O O
regulated O O
, O O
we O O
cloned O O
the O O
MAT2B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
determined O O
its O O
organization O O
, O O
characterized O O
its O O
5'-flanking B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
elucidated O O
the O O
in O O
vitro O O
and O O
in O O
vivo O O
regulation O O
of O O
its O O
promoter B B_GENE
. O O

Transcription O O
of O O
the O O
MAT2B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
initiates O O
at O O
position O O
-203 O O
relative O O
to O O
the O O
translation B B_PERSON/B_ORGANIZATION
start I I_PERSON/I_ORGANIZATION
site I I_PERSON/I_ORGANIZATION
. O O

Promoter B B_PERSON
deletion I I_PERSON
analysis I I_PERSON
defined O O
a O O
minimal B B_GENE/B_LOCATION
promoter I B_GENE/I_LOCATION
between O O
positions B B_NUMBER[MEASURE]/B_LOCATION
+52 I I_NUMBER[MEASURE]/I_LOCATION
and I I_NUMBER[MEASURE]/I_LOCATION
+93 I I_NUMBER[MEASURE]/I_LOCATION
base O O
pairs O O
, O O
a O O
GC-rich B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
region I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Inclusion O O
of O O
the O O
sequences O O
between O O
-4 O O
and O O
+52 O O
enhanced O O
promoter O O
activity O O
; O O
this O O
was O O
primarily O O
because O O
of O O
an O O
Sp1 B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
recognition I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
site I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
+9/+15 O O
. O O

The O O
inclusion O O
of O O
sequences O O
up O O
to O O
position O O
-115 O O
provided O O
full O O
activity O O
; O O
this O O
was O O
attributed O O
to O O
a O O
TATA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O O
-32 O O
. O O

The O O
Sp1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O O
position O O
+9 O O
was O O
key O O
for O O
the O O
formation O O
of O O
protein.DNA O O
complexes O O
. O O

Mutation O O
of O O
both O O
the O O
Sp1 B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
at O O
+9 O O
and O O
the O O
TATA B B_GENE/B_MEASURE
at O O
-32 O O
reduced O O
promoter O O
activity O O
to O O
its O O
minimal O O
level O O
. O O

Supershift O O
assays O O
showed O O
no O O
effect O O
of O O
the O O
anti-Sp1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
complex O O
formation O O
, O O
whereas O O
the O O
anti-Sp3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
a O O
strong O O
effect O O
on O O
protein.DNA O O
complex O O
formation O O
, O O
suggesting O O
that O O
Sp3 B B_GENE
is O O
one O O
of O O
the O O
main O O
factors O O
binding O O
to O O
this O O
Sp1 B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
. O O

Chromatin O O
immunoprecipitation O O
assays O O
supported O O
the O O
involvement O O
of O O
both O O
Sp1 B B_GENE/B_DISEASE
and O O
Sp3 B B_GENE
in O O
complexes O O
formed O O
on O O
the O O
MAT2B B B_GENE
promoter I I_GENE
. O O

The O O
data O O
show O O
that O O
the O O
5'-untranslated B B_GENE
sequences I I_GENE
play O O
an O O
important O O
role O O
in O O
regulating O O
the O O
MAT2B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
identifies O O
the O O
Sp1 B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
at O O
+9 O O
as O O
a O O
potential O O
target O O
for O O
modulating O O
MAT2B O O
expression O O
, O O
a O O
process O O
that O O
can O O
have O O
a O O
major O O
effect O O
on O O
intracellular O O
AdoMet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
. O O

Molecular O O
pathogenesis O O
of O O
influenza O O
A O O
virus O O
infection O O
and O O
virus-induced O O
regulation O O
of O O
cytokine B B_GENE
gene I I_GENE
expression O O
. O O

Despite O O
vaccines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
antiviral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
substances O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
influenza O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
still O O
causes O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
morbidity O I_DISEASE_ADJECTIVE[DISEASE]
and O O
mortality O B_DISEASE/B_LOCATION
world O I_DISEASE/I_LOCATION
wide O O
. O O

Better O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
understanding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
influenza O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
virus O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
replication O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
pathogenesis O B_DISEASE
and O O
host O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
required O O
for O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
more O O
efficient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
means O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
prevention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
influenza O B_DISEASE/B_LOCATION
. O O

Influenza O B_DISEASE/B_MEASURE
A O O
virus O B_VIRUS[BIO]/B_DISEASE
, O O
which O O
replicates O O
in O O
epithelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
regulates O O
host O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
translational O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
activates O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
as O O
well O O
as O O
downregulates O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
apoptotic O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
pathways O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Influenza O O
A O O
virus O O
infection O O
results O O
in O O
the O O
production O O
of O O
chemotactic O O
( O O
RANTES B B_GENE/B_LOCATION
, O O
MIP-1 B B_LOCATION/B_ORGANIZATION
alpha I I_LOCATION/I_ORGANIZATION
, O O
MCP-1 B B_GENE/B_LOCATION
, O O
MCP-3 B B_GENE
, O O
and O O
IP-10 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
pro-inflammatory O O
( O O
IL-1 B B_GENE
beta I I_GENE
, O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
IL-18 B B_GENE
, O O
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
and O O
antiviral B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IFN-alpha/beta I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cytokines I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Cytokine O O
gene O O
expression O O
is O O
associated O O
with O O
the O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
, O O
AP-1 B B_GENE
, O O
STAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IRF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transducing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
influenza O O
A O O
virus-infected O O
cells O O
. O O

In O O
addition O O
of O O
upregulating O O
cytokine B B_GENE
gene I I_GENE
expression O O
, O O
influenza O O
A O O
virus O O
infection O O
activates O O
caspase-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
is O O
involved O O
in O O
the O O
proteolytic O O
processing O O
of O O
proIL-1 B B_GENE
beta I I_GENE
and O O
proIL-18 B B_GENE
into O O
their O O
biologically O O
active O O
forms O O
. O O

Influenza O O
A O O
virus-induced O O
IFN-alpha/beta B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
essential O O
in O O
host O O
's O O
antiviral O O
defence O O
by O O
activating O O
the O O
expression O O
of O O
antiviral B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Mx I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
PKR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oligoadenylate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthetase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

IFN-alpha/beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O O
prolongs O O
T O O
cell O O
survival O O
, O O
upregulates O O
IL-12 O O
and O O
IL-18 O O
receptor O O
gene O O
expression O O
and O O
together O O
with O O
IL-18 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulates O O
NK O O
and O O
T O O
cell O O
IFN-gamma O O
production O O
and O O
the O O
development O O
of O O
Th1-type O O
immune O O
response O O
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hprt O B_GENE
and O O
lacI O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
frequency O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
adduct O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
formation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
N-hydroxy-2-acetylaminofluorene-treated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Big O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
Blue O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
rats O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

N-Hydroxy-2-acetylaminofluorene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
N-OH-AAF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
the O O
proximate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
carcinogenic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
metabolite O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
powerful O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rat O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
liver O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
carcinogen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2-acetylaminofluorene O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
transgenic O B_LOCATION/B_DISEASE
Big O I_LOCATION/I_DISEASE
Blue O I_LOCATION/I_DISEASE
( O O
R O B_OTHER/B_COLOR
) O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
used O O
to O O
examine O O
the O O
relationship O B_PERSON/B_MEASURE
between O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutagenicity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
DNA O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adduct O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
formation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
N-OH-AAF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
target O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
liver O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
compared O O
with O O
that O O
in O O
nontarget O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
tissues O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Male O B_PERSON/B_BIO
rats O I_PERSON/I_BIO
were O O
given O O
one O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
two O B_NUMBER[MEASURE]/B_PERSON
, O O
or O O
four O B_NUMBER[MEASURE]/B_PERSON
doses O I_NUMBER[MEASURE]/I_PERSON
of O O
25 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N-OH-AAF/kg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
i.p. O B_TIME[MEASURE]/B_LOCATION
injection O O
at O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
4-day O O
intervals O B_TIME[MEASURE]/B_LOCATION
, O I_TIME[MEASURE]/I_LOCATION
and O O
groups O O
of O B_ORGANIZATION/B_MEASURE
treated O O
and O O
control O O
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
euthanized O O
up O O
to O O
10 O O
weeks O B_NUMBER[MEASURE]/B_ENT
after O I_NUMBER[MEASURE]/I_ENT
beginning O O
the O O
dosing O O
. O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Mutant O O
frequencies O O
were O O
measured O O
in O O
the O O
spleen B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
lymphocyte I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
hprt I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
gene I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
, O O
and O O
lacI O O
mutant O O
frequencies O O
were O O
determined O O
in O O
the O O
liver O O
and O O
spleen O O
lymphocytes O O
. O O

At O O
6 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
after O O
beginning O O
the O O
dosing O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
the O O
hprt O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutant O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
frequency O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
spleen O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
from O O
the O O
four-dose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
16.5 O B_MEASURE
x O I_MEASURE
10 O I_MEASURE
( O O
-6 O B_MEASURE
) O O
compared O O
with O O
3.2 O B_MEASURE
x O O
10 O B_MEASURE
( O O
-6 O O
) O O
in O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Also O O
at O O
6 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O O
one O B_NUMBER[MEASURE]/B_PERSON
, O O
two O B_NUMBER[MEASURE]/B_PERSON
, O O
or O O
four O B_NUMBER[MEASURE]/B_PERSON
doses O I_NUMBER[MEASURE]/I_PERSON
of O O
N-OH-AAF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
lacI O O
mutant O B_MEASURE/B_LOCATION
frequencies O B_MEASURE/I_LOCATION
in O O
the O O
liver O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
of O O
97.6 O B_MEASURE
, O O
155.6 O B_MEASURE
, O O
and O O
406.8 O B_MEASURE
x O O
10 O B_NUMBER[MEASURE]
( O O
-6 O B_MEASURE
) O O
, O O
respectively O O
, O O
compared O O
with O O
a O O
control O B_MEASURE
frequency O I_MEASURE
of O O
25.7 O B_TIME[MEASURE]
x O O
10 O B_NUMBER[MEASURE]
( O O
-6 O O
) O O
; O O
rats O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O O
four O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
had O O
lacI O O
mutant O B_MEASURE/B_LOCATION
frequencies O B_MEASURE/I_LOCATION
in O O
spleen O B_BODY_PART_OR_ORGAN_COMPONENT
lymphocytes O I_BODY_PART_OR_ORGAN_COMPONENT
of O O
55.8 O B_TIME[MEASURE]
x O O
10 O B_NUMBER[MEASURE]
( O O
-6 O B_MEASURE
) O O
compared O O
with O O
a O O
control O B_MEASURE/B_LOCATION
frequency O I_MEASURE/I_LOCATION
of O O
20.4 O B_MEASURE
x O O
10 O B_NUMBER[MEASURE]
( O O
-6 O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

Additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
rats O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
evaluated O O
for O O
DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adduct O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
formation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
spleen O B_BODY_PART_OR_ORGAN_COMPONENT
lymphocytes O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
marrow O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
by O O
( O O
32 O B_MEASURE
) O O
P-postlabeling O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Adduct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
conducted O O
1 O B_TIME[MEASURE]/B_LOCATION
day O I_TIME[MEASURE]/I_LOCATION
after O O
one O B_NUMBER[MEASURE]/B_DISEASE
, O O
two O B_NUMBER[MEASURE]/B_PERSON
, O O
and O O
four O B_NUMBER[MEASURE]/B_LOCATION
treatments O I_NUMBER[MEASURE]/I_LOCATION
with O O
N-OH-AAF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
5 O B_NUMBER[MEASURE]/B_ENT
days O I_NUMBER[MEASURE]/I_ENT
after O O
one O B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
9 O B_NUMBER[MEASURE]/B_ENT
days O I_NUMBER[MEASURE]/I_ENT
after O O
two O B_NUMBER[MEASURE]/B_PERSON
treatments O I_NUMBER[MEASURE]/I_PERSON
. O O

N- O O
( O O
Deoxyguanosin-8-yl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
-2-aminofluorene O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
the O O
major O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
DNA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
adduct O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
identified O O
in O O
all O O
the O O
tissues O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examined O O
. O O

Adduct O B_MEASURE/B_PERSON
concentrations O I_MEASURE/I_PERSON
increased O O
with O O
total O B_MEASURE/B_PERSON
dose O I_MEASURE/I_PERSON
to O O
maximum O B_MEASURE
values O I_MEASURE
in O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
taken O O
1 O B_TIME[MEASURE]/B_LOCATION
day O B_TIME[MEASURE]/I_LOCATION
after O O
two O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
and O O
remained O O
essentially O O
the O O
same O B_MEASURE/B_LOCATION
after O O
four O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
doses O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
taken O O
after O O
four O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
adduct O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
103 O B_MEASURE
, O O
28 O B_MEASURE
, O O
and O O
7 O B_MEASURE
fmol/microg O I_MEASURE
of O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
spleen O B_BODY_PART_OR_ORGAN_COMPONENT
lymphocytes O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
marrow O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
the O O
extent O B_DISEASE/B_MEASURE
of O O
both O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
adduct O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
formation O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
mutant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
correlates O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
organ O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
specificity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
N-OH-AAF O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carcinogenesis O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
rat O B_SPECIES[BIO]/B_GENE
. O O

Environ. O O
Mol. O O
Mutagen. O O
37 O B_MEASURE
: O O
195-202 O B_MEASURE
, O O
2001 O B_MEASURE/B_LOCATION
. O O

Published O O
2001 O B_PERSON/B_ENT
Wiley-Liss O I_PERSON/I_ENT
, O O
Inc O B_ORGANIZATION/B_PERSON
. O O

Expression O O
of O O
Mad1 B B_GENE/B_BIO
in O O
T O O
cells O O
leads O O
to O O
reduced O O
thymic O O
cellularity O O
and O O
impaired O O
mitogen-induced O O
proliferation O O
. O O

To O O
investigate O O
Mad1 B B_GENE/B_PERSON
function O O
in O O
vivo O O
, O O
transgenic O O
mice O O
were O O
generated O O
that O O
express O O
a O O
Mad1 B B_GENE
transgene I I_GENE
in O O
T O O
lineage O O
cells O O
under O O
the O O
control O O
of O O
the O O
proximal B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
lck I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
promoter I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Thymus O B_MEASURE/B_PERSON
size O B_MEASURE/I_PERSON
in O O
lck-Mad1 O B_DISEASE/B_PERSON
transgenic O I_DISEASE/I_PERSON
mice O I_DISEASE/I_PERSON
is O O
drastically O O
reduced O O
although O O
representation O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
various O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
thymocyte O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
sub O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
populations O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
appears O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
investigate O O
more O O
closely O O
any O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
Mad1 O B_GENE
expression O I_GENE
on O O
thymocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O O
we O O
examined O O
thymic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
selection O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
MHC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I-restricted O O
H-Y-TCR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transgenic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mice O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Mad1 O B_GENE
expression O I_GENE
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
reduces O O
the O O
efficiency O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
positive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
selection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Furthermore O O
, O O
thymocytes O O
and O O
splenic O O
T O O
cells O O
from O O
lck-Mad1 O O
transgenic O O
mice O O
display O O
a O O
profound O O
proliferative O O
defect O O
in O O
response O O
to O O
activation O O
with O O
either O O
PMA/Ionomycin O O
or O O
immobilized B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
anti-CD3/CD28 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

This O O
proliferative O O
defect O O
is O O
not O O
reversed O O
by O O
addition O O
of O O
exogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
IL-2 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
is O O
p53-independent O O
. O O

The O O
growth O O
inhibition O O
caused O O
by O O
Mad1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
is O O
overcome O O
by O O
expression O O
of O O
active B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
c-Myc I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Differential O O
requirement O O
for O O
the O O
transcription B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
factor I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
PU.1 I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
generation O O
of O O
natural O O
killer O O
cells O O
versus O O
B O O
and O O
T O O
cells O O
. O O

PU.1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
member O O
of O O
the O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
required O O
for O O
the O O
development O O
of O O
various O O
lymphoid O O
and O O
myeloid O O
cell O O
lineages O O
, O O
but O O
its O O
role O O
in O O
natural O O
killer O O
( O O
NK O O
) O O
cell O O
development O O
is O O
not O O
known O O
. O O

The O O
study O O
shows O O
that O O
PU.1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
expressed O O
in O O
NK O O
cells O O
and O O
that O O
, O O
on O O
cell O O
transfer O O
into O O
alymphoid O O
Rag2/gammac O O
( O O
-/- O O
) O O
mice O O
, O O
hematopoietic O O
progenitors O O
of O O
PU.1 O O
( O O
-/- O O
) O O
fetal O O
liver O O
cells O O
could O O
generate O O
functional O O
NK O O
cells O O
but O O
not O O
B O O
or O O
T O O
cells O O
. O O

Nevertheless O O
, O O
the O O
numbers O B_MEASURE
of O O
bone O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
marrow O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
NK O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
precursors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
splenic O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
mature O O
NK O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
reduced O O
compared O O
to O O
controls O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Moreover O O
, O O
PU.1 O O
( O O
-/- O O
) O O
NK O O
cells O O
displayed O O
reduced O O
expression O O
of O O
the O O
receptors O O
for O O
stem B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
interleukin B B_GENE
( I I_GENE
IL I I_GENE
) I I_GENE
-7 I I_GENE
, O O
suggesting O O
a O O
nonredundant O O
role O O
for O O
PU.1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
regulating O O
the O O
expression O O
of O O
these O O
cytokine B B_GENE
receptor I I_GENE
genes I I_GENE
during O O
NK O O
cell O O
development O O
. O O

PU.1 O O
( O O
-/- O O
) O O
NK O O
cells O O
also O O
showed O O
defective O O
expression O O
of O O
inhibitory O O
and O O
activating O O
members O O
of O O
the O O
Ly49 B B_GENE/B_PERSON
family I I_GENE/I_PERSON
and O O
failed O O
to O O
proliferate O O
in O O
response O O
to O O
IL-2 B B_GENE
and O O
IL-12 B B_GENE
. O O

Thus O O
, O O
despite O O
the O O
less O O
stringent O O
requirement O O
for O O
PU.1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
NK O O
cell O O
development O O
compared O O
to O O
B O O
and O O
T O O
cells O O
, O O
PU.1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulates O O
NK O O
cell O O
differentiation O O
and O O
homeostasis O O
. O O

Benzene-extracted O O
components O O
are O O
important O O
for O O
the O O
major O O
activity O O
of O O
diesel O O
exhaust O O
particles O O
: O O
effect O O
on O O
interleukin-8 B B_GENE
gene I I_GENE
expression O O
in O O
human O O
bronchial O O
epithelial O O
cells O O
. O O

Epidemiologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
suggest O O
that O O
diesel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exhaust O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
particles O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DEPs O B_DISEASE
) O O
may O O
be O O
related O O
to O O
increasing O O
respiratory O B_DISEASE_ADJECTIVE[DISEASE]
mortality O I_DISEASE_ADJECTIVE[DISEASE]
and O O
morbidity O B_DISEASE
. O O

We O O
have O O
shown O O
that O O
DEPs O O
augmented O O
the O O
production O O
of O O
inflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
human O O
airway O O
epithelial O O
cells O O
in O O
vitro O O
. O O

To O O
better O O
understand O O
the O O
mechanisms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
their O O
proinflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
studied O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
several O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
components O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
extracted O O
from O O
DEPs O B_DISEASE/B_BIO
on O O
interleukin O B_GENE
( O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
-8 O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
bronchial O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
epithelial O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cell O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
line O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
BEAS-2B O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_NUMBER[MEASURE]
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_NUMBER[MEASURE]
airway O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_NUMBER[MEASURE]
epithelial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_NUMBER[MEASURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_NUMBER[MEASURE]
obtained O O
from O O
very O O
peripheral O B_PERSON/B_TIME[MEASURE]
airways O B_PERSON/I_TIME[MEASURE]
by O O
an O O
ultrathin O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bronchoscope O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
used O O
several O O
agents O O
active O O
on O O
signal O O
transduction O O
pathways O O
in O O
cytokine O O
expression O O
, O O
such O O
as O O
the O O
protein O O
kinase O O
C O O
inhibitor O O
staurosporin O O
, O O
antioxidant O O
agents O O
including O O
N-acetyl O O
cysteine O O
( O O
NAC O O
) O O
and O O
pyrrolidine O O
dithiocarbamate O O
( O O
PDTC O O
) O O
, O O
and O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE/B_LOCATION
) O O
inhibitor O O
SB203580 O O
. O O

Benzene-extracted O O
components O O
showed O O
effects O O
mimicking O O
DEPs O O
on O O
IL-8 O O
gene O O
expression O O
, O O
release O O
of O O
several O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
IL-8 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
; O O
granulocyte B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
macrophage I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
and O O
regulated O O
on O O
activation O O
, O O
normal O O
T O O
cells O O
expressed O O
and O O
secreted O O
) O O
and O O
nuclear O O
factor O O
( O O
NF O O
) O O
-kappa O O
B O O
activation O O
. O O

We O O
also O O
found O O
that O O
NAC O O
, O O
PDTC O O
, O O
and O O
SB203580 O O
suppressed O O
the O O
activities O O
of O O
DEPs O O
and O O
their O O
benzene O O
extracts O O
, O O
suggesting O O
the O O
roles O O
of O O
oxidants-mediated O O
NF-kappa O O
B O O
activation O O
and O O
p38MAPK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathways O O
. O O

Finally O O
, O O
benzo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
a O O
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pyrene O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
important O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
in O O
the O O
benzene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
component O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
replicated O O
the O O
activities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
shown O O
by O O
DEPs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

The O O
nuclear B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
PPAR I I_GENE/I_LOCATION
gamma I I_GENE/I_LOCATION
is O O
expressed O O
by O O
mouse O O
T O O
lymphocytes O O
and O O
PPAR O O
gamma O O
agonists O O
induce O O
apoptosis O O
. O O

Peroxisome B B_GENE/B_LOCATION
proliferator-activated I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
PPAR I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
-gamma I I_GENE/I_LOCATION
is O O
a O O
nuclear B B_GENE
hormone I I_GENE
receptor I I_GENE
that O O
serves O O
as O O
a O O
trans O O
factor O O
to O O
regulate O O
lipid O O
metabolism O O
. O O

Intense O O
interest O O
is O O
focused O O
on O O
PPAR-gamma B B_GENE
and O O
its O O
ligands O O
owing O O
to O O
its O O
putative O O
role O O
in O O
adipocyte O O
differentiation O O
. O O

Little O O
is O O
known O O
, O O
however O O
, O O
about O O
the O O
functions O O
of O O
PPAR-gamma B B_GENE
in O O
the O O
immune O O
system O O
, O O
especially O O
in O O
T O O
lymphocytes O O
. O O

We O O
demonstrate O O
that O O
both O O
naive O O
and O O
activated O O
ovalbumin-specific O O
T O O
cells O O
from O O
DO11.10-transgenic O O
mice O O
express O O
PPAR-gamma B B_GENE
mRNA O O
and O O
protein O O
. O O

In O O
order O O
to O O
determine O O
the O O
function O O
of O O
PPAR-gamma B B_GENE
, O O
T O O
cells O O
were O O
stimulated O O
with O O
phorbol O O
12-myristate O O
13-acetate O O
and O O
ionomycin O O
or O O
antigen O O
and O O
antigen-presenting O O
cells O O
. O O

Simultaneous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
PPAR-gamma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligands O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
e.g. O B_MEASURE/B_DISEASE
15-deoxy-Delta O O
( O B_GENE/B_MEASURE
12 O O
, O B_MEASURE
14 O O
) O B_MEASURE
-prostaglandin O O
J O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2 O O
) O B_NUMBER[MEASURE]
, O O
troglitazone O O
) O B_MEASURE
showed O O
drastic O O
inhibition O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proliferation O O
and O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
significant O O
decreases O B_DISEASE_ADJECTIVE[DISEASE]
in O I_DISEASE_ADJECTIVE[DISEASE]
cell O O
viability O B_DISEASE_ADJECTIVE[DISEASE]
. O I_DISEASE_ADJECTIVE[DISEASE]

The O O
decrease O O
in O O
cell O O
viability O O
was O O
due O O
to O O
apoptosis O O
of O O
the O O
T O O
lymphocytes O O
, O O
and O O
occurred O O
only O O
when O O
cells O O
were O O
treated O O
with O O
PPAR-gamma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
not O O
PPAR-alpha O O
agonists O O
, O O
revealing O O
specificity O O
of O O
this O O
response O O
for O O
PPAR-gamma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
observations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
PPAR-gamma O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
agonists O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
play O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
regulating O O
T O B_OTHER/B_GENE
cell-mediated O O
immune O B_DISEASE_ADJECTIVE[DISEASE]
responses O I_DISEASE_ADJECTIVE[DISEASE]
by O O
inducing O O
apoptosis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

T O B_DISEASE/B_GENE
cell O B_DISEASE/I_GENE
death O B_DISEASE/I_GENE
via O O
PPAR-gamma O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ligation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
act O O
as O O
a O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anti-inflammatory O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
signal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
immune O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
ligands O B_PERSON/B_LOCATION
could O O
possibly O O
be O O
used O O
to O O
control O O
disorders O B_DISEASE/B_LOCATION
in O O
which O O
excessive O B_DISEASE
inflammation O I_DISEASE
occurs O O
. O O

Suppression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
lung O B_DISEASE/B_GENE
inflammation O I_DISEASE/I_GENE
in O O
rats O B_BIO/B_DISEASE
by O O
prevention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
NF-kappaB O B_DISEASE/B_GENE
activation O I_DISEASE/I_GENE
in O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

Activation O O
of O O
NF-kappaB B B_GENE
and O O
production O O
of O O
NF-kappaB B B_GENE
-dependent O O
chemokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
thought O O
to O O
be O O
involved O O
in O O
the O O
pathogenesis O O
of O O
neutrophilic O O
lung O O
inflammation O O
. O O

Calpain-1 O O
inhibitor O O
( O O
CI-1 O O
) O O
blocks O O
activation O O
of O O
NF-kappaB B B_GENE
by O O
preventing O O
proteolysis O O
of O O
the O O
inhibitory O O
protein O O
IkappaB-alpha B B_GENE
by O O
the O O
ubiquitin/proteasome O O
pathway O O
. O O

We O O
hypothesized O O
that O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
proteasome O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
CI-1 O O
would O O
block O O
NF-kappaB O B_DISEASE
activation O I_DISEASE
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
after O O
intraperitoneal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
i.p. O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
treatment O O
with O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
bacterial O O
lipopolysaccharide O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O B_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LPS O O
) O B_LOCATION/B_ORGANIZATION
, O O
and O O
that O O
NF-kappaB O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
would O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
be O O
associated O O
with O O
suppression O O
of O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemokine O O
gene O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attenuation O O
of O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neutrophilic O O
alveolitis O B_DISEASE
. O I_DISEASE

We O O
treated O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
a O O
single O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
i.p. O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
CI-1 O O
( O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg/kg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
two O B_MEASURE/B_ENT
hours O I_MEASURE/I_ENT
prior O I_MEASURE/I_ENT
to O O
i.p. O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
7 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg/kg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
. O O

Treatment O O
with O O
Cl-1 O O
prevented O O
degradation O O
of O O
IkappaB-alpha B B_GENE
and O O
activation O O
of O O
NF-kappaB B B_GENE
in O O
the O O
liver O O
in O O
response O O
to O O
LPS O O
; O O
however O O
, O O
Cl-1 O O
treatment O O
had O O
no O O
detected O O
effect O O
on O O
NF-kappaB O O
activation O O
in O O
lung O O
tissue O O
. O O

CI-1 O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prior O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resulted O O
in O O
40 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
lower O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
MIP-2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
concentration O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
lung O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lavage O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
fluid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
compared O O
to O O
rats O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O O
with O O
vehicle O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prior O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
502 O B_MEASURE/B_LOCATION
+/- O I_MEASURE/I_LOCATION
112 O I_MEASURE/I_LOCATION
pg/ml O I_MEASURE/I_LOCATION
vs. O I_MEASURE/I_LOCATION
859 O O
+/-144 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pg/ml O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
P O O
< O B_MEASURE
0.05 O I_MEASURE
) O I_MEASURE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
CI-1 O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
substantially O O
inhibited O O
LPS-induced O B_DISEASE
neutrophilic O I_DISEASE
alveolitis O I_DISEASE
( O O
2.7+ O B_MEASURE
/- O O
1.2 O B_MEASURE
x O O
10 O B_MEASURE
( O O
5 O B_MEASURE
) O O
vs. O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
43.7 O O
+/- O B_TIME[MEASURE]
12.2 O O
x O B_MEASURE
10 O O
( O B_NUMBER[MEASURE]
5 O O
) O B_NUMBER[MEASURE]
lung O O
lavage O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
neutrophils O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
P O O
< O B_MEASURE
0.01 O I_MEASURE
) O I_MEASURE
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
NF-kappaB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibition O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
can O O
alter O O
lung O B_DISEASE_ADJECTIVE[DISEASE]
inflammation O I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
systemic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
LPS O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
suggest O O
that O O
a O O
liver-lung O O
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contributes O O
to O O
the O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
lung O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

Notch1 B B_GENE
regulates O O
maturation O O
of O O
CD4+ O O
and O O
CD8+ O O
thymocytes O O
by O O
modulating O O
TCR O O
signal O O
strength O O
. O O

Notch O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulates O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
fate O I_DISEASE_ADJECTIVE[DISEASE]
decisions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
lineages O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
. O O

We O O
demonstrate O O
in O O
this O O
report O O
that O O
retroviral O O
expression O O
of O O
activated O O
Notch1 B B_GENE
in O O
mouse O O
thymocytes O O
abrogates O O
differentiation O O
of O O
immature O O
CD4+CD8+ O O
thymocytes O O
into O O
both O O
CD4 O O
and O O
CD8 O O
mature O O
single-positive O O
T O O
cells O O
. O O

The O O
ability O O
of O O
Notch1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
inhibit O O
T O O
cell O O
development O O
was O O
observed O O
in O O
vitro O O
and O O
in O O
vivo O O
with O O
both O O
normal O O
and O O
TCR O O
transgenic O O
thymocytes O O
. O O

Notch1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-mediated O O
developmental O O
arrest O O
was O O
dose O O
dependent O O
and O O
was O O
associated O O
with O O
impaired O O
thymocyte O O
responses O O
to O O
TCR O O
stimulation O O
. O O

Notch1 B B_PERSON/B_PROTEIN[GENE]
also O O
inhibited O O
TCR-mediated O O
signaling O O
in O O
Jurkat O O
T O O
cells O O
. O O

These O O
data O O
indicate O O
that O O
constitutively O O
active O O
Notch1 B B_GENE/B_LOCATION
abrogates O O
CD4+ O O
and O O
CD8+ O O
maturation O O
by O O
interfering O O
with O O
TCR O O
signal O O
strength O O
and O O
provide O O
an O O
explanation O O
for O O
the O O
physiological O O
regulation O O
of O O
Notch O O
expression O O
during O O
thymocyte O O
development O O
. O O

Expression O O
of O O
SART3 B B_GENE
antigen I I_GENE
and O O
induction O O
of O O
CTLs O O
by O O
SART3-derived O O
peptides O O
in O O
breast O O
cancer O O
patients O O
. O O

We O O
recently O O
reported O O
the O O
SART3 B B_BIO/B_DISEASE
tumour-rejection I I_BIO/I_DISEASE
antigen I I_BIO/I_DISEASE
as O O
possessing O O
tumour O O
epitopes O O
capable O O
of O O
inducing O O
HLA-class O O
I-restricted O O
cytotoxic O O
T O O
lymphocytes O O
( O O
CTLs O O
) O O
. O O

This O O
study O O
investigated O O
expression O O
of O O
the O O
SART3 B B_GENE
antigen I I_GENE
in O O
breast O O
cancer O O
to O O
explore O O
an O O
appropriate O O
molecule O O
for O O
use O O
in O O
specific O O
immunotherapy O O
of O O
breast O O
cancer O O
patients O O
. O O

The O O
SART3 B B_GENE
antigen I I_GENE
was O O
detected O O
in O O
all O O
of O O
the O O
breast O O
cancer O O
cell O O
lines O O
tested O O
, O O
30 O O
of O O
40 O O
( O O
75 O O
% O O
) O O
breast O O
cancer O O
tissue O O
samples O O
, O O
and O O
0 O O
of O O
3 O O
non-tumourous O O
breast O O
tissue O O
samples O O
. O O

SART3 O O
derived O O
peptides O O
at O O
positions B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
109-118 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
315-323 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
HLA-A24 O O
restricted O O
CTLs O O
that O O
reacted O O
to O O
breast O O
cancer O O
cells O O
from O O
the O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMCs O O
) O O
of O O
breast O O
cancer O O
patients O O
. O O

Therefore O O
, O O
the O O
SART3 B B_GENE
antigen I I_GENE
and O O
its O O
peptides O O
could O O
be O O
an O O
appropriate O O
molecule O O
for O O
use O O
in O O
specific O O
immunotherapy O O
of O O
the O O
majority O O
of O O
HLA-A24-positive O O
breast O O
cancer O O
patients O O

Autostimulation O O
of O O
the O O
Epstein-Barr O O
virus O O
BRLF1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
mediated O O
through O O
consensus O O
Sp1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Sp3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
an O O
essential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
step O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
in O O
the O O
lytic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cascade O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
Rta O B_BIO/B_GENE
homologues O I_BIO/I_GENE
of O O
gammaherpesviruses O B_BACTERIUM[BIO]/B_GENE
all O O
activate O O
their O O
own O B_GENE
expression O I_GENE
. O O

Consistent O O
with O O
this O O
biologic O O
function O O
, O O
the O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
Rta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
powerfully O O
stimulates O O
the O O
promoter B B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
its O O
own O O
gene O O
, O O
Rp B B_GENE/B_DISEASE
, O O
in O O
EBV-positive O O
B O O
cells O O
in O O
transient-transfection O O
reporter-based O O
assays O O
. O O

We O O
analyzed O O
the O O
activity O O
of O O
RpCAT B B_GENE/B_BACTERIUM[BIO]
in O O
response O O
to O O
Rta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O O
deletional O O
and O O
site-directed O O
mutagenesis O O
. O O

Two O O
cognate B B_LOCATION/B_BIO
Sp1 I I_LOCATION/I_BIO
binding I I_LOCATION/I_BIO
sites I I_LOCATION/I_BIO
located O O
at O O
-279 O O
and O O
-45 O O
relative O O
to O O
the O O
transcriptional B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
start I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
site I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
proved O O
crucial O O
for O O
Rta-mediated O O
activation O O
. O O

Previously O O
described O O
binding O O
sites O O
for O O
the O O
cellular O O
transcription B B_GENE/B_BIO
factor I I_GENE/I_BIO
Zif268 I I_GENE/I_BIO
and O O
the O O
viral B B_GENE/B_BIO
transactivator I I_GENE/I_BIO
ZEBRA I I_GENE/I_BIO
were O O
found O O
to O O
be O O
dispensable O O
for O O
activation O O
of O O
RpCAT B B_GENE/B_BACTERIUM[BIO]
by O O
Rta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Gel O O
shift O O
analysis O O
, O O
using O O
extracts O O
of O O
B O O
cells O O
in O O
latency O O
or O O
induced O O
into O O
the O O
lytic O O
cycle O O
, O O
identified O O
Sp1 B B_GENE/B_LOCATION
and O O
Sp3 B B_GENE
as O O
the O O
predominant O O
cellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bound O O
to O O
Rp B B_PROTEIN[GENE]/B_DISEASE
near O O
-45 O O
. O O

During O O
the O O
lytic O O
cycle O O
, O O
ZEBRA B B_PERSON/B_GENE
bound O O
Rp B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
near O O
the O O
Sp1/Sp3 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
site I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
binding O O
of O O
Sp1 B B_GENE/B_LOCATION
and O O
Sp3 B B_GENE/B_DISEASE
to O O
Rp B B_GENE/B_DISEASE
correlated O O
with O O
the O O
reporter O O
activities O O
in O O
the O O
mutagenesis O O
study O O
, O O
establishing O O
a O O
direct O O
link O O
between O O
transcriptional O O
activation O O
of O O
Rp B B_GENE/B_DISEASE
by O O
Rta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
DNA O O
binding O O
by O O
Sp1 B B_GENE/B_LOCATION
and/or O O
Sp3 B B_GENE/B_LOCATION
. O O

The O O
relative O O
abundance O O
or O O
functional O O
state O O
of O O
the O O
cellular O O
Sp1 B B_GENE/B_LOCATION
and O O
Sp3 B B_GENE
transcription B I_GENE
factors I I_GENE
may O O
be O O
altered O O
in O O
response O O
to O O
stimuli O O
that O O
induce O O
the O O
BRLF1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
thereby O O
contribute O O
to O O
the O O
activation O O
of O O
the O O
viral O O
lytic O O
cycle O O
. O O

Gene O O
transfer O O
of O O
antisense O O
hypoxia B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inducible I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhances O O
the O O
therapeutic O O
efficacy O O
of O O
cancer O O
immunotherapy O O
. O O

Solid O B_DISEASE/B_PERSON
tumors O I_DISEASE/I_PERSON
meet O O
their O O
demands O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
nascent O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vessels O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
increased O O
glycolysis O B_ORGAN_OR_TISSUE_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE
, O O
to O O
combat O O
hypoxia O B_DISEASE
, O O
by O O
activating O O
multiple O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
involved O O
in O O
angiogenesis O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
glucose O B_DISEASE
metabolism O I_DISEASE
. O O

Hypoxia B B_GENE/B_MEASURE
inducible I I_GENE/I_MEASURE
factor-1 I I_GENE/I_MEASURE
( O O
HIF-1 B B_GENE/B_DISEASE
) O O
is O O
a O O
constitutively O O
expressed O O
basic O O
helix-loop-helix B B_GENE
transcription I I_GENE
factor I I_GENE
, O O
formed O O
by O O
the O O
assembly O O
of O O
HIF-1alpha B B_GENE
and O O
HIF-1beta B B_GENE
( O O
Arnt B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
, O O
that O O
is O O
stablized O O
in O O
response O O
to O O
hypoxia O O
, O O
and O O
rapidly O O
degraded O O
under O O
normoxic O O
conditions O O
. O O

It O O
activates O O
the O O
transcription O B_GENE
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
important O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
maintaining O O
oxygen O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
homeostasis O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

Here O O
, O O
we O O
demonstrate O O
that O O
engineered O O
down-regulation O O
of O O
HIF-1alpha B B_GENE
by O O
intratumoral O O
gene O O
transfer O O
of O O
an O O
antisense B B_GENE
HIF-1alpha I I_GENE
plasmid I I_GENE
leads O O
to O O
the O O
down-regulation O O
of O O
VEGF B B_GENE/B_DISEASE
, O O
and O O
decreased O O
tumor O O
microvessel O O
density O O
. O O

Antisense O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
HIF-1alpha O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
monotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
resulted O O
in O O
the O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
permanent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rejection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
0.1 O B_MEASURE
cm O I_MEASURE
in O O
diameter O B_MEASURE/B_LOCATION
) O O
EL-4 O O
tumors O B_DISEASE
, O O
which O O
is O O
unusual O B_DISEASE_ADJECTIVE[DISEASE]
for O O
an O O
anti-angiogenic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
agent O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
where O O
transient O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suppression O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
tumor O B_DISEASE
growth O I_DISEASE
is O O
the O O
norm O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
induced O O
NK O B_DISEASE_ADJECTIVE[DISEASE]
cell O I_DISEASE_ADJECTIVE[DISEASE]
-dependent O I_DISEASE_ADJECTIVE[DISEASE]
rejection O I_DISEASE_ADJECTIVE[DISEASE]
of O O
tumors O B_DISEASE
, O O
but O O
failed O O
to O O
stimulate O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
-mediated O O
anti-tumor O B_DISEASE
immunity O I_DISEASE
, O O
and O O
synergized O O
with O O
B7-1-mediated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
immunotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
cause O O
the O O
NK O B_DISEASE_ADJECTIVE[DISEASE]
cell O I_DISEASE_ADJECTIVE[DISEASE]
and O O
CD8 O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
T O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cell O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
-dependent O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rejection O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
larger O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
EL-4 O O
tumors O B_DISEASE
( O O
0.4 O B_MEASURE
cm O I_MEASURE
in O O
diameter O B_MEASURE/B_LOCATION
) O O
that O O
were O O
refractory O B_DISEASE_ADJECTIVE[DISEASE]
to O O
monotherapies O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Mice O B_BIO/B_PERSON
cured O O
of O O
their O O
tumors O B_DISEASE
by O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
resisted O O
a O O
rechallenge O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
with O O
parental O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tumor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
cells O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
indicating O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antitumor O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
immunity O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
had O O
been O O
achieved O O
. O O

In O O
summary O O
, O O
whilst O O
intensive O O
investigations O O
are O O
in O O
progress O O
to O O
target O O
the O O
many O O
HIF-1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
effectors O O
, O O
the O O
results O O
herein O O
indicate O O
that O O
blocking O O
hypoxia-inducible O O
pathways O O
and O O
enhancing O O
NK-mediated O O
antitumor O O
immunity O O
by O O
targeting O O
HIF-1 B B_GENE/B_DISEASE
itself O O
may O O
be O O
advantageous O O
, O O
especially O O
when O O
combined O O
with O O
cancer O O
immunotherapy O O
. O O

Runx2 B B_GENE
: O O
a O O
novel O O
oncogenic O O
effector O O
revealed O O
by O O
in O O
vivo O O
complementation O O
and O O
retroviral O O
tagging O O
. O O

The O O
Runx2 B B_GENE
( O O
Cbfa1 B B_GENE
, O O
Pebp2alphaA B B_GENE/B_DISEASE
, O O
Aml3 B B_GENE
) O O
gene O O
was O O
previously O O
identified O O
as O O
a O O
frequent O O
target O O
for O O
transcriptional O O
activation O O
by O O
proviral O O
insertion O O
in O O
T-cell O O
lymphomas O O
of O O
CD2-MYC O O
transgenic O O
mice O O
. O O

We O O
have O O
recently O O
shown O O
that O O
over-expression O O
of O O
the O O
full-length O O
, O O
most O O
highly O O
expressed O O
Runx2 B B_GENE
isoform O O
in O O
the O O
thymus O O
perturbs O O
T-cell O O
development O O
, O O
leads O O
to O O
development O O
of O O
spontaneous O O
lymphomas O O
at O O
low O O
frequency O O
and O O
is O O
strongly O O
synergistic O O
with O O
Myc B B_DISEASE/B_SPECIES[BIO]
. O O

To O O
gain O O
further O O
insight O O
into O O
the O O
relationship O O
of O O
Runx2 B B_GENE
to O O
other O O
lymphomagenic O O
pathways O O
, O O
we O O
tested O O
the O O
effect O O
of O O
combining O O
the O O
CD2-Runx2 B B_GENE
transgene I I_GENE
either O O
with O O
a O O
Pim1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transgene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
E B B_GENE
( I I_GENE
mu I I_GENE
) I I_GENE
-Pim1 I I_GENE
) O O
or O O
with O O
the O O
p53 B B_GENE/B_MEASURE
null O O
genotype O O
, O O
as O O
each O O
of O O
these O O
displays O O
independent O O
synergy O O
with O O
Myc B B_GENE/B_SPECIES[BIO]
. O O

In O O
both O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
observed O O
synergistic O B_DISEASE
tumour O I_DISEASE
development O I_DISEASE
. O O

However O O
, O O
Runx2 B B_GENE/B_MEASURE
appeared O O
to O O
have O O
a O O
dominant O O
effect O O
on O O
the O O
tumour O O
phenotype O O
in O O
each O O
case O O
, O O
with O O
most O O
tumours O O
conforming O O
to O O
the O O
CD3 O O
( O O
+ O O
) O O
, O O
CD8 O O
( O O
+ O O
) O O
, O O
CD4 O O
( O O
+/- O O
) O O
phenotype O O
seen O O
in O O
CD2-Runx2 O O
mice O O
. O O

Neonatal O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
CD2-Runx2 O B_PERSON/B_SPECIES[BIO]
mice O I_PERSON/I_SPECIES[BIO]
with O O
Moloney O B_VIRUS[BIO]/B_LOCATION
murine O I_VIRUS[BIO]/I_LOCATION
leukaemia O I_VIRUS[BIO]/I_LOCATION
virus O I_VIRUS[BIO]/I_LOCATION
( O O
Moloney O B_VIRUS[BIO]/B_LOCATION
MLV O B_VIRUS[BIO]/I_LOCATION
) O O
also O O
led O O
to O O
a O O
dramatic O B_DISEASE_ADJECTIVE[DISEASE]
acceleration O I_DISEASE_ADJECTIVE[DISEASE]
of O O
tumour O B_DISEASE/B_ORGANISM_FUNCTION
onset O I_DISEASE/I_ORGANISM_FUNCTION
. O O

Analysis O O
of O O
known O O
Moloney B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
MLV I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
target I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
these O O
lymphomas O O
showed O O
a O O
high O O
frequency O O
of O O
rearrangement O O
at O O
c-Myc B B_GENE/B_DISEASE
or O O
N-Myc B B_GENE
( O O
82 O O
% O O
) O O
, O O
and O O
a O O
significant O O
number O O
at O O
Pim1 B B_GENE
or O O
Pim2 B B_GENE
( O O
23 O O
% O O
) O O
, O O
and O O
at O O
Pal1/Gfi1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
18 O O
% O O
) O O
. O O

These O O
results O O
indicate O O
that O O
Runx2 B B_GENE
makes O O
a O O
distinct O O
contribution O O
to O O
T-cell O O
lymphoma O O
development O O
which O O
does O O
not O O
coincide O O
with O O
any O O
of O O
the O O
oncogene O O
complementation O O
groups O O
previously O O
identified O O
by O O
retroviral O O
tagging O O
. O O

The O O
involvement O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-related O O
apoptosis-inducing O O
ligand O O
in O O
the O O
enhanced O O
cytotoxicity O O
of O O
IFN-beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-stimulated O O
human O O
dendritic O O
cells O O
to O O
tumor O O
cells O O
. O O

TNF-alpha B B_DISEASE/B_GENE
-related O O
apoptosis-inducing O O
ligand O O
( O O
TRAIL O O
) O O
is O O
characterized O O
by O O
its O O
preferential O O
induction O O
of O O
apoptosis O O
of O O
tumor O O
cells O O
but O O
not O O
normal O O
cells O O
. O O

Dendritic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
) O O
, O O
besides O O
their O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
APCs O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
now O O
have O O
been O O
demonstrated O O
to O O
exert O O
cytotoxicity O B_DISEASE_ADJECTIVE[DISEASE]
or O O
cytostasis O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
some O O
tumor O B_DISEASE
cells O I_DISEASE
. O O

Here O O
, O O
we O O
report O O
that O O
both O O
human O B_GENE
CD34 O I_GENE
( O O
+ O B_OTHER/B_DISEASE
) O O
stem O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
-derived O O
DCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
CD34DCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
) O O
and O O
human O B_GENE
CD14 O I_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
monocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
-derived O O
DCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
MoDCs O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
express O O
TRAIL O B_GENE
and O O
exhibit O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cytotoxicity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
some O O
types O B_MEASURE/B_DISEASE
of O O
tumor O B_DISEASE
cells O I_DISEASE
partially O O
through O O
TRAIL O B_GENE
. O O

Moderate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
TRAIL O B_GENE
appeared O O
on O O
CD34DCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
the O O
8th O B_TIME[MEASURE]/B_LOCATION
day O B_TIME[MEASURE]/I_LOCATION
of O O
culture O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
and O O
was O O
also O O
seen O O
on O O
freshly O O
isolated O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

The O O
level O B_MEASURE
of O O
TRAIL O B_GENE
expression O I_GENE
remained O O
constant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
until O O
DC O B_TIME[MEASURE]/B_LOCATION
maturation O I_TIME[MEASURE]/I_LOCATION
. O O

TRAIL O O
expression O O
on O O
immature O O
CD34DCs O O
or O O
MoDCs O O
was O O
greatly O O
up-regulated O O
after O O
IFN-beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O O
. O O

Moreover O O
, O O
IFN-beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
could O O
strikingly O O
enhance O O
the O O
ability O O
of O O
CD34DCs O O
or O O
MoDCs O O
to O O
kill O O
TRAIL-sensitive O O
tumor O O
cells O O
, O O
but O O
LPS O O
did O O
not O O
have O O
such O O
an O O
effect O O
. O O

The O O
up-regulation O O
of O O
TRAIL O O
on O O
IFN-beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-stimulated O O
DCs O O
partially O O
contributed O O
to O O
the O O
increased O O
cytotoxicity O O
of O O
DCS O O
: O O
Pretreatment O O
of O O
TRAIL-sensitive O O
tumor O O
cells O O
with O O
caspase-3 O O
inhibitor O O
could O O
significantly O O
increase O O
their O O
resistance O O
to O O
the O O
cytotoxicity O O
of O O
IFN-beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-stimulated O O
DCS O O
: O O
In O O
contrast O O
, O O
NF-kappaB O O
inhibitor O O
could O O
significantly O O
increase O O
the O O
sensitivity O O
of O O
tumor O O
cells O O
to O O
the O O
killing O O
by O O
nonstimulated O O
or O O
LPS-stimulated O O
DCS O O
: O O
Our O O
studies O O
demonstrate O O
that O O
IFN-beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-stimulated O O
DCs O O
are O O
functionally O O
cytotoxic O O
. O O

Thus O O
, O O
an O O
innate O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
DC-mediated O B_DISEASE
antitumor O I_DISEASE
immunity O I_DISEASE
might O O
exist O O
in O O
vivo O B_PERSON/B_DISEASE
in O O
which O O
DCs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
act O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O O
effectors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
directly O O
kill O O
tumor O B_DISEASE
cells O I_DISEASE
partially O O
via O O
TRAIL O B_GENE
. O O

Subsequently O O
, O O
DCs O O
act O O
as O O
APCs O O
involved O O
in O O
the O O
uptake O O
, O O
processing O O
, O O
and O O
presentation O O
of O O
apoptotic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
tumor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
Ags I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
to O O
cross-prime O O
CD8 O O
( O O
+ O O
) O O
CTL O O
cells O O
. O O

Tumor O B_PERSON/B_DISEASE
cells O I_PERSON/I_DISEASE
regulate O O
the O O
lytic O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
tumor-specific O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cytotoxic O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
t O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
by O O
modulating O O
the O O
inhibitory O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
natural O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
killer O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Tumor-infiltrating O O
p58+ O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O O
a O O
renal O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
tumor O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
specifically O O
expanded O O
in O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
tumor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cell O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
cloned O O
. O O

These O O
p58+ O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
were O O
found O O
to O O
express O O
a O O
memory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
corresponded O O
to O O
clonal O O
TCRBV3 O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
T-cell O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
expansion O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

Functionally O O
, O O
p58 O B_NUMBER[MEASURE]/B_PERSON
( O O
+ O O
) O O
CTLs O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
displayed O O
a O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lytic O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
HLA-A2 O B_DISEASE
tumor O I_DISEASE
and O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O O

However O O
, O O
this O O
lytic O O
activity O O
was O O
significantly O O
increased O O
after O O
blockade O O
of O O
p58 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
specific O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Interestingly O O
, O O
we O O
demonstrated O O
that O O
stimulation O O
by O O
tumor O O
cells O O
was O O
required O O
to O O
trigger O O
the O O
inhibitory O O
effect O O
of O O
p58 B B_GENE
on O O
the O O
lytic O O
activity O O
of O O
antigen-specific O O
CTLs O O
and O O
that O O
stimulation O O
of O O
the O O
inhibitory O O
function O O
of O O
p58 B B_GENE
by O O
tumor O O
cells O O
correlated O O
with O O
an O O
inhibition O O
of O O
nuclear O O
factor-kappaB O O
activation O O
in O O
p58+ O O
tumor-specific O O
CTLS O O
. O O

T-cell B B_GENE
factor-1 I I_GENE
expression O O
during O O
human O O
natural O O
killer O O
cell O O
development O O
and O O
in O O
circulating O O
CD56 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
+ I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
bright O O
natural O O
killer O O
cells O O
. O O

Transcription B B_GENE/B_PERSON
factors I I_GENE/I_PERSON
are O O
essential O O
to O O
govern O O
differentiation O O
along O O
the O O
lymphoid O O
lineage O O
from O O
uncommitted O O
hematopoietic O O
stem O O
cells O O
. O O

Although O O
many O O
of O O
these O O
transcription B B_GENE/B_BIO
factors I I_GENE/I_BIO
have O O
putative O O
roles O O
based O O
on O O
murine O O
knockout O O
experiments O O
, O O
their O O
function O O
in O O
human O O
lymphoid O O
development O O
is O O
less O O
known O O
and O O
was O O
studied O O
further O O
. O O

Transcription O B_DISEASE_ADJECTIVE[DISEASE]
factor O I_DISEASE_ADJECTIVE[DISEASE]
expression O I_DISEASE_ADJECTIVE[DISEASE]
in O O
fresh O B_TIME[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
cultured O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adult O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marrow O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
umbilical O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cord O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
evaluated O O
. O O

We O O
found O O
that O O
fresh O O
CD34 O O
( O O
+ O O
) O O
Lin O O
( O O
- O O
) O O
cells O O
that O O
are O O
human O O
leukocyte O O
antigen O O
( O O
HLA O O
) O O
-DR O O
( O O
- O O
) O O
or O O
CD38 O O
( O O
- O O
) O O
constitutively O O
express O O
GATA-3 B B_GENE
but O O
not O O
T-cell B B_GENE/B_DISEASE
factor-1 I I_GENE/I_DISEASE
( O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
Id-3 B B_GENE
. O O

Culture O O
with O O
the O O
murine O O
fetal O O
liver O O
cell O O
line O O
AFT024 O O
and O O
defined O O
cytokines B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
was O O
capable O O
of O O
inducing O O
TCF-1 B B_GENE/B_DISEASE
mRNA I I_GENE/I_DISEASE
. O O

However O O
, O O
no O O
T-cell B B_GENE
receptor I I_GENE
gene I I_GENE
rearrangement O O
was O O
identified O O
in O O
cultured O O
progeny O O
. O O

Id-3 B B_GENE/B_LOCATION
, O O
a O O
basic B B_GENE/B_MEASURE
helix I I_GENE/I_MEASURE
loop I I_GENE/I_MEASURE
helix I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
with O O
dominant O O
negative O O
function O O
for O O
T-cell O O
differentiation O O
transcription B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
also O O
was O O
upregulated O O
and O O
may O O
explain O O
unsuccessful O O
T-cell O O
maturation O O
. O O

To O O
better O O
understand O O
the O O
developmental O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
link O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
between O O
natural O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
killer O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
NK O B_LOCATION/B_PERSON
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
derived O O
from O O
progenitors O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
we O O
studied O O
NK O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
cell O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
subsets O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
circulating O O
in O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
. O O

CD56 O O
( O O
+bright O O
) O O
, O O
but O O
not O O
CD56 O O
( O O
+dim O O
) O O
, O O
NK O O
cells O O
constitutively O O
express O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
reverse O O
transcriptase O O
polymerase O O
chain O O
reaction O O
and O O
Western O O
blot O O
analysis O O
. O O

The O O
TCF-1 B B_GENE
isoform I I_GENE
found O O
in O O
CD56 O O
( O O
+bright O O
) O O
cells O O
, O O
which O O
express O O
lectin B B_GENE
but O O
not O O
immunoglobulin B B_GENE/B_LOCATION
class I I_GENE/I_LOCATION
I I I_GENE/I_LOCATION
recognizing O O
inhibitory B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
was O O
identical O O
to O O
that O O
induced O O
in O O
NK O O
cell O O
differentiation O O
culture O O
and O O
was O O
distinctly O O
different O O
from O O
isoforms O O
in O O
T O O
cells O O
. O O

These O O
results O O
suggest O O
that O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O O
not O O
target O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
killer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
immunoglobulin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
TCF-1 B B_LOCATION
is O O
uniquely O O
expressed O O
in O O
circulating O O
CD56 O O
( O O
+bright O O
) O O
NK O O
cells O O
, O O
and O O
specific O O
TCF-1 B B_GENE/B_BIO
isoforms I I_GENE/I_BIO
may O O
play O O
an O O
important O O
role O O
in O O
regulating O O
NK O O
differentiation O O
from O O
a O O
common O O
NK/T-cell O O
progenitor O O
. O O

Transcriptional O O
activation O O
by O O
a O O
matrix B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associating I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region-binding I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

contextual O O
requirements O O
for O O
the O O
function O O
of O O
bright B B_PERSON/B_ORGANIZATION
. O O

Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
B B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
regulator I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
IgH I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
a O O
B O O
cell O O
-specific O O
, O O
matrix B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
associating I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
transactivates O O
gene O O
expression O O
from O O
the O O
IgH B B_GENE
intronic I I_GENE
enhancer I I_GENE
( O O
E B B_PROTEIN[GENE]/B_PERSON
mu I I_PROTEIN[GENE]/I_PERSON
) O O
. O O

We O O
show O O
here O O
that O O
Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
has O O
multiple O O
contextual O O
requirements O O
to O O
function O O
as O O
a O O
transcriptional B B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Bright B B_PERSON/B_GENE
can O O
not O O
transactivate O O
via O O
out O O
of O O
context O O
, O O
concatenated B B_LOCATION
binding I I_LOCATION
sites I I_LOCATION
. O O

Transactivation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
maximal O B_DISEASE_ADJECTIVE[DISEASE]
on O O
integrated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substrates O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Two O O
of O O
the O O
three O O
previously O O
identified O O
binding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
E B B_GENE
mu I I_GENE
are O O
required O O
for O O
full O O
Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
transactivation O O
. O O

The O O
Bright B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
DNA I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
binding I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
domain I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
defined O O
a O O
new O O
family O O
, O O
which O O
includes O O
SWI1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
component O O
of O O
the O O
SWI.SNF B B_LOCATION/B_BIO
complex I I_LOCATION/I_BIO
shown O O
to O O
have O O
high O O
mobility O O
group-like O O
DNA O O
binding O O
characteristics O O
. O O

Similar O O
to O O
one O O
group O O
of O O
high B B_BIO/B_GENE
mobility I I_BIO/I_GENE
group I I_BIO/I_GENE
box I I_BIO/I_GENE
proteins I I_BIO/I_GENE
, O O
Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
distorts O O
E B B_GENE/B_LOCATION
mu I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
-containing O O
DNA O O
on O O
binding O O
, O O
supporting O O
the O O
concept O O
that O O
it O O
mediates O O
E B B_GENE
mu I I_GENE
remodeling O O
. O O

Transfection O O
studies O O
further O O
implicate O O
Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
facilitating O O
spatially O O
separated O O
promoter-enhancer O O
interactions O O
in O O
both O O
transient O O
and O O
stable O O
assays O O
. O O

Finally O O
, O O
we O O
show O O
that O O
overexpression O O
of O O
Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
leads O O
to O O
enhanced O O
DNase O O
I O O
sensitivity O O
of O O
the O O
endogenous O O
E B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
mu I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
matrix O O
associating O O
regions O O
. O O

These O O
data O O
further O O
suggest O O
that O O
Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
may O O
contribute O O
to O O
increased O O
gene O O
expression O O
by O O
remodeling O O
the O O
immunoglobulin B B_GENE
locus I I_GENE
during O O
B O O
cell O O
development O O
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
BCL-6 O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
in O O
classic O B_DISEASE
Hodgkin O I_DISEASE
disease O I_DISEASE
of O O
the O O
B- O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
T-cell O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
type O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

BCL-6 B B_GENE
is O O
essential O O
for O O
germinal O O
center O O
formation O O
and O O
thus O O
for O O
affinity O O
maturation O O
of O O
immunoglobulin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
Ig I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
somatic O O
mutations O O
. O O

The O O
5'-noncoding B B_GENE/B_LOCATION
region I I_GENE/I_LOCATION
of O O
the O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
even O O
a O O
target O O
for O O
the O O
mutation O O
machinery O O
. O O

Translocations O O
of O O
the O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
heterologous B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
mutations O O
of O O
its O O
5'-noncoding B B_GENE/B_MEASURE
regulatory I I_GENE/I_MEASURE
region I I_GENE/I_MEASURE
were O O
reported O O
to O O
be O O
potential O O
mechanisms O O
for O O
deregulating O O
BCL-6 B B_GENE
expression O O
and O O
for O O
playing O O
a O O
role O O
in O O
the O O
genesis O O
of O O
non-Hodgkin O O
lymphoma O O
. O O

In O O
line O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
this O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
B-cell O B_DISEASE/B_PERSON
lymphoma O I_DISEASE/I_PERSON
with O O
somatic O B_DISEASE/B_GENE
mutations O I_DISEASE/I_GENE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
diffuse O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
large O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
B-cell O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
lymphoma O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
follicular O B_DISEASE/B_GENE
lymphoma O I_DISEASE/I_GENE
, O O
also O O
carry O O
BCL-6 O B_DISEASE/B_GENE
mutations O I_DISEASE/I_GENE
, O O
some O O
of O O
which O O
are O O
recurrently O O
detectable O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Classic O B_DISEASE/B_GENE
Hodgkin O B_DISEASE/I_GENE
disease O B_DISEASE/I_GENE
( O O
cHD O B_LOCATION/B_ORGANIZATION
) O O
is O O
also O O
derived O O
from O O
B O B_DISEASE/B_BIO
cells O I_DISEASE/I_BIO
with O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loads O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
somatic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
thus O O
a O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
candidate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
BCL-6 O B_DISEASE
mutations O I_DISEASE
. O O

To O O
determine O O
the O O
presence O O
and O O
potential O O
role O O
of O O
BCL-6 O O
mutations O O
in O O
cHD O O
, O O
the O O
5'-noncoding B B_GENE/B_MEASURE
BCL-6 I B_GENE/I_MEASURE
proportion O O
of O O
single O O
Hodgkin O O
and O O
Reed-Sternberg O O
( O O
HRS O O
) O O
cells O O
from O O
6 O O
cases O O
of O O
cHD O O
and O O
6 O O
cases O O
of O O
HD-derived O O
cell O O
lines O O
was O O
analyzed O O
. O O

All O O
B-cell-derived O B_DISEASE/B_BIO
HD O I_DISEASE/I_BIO
cases O I_DISEASE/I_BIO
and O O
cell O B_DISEASE/B_PERSON
lines O I_DISEASE/I_PERSON
harbored O O
BCL-6 O B_DISEASE/B_GENE
mutations O B_DISEASE/I_GENE
. O O

In O O
contrast O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
both O O
T-cell-derived O B_DISEASE/B_BIO
HD O I_DISEASE/I_BIO
cases O I_DISEASE/I_BIO
and O O
cell O B_DISEASE/B_ORGANIZATION
lines O I_DISEASE/I_ORGANIZATION
were O O
devoid O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O O
BCL-6 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

With O O
only O O
one O O
exception O O
, O O
there O O
were O O
no O O
lymphoma-specific O O
recurrent O O
BCL-6 O O
mutations O O
detected O O
, O O
and O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
absent O O
from O O
the O O
HRS O O
cells O O
of O O
most O O
cases O O
. O O

In O O
conclusion O O
, O O
( O O
1 O O
) O O
somatic O O
BCL-6 O O
mutations O O
are O O
restricted O O
to O O
cHD O O
cases O O
of O O
B-cell O O
origin O O
, O O
and O O
( O O
2 O O
) O O
the O O
BCL-6 O O
mutations O O
represent O O
mostly O O
irrelevant O O
somatic O O
base O O
substitutions O O
without O O
consequences O O
for O O
BCL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
and O O
the O O
pathogenesis O O
of O O
cHD O O
. O O

Gadd45gamma B B_GENE
is O O
dispensable O O
for O O
normal O O
mouse O O
development O O
and O O
T-cell O O
proliferation O O
. O O

Gadd45gamma B B_GENE
, O O
a O O
family O O
member O O
of O O
the O O
growth B B_GENE/B_BIO
arrest I I_GENE/I_BIO
and I I_GENE/I_BIO
DNA I I_GENE/I_BIO
damage-inducible I I_GENE/I_BIO
gene I I_GENE/I_BIO
family I I_GENE/I_BIO
45 I I_GENE/I_BIO
( O O
Gadd45 B B_GENE
) O O
, O O
is O O
strongly O O
induced O O
by O O
interleukin-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IL-2 B B_GENE
) O O
in O O
peripheral O O
T O O
cells O O
. O O

While O O
in O O
most O O
tissues O O
all O O
Gadd45 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
members I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
are O O
expressed O O
, O O
Gadd45gamma B B_GENE
is O O
the O O
only O O
member O O
that O O
is O O
induced O O
by O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Here O O
we O O
show O O
that O O
the O O
IL-2 B B_GENE
-induced O O
expression O O
of O O
Gadd45gamma B B_GENE
is O O
dependent O O
on O O
a O O
signaling O O
pathway O O
mediated O O
by O O
the O O
tyrosine B B_GENE
kinase I I_GENE
Jak3 I I_GENE
and O O
the O O
transcription B B_GENE
factors I I_GENE
Stat5a B I_GENE
and O O
Stat5b B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
signal B B_GENE/B_MEASURE
transducer I I_GENE/I_MEASURE
and I I_GENE/I_MEASURE
activator I I_GENE/I_MEASURE
of I I_GENE/I_MEASURE
transcription I I_GENE/I_MEASURE
) O O
. O O

Previous O O
studies O O
with O O
ectopically O O
overexpressed O O
Gadd45gamma B B_GENE
in O O
various O O
cell O O
lines O O
implicated O O
its O O
function O O
in O O
negative O O
growth O O
control O O
. O O

To O O
analyze O O
the O O
physiological O O
role O O
of O O
Gadd45gamma B B_GENE/B_BIO
we O O
used O O
homologous O O
recombination O O
to O O
generate O O
mice O O
lacking O O
Gadd45gamma B B_GENE
. O O

Gadd45gamma B B_GENE/B_DISEASE
-deficient O O
mice O O
develop O O
normally O O
, O O
are O O
indistinguishable O O
from O O
their O O
littermates O O
, O O
and O O
are O O
fertile O O
. O O

Furthermore O O
, O O
hematopoiesis O O
in O O
mice O O
lacking O O
Gadd45gamma B B_GENE
is O O
not O O
impaired O O
and O O
Gadd45gamma B B_GENE
-deficient O O
T O O
lymphocytes O O
show O O
normal O O
responses O O
to O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
data O O
demonstrate O O
that O O
Gadd45gamma B B_GENE
is O O
not O O
essential O O
for O O
normal O O
mouse O O
development O O
and O O
hematopoiesis O O
, O O
possibly O O
due O O
to O O
functional O O
redundancy O O
among O O
the O O
Gadd45 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
members I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Gadd45gamma B B_GENE
is O O
also O O
dispensable O O
for O O
IL-2 B B_GENE
-induced O O
T-cell O O
proliferation O O
. O O

Decreased O O
expression O O
of O O
c-myc B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
thymuses O O
from O O
myasthenia O O
gravis O O
patients O O
. O O

The O O
thymus O B_BODY_PART_OR_ORGAN_COMPONENT
is O O
a O O
critical O B_LOCATION/B_PERSON
organ O I_LOCATION/I_PERSON
for O O
the O O
elimination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
autoreactive O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
T O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
by O O
apoptosis O B_DISEASE
. O O

We O O
studied O O
the O O
expression O O
of O O
apoptosis-associated O O
genes O O
, O O
bcl-xL B B_GENE
, O O
bad B B_GENE/B_DISEASE
, O O
caspase-3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
c-myc B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
myasthenia O O
gravis O O
( O O
MG O O
) O O
thymuses O O
. O O

We O O
observed O O
that O O
the O O
mRNA O O
levels O O
of O O
myc B B_GENE
family I I_GENE
genes I I_GENE
, O O
c-myc B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
max B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
were O O
markedly O O
reduced O O
in O O
MG O O
thymuses O O
. O O

These O O
results O O
indicate O O
that O O
c-myc B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-mediated O O
signaling O O
is O O
abnormal O O
in O O
MG O O
thymuses O O
. O O

The O O
levels O O
of O O
molecules O O
whose O O
expressions O O
are O O
associated O O
with O O
myc B B_DISEASE/B_SPECIES[BIO]
, O O
such O O
as O O
STAM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
prothymosin-alpha B B_GENE/B_LOCATION
, O O
and O O
NFkappaB B B_GENE

Immunohistochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
interferon-gamma-producing O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
dermatophytosis O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Skin O O
lesions O O
of O O
dermatophytosis O O
are O O
thought O O
to O O
be O O
a O O
result O O
of O O
a O O
T O O
cell O O
-dependent O O
inflammatory O O
response O O
that O O
is O O
mediated O O
by O O
various O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
examined O O
whether O O
IFN-gamma-positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
as O O
expression O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
Th1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
skin O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lesions O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
dermatophytosis O B_DISEASE/B_LOCATION
in O O
situ O B_PERSON/B_SPECIES[BIO]
by O O
immunohistochemical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Mixtures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
CD4-positive O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
CD8-positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
found O O
to O O
be O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
dermal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infiltrates O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
lesions O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Considerable O B_MEASURE/B_LOCATION
numbers O B_MEASURE/I_LOCATION
of O O
CD1a-positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
detected O O
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
dermis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
epidermis O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

A O O
marked O B_LOCATION/B_MEASURE
accumulation O I_LOCATION/I_MEASURE
of O O
CD68-positive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
dermis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

IFN-gamma-positive O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
dermis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
lesions O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
pattern O O
of O O
IFN-gamma B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
staining O O
appeared O O
to O O
be O O
intracellular O O
in O O
mononuclear O O
lymphoid O O
cells O O
. O O

The O O
staining O O
was O O
considered O O
to O O
be O O
highly O O
specific O O
because O O
it O O
could O O
be O O
completely O O
blocked O O
by O O
preabsorption O O
with O O
recombinant B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IFN-gamma I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
the O O
skin O B_DISEASE_ADJECTIVE[DISEASE]
lesions O I_DISEASE_ADJECTIVE[DISEASE]
of O O
dermatophytosis O B_DISEASE/B_LOCATION
may O O
be O O
associated O O
with O O
a O O
Th1 O B_DISEASE/B_BIO
response O I_DISEASE/I_BIO
. O O

Th1 O O
response O O
, O O
which O O
is O O
characterized O O
by O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
release O O
, O O
is O O
thought O O
to O O
be O O
involved O O
in O O
the O O
host O O
defense O O
against O O
dermatophytes O O
and O O
to O O
reflect O O
cutaneous O O
reaction O O
in O O
dermatophytosis O O
. O O

Regulation O O
of O O
the O O
helix-loop-helix B B_GENE/B_BIO
proteins I I_GENE/I_BIO
, O O
E2A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Id3 B B_GENE
, O O
by O O
the O O
Ras B B_GENE/B_DISEASE
- O O
ERK B B_GENE
MAPK B I_GENE
cascade O O
. O O

Activation O O
of O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE
) O O
pathways O O
leads O O
to O O
cellular O O
differentiation O O
and/or O O
proliferation O O
in O O
a O O
wide O O
variety O O
of O O
cell O O
types O O
, O O
including O O
developing O O
thymocytes O O
. O O

The O O
basic B B_PROTEIN[GENE]
helix-loop-helix I I_PROTEIN[GENE]
( I I_PROTEIN[GENE]
bHLH I I_PROTEIN[GENE]
) I I_PROTEIN[GENE]
proteins I I_PROTEIN[GENE]
E12 B I_PROTEIN[GENE]
and O O
E47 B B_PROTEIN[GENE]
and O O
an O O
inhibitor B B_PROTEIN[GENE]
HLH I I_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
, O O
Id3 B B_GENE
, O O
play O O
key O O
roles O O
in O O
thymocyte O O
differentiation O O
. O O

We O O
show O O
here O O
that O O
E2A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
DNA O O
binding O O
is O O
lowered O O
in O O
primary O O
immature O O
thymocytes O O
consequent O O
to O O
T O O
cell O O
receptor O O
( O O
TCR O O
) O O
-mediated O O
ligation O O
. O O

Whereas O O
expression O O
of O O
E2A O O
mRNA O O
and O O
protein O O
are O O
unaltered O O
, O O
Id3 B B_GENE/B_PERSON
transcripts I I_GENE/I_PERSON
are O O
rapidly O O
induced O O
upon O O
signaling O O
from O O
the O O
TCR B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Activation O O
of O O
Id3 O O
transcription O O
is O O
regulated O O
in O O
a O O
dose-dependent O O
manner O O
by O O
the O O
extracellular O O
signal-regulated O O
kinase O O
( O O
ERK B B_GENE
) O O
MAPK B B_GENE/B_LOCATION
module O O
. O O

These O O
observations O O
directly O O
connect O O
the O O
ERK B B_GENE
MAPK B I_GENE
cascade O O
and O O
HLH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
linear O O
pathway O O
. O O

Retinoic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
acid O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
up-regulates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
myeloid O O
ICAM-3 O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
cell-specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
fashion O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
-- O O
evidence O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
retinoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
signaling O O
pathways O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O O
the O O
mast O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lineage O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Investigation O O
of O O
mast O O
cell O O
responsiveness O O
toward O O
retinoic O O
acid O O
( O O
RA O O
) O O
revealed O O
selective O O
promotion O O
of O O
ICAM-3 B B_GENE
expression O O
in O O
the O O
human O O
mast O O
cell O O
line O O
HMC-1 O O
. O O

This O O
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
dose- O B_MEASURE
and O O
time-dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
detectable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
Western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
ELISA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
Northern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

ICAM-3 B B_GENE/B_MEASURE
modulation O O
was O O
found O O
to O O
be O O
cell-type O O
dependent O O
, O O
detectable O O
also O O
for O O
HL-60 O O
cells O O
and O O
monocytes O O
but O O
not O O
U-937 O O
and O O
only O O
weakly O O
for O O
KU812 O O
cells O O
. O O

Terminally O O
differentiated O O
skin O O
mast O O
cells O O
also O O
failed O O
to O O
up-modulate O O
their O O
ICAM-3 B B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
suggesting O O
the O O
requirement O O
for O O
some O O
degree O O
of O O
immaturity O O
for O O
the O O
process O O
. O O

RA-mediated O O
effects O O
on O O
ICAM-1 B B_GENE
expression O O
, O O
studied O O
in O O
parallel O O
, O O
were O O
clearly O O
distinct O O
from O O
those O O
on O O
ICAM-3 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Investigation O O
of O O
retinoid B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
expression O O
, O O
known O O
to O O
mediate O O
intracellular O O
RA O O
signaling O O
, O O
revealed O O
presence O O
of O O
RAR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RAR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RXR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RXR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
all O O
cell O O
lines O O
studied O O
, O O
and O O
HMC-1 O O
cells O O
were O O
the O O
only O O
line O O
lacking O O
RXR B B_GENE/B_MEASURE
alpha I I_GENE/I_MEASURE
. O O

RAR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
not O O
expressed O O
at O O
baseline O O
, O O
was O O
induced O O
by O O
RA O O
in O O
a O O
fashion O O
obviously O O
correlating O O
with O O
ICAM-3 B B_GENE/B_LOCATION
up-regulation O O
. O O

Increased O O
ICAM-3 B B_GENE
expression O O
was O O
of O O
functional O O
significance O O
, O O
such O O
that O O
processes O O
stimulated O O
or O O
co-stimulated O O
via O O
ICAM-3 B B_GENE
( O O
homotypic O O
aggregation O O
, O O
IL-8 O O
secretion O O
) O O
were O O
clearly O O
enhanced O O
upon O O
RA O O
pretreatment O O
, O O
suggesting O O
that O O
RA O O
may O O
contribute O O
via O O
hitherto O O
unrecognized O O
pathways O O
to O O
immune O O
function O O
and O O
host O O
defense O O
. O O

CD28 B B_GENE
and O O
T O O
cell O O
co-stimulation O O
. O O

Over O O
the O O
last O B_TIME[MEASURE]/B_LOCATION
decade O I_TIME[MEASURE]/I_LOCATION
the O O
concept O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
T O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
co-stimulation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
emerged O O
to O O
take O O
a O O
central O B_LOCATION/B_PERSON
role O I_LOCATION/I_PERSON
in O O
the O O
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
T O B_DISEASE
cell O I_DISEASE
activation O I_DISEASE
. O O

However O O
, O O
the O O
exact O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
definition O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
co-stimulation O B_DISEASE/B_LOCATION
is O O
still O O
unclear O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
we O O
re-examine O O
the O O
concept O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
co-stimulation O B_DISEASE/B_PERSON
. O O

We O O
suggest O O
that O O
while O O
co-stimulation O B_DISEASE/B_GENE
is O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
there O O
is O O
little O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
link O O
co-stimulation O B_DISEASE/B_GENE
with O O
T O B_DISEASE
cell O I_DISEASE
anergy O I_DISEASE
. O O

We O O
then O O
suggest O O
a O O
framework O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
studying O O
co-stimulation O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Focusing O O
on O O
recent O O
advances O O
in O O
our O O
understanding O O
of O O
CD28 B B_GENE/B_DISEASE
, O O
we O O
discuss O O
four O O
areas O O
of O O
T O O
cell O O
activation O O
where O O
co-stimulation O O
may O O
play O O
a O O
role O O
. O O

Regulation O O
of O O
activator B B_GENE
protein-1 I I_GENE
and O O
NF-kappa B B_GENE
B I I_GENE
in O O
CD8+ O O
T O O
cells O O
exposed O O
to O O
peripheral B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
self-antigens I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
transcriptional O O
events O O
that O O
control O O
T O O
cell O O
tolerance O O
to O O
peripheral B B_DISEASE
self I I_DISEASE
Ags I I_DISEASE
are O O
still O O
unknown O O
. O O

In O O
this O O
study O O
, O O
we O O
analyzed O O
the O O
regulation O O
of O O
AP-1 B B_GENE/B_LOCATION
- O O
and O O
NF-kappa B B_GENE
B I I_GENE
-mediated O O
transcription O O
during O O
in O O
vivo O O
induction O O
of O O
tolerance O O
to O O
a O O
self B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ag I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expressed O O
exclusively O O
on O O
hepatocytes O O
. O O

Naive O O
CD8 O O
( O O
+ O O
) O O
Desire O O
( O O
Des O O
) O O
( O O
+ O O
) O O
T O O
cells O O
isolated O O
from O O
the O O
Des O O
TCR-transgenic O O
mice O O
that O O
are O O
specific O O
for O O
the O O
H-2K B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
b I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ag I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
transferred O O
into O O
Alb-K O O
( O O
b O O
) O O
-transgenic O O
mice O O
that O O
express O O
the O O
H-2K B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
b I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
Ag I I_GENE/I_LOCATION
on O O
hepatocytes O O
only O O
. O O

Tolerance O B_DISEASE
develops O O
in O O
these O O
mice O B_BIO/B_PERSON
. O O

We O O
found O O
that O O
the O O
self-reactive O B_GENE
CD8 O I_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
Des O B_GENE/B_DISEASE
( O O
+ O B_GENE/B_DISEASE
) O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O O
transiently O O
activated O O
, O O
then O O
became O O
unresponsive O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O O
were O O
further O O
deleted O O
. O O

In O O
contrast O O
to O O
CD8 O O
( O O
+ O O
) O O
Des O O
( O O
+ O O
) O O
T O O
cells O O
activated O O
in O O
vivo O O
with O O
APCs O O
, O O
which O O
express O O
high O O
AP-1 B B_GENE
and O O
high O O
NF-kappa B B_GENE
B I I_GENE
transcriptional O O
activity O O
, O O
the O O
unresponsive O O
CD8 O O
( O O
+ O O
) O O
Des O O
( O O
+ O O
) O O
T O O
cells O O
expressed O O
no O O
AP-1 B B_GENE
and O O
only O O
weak O O
NF-kappa B B_GENE
B I I_GENE
transcriptional O O
activity O O
. O O

The O O
differences O O
in O O
NF-kappa B B_GENE/B_DISEASE
B I I_GENE/I_DISEASE
transcriptional O O
activity O O
correlated O O
with O O
the O O
generation O O
of O O
distinct O O
NF-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Indeed O O
, O O
in O O
vivo O O
primed O O
T O O
cells O O
predominantly O O
express O O
p50/p50 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p65/p50 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
these O O
p50-containing B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complexes I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O O
barely O O
detectable O O
in O O
tolerant O O
T O O
cells O O
that O O
express O O
p65- B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Rel-containing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
observations O O
suggest O O
that O O
fine O O
regulation O O
of O O
NF-kappa B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complex I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
formation O O
may O O
determine O O
T O O
cell O O
fate O O
. O O

Transcriptional O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulation O B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

Lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
have O O
been O O
used O O
to O O
investigate O O
many O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cellular O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
lineage O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
commitment O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O O
differentiation O B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
, O O
proliferation O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
apoptosis O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

The O O
transcription B B_GENE
factors I I_GENE
that O O
mediate O O
these O O
processes O O
are O O
often O O
expressed O O
broadly O O
in O O
many O O
cell O O
types O O
. O O

The O O
emerging O O
theme O O
is O O
one O O
of O O
cell-type-specific O O
regulation O O
, O O
affecting O O
not O O
only O O
the O O
functional O O
activation O O
of O O
transcription B B_GENE
factors I I_GENE
but O O
also O O
their O O
access O O
to O O
appropriate O O
regions O O
of O O
DNA O O
. O O

Existence O O
of O O
retinoic B B_GENE
acid-receptor I I_GENE
-independent O O
retinoid B B_GENE
X-receptor I I_GENE
-dependent O O
pathway O O
in O O
myeloid O O
cell O O
function O O
. O O

We O O
previously O O
reported O O
that O O
ER-27191 O O
( O O
4- O O
[ O O
4 O O
, O O
5 O O
, O O
7 O O
, O O
8 O O
, O O
9 O O
, O O
10-hexahydro-7 O O
, O O
7 O O
, O O
10 O O
, O O
10-tetramethyl-1- O O
( O O
3-pyridylmethyl O O
) O O
anthra O O
[ O O
1 O O
, O O
2-b O O
] O O
pyrrol-3-yl O O
] O O
benzoic O O
acid O O
) O O
is O O
a O O
potent O O
antagonist O O
of O O
retinoic B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RAR B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
ER-35795 O O
( O O
( O O
2E O O
, O O
4E O O
, O O
6E O O
) O O
-7- O O
[ O O
1- O O
( O O
1-methylethyl O O
) O O
-8-chloro-1 O O
, O O
2 O O
, O O
3 O O
, O O
4-tetrahydroquinolin-6-yl O O
] O O
-6-fluoro-3-methyl-2 O O
, O O
4 O O
, O O
6-nonatrienoic O O
acid O O
) O O
is O O
a O O
novel O O
retinoid B B_GENE/B_MEASURE
X I B_GENE/I_MEASURE
receptor I B_GENE/I_MEASURE
( O O
RXR B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
-specific O O
agonist O O
. O O

By O O
using O O
these O O
compounds O O
, O O
we O O
investigated O O
whether O O
distinct O O
RAR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O O
and O O
RXR B B_PROTEIN[GENE]/B_LOCATION
-dependent O O
pathways O O
operate O O
to O O
mediate O O
the O O
diverse O O
activities O O
of O O
retinoids O O
, O O
particularly O O
, O O
the O O
effects O O
of O O
the O O
RXR B B_GENE/B_LOCATION
pathway O O
on O O
cellular O O
function O O
. O O

ER-27191 O O
completely O O
antagonized O O
HL60 O B_DISEASE
cell O I_DISEASE
differentiation O I_DISEASE
induced O O
by O O
all-trans-retinoic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
atRA O B_LOCATION/B_ORGANIZATION
) O O
. O O

However O O
, O O
the O O
differentiation O O
induced O O
by O O
the O O
ER-35795 O O
was O O
not O O
antagonized O O
at O O
all O O
by O O
the O O
RAR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O O
, O O
but O O
was O O
inhibited O O
by O O
an O O
RXR B B_GENE/B_LOCATION
homodimer I I_GENE/I_LOCATION
antagonist O O
( O O
LGD100754 O O
, O O
( O O
2E O O
, O O
4E O O
, O O
6Z O O
) O O
-7- O O
( O O
3-n-propoxy-5 O O
, O O
6 O O
, O O
7 O O
, O O
8-tetrahydro-5 O O
, O O
5 O O
, O O
8 O O
, O O
8-tetramethylnaphthalen-2-yl O O
) O O
-3-methylocta-2 O O
, O O
4 O O
, O O
6-trienoic O O
acid O O
) O O
. O O

Its O O
agonistic O O
action O O
on O O
RXR/RAR B B_GENE/B_LOCATION
heterodimer I I_GENE/I_LOCATION
, O O
on O O
the O O
other O O
hand O O
, O O
was O O
neutralized O O
by O O
the O O
RAR B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O O
. O O

During O O
HL60 O O
cell O O
differentiation O O
, O O
atRA O O
induced O O
RARbeta B B_GENE/B_DISEASE
mRNA I I_GENE/I_DISEASE
, O O
while O O
the O O
RXR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
had O O
no O O
effect O O
. O O

Interestingly O O
, O O
a O O
functional O O
RXR B B_GENE/B_LOCATION
-pathway O O
was O O
also O O
seen O O
in O O
lipopolysaccharide-induced O O
inhibition O O
of O O
mouse O O
splenocyte O O
proliferation O O
. O O

These O O
results O O
strongly O O
suggest O O
the O O
existence O O
of O O
a O O
pharmacological O O
RXR B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-dependent O O
pathway O O
that O O
is O O
activated O O
by O O
a O O
ligand O O
that O O
can O O
bind O O
to O O
RXR B B_GENE/B_LOCATION
. O O

Targeting O O
Src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homology I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain-containing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SHP-1 B B_GENE/B_DISEASE
) O O
into O O
lipid O O
rafts O O
inhibits O O
CD3 B B_GENE
-induced O O
T O O
cell O O
activation O O
. O O

To O O
study O O
the O O
mechanism O O
by O O
which O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PTPs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
regulate O O
CD3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
tyrosine O O
phosphorylation O O
, O O
we O O
investigated O O
the O O
distribution O O
of O O
PTPs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
subdomains O O
of O O
plasma O O
membrane O O
. O O

We O O
report O O
here O O
that O O
the O O
bulk O O
PTP B B_ENZYME[GENE]
activity O O
associated O O
with O O
T O O
cell O O
membrane O O
is O O
present O O
outside O O
the O O
lipid O O
rafts O O
, O O
as O O
determined O O
by O O
sucrose O O
density O O
gradient O O
sedimentation O O
. O O

In O O
Jurkat O O
T O O
cells O O
, O O
approximately O O
5 O O
-- O O
10 O O
% O O
of O O
Src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homology I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain-containing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SHP-1 B B_GENE/B_DISEASE
) O O
is O O
constitutively O O
associated O O
with O O
plasma O O
membrane O O
, O O
and O O
nearly O O
50 O O
% O O
of O O
SHP-2 B B_GENE/B_BIO
is O O
translocated O O
to O O
plasma O O
membrane O O
after O O
vanadate O O
treatment O O
. O O

Similar O O
to O O
transmembrane B B_GENE
PTP I I_GENE
, O O
CD45 B B_GENE/B_TIME[MEASURE]
, O O
the O O
membrane-associated O O
populations O O
of O O
SHP-1 B B_GENE
and O O
SHP-2 B B_GENE
are O O
essentially O O
excluded O O
from O O
lipid O O
rafts O O
, O O
where O O
other O O
signaling B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
molecules I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such O O
as O O
Lck B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
linker I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
CD3 B B_GENE
zeta I I_GENE
are O O
enriched O O
. O O

We O O
further O O
demonstrated O O
that O O
CD3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
tyrosine O O
phosphorylation O O
of O O
these O O
substrates O O
is O O
largely O O
restricted O O
to O O
lipid O O
rafts O O
, O O
unless O O
PTPs B B_GENE/B_PERSON
are O O
inhibited O O
. O O

It O O
suggests O O
that O O
a O O
restricted O O
partition O O
of O O
PTPs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
among O O
membrane O O
subdomains O O
may O O
regulate O O
protein O O
tyrosine O O
phosphorylation O O
in O O
T O O
cell O O
membrane O O
. O O

To O O
test O O
this O O
hypothesis O O
, O O
we O O
targeted O O
SHP-1 B B_GENE
into O O
lipid O O
rafts O O
by O O
using O O
the O O
N-terminal B B_GENE
region I I_GENE
of I I_GENE
Lck I I_GENE
( O O
residues B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
14 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
results O O
indicate O O
that O O
the O O
expression O O
of O O
Lck/SHP-1 B B_GENE
chimera I I_GENE
inside O O
lipid O O
rafts O O
profoundly O O
inhibits O O
CD3 B B_GENE
-induced O O
tyrosine O O
phosphorylation O O
of O O
CD3 B B_GENE
zeta/epsilon I I_GENE
, O O
IL-2 O O
generation O O
, O O
and O O
nuclear O O
mobilization O O
of O O
NF-AT B B_GENE
. O O

Collectively O O
, O O
these O O
results O O
suggest O O
that O O
the O O
exclusion O O
of O O
PTPs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
from O O
lipid O O
rafts O O
may O O
be O O
a O O
mechanism O O
that O O
potentiates O O
TCR B B_GENE
/ O O
CD3 B B_GENE/B_LOCATION
activation O O

An O O
instructive O O
component O O
in O O
T O O
helper O O
cell O O
type O O
2 O O
( O O
Th2 O O
) O O
development O O
mediated O O
by O O
GATA-3 B B_GENE
. O O

Although O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-12 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IL-4 B B_MEASURE/B_GENE
polarize O O
naive O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
toward O O
T O O
helper O O
cell O O
type O O
1 O O
( O O
Th1 O O
) O O
or O O
Th2 O O
phenotypes O O
, O O
it O O
is O O
not O O
known O O
whether O O
cytokines B B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
instruct O O
the O O
developmental O O
fate O O
in O O
uncommitted O O
progenitors O O
or O O
select O O
for O O
outgrowth O O
of O O
cells O O
that O O
have O O
stochastically O O
committed O O
to O O
a O O
particular O O
fate O O
. O O

To O O
distinguish O O
these O O
instructive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
selective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
we O O
used O O
surface O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
affinity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
matrix O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
technology O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
isolate O O
committed O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
based O O
on O O
cytokine O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretion O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenotype O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
developed O O
retroviral-based O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tagging O O
approaches O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
to O O
directly O O
monitor O O
individual O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
progenitor O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fate O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
decisions O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O O
the O O
clonal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
population O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

We O O
observe O O
IL-4 B B_GENE/B_MEASURE
-dependent O O
redirection O O
of O O
phenotype O O
in O O
cells O O
that O O
have O O
already O O
committed O O
to O O
a O O
non-IL-4-producing O O
fate O O
, O O
inconsistent O O
with O O
predictions O O
of O O
the O O
selective O O
model O O
. O O

Further O O
, O O
retroviral O O
tagging O O
of O O
naive O O
progenitors O O
with O O
the O O
Th2-specific B B_GENE
transcription I I_GENE
factor I I_GENE
GATA-3 I I_GENE
provided O O
direct O O
evidence O O
for O O
instructive O O
differentiation O O
, O O
and O O
no O O
evidence O O
for O O
the O O
selective O O
outgrowth O O
of O O
cells O O
committed O O
to O O
either O O
the O O
Th1 O O
or O O
Th2 O O
fate O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
would O O
seem O O
to O O
exclude O O
selection O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O O
an O O
exclusive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Th1 O B_LOCATION/B_PERSON
/ O O
Th2 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
support O O
an O O
instructive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
cytokine-driven O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptional O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programming O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fate O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
decisions O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
vitro-activated O O
human O O
lupus O O
T O O
cells O O
express O O
normal O O
estrogen B B_GENE
receptor I I_GENE
proteins I I_GENE
which O O
bind O O
to O O
the O O
estrogen B B_GENE/B_LOCATION
response I I_GENE/I_LOCATION
element I I_GENE/I_LOCATION
. O O

We O O
have O O
shown O O
that O O
estrogen B B_GENE/B_NUMBER[MEASURE]
receptor I I_GENE/I_NUMBER[MEASURE]
( O O
ERalpha B B_GENE/B_LOCATION
, O O
ERbeta B B_GENE/B_LOCATION
) O O
transcripts O O
are O O
expressed O O
in O O
SLE O O
and O O
normal O O
T O O
cells O O
. O O

In O O
this O O
study O O
, O O
T O O
cell O O
nuclear O O
extracts O O
from O O
female O O
lupus O O
patients O O
and O O
normal O O
donors O O
were O O
tested O O
for O O
biologically O O
active O O
ER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
capable O O
of O O
binding O O
to O O
the O O
human B B_GENE
estrogen I I_GENE
response I I_GENE
element I I_GENE
( O O
hERE B B_GENE/B_BIO
) O O
by O O
electrophoretic O O
mobility O O
shift O O
assays O O
. O O

When O O
peripheral O O
blood O O
T O O
cells O O
were O O
stimulated O O
with O O
17beta-estradiol O O
( O O
E2 O O
) O O
, O O
PMA O O
and O O
ionomycin O O
, O O
two O O
major O O
retarded O O
bands O O
in O O
T O O
cell O O
nuclear O O
extracts O O
exhibited O O
a O O
migration O O
pattern O O
similar O O
to O O
slow O O
migrating O O
protein-ERE B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
complexes I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
human O O
breast O O
cancer O O
cell O O
extracts O O
. O O

T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cultured O O
only O O
with O O
E2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
did O O
not O O
have O O
these O O
complexes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
formation O O
of O O
the O O
complexes O O
was O O
inhibited O O
by O O
competition O O
with O O
the O O
hERE O O
cold O O
oligonucleotide O O
and O O
partially O O
with O O
anti-ERalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

There O O
was O O
no O O
notable O O
difference O O
in O O
the O O
migration O O
pattern O O
of O O
ERE-binding B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
between O O
the O O
SLE O O
and O O
normal O O
T O O
cell O O
extracts O O
. O O

Together O O
, O O
these O O
results O O
suggest O O
that O O
activated O O
human O O
T O O
cells O O
, O O
whether O O
lupus-derived O O
or O O
normal-derived O O
, O O
contain O O
biologically O O
active O O
ERalpha B B_GENE
proteins I I_GENE
. O O

Other O B_PERSON/B_GENE
factors O I_PERSON/I_GENE
may O O
be O O
responsible O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O O
differential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
sensitivity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
lupus O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
to O O
estrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Mechanism O O
of O O
the O O
inhibitory O O
effect O O
of O O
protease O O
inhibitor O O
on O O
tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
production O O
of O O
monocytes O O
. O O

If O O
the O O
inflammatory O B_DISEASE/B_MEASURE
response O I_DISEASE/I_MEASURE
becomes O O
excessive O B_DISEASE_ADJECTIVE[DISEASE]
or O O
uncontrolled O B_DISEASE_ADJECTIVE[DISEASE]
by O O
some O O
stimuli O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
inappropriate O B_DISEASE/B_PERSON
inflammatory O I_DISEASE/I_PERSON
responses O I_DISEASE/I_PERSON
occur O O
. O O

Monocytes O O
are O O
extremely O O
important O O
cells O O
for O O
regulating O O
the O O
cytokine O O
network O O
and O O
tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
necrosis I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TNFalpha B B_GENE/B_LOCATION
) O O
and O O
interleukin- B B_GENE
( I I_GENE
IL I I_GENE
) I I_GENE
10 I I_GENE
, O O
which O O
are O O
mainly O O
synthesized O O
by O O
monocytes O O
, O O
are O O
representative O O
cytokines B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
play O O
a O O
central O O
role O O
in O O
the O O
cytokine O O
network O O
. O O

Protease O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O O
gabexate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mesilate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GM O B_ORGANIZATION/B_LOCATION
) O O
and O O
ulinastatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
UTI O B_ORGANIZATION/B_LOCATION
) O O
have O O
been O O
shown O O
to O O
have O O
various O B_DISEASE_ADJECTIVE[DISEASE]
beneficial O I_DISEASE_ADJECTIVE[DISEASE]
effects O I_DISEASE_ADJECTIVE[DISEASE]
by O O
inhibiting O O
the O O
activation O B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
but O O
the O O
mechanism O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
this O O
has O O
yet O O
to O O
be O O
fully O O
elucidated O O
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
we O O
investigated O O
the O O
mechanism O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
inhibitory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
protease O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
proinflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
cytokine O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
production O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
lipopolysaccharide- O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
stimulated O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

LPS-stimulated O B_PERSON
monocytes O I_PERSON
were O O
treated O O
with O O
GM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O O
UTI O B_DISEASE/B_PROTEIN[GENE]
. O O

The O O
value O O
of O O
TNFalpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IL-10 B B_GENE
in O O
the O O
culture O O
medium O O
of O O
monocytes O O
was O O
measured O O
and O O
each O O
mRNA O O
expression O O
was O O
assayed O O
. O O

The O O
inhibitory O O
effect O O
of O O
protease O O
inhibitors O O
on O O
the O O
activity O O
of O O
intracellular O O
signal O O
transduction O O
pathways O O
such O O
as O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PKC B B_GENE
) O O
and O O
nuclear B B_GENE
factor I I_GENE
kappa I I_GENE
B I I_GENE
( O O
NFkappaB B B_GENE
) O O
were O O
also O O
evaluated O O
. O O

GM O O
decreased O O
the O O
TNFalpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
of O O
LPS-stimulated O O
monocytes O O
as O O
shown O O
by O O
the O O
inhibition O O
of O O
mRNA O O
expression O O
and O O
increased O O
the O O
IL-10 B B_GENE
production O O
of O O
LPS-stimulated O O
monocytes O O
. O O

GM O O
also O O
suppressed O O
the O O
NFkappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activity O O
of O O
LPS-stimulated O O
monocytes O O
. O O

UTI O O
decreased O O
the O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O O
of O O
LPS-stimulated O O
monocytes O O
, O O
but O O
did O O
not O O
inhibit O O
the O O
TNFalpha B B_GENE
mRNA I I_GENE
expression O O
. O O

The O O
present O O
study O O
shows O O
that O O
the O O
inhibitory O O
effect O O
of O O
GM O O
on O O
the O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O O
of O O
activated O O
human O O
monocytes O O
is O O
mediated O O
by O O
the O O
suppression O O
of O O
NFkappaB B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
, O O
while O O
the O O
mechanism O O
of O O
UTI O O
inhibiting O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O O
of O O
human O O
monocytes O O
may O O
be O O
due O O
to O O
the O O
inhibition O O
of O O
either O O
the O O
translation O O
or O O
secretion O O
of O O
TNFalpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Homocysteine O O
stimulates O O
the O O
expression O O
of O O
monocyte B B_GENE
chemoattractant I I_GENE
protein-1 I I_GENE
in O O
endothelial O O
cells O O
leading O O
to O O
enhanced O O
monocyte O O
chemotaxis O O
. O O

Hyperhomocysteinemia O B_DISEASE
has O O
been O O
identified O O
as O O
an O O
independent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factor O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
atherosclerosis O B_DISEASE
. O O

The O O
infiltration O B_DISEASE/B_TIME[MEASURE]
of O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
into O O
the O O
arterial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wall O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
key O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
events O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
during O O
atherogenesis O B_DISEASE/B_LOCATION
. O O

Monocyte B B_GENE
chemoattractant I I_GENE
protein-1 I I_GENE
( O O
MCP-1 B B_GENE/B_DISEASE
) O O
is O O
a O O
potent O O
chemokine B B_GENE
that O O
stimulates O O
the O O
migration O O
of O O
monocytes O O
into O O
the O O
intima O O
of O O
the O O
arterial O O
wall O O
. O O

The O O
mechanism O B_LOCATION
by O O
which O O
increased O O
monocyte O B_DISEASE
infiltration O I_DISEASE
occurs O O
in O O
atherosclerotic O B_DISEASE
lesions O I_DISEASE
in O O
patients O B_PERSON/B_BIO
with O O
hyperhomocysteinemia O B_DISEASE/B_LOCATION
has O O
not O O
been O O
delineated O O
. O O

The O O
objective O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
the O O
effect O O
of O O
homocysteine O O
on O O
MCP-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
in O O
endothelial O O
cells O O
. O O

Cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
incubated O O
with O O
homocysteine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
secretion O O
of O O
MCP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
significantly O O
increased O O
( O O
195 O O
% O O
as O O
compared O O
to O O
the O O
control O O
) O O
in O O
cells O O
treated O O
with O O
pathological O O
concentrations O O
of O O
homocysteine O O
. O O

Such O O
effect O O
was O O
accompanied O O
by O O
an O O
increased O O
expression O O
of O O
MCP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
176 O O
% O O
as O O
compared O O
to O O
the O O
control O O
) O O
in O O
endothelial O O
cells O O
which O O
resulted O O
in O O
enhanced O O
monocyte O O
chemotaxis O O
. O O

The O O
p38 B B_GENE
MAP I I_GENE
kinase I I_GENE
as O O
well O O
as O O
other O O
members O O
of O O
the O O
p38 O O
MAP O O
kinase O O
pathway O O
, O O
including O O
MKK3 B B_GENE
, O O
MKK6 B B_GENE
, O O
ATF-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Elk-1 B B_GENE
, O O
were O O
activated O O
in O O
homocysteine-treated O O
cells O O
. O O

Homocysteine-induced O O
MCP-1 B B_GENE
expression O O
and O O
subsequent O O
monocyte O O
chemotaxis O O
were O O
blocked O O
by O O
a O O
p38 B B_GENE
MAP I I_GENE
kinase I I_GENE
inhibitor O O
( O O
SB203580 O O
) O O
suggesting O O
that O O
the O O
p38 B B_GENE
MAP I I_GENE
kinase I I_GENE
pathway O O
might O O
be O O
involved O O
in O O
homocysteine-induced O O
MCP-1 B B_GENE
expression O O
in O O
endothelial O O
cells O O
. O O

In O O
contrast O O
, O O
staurosporine O O
, O O
a O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
, O O
had O O
no O O
effect O O
on O O
homocysteine-induced O O
MCP-1 B B_GENE
expression O O
. O O

In O O
conclusion O O
, O O
our O O
results O O
indicate O O
that O O
homocysteine O O
stimulates O O
MCP-1 B B_GENE
expression O O
in O O
endothelial O O
cells O O
leading O O
to O O
enhanced O O
monocyte O O
chemotaxis O O
. O O

Inducible O B_DISEASE_ADJECTIVE[DISEASE]
resistance O I_DISEASE_ADJECTIVE[DISEASE]
to O O
Fas-mediated O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
apoptosis O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
B O B_DISEASE
cells O I_DISEASE
. O O

Apoptosis O O
produced O O
in O O
B O O
cells O O
through O O
Fas B B_GENE/B_DISEASE
( O O
APO-1 B B_GENE/B_LOCATION
, O O
CD95 B B_PROTEIN[GENE]/B_LOCATION
) O O
triggering O O
is O O
regulated O O
by O O
signals O O
derived O O
from O O
other O O
surface O O
receptors O O
: O O
CD40 O O
engagement O O
produces O O
upregulation O O
of O O
Fas B B_GENE
expression O O
and O O
marked O O
susceptibility O O
to O O
Fas B B_GENE/B_DISEASE
-induced O O
cell O O
death O O
, O O
whereas O O
antigen O O
receptor O O
engagement O O
, O O
or O O
IL-4R O O
engagement O O
, O O
inhibits O O
Fas B B_GENE/B_PERSON
killing O O
and O O
in O O
so O O
doing O O
induces O O
a O O
state O O
of O O
Fas B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-resistance O O
, O O
even O O
in O O
otherwise O O
sensitive O O
, O O
CD40 B B_GENE
-stimulated O O
targets O O
. O O

Surface B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunoglobulin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IL-4R B B_GENE
utilize O O
at O O
least O O
partially O O
distinct O O
pathways O O
to O O
produce O O
Fas B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-resistance O O
that O O
differentially O O
depend O O
on O O
PKC B B_GENE
and O O
STAT6 B B_GENE
, O O
respectively O O
. O O

Further O O
, O O
surface O O
immunoglobulin O O
signaling O O
for O O
inducible O O
Fas B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-resistance O O
bypasses O O
Btk B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
requires O O
NF-kappaB B B_GENE
, O O
and O O
entails O O
new O O
macromolecular O O
synthesis O O
. O O

Terminal O O
effectors O O
of O O
B O O
cell O O
Fas B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-resistance O O
include O O
the O O
known O O
anti-apoptotic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
products I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
Bcl-xL B B_GENE/B_LOCATION
and O O
FLIP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
a O O
novel O O
anti-apoptotic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
encodes O O
FAIM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Fas B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Apoptosis I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Inhibitory I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Molecule I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

faim B B_PERSON/B_GENE
was O O
identified O O
by O O
differential O O
display O O
and O O
exists O O
in O O
two O O
alternatively O O
spliced O O
forms O O
; O O
faim-S B B_PERSON/B_PROTEIN[GENE]
is O O
broadly O O
expressed O O
, O O
but O O
faim-L O O
expression O O
is O O
tissue-specific O O
. O O

The O O
FAIM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
highly O O
evolu- O O
tionarily O O
conserved O O
, O O
suggesting O O
an O O
important O O
role O O
for O O
this O O
molecule O O
throughout O O
phylogeny O O
. O O

Inducible O O
resistance O O
to O O
Fas B B_GENE/B_PERSON
killing O O
is O O
hypothesized O O
to O O
protect O O
foreign O O
antigen-specific O O
B O O
cells O O
during O O
potentially O O
hazardous O O
interactions O O
with O O
FasL-bearing O O
T O O
cells O O
, O O
whereas O O
autoreactive O O
B O O
cells O O
fail O O
to O O
become O O
Fas B B_GENE/B_DISEASE
-resistant O O
and O O
are O O
deleted O O
via O O
Fas B B_GENE
-dependent O O
cytotoxicity O O
. O O

Inadvertent O O
or O O
aberrant O O
acquisition O O
of O O
Fas B B_GENE/B_DISEASE
-resistance O O
may O O
permit O O
autoreactive O O
B O O
cells O O
to O O
escape O O
Fas B B_GENE/B_LOCATION
deletion O O
, O O
and O O
malignant O O
lymphocytes O O
to O O
impede O O
anti-tumor O O
immunity O O
. O O

Stromal B B_GENE
cell-derived I I_GENE
factor I I_GENE
1 I I_GENE
alpha I I_GENE
-induced O O
chemotaxis O O
in O O
T O O
cells O O
is O O
mediated O O
by O O
nitric O O
oxide O O
signaling O O
pathways O O
. O O

Stromal B B_GENE
cell-derived I I_GENE
factor I I_GENE
1 I I_GENE
alpha I I_GENE
( O O
SDF1 B B_GENE
alpha I I_GENE
) O O
and O O
its O O
cognate O O
chemokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CXCR4 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
act O O
as O O
potent O O
chemoattractants O O
and O O
regulate O O
trafficking O O
and O O
homing O O
of O O
hematopoietic O O
progenitor O O
cells O O
and O O
lymphocytes O O
. O O

However O O
, O O
the O O
molecular O O
mechanisms O O
regulating O O
SDF1 B B_GENE
alpha I I_GENE
-driven O O
cell O O
migration O O
are O O
not O O
well O O
defined O O
. O O

In O O
this O O
study O O
, O O
we O O
have O O
explored O O
the O O
roles O O
of O O
the O O
second O O
messenger O O
NO O O
and O O
the O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
SDF1 B B_GENE
alpha I I_GENE
-induced O O
T O O
cell O O
migration O O
. O O

SDF1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
treatment O O
of O O
Jurkat O O
T O O
cells O O
increased O O
the O O
activity O O
of O O
NO B B_GENE
synthase I I_GENE
, O O
which O O
catalyzes O O
the O O
generation O O
of O O
NO O O
. O O

We O O
observed O O
that O O
pretreatment O O
of O O
Jurkat O O
cells O O
or O O
activated O O
PBLs O O
with O O
several O O
NO O O
donors O O
significantly O O
enhanced O O
the O O
SDF1 B B_GENE
alpha I I_GENE
-induced O O
migration O O
, O O
whereas O O
various O O
inhibitors O O
of O O
NO B B_GENE
synthase I I_GENE
markedly O O
abrogated O O
the O O
chemotactic O O
response O O
in O O
a O O
concentration-dependent O O
manner O O
. O O

Furthermore O O
, O O
we O O
observed O O
that O O
inhibitors O O
of O O
the O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
is O O
linked O O
to O O
NO O O
signaling O O
pathways O O
, O O
also O O
significantly O O
blocked O O
the O O
SDF1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
chemotactic O O
response O O
. O O

However O O
, O O
these O O
compounds O O
did O O
not O O
have O O
a O O
significant O O
effect O O
on O O
SDF1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-induced O O
mitogen-activated O O
protein O O
kinase O O
activity O O
. O O

In O O
addition O O
, O O
the O O
MAP/Erk O O
kinase O O
kinase O O
inhibitor O O
PD98059 O O
did O O
not O O
abrogate O O
SDF1 B B_GENE
alpha I I_GENE
-induced O O
chemotaxis O O
. O O

AKT B B_GENE
, O O
which O O
has O O
been O O
shown O O
to O O
mediate O O
NO O O
production O O
, O O
was O O
also O O
phosphorylated O O
upon O O
SDF1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O O
. O O

These O O
studies O O
suggest O O
that O O
NO-related O O
signaling O O
pathways O O
may O O
mediate O O
SDF1 B B_GENE
alpha I I_GENE
-induced O O
chemotaxis O O
, O O
but O O
not O O
mitogen-activated B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
activation O O
. O O

The O O
lack O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
NF-kappa O B_GENE
B O I_GENE
transactivation O I_GENE
and O O
PKC O B_GENE
epsilon O I_GENE
expression O I_GENE
in O O
CD4 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
CD8 O B_GENE
( O O
+ O B_DISEASE/B_PROTEIN[GENE]
) O O
thymocytes O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlates O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O O
negative O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
selection O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Deletion O O
of O O
autoreactive O O
thymocytes O O
at O O
the O O
DP O O
stage O O
is O O
the O O
basis O O
for O O
tolerance O O
to O O
thymus-expressed B B_DISEASE
self I I_DISEASE
antigens I I_DISEASE
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
we O O
investigated O O
whether O O
distinct O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signalling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
induced O O
in O O
DP O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
thymocytes O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
as O O
compared O O
to O O
mature O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
upon O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
antigen O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Using O O
triple O O
transgenic O O
mice O O
expressing O O
a O O
TCR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transgene I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
dominant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
negative I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ras/Mek I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
reporter B B_GENE
gene I I_GENE
construct I I_GENE
with O O
AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
showed O O
a O O
complete O O
lack O O
of O O
transcriptional O O
activity O O
of O O
NF-kappa B B_GENE
B I I_GENE
but O O
not O O
AP-1 B B_GENE
in O O
DP O O
thymocytes O O
, O O
whereas O O
both O O
were O O
transcriptionally O O
active O O
in O O
mature O O
T O O
cells O O
after O O
antigenic O O
stimulation O O
. O O

Lack O O
of O O
NF-kappa B B_GENE/B_DISEASE
B I I_GENE/I_DISEASE
induction O O
correlated O O
with O O
increased O O
death O O
in O O
response O O
to O O
antigen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

AP-1 B B_GENE/B_DISEASE
induction O O
was O O
dependent O O
on O O
the O O
integrity O O
of O O
the O O
ras/Mek O O
pathway O O
indicating O O
that O O
this O O
pathway O O
was O O
activated O O
in O O
the O O
DP O O
thymocytes O O
. O O

In O O
contrast O O
, O O
we O O
found O O
a O O
complete O O
lack O O
of O O
constitutive O O
expression O O
of O O
the O O
epsilon B B_PROTEIN[GENE]
isoform I I_PROTEIN[GENE]
of I I_PROTEIN[GENE]
Protein I I_PROTEIN[GENE]
Kinase I I_PROTEIN[GENE]
C I I_PROTEIN[GENE]
( O O
PKC B B_GENE
) O O
in O O
DP O O
thymocytes O O
, O O
although O O
it O O
was O O
present O O
in O O
mature O O
thymocytes O O
and O O
peripheral O O
T O O
cells O O
. O O

Taken O O
together O O
the O O
results O O
suggest O O
that O O
the O O
lack O O
of O O
PKC B B_GENE
epsilon I I_GENE
in O O
DP O O
thymocytes O O
could O O
lead O O
to O O
the O O
absence O O
of O O
NF-kappa B B_GENE
B I I_GENE
activity O O
after O O
antigenic O O
stimulation O O
contributing O O
to O O
negative O O
selection O O
. O O

Cell O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Death O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Differentiation O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
( O O
2000 O B_NUMBER[MEASURE]
) O O
7 O B_MEASURE
, O O
1253 O B_MEASURE
- O O
1262 O B_MEASURE
. O O

CD2 O O
stimulation O O
leads O O
to O O
the O O
delayed O O
and O O
prolonged O O
activation O O
of O O
STAT1 B B_GENE
in O O
T O O
cells O O
but O O
not O O
NK O O
cells O O
. O O

OBJECTIVE O O
: O O
T O O
lymphocytes O O
can O O
be O O
activated O O
by O O
soluble O O
factors O O
such O O
as O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
through O O
direct O O
cell-cell O O
interactions O O
. O O

Although O O
cytokine B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
are O O
known O O
to O O
signal O O
through O O
STAT B B_GENE
family I I_GENE
transcription I I_GENE
factors I I_GENE
, O O
the O O
mechanisms O O
by O O
which O O
other O O
cell-surface B B_GENE/B_BIO
molecules I I_GENE/I_BIO
, O O
such O O
as O O
CD2 B B_GENE
, O O
transduce O O
signals O O
is O O
unclear O O
. O O

The O O
goal O O
of O O
this O O
study O O
was O O
to O O
determine O O
whether O O
stimulation O O
of O O
T O O
cells O O
through O O
CD2 B B_GENE
recapitulates O O
aspects O O
of O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
T-cell O O
activation O O
by O O
use O O
of O O
STAT B B_GENE
transcription I I_GENE
factors I I_GENE
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
T O O
cells O O
were O O
treated O O
with O O
anti-CD2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
cells O O
bearing O O
the O O
natural O O
CD2 B B_GENE
ligand I I_GENE
CD58 I I_GENE
, O O
after O O
which O O
signaling O O
through O O
STAT B B_GENE
transcription I I_GENE
factors I I_GENE
was O O
assessed O O
. O O

RESULTS O O
: O O
Stimulation O O
of O O
CD2 B B_GENE
on O O
primary O O
T O O
lymphocytes O O
leads O O
to O O
the O O
tyrosine O O
phosphorylation O O
, O O
nuclear O O
translocation O O
, O O
and O O
DNA O O
binding O O
of O O
STAT1 B B_GENE
. O O

In O O
contrast O O
to O O
stimulation O O
by O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
activation O O
of O O
STAT1 B B_GENE
in O O
response O O
to O O
CD2 O O
ligation O O
is O O
delayed O O
and O O
does O O
not O O
involve O O
Jak B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
while O O
STAT O O
phosphorylation O O
induced O O
by O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
generally O O
transient O O
, O O
STAT1 O O
phosphorylation O O
following O O
CD2 O O
stimulation O O
persists O O
for O O
a O O
period O O
of O O
days O O
. O O

Transcription O O
of O O
key O O
target O O
genes O O
such O O
as O O
IRF1 B B_GENE
and O O
c-fos B B_GENE
proceeds O O
with O O
delayed O O
kinetics O O
following O O
CD2 O O
stimulation O O
, O O
suggesting O O
that O O
this O O
unique O O
pattern O O
of O O
STAT O O
activation O O
may O O
lead O O
to O O
a O O
distinct O O
cellular O O
response O O
following O O
CD2 O O
ligation O O
. O O

This O O
pathway O O
appears O O
to O O
be O O
restricted O O
to O O
T O O
cells O O
, O O
as O O
stimulation O O
of O O
CD2 B B_GENE
on O O
NK O O
cells O O
does O O
not O O
lead O O
to O O
STAT1 O O
activation O O
. O O

CONCLUSION O O
: O O
Stimulation O O
of O O
T O O
cells O O
through O O
cell-surface B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
such O O
as O O
CD2 B B_GENE
involves O O
activation O O
of O O
STAT B B_GENE
transcription I I_GENE
factors I I_GENE
, O O
thus O O
recapitulating O O
elements O O
of O O
cytokine O O
signaling O O
. O O

NFATc1 B B_GENE
and O O
NFATc2 B B_GENE
together O O
control O O
both O O
T O O
and O O
B O O
cell O O
activation O O
and O O
differentiation O O
. O O

NFAT B B_GENE/B_PERSON
transcription I I_GENE/I_PERSON
factors I I_GENE/I_PERSON
play O O
critical O O
roles O O
in O O
gene O O
transcription O O
during O O
immune O O
responses O O
. O O

To O O
investigate O O
further O O
the O O
two O O
most O O
prominent O O
NFAT B B_GENE/B_PERSON
family I I_GENE/I_PERSON
members I I_GENE/I_PERSON
, O O
NFATc1 B B_GENE
and O O
NFATc2 B B_GENE
, O O
we O O
generated O O
mice O O
bearing O O
lymphoid O O
systems O O
devoid O O
of O O
both O O
. O O

Doubly O O
deficient O O
T O O
cells O O
displayed O O
cell O O
surface O O
markers O O
of O O
activation O O
yet O O
were O O
significantly O O
deficient O O
in O O
the O O
development O O
of O O
multiple O O
effector O O
functions O O
, O O
including O O
Th B B_GENE
cytokine I I_GENE
production O O
, O O
surface B B_GENE
effector I I_GENE
molecule I I_GENE
expression O O
, O O
and O O
cytolytic O O
activity O O
. O O

Nevertheless O O
, O O
doubly O O
deficient O O
B O O
cells O O
were O O
hyperactivated O O
, O O
as O O
evidenced O O
by O O
extremely O O
elevated O O
serum O O
IgG1 B B_GENE
and O O
IgE B B_GENE/B_DISEASE
, O O
as O O
well O O
as O O
plasma O O
cell O O
expansion O O
and O O
infiltration O O
of O O
end O O
organs O O
. O O

Thus O O
, O O
in O O
T O O
cells O O
, O O
NFATc1 B B_GENE
and O O
NFATc2 B B_GENE
are O O
dispensable O O
for O O
inflammatory O O
reactivity O O
but O O
are O O
required O O
for O O
effector O O
differentiation O O
, O O
while O O
in O O
B O O
cells O O
, O O
NFATs B B_GENE/B_PERSON
regulate O O
both O O
normal O O
homeostasis O O
and O O
differentiation O O
. O O

Epstein-barr O O
virus O O
immediate-early B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BZLF1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
SUMO-1 O O
modified O O
and O O
disrupts O O
promyelocytic O O
leukemia O O
bodies O O
. O O

Although O O
the O O
immediate-early B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O O
both O O
herpes O O
simplex O O
virus O O
( O O
HSV O O
) O O
and O O
cytomegalovirus O O
( O O
CMV O O
) O O
are O O
known O O
to O O
modify O O
promyelocytic O O
leukemia O O
( O O
PML O O
) O O
( O O
ND10 O O
) O O
bodies O O
in O O
the O O
nucleus O O
of O O
the O O
host O O
cell O O
, O O
it O O
has O O
been O O
unclear O O
whether O O
lytic O O
infection O O
with O O
gamma O O
herpesviruses O O
induces O O
a O O
similar O O
effect O O
. O O

The O O
PML B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
induced O O
by O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
involved O O
in O O
major B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
histocompatibility I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complex I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
class I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
I I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
presentation O O
, O O
and O O
necessary O O
for O O
certain O O
types O O
of O O
apoptosis O O
. O O

Therefore O O
, O O
it O O
is O O
likely O B_DISEASE_ADJECTIVE[DISEASE]
that O O
PML O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
bodies O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
function O O
in O O
an O O
antiviral O B_MEASURE/B_LOCATION
capacity O B_MEASURE/I_LOCATION
. O O

SUMO-1 O O
modification O O
of O O
PML B B_GENE/B_DISEASE
is O O
known O O
to O O
be O O
required O O
for O O
the O O
formation O O
of O O
PML O O
bodies O O
. O O

To O O
examine O O
whether O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
lytic O O
replication O O
interferes O O
with O O
PML O O
bodies O O
, O O
we O O
expressed O O
the O O
EBV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immediate-early I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BZLF1 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Z I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
BRLF1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
R I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
EBV-positive O O
cell O O
lines O O
and O O
examined O O
PML B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
localization O O
. O O

Both O O
Z O O
and O O
R O O
expression O O
resulted O O
in O O
PML B B_DISEASE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
dispersion O O
in O O
EBV-positive O O
cells O O
. O O

Z O B_OTHER/B_LOCATION
but O O
not O O
R O B_PROTEIN[GENE]/B_LOCATION
expression O I_PROTEIN[GENE]/I_LOCATION
is O O
sufficient O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
disrupt O O
PML O B_DISEASE/B_GENE
bodies O I_DISEASE/I_GENE
in O O
EBV-negative O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lines O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
show O O
that O O
dispersion O O
of O O
PML O O
bodies O O
by O O
Z B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requires O O
a O O
portion O O
of O O
the O O
transcriptional B B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation I B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Z B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
not O O
the O O
DNA-binding O O
function O O
. O O

As O O
was O O
previously O O
reported O O
for O O
the O O
HSV-1 B B_DISEASE/B_BIO
ICP0 I I_DISEASE/I_BIO
and I I_DISEASE/I_BIO
CMV I I_DISEASE/I_BIO
IE1 I I_DISEASE/I_BIO
proteins I I_DISEASE/I_BIO
, O O
Z B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduces O O
the O O
amount O O
of O O
SUMO-1-modified B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PML I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
also O O
found O O
that O O
Z B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itself O O
is O O
SUMO-1 O O
modified O O
( O O
through O O
amino O O
acid O O
12 O O
) O O
and O O
that O O
Z B B_OTHER/B_PROTEIN[GENE]
competes O O
with O O
PML B B_GENE/B_DISEASE
for O O
limiting O O
amounts O O
of O O
SUMO-1 B B_GENE
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
disruption O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
PML O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bodies O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
efficient O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
lytic O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
replication O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
EBV O B_VIRUS[BIO]/B_DISEASE
. O O

Furthermore O O
, O O
Z B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
potentially O O
alter O O
the O O
function O O
of O O
a O O
variety O O
of O O
cellular O O
proteins O O
by O O
inhibiting O O
SUMO-1 O O
modification O O

Suppression O O
of O O
nuclear B B_GENE/B_DISEASE
factor-kappaB I I_GENE/I_DISEASE
and O O
stimulation O O
of O O
inhibitor B B_GENE
kappaB I I_GENE
by O O
troglitazone O O
: O O
evidence O O
for O O
an O O
anti-inflammatory O O
effect O O
and O O
a O O
potential O O
antiatherosclerotic O O
effect O O
in O O
the O O
obese O O
. O O

To O O
elucidate O O
whether O O
troglitazone O O
exerts O O
an O O
antiinflammatory O O
effect O O
in O O
humans O O
, O O
in O O
vivo O O
, O O
we O O
investigated O O
the O O
suppression O O
of O O
nuclear B B_GENE
factor I I_GENE
kappaB I I_GENE
( O O
NFkappaB B B_GENE
) O O
in O O
mononuclear O O
cells O O
( O O
MNC O O
) O O
by O O
this O O
drug O O
. O O

We O O
measured O O
intranuclear B B_GENE/B_DISEASE
NFkappaB I I_GENE/I_DISEASE
, O O
total O O
cellular B B_GENE
NFkappaB I I_GENE
, O O
inhibitor B B_GENE
kappaB I I_GENE
( I I_GENE
IkappaB I I_GENE
) I I_GENE
alpha I I_GENE
, O O
reactive O O
oxygen O O
species O O
( O O
ROS O O
) O O
generation O O
, O O
and O O
p47 B B_GENE
( I I_GENE
phox I I_GENE
) I I_GENE
subunit I I_GENE
( O O
a O O
key O O
component O O
protein O O
of O O
nicotinamide B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adenine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dinucleotide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
MNC O O
. O O

Plasma B B_MEASURE/B_LOCATION
tumor I I_MEASURE/I_LOCATION
necrosis I I_MEASURE/I_LOCATION
factor I I_MEASURE/I_LOCATION
( I I_MEASURE/I_LOCATION
TNF I I_MEASURE/I_LOCATION
) I I_MEASURE/I_LOCATION
-alpha I I_MEASURE/I_LOCATION
, O O
soluble B B_GENE
intercellular I I_GENE
adhesion I I_GENE
molecule-1 I I_GENE
( O O
sICAM-1 B B_GENE/B_LOCATION
) O O
, O O
monocyte B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chemoattractant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MCP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
plasminogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activator I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibitor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
type I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
PAI-1 B B_GENE/B_LOCATION
) O O
, O O
C-reactive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CRP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
-10 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
antiinflammatory B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokine I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
concentrations O O
were O O
also O O
measured O O
as O O
mediators O O
of O O
inflammatory O O
activity O O
that O O
are O O
regulated O O
by O O
the O O
proinflammatory B B_GENE
transcription I I_GENE
factor I I_GENE
NFkappaB I I_GENE
. O O

Seven O B_PERSON
nondiabetic O I_PERSON
obese O I_PERSON
patients O I_PERSON
were O O
given O O
400 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
troglitazone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
daily O O
for O O
4 O B_TIME[MEASURE]/B_DISEASE
weeks O B_TIME[MEASURE]/I_DISEASE
. O O

Blood O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
collected O O
before O O
and O O
at O O
weekly O B_TIME[MEASURE]/B_LOCATION
intervals O B_TIME[MEASURE]/I_LOCATION
thereafter O O
. O O

MNC O O
were O O
separated O O
; O O
and O O
the O O
levels O O
of O O
intranuclear B B_GENE
NFkappaB I I_GENE
, O O
total O O
cellular B B_GENE
NFkappaB I I_GENE
, O O
IkappaBalpha B B_GENE
, O O
and O O
p47 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
phox I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
subunit I I_GENE/I_LOCATION
and O O
ROS O O
generation O O
were O O
determined O O
. O O

Plasma O O
was O O
used O O
to O O
measure O O
insulin O O
glucose O O
, O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
sICAM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
MCP-1 B B_GENE
, O O
PAI-1 B B_GENE
, O O
CRP B B_GENE
, O O
and O O
IL-10 B B_GENE
. O O

Plasma O B_GENE
insulin O I_GENE
concentrations O I_GENE
fell O O
significantly O O
at O O
week O B_TIME[MEASURE]
1 O I_TIME[MEASURE]
, O O
from O O
31.2 O B_MEASURE
+/- O O
29.1 O B_MEASURE
to O O
14.2 O B_MEASURE
+/- O O
11.4 O B_MEASURE
mU/L O I_MEASURE
( O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
0.01 O I_MEASURE/I_LOCATION
) O O
and O O
remained O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
throughout O O
4 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Plasma O B_MEASURE/B_PERSON
glucose O B_MEASURE/I_PERSON
concentrations O B_MEASURE/I_PERSON
did O O
not O O
alter O O
significantly O O
. O O

There O O
was O O
a O O
fall O O
in O O
intranuclear B B_GENE
NFkappaB I I_GENE
, O O
total O O
cellular B B_GENE
NFkappaB I I_GENE
, O O
and O O
p47 B B_GENE
( I I_GENE
phox I I_GENE
) I I_GENE
subunit I I_GENE
, O O
with O O
an O O
increase O O
in O O
cellular O O
IkappaBalpha B B_GENE
at O O
week O O
2 O O
, O O
which O O
persisted O O
until O O
week O O
4 O O
. O O

There O O
was O O
a O O
parallel O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fall O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
ROS O B_DISEASE/B_GENE
generation O I_DISEASE/I_GENE
by O O
MNC O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
at O O
week O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O O
this O O
progressed O O
and O O
persisted O O
until O O
week O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
4 O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
P O B_MEASURE
< O I_MEASURE
0.001 O I_MEASURE
) O O
. O O

Plasma O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
sICAM-1 B B_GENE
, O O
MCP-1 B B_GENE
, O O
and O O
PAI-1 B B_GENE
concentrations O O
fell O O
significantly O O
at O O
week O O
4 O O
. O O

Plasma O O
IL-10 B B_GENE
concentration O O
increased O O
significantly O O
, O O
whereas O O
plasma B B_GENE
CRP I I_GENE
concentrations O O
decreased O O
. O O

We O O
conclude O O
that O O
troglitazone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
has O O
an O O
antiinflammatory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
may O O
contribute O O
to O O
its O O
putative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
antiatherosclerotic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
effects O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Tyrosine O O
phosphorylation-dependent O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
. O O

Requirement O O
for O O
p56 B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
LCK I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
ZAP-70 I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Phosphorylation O O
of O O
the O O
N-terminal B B_GENE/B_MEASURE
domain I I_GENE/I_MEASURE
of O O
I B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O O
activation O O
of O O
the O O
transcription B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
B I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
serine O O
phosphorylation O O
has O O
been O O
shown O O
to O O
induce O O
ubiquitination O O
and O O
subsequent O O
proteasome-mediated O O
degradation O O
of O O
I B B_GENE
kappa I I_GENE
B-alpha I I_GENE
, O O
little O O
is O O
known O O
about O O
the O O
mechanisms O O
that O O
lead O O
to O O
release O O
of O O
active O O
NF-kappa B B_GENE
B I I_GENE
in O O
T O O
cells O O
as O O
a O O
consequence O O
of O O
tyrosine O O
phosphorylation O O
of O O
I B B_GENE
kappa I I_GENE
B-alpha I I_GENE
[ O O
Imbert O O
, O O
V. O O
, O O
Rupec O O
, O O
R.A. O O
, O O
Livolsi O O
, O O
A. O O
, O O
Pahl O O
, O O
H.L. O O
, O O
Traenckner O O
, O O
B.M. O O
, O O
Mueller-Dieckmann O O
, O O
C. O O
, O O
Farahifar O O
, O O
D. O O
, O O
Rossi O O
, O O
B. O O
, O O
Auberger O O
, O O
P. O O
, O O
Baeuerle O O
, O O
P. O O
& O O
Peyron O O
, O O
J.F. O O
( O O
1996 O O
) O O
Cell O O
86 O O
, O O
787 O O
-- O O
798 O O
] O O
. O O

The O O
involvement O O
of O O
the O O
tyrosine B B_GENE
kinases I I_GENE
p56 B I_GENE
( I I_GENE
lck I I_GENE
) I I_GENE
and O O
ZAP-70 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
reaction O O
is O O
demonstrated O O
here O O
using O O
specific O O
pharmacological O O
inhibitors O O
and O O
Jurkat O O
mutants O O
unable O O
to O O
express O O
these O O
kinases B B_ENZYME[GENE]
. O O

Although O O
the O O
inhibitors O O
prevented O O
both O O
pervanadate-induced O O
phosphorylation O O
of O O
I B B_GENE
kappa I I_GENE
B-alpha I I_GENE
on O O
Tyr42 O O
and O O
NF-kappa B B_GENE
B I I_GENE
activation O O
, O O
we O O
observed O O
that O O
, O O
in O O
p56 O O
( O O
lck O O
) O O
-deficient O O
Jurkat O O
mutants O O
, O O
NF-kappa B B_GENE
B I I_GENE
could O O
still O O
associate O O
with O O
I B B_GENE
kappa I I_GENE
B-alpha I I_GENE
despite O O
phosphorylation O O
on O O
Tyr42 O O
. O O

Furthermore O O
, O O
the O O
SH2 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
p56 B B_GENE
( I I_GENE
lck I I_GENE
) I I_GENE
appeared O O
to O O
be O O
required O O
for O O
pervanadate-induced O O
NF-kappa B B_GENE
B I I_GENE
activation O O
but O O
not O O
for O O
Tyr42 O O
phosphorylation O O
. O O

These O O
results O O
show O O
that O O
p56 B B_GENE
( I I_GENE
lck I I_GENE
) I I_GENE
and O O
ZAP-70 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
key O O
components O O
of O O
the O O
signaling O O
pathway O O
that O O
leads O O
to O O
phosphotyrosine-dependent O O
NF-kappa B B_GENE
B I I_GENE
activation O O
in O O
T O O
cells O O
and O O
confirm O O
that O O
tyrosine B B_GENE
kinases I I_GENE
must O O
control O O
at O O
least O O
two O O
different O O
steps O O
to O O
induce O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
. O O

Finally O O
, O O
we O O
show O O
that O O
H O O
( O O
2 O O
) O O
O O O
( O O
2 O O
) O O
, O O
which O O
stimulates O O
p56 B B_GENE
( I I_GENE
lck I I_GENE
) I I_GENE
and O O
ZAP-70 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
T O O
cells O O
, O O
is O O
an O O
activator O O
of O O
NF-kappa B B_GENE/B_DISEASE
B I I_GENE/I_DISEASE
through O O
tyrosine O O
phosphorylation O O
of O O
I B B_GENE
kappa I I_GENE
B-alpha I I_GENE
. O O

Specific O O
missense O O
mutations O O
in O O
NEMO B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
result O O
in O O
hyper-IgM O O
syndrome O O
with O O
hypohydrotic O O
ectodermal O O
dysplasia O O
. O O

The O O
gene O O
that O O
encodes O O
nuclear B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
kappaB I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
NF-kappaB I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
essential I I_GENE/I_LOCATION
modulator I I_GENE/I_LOCATION
( O O
or O O
NEMO B B_ENZYME[GENE]/B_PERSON
, O O
also O O
known O O
as O O
IKKgamma B B_GENE/B_LOCATION
) O O
is O O
required O O
for O O
activation O O
of O O
the O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
NF-kappaB I I_GENE/I_LOCATION
. O O

We O O
describe O O
mutations O O
in O O
the O O
putative B B_GENE/B_LOCATION
zinc-finger I I_GENE/I_LOCATION
domain I I_GENE/I_LOCATION
of O O
NEMO B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
result O O
in O O
an O O
X-linked O O
primary O O
immunodeficiency O O
characterized O O
by O O
hyper-IgM O O
syndrome O O
and O O
hypohydrotic O O
ectodermal O O
dysplasia O O
( O O
XHM-ED O O
) O O
. O O

These O O
mutations O O
prevent O O
CD40 B B_GENE
ligand I I_GENE
( O O
CD40L B B_GENE
) O O
-mediated O O
degradation O O
of O O
inhibitor O O
of O O
NF-kappaB B B_GENE
alpha I I_GENE
( O O
IkappaB-alpha B B_GENE/B_DISEASE
) O O
and O O
account O O
for O O
the O O
following O O
observations O O
: O O
B O O
cells O O
from O O
XHM-ED O O
patients O O
are O O
unable O O
to O O
undergo O O
immunoglobulin O O
class-switch O O
recombination O O
and O O
antigen-presenting O O
cells O O
( O O
APCs O O
) O O
are O O
unable O O
to O O
synthesize O O
the O O
NF-kappaB-regulated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
interleukin B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
12 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-12 B B_GENE/B_MEASURE
) O O
or O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
when O O
stimulated O O
with O O
CD40L B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Nevertheless O O
, O O
innate O O
immunity O O
is O O
preserved O O
in O O
XHM-ED O O
patients O O
because O O
APCs O O
retain O O
the O O
capacity O O
to O O
respond O O
to O O
stimulation O O
by O O
lipopolysaccharide O O
or O O
Staphylococcus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
aureus I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
Cowan I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
's I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
antigen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O O
SAC B B_MEASURE/B_DISEASE
) O O
. O O

Overall O O
, O O
the O O
phenotype O O
observed O O
in O O
XHM-ED O O
patients O O
shows O O
that O O
the O O
putative B B_GENE_EXPRESSION_ADJECTIVE[GENE]
zinc-finger I I_GENE_EXPRESSION_ADJECTIVE[GENE]
domain I I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
NEMO B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
a O O
regulatory O O
function O O
and O O
demonstrates O O
the O O
definite O O
requirement O O
of O O
CD40 B B_GENE
-mediated O O
NF-kappaB O O
activation O O
for O O
B O O
cell O O
immunoglobulin O O
class-switching O O
. O O

Granulocytic O B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_DISEASE_ADJECTIVE[DISEASE]
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
NB4 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
promyelocytic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukemia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
all-trans O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
retinoic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
metabolites O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
metabolism O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
all-trans O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
retinoic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
ATRA O B_LOCATION/B_ORGANIZATION
) O O
has O O
been O O
reported O O
to O O
be O O
partly O O
responsible O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
in O O
vivo O B_DISEASE_ADJECTIVE[DISEASE]
resistance O I_DISEASE_ADJECTIVE[DISEASE]
to O O
ATRA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seen O O
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
human O B_DISEASE/B_PERSON
acute O I_DISEASE/I_PERSON
promyelocytic O I_DISEASE/I_PERSON
leukemia O I_DISEASE/I_PERSON
( O O
APL O B_DISEASE
) O O
. O O

However O O
, O O
ATRA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
metabolism O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
appears O O
to O O
be O O
involved O O
in O O
the O O
growth O B_DISEASE/B_ORGANISM_FUNCTION
inhibition O I_DISEASE/I_ORGANISM_FUNCTION
of O O
several O B_DISEASE
cancer O I_DISEASE
cell O I_DISEASE
lines O I_DISEASE
in O O
vitro O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
evaluate O O
the O O
in O O
vitro O O
activity O O
of O O
the O O
principal O O
metabolites O O
of O O
ATRA O O
[ O O
4-hydroxy-retinoic O O
acid O O
( O O
4-OH-RA O O
) O O
, O O
18-hydroxy-retinoic O O
acid O O
( O O
18-OH-RA O O
) O O
, O O
4-oxo-retinoic O O
acid O O
( O O
4-oxo-RA O O
) O O
, O O
and O O
5 O O
, O O
6-epoxy-retinoic O O
acid O O
( O O
5 O O
, O O
6-epoxy-RA O O
) O O
] O O
in O O
NB4 O O
, O O
a O O
human O O
promyelocytic O O
leukemia O O
cell O O
line O O
that O O
exhibits O O
the O O
APL O O
diagnostic O O
t O O
( O O
15 O O
; O O
17 O O
) O O
chromosomal O O
translocation O O
and O O
expresses O O
the O O
PML-RAR B B_GENE/B_DISEASE
alpha I I_GENE/I_DISEASE
fusion I I_GENE/I_DISEASE
protein I I_GENE/I_DISEASE
. O O

We O O
established O O
that O O
the O O
four O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ATRA O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
metabolites O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
indeed O O
formed O O
by O O
the O O
NB4 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
vitro O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

NB4 O B_DISEASE/B_GENE
cell O B_DISEASE/I_GENE
growth O B_DISEASE/I_GENE
was O O
inhibited O O
( O O
69-78 O B_MEASURE
% O I_MEASURE
at O O
120 O B_MEASURE
h O O
) O O
and O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycle O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
progression O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
G1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
82-85 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
at O O
120 O B_MEASURE
h O O
) O O
was O O
blocked O O
by O O
ATRA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
all O O
of O O
the O O
metabolites O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
1 O B_TIME[MEASURE]/B_DISEASE
microM O I_TIME[MEASURE]/I_DISEASE
concentration O I_TIME[MEASURE]/I_DISEASE
. O O

ATRA O O
and O O
its O O
metabolites O O
could O O
induce O O
NB4 O O
cells O O
differentiation O O
with O O
similar O O
activity O O
, O O
as O O
evaluated O O
by O O
cell O O
morphology O O
, O O
by O O
the O O
nitroblue O O
tetrazolium O O
reduction O O
test O O
( O O
82-88 O O
% O O
at O O
120 O O
h O O
) O O
or O O
by O O
the O O
expression O O
of O O
the O O
maturation B B_GENE
specific I I_GENE
cell I I_GENE
surface I I_GENE
marker I I_GENE
CD11c I I_GENE
. O O

In O O
addition O O
, O O
nuclear O O
body O O
reorganization O O
to O O
macropunctated O O
structures O O
, O O
as O O
well O O
as O O
the O O
degradation O O
of O O
PML-RAR B B_GENE
alpha I I_GENE
, O O
was O O
found O O
to O O
be O O
similar O O
for O O
ATRA O O
and O O
all O O
of O O
its O O
metabolites O O
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
relative O B_MEASURE/B_LOCATION
potency O I_MEASURE/I_LOCATION
of O O
the O O
retinoids O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
using O O
the O O
nitroblue O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tetrazolium O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
reduction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
test O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O O
effective O B_MEASURE/B_LOCATION
concentrations O B_MEASURE/I_LOCATION
required O O
to O O
differentiate O O
50 O B_LOCATION/B_MEASURE
% O B_LOCATION/I_MEASURE
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
in O O
72 O B_NUMBER[MEASURE]
h O O
as O O
follows O O
: O O
ATRA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
15.8 O B_MEASURE
+/- O I_MEASURE
1.7 O I_MEASURE
nM O I_MEASURE
; O O
4-oxo-RA O B_LOCATION/B_ORGANIZATION
, O O
38.3 O B_MEASURE
+/- O I_MEASURE
1.3 O I_MEASURE
nM O I_MEASURE
; O O
18-OH-RA O B_LOCATION/B_ORGANIZATION
, O O
55.5 O B_MEASURE
+/- O I_MEASURE
1.8 O I_MEASURE
nM O I_MEASURE
; O O
4-OH-RA O B_LOCATION/B_PERSON
, O O
79.8 O B_MEASURE
+/- O O
1.8 O B_MEASURE/B_LOCATION
nM O I_MEASURE/I_LOCATION
; O O
and O O
5 O B_MEASURE/B_LOCATION
, O O
6-epoxy-RA O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
99.5 O B_MEASURE/B_LOCATION
+/- O I_MEASURE
1.5 O I_MEASURE
nM O I_MEASURE
. O O

The O O
ATRA O O
metabolites O O
were O O
found O O
to O O
exert O O
their O O
differentiation O O
effects O O
via O O
the O O
RAR B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
nuclear I I_GENE/I_LOCATION
receptors I I_GENE/I_LOCATION
, O O
because O O
the O O
RAR O O
alpha-specific O O
antagonist O O
BMS614 O O
blocked O O
metabolite-induced O O
CD11c O O
expression O O
in O O
NB4 O O
cells O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O O
that O O
the O O
principal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ATRA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Phase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolites O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
elicit O O
leukemia O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
differentiation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
through O O
the O O
RAR O B_GENE
alpha O I_GENE
signaling O O
pathway O B_LOCATION/B_ORGANIZATION
, O O
and O O
they O O
suggest O O
that O O
these O O
metabolites O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O O
play O O
a O O
role O B_TIME[MEASURE]/B_PERSON
in O O
ATRA O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antileukemic O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Expression O O
of O O
oestrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
progesterone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
mast O O
cells O O
alone O O
, O O
but O O
not O O
lymphocytes O O
, O O
macrophages O O
or O O
other O O
immune O O
cells O O
in O O
human O O
upper O O
airways O O
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Nasal O B_DISEASE/B_LOCATION
polyposis O I_DISEASE/I_LOCATION
often O O
coexists O O
with O O
asthma O B_DISEASE
in O O
airway O B_DISEASE/B_PERSON
inflammatory O I_DISEASE/I_PERSON
conditions O I_DISEASE/I_PERSON
characterised O O
by O O
the O O
infiltration O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
range O B_LOCATION/B_MEASURE
of O O
immune O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
potentially O O
important O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
role O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
ovarian O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormones O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
implicated O O
in O O
airway O B_DISEASE/B_ORGANISM_FUNCTION
inflammation O I_DISEASE/I_ORGANISM_FUNCTION
but O O
the O O
cellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
such O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
not O O
known O O
. O O

METHODS O O
: O O
Expression O O
of O O
oestrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
ER B B_LOCATION/B_ORGANIZATION
) O O
and O O
progesterone B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PR B B_LOCATION/B_ORGANIZATION
) O O
was O O
examined O O
using O O
immunohistochemistry O O
in O O
formalin O O
fixed O O
nasal O O
polyp O O
tissues O O
from O O
47 O O
subjects O O
. O O

The O O
cells O O
positive O O
for O O
ER B B_LOCATION
or O O
PR B B_LOCATION
were O O
confirmed O O
by O O
spatial O O
location O O
, O O
dual O O
immunolabelling O O
, O O
and O O
histochemical O O
staining O O
. O O

RESULTS O O
: O O
Consistent O O
with O O
the O O
known O O
features O O
of O O
nasal O O
polyps O O
, O O
CD4+ O O
( O O
T O O
helper/inducer O O
) O O
, O O
CD8+ O O
( O O
cytotoxic/suppressor O O
) O O
, O O
CD68+ O O
( O O
macrophages O O
) O O
, O O
mast O O
cells O O
, O O
eosinophils O O
and O O
neutrophils O O
were O O
all O O
clearly O O
detected O O
by O O
their O O
relevant O O
monoclonal B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
appropriate O O
histochemical O O
staining O O
, O O
but O O
only O O
mast O O
cells O O
tested O O
positive O O
for O O
ER B B_LOCATION
/PR O O
labelling O O
with O O
their O O
polyclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
monoclonal I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
antibodies I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
frequencies O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
expression O B_DISEASE/B_GENE
were O O
61.7 O B_MEASURE
% O I_MEASURE
for O O
ER O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
positive O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
59.6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
for O O
PR O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
positive O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cells O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

The O O
expression O O
of O O
ER B B_PROTEIN[GENE]/B_LOCATION
/ O O
PR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
independent O O
of O O
patient O O
sex O O
and O O
age O O
but O O
was O O
highly O O
correlated O O
with O O
the O O
numbers O O
of O O
mast O O
cells O O
( O O
r O O
= O O
0.973 O O
, O O
p O O
< O O
0.001 O O
for O O
ER B B_PROTEIN[GENE]/B_LOCATION
; O O
r O O
= O O
0.955 O O
, O O
p O O
< O O
0.001 O O
for O O
PR B B_LOCATION
) O O
. O O

Fewer O O
than O O
5 O O
% O O
of O O
mast O O
cells O O
were O O
found O O
to O O
be O O
negative O O
for O O
ER B B_LOCATION
/ O O
PR B B_LOCATION
expression O O
. O O

CONCLUSIONS O O
: O O
Mast O O
cells O O
alone O O
, O O
but O O
not O O
lymphocytes O O
, O O
macrophages O O
, O O
or O O
other O O
immune O O
cells O O
, O O
express O O
ER B B_LOCATION
/ O O
PR B B_LOCATION
in O O
human O O
upper O O
airways O O
. O O

Numerous O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ER/PR O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
positive O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mast O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cells O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
exist O O
in O O
nasal O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
polyps O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
indicating O O
that O O
this O O
may O O
be O O
a O O
major O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
route O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
involvement O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sex O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hormones O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
airway O B_DISEASE/B_BIO
inflammation O I_DISEASE/I_BIO
when O O
exposed O O
to O O
the O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
varying O O
concentration O B_MEASURE
of O O
oestrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
progesterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
characteristic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
females O B_PERSON/B_BIO
. O O

NF O B_GENE
kappa O I_GENE
b O O
signaling O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
posthypoxic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
endothelial O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
: O O
relevance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
E-selectin O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
neutrophil O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
adhesion O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

Our O O
previous O O
studies O O
have O O
implicated O O
the O O
nuclear O O
transcription O O
factor O O
kappa O O
B O O
( O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
) O O
in O O
the O O
regulation O O
of O O
adhesion B B_GENE
molecule I I_GENE
expression O O
in O O
endothelial O O
cells O O
exposed O O
to O O
anoxia-reoxygenation O O
( O O
A/R O O
) O O
or O O
a O O
redox O O
imbalance O O
. O O

The O O
objectives O O
of O O
this O O
study O O
were O O
( O O
1 O O
) O O
to O O
define O O
the O O
kinetics O O
of O O
NF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kappa I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
by O O
examining O O
I O O
kappa O O
B O O
alpha O O
degradation O O
and O O
the O O
nuclear O O
translocation O O
of O O
p65 B B_GENE
in O O
response O O
to O O
A/R O O
or O O
redox O O
imbalance O O
( O O
induced O O
by O O
treatment O O
of O O
cells O O
with O O
diamide O O
and O O
buthionine O O
sulfoximine O O
) O O
and O O
( O O
2 O O
) O O
to O O
determine O O
whether O O
the O O
signal O O
for O O
I O O
kappa O O
B O O
alpha O O
degradation O O
, O O
nuclear O O
translocation O O
of O O
p65 B B_GENE
, O O
and O O
E-selectin B B_GENE
-mediated O O
neutrophil O O
adhesion O O
is O O
related O O
to O O
the O O
activity O O
of O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PTK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
, O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PTPase B B_GENE/B_LOCATION
) O O
and/or O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
C I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PKC B B_GENE/B_DISEASE
) O O
. O O

The O O
results O O
demonstrate O O
that O O
both O O
A/R O O
and O O
redox O O
imbalance O O
led O O
to O O
I O O
kappa O O
B O O
alpha O O
degradation O O
within O O
30 O O
min O O
and O O
the O O
concomitant O O
appearance O O
of O O
p65 B B_GENE
in O O
the O O
nucleus O O
, O O
consistent O O
with O O
rapid O O
cytosolic O O
activation O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
and O O
subsequent O O
nuclear O O
translocation O O
of O O
the O O
activated B B_GENE
p65 I I_GENE
subunit I I_GENE
. O O

Inhibition O O
of O O
PKC B B_GENE
blocked O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degradation O O
and O O
p65 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
translocation O O
in O O
A/R-challenged O O
, O O
but O O
not O O
redox-altered O O
, O O
endothelial O O
cells O O
. O O

However O O
, O O
both O O
A/R- O O
and O O
redox-induced O O
NF O O
kappa O O
B O O
activation O O
was O O
blocked O O
by O O
inhibition O O
of O O
PTK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Similarly O O
, O O
A/R-induced O O
E-selectin O O
expression O O
and O O
neutrophil-endothelial O O
cell O O
adhesion O O
were O O
blocked O O
by O O
inhibition O O
of O O
PKC B B_GENE/B_LOCATION
or O O
PTK B B_LOCATION/B_GENE
, O O
while O O
only O O
PTK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O O
the O O
redox-induced O O
adhesion O O
response O O
. O O

Pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
with O O
N-acetyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effectively O O
blocked O O
A/R- O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
redox-induced O O
I O O
kappa O B_DISEASE_ADJECTIVE[DISEASE]
B O I_DISEASE_ADJECTIVE[DISEASE]
degradation O I_DISEASE_ADJECTIVE[DISEASE]
and O O
significantly O O
attenuated O O
the O O
respective O B_DISEASE_ADJECTIVE[DISEASE]
neutrophil O I_DISEASE_ADJECTIVE[DISEASE]
adhesion O I_DISEASE_ADJECTIVE[DISEASE]
responses O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Collectively O O
, O O
these O O
findings O O
indicate O O
that O O
A/R-induced O O
E-selectin O O
expression O O
and O O
neutrophil-endothelial O O
cell O O
adhesion O O
are O O
mediated O O
by O O
both O O
PKC B B_GENE
and O O
PTK B B_GENE/B_LOCATION
, O O
which O O
signal O O
rapid O O
activation O O
of O O
NF B B_GENE
kappa I I_GENE
B I I_GENE
. O O

This O O
A/R-induced O O
NF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
response O O
appears O O
to O O
be O O
mediated O O
, O O
at O O
least O O
in O O
part O O
, O O
by O O
intracellular O O
redox O O
imbalance O O
. O O

Copyright O B_MEASURE/B_PERSON
2001 O I_MEASURE/I_PERSON
S. O O
Karger O B_PERSON
AG O I_PERSON
, O O
Basel O B_LOCATION/B_ORGANIZATION

Induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
apoptosis O B_DISEASE/B_GENE
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
herbicide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
4-dichlorophenoxyacetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Dimethylammonium O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
salt O B_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
2 O B_NUMBER[MEASURE]
, O O
4-dichlorophenoxyacetic O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DMA-2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
4-D O B_MEASURE
) O O
is O O
a O O
widely O O
used O O
herbicide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
is O O
considered O O
moderately O O
toxic O B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O O
found O O
that O O
DMA-2 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
4-D O B_NUMBER[MEASURE]/B_LOCATION
is O O
able O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
cause O O
apoptosis O B_DISEASE
in O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
healthy O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
individuals O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
Jurkat O B_PERSON/B_DISEASE
T O I_PERSON/I_DISEASE
cells O I_PERSON/I_DISEASE
. O O

Apoptosis O O
induced O O
by O O
DMA-2 O O
, O O
4-D O O
was O O
dose O O
and O O
time O O
dependent O O
, O O
independent O O
of O O
Fas B B_GENE
, O O
TNF B B_GENE
receptor I I_GENE
1 I I_GENE
or O O
the O O
aromatic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hydrocarbon I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
involved O O
disruption O O
of O O
the O O
mitochondrial O O
transmembrane O O
potential O O
and O O
activation O O
of O O
caspase-9 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

ZVAD-FMK O O
, O O
a O O
broad-spectrum O O
inhibitor O O
of O O
caspases B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
blocked O O
DMA-2 O O
, O O
4-D-induced O O
apoptosis O O
completely O O
. O O

While O O
an O O
inhibitor O O
of O O
caspase-9 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
well O O
as O O
caspase-9 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
caspase-3 O O
inhibitors O O
in O O
combination O O
, O O
strongly O O
blocked O O
DMA-2 O O
, O O
4-D-induced O O
apoptosis O O
, O O
an O O
inhibitor O O
of O O
caspase-3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
had O O
a O O
moderate O O
inhibitory O O
effect O O
. O O

Unlike O O
Fas B B_GENE
-mediated O O
apoptosis O O
, O O
the O O
initiator B B_PERSON/B_ENZYME[GENE]
caspase I I_PERSON/I_ENZYME[GENE]
, O O
caspase-8 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
not O O
involved O O
in O O
DMA-2 O O
, O O
4-D-induced O O
apoptosis O O
. O O

Transfection O O
of O O
Jurkat O O
cells O O
with O O
Bcl-2 B B_GENE
prevented O O
DMA-2 O O
, O O
4-D-induced O O
disruption O O
of O O
the O O
mitochondrial O O
transmembrane O O
potential O O
and O O
led O O
to O O
a O O
complete O O
blockage O O
of O O
apoptosis O O
. O O

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
DMA-2 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
4-D O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kills O O
human O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
initiating O O
apoptosis O B_DISEASE
via O O
a O O
direct O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O O
mitochondria O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

The O O
activation O O
of O O
caspases B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
occurs O O
downstream O O
of O O
mitochondrial O O
damage O O
, O O
and O O
the O O
dysfunction O O
of O O
mitochondria O O
appears O O
to O O
be O O
sufficient O O
for O O
triggering O O
all O O
downstream O O
events O O
leading O O
to O O
apoptosis O O
. O O

Inhibition O O
of O O
Th1 O O
differentiation O O
by O O
IL-6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
mediated O O
by O O
SOCS1 B B_GENE
. O O

Interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
a O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
by O O
immune O O
and O O
nonimmune O O
cells O O
and O O
exhibits O O
functional O O
pleiotropy O O
and O O
redundancy O O
. O O

IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plays O O
an O O
important O O
role O O
in O O
the O O
differentiation O O
of O O
several O O
cell O O
types O O
. O O

Here O O
, O O
we O O
describe O O
a O O
novel O O
function O O
of O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
: O O
the O O
negative O O
regulation O O
of O O
CD4 B B_GENE
+ O O
Th1 O O
cell O O
differentiation O O
. O O

While O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-directed O O
CD4 B B_GENE/B_DISEASE
+ O O
Th2 O O
differentiation O O
is O O
mediated O O
by O O
IL-4 B B_GENE
, O O
inhibition O O
of O O
Th1 O O
differentiation O O
by O O
IL-6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
independent O O
of O O
IL-4 B B_GENE
. O O

IL-6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
upregulates O O
suppressor B B_GENE
of I I_GENE
cytokine I I_GENE
signaling I I_GENE
1 I I_GENE
( O O
SOCS1 B B_GENE/B_LOCATION
) O O
expression O O
in O O
activated O O
CD4+ O O
T O O
cells O O
, O O
thereby O O
interfering O O
with O O
signal B B_GENE
transducer I I_GENE
and I I_GENE
activator I I_GENE
of I I_GENE
transcription I I_GENE
1 I I_GENE
( O O
STAT1 B B_GENE
) O O
phosphorylation O O
induced O O
by O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IFNgamma B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Inhibition O O
of O O
IFNgamma B B_GENE/B_LOCATION
receptor-mediated O O
signals O O
by O O
IL-6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prevents O O
autoregulation O O
of O O
IFNgamma B B_GENE
gene I I_GENE
expression O O
by O O
IFNgamma B B_GENE
during O O
CD4+ O O
T O O
cell O O
activation O O
, O O
thereby O O
preventing O O
Th1 O O
differentiation O O
. O O

Thus O O
, O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promotes O O
CD4 B B_GENE/B_LOCATION
+ O O
Th2 O O
differentiation O O
and O O
inhibits O O
Th1 O O
differentiation O O
by O O
two O O
independent O O
molecular O O
mechanisms O O
. O O

Interaction O O
between O O
CCAAT/enhancer B B_GENE
binding I I_GENE
protein I I_GENE
and O O
cyclic B B_GENE
AMP I I_GENE
response I I_GENE
element I I_GENE
binding I I_GENE
protein I I_GENE
1 I I_GENE
regulates O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
transcription O O
in O O
cells O O
of O O
the O O
monocyte/macrophage O O
lineage O O
. O O

Recent O O
observations O O
have O O
shown O O
two O O
CCAAT/enhancer B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
C/EBP I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
to O O
be O O
critically O O
important O O
for O O
efficient O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
replication O O
within O O
cells O O
of O O
the O O
monocyte/macrophage O O
lineage O O
, O O
a O O
cell O O
type O O
likely O O
involved O O
in O O
transport O O
of O O
the O O
virus O O
to O O
the O O
brain O O
. O O

Additionally O O
, O O
sequence O O
variation O O
at O O
C/EBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
lies O O
immediately O O
upstream O O
of O O
the O O
distal B B_GENE/B_DISEASE
nuclear I I_GENE/I_DISEASE
factor I I_GENE/I_DISEASE
kappa I I_GENE/I_DISEASE
B I I_GENE/I_DISEASE
site I I_GENE/I_DISEASE
and O O
immediately O O
downstream O O
of O O
a O O
binding O O
site O O
for O O
activating B B_GENE
transcription I I_GENE
factor I I_GENE
( O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
/ O O
cyclic B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
AMP I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
response I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
element I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CREB B B_GENE/B_LOCATION
) O O
, O O
has O O
been O O
shown O O
to O O
affect O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
long I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeat I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LTR B B_GENE/B_DISEASE
) O O
activity O O
. O O

Given O O
that O O
C/EBP B B_GENE/B_PERSON
proteins I I_GENE/I_PERSON
have O O
been O O
shown O O
to O O
interact O O
with O O
many O O
other O O
transcription B B_GENE/B_BIO
factors I I_GENE/I_BIO
including O O
members O O
of O O
the O O
ATF/CREB B B_GENE/B_MEASURE
family I I_GENE/I_MEASURE
, O O
we O O
proceeded O O
to O O
determine O O
whether O O
an O O
adjacent O O
ATF/CREB B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
could O O
affect O O
C/EBP B B_GENE
protein I I_GENE
binding O O
to O O
C/EBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Electrophoretic O O
mobility O O
shift O O
analyses O O
indicated O O
that O O
selected O O
ATF/CREB B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
site I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variants I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
assisted O O
in O O
the O O
recruitment O O
of O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
an O O
adjacent O O
, O O
naturally O O
occurring O O
, O O
low-affinity O O
C/EBP B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

This O O
biophysical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O O
to O O
occur O O
via O O
at O O
least O O
two O B_MEASURE/B_BIO
mechanisms O B_MEASURE/I_BIO
. O O

First O O
, O O
low O O
amounts O O
of O O
CREB-1 B B_GENE
and O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
appear O O
to O O
heterodimerize O O
and O O
bind O O
to O O
a O O
site O O
consisting O O
of O O
a O O
half O O
site O O
from O O
both O O
the O O
ATF/CREB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C/EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O O
, O O
CREB-1 B B_GENE/B_BIO
homodimers I I_GENE/I_BIO
bind O O
to O O
the O O
ATF/CREB B B_GENE
site I I_GENE
and O O
recruit O O
C/EBP B B_GENE/B_BIO
dimers I I_GENE/I_BIO
to O O
their O O
cognate O O
weak B B_LOCATION/B_GENE
binding I I_LOCATION/I_GENE
sites I I_LOCATION/I_GENE
. O O

This O O
interaction O O
is O O
reciprocal O O
, O O
since O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dimer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding O O
to O O
a O O
strong O O
C/EBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leads O O
to O O
enhanced O O
CREB-1 B B_GENE
recruitment O O
to O O
ATF/CREB B B_GENE/B_LOCATION
sites I I_GENE/I_LOCATION
that O O
are O O
weakly O O
bound O O
by O O
CREB B B_GENE
. O O

Sequence O O
variation O O
at O O
both O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ATF/CREB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
affects O O
the O O
molecular O O
interactions O O
involved O O
in O O
mediating O O
both O O
of O O
these O O
mechanisms O O
. O O

Most O O
importantly O O
, O O
sequence O O
variation O O
at O O
the O O
ATF/CREB B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
affected O O
basal O O
LTR B B_GENE/B_DISEASE
activity O O
as O O
well O O
as O O
LTR B B_GENE/B_DISEASE
function O O
following O O
interleukin-6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stimulation O O
, O O
a O O
treatment O O
that O O
leads O O
to O O
increases O O
in O O
C/EBP O O
activation O O
. O O

Thus O O
, O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ATF/CREB B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence O O
variation O O
may O O
modulate O O
cellular O O
signaling O O
at O O
the O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
through O O
the O O
C/EBP O O
pathway O O

Selective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
inhibition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
interleukin-4 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
aspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicated O O
that O O
aspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
acetylsalicylic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
acid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
ASA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
can O O
have O O
profound O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
immunomodulatory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
by O O
regulating O O
cytokine O B_GENE
gene O I_GENE
expression O I_GENE
in O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
types O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
cells O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

This O O
study O O
is O O
the O O
first O O
in O O
which O O
concentrations O O
of O O
ASA O O
in O O
the O O
therapeutic O O
range O O
were O O
found O O
to O O
significantly O O
reduce O O
interleukin B B_GENE
( I I_GENE
IL I I_GENE
) I I_GENE
-4 I I_GENE
secretion O O
and O O
RNA O O
expression O O
in O O
freshly O O
isolated O O
and O O
mitogen-primed O O
human O O
CD4+ O O
T O O
cells O O
. O O

In O O
contrast O O
, O O
ASA O O
did O O
not O O
affect O O
IL-13 B B_GENE
, O O
interferon-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
IL-2 B B_GENE
expression O O
. O O

ASA O O
inhibited O O
IL-4 B B_GENE
, O O
but O O
not O O
IL-2 B B_GENE
, O O
promoter-driven O O
chloramphenicol O O
acetyltransferase O O
expression O O
in O O
transiently O O
transfected O O
Jurkat O O
T O O
cells O O
. O O

The O O
structurally O O
unrelated O O
nonsteroidal O O
anti-inflammatory O O
drugs O O
indomethacin O O
and O O
flurbiprofen O O
did O O
not O O
affect O O
cytokine O O
gene O O
expression O O
in O O
T O O
cells O O
, O O
whereas O O
the O O
weak O O
cyclo-oxygenase O O
inhibitor O O
salicylic O O
acid O O
was O O
at O O
least O O
as O O
effective O O
as O O
ASA O O
in O O
inhibiting O O
IL-4 B B_GENE/B_PERSON
expression O O
and O O
promoter O O
activity O O
. O O

The O O
inhibitory O O
effect O O
of O O
ASA O O
on O O
IL-4 O O
transcription O O
was O O
not O O
mediated O O
by O O
decreased O O
nuclear O O
expression O O
of O O
the O O
known O O
salicylate B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
target I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-kappaB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
was O O
accompanied O O
by O O
reduced O O
binding O O
of O O
an O O
inducible O O
factor O O
to O O
an O O
IL-4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
upstream O O
of O O
, O O
but O O
not O O
overlapping O O
, O O
the O O
NF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappaB-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
is O O
concluded O O
that O O
anti-inflammatory O O
salicylates O O
, O O
by O O
means O O
of O O
a O O
previously O O
unrecognized O O
mechanism O O
of O O
action O O
, O O
can O O
influence O O
the O O
nature O O
of O O
adaptive O O
immune O O
responses O O
by O O
selectively O O
inhibiting O O
the O O
expression O O
of O O
IL-4 B B_GENE
, O O
a O O
critical O O
effector O O
of O O
these O O
responses O O
, O O
in O O
CD4+ O O
T O O
cells O O
. O O

Molecular O O
and O O
cellular O O
mediators O O
of O O
interleukin-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-dependent O O
acute O O
inflammatory O O
arthritis O O
. O O

OBJECTIVE O O
: O O
To O O
examine O O
the O O
molecular O O
and O O
cellular O O
mechanisms O O
in O O
a O O
model O O
of O O
acute O O
inflammatory O O
monarticular O O
arthritis O O
induced O O
by O O
methylated B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bovine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
serum I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
albumin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
mBSA B B_LOCATION/B_ORGANIZATION
) O O
and O O
interleukin-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-1 B B_GENE
) O O
. O O

METHODS O O
: O O
Mice O O
were O O
injected O O
intraarticularly O O
with O O
mBSA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
day O O
0 O O
and O O
subcutaneously O O
with O O
recombinant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
human I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IL-1beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
days O O
0-2 O O
. O O

At O O
day O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
7 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
knee O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
joints O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
removed O O
and O O
assessed O O
histologically O O
. O O

Flow O O
cytometry O O
and O O
RNase O O
protection O O
were O O
used O O
to O O
analyze O O
IL-1 B B_GENE/B_MEASURE
-dependent O O
events O O
. O O

RESULTS O O
: O O
C57BL/6 O O
( O O
B6 O O
) O O
, O O
129/Sv O O
, O O
and O O
( O O
B6 O O
x O O
129/ O O
Sv O O
) O O
F1 O O
hybrid O O
mice O O
, O O
all O O
H-2b O O
strains O O
, O O
were O O
susceptible O O
to O O
mBSA B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/IL-1-induced O O
arthritis O O
, O O
whereas O O
C3H/HeJ O O
( O O
H-2k O O
) O O
mice O O
were O O
not O O
. O O

B6 O O
mice O O
lacking O O
T O O
and O O
B O O
cells O O
( O O
RAG1-/- O O
) O O
or O O
major B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
histocompatibility I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complex I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MHC I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
class I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
II I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
antigens I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
MHCII-/- O O
) O O
, O O
and O O
B6 O O
mice O O
treated O O
with O O
a O O
CD4+ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
T I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
cell-depleting I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
monoclonal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
were O O
resistant O O
to O O
disease O O
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
B O B_GENE/B_PERSON
cell-deficient O I_GENE/I_PERSON
( O O
muMT/ O B_PROTEIN[GENE]/B_LOCATION
muMT O I_PROTEIN[GENE]/I_LOCATION
) O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developed O O
arthritis O B_DISEASE
at O O
an O O
incidence O B_MEASURE/B_LOCATION
and O O
severity O B_MEASURE/B_PERSON
similar O I_MEASURE/I_PERSON
to O O
that O O
of O O
controls O B_DISEASE/B_PERSON
. O O

RelB-deficient O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
RelB-/- O O
) O O
bone O B_SPECIES[BIO]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
marrow O I_SPECIES[BIO]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chimeric O I_SPECIES[BIO]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mice O I_SPECIES[BIO]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
had O O
arthritis O B_DISEASE
that O O
was O O
significantly O O
reduced O O
in O O
incidence O B_MEASURE
and O O
severity O B_MEASURE
. O O

In O O
B6 O O
mice O O
, O O
flow O O
cytometry O O
demonstrated O O
an O O
IL-1-dependent O O
leukocyte O O
infiltration O O
into O O
the O O
synovial O O
compartment O O
and O O
RNase O O
protection O O
assays O O
revealed O O
induction O O
of O O
messenger B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
mRNA B B_GENE
) O O
for O O
the O O
chemokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
monocyte B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chemoattractant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
macrophage B B_PROTEIN[GENE]/B_MEASURE
inhibitory I I_PROTEIN[GENE]/I_MEASURE
protein I I_PROTEIN[GENE]/I_MEASURE
2 I I_PROTEIN[GENE]/I_MEASURE
( O O
MIP-2 B B_GENE/B_DISEASE
) O O
, O O
RANTES B B_GENE
, O O
MIP-1alpha B B_GENE
, O O
and O O
MIP-1beta B B_GENE
, O O
in O O
vivo O O
and O O
in O O
vitro O O
. O O

CONCLUSION O O
: O O
Arthritis O O
induced O O
by O O
mBSA B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
IL-1 B B_LOCATION/B_PERSON
is O O
strain O O
specific O O
and O O
dependent O O
on O O
CD4+ O O
T O O
lymphocytes O O
and O O
at O O
least O O
partially O O
on O O
RelB B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
on O O
B O O
lymphocytes O O
or O O
antibody B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

IL-1 B B_GENE/B_LOCATION
contributes O O
to O O
leukocyte O O
recruitment O O
to O O
the O O
synovium O O
and O O
directly O O
induces O O
chemokine O O
mRNA O O
production O O
by O O
synovial O O
cells O O
. O O

This O O
model O O
of O O
acute O O
monarticular O O
arthritis O O
is O O
particularly O O
suitable O O
for O O
further O O
investigations O O
into O O
cell-mediated O O
immunity O O
in O O
arthritis O O
and O O
the O O
role O O
of O O
IL-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Positive O O
and O O
negative O O
regulation O O
of O O
granulopoiesis O O
by O O
endogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RARalpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
is O O
always O O
associated O O
with O O
chromosomal O O
translocations O O
that O O
disrupt O O
the O O
retinoic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RARalpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Whether O O
these O O
translocations O O
relate O O
to O O
a O O
role O O
for O O
endogenous B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RARalpha I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
normal O O
granulopoiesis O O
remains O O
uncertain O O
because O O
most O O
studies O O
addressing O O
this O O
question O O
have O O
used O O
non-physiological O O
overexpression O O
systems O O
. O O

Granulocyte O O
differentiation O O
in O O
cells O O
derived O O
from O O
RARalpha-deficient O O
( O O
RARalpha O O
( O O
-/- O O
) O O
) O O
mice O O
was O O
studied O O
and O O
evaluated O O
in O O
the O O
context O O
of O O
agonist-bound B B_DISEASE/B_GENE
and I I_DISEASE/I_GENE
ligand-free I I_DISEASE/I_GENE
RARalpha I I_DISEASE/I_GENE
. O O

Our O O
results O O
demonstrate O O
that O O
RARalpha B B_GENE
is O O
dispensable O O
for O O
granulopoiesis O O
, O O
as O O
RARalpha O O
( O O
-/- O O
) O O
mice O O
have O O
a O O
normal O O
granulocyte O O
population O O
despite O O
an O O
impaired O O
ability O O
to O O
respond O O
to O O
retinoids O O
. O O

However O O
, O O
although O O
it O O
is O O
not O O
absolutely O O
required O O
, O O
RARalpha B B_GENE
can O O
bidirectionally O O
modulate O O
granulopoiesis O O
. O O

RARalpha B B_GENE
stimulates O O
differentiation O O
in O O
response O O
to O O
exogenous O O
retinoic O O
acid O O
. O O

Furthermore O O
, O O
endogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
retinoids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
control O O
granulopoiesis O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
either O O
vitamin O B_PERSON/B_BIO
A-deficient O I_PERSON/I_BIO
mice O I_PERSON/I_BIO
or O O
animals O B_BIO/B_PERSON
treated O O
with O O
an O O
RAR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antagonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
accumulate O O
more O O
immature O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
granulocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
in O O
their O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
marrow O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Conversely O O
, O O
RARalpha B B_GENE
acts O O
to O O
limit O O
differentiation O O
in O O
the O O
absence O O
of O O
ligand B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
because O O
granulocyte O O
precursors O O
from O O
RARalpha O O
( O O
-/- O O
) O O
mice O O
differentiate O O
earlier O O
in O O
culture O O
. O O

Thus O O
, O O
the O O
block O O
in O O
granulopoiesis O O
exerted O O
by O O
RARalpha B B_GENE/B_LOCATION
fusion B I_GENE/I_LOCATION
proteins I I_GENE/I_LOCATION
expressed O O
in O O
APL O O
cells O O
may O O
correspond O O
to O O
an O O
amplification O O
of O O
a O O
normal O O
function O O
of O O
unliganded B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
RARalpha I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Expression O O
and O O
function O O
of O O
a O O
stem B B_GENE/B_PERSON
cell I I_GENE/I_PERSON
promoter I I_GENE/I_PERSON
for O O
the O O
murine B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
CBFalpha2 I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
: O O
distinct O O
roles O O
and O O
regulation O O
in O O
natural O O
killer O O
and O O
T O O
cell O O
development O O
. O O

The O O
Runt B B_GENE/B_MEASURE
family I I_GENE/I_MEASURE
transcription I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
CBFalpha2 B I_GENE/I_MEASURE
( O O
AML1 B B_GENE/B_DISEASE
, O O
PEBP2alphaB B B_GENE/B_DISEASE
, O O
or O O
Runx1 B B_GENE/B_DISEASE
) O O
is O O
required O O
by O O
hematopoietic O O
stem O O
cells O O
and O O
expressed O O
at O O
high O O
levels O O
in O O
T-lineage O O
cells O O
. O O

In O O
human O O
T O O
cells O O
CBFalpha2 B B_GENE
is O O
usually O O
transcribed O O
from O O
a O O
different B B_MEASURE/B_BIO
promoter I I_MEASURE/I_BIO
( O O
distal B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
promoter I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
than O O
in O O
myeloid O O
cells O O
( O O
proximal B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
, O O
but O O
the O O
developmental O O
and O O
functional O O
significance O O
of O O
this O O
promoter O O
switch O O
has O O
not O O
been O O
known O O
. O O

Here O O
, O O
we O O
report O O
that O O
both O O
coding B B_LOCATION/B_PERSON
and I I_LOCATION/I_PERSON
noncoding I I_LOCATION/I_PERSON
sequences I I_LOCATION/I_PERSON
of O O
the O O
distal B B_GENE
5 I I_GENE
' I I_GENE
end I I_GENE
are O O
highly O O
conserved O O
between O O
the O O
human B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
murine I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
distal B B_GENE
promoter I I_GENE
is O O
responsible O O
for O O
the O O
overwhelming O O
majority O O
of O O
CBFalpha2 O O
expression O O
in O O
murine O O
hematopoietic O O
stem O O
cells O O
as O O
well O O
as O O
in O O
T O O
cells O O
. O O

Distal O B_GENE
promoter O I_GENE
activity O I_GENE
is O O
maintained O O
throughout O O
T O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O O
at O O
lower O B_MEASURE/B_LOCATION
levels O I_MEASURE/I_LOCATION
in O O
B O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
development O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
but O O
downregulated O O
in O O
natural O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
killer O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
development O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
distal B B_PROTEIN[GENE]
N-terminal I I_PROTEIN[GENE]
isoform I I_PROTEIN[GENE]
binds O O
to O O
functionally O O
important O O
regulatory B B_GENE/B_LOCATION
sites I I_GENE/I_LOCATION
from O O
known O O
target B B_GENE
genes I I_GENE
with O O
two- O O
to O O
threefold O O
higher O O
affinity O O
than O O
the O O
proximal B B_LOCATION/B_GENE
N-terminal I I_LOCATION/I_GENE
isoform I I_LOCATION/I_GENE
. O O

Neither O O
full-length B B_GENE
isoform I I_GENE
alters O O
growth O O
of O O
a O O
myeloid O O
cell O O
line O O
under O O
nondifferentiating O O
conditions O O
, O O
but O O
the O O
proximal B B_GENE
isoform I I_GENE
selectively O O
delays O O
mitotic O O
arrest O O
of O O
the O O
cell O O
line O O
under O O
differentiating O O
conditions O O
, O O
resulting O O
in O O
the O O
generation O O
of O O
greater O O
numbers O O
of O O
neutrophils O O
. O O

Constitutive O B_GENE
PI3-K O I_GENE
activity O I_GENE
is O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
proliferation O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
but O O
not O O
survival O B_DISEASE_ADJECTIVE[DISEASE]
, O O
of O O
Theileria O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
parva-transformed O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Theileria O B_DISEASE/B_BACTERIUM[BIO]
is O O
an O O
intracellular O B_SPECIES[BIO]/B_DISEASE
parasite O I_SPECIES[BIO]/I_DISEASE
that O O
causes O O
lymphoproliferative O B_DISEASE
disorders O I_DISEASE
in O O
cattle O B_BIO/B_PERSON
, O O
and O O
infection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
leucocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
induces O O
a O O
transformed O B_DISEASE/B_LOCATION
phenotype O I_DISEASE/I_LOCATION
similar O I_DISEASE/I_LOCATION
to O O
tumour O B_DISEASE
cells O I_DISEASE
, O O
but O O
the O O
mechanisms O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O O
which O O
the O O
parasite O B_SPECIES[BIO]/B_DISEASE
induces O O
this O O
phenotype O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
not O O
understood O O
. O O

Here O O
, O O
we O O
show O O
that O O
infected O O
B O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
display O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constitutive O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphoinositide O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3-kinase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI3-K O B_GENE
) O O
activity O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
, O O
which O O
appears O O
to O O
be O O
necessary O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
proliferation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
but O O
not O O
survival O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Importantly O O
, O O
we O O
demonstrate O O
that O O
one O O
mechanism O O
by O O
which O O
PI3-K B B_GENE/B_VIRUS[BIO]
mediates O O
the O O
proliferation O O
of O O
infected O O
B O O
lymphocytes O O
is O O
through O O
the O O
induction O O
of O O
a O O
granulocyte-monocyte B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GM-CSF B B_LOCATION/B_PERSON
) O O
-dependent O O
autocrine O O
loop O O
. O O

PI3-K B B_PERSON
induction O O
of O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
appears O O
to O O
be O O
at O O
the O O
transcriptional O O
level O O
and O O
, O O
consistently O O
, O O
we O O
demonstrate O O
that O O
PI3-K B B_GENE
is O O
also O O
involved O O
in O O
the O O
constitutive O O
induction O O
of O O
AP-1 B B_GENE
and O O
NF-kappaB B B_GENE
, O O
which O O
characterizes O O
Theileria-infected O O
leucocytes O O
. O O

Taken O O
together O O
, O O
our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
highlight O O
a O O
novel O B_LOCATION
strategy O I_LOCATION
exploited O O
by O O
the O O
intracellular O B_SPECIES[BIO]
parasite O I_SPECIES[BIO]
Theileria O I_SPECIES[BIO]
to O O
induce O O
continued O B_DISEASE
proliferation O I_DISEASE
of O O
its O O
host O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leucocyte O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Lymphokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dependence O O
of O O
STAT3 O O
activation O O
produced O O
by O O
surface O O
immunoglobulin O O
cross-linking O O
and O O
by O O
phorbol O O
ester O O
plus O O
calcium O O
ionophore O O
treatment O O
in O O
B O O
cells O O
. O O

Stimulation O O
of O O
B O O
cells O O
by O O
surface B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoglobulin I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
sIg B B_PROTEIN[GENE]/B_LOCATION
) O O
triggering O O
, O O
or O O
through O O
the O O
mitogenic O O
combination O O
of O O
phorbol O O
ester O O
and O O
calcium O O
ionophore O O
, O O
is O O
accompanied O O
by O O
activation O O
of O O
STAT B B_GENE
transcription I I_GENE
factors I I_GENE
. O O

The O O
mechanism O O
responsible O O
for O O
the O O
delayed O O
nuclear O O
accumulation O O
of O O
phosphorylated B B_GENE/B_DISEASE
STAT3 I I_GENE/I_DISEASE
was O O
examined O O
in O O
detail O O
, O O
focusing O O
on O O
the O O
role O O
of O O
B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell-derived I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lymphokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

sIg B B_GENE
-induced O O
activation O O
of O O
STAT3 B B_GENE
was O O
partially O O
inhibited O O
in O O
B O O
cells O O
obtained O O
from O O
IL-6- O O
or O O
IL-10-deficient O O
mice O O
, O O
and O O
was O O
partially O O
blocked O O
by O O
neutralizing B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
directed O O
against O O
either O O
of O O
these O O
lymphokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

sIg B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
STAT3 O O
activation O O
was O O
completely O O
inhibited O O
by O O
combining O O
IL-6- B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
IL-10-specific I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
neutralizing I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
or O O
by O O
adding O O
individual O O
neutralizing B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
B O O
cells O O
obtained O O
from O O
lymphokine-deficient O O
animals O O
. O O

In O O
contrast O O
, O O
IL-10 B B_GENE
alone O O
appeared O O
to O O
account O O
for O O
STAT3 O O
activation O O
resulting O O
from O O
B O O
cell O O
stimulation O O
with O O
phorbol O O
ester O O
and O O
calcium O O
ionophore O O
. O O

In O O
keeping O O
with O O
these O O
results O O
, O O
soluble O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
IL-10 B B_GENE
were O O
found O O
in O O
supernatant O O
fluid O O
obtained O O
from O O
stimulated O O
B O O
cells O O
. O O

This O O
work O O
indicates O O
that O O
a O O
lymphokine O O
pathway O O
is O O
responsible O O
for O O
STAT3 O O
activation O O
that O O
occurs O O
late O O
after O O
B O O
cell O O
stimulation O O
, O O
and O O
points O O
out O O
differences O O
in O O
B O O
cell O O
activation O O
that O O
result O O
from O O
stimulation O O
through O O
the O O
antigen B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
receptor I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
through O O
pharmacological O O
mimicry O O
of O O
signaling B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mediators I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Transcription B B_GENE
factor I I_GENE
AP-4 I I_GENE
is O O
a O O
ligand B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
immunoglobulin-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E-box I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Immunoglobulin B B_GENE/B_BIO
( I I_GENE/I_BIO
Ig I I_GENE/I_BIO
) I I_GENE/I_BIO
-kappa I I_GENE/I_BIO
promoters I I_GENE/I_BIO
from O O
humans O O
and O O
mice O O
share O O
conserved B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
octamer B B_LOCATION/B_MEASURE
element I I_LOCATION/I_MEASURE
is O O
common O O
to O O
all O O
Ig B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
pivotal O O
for O O
their O O
function O O
. O O

However O O
, O O
other O O
conserved B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
that O O
differ O O
between O O
Ig B B_GENE/B_BIO
variable I I_GENE/I_BIO
gene I I_GENE/I_BIO
families I I_GENE/I_BIO
, O O
are O O
required O O
for O O
normal O O
promoter O O
function O O
. O O

These O O
conserved O O
motifs O O
do O O
not O O
stimulate O O
transcription O O
in O O
the O O
absence O O
of O O
an O O
octamer B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

One O O
example O O
is O O
an O O
E-box B B_GENE
of O O
the O O
E47/E12 B B_GENE/B_MEASURE
type I I_GENE/I_MEASURE
( I I_GENE/I_MEASURE
5'-CAGCTG-3 I I_GENE/I_MEASURE
' I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
, O O
which O O
is O O
found O O
in O O
all O O
promoters O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
murine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ig-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subgroups/families I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
the O O
exception O O
of O O
subgroups O O
II O O
and O O
VI O O
and O O
their O O
related O O
murine B B_LOCATION/B_GENE
families I I_LOCATION/I_GENE
. O O

In O O
the O O
present O O
study O O
we O O
show O O
that O O
the O O
ubiquitously O O
expressed O O
transcription B B_GENE
factor I I_GENE
AP-4 I I_GENE
, O O
and O O
not O O
E47 B B_GENE
, O O
interacts O O
specifically O O
with O O
the O O
kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E-boxes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
when O O
tested O O
in O O
electrophoretic O O
mobility-shift O O
assays O O
using O O
nuclear O O
extracts O O
derived O O
from O O
human O O
and O O
murine O O
B-cell O O
lines O O
. O O

Furthermore O O
, O O
AP-4 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
unlike O O
E47 B B_GENE
, O O
did O O
not O O
act O O
as O O
a O O
transactivator B B_GENE
, O O
which O O
is O O
in O O
agreement O O
with O O
previous O O
studies O O
on O O
intact O O
kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
showing O O
that O O
transcription O O
is O O
absent O O
when O O
the O O
octamer B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
has O O
been O O
mutated O O
. O O

Based O O
on O O
these O O
data O O
, O O
and O O
the O O
conservation O O
of O O
the O O
5'-CAGCTG-3 B B_GENE/B_MEASURE
' I I_GENE/I_MEASURE
motif I I_GENE/I_MEASURE
among O O
human B B_GENE/B_PERSON
and I I_GENE/I_PERSON
murine I I_GENE/I_PERSON
kappa I I_GENE/I_PERSON
promoters I I_GENE/I_PERSON
, O O
we O O
propose O O
that O O
AP-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
major B B_PERSON/B_LOCATION
ligand I I_PERSON/I_LOCATION
for O O
Ig-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E-boxes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
16-mer O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RQIKIWFQNRRMKWKK O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
from O O
antennapedia O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
preferentially O O
targets O O
the O O
Class O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I O O
pathway O O
. O O

Translocation O O
of O O
antigenic O O
peptides O O
into O O
the O O
cytosol O O
of O O
antigen O O
presenting O O
cells O O
facilitates O O
proteosomal O O
processing O O
and O O
loading O O
into O O
Class B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
I I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
MHC O O
presentation O O
on O O
the O O
cell O O
surface O O
. O O

The O O
DNA B B_GENE/B_MEASURE
binding I I_GENE/I_MEASURE
domain I I_GENE/I_MEASURE
of O O
the O O
Drosophila B B_GENE
transcription I I_GENE
factor I I_GENE
( O O
Antennapedia B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
a O O
60 B B_GENE
amino I I_GENE
acid I I_GENE
protein I I_GENE
, O O
is O O
rapidly O O
taken O O
up O O
by O O
cells O O
and O O
has O O
been O O
fused O O
to O O
selected O O
antigens B B_GENE/B_DISEASE
to O O
enhance O O
their O O
immunogenicity O O
. O O

We O O
now O O
demonstrate O O
that O O
a O O
16 O B_PROTEIN[GENE]
amino O I_PROTEIN[GENE]
acid O I_PROTEIN[GENE]
peptide O I_PROTEIN[GENE]
from O O
antennapedia O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
can O O
facilitate O O
the O O
cytoplasmic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
uptake O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O O
CTL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
epitope O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
9-mer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
peptides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Synthetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
peptides O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
made O O
containing O O
the O O
16-mer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
antennapedia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
linked O O
in O O
tandem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
the O O
ovalbumin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
SIINFEKL O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CTL O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
peptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
complex O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O O
shown O O
to O O
rapidly O O
internalise O O
into O O
APCs O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
by O O
confocal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
CTL O B_DISEASE/B_GENE
in O O
C57BL/6 O B_SPECIES[BIO]/B_PERSON
mice O I_SPECIES[BIO]/I_PERSON
and O O
protected O O
them O O
against O O
growth O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
an O O
ovalbumin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expressing O O
tumour O B_DISEASE
cell O I_DISEASE
line O I_DISEASE
( O O
E.G7-OVA O B_DISEASE/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

The O O
ability O O
of O O
the O O
hybrid O O
peptide O O
to O O
be O O
processed O O
and O O
presented O O
by O O
APCs O O
was O O
similar O O
, O O
whether O O
the O O
SIINFEKL O O
sequence O O
was O O
appended O O
at O O
the O O
C-terminus B B_LOCATION/B_MEASURE
or O O
N-terminus B B_LOCATION
of O O
the O O
Antennapedia O O
peptide O O
. O O

The O O
production O B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
synthetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
other O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CTL O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
peptide O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
epitopes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
useful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
priming O O
CTLs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]

Bone O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
marrow O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promote O O
TH2 O B_DISEASE
polarization O I_DISEASE
and O O
inhibit O O
virus-specific O B_DISEASE/B_GENE
CTL O I_DISEASE/I_GENE
generation O I_DISEASE/I_GENE
. O O

This O O
laboratory O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recently O O
reported O O
that O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marrow O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BMC O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
inhibit O O
the O O
generation O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
virus-specific O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CTL O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
culture O B_LOCATION/B_SPECIES[BIO]
. O O

The O O
culture O O
supernatants O O
contained O O
increased O O
levels O O
of O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PGE I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
shown O O
to O O
favor O O
TH2 O O
cell O O
development O O
) O O
and O O
also O O
inhibited O O
EBV-CTL O O
effector O O
cell O O
development O O
. O O

In O O
this O O
study O O
, O O
we O O
obtained O O
PBL O O
from O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
IgG B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positive O O
kidney O O
transplant O O
recipients O O
( O O
R O O
) O O
and O O
their O O
living-related O O
donors O O
( O O
LRD O O
) O O
one O O
year O O
after O O
renal O O
transplantation O O
. O O

EBV-specific O B_DISEASE/B_PERSON
CTL O I_DISEASE/I_PERSON
were O O
then O O
generated O O
in O O
vitro O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
stimulating O O
PBL O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
with O O
autologous O B_DISEASE/B_PROTEIN[GENE]
EBV-transformed O B_DISEASE/I_PROTEIN[GENE]
B O B_DISEASE/I_PROTEIN[GENE]
cells O B_DISEASE/I_PROTEIN[GENE]
( O O
EBV-B O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
in O O
the O O
presence O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
absence O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
autologous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
BMC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
addition O O
of O O
BMC O O
to O O
the O O
EBV-CTL O O
generation O O
cultures O O
increased O O
the O O
intracellular O O
expression O O
in O O
CD3+ O O
cells O O
of O O
IL-4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-10 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-13 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
CD3+ O O
cells O O
also O O
expressed O O
increased O O
levels O O
of O O
the O O
TH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
associated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CCR3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
was O O
even O O
observed O O
by O O
preparing O O
EBV-CTL O B_DISEASE/B_MEASURE
generating O O
cultures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
trans-wells O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
separated O O
the O O
autologous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
BMC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
the O O
PBL O B_GENE
+ O O
EBV-B O B_DISEASE/B_LOCATION
. O O

It O O
was O O
then O O
observed O O
that O O
CD3+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
obtained O O
after O O
7 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
culture O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
in O O
the O O
presence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
autologous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
BMC O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
could O O
be O O
used O O
as O O
inhibitors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
EBV-CTL O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
generation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Protein B B_GENE
Kinase I I_GENE
A I I_GENE
( O O
PKA B B_GENE/B_LOCATION
) O O
, O O
a O O
cAMP B B_ENZYME[GENE]/B_LOCATION
kinase I I_ENZYME[GENE]/I_LOCATION
that O O
is O O
involved O O
in O O
the O O
upregulation O O
of O O
TH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
, O O
was O O
increased O O
in O O
EBV-CTL O O
cultures O O
by O O
the O O
presence O O
of O O
BMC O O
. O O

Additionally O O
, O O
IL-4-mediated O O
signal O O
transduction O O
and O O
activation O O
of O O
transcription O O
( O O
STAT-6 B B_GENE/B_LOCATION
) O O
phosphorylation O O
was O O
slightly O O
increased O O
. O O

These O O
results O O
show O O
that O O
the O O
BMC O O
inhibition O O
is O O
mediated O O
by O O
soluble B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
that O O
cell-cell O O
contact O O
in O O
this O O
autologous O O
system O O
is O O
not O O
required O O
, O O
so O O
that O O
BMC O O
( O O
at O O
least O O
partially O O
, O O
via O O
cytokine O O
production O O
) O O
promote O O
TH2 O O
polarization O O
in O O
culture O O
. O O

Moreover O O
, O O
TH2 O O
cells O O
induced O O
by O O
culturing O O
with O O
autologous O O
BMC O O
directly O O
inhibit O O
EBV-CTL O O
generation O O
, O O
and O O
TH2 B B_LOCATION/B_PERSON
associated O O
PKA B B_GENE
, O O
CCR3 B B_GENE/B_LOCATION
, O O
and O O
STAT-6 B B_GENE
phosphorylation O O
are O O
enhanced O O
by O O
BMC O O
. O O

Reduction O O
in O O
DNA O O
binding O O
activity O O
of O O
the O O
transcription B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Pax-5a B I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
B O O
lymphocytes O O
of O O
aged O O
mice O O
. O O

Aging O B_DISEASE/B_LOCATION
has O O
been O O
associated O O
with O O
intrinsic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
humoral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
immune O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
response O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
may O O
lead O O
to O O
an O O
increased O O
occurrence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
autoimmune O B_DISEASE/B_BIO
disorders O I_DISEASE/I_BIO
and O O
pathogenic O B_DISEASE
susceptibility O I_DISEASE
. O O

The O O
transcription B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
factor I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
Pax-5 B I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
is O O
a O O
key O O
regulator O O
of O O
B O O
cell O O
development O O
. O O

Pax-5a/B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell-specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
an O O
alternatively B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
spliced I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoform I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Pax-5d I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
may O O
have O O
opposing O O
functions O O
in O O
transcriptional O O
regulation O O
due O O
to O O
the O O
lack O O
of O O
a O O
transactivation B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
in O O
Pax-5d B B_GENE/B_SPECIES[BIO]
. O O

To O O
study O O
B O O
cell O O
-specific O O
changes O O
that O O
occur O O
during O O
the O O
aging O O
process O O
, O O
we O O
investigated O O
expression O O
patterns O O
of O O
Pax-5a B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5d I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mature O O
B O O
cells O O
of O O
young O O
and O O
aged O O
mice O O
. O O

RNase O O
protection O O
assays O O
showed O O
a O O
similar O O
transcriptional O O
pattern O O
for O O
both O O
age O O
groups O O
that O O
indicates O O
that O O
aging O O
has O O
no O O
affect O O
on O O
transcription O O
initiation O O
or O O
alternative O O
splicing O O
for O O
either O O
isoform B B_GENE/B_LOCATION
. O O

In O O
contrast O O
, O O
a O O
significant O O
reduction O O
in O O
the O O
DNA O O
binding O O
activity O O
of O O
Pax-5a B B_GENE
but O O
not O O
Pax-5d B B_GENE
protein O O
was O O
observed O O
in O O
aged O O
B O O
cells O O
in O O
vitro O O
, O O
while O O
Western O O
blot O O
analyses O O
showed O O
that O O
similar O O
levels O O
of O O
Pax-5a B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5d I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins O O
were O O
present O O
in O O
both O O
age O O
groups O O
. O O

The O O
observed O O
decrease O O
in O O
Pax-5a B B_GENE
binding O O
activity O O
correlated O O
with O O
changes O O
in O O
expression O O
of O O
two O O
Pax-5 B B_GENE/B_LOCATION
target I I_GENE/I_LOCATION
genes I I_GENE/I_LOCATION
in O O
aged O O
B O O
cells O O
. O O

Expression O O
of O O
the O O
Ig B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
secreted O O
form O O
of O O
Ig B B_GENE
mu I I_GENE
, O O
which O O
are O O
both O O
known O O
to O O
be O O
suppressed O O
by O O
Pax-5a B B_GENE
in O O
mature O O
B O O
cells O O
, O O
were O O
increased O O
in O O
B O O
cells O O
of O O
aged O O
mice O O
. O O

Together O O
, O O
our O O
studies O O
suggest O O
that O O
changes O O
associated O O
with O O
the O O
aging O O
phenotype O O
cause O O
posttranslational O O
modification O O
( O O
s O O
) O O
of O O
Pax-5a B B_GENE
but O O
not O O
Pax-5d B B_GENE
, O O
which O O
may O O
lead O O
to O O
an O O
abnormal O O
B O O
cell O O
phenotype O O
in O O
aged O O
mice O O
, O O
associated O O
with O O
elevated O O
levels O O
of O O
J B B_GENE
chain I I_GENE
, O O
and O O
secretion O O
of O O
IgM B B_GENE

NF-kappa B B_PERSON/B_LOCATION
B/Rel I I_PERSON/I_LOCATION
participation O O
in O O
the O O
lymphokine-dependent O O
proliferation O O
of O O
T O O
lymphoid O O
cells O O
. O O

Proliferative O O
responses O O
of O O
lymphoid O O
cells O O
to O O
IL-2 B B_GENE
and O O
IL-4 B B_GENE
depend O O
on O O
activation O O
of O O
the O O
cells O O
, O O
but O O
the O O
mechanism O O
( O O
s O O
) O O
by O O
which O O
activation O O
enhances O O
cellular O O
competence O O
to O O
respond O O
to O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
not O O
fully O O
understood O O
. O O

The O O
NF-kappaB/Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
represents O O
one O O
signal O O
transduction O O
pathway O O
induced O O
during O O
such O O
activation O O
. O O

We O O
show O O
in O O
this O O
study O O
that O O
inhibition O O
of O O
NF-kappaB B B_GENE
through O O
the O O
expression O O
of O O
an O O
IkappaBalpha B B_GENE/B_DISEASE
( O O
inhibitory B B_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
that O O
dissociates O O
from O O
NF-kappaB B B_GENE
) O O
mutant O O
refractory O O
to O O
signal-induced O O
degradation O O
( O O
IkappaBalpha B B_GENE/B_DISEASE
( I I_GENE/I_DISEASE
DeltaN I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
) O O
interfered O O
with O O
the O O
acquisition O O
of O O
competence O O
to O O
proliferate O O
in O O
response O O
to O O
IL-4 B B_GENE
as O O
well O O
as O O
IL-2 B B_GENE
. O O

Thymocytes O O
and O O
T O O
cells O O
from O O
IkappaBalpha B B_GENE/B_PERSON
( I I_GENE/I_PERSON
DeltaN I I_GENE/I_PERSON
) I I_GENE/I_PERSON
transgenic O O
mice O O
expressed O O
normal O O
levels O O
of O O
IL-2R B B_GENE
subunits I I_GENE
. O O

However O O
, O O
transgenic O O
cells O O
exhibited O O
a O O
dramatic O O
defect O O
in O O
Stat5A O O
activation O O
treatment O O
with O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
a O O
similar O O
defect O O
was O O
observed O O
for O O
IL-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
Stat5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

In O O
contrast O O
, O O
T O O
lymphoid O O
cells O O
with O O
inhibition O O
of O O
NF-kappaB B B_GENE
showed O O
normal O O
insulin O O
receptor O O
substrate-2 O O
phosphorylation O O
and O O
only O O
a O O
modest O O
decrease O O
in O O
Stat6 O O
activation O O
and O O
insulin O O
receptor O O
substrate-1 O O
phosphorylation O O
after O O
IL-4 O O
stimulation O O
. O O

These O O
results O O
indicate O O
that O O
the O O
NF-kappaB/Rel/IkappaBalpha O O
system O O
can O O
regulate O O
cytokine B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
receptor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
capacitation O O
through O O
effects O O
on O O
the O O
induction O O
of O O
downstream O O
signaling O O
by O O
the O O
Stat B B_GENE
transcription I I_GENE
factor I I_GENE
family I I_GENE
. O O

BMS-189453 O O
, O O
a O O
novel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
retinoid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
is O O
a O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testicular O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BMS-189453 O O
is O O
a O O
synthetic O O
retinoid O O
that O O
acts O O
as O O
an O O
antagonist O O
at O O
retinoic B B_GENE/B_DISEASE
acid I I_GENE/I_DISEASE
receptors I I_GENE/I_DISEASE
alpha I I_GENE/I_DISEASE
, I I_GENE/I_DISEASE
beta I I_GENE/I_DISEASE
, I I_GENE/I_DISEASE
and I I_GENE/I_DISEASE
gamma I I_GENE/I_DISEASE
. O O

In O O
Sprague O O
Dawley O O
rats O O
at O O
daily O O
oral O O
doses O O
of O O
15 O O
, O O
60 O O
, O O
or O O
240 O O
mg/kg O O
for O O
1 O O
month O O
, O O
BMS-189453 O O
produced O O
increases O O
in O O
leukocyte O O
counts O O
, O O
alkaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
phosphatase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
and O O
alanine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
aminotransferase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
levels O O
, O O
and O O
marked O O
testicular O O
degeneration O O
and O O
atrophy O O
at O O
all O O
doses O O
. O O

Significant O B_DISEASE_ADJECTIVE[DISEASE]
overt O I_DISEASE_ADJECTIVE[DISEASE]
signs O I_DISEASE_ADJECTIVE[DISEASE]
of O O
toxicity O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
deaths O B_DISEASE
occurred O O
at O O
240 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
mg/kg O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
, O O
whereas O O
body-weight O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
food-consumption O B_DISEASE
decreases O I_DISEASE
occurred O O
at O O
60 O B_MEASURE
and O O
240 O B_MEASURE/B_LOCATION
mg/kg O I_MEASURE/I_LOCATION
. O O

When O O
BMS-189453 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
administered O O
to O O
male O B_SPECIES[BIO]/B_PERSON
rats O I_SPECIES[BIO]/I_PERSON
at O O
daily O B_MEASURE/B_LOCATION
doses O I_MEASURE/I_LOCATION
ranging O O
from O O
12.5 O B_TIME[MEASURE]
to O O
100 O B_MEASURE
mg/kg O I_MEASURE
for O O
1 O B_TIME[MEASURE]/B_PERSON
week O B_TIME[MEASURE]/I_PERSON
, O O
only O O
minimal O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testicular O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O O
at O O
all O O
doses O B_TIME[MEASURE]/B_LOCATION
, O O
shortly O O
after O O
the O O
dosing O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
period O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

However O O
, O O
after O O
a O O
1-month O B_TIME[MEASURE]
drug-free O I_TIME[MEASURE]
observation O I_TIME[MEASURE]
period O I_TIME[MEASURE]
, O O
marked O O
testicular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
atrophy O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
all O O
doses O B_TIME[MEASURE]/B_LOCATION
. O O

BMS-189453 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
then O O
administered O O
at O O
doses O B_MEASURE
of O O
2 O B_NUMBER[MEASURE]
, O O
10 O B_MEASURE
, O O
or O O
50 O B_MEASURE
mg/kg O I_MEASURE
to O O
male O B_SPECIES[BIO]/B_PERSON
rats O I_SPECIES[BIO]/I_PERSON
for O O
1 O B_NUMBER[MEASURE]
, O O
3 O B_NUMBER[MEASURE]
, O O
or O O
7 O B_NUMBER[MEASURE]/B_LOCATION
consecutive O I_NUMBER[MEASURE]/I_LOCATION
days O I_NUMBER[MEASURE]/I_LOCATION
. O O

Dose- O B_TIME[MEASURE]/B_PERSON
and O O
duration-dependent O B_DISEASE
testicular O I_DISEASE
toxicity O I_DISEASE
that O O
occurred O O
after O O
a O O
1-month O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
did O O
not O O
recover O O
, O O
and O O
, O O
in O O
some O O
cases O B_PERSON/B_LOCATION
, O O
was O O
more O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
4 O I_DISEASE_ADJECTIVE[DISEASE]
months O I_DISEASE_ADJECTIVE[DISEASE]
after O O
the O O
last O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dose O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
rabbits O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administered O O
BMS-189453 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
oral O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
2 O B_NUMBER[MEASURE]
, O O
10 O B_MEASURE
, O O
or O O
50 O B_MEASURE
mg/kg O I_MEASURE
for O O
1 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
week O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
testicular O B_DISEASE
degeneration O I_DISEASE
and O O
atrophy O B_DISEASE/B_ORGANISM_FUNCTION
were O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
high-dose O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
1 O B_TIME[MEASURE]
month O I_TIME[MEASURE]
following O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

These O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O O
that O O
retinoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonists O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
selectively O O
produce O O
progressive O B_DISEASE_ADJECTIVE[DISEASE]
and O O
prolonged O B_DISEASE
testicular O I_DISEASE
toxicity O I_DISEASE
after O O
single O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
repeated O O
oral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O O
are O O
otherwise O O
well O O
tolerated O O
. O O

Sequential O O
involvement O O
of O O
NFAT B B_GENE
and O O
Egr B B_GENE
transcription B I_GENE
factors I I_GENE
in O O
FasL O O
regulation O O
. O O

The O O
critical O O
function O O
of O O
NFAT B B_GENE
proteins I I_GENE
in O O
maintaining O O
lymphoid O O
homeostasis O O
was O O
revealed O O
in O O
mice O O
lacking O O
both O O
NFATp B B_GENE
and O O
NFAT4 B B_GENE
( O O
DKO O O
) O O
. O O

DKO O O
mice O O
exhibit O O
increased O O
lymphoproliferation O O
, O O
decreased O O
activation-induced O O
cell O O
death O O
, O O
and O O
impaired O O
induction O O
of O O
FasL B B_GENE
. O O

The O O
transcription B B_GENE
factors I I_GENE
Egr2 B I_GENE
and O O
Egr3 B B_GENE
are O O
potent O O
activators O O
of O O
FasL O O
expression O O
. O O

Here O O
we O O
find O O
that O O
Egr2 B B_GENE
and O O
Egr3 B B_GENE
are O O
NFAT B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
target I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
genes I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Activation O O
of O O
FasL B B_GENE
occurs O O
via O O
the O O
NFAT B B_GENE
-dependent O O
induction O O
of O O
Egr3 B B_GENE
, O O
as O O
demonstrated O O
by O O
the O O
ability O O
of O O
exogenously O O
provided O O
NFATp B B_GENE
to O O
restore O O
Egr B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-dependent O O
FasL O O
promoter O O
activity O O
in O O
DKO O O
lymph O O
node O O
cells O O
. O O

Further O O
, O O
Egr3 B B_GENE
expression O O
is O O
enriched O O
in O O
Th1 O O
cells O O
, O O
suggesting O O
a O O
molecular O O
basis O O
for O O
the O O
known O O
preferential O O
expression O O
of O O
FasL B B_GENE
in O O
the O O
Th1 O O
versus O O
Th2 O O
subset O O
. O O

Mechanisms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
clinical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relevance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
nongenomic O B_DISEASE
glucocorticoid O I_DISEASE
actions O I_DISEASE
. O O

Glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O O
profound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti-inflammatory O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
immunosuppressive O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
actions O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
when O O
used O O
therapeutically O O
. O O

The O O
therapeutic O B_MEASURE/B_DISEASE
dose O I_MEASURE/I_DISEASE
is O O
quite O O
variable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
depends O O
on O O
the O O
disease O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
ranges O O
from O O
very O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
extremely O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

The O O
rationale O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
the O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
various O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dosage O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
regimens O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
specific O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indications O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
existence O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
three O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
distinct O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
therapeutically O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
genomic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nongenomic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
unspecific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nongenomic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Genomic O O
effects O O
are O O
mediated O O
by O O
cytosolic B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O O
alter O O
expression O O
of O O
specific O O
genes O O
. O O

Specific O O
nongenomic O O
effects O O
occur O O
within O O
a O O
few O O
minutes O O
and O O
are O O
mediated O O
by O O
steroid-selective B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
membrane I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Unspecific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
nongenomic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
occur O O
within O O
seconds O B_MEASURE/B_BIO
, O O
but O O
only O O
at O O
high O B_TIME[MEASURE]/B_LOCATION
glucocorticoid O I_TIME[MEASURE]/I_LOCATION
dosages O I_TIME[MEASURE]/I_LOCATION
, O O
and O O
seem O O
to O O
result O O
from O O
direct O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
biological O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
membranes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

For O O
unspecific O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nongenomic O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
methylprednisolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
shown O O
to O O
inhibit O O
cation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
cycling O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
across O O
the O O
plasma O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membrane O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
to O O
have O O
little O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
protein O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
synthesis O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

Thus O O
, O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
diminish O O
or O O
prevent O O
the O O
acute O B_DISEASE
immune O I_DISEASE
response O I_DISEASE
by O O
interfering O O
with O O
processes O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
the O O
rise O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
intracellular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Ca2+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
concentration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

It O O
is O O
proposed O O
that O O
the O O
additional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapeutic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
benefit O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
higher O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
obtained O O
via O O
these O O
nongenomic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

High O O
glucose-induced O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
( O O
ICAM-1 B B_GENE/B_DISEASE
) O O
expression O O
through O O
an O O
osmotic O O
effect O O
in O O
rat O O
mesangial O O
cells O O
is O O
PKC-NF-kappa O O
B-dependent O O
. O O

AIMS/HYPOTHESIS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Infiltration O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
mononuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
and O O
glomerular O B_DISEASE
enlargement O I_DISEASE
accompanied O O
by O O
glomerular O B_DISEASE/B_GENE
cell O I_DISEASE/I_GENE
proliferation O I_DISEASE/I_GENE
are O O
very O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
pathophysiology O B_DISEASE
of O O
diabetes O B_DISEASE
. O O

To O O
clarify O O
the O O
mechanism O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
diabetic O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nephropathy O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
we O O
measured O O
[ O O
3H O B_MEASURE/B_BIO
] O B_MEASURE/I_BIO
-thymidine O B_MEASURE/I_BIO
incorporation O B_MEASURE/I_BIO
and O O
cell O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
numbers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
show O O
the O O
influence O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ambient O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
osmotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O O
rat O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mesangial O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
proliferation O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
also O O
measured O O
the O O
effect O O
of O O
high O O
glucose O O
on O O
the O O
expression O O
of O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
and O O
vascular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
by O O
flow O O
cytometry O O
and O O
semiquantitative O O
RT-PCR O O
in O O
mesangial O O
cells O O
and O O
the O O
adhesion O O
of O O
leukocytes O O
to O O
mesangial O O
cells O O
. O O

METHODS/RESULTS O O
: O O
Cells O O
exposed O O
to O O
high O O
D-glucose O O
( O O
30 O O
mmol/l O O
) O O
caused O O
an O O
increase O O
in O O
[ O O
3H O O
] O O
-thymidine O O
incorporation O O
and O O
cell O O
numbers O O
at O O
24 O O
and O O
48 O O
h O O
and O O
normalized O O
at O O
72 O O
h O O
( O O
p O O
< O O
0.05 O O
) O O
, O O
whereas O O
these O O
changes O O
were O O
not O O
found O O
in O O
high O O
mannitol O O
( O O
30 O O
mmol/l O O
) O O
, O O
IL-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
or O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-stimulated O O
mesangial O O
cells O O
. O O

Cells O O
exposed O O
to O O
high-glucose O O
( O O
15 O O
, O O
30 O O
, O O
or O O
60 O O
mmol/l O O
) O O
or O O
osmotic O O
agents O O
( O O
L-glucose O O
, O O
raffinose O O
and O O
mannitol O O
) O O
showed O O
that O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
expression O O
began O O
to O O
increase O O
after O O
24 O O
h O O
, O O
reached O O
its O O
maximum O O
at O O
24 O O
and O O
48 O O
h O O
and O O
gradually O O
decreased O O
afterwards O O
. O O

The O O
stimulatory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
high O B_DISEASE_ADJECTIVE[DISEASE]
glucose O I_DISEASE_ADJECTIVE[DISEASE]
and O O
high O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mannitol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
mRNA O B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_GENE
expression O I_CELL_FUNCTION[ORGANISM_FUNCTION]/I_GENE
were O O
observed O O
as O O
early O O
as O O
6 O B_MEASURE
h O O
and O O
reached O O
its O O
maximum O B_MEASURE/B_LOCATION
at O O
12 O B_MEASURE
h O O
. O O

Up-regulation O O
of O O
ICAM-1 B B_GENE
protein O O
and O O
mRNA O O
was O O
also O O
found O O
in O O
IL-1-beta B B_DISEASE_ADJECTIVE[DISEASE]
and O O
TNF-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
-stimulated O O
mesangial O O
cells O O
. O O

Neither O O
vascular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
protein O O
nor O O
mRNA O O
expression O O
was O O
, O O
however O O
, O O
affected O O
by O O
high O O
glucose O O
and O O
high O O
mannitol O O
. O O

Notably O O
, O O
the O O
protein O O
kinase O O
C O O
inhibitors O O
calphostin O O
C O O
and O O
staurosporine O O
reduced O O
high O O
glucose- O O
or O O
high O O
mannitol-induced O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
mRNA O O
expression O O
and O O
high O O
glucose-induced O O
proliferation O O
. O O

Furthermore O O
, O O
the O O
NF-kappa O O
B O O
inhibitor O O
N-tosyl-L-phenylalanine O O
chloromethyl O O
ketone O O
reduced O O
high O O
glucose- O O
or O O
high O O
mannitol-induced O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
mRNA O O
expression O O
and O O
high O O
glucose-induced O O
proliferation O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O O
that O O
high O B_DISEASE_ADJECTIVE[DISEASE]
glucose O I_DISEASE_ADJECTIVE[DISEASE]
( O O
15 O B_MEASURE
, O O
30 O B_MEASURE
mmol/l O I_MEASURE
) O O
or O O
high O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
concentrations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
osmotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
remarkably O O
increased O O
the O O
number O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
adherent O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leukocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
mesangial O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O B_MEASURE/B_LOCATION
< O B_MEASURE/I_LOCATION
0.01 O B_MEASURE/I_LOCATION
) O O
compared O O
with O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mmol/l O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D-glucose O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Functional O O
blocking O O
of O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
on O O
mesangial O O
cells O O
with O O
rat B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
intercellular I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecule-1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
monoclonal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
calphostin O O
C O O
, O O
staurosporine O O
, O O
or O O
N-tosyl-L-phenylalanine O O
chloromethyl O O
ketone O O
significantly O O
inhibited O O
high O O
glucose- O O
or O O
high O O
mannitol-induced O O
increase O O
in O O
leukocyte O O
adhesion O O
( O O
p O O
< O O
< O O
0.05 O O
) O O
. O O

CONCLUSION/INTERPRETATION O O
: O O
These O O
results O O
suggest O O
that O O
high O O
glucose O O
can O O
upregulate O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
protein O O
and O O
mRNA O O
expression O O
but O O
not O O
vascular O O
adhesion O O
molecule-1 O O
expression O O
in O O
mesangial O O
cells O O
and O O
promote O O
leukocyte O O
adhesion O O
through O O
up-regulation O O
of O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
through O O
osmotic O O
effect O O
, O O
possibly O O
depending O O
on O O
the O O
protein B B_GENE/B_LOCATION
kinase I I_GENE/I_LOCATION
C I I_GENE/I_LOCATION
nuclear B I_GENE/I_LOCATION
factor-kappa I I_GENE/I_LOCATION
B I I_GENE/I_LOCATION
( O O
PKC B B_GENE
- O O
NF-kappa B B_PROTEIN[GENE]/B_LOCATION
B I I_PROTEIN[GENE]/I_LOCATION
) O O
pathway O O
. O O

High O B_DISEASE/B_GENE
glucose O B_DISEASE/I_GENE
itself O O
can O O
also O O
promote O O
mesangial O B_DISEASE/B_GENE
cell O I_DISEASE/I_GENE
proliferation O I_DISEASE/I_GENE
through O O
the O O
PKC-NF-kappa O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
B O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
pathways O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

We O O
conclude O O
that O O
hyperglycaemia O B_DISEASE
in O O
itself O O
seems O O
to O O
be O O
an O O
important O B_DISEASE_ADJECTIVE[DISEASE]
factor O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
early O B_DISEASE
diabetic O I_DISEASE
nephropathy O I_DISEASE
. O O

Combined O O
corticosteroid/ O O
granulocyte B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
colony-stimulating I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
G-CSF B B_LOCATION/B_GENE
) O O
therapy O O
in O O
the O O
treatment O O
of O O
severe O O
congenital O O
neutropenia O O
unresponsive O O
to O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Activated O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synergize O O
with O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
signals O O
. O O

More O O
than O O
90 O O
% O O
of O O
patients O O
with O O
severe O O
congenital O O
neutropenia O O
( O O
SCN O O
) O O
respond O O
to O O
granulocyte B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
G-CSF B B_LOCATION/B_ORGANIZATION
) O O
therapy O O
. O O

The O O
basis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
refractory O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
state O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
remaining O O
patients O B_PERSON/B_BIO
is O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
address O O
this O O
issue O O
, O O
we O O
studied O O
a O O
child O O
with O O
SCN O O
who O O
was O O
totally O O
unresponsive O O
to O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
had O O
a O O
novel O O
point O O
mutation O O
in O O
the O O
extracellular B B_GENE
domain I I_GENE
of O O
the O O
G-CSF B B_GENE
receptor I I_GENE
( O O
GCSF-R B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Marrow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stromal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
support O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
granulopoiesis O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
evaluated O O
by O O
plating O O
CD34 O B_GENE
( O O
+ O B_OTHER/B_DISEASE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
on O O
preformed O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stromal O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
layers O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Nonadherent O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
were O O
harvested O O
and O O
assayed O O
in O O
clonogenic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assays O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
granulocytic O B_DISEASE_ADJECTIVE[DISEASE]
colony O I_DISEASE_ADJECTIVE[DISEASE]
production O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
in O O
vitro O O
effect O O
of O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
corticosteroids O O
on O O
granulopoiesis O O
was O O
evaluated O O
in O O
clonogenic O O
assays O O
of O O
marrow O O
mononuclear O O
cells O O
, O O
by O O
proliferation O O
studies O O
of O O
the O O
murine O O
myeloid O O
cell O O
line O O
32D O O
expressing O O
the O O
patient O O
's O O
mutated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
G-CSFR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
by O O
measuring O O
STAT5 O O
activation O O
in O O
nuclear O O
extracts O O
from O O
stimulated O O
cells O O
. O O

Patient O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
's O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stroma O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supported O O
granulopoiesis O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
derived O O
from O O
control O B_GENE
marrow O I_GENE
CD34 O I_GENE
( O O
+ O B_OTHER/B_DISEASE
) O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
a O O
normal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
manner O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Normal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
stroma O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
however O O
, O O
failed O O
to O O
induce O O
granulopoiesis O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
patient O B_GENE
's O I_GENE
CD34 O I_GENE
( O O
+ O B_OTHER/B_DISEASE
) O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Clonogenic O O
assays O O
of O O
the O O
patient O O
's O O
marrow O O
mononuclear O O
cells O O
incorporating O O
either O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
hydrocortisone O O
produced O O
little O O
neutrophil O O
growth O O
. O O

In O O
contrast O O
, O O
inclusion O O
of O O
both O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
hydrocortisone O O
in O O
the O O
cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
`` I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocktail I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
'' I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markedly O O
increased O O
the O O
neutrophil O O
numbers O O
. O O

Proliferation O O
of O O
32D O O
cells O O
expressing O O
the O O
mutated B B_GENE
receptor I I_GENE
and O O
STAT5 O O
activation O O
were O O
improved O O
by O O
a O O
combination O O
of O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dexamethasone O O
. O O

When O O
small O O
daily O O
doses O O
of O O
oral O O
prednisone O O
were O O
then O O
administered O O
to O O
the O O
patient O O
with O O
conventional O O
doses O O
of O O
subcutaneous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G-CSF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
patient O O
responded O O
with O O
increased O O
neutrophil O O
numbers O O
and O O
with O O
a O O
complete O O
reversal O O
of O O
the O O
infectious O O
problems O O
. O O

These O O
data O O
provide O O
insight O O
into O O
SCN O O
unresponsive O O
to O O
standard O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
and O O
to O O
the O O
potential O O
corrective O O
action O O
of O O
combined O O
treatment O O
with O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
corticosteroids O O
through O O
synergistic O O
activation O O
of O O
STAT5 B B_GENE
. O O

Human O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
renal O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mesangial O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
a O O
target O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
anti-inflammatory O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
action O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
9-cis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retinoic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mesangial O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
play O O
an O O
active O B_DISEASE_ADJECTIVE[DISEASE]
role O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
to O O
glomerular O B_DISEASE
injury O I_DISEASE
. O O

We O O
have O O
studied O O
in O O
cultured O O
human O O
mesangial O O
cells O O
( O O
CHMC O O
) O O
several O O
effects O O
of O O
9-cis O O
retinoic O O
acid O O
( O O
9-cRA O O
) O O
, O O
an O O
activator O O
of O O
both O O
retinoic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
RARs B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
retinoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RXRs B B_LOCATION/B_ORGANIZATION
) O O
. O O

9-cRA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O O
foetal O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
calf O I_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
serum-induced O O
CHMC O B_DISEASE_ADJECTIVE[DISEASE]
proliferation O I_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
also O O
prevented O O
CHMC O B_DISEASE/B_GENE
death O I_DISEASE/I_GENE
induced O O
by O O
the O O
inflammatory O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
mediator O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
H O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
( O O
2 O B_NUMBER[MEASURE]/B_LOCATION
) O O
O O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

This O O
preventive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
due O O
to O O
any O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
H O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
2 O B_MEASURE/B_LOCATION
) O O
O O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O B_NUMBER[MEASURE]/B_LOCATION
) O O
catabolism O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
it O O
persisted O O
even O O
when O O
both O O
catalase O B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
glutathione O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthesis O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
inhibited O O
. O O

Finally O O
, O O
9-cRA O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diminished O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monocyte O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adhesion O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
FCS-stimulated O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CHMC O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Interestingly O O
, O O
the O O
retinoid O O
also O O
inhibited O O
in O O
FCS-stimulated O O
cells O O
the O O
protein O O
expression O O
of O O
two O O
mesangial B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adhesion I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
fibronectin B B_GENE
and O O
osteopontin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
it O O
did O O
not O O
modify O O
the O O
protein O O
expression O O
of O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
and O O
vascular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
. O O

All O O
major O O
RARs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RXRs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isotypes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
expressed O O
in O O
CHMC O O
regardless O O
of O O
the O O
presence O O
or O O
absence O O
of O O
9-cRA O O
. O O

Transcripts O O
to O O
RAR-alpha B B_GENE
, O O
RAR-beta B B_GENE
and O O
RXR-alpha B B_GENE/B_LOCATION
increased O O
after O O
incubation O O
with O O
9-cRA O O
whereas O O
RXR-gamma B B_GENE
was O O
inhibited O O
, O O
suggesting O O
a O O
major O O
role O O
for O O
RARs B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
RXRs B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
9-cRA-anti-inflammatory O O
effects O O
. O O

9-cRA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
toxic O B_DISEASE_ADJECTIVE[DISEASE]
only O O
at O O
50 O B_NUMBER[MEASURE]
microM O O
( O O
a O O
concentration O B_MEASURE
50 O I_MEASURE
- O O
5000 O B_MEASURE
times O I_MEASURE
higher O I_MEASURE
than O O
required O O
for O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
above O O
) O O
. O O

Cell O B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
death O I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
occurred O O
by O O
apoptosis O B_DISEASE/B_GENE
, O O
whose O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
associated O O
with O O
a O O
pronounced O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
catalase O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
reduced O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
glutathione O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
content O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
being O O
more O O
effectively O O
induced O O
by O O
all-trans O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
retinoic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Modulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
oxidant/antioxidant O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
balance O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
failed O O
to O O
inhibit O O
apoptosis O B_DISEASE
. O O

We O O
conclude O O
that O O
mesangial O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
might O O
be O O
a O O
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
for O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
inflammatory O B_DISEASE
glomerulopathies O I_DISEASE
with O O
9-cRA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Expression O O
of O O
mammalian B B_GENE
defensin I I_GENE
genes I I_GENE
. O O

Antimicrobial O B_PERSON/B_DISEASE
peptides O I_PERSON/I_DISEASE
are O O
a O O
prevalent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanism O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
host O B_DISEASE
defense O I_DISEASE
found O O
throughout O O
nature O B_BIO/B_DISEASE
. O O

In O O
mammals O O
, O O
defensins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
are O O
among O O
the O O
most O O
abundant O O
of O O
these O O
broad-spectrum O O
antibiotics O O
, O O
and O O
are O O
expressed O O
in O O
epithelial O O
and O O
hematopoietic O O
cells O O
. O O

The O O
defensin O B_GENE/B_BIO
peptides O I_GENE/I_BIO
are O O
especially O O
abundant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
neutrophils O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O O
however O O
, O O
gene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
limited O O
to O O
the O O
promyelocyte O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
stage O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
epithelial O O
cells O O
, O O
defensin B B_GENE/B_BIO
genes I I_GENE/I_BIO
are O O
found O O
as O O
both O O
constitutively O O
expressed O O
and O O
inducible O O
. O O

Induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
has O O
been O O
observed O O
in O O
vitro O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
bacterial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
lipopolysaccharide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
as O O
well O O
as O O
inflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mediators O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
vivo O O
, O O
up-regulation O O
of O O
several O O
defensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
occurs O O
in O O
both O O
infectious O O
and O O
inflammatory O O
states O O
. O O

Gene O O
regulation O O
occurs O O
via O O
signal O O
transduction O O
pathways O O
common O O
to O O
other O O
innate O O
immune O O
responses O O
, O O
utilizing O O
transcription B B_GENE
factors I I_GENE
such O O
as O O
nuclear B B_GENE
factor I I_GENE
( I I_GENE
NF I I_GENE
) I I_GENE
-kappaB I I_GENE
and O O
NF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interleukin-6 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Together O O
, O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
suggest O O
a O O
broad-based O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
innate O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
host O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
defense O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
whereby O O
potent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
antimicrobial O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
peptides O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
present O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
prevent O O
initial O B_DISEASE_ADJECTIVE[DISEASE]
colonization O I_DISEASE_ADJECTIVE[DISEASE]
by O O
pathogenic O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
microorganisms O I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
recognition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
bacteria O B_BIO/B_DISEASE
coupled O O
with O O
a O O
nascent O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
response O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
can O O
bolster O O
this O O
defense O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O O
a O O
coordinated O B_MEASURE
up-regulation O I_MEASURE
of O O
the O O
peptides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Multiple O O
signals O O
required O O
for O O
cyclic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AMP-responsive I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CREB B B_GENE/B_LOCATION
) O O
binding O O
protein O O
interaction O O
induced O O
by O O
CD3/CD28 O O
costimulation O O
. O O

The O O
optimal O O
activation O O
of O O
cAMP-responsive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CREB B B_GENE/B_LOCATION
) O O
, O O
similar O O
to O O
the O O
full O O
activation O O
of O O
T O O
lymphocytes O O
, O O
requires O O
the O O
stimulation O O
of O O
both O O
CD3 B B_GENE
and O O
CD28 B B_GENE
. O O

Using O O
a O O
reporter O O
system O O
to O O
detect O O
interaction O O
of O O
CREB B B_GENE
and O O
CREB-binding B B_GENE
protein I I_GENE
( O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
in O O
this O O
study O O
we O O
found O O
that O O
CREB B B_GENE
binds O O
to O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
by O O
engagement O O
of O O
both O O
CD3 B B_GENE
and O O
CD28 B B_GENE
. O O

CD3/CD28 B B_GENE
-promoted O O
CREB B B_GENE/B_LOCATION
- O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O O
was O O
dependent O O
on O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAPK B B_GENE/B_LOCATION
) O O
and O O
calcium/calmodulin-dependent B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CaMK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
addition O O
to O O
the O O
previously O O
identified O O
extracellular O O
signal-regulated O O
kinase O O
pathway O O
. O O

Extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CaMKIV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
p38 B B_GENE
MAPK I I_GENE
were O O
also O O
the O O
kinases O O
involved O O
in O O
CREB B B_GENE
Ser O O
( O O
133 O O
) O O
phosphorylation O O
induced O O
by O O
CD3/CD28 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
reconstitution O O
experiment O O
illustrated O O
that O O
optimum O O
CREB B B_GENE
- O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O O
and O O
CREB B B_GENE
trans-activation O O
were O O
attained O O
when O O
these O O
three O O
kinase O O
pathways O O
were O O
simultaneously O O
activated O O
in O O
T O O
cells O O
. O O

Our O O
results O O
demonstrate O O
that O O
coordinated O O
activation O O
of O O
different O O
kinases B B_GENE/B_LOCATION
leads O O
to O O
full O O
activation O O
of O O
CREB B B_GENE
. O O

Notably O O
, O O
CD28 O O
ligation O O
activated O O
p38 B B_GENE
MAPK I I_GENE
and O O
CaMKIV B B_GENE
, O O
the O O
kinases B B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O O
by O O
CD3 O O
engagement O O
, O O
suggesting O O
that O O
CD28 B B_GENE
acts O O
by O O
increasing O O
the O O
activation O O
extent O O
of O O
p38 B B_GENE
MAPK I I_GENE
and O O
CaMKIV B B_GENE
. O O

These O O
results O O
support O O
the O O
model O O
of O O
a O O
minimum O O
activation O O
threshold O O
for O O
CREB B B_GENE
- O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O O
that O O
can O O
be O O
reached O O
only O O
when O O
both O O
CD3 B B_GENE
and O O
CD28 B B_GENE
are O O
stimulated O O
. O O

The O O
murine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL-2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
distal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
responsive O O
to O O
the O O
Ah B B_GENE
receptor I I_GENE
, O O
a O O
member O O
of O O
the O O
evolutionarily O O
conserved O O
bHLH-PAS B B_GENE/B_LOCATION
transcription I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
family I I_GENE/I_LOCATION
. O O

Signaling O O
through O O
the O O
TCR B B_GENE
and O O
costimulatory O O
signals O O
primarily O O
control O O
transcription O O
of O O
the O O
IL-2 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
in O O
naive O O
T O O
cells O O
. O O

The O O
minimal B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
necessary O O
for O O
this O O
expression O O
lies O O
proximal O O
, O O
between O O
-300 O O
and O O
the O O
transcription B B_GENE/B_LOCATION
start I B_GENE/I_LOCATION
site I B_GENE/I_LOCATION
. O O

We O O
had O O
previously O O
shown O O
that O O
activation O O
of O O
the O O
arylhydrocarbon B B_GENE/B_PERSON
receptor I I_GENE/I_PERSON
( O O
AHR B B_LOCATION/B_ORGANIZATION
) O O
, O O
a O O
member O O
of O O
the O O
bHLH-PAS B B_GENE/B_MEASURE
family I I_GENE/I_MEASURE
of I I_GENE/I_MEASURE
transcription I I_GENE/I_MEASURE
factors I I_GENE/I_MEASURE
, O O
leads O O
to O O
increased O O
mRNA O O
expression O O
of O O
IL-2 B B_GENE
in O O
murine O O
fetal O O
thymocytes O O
. O O

The O O
AHR B B_GENE/B_DISEASE
is O O
abundant O O
in O O
the O O
thymus O O
and O O
may O O
play O O
a O O
role O O
for O O
the O O
development O O
of O O
the O O
immune O O
system O O
. O O

Moreover O O
, O O
its O O
overactivation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
chemicals O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
such O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O O
dioxins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
leads O O
to O O
immunosuppression O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
thymic O B_DISEASE
involution O I_DISEASE
. O O

Binding O O
motifs O O
for O O
the O O
liganded B B_GENE/B_BACTERIUM[BIO]
AHR I I_GENE/I_BACTERIUM[BIO]
can O O
be O O
identified O O
in O O
the O O
distal B B_LOCATION/B_BIO
region I I_LOCATION/I_BIO
-1300 I I_LOCATION/I_BIO
to I I_LOCATION/I_BIO
-800 I I_LOCATION/I_BIO
of O O
the O O
mouse B B_GENE/B_LOCATION
IL-2 I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
. O O

We O O
show O O
here O O
that O O
these O O
DNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
motifs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
so-called O O
dioxin B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elements I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
after O O
binding O O
to O O
the O O
liganded B B_GENE/B_BACTERIUM[BIO]
AHR I I_GENE/I_BACTERIUM[BIO]
are O O
sufficient O O
to O O
transactivate O O
luciferase O O
expression O O
in O O
a O O
reporter O O
gene O O
system O O
. O O

The O O
IL-2 B B_GENE/B_DISEASE
gene I I_GENE/I_DISEASE
can O O
be O O
induced O O
by O O
the O O
AHR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O O
in O O
thymocytes O O
in O O
vivo O O
after O O
injection O O
of O O
2 O O
, O O
3 O O
, O O
7 O O
, O O
8-tetrachlorodibenzo-p-dioxin O O
, O O
a O O
potent O O
ligand O O
of O O
the O O
AHR B B_GENE/B_DISEASE
. O O

The O O
AHR B B_GENE/B_DISEASE
mediates O O
the O O
IL-2 O O
induction O O
as O O
shown O O
with O O
AHR B B_GENE/B_DISEASE
-deficient O O
mice O O
. O O

However O O
, O O
in O O
spleen O O
cells O O
in O O
vitro O O
costimulation O O
via O O
the O O
TCR B B_GENE
is O O
necessary O O
for O O
optimal O O
IL-2 B B_GENE
gene I I_GENE
induction O O
. O O

Thus O O
, O O
the O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
novel O O
distal B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
regulatory I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
elements I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
that O O
can O O
be O O
addressed O O
by O O
the O O
AHR B B_DISEASE/B_GENE
to O O
induce O O
IL-2 B B_GENE/B_DISEASE
and O O
can O O
cooperate O O
with O O
the O O
proximal B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION

Visualization O O
of O O
Syk-antigen B B_GENE/B_BIO
receptor I I_GENE/I_BIO
interactions O O
using O O
green B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
differential O O
roles O O
for O O
Syk B B_GENE/B_PERSON
and O O
Lyn B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
regulation O O
of O O
receptor O O
capping O O
and O O
internalization O O
. O O

The O O
cross-linking O O
of O O
the O O
B B B_GENE
cell I I_GENE
Ag I I_GENE
receptor I I_GENE
( O O
BCR B B_LOCATION/B_ORGANIZATION
) O O
is O O
coupled O O
to O O
the O O
stimulation O O
of O O
multiple O O
intracellular O O
signal O O
transduction O O
cascades O O
via O O
receptor-associated O O
, O O
protein B B_GENE/B_BIO
tyrosine I I_GENE/I_BIO
kinases I I_GENE/I_BIO
of O O
both O O
the O O
Src B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
Syk I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
families I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

To O O
monitor O O
changes O O
in O O
the O O
subcellular O O
distribution O O
of O O
Syk B B_GENE/B_BACTERIUM[BIO]
in O O
B O O
cells O O
responding O O
to O O
BCR B B_GENE
cross-linking O O
, O O
we O O
expressed O O
in O O
Syk B B_GENE/B_BACTERIUM[BIO]
-deficient O O
DT40 O O
B O O
cells O O
a O O
fusion B B_GENE
protein I I_GENE
consisting O O
of O O
Syk B B_GENE/B_BACTERIUM[BIO]
coupled O O
to O O
green B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Treatment O O
of O O
these O O
cells O O
with O O
anti-IgM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Abs I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
leads O O
to O O
the O O
recruitment O O
of O O
the O O
kinase B B_GENE
from O O
cytoplasmic O O
and O O
nuclear O O
compartments O O
to O O
the O O
site O O
of O O
the O O
cross-linked B B_GENE
receptor I I_GENE
at O O
the O O
plasma O O
membrane O O
. O O

The O O
Syk-receptor B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
aggregate O O
into O O
membrane O O
patches O O
that O O
redistribute O O
to O O
form O O
a O O
cap O O
at O O
one O O
pole O O
of O O
the O O
cell O O
. O O

Syk B B_GENE/B_BACTERIUM[BIO]
is O O
not O O
demonstrably O O
associated O O
with O O
the O O
internalized B B_DISEASE/B_GENE
receptor I I_DISEASE/I_GENE
. O O

Catalytically O O
active O O
Syk B B_GENE/B_BACTERIUM[BIO]
promotes O O
and O O
stabilizes O O
the O O
formation O O
of O O
tightly B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
capped I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
BCR I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
the O O
plasma O O
membrane O O
. O O

Lyn B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
not O O
required O O
for O O
the O O
recruitment O O
of O O
Syk B B_GENE/B_BACTERIUM[BIO]
to O O
the O O
cross-linked B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O O
but O O
is O O
required O O
for O O
the O O
internalization O O
of O O
the O O
clustered O O
BCR B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
absence O O
of O O
Lyn B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
receptor-Syk B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complexes I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
at O O
the O O
plasma O O
membrane O O
are O O
long O O
lived O O
, O O
and O O
the O O
receptor-mediated O O
activation O O
of O O
the O O
NF-AT B B_GENE
transcription I I_GENE
factor I I_GENE
is O O
enhanced O O
. O O

Thus O O
, O O
Lyn B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
appears O O
to O O
function O O
to O O
negatively O O
regulate O O
aspects O O
of O O
BCR B B_GENE
-dependent O O
signaling O O
by O O
stimulating O O
receptor O O
internalization O O
and O O
down-regulation O O
. O O

Renal O O
interstitial O O
fibrosis O O
is O O
reduced O O
in O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1a I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-deficient O O
mice O O
. O O

Unilateral O B_DISEASE
ureteral O I_DISEASE
obstruction O I_DISEASE
( O O
UUO O B_LOCATION/B_ORGANIZATION
) O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
tubulointerstitial O B_DISEASE_ADJECTIVE[DISEASE]
fibrosis O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
affected O O
kidney O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
by O O
stimulating O O
the O O
renin-angiotensin O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
study O O
established O O
a O O
UUO O O
model O O
in O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1a I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AT1a B B_PROTEIN[GENE]/B_LOCATION
) O O
deficient O O
( O O
mutant O O
) O O
mice O O
to O O
elucidate O O
the O O
role O O
of O O
angiotensin B B_DISEASE/B_GENE
II I B_DISEASE/I_GENE
through O O
AT1a B B_GENE
on O O
the O O
fibrosis O O
of O O
the O O
obstructed O O
kidney O O
( O O
OBK O O
) O O
. O O

The O O
relative O O
volume O O
of O O
the O O
tubulointerstitium O O
was O O
measured O O
by O O
an O O
image O O
analyzer O O
; O O
deposition O O
of O O
collagen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
types I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
III I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
monocyte O O
/ O O
macrophage O O
infiltration O O
were O O
histologically O O
examined O O
using O O
specific B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Also O O
determined O O
were O O
the O O
mRNA O O
levels O O
of O O
transforming B B_GENE
growth I I_GENE
factor-beta I I_GENE
by O O
Northern O O
blot O O
analysis O O
. O O

Nuclear B B_GENE
factor-kappaB I I_GENE
activity O O
was O O
assessed O O
by O O
gel O O
shift O O
assay O O
. O O

UUO O O
in O O
wild O O
mice O O
resulted O O
in O O
a O O
marked O O
expansion O O
of O O
relative O O
volume O O
of O O
the O O
tubulointerstitium O O
, O O
together O O
with O O
increased O O
deposition O O
of O O
collagen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
types I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
III I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
number O O
of O O
infiltrated O O
monocytes O O
/ O O
macrophages O O
in O O
the O O
interstitium O O
, O O
relative O O
to O O
sham-operated O O
mice O O
. O O

In O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
these O O
changes O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
significantly O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
mutant O B_PERSON/B_MEASURE
mice O I_PERSON/I_MEASURE
with O O
UUO O B_DISEASE
. O O

The O O
mRNA O O
level O O
of O O
transforming B B_GENE
growth I I_GENE
factor-beta I I_GENE
was O O
significantly O O
higher O O
in O O
the O O
OBK O O
of O O
wild O O
mice O O
with O O
UUO O O
compared O O
with O O
sham-operated O O
mice O O
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
mRNA O B_MEASURE
level O I_MEASURE
in O O
the O O
OBK O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mutant O B_BIO/B_GENE
mice O I_BIO/I_GENE
was O O
significantly O O
less O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
in O O
wild O B_BIO/B_PERSON
mice O I_BIO/I_PERSON
. O O

Finally O O
, O O
UUO O O
resulted O O
in O O
activation O O
of O O
nuclear B B_GENE
factor-kappaB I I_GENE
in O O
wild O O
mice O O
but O O
was O O
inhibited O O
in O O
the O O
OBK O O
of O O
mutant O O
mice O O
. O O

The O O
results O O
provide O O
direct O O
evidence O O
that O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acting O O
via O O
the O O
AT1a B B_PROTEIN[GENE]/B_LOCATION
plays O O
a O O
pivotal O O
role O O
in O O
the O O
development O O
of O O
tubulointerstitial O O
fibrosis O O
in O O
UUO O O
. O O

HLA-DQ B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
tetramers I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
identify O O
epitope-specific O O
T O O
cells O O
in O O
peripheral O O
blood O O
of O O
herpes O O
simplex O O
virus O O
type O O
2-infected O O
individuals O O
: O O
direct O O
detection O O
of O O
immunodominant O O
antigen-responsive O O
cells O O
. O O

Ag-specific O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CD4+ O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
peripheral O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
blood O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
in O O
low O B_DISEASE/B_BIO
frequency O I_DISEASE/I_BIO
, O O
where O O
they O O
undergo O O
recruitment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
expansion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
during O O
immune O B_DISEASE/B_ORGANISM_FUNCTION
responses O I_DISEASE/I_ORGANISM_FUNCTION
and O O
in O O
the O O
pathogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
numerous O B_DISEASE/B_LOCATION
autoimmune O I_DISEASE/I_LOCATION
diseases O I_DISEASE/I_LOCATION
. O O

MHC B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tetramers I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
which O O
constitute O O
a O O
labeled B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
MHC-peptide I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
ligand I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
suitable O O
for O O
binding O O
to O O
the O O
Ag-specific B B_GENE
receptor I I_GENE
on O O
T O O
cells O O
, O O
provide O O
a O O
novel O O
approach O O
for O O
the O O
detection O O
and O O
characterization O O
of O O
such O O
rare O O
cells O O
. O O

In O O
this O O
study O O
, O O
we O O
utilized O O
this O O
technology O O
to O O
identify O O
HLA B B_GENE
DQ I I_GENE
-restricted O O
Ag-specific O O
T O O
cells O O
in O O
the O O
peripheral O O
blood O O
of O O
human O O
subjects O O
and O O
to O O
identify O O
immunodominant O O
epitopes O O
associated O O
with O O
viral O O
infection O O
. O O

Peptides O O
representing O O
potential O O
epitope B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regions I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
VP16 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
HSV-2 O O
were O O
loaded O O
onto O O
recombinant B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DQ0602 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecules I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
generate O O
a O O
panel O O
of O O
Ag-specific B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DQ0602 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetramers I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

VP16 B B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Ag I I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
-specific O O
DQ-restricted O O
T O O
cells O O
were O O
identified O O
and O O
expanded O O
from O O
the O O
peripheral O O
blood O O
of O O
HSV-2-infected O O
individuals O O
, O O
representing O O
two O O
predominant O O
epitope O O
specificities O O
. O O

Although O O
the O O
VP16 O O
369-380 O O
peptide O O
has O O
a O O
lower O O
binding O O
affinity O O
for O O
DQ0602 B B_GENE
molecules I I_GENE
than O O
the O O
VP16 O O
33-52 O O
peptide O O
, O O
T O O
cells O O
that O O
recognized O O
the O O
VP16 O O
369-380 O O
peptide O O
occurred O O
at O O
a O O
much O O
higher O O
frequency O O
than O O
those O O
that O O
were O O
specific O O
for O O
the O O
VP16 O O
33-52 O O
peptide O O
. O O

Down-regulation O O
of O O
BOB.1/OBF.1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Oct2 B B_GENE
in O O
classical O O
Hodgkin O O
disease O O
but O O
not O O
in O O
lymphocyte O O
predominant O O
Hodgkin O O
disease O O
correlates O O
with O O
immunoglobulin O O
transcription O O
. O O

In O O
contrast O O
to O O
the O O
tumor O O
cells O O
( O O
L O O
& O O
H O O
cells O O
) O O
of O O
lymphocyte O O
predominant O O
Hodgkin O O
disease O O
( O O
LPHD O O
) O O
, O O
Hodgkin O O
and O O
Reed-Sternberg O O
( O O
HRS O O
) O O
cells O O
of O O
classical O O
Hodgkin O O
disease O O
( O O
cHD O O
) O O
are O O
unable O O
to O O
transcribe O O
immunoglobulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
despite O O
the O O
presence O O
of O O
rearranged B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
immunoglobulin I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Although O O
initial O O
studies O O
have O O
suggested O O
crippling O O
immunoglobulin O O
gene O O
mutations O O
to O O
be O O
the O O
cause O O
of O O
absent O O
immunoglobulin O O
expression O O
in O O
cHD O O
, O O
recent O O
work O O
of O O
our O O
group O O
has O O
demonstrated O O
an O O
impaired O O
activation O O
of O O
the O O
immunoglobulin B B_GENE
promoter I I_GENE
as O O
a O O
superior O O
mechanism O O
. O O

As O O
immunoglobulin O O
transcription O O
is O O
mainly O O
regulated O O
by O O
the O O
B-cell B B_GENE
transcription I I_GENE
factors I I_GENE
Oct2 B I_GENE
and O O
BOB.1/OBF.1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
analyzed O O
35 O O
cases O O
of O O
LPHD O O
, O O
32 O O
cases O O
of O O
cHD O O
, O O
and O O
2 O O
Hodgkin O O
disease O O
cell O O
lines O O
for O O
the O O
expression O O
of O O
these O O
transcription B B_GENE
factors I I_GENE
and O O
also O O
in O O
parallel O O
for O O
immunoglobulin O O
expression O O
. O O

Our O O
results O O
demonstrate O O
an O O
absence O O
of O O
Oct2 B B_GENE/B_DISEASE
and/or O O
BOB.1/OBF.1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cHD O O
and O O
a O O
striking O O
overexpression O O
of O O
Oct2 B B_GENE
in O O
LPHD O O
. O O

Immunoglobulin O B_GENE/B_DISEASE
expression O B_GENE/I_DISEASE
was O O
lacking O O
in O O
cHD O B_DISEASE
but O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
LPHD O B_DISEASE
. O O

Furthermore O O
, O O
the O O
reintroduction O O
of O O
BOB.1/OBF.1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Oct2 B B_GENE
into O O
cultured O O
HRS O O
cells O O
restored O O
the O O
activity O O
of O O
cotransduced O O
immunoglobulin B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
constructs I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Our O O
findings O O
dismiss O O
the O O
concept O O
that O O
the O O
different O O
immunoglobulin O O
expression O O
in O O
cHD O O
and O O
LPHD O O
is O O
due O O
to O O
disrupting O O
mutations O O
of O O
immunoglobulin B B_GENE
V I I_GENE
genes I I_GENE
in O O
cHD O O
but O O
is O O
most O O
likely O O
due O O
to O O
a O O
down-regulation O O
of O O
Oct2 B B_GENE
and/or O O
BOB.1/OBF.1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
study O O
further O O
revealed O O
Oct2 B B_GENE
as O O
a O O
new O O
and O O
valuable O O
marker O O
for O O
the O O
identification O O
of O O
L O O
& O O
H O O
cells O O
and O O
their O O
distinction O O
from O O
HRS O O
cells O O
. O O

The O O
impairment O O
of O O
immunoglobulin O O
transcription O O
with O O
a O O
down-regulated O O
synthesis O O
of O O
Oct2 B B_GENE
and O O
BOB.1/OBF.1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
first O O
established O O
general O O
recurrent O O
defect O O
found O O
in O O
HRS O O
cells O O
. O O

Constitutive O O
expression O O
of O O
NF-kappa B B_GENE
B I I_GENE
is O O
a O O
characteristic O O
feature O O
of O O
mycosis O O
fungoides O O
: O O
implications O O
for O O
apoptosis O O
resistance O O
and O O
pathogenesis O O
. O O

The O O
NF-kappa B B_GENE
B I I_GENE
family I I_GENE
of I I_GENE
transcription I I_GENE
factors I I_GENE
is O O
an O O
important O O
regulator O O
of O O
genes O O
expressed O O
during O O
inflammatory O O
responses O O
, O O
immunoglobulin O O
( O O
Ig O O
) O O
class O O
switching O O
, O O
cellular O O
differentiation O O
, O O
and O O
apoptosis O O
. O O

Recently O O
, O O
members O O
of O O
the O O
NF-kappaB B B_GENE/B_BIO
family I I_GENE/I_BIO
, O O
including O O
p65 B B_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
, O O
have O O
been O O
implicated O O
in O O
promoting O O
survival O O
of O O
various O O
hematopoeitic O O
neoplasms O O
, O O
including O O
T O O
cell O O
malignancies O O
such O O
as O O
adult O O
T O O
cell O O
leukemia-lymphoma O O
. O O

We O O
investigated O O
the O O
expression O O
of O O
active B B_GENE
NF-kappa I I_GENE
B I I_GENE
p65 I I_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
in O O
cases O O
of O O
mycosis O O
fungoides O O
( O O
MF O O
) O O
and O O
the O O
effect O O
of O O
chemical O O
inhibitors O O
of O O
NF-kappa B B_GENE
B I I_GENE
on O O
apoptosis O O
in O O
cutaneous O O
T O O
cell O O
lymphoma O O
( O O
CTCL O O
) O O
cell O O
lines O O
. O O

Paraffin-embedded O O
tissues O O
from O O
23 O O
cutaneous O O
lesions O O
and O O
a O O
single O O
lymph O O
node O O
biopsy O O
from O O
patients O O
diagnosed O O
with O O
MF O O
were O O
evaluated O O
for O O
p65 O O
( O O
Rel O O
A O O
) O O
expression O O
by O O
using O O
a O O
monoclonal B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mouse I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibody I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
detects O O
the O O
activated O O
form O O
of O O
p65 B B_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
. O O

Apoptosis O B_DISEASE/B_GENE
after O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
the O O
NF-kappa O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gliotoxin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
MG132 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
BAY O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
11-7082 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
BAY O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
11-7085 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
quantitatively O O
measured O O
in O O
the O O
CTCL O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lines O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
HuT-78 O O
and O O
HH O B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
by O O
propidium O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
iodide O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI O B_PROTEIN[GENE]
) O O
/cell O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
a O O
hypodiploid O B_DISEASE_ADJECTIVE[DISEASE]
( O O
sub-G O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O B_MEASURE/B_LOCATION
) O O
) O O
population O B_PERSON/B_LOCATION
and O O
by O O
determination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
increased O O
Annexin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
V/7-amino-actinomycin O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
7-AAD O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Nuclear O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
extracts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
CTCL O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
before O O
and O O
after O O
chemical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
inhibition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
were O O
analyzed O O
for O O
NF-kappa O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA-binding O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
electrophoretic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mobility O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
shift O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EMSA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
with O O
quantitative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
densitometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Nuclear O O
expression O O
of O O
p65 B B_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
before O O
and O O
after O O
treatment O O
with O O
the O O
various O O
inhibitory O O
compounds O O
was O O
measured O O
by O O
immunofluorescence O O
staining O O
in O O
each O O
CTCL O O
cell O O
line O O
. O O

Neoplastic O O
T O O
lymphocytes O O
from O O
22 O O
of O O
24 O O
cases O O
of O O
MF O O
showed O O
strong O O
nuclear O O
and O O
cytoplasmic O O
expression O O
of O O
active B B_GENE
p65 I I_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
. O O

Compared O O
with O O
untreated O B_PERSON/B_BIO
control O I_PERSON/I_BIO
cells O I_PERSON/I_BIO
, O O
a O O
marked O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
apoptosis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
NF-kappa O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
B O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DNA-binding O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activity O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
and O O
a O O
marked O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
nuclear O B_GENE
p65 O I_GENE
( O O
Rel O B_GENE/B_DISEASE
A O I_GENE/I_DISEASE
) O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
seen O O
in O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
from O O
both O O
CTCL O B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
after O O
chemical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
NF-kappa O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
B O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
inhibition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
data O O
show O O
that O O
the O O
active O O
form O O
of O O
NF-kappa B B_GENE
B I I_GENE
p65 I I_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
is O O
commonly O O
expressed O O
in O O
neoplastic O O
T O O
lymphocytes O O
in O O
patients O O
with O O
MF O O
. O O

In O O
CTCL O O
cell O O
lines O O
, O O
the O O
significant O O
decrease O O
in O O
nuclear O O
NF-kappa O O
B O O
expression O O
and O O
the O O
marked O O
increase O O
in O O
spontaneous O O
apoptosis O O
caused O O
by O O
chemical O O
NF-kappa O O
B O O
inhibition O O
suggest O O
a O O
critical O O
role O O
for O O
NF-kappa B B_GENE
B I I_GENE
in O O
the O O
pathogenesis O O
and O O
tumor O O
cell O O
maintenance O O
of O O
CTCLs O O
. O O

HUM O B_TIME[MEASURE]
PATHOL O I_TIME[MEASURE]
31 O I_TIME[MEASURE]
: O O
1482-1490 O B_MEASURE/B_PERSON
. O O

Human O O
T-cell O O
leukemia O O
virus O O
type O O
1 O O
tax B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activates O O
transcription O O
through O O
AP-1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O O
inducing O O
DNA O O
binding O O
activity O O
in O O
T O O
cells O O
. O O

Human O O
T-cell O O
leukemia O O
virus O O
type O O
1 O O
( O O
HTLV-1 O O
) O O
Tax B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O O
the O O
expression O O
of O O
various O O
family O O
members O O
of O O
the O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
AP-1 I I_GENE/I_LOCATION
, O O
such O O
as O O
c-Jun B B_GENE
, O O
JunD B B_GENE/B_DISEASE
, O O
c-Fos B B_GENE
, O O
and O O
Fra-1 B B_GENE
, O O
at O O
the O O
level O O
of O O
RNA O O
expression O O
in O O
T O O
cells O O
. O O

We O O
examined O O
the O O
activity O O
of O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
transcription O O
through O O
AP-1-binding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
T O O
cells O O
. O O

Transient O O
transfection O O
studies O O
showed O O
that O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activated O O
the O O
expression O O
of O O
a O O
luciferase B B_GENE/B_MEASURE
gene I I_GENE/I_MEASURE
regulated O O
by O O
two O O
copies O O
of O O
an O O
AP-1 B B_GENE/B_MEASURE
site I I_GENE/I_MEASURE
in O O
the O O
human O O
Jurkat O O
T-cell O O
line O O
. O O

Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activates O O
the O O
expression O O
of O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cellular I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
through O O
two O O
different O O
enhancers O O
: O O
a O O
cAMP-responsive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CRE I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
kappaB B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
. O O

Two O O
Tax B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentially O O
activated O O
expression O O
of O O
these O O
two O O
elements O O
. O O

Tax703 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preferentially O O
activated O O
the O O
kappaB B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
but O O
not O O
the O O
CRE-like O O
one O O
, O O
whereas O O
TaxM22 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O O
the O O
reverse O O
. O O

In O O
addition O O
, O O
Tax703 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
TaxM22 B B_GENE
, O O
converted O O
cell O O
growth O O
of O O
a O O
mouse O O
T-cell O O
line O O
from O O
being O O
interleukin O O
( O O
IL O O
) O O
-2-dependent O O
to O O
being O O
IL-2-independent O O
. O O

Unlike O O
the O O
wild-type B B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tax I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Tax703 B B_GENE/B_ORGANIZATION
and O O
TaxM22 B B_GENE/B_MEASURE
only O O
weakly O O
activated O O
the O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
T-cell O O
line O O
. O O

Thus O O
, O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
seems O O
to O O
activate O O
the O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O O
mechanisms O O
distinct O O
from O O
those O O
of O O
kappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CRE-like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
the O O
activation O O
of O O
the O O
AP-1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
dispensable O O
for O O
IL-2-independent O O
growth O O
of O O
CTLL-2 O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
showed O O
that O O
Tax B B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
strong O O
binding O O
activity O O
to O O
an O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
CTLL-2 O O
, O O
whereas O O
Tax703 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
, O O
indicating O O
that O O
the O O
induction O O
of O O
binding O O
activity O O
to O O
the O O
AP-1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
essential O O
for O O
the O O
transcriptional O O
activation O O
by O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
binding B B_GENE/B_LOCATION
complex I I_GENE/I_LOCATION
induced O O
by O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
CTLL-2 O O
contained O O
JunD B B_GENE/B_DISEASE
and O O
Fra-2 B B_GENE/B_LOCATION
. O O

Other O O
AP-1 B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
undetectable O O
. O O

Activation O O
of O O
transcription O O
through O O
the O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Jurkat O O
cells O O
by O O
JunD B B_GENE/B_DISEASE
and/or O O
Fra-2 B B_GENE
was O O
weak O O
. O O

c-Jun B B_GENE
, O O
JunB B B_GENE/B_BACTERIUM[BIO]
, O O
and O O
c-Fos B B_GENE
activation O O
was O O
greater O O
, O O
although O O
the O O
level O O
was O O
still O O
less O O
than O O
that O O
with O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Thus O O
, O O
the O O
induction O O
of O O
AP-1 B B_GENE
mRNA I I_GENE
by O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
not O O
be O O
sufficient O O
for O O
a O O
complete O O
activation O O
of O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
results O O
suggest O O
that O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activates O O
the O O
transcription O O
of O O
cellular B B_GENE/B_LOCATION
genes I I_GENE/I_LOCATION
with O O
AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
inducing O O
the O O
DNA-binding O O
activity O O
of O O
AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
T O O
cells O O
, O O
a O O
mechanism O O
distinct O O
from O O
those O O
of O O
CRE-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappaB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Copyright O B_LOCATION/B_PERSON
2001 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Strict O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
human O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
immunodeficiency O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
virus O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
type O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
replication O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
by O O
a O O
genetic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
switch O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
Tet O B_GENE/B_BACTERIUM[BIO]
for O O
Tat O B_GENE
. O O

Live-attenuated O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunodeficiency O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
virus O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
type O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
HIV-1 O B_DISEASE/B_GENE
) O O
variants O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
shown O O
great O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promise O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
AIDS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
vaccines O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
but O O
continued O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replication O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
lead O O
to O O
the O O
selection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
faster-replicating O O
variants O B_DISEASE/B_BIO
that O O
are O O
pathogenic O B_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
therefore O O
designed O O
HIV-1 B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
genomes I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
that O O
replicate O O
exclusively O O
upon O O
addition O O
of O O
the O O
nontoxic O O
effector O O
doxycycline O O
( O O
dox O O
) O O
. O O

This O O
was O O
achieved O O
by O O
replacement O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
viral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
TAR-Tat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
transcriptional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
activation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
by O O
the O O
Escherichia O B_BACTERIUM[BIO]/B_GENE
coli-derived O B_BACTERIUM[BIO]/I_GENE
Tet O B_BACTERIUM[BIO]/I_GENE
system O B_BACTERIUM[BIO]/I_GENE
for O O
inducible O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
designer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
`` O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
HIV-rtTA O O
'' O B_DISEASE/B_GENE
viruses O O
replicate O O
in O O
a O O
strictly O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
dox-dependent O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
manner O O
both O O
in O O
a O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
T-cell O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
line O O
and O O
in O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
primary O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O O
, O O
and O O
the O B_MEASURE/B_LOCATION
rate O O
of O B_TIME[MEASURE]/B_DISEASE
replication O O
can O O
be O O
fine-tuned O O
by O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simple O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variation O O
of O O
the O B_MEASURE/B_BIO
dox O B_MEASURE/I_BIO
concentration O O

These O O
HIV-rtTA O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
viruses O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O O
a O O
tool O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
to O O
perform O O
genetics O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
e.g. O O
, O O
selection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
optimization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
experiments O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O O
with O O
the O O
E. O O
coli-derived O B_SPECIES[BIO]/B_GENE
Tet O I_SPECIES[BIO]/I_GENE
reagents O I_SPECIES[BIO]/I_GENE
in O O
a O O
eukaryotic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
background O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Furthermore O O
, O O
such O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
viruses O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
represent O O
improved O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
vaccine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
candidates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
because O O
their O O
replication O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
turned O O
on O O
and O O
off O O
at O O
will O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Synovial O O
fluid O O
induced O O
nuclear B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
factor-kappaB I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DNA O O
binding O O
in O O
a O O
monocytic O O
cell O O
line O O
. O O

OBJECTIVE O O
: O O
To O O
determine O O
the O O
effects O O
of O O
synovial O O
fluids O O
( O O
SF O O
) O O
on O O
DNA O O
binding O O
activity O O
of O O
transcription B B_GENE
factor I I_GENE
nuclear B I_GENE
factor-kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
in O O
the O O
Mono O O
Mac O O
6 O O
monocytic/macrophage O O
cell O O
line O O
as O O
a O O
model O O
for O O
the O O
interaction O O
between O O
SF O O
and O O
synovial O O
tissue O O
macrophages O O
in O O
arthritis O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
: O O
Mono O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
Mac O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
6 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
incubated O O
with O O
SF O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
knee O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
joints O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
human O B_PERSON
subjects O I_PERSON
with O O
rheumatoid O B_DISEASE
arthritis O I_DISEASE
( O O
RA O B_LOCATION
) O O
, O O
undifferentiated O B_DISEASE
seronegative O I_DISEASE
oligoarthritis O I_DISEASE
, O O
and O O
osteoarthritis O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
OA O B_LOCATION
) O O
. O O

Nuclear O O
extracts O O
prepared O O
from O O
the O O
Mono O O
Mac O O
6 O O
cells O O
and O O
RA O O
synovial O O
tissue O O
were O O
analyzed O O
by O O
electrophoretic O O
mobility O O
shift O O
analysis O O
( O O
EMSA O O
) O O
for O O
NF-kappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O O
: O O
Induction O O
of O O
NF-kappaB B B_GENE
DNA O O
binding O O
by O O
the O O
p65 B B_GENE
( I I_GENE
RelA I I_GENE
) I I_GENE
/p50 I I_GENE
heterodimer I I_GENE
was O O
observed O O
in O O
response O O
to O O
incubation O O
of O O
Mono O O
Mac O O
6 O O
cells O O
with O O
SF O O
( O O
20 O O
% O O
in O O
culture O O
medium O O
) O O
from O O
5 O O
of O O
8 O O
subjects O O
with O O
RA O O
, O O
4 O O
of O O
5 O O
with O O
OA O O
, O O
and O O
none O O
of O O
3 O O
with O O
undifferentiated O O
seronegative O O
oligoarthritis O O
. O O

Incubation O O
of O O
SF O O
with O O
neutralizing B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
against O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TNF-alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
against O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
significantly O O
reduced O O
the O O
induction O O
of O O
p65/p50 O O
binding O O
activity O O
in O O
SF O O
from O O
subjects O O
with O O
RA O O
and O O
OA O O
. O O

Unexpectedly O O
, O O
a O O
slowly O O
migrating O O
SF O O
inducible O O
NF-kappaB B B_GENE
-binding O O
complex O O
was O O
observed O O
in O O
EMSA O O
of O O
Mono O O
Mac O O
6 O O
cells O O
after O O
incubation O O
with O O
SF O O
from O O
5 O O
of O O
8 O O
RA O O
and O O
2 O O
of O O
5 O O
OA O O
subjects O O
. O O

The O O
induction O O
of O O
this O O
complex O O
by O O
SF O O
was O O
not O O
affected O O
by O O
neutralization O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
SF O O
, O O
and O O
the O O
complex O O
was O O
not O O
inducible O O
by O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
IL-1beta O O
, O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
IL-1beta B B_GENE
, O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
platelet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
derived I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
lipopolysaccharide O O
, O O
or O O
tetradecanoyl O O
phorbol O O
acetate O O
. O O

The O O
slowly O O
migrating B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complex I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
could O O
not O O
be O O
supershifted O O
with O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
against O O
NF-kappaB B B_GENE
, O O
Jun B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
the O O
transcriptional O O
coactivators O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
NF-kappaB-binding B B_PROTEIN[GENE]/B_MEASURE
complex I I_PROTEIN[GENE]/I_MEASURE
with O O
similar O O
slow O O
mobility O O
was O O
observed O O
in O O
nuclear O O
extracts O O
prepared O O
from O O
fresh O O
human O O
RA O O
synovial O O
tissue O O
. O O

CONCLUSION O O
: O O
Biological O O
activity O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
SF O O
from O O
RA O O
and O O
OA O O
subjects O O
is O O
capable O O
of O O
inducing O O
p65/p50 B B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
NF-kappaB I I_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
DNA O O
binding O O
activity O O
in O O
macrophages O O
. O O

A O O
property O O
of O O
SF O O
that O O
is O O
independent O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
other O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
responsible O O
for O O
the O O
induction O O
of O O
a O O
novel O O
slowly O O
migrating O O
NF-kappaB-binding B B_DISEASE/B_GENE
complex I I_DISEASE/I_GENE
. O O

Soluble O O
mediators O O
in O O
SF O O
of O O
subjects O O
with O O
RA O O
and O O
OA O O
can O O
therefore O O
modulate O O
binding O O
of O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
NF-kappaB B B_GENE
binding I I_GENE
site I I_GENE
in O O
macrophages O O
and O O
may O O
play O O
a O O
role O O
in O O
inflammatory O O
gene O O
expression O O
in O O
arthritis O O
. O O

Peroxisome B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor-gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
agonists O O
and O O
15-deoxy-Delta O O
( O O
12 O O
, O O
14 O O
) O O
( O O
12 O O
, O O
14 O O
) O O
-PGJ O O
( O O
2 O O
) O O
induce O O
apoptosis O O
in O O
normal O O
and O O
malignant O O
B-lineage O O
cells O O
. O O

The O O
research O O
described O O
herein O O
evaluates O O
the O O
expression O O
and O O
functional O O
significance O O
of O O
peroxisome B B_GENE
proliferator I I_GENE
activator I I_GENE
receptor-gamma I I_GENE
( I I_GENE
PPAR-gamma I I_GENE
) I I_GENE
on O O
B-lineage O O
cells O O
. O O

Normal O O
mouse O O
B O O
cells O O
and O O
a O O
variety O O
of O O
B O O
lymphoma O O
cells O O
reflective O O
of O O
stages O O
of O O
B O O
cell O O
differentiation O O
( O O
e.g. O O
, O O
70Z/3 O O
, O O
CH31 O O
, O O
WEHI-231 O O
, O O
CH12 O O
, O O
and O O
J558 O O
) O O
express O O
PPAR-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
, O O
by O O
Western O O
blot O O
analysis O O
, O O
the O O
67-kDa B B_GENE
PPAR-gamma I I_GENE
protein I I_GENE
. O O

15-Deoxy-Delta O O
( O O
12 O B_MEASURE
, O O
14 O B_MEASURE
) O O
-PGJ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
2 O B_NUMBER[MEASURE]
) O O
( O O
15d-PGJ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
2 O B_NUMBER[MEASURE]
) O O
) O O
, O O
a O O
PPAR-gamma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
agonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
has O O
a O O
dose-dependent O B_DISEASE_ADJECTIVE[DISEASE]
antiproliferative O I_DISEASE_ADJECTIVE[DISEASE]
and O O
cytotoxic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
malignant O B_DISEASE
B O I_DISEASE
cells O I_DISEASE
as O O
shown O O
by O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 O B_NUMBER[MEASURE]
) O O
H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
thymidine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
3- O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
[ O O
4 O B_NUMBER[MEASURE]
, O O
5-dimethylthiazol-2-yl O B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-2 O O
, O O
5-diphenyltetrazolium O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bromide O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Only O O
PPAR-gamma O O
agonists O O
( O O
thiazolidinediones O O
) O O
, O O
and O O
not O O
PPAR-alpha O O
agonists O O
, O O
mimicked O O
the O O
effect O O
of O O
15d-PGJ O O
( O O
2 O O
) O O
on O O
B-lineage O O
cells O O
, O O
indicating O O
that O O
the O O
mechanism O O
by O O
which O O
15d-PGJ O O
( O O
2 O O
) O O
negatively O O
affects O O
B-lineage O O
cells O O
involves O O
in O O
part O O
PPAR-gamma B B_GENE
. O O

The O O
mechanism O B_LOCATION
by O O
which O O
PPAR-gamma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agonists O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
induce O O
cytotoxicity O B_DISEASE/B_GENE
is O O
via O O
apoptosis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
shown O O
by O O
annexin O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
V O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
staining O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
as O O
confirmed O O
by O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]
fragmentation O I_DISEASE_ADJECTIVE[DISEASE]
detected O O
using O O
the O O
TUNEL O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Interestingly O O
, O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
PGF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2alpha O B_PROTEIN[GENE]/B_MEASURE
) O O
, O O
which O O
was O O
not O O
known O O
to O O
affect O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O O
dramatically O O
attenuated O O
the O O
deleterious O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
PPAR-gamma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agonists O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
B O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphomas O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Surprisingly O O
, O O
15d-PGJ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
2 O B_NUMBER[MEASURE]
) O O
induced O O
a O O
massive O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
nuclear O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mitogen-activated O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
kinase O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
and O O
pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
with O O
PGF O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2alpha O B_PROTEIN[GENE]/B_MEASURE
) O O
blunted O O
the O O
mitogen-activated O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
is O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
evaluating O O
PPAR-gamma O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
significance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
B O B_DISEASE/B_LOCATION
lymphocytes O I_DISEASE/I_LOCATION
. O O

PPAR-gamma O B_PERSON/B_LOCATION
agonists O I_PERSON/I_LOCATION
may O O
serve O O
as O O
a O O
counterbalance O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
the O O
stimulating O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PGs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
namely O O
PGE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
2 O B_NUMBER[MEASURE]/B_LOCATION
) O O
, O O
which O O
promotes O O
B O B_DISEASE
cell O I_DISEASE
differentiation O I_DISEASE
. O O

Finally O O
, O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
PGs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O O
15d-PGJ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
2 O B_NUMBER[MEASURE]/B_LOCATION
) O O
, O O
and O O
synthetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PPAR-gamma O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
agonists O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
induce O O
apoptosis O B_DISEASE/B_GENE
in O O
B-lineage O B_DISEASE/B_BIO
cells O I_DISEASE/I_BIO
may O O
lead O O
to O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
novel O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapies O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
fatal O B_DISEASE/B_LOCATION
B O I_DISEASE/I_LOCATION
lymphomas O I_DISEASE/I_LOCATION

Inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
STAT3 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leads O O
to O O
apoptosis O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
leukemic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
large O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
granular O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
decreased O O
Mcl-1 O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

Large O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
granular O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocyte O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
LGL O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
leukemia O B_DISEASE
is O O
characterized O O
by O O
the O O
expansion O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
antigen-activated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytotoxic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
leukemic O O
cells O O
are O O
resistant O O
to O O
Fas-mediated O O
apoptosis O O
despite O O
expressing O O
high O O
levels O O
of O O
Fas B B_GENE
. O O

We O O
found O O
that O O
leukemic O O
LGL O O
from O O
19 O O
patients O O
displayed O O
high O O
levels O O
of O O
activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
STAT3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Treatment O O
of O O
leukemic O O
LGL O O
with O O
the O O
JAK-selective O O
tyrosine O O
kinase O O
inhibitor O O
AG-490 O O
induced O O
apoptosis O O
with O O
a O O
corresponding O O
decrease O O
in O O
STAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-DNA O O
binding O O
activity O O
. O O

Moreover O O
, O O
using O O
an O O
antisense O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oligonucleotide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
approach O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
diminish O O
STAT3 O B_GENE/B_DISEASE
expression O I_GENE/I_DISEASE
, O O
we O O
found O O
that O O
Fas O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sensitivity O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
restored O O
in O O
leukemic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
LGL O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

AG-490-induced O B_DISEASE/B_GENE
apoptosis O I_DISEASE/I_GENE
in O O
leukemic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
LGL O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
independent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
Bcl-xL O B_GENE
or O O
Bcl-2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
we O O
found O O
that O O
the O O
Bcl-2-family B B_DISEASE_ADJECTIVE[DISEASE]
protein I I_DISEASE_ADJECTIVE[DISEASE]
Mcl-1 I I_DISEASE_ADJECTIVE[DISEASE]
was O O
significantly O O
reduced O O
by O O
AG-490 O O
treatment O O
. O O

Activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
STAT3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
shown O O
to O O
bind O O
an O O
SIE-related B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
murine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mcl-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Using O O
a O O
luciferase O O
reporter O O
assay O O
, O O
we O O
demonstrated O O
that O O
v-src O O
overexpression O O
in O O
NIH3T3 O O
induced O O
STAT3 B B_GENE
-dependent O O
transcriptional O O
activity O O
from O O
the O O
mcl-1 B B_GENE
promoter I I_GENE
and O O
increased O O
endogenous O O
Mcl-1 O O
protein O O
levels O O
. O O

We O O
conclude O O
that O O
STAT3 B B_GENE
activation O O
contributed O O
to O O
accumulation O O
of O O
the O O
leukemic O O
LGL O O
clones O O
. O O

These O O
findings O O
suggest O O
that O O
investigation O O
should O O
focus O O
on O O
novel O O
strategies O O
targeting O O
STAT3 B B_GENE
in O O
the O O
treatment O O
of O O
LGL O O
leukemia O O
. O O

Decreased O O
immediate O O
inflammatory B B_GENE/B_DISEASE
gene I I_GENE/I_DISEASE
induction O O
in O O
activating B B_GENE/B_PERSON
transcription I I_GENE/I_PERSON
factor-2 I I_GENE/I_PERSON
mutant O O
mice O O
. O O

Transcription B B_GENE
factor I I_GENE
activating I I_GENE
transcription I I_GENE
factor I I_GENE
( I I_GENE
ATF I I_GENE
) I I_GENE
-2 I I_GENE
is O O
activated O O
by O O
inflammatory O O
signals O O
transduced O O
by O O
the O O
JNK O O
and O O
p38 O O
MAP O O
kinase O O
pathways O O
. O O

To O O
better O O
define O O
the O O
role O O
of O O
ATF-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
inflammation O O
, O O
adult O O
mice O O
expressing O O
small O O
amounts O O
of O O
a O O
mutant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ATF-2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
challenged O O
with O O
lipopolysaccharide O O
( O O
LPS O O
) O O
, O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
antibody I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
or O O
virus O O
. O O

Within O O
3 O O
h O O
of O O
challenge O O
by O O
LPS O O
, O O
ATF-2 O O
mutant O O
mice O O
had O O
decreased O O
induction O O
of O O
the O O
adhesion B B_GENE
molecules I I_GENE
E-selectin B I_GENE
, O O
P-selectin B B_GENE
and O O
VCAM-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
as O O
well O O
as O O
the O O
cytokines B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumor B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necrosis I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor-alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL-1beta B B_GENE
and O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
compared O O
with O O
control O O
mice O O
. O O

Stimulation O O
of O O
T O O
lymphocytes O O
by O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O O
showed O O
less O O
induction O O
of O O
IL-1 B B_GENE
and O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
ATF-2 O O
mutant O O
tissues O O
. O O

ATF-2 O O
mutant O O
thymocytes O O
treated O O
with O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
vitro O O
demonstrated O O
reduced O O
induction O O
of O O
c-Jun B B_GENE
, O O
JunB B B_GENE/B_BACTERIUM[BIO]
, O O
JunD B B_GENE/B_DISEASE
and O O
Fra-2 B B_GENE
. O O

However O O
, O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
what O O
was O O
observed O O
after O O
p38 O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
kinase O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibition O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
relative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ATF-2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
deficiency O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
did O O
not O O
prevent O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
mononuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infiltrate O O
in O O
the O O
week O B_BODY_PART_OR_ORGAN_COMPONENT
following O O
an O O
inflammatory O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulus O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

ATF-2 O O
mutant O B_BIO/B_PERSON
mice O I_BIO/I_PERSON
proved O O
more O O
susceptible O B_DISEASE_ADJECTIVE[DISEASE]
to O O
death O B_DISEASE
than O O
control O B_PERSON/B_BIO
mice O I_PERSON/I_BIO
from O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
plus O O
D-galactosamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
injection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
Coxsackievirus O B_DISEASE
B3 O I_DISEASE
infection O I_DISEASE
and O O
had O O
a O O
higher O B_MEASURE/B_DISEASE
incidence O I_MEASURE/I_DISEASE
of O O
mononuclear O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pulmonary O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infiltrates O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O O
Herpes O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simplex O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
virus-1 O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

ATF-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
essential O O
for O O
maximal O O
immediate O O
induction O O
of O O
adhesion B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
cytokine B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
, O O
but O O
at O O
later O O
time O O
points O O
may O O
even O O
protect O O
against O O
overactive O O
immune O O
responses O O
. O O

LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
TNF-like B B_GENE
molecule I I_GENE
, O O
costimulates O O
T O O
cell O O
proliferation O O
and O O
is O O
required O O
for O O
dendritic O O
cell O O
-mediated O O
allogeneic O O
T O O
cell O O
response O O
. O O

LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
recently O O
identified O O
member O O
of O O
the O O
TNF B B_GENE/B_BIO
superfamily I I_GENE/I_BIO
and O O
its O O
receptors O O
, O O
herpesvirus B B_GENE
entry I I_GENE
mediator I I_GENE
and O O
lymphotoxin B B_GENE
beta I I_GENE
receptor I I_GENE
, O O
are O O
found O O
in O O
T O O
cells O O
and O O
stromal O O
cells O O
. O O

In O O
this O O
study O O
, O O
we O O
demonstrate O O
that O O
LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
selectively O O
expressed O O
on O O
immature O O
dendritic O O
cells O O
( O O
DCs O O
) O O
generated O O
from O O
human O O
PBMCs O O
. O O

In O O
contrast O O
, O O
LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
detectable O O
in O O
DCs O O
either O O
freshly O O
isolated O O
from O O
PBMCs O O
or O O
rendered O O
mature O O
in O O
vitro O O
by O O
LPS O O
treatment O O
. O O

Blockade O O
of O O
LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
its O O
soluble B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
lymphotoxin B B_GENE/B_LOCATION
beta I I_GENE/I_LOCATION
receptor-Ig I I_GENE/I_LOCATION
or O O
HVEM-Ig B B_GENE
, O O
inhibits O O
the O O
induction O O
of O O
DC O O
-mediated O O
primary O O
allogeneic O O
T O O
cell O O
response O O
. O O

Furthermore O O
, O O
engagement O O
of O O
LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
costimulates O O
human O O
T O O
cell O O
proliferation O O
, O O
amplifies O O
the O O
NF-kappaB O O
signaling O O
pathway O O
, O O
and O O
preferentially O O
induces O O
the O O
production O O
of O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
IL-4 B B_GENE
, O O
in O O
the O O
presence O O
of O O
an O O
antigenic O O
signal O O
. O O

Our O O
results O O
suggest O O
that O O
LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
costimulatory B B_GENE/B_LOCATION
molecule I I_GENE/I_LOCATION
involved O O
in O O
DC O O
-mediated O O
cellular O O
immune O O
responses O O
. O O

Suppression O O
of O O
HIV O O
type O O
1 O O
replication O O
by O O
a O O
dominant-negative B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Ets-1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mutant I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Activity O O
of O O
the O O
distal B B_GENE/B_BIO
region I I_GENE/I_BIO
of O O
the O O
human O O
immunodeficiency O O
virus O O
( O O
HIV-1 O O
) O O
long B B_GENE
terminal I I_GENE
repeat I I_GENE
( O O
LTR B B_GENE/B_DISEASE
) O O
, O O
which O O
contains O O
binding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
Ets-1 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
USF-1 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
integral O O
for O O
HIV-1 O O
replication O O
. O O

The O O
Ets-1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
USF-1 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
play O O
a O O
critical O O
role O O
in O O
the O O
activity O O
of O O
the O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
distal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
indicated O O
by O O
the O O
potent O O
dominant O O
negative O O
effect O O
of O O
a O O
mutant B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Ets-1 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
lacking I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
trans-activation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
domains I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
on O O
the O O
transcriptional O O
activity O O
of O O
the O O
LTR B B_GENE/B_DISEASE
. O O

To O O
determine O O
the O O
biological O O
relevance O O
of O O
the O O
Ets-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
USF-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
HIV-1 O O
replication O O
, O O
we O O
examined O O
the O O
effect O O
of O O
expression O O
of O O
the O O
dominant-negative O O
mutant O O
of O O
Ets-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
dnEts-1 B B_PROTEIN[GENE]
) O O
on O O
HIV-1 O O
infection O O
of O O
T O O
cells O O
. O O

We O O
demonstrated O O
that O O
expression O O
of O O
dnEts B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markedly O O
suppressed O O
HIV-1 O O
infection O O
of O O
a O O
T O O
cell O O
line O O
. O O

This O O
finding O O
indicates O O
that O O
formation O O
of O O
a O O
transcriptionaly B B_GENE/B_LOCATION
active I B_GENE/I_LOCATION
USF-1/Ets-1 I B_GENE/I_LOCATION
complex I B_GENE/I_LOCATION
is O O
important O O
in O O
the O O
productive O O
infection O O
of O O
cells O O
by O O
HIV-1 O O
, O O
and O O
suggests O O
that O O
inhibition O O
of O O
the O O
interaction O O
between O O
USF-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Ets-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
provide O O
a O O
new O O
target O O
for O O
anti-HIV-1 O O
gene O O
therapy O O
. O O

Human O O
eosinophils O O
constitutively O O
express O O
nuclear B B_GENE
factor I I_GENE
of I I_GENE
activated I I_GENE
T I I_GENE
cells I I_GENE
p I I_GENE
and I I_GENE
c I I_GENE
. O O

BACKGROUND O O
: O O
Eosinophils O O
are O O
now O O
known O O
to O O
produce O O
a O O
variety O O
of O O
proinflammatory B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytokines I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
although O O
the O O
molecular O O
factors O O
that O O
regulate O O
their O O
production O O
are O O
poorly O O
understood O O
. O O

The O O
expression O O
of O O
almost O O
all O O
of O O
the O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
produced O O
by O O
eosinophils O O
, O O
including O O
the O O
proallergic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
now O O
known O O
to O O
be O O
regulated O O
at O O
the O O
level O O
of O O
transcription O O
by O O
members O O
of O O
the O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NFAT B B_GENE/B_LOCATION
) O O
family O O
of O O
transcription O O
factors O O
. O O

OBJECTIVE O O
: O O
We O O
sought O O
to O O
characterize O O
the O O
expression O O
of O O
different O O
NFAT B B_GENE
proteins I I_GENE
in O O
resting O O
and O O
activated O O
eosinophils O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Nuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
whole O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
extracts O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
obtained O O
from O O
both O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
eosinophils O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
and O O
those O O
obtained O O
from O O
bronchoalveolar O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lavage O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fluid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
asthmatic O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
after O O
endobronchial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
allergen O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
challenge O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

NFAT B B_GENE
expression O O
was O O
determined O O
by O O
using O O
immunoprecipitation O O
and O O
Western O O
blot O O
analysis O O
, O O
DNA-binding O O
assays O O
, O O
and O O
RT-PCR O O
analysis O O
of O O
eosinophil B B_GENE
mRNA I I_GENE
. O O

RESULTS O O
: O O
Both O O
peripheral O O
blood O O
and O O
bronchoalveolar O O
lavage O O
fluid O O
eosinophils O O
expressed O O
NFATp B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NFATc I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Unlike O O
activated O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
which O O
express O O
multiple O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NFATc O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
eosinophils O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
preferentially O O
express O O
the O O
approximately O O
85-kd O B_PROTEIN[GENE]/B_MEASURE
isoform O I_PROTEIN[GENE]/I_MEASURE
. O O

In O O
addition O O
, O O
eosinophils O O
were O O
found O O
to O O
constitutively O O
express O O
NFATc B B_GENE
mRNA I I_GENE
. O O

A O O
brief O O
incubation O O
with O O
the O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
H I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-4 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IL-5 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
sufficient O O
to O O
induce O O
the O O
nuclear O O
translocation O O
of O O
NFATc B B_GENE
. O O

Eosinophil O O
nuclear O O
extracts O O
contain O O
multiple O O
factors O O
that O O
can O O
specifically O O
recognize O O
the O O
IL-4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NFAT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
DNA-binding O O
assays O O
, O O
including O O
NFATp B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSION O O
: O O
NFATp B B_GENE
and O O
NFATc B B_GENE
can O O
regulate O O
the O O
expression O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
other O O
genes O O
in O O
eosinophils O O
but O O
appear O O
to O O
be O O
regulated O O
by O O
a O O
novel O O
signal O O
transduction O O
mechanism O O
in O O
these O O
cells O O
. O O

BLyS B B_GENE/B_DISEASE
BINDS O O
TO O O
B O O
CELLS O O
WITH O O
HIGH O O
AFFINITY O O
AND O O
INDUCES O O
ACTIVATION O O
OF O O
THE O O
TRANSCRIPTION B B_LOCATION/B_GENE
FACTORS I I_LOCATION/I_GENE
NF-kappaB B I_LOCATION/I_GENE
AND O O
ELF-1 B B_GENE
. O O

B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphocyte I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stimulator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
BLyS B B_LOCATION/B_DISEASE
) O O
is O O
a O O
novel O O
member O O
of O O
the O O
TNF B B_GENE/B_LOCATION
family I I_GENE/I_LOCATION
of I I_GENE/I_LOCATION
proteins I I_GENE/I_LOCATION
expressed O O
by O O
myeloid O O
cells O O
as O O
membrane-bound O O
and O O
soluble O O
forms O O
. O O

BLyS B B_GENE/B_DISEASE
was O O
shown O O
to O O
act O O
specifically O O
on O O
B O O
cells O O
, O O
inducing O O
proliferation O O
and O O
immunoglobulin O O
production O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

The O O
present O O
study O O
was O O
undertaken O O
to O O
characterize O O
binding O O
of O O
radiolabeled B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
BLyS I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
its O O
cognate B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
human O O
B O O
lymphocytes O O
and O O
examine O O
intracellular O O
events O O
initiated O O
by O O
BLyS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
binding O O
. O O

Similar O O
to O O
other O O
TNF B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
family I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
members I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
BLyS B B_GENE/B_DISEASE
is O O
present O O
in O O
solution O O
as O O
a O O
homotrimer B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
determined O O
by O O
gel O O
filtration O O
chromatography O O
and O O
light O O
scattering O O
analysis O O
. O O

BLyS B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
binding O O
to O O
B O O
cells O O
is O O
specific O O
as O O
other O O
TNF B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tested O O
did O O
not O O
compete O O
for O O
( O O
125 O O
) O O
I- O O
BLyS B B_GENE/B_DISEASE
binding O O
. O O

Analysis O O
of O O
equilibrium O O
binding O O
of O O
( B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
125 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
I-labeled I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
BLyS I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
purified O O
human O O
tonsillar O O
B O O
cells O O
demonstrated O O
saturable O O
binding O O
. O O

Scatchard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
binding O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
revealed O O
a O O
single O B_MEASURE/B_LOCATION
class O I_MEASURE/I_LOCATION
of O O
high-affinity O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
binding O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
B O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
approximately O O
2600 O B_NUMBER[MEASURE]
binding O O
sites O B_LOCATION/B_ENT
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
and O O
an O O
apparent O B_MEASURE/B_LOCATION
dissociation O I_MEASURE/I_LOCATION
constant O I_MEASURE/I_LOCATION
( O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
) O O
of O O
about O O
0.1 O B_MEASURE
nM O I_MEASURE
. O O

In O O
addition O O
we O O
report O O
that O O
BLyS B B_GENE/B_DISEASE
binding O O
to O O
B O O
cells O O
results O O
in O O
the O O
activation O O
of O O
NF-kappaB B B_GENE
and O O
the O O
Ets B B_GENE/B_PERSON
family I I_GENE/I_PERSON
transcription I I_GENE/I_PERSON
factor I I_GENE/I_PERSON
, O O
ELF-1 B B_GENE
, O O
and O O
in O O
the O O
induction O O
of O O
mRNA O O
for O O
Polo-like B B_GENE
kinase I I_GENE
( O O
PLK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Copyright O B_LOCATION/B_PERSON
2001 O I_LOCATION/I_PERSON
Academic O I_LOCATION/I_PERSON
Press O I_LOCATION/I_PERSON
. O O

Design O O
and O O
use O O
of O O
an O O
inducibly O O
activated O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
Nef B B_BIO/B_GENE
to O O
study O O
immune O O
modulation O O
. O O

The O O
Nef B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
has O O
been O O
shown O O
to O O
enhance O O
the O O
infectivity O O
of O O
virus O O
particles O O
, O O
downmodulate O O
cell B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
surface I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
and O O
associate O O
with O O
many O O
intracellular B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
are O O
thought O O
to O O
facilitate O O
HIV O O
infection O O
. O O

One O O
of O O
the O O
challenges O O
in O O
defining O O
the O O
molecular O O
events O O
regulated O O
by O O
Nef B B_GENE/B_BACTERIUM[BIO]
has O O
been O O
obtaining O O
good O O
expression O O
of O O
Nef B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
T O O
cells O O
. O O

This O O
has O O
been O O
attributed O O
to O O
effects O O
of O O
Nef B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
on O O
cell O O
proliferation O O
and O O
apoptosis O O
. O O

We O O
have O O
designed O O
a O O
Nef B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
is O O
readily O O
expressed O O
in O O
T-cell O O
lines O O
and O O
whose O O
function O O
is O O
inducibly O O
activated O O
. O O

It O O
is O O
composed O O
of O O
a O O
fusion O O
between O O
full-length B B_GENE
Nef I I_GENE
and O O
the O O
estrogen B B_PROTEIN[GENE]/B_LOCATION
receptor I I_PROTEIN[GENE]/I_LOCATION
hormone-binding I I_PROTEIN[GENE]/I_LOCATION
domain I I_PROTEIN[GENE]/I_LOCATION
( O O
Nef-ER B B_GENE/B_DISEASE
) O O
. O O

The O O
Nef-ER B B_ENZYME[GENE]/B_LOCATION
is O O
kept O O
in O O
an O O
inactive O O
state O O
due O O
to O O
steric O O
hindrance O O
, O O
and O O
addition O O
of O O
the O O
membrane-permeable O O
drug O O
4-hydroxytamoxifen O O
( O O
4-HT O O
) O O
, O O
which O O
binds O O
to O O
the O O
ER B B_GENE
domain I I_GENE
, O O
leads O O
to O O
inducible O O
activation O O
of O O
Nef-ER B B_GENE/B_LOCATION
within O O
cells O O
. O O

We O O
demonstrate O O
that O O
Nef-ER B B_GENE
inducibly O O
associates O O
with O O
the O O
62-kDa B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
Ser/Thr I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
kinase I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
is O O
localized O O
to O O
specific O O
membrane O O
microdomains O O
( O O
lipid O O
rafts O O
) O O
only O O
after O O
activation O O
. O O

Using O O
this O O
inducible O O
Nef B B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
also O O
compared O O
the O O
specific O O
requirements O O
for O O
CD4 B B_GENE
and O O
HLA-A2 B B_GENE
downmodulation O O
in O O
a O O
SupT1 O O
T-cell O O
line O O
. O O

Half-maximal O O
downmodulation O O
of O O
cell B B_GENE
surface I I_GENE
CD4 I I_GENE
required O O
very O O
little O O
active O O
Nef-ER B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
occurred O O
as O O
early O O
as O O
4 O O
h O O
after O O
addition O O
of O O
4-HT O O
. O O

In O O
contrast O O
, O O
50 O O
% O O
downmodulation O O
of O O
HLA-A2 B B_GENE
by O O
Nef B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
required O O
16 O O
to O O
24 O O
h O O
and O O
about O O
50- O O
to O O
100-fold-greater O O
concentrations O O
of O O
4-HT O O
. O O

These O O
data O O
suggest O O
that O O
HLA-A2 B B_GENE
downmodulation O O
may O O
require O O
certain O O
threshold O O
levels O O
of O O
active O O
Nef B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O O

The O O
differential O O
timing O O
of O O
CD4 B B_GENE/B_DISEASE
and O O
HLA-A2 B B_GENE
downmodulation O O
may O O
have O O
implications O O
for O O
HIV O O
pathogenesis O O
and O O
immune O O
evasion O O
. O O

Regulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chemokine O B_GENE
mRNA O I_GENE
expression O I_GENE
in O O
a O O
rat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
vanadium-induced O B_DISEASE
pulmonary O I_DISEASE
inflammation O I_DISEASE
. O O

Environmental O B_ORGANIZATION/B_PERSON
and O O
occupational O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exposure O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
vanadium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dusts O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
results O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
toxic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mainly O O
confined O O
to O O
the O O
respiratory O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Using O O
a O O
rat O O
model O O
of O O
acute O O
lung O O
inflammation O O
induced O O
by O O
intratracheal O O
instillation O O
of O O
sodium O O
metavanadate O O
( O O
NaVO3 O O
) O O
at O O
the O O
dose O O
of O O
200 O O
microg O O
V/kg O O
, O O
we O O
investigated O O
the O O
relationship O O
between O O
the O O
cytologic O O
characterization O O
of O O
pulmonary O O
inflammation O O
and O O
the O O
expression O O
of O O
chemokine B B_GENE
mRNA I I_GENE
. O O

Significant O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
polymorphonuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukocyte O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PMN O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
influx O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0.01 O B_MEASURE
) O O
into O O
the O O
lung O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O O
noted O O
4 O B_MEASURE/B_LOCATION
h O O
after O O
NaVO3 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
instillation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
whereas O O
alveolar O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AMs O B_LOCATION/B_ORGANIZATION
) O O
in O O
bronchoalveolar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
lavage O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
BAL O B_LOCATION
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
appeared O O
to O O
decrease O O
significantly O O
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
neither O O
PMNs O B_LOCATION
nor O O
AMs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
changed O O
substantially O O
1 O B_MEASURE/B_LOCATION
h O O
after O O
NaVO3 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
instillation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

By O O
Northern O O
analysis O O
, O O
macrophage B B_GENE
inflammatory I I_GENE
protein I I_GENE
( I I_GENE
MIP I I_GENE
) I I_GENE
-2 I I_GENE
mRNA I I_GENE
in O O
BAL O O
cells O O
increased O O
markedly O O
1 O O
h O O
after O O
NaVO3 O O
instillation O O
and O O
reduced O O
a O O
little O O
bit O O
at O O
4 O O
h O O
, O O
whereas O O
MIP-1alpha B B_GENE/B_LOCATION
mRNA I I_GENE/I_LOCATION
in O O
BAL O O
cells O O
was O O
expressed O O
relatively O O
high O O
1 O O
h O O
after O O
NaVO3 O O
instillation O O
, O O
although O O
a O O
basal O O
expression O O
was O O
detected O O
in O O
control O O
group O O
, O O
and O O
returned O O
rapidly O O
nearly O O
to O O
control O O
level O O
at O O
4 O O
h O O
. O O

Since O O
MIP-2 B B_GENE
is O O
a O O
potent O O
PMN O O
chemoattractant O O
and O O
MIP-1alpha B B_GENE
is O O
a O O
potent O O
macrophage/monocyte O O
chemoattractant O O
has O O
been O O
well O O
known O O
. O O

The O O
facts O O
that O O
PMN O O
influx O O
was O O
preceded O O
by O O
increased O O
MIP-2 O O
mRNA O O
expression O O
, O O
suggesting O O
that O O
MIP-2 B B_LOCATION/B_ORGANIZATION
is O O
involved O O
in O O
the O O
development O O
of O O
NaVO3-induced O O
pulmonary O O
inflammation O O
, O O
whereas O O
increased O O
MIP-1alpha B B_GENE/B_LOCATION
mRNA I I_GENE/I_LOCATION
expression O O
was O O
followed O O
by O O
decreased O O
AMs O O
in O O
BAL O O
cells O O
, O O
suggesting O O
AMs O O
might O O
be O O
activated O O
by O O
MIP-1alpha B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
adherent O O
to O O
the O O
lining O O
surface O O
of O O
the O O
airways O O
and O O
then O O
resistant O O
to O O
be O O
washed O O
out O O
. O O

To O O
delineate O O
the O O
mechanisms O O
of O O
transcriptional O O
activation O O
, O O
we O O
recently O O
cloned O O
the O O
5'-flanking B B_GENE/B_LOCATION
region I I_GENE/I_LOCATION
of O O
the O O
MIP-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
promotor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
consensus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
transcription B B_GENE
factor I I_GENE
nuclear I I_GENE
factor I I_GENE
kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
and O O
activator B B_GENE
protein-1 I I_GENE
( O O
AP-1 B B_GENE/B_DISEASE
) O O
. O O

Using O O
electrophoretic O O
mobility O O
shift O O
assay O O
, O O
increased O O
nuclear O O
NF-kappaB B B_GENE
, O O
not O O
AP-1 B B_GENE
, O O
binding O O
activity O O
was O O
detected O O
1 O O
h O O
after O O
NaVO3 O O
instillation O O
, O O
which O O
correlated O O
with O O
the O O
induction O O
of O O
MIP-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

p65 B B_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
and O O
p50 B B_GENE/B_BIO
protein I I_GENE/I_BIO
appears O O
to O O
be O O
involved O O
in O O
MIP-2 O O
NF-kappaB B B_GENE
binding O O
. O O

Taken O O
together O O
, O O
our O O
studies O O
suggest O O
that O O
MIP-2 B B_GENE
is O O
an O O
important O O
mediator O O
of O O
NaVO3-induced O O
pulmonary O O
inflammation O O
in O O
the O O
rat O O
model O O
. O O

In O O
addition O O
, O O
elevated O O
MIP-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
are O O
accompanied O O
by O O
increased O O
NF-kappaB B B_GENE
binding O O
activity O O
in O O
BAL O O
cells O O
, O O
suggesting O O
possible O O
MIP-2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transcriptional O O
regulation O O
through O O
NF-kappaB B B_GENE
. O O

Activation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
signal O B_GENE
transduction O I_GENE
and O O
apoptosis O B_DISEASE/B_GENE
in O O
healthy O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphomonocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
exposed O O
to O O
bystander O O
HIV-1-infected O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Persistent O B_DISEASE_ADJECTIVE[DISEASE]
activation O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
immune O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
system O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
hallmarks O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
HIV-1 O B_DISEASE
infection O I_DISEASE
. O O

In O O
this O O
study O O
we O O
analysed O O
the O O
induction O O
of O O
factors O O
involved O O
in O O
cytokine O O
signal O O
transduction O O
, O O
such O O
as O O
STAT B B_GENE
1 I I_GENE
proteins I I_GENE
and O O
IRF-1 B B_GENE
mRNA I I_GENE
, O O
in O O
normal O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMC O O
) O O
exposed O O
to O O
HIV-infected O O
cells O O
, O O
and O O
the O O
induction O O
of O O
apoptosis O O
. O O

Western O O
blot O O
analyses O O
and O O
reverse O O
transcriptase-polymerase O O
chain O O
reaction O O
results O O
indicate O O
that O O
both O O
cells O O
infected O O
with O O
a O O
X4 O O
strain O O
and O O
cells O O
infected O O
with O O
a O O
R5 O O
strain O O
are O O
able O O
to O O
increase O O
intracellular O O
levels O O
of O O
STAT B B_GENE/B_PERSON
1alpha I I_GENE/I_PERSON
and I I_GENE/I_PERSON
beta I I_GENE/I_PERSON
proteins O O
as O O
well O O
as O O
IRF-1 B B_GENE
mRNA I I_GENE
. O O

This O O
effect O O
was O O
prevented O O
by O O
neutralizing O O
antibodies O O
against O O
interferon-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IFN-alpha B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

HIV-1-infected O O
cells O O
dose-dependently O O
induced O O
apoptotic O O
commitment O O
in O O
normal O O
PBMC O O
, O O
as O O
revealed O O
by O O
DNA O O
fragmentation O O
analysis O O
, O O
but O O
this O O
was O O
not O O
accompanied O O
by O O
an O O
increase O O
of O O
caspase-3 O O
activity O O
, O O
even O O
if O O
a O O
slight O O
up-regulation O O
of O O
IL-1beta-converting B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
detected O O
. O O

Apoptosis O O
induction O O
could O O
be O O
abrogated O O
mainly O O
by O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
tumour B B_GENE
necrosis I I_GENE
factor-alpha I I_GENE
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
, O O
to O O
a O O
lesser O O
extent O O
, O O
by O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
against O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

All O O
these O O
findings O O
suggest O O
that O O
uninfected O O
PBMC O O
can O O
undergo O O
activation O O
of O O
signal O O
transduction O O
and O O
apoptosis O O
after O O
exposure O O
to O O
bystander O O
HIV-infected O O
cells O O
, O O
subsequent O O
to O O
the O O
induction O O
of O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
such O O
as O O
IFNs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
physical O O
association O O
of O O
protein B B_GENE
kinase I I_GENE
C I I_GENE
theta I I_GENE
with O O
a O O
lipid O O
raft-associated O O
inhibitor O O
of O O
kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IKK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plays O O
a O O
role O O
in O O
the O O
activation O O
of O O
the O O
NF-kappa O O
B O O
cascade O O
by O O
TCR B B_GENE
and O O
CD28 B B_GENE
. O O

We O O
investigated O O
the O O
role O O
of O O
protein B B_GENE
kinase I I_GENE
C I I_GENE
theta I I_GENE
( O O
PKCtheta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
the O O
activation O O
of O O
the O O
NF-kappaB B B_GENE/B_DISEASE
cascade O O
in O O
primary O O
human O O
CD4 O O
( O O
+ O O
) O O
lymphocytes O O
. O O

Among O O
six O O
or O O
so O O
PKC B B_GENE
isoforms I I_GENE
expressed O O
in O O
T O O
cells O O
, O O
only O O
PKCtheta B B_NUMBER[MEASURE]/B_ORGANIZATION
participates O O
in O O
the O O
assembly O O
of O O
the O O
supramolecular O O
activation O O
clusters O O
at O O
the O O
contact O O
site O O
of O O
the O O
TCR B B_GENE
with O O
Ag B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Signaling O O
via O O
both O O
the O O
TCR B B_GENE
and O O
CD28 B B_GENE
is O O
required O O
for O O
optimal O O
activation O O
of O O
the O O
multisubunit B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IkappaB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IKK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
primary O O
human O O
T O O
lymphocytes O O
; O O
this O O
activation O O
could O O
be O O
inhibited O O
by O O
a O O
Ca O O
( O O
2+ O O
) O O
-independent O O
PKC O O
isoform O O
inhibitor O O
, O O
rottlerin O O
. O O

Moreover O O
, O O
endogenous O O
PKCtheta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
physically O O
associates O O
with O O
activated O O
IKK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
CD3/CD28-costimulated O O
primary O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
. O O

The O O
same O O
set O O
of O O
stimuli O O
also O O
induced O O
relocation O O
of O O
endogenous O O
PKCtheta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IKKs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
a O O
GM1 O O
ganglioside-enriched O O
, O O
detergent-insoluble O O
membrane O O
compartment O O
in O O
primary O O
T O O
cells O O
. O O

IKKs B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
recruited O O
to O O
these O O
lipid O O
rafts O O
were O O
capable O O
of O O
phosphorylating O O
a O O
recombinant O O
IkappaBalpha O O
sustrate O O
. O O

Confocal O O
microscopy O O
further O O
demonstrated O O
that O O
exogenously O O
expressed O O
PKCtheta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IKKss B B_GENE
colocalize O O
in O O
the O O
membrane O O
of O O
CD3/CD28-costimulated O O
Jurkat O O
T O O
cells O O
. O O

Constitutively O O
active O O
but O O
not O O
kinase-inactive B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
PKCtheta I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activated O O
IKKbeta B B_GENE
in O O
Jurkat O O
T O O
cells O O
. O O

Expression O O
of O O
dominant-active B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PKCtheta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O O
had O O
stimulatory O O
effects O O
on O O
the O O
CD28 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
IL-2 B B_GENE
promoter I I_GENE
. O O

Taken O O
together O O
, O O
these O O
data O O
show O O
that O O
the O O
activation O O
of O O
PKCtheta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
the O O
TCR B B_GENE
and O O
CD28 B B_GENE
plays O O
an O O
important O O
role O O
in O O
the O O
assembly O O
and O O
activation O O
of O O
IKK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
T O O
cell O O
membrane O O

T-cell O O
-mediated O O
regulation O O
of O O
osteoclastogenesis O O
by O O
signalling O O
cross-talk O O
between O O
RANKL B B_GENE
and O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Bone O O
resorption O O
is O O
regulated O O
by O O
the O O
immune O O
system O O
, O O
where O O
T-cell O O
expression O O
of O O
RANKL B B_GENE
( O O
receptor B B_GENE/B_DISEASE
activator I I_GENE/I_DISEASE
of I I_GENE/I_DISEASE
nuclear I I_GENE/I_DISEASE
factor I I_GENE/I_DISEASE
( I I_GENE/I_DISEASE
NF I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
-kappaB I I_GENE/I_DISEASE
ligand I I_GENE/I_DISEASE
) O O
, O O
a O O
member O O
of O O
the O O
tumour-necrosis B B_GENE/B_BIO
factor I I_GENE/I_BIO
family I I_GENE/I_BIO
that O O
is O O
essential O O
for O O
osteoclastogenesis O O
, O O
may O O
contribute O O
to O O
pathological O O
conditions O O
, O O
such O O
as O O
autoimmune O O
arthritis O O
. O O

However O O
, O O
whether O O
activated O O
T O O
cells O O
maintain O O
bone O O
homeostasis O O
by O O
counterbalancing O O
the O O
action O O
of O O
RANKL B B_GENE
remains O O
unknown O O
. O O

Here O O
we O O
show O O
that O O
T-cell O O
production O O
of O O
interferon B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IFN I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
strongly O O
suppresses O O
osteoclastogenesis O O
by O O
interfering O O
with O O
the O O
RANKL B B_GENE
-RANK O O
signalling O O
pathway O O
. O O

IFN-gamma B B_DISEASE/B_GENE
induces O O
rapid O O
degradation O O
of O O
the O O
RANK B B_ENZYME[GENE]/B_PERSON
adapter I I_ENZYME[GENE]/I_PERSON
protein I I_ENZYME[GENE]/I_PERSON
, O O
TRAF6 B B_GENE
( O O
tumour B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor-associated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
which O O
results O O
in O O
strong O O
inhibition O O
of O O
the O O
RANKL B B_GENE
-induced O O
activation O O
of O O
the O O
transcription B B_GENE
factor I I_GENE
NF-kappaB B I_GENE
and O O
JNK B B_GENE
. O O

This O O
inhibition O O
of O O
osteoclastogenesis O O
is O O
rescued O O
by O O
overexpressing O O
TRAF6 B B_GENE
in O O
precursor O O
cells O O
, O O
which O O
indicates O O
that O O
TRAF6 B B_GENE
is O O
the O O
target O O
critical O O
for O O
the O O
IFN-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
action O O
. O O

Furthermore O O
, O O
we O O
provide O O
evidence O O
that O O
the O O
accelerated O O
degradation O O
of O O
TRAF6 B B_GENE
requires O O
both O O
its O O
ubiquitination O O
, O O
which O O
is O O
initiated O O
by O O
RANKL B B_GENE
, O O
and O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-induced O O
activation O O
of O O
the O O
ubiquitin-proteasome O O
system O O
. O O

Our O O
study O O
shows O O
that O O
there O O
is O O
cross-talk O O
between O O
the O O
tumour B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IFN B B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
families I I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
through O O
which O O
IFN-gamma B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O O
a O O
negative O O
link O O
between O O
T-cell O O
activation O O
and O O
bone O O
resorption O O
. O O

Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
offer O O
a O O
therapeutic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
treat O O
the O O
inflammation-induced O B_DISEASE_ADJECTIVE[DISEASE]
tissue O I_DISEASE_ADJECTIVE[DISEASE]
breakdown O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Stromal-derived B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
thrombopoietin B B_GENE
regulate O O
distinct O O
aspects O O
of O O
human O O
megakaryopoiesis O O
. O O

The O O
role O O
of O O
the O O
chemokine B B_GENE
binding O O
stromal-derived B B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I I_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 I I_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
SDF-1 B B_GENE
) O O
in O O
normal O O
human O O
megakaryopoiesis O O
at O O
the O O
cellular O O
and O O
molecular O O
levels O O
and O O
its O O
comparison O O
with O O
that O O
of O O
thrombopoietin B B_GENE
( O O
TPO B B_PROTEIN[GENE]
) O O
have O O
not O O
been O O
determined O O
. O O

In O O
this O O
study O O
it O O
was O O
found O O
that O O
SDF-1 B B_GENE/B_LOCATION
, O O
unlike O O
TPO B B_GENE
, O O
does O O
not O O
stimulate O O
alpha O O
( O O
IIb O O
) O O
beta O O
( O O
3 O O
) O O
( O O
+ O O
) O O
cell O O
proliferation O O
or O O
differentiation O O
or O O
have O O
an O O
antiapoptotic O O
effect O O
. O O

However O O
, O O
it O O
does O O
induce O O
chemotaxis O O
, O O
trans-Matrigel O O
migration O O
, O O
and O O
secretion O O
of O O
matrix O O
metalloproteinase B B_ENZYME[GENE]
9 I I_ENZYME[GENE]
( O O
MMP-9 B B_TIME[MEASURE]/B_GENE
) O O
and O O
vascular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
endothelial I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
VEGF B B_GENE
) O O
by O O
these O O
cells O O
, O O
and O O
both O O
SDF-1 B B_GENE
and O O
TPO B B_GENE
increase O O
the O O
adhesion O O
of O O
alpha O O
( O O
IIb O O
) O O
beta O O
( O O
3 O O
) O O
( O O
+ O O
) O O
cells O O
to O O
fibrinogen B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
vitronectin B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Investigating O O
the O O
intracellular O O
signaling O O
pathways O O
induced O O
by O O
SDF-1 B B_GENE
and O O
TPO B B_GENE/B_DISEASE
revealed O O
some O O
overlapping O O
patterns O O
of O O
protein O O
phosphorylation/activation O O
( O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MAPK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p42/44 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
MAPK B B_GENE
p38 I I_GENE
, O O
and O O
AKT B B_GENE
[ I I_GENE
protein I I_GENE
kinase I I_GENE
B I I_GENE
] I I_GENE
) O O
and O O
some O O
that O O
were O O
distinct O O
for O O
TPO B B_GENE/B_DISEASE
( O O
eg O O
, O O
JAK-STAT B B_GENE
) O O
and O O
for O O
SDF-1 B B_GENE
( O O
eg O O
, O O
NF-kappa B B_GENE
B I I_GENE
) O O
. O O

It O O
was O O
also O O
found O O
that O O
though O O
inhibition O O
of O O
phosphatidyl-inositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3-kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI-3K B B_GENE
) O O
by O O
LY294002 O O
in O O
alpha O O
( O O
IIb O O
) O O
beta O O
( O O
3 O O
) O O
( O O
+ O O
) O O
cells O O
induced O O
apoptosis O O
and O O
inhibited O O
chemotaxis O O
adhesion O O
and O O
the O O
secretion O O
of O O
MMP-9 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
VEGF B B_GENE
, O O
the O O
inhibition O O
of O O
MAPK B B_GENE
p42/44 I I_GENE
( O O
by O O
the O O
MEK O O
inhibitor O O
U0126 O O
) O O
had O O
no O O
effect O O
on O O
the O O
survival O O
, O O
proliferation O O
, O O
and O O
migration O O
of O O
these O O
cells O O
. O O

Hence O O
, O O
it O O
is O O
suggested O O
that O O
the O O
proliferative O O
effect O O
of O O
TPO B B_GENE
is O O
more O O
related O O
to O O
activation O O
of O O
the O O
JAK-STAT O O
pathway O O
( O O
unique O O
to O O
TPO B B_GENE
) O O
, O O
and O O
the O O
PI-3K-AKT O O
axis O O
is O O
differentially O O
involved O O
in O O
TPO- O O
and O O
SDF-1-dependent O O
signaling O O
. O O

Accordingly O O
, O O
PI-3K B B_GENE
is O O
involved O O
in O O
TPO B B_GENE
-mediated O O
inhibition O O
of O O
apoptosis O O
, O O
TPO- O O
and O O
SDF-1-regulated O O
adhesion O O
to O O
fibrinogen B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
vitronectin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
SDF-1 B B_GENE
-mediated O O
migration O O
. O O

This O O
study O O
expands O O
the O O
understanding O O
of O O
the O O
role O O
of O O
SDF-1 B B_GENE/B_LOCATION
and O O
TPO B B_GENE/B_LOCATION
in O O
normal O O
human O O
megakaryopoiesis O O
and O O
indicates O O
the O O
molecular O O
basis O O
of O O
the O O
observed O O
differences O O
in O O
cellular O O
responses O O
. O O

( O O
Blood. O O
2000 O B_MEASURE
; O O
96 O B_MEASURE
: O O
4142-4151 O B_MEASURE/B_LOCATION
) O O

Adhesion O O
of O O
immature O O
and O O
mature O O
T O O
cells O O
induces O O
in O O
human O O
thymic O O
epithelial O O
cells O O
( O O
TEC O O
) O O
activation O O
of O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
trascription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NF-kappaB B B_GENE
and O O
NF-IL6 B B_GENE
) O O
and O O
IL-6 O O
gene O O
expression O O
: O O
role O O
of O O
alpha3beta1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha6beta4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
integrins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
precursors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
homed O O
to O O
thymus O O
develop O O
in O O
close O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
contact O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
with O O
stromal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Among O O
them O O
, O O
thymic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
epithelial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TEC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
are O O
known O O
to O O
exert O O
dominant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
roles O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
their O O
survival O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
and O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
shaping O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

Key O O
molecules O O
mediating O O
TEC O O
/ O O
thymocytes O O
interactions O O
include O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
growth B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
secreted O O
by O O
the O O
two O O
cell O O
types O O
and O O
adhesion B B_GENE/B_BIO
receptors I I_GENE/I_BIO
mediating O O
cell O O
contact O O
. O O

Signaling O O
events O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
triggered O O
in O O
thymocytes O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
by O O
adhesion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
epithelial O B_DISEASE/B_GENE
cells O B_DISEASE/I_GENE
have O O
been O O
extensively O O
investigated O O
, O O
whereas O O
little O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
on O O
the O O
opposite O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
phenomenon O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
previously O O
investigated O O
this O O
issue O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
a O O
co-culture O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
composed O O
of O O
TEC O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cultures O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
derived O O
from O O
human O B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
normal O I_SPECIES[BIO]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
thymus O I_SPECIES[BIO]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
heterologous O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
thymocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
demonstrated O O
that O O
thymocytes O O
adhere O O
to O O
TEC O O
involving O O
beta1 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
beta4 I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
integrins I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
induce O O
the O O
clustering O O
of O O
alpha3beta1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha6beta4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
at O O
the O O
TEC O O
surface O O
. O O

In O O
addition O O
thymocyte O O
adhesion O O
was O O
followed O O
by O O
activation O O
of O O
NF-kappaB B B_GENE
and O O
NF-IL6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
enhanced O O
IL-6 O O
production O O
. O O

The O O
two O O
latter O O
phenomena O O
were O O
reproduced O O
by O O
the O O
cross-linking O O
of O O
the O O
alpha3 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
alpha6 B B_PROTEIN[GENE]/B_MEASURE
, O O
beta1 B B_GENE
and I I_GENE
beta4 I I_GENE
integrins I I_GENE
, O O
thus O O
implying O O
that O O
the O O
alpha3beta1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha6beta4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
signal O O
during O O
thymocyte O O
adhesion O O
. O O

We O O
have O O
extended O O
our O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
work O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigating O O
in O O
the O O
same O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
experimental O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
setting O O
the O O
inducing O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
non O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O O
or O O
activated O O
policlonal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
or O O
clonal O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mature O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
as O O
representative O B_PERSON/B_LOCATION
of O O
the O O
more O O
mature O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
thymocyte O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
subset O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O O

We O O
found O O
that O O
adhesion O O
of O O
unstimulated O O
T O O
cell O O
i O O
) O O
involved O O
beta1 O O
, O O
but O O
not O O
beta4 O O
integrin O O
functions O O
at O O
the O O
surface O O
ii O O
) O O
induced O O
the O O
clustering O O
of O O
alpha3beta1 B B_GENE
, O O
but O O
not O O
alpha2beta1 B B_GENE
heterodimers I I_GENE
at O O
the O O
TEC O O
surface O O
and O O
iii O O
) O O
up-regulated O O
the O O
nuclear O O
binding O O
activity O O
of O O
NF-kappaB B B_GENE
transcription I I_GENE
factor I I_GENE
and O O
the O O
IL-6 O O
secretion O O
. O O

We O O
propose O O
that O O
alpha3beta1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha6beta4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
induced O O
to O O
cluster O O
at O O
the O O
TEC O O
surface O O
recognizing O O
yet O O
unknown O O
cellular B B_BIO/B_LOCATION
ligands I I_BIO/I_LOCATION
differentially O O
expressed O O
during O O
T O O
cell O O
development O O
. O O

Identification O O
and O O
characterization O O
of O O
SKAT-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
novel O O
Th2-specific B B_GENE/B_PERSON
zinc I I_GENE/I_PERSON
finger I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
. O O

We O O
have O O
identified O O
a O O
novel O O
Kruppel-type B B_GENE/B_PERSON
zinc I I_GENE/I_PERSON
finger I I_GENE/I_PERSON
( I I_GENE/I_PERSON
ZF I I_GENE/I_PERSON
) I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
, O O
SKAT-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
selectively O O
expressed O O
by O O
murine O O
Th2 O O
cells O O
. O O

The O O
protein O O
encoded O O
by O O
this O O
gene O O
has O O
14 O O
C2H2-type O O
ZF O O
tandemly O O
arrayed O O
at O O
its O O
C B B_PROTEIN[GENE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
terminus I B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
N-terminal B B_PROTEIN[GENE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SCAN B I_PROTEIN[GENE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
box I I_PROTEIN[GENE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
KRAB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

SKAT-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
tissue O O
restricted O O
in O O
expression O O
at O O
the O O
RNA O O
level O O
, O O
detectable O O
only O O
in O O
brain O O
and O O
at O O
low O O
levels O O
in O O
kidney O O
and O O
spleen O O
and O O
few O O
hematopoietic O O
cell O O
lines O O
. O O

By O O
in O O
situ O O
hybridization O O
, O O
SKAT-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
was O O
found O O
to O O
peak O O
in O O
antigen-stimulated O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
after O O
2-3 O O
days O O
of O O
culture O O
under O O
Th2 O O
but O O
not O O
Th1 O O
biasing O O
conditions O O
. O O

This O O
pattern O O
of O O
expression O O
closely O O
mirrored O O
that O O
of O O
GATA-3 B B_GENE
in O O
the O O
same O O
cells O O
. O O

In O O
transient O O
transfection O O
experiments O O
in O O
phorbol O O
12-myristate O O
13-acetate/ionomycin-stimulated O O
EL4 O O
cells O O
, O O
SKAT-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
to O O
up-regulate O O
the O O
activity O O
of O O
the O O
IL-4 B B_GENE
but I I_GENE
not I I_GENE
the I I_GENE
IL-5 I I_GENE
promoter I I_GENE
, O O
contrasting O O
with O O
the O O
ability O O
of O O
GATA-3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
activate O O
both O O
promoters B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

This O O
result O O
was O O
confirmed O O
using O O
clones O O
of O O
EL4 O O
cells O O
stably O O
expressing O O
an O O
inducible O O
form O O
of O O
SKAT-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
thus O O
SKAT-2 B B_LOCATION/B_PERSON
is O O
a O O
novel O O
Th2-specific B B_GENE/B_PERSON
gene I I_GENE/I_PERSON
that O O
may O O
play O O
a O O
role O O
in O O
selective O O
regulation O O
of O O
cytokine B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
in O O
T O O
cells O O
. O O

hsp70 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interacting I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Hip I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O O
not O O
affect O O
glucocorticoid B B_GENE
receptor I I_GENE
folding O O
by O O
the O O
hsp90-based O O
chaperone O O
machinery O O
except O O
to O O
oppose O O
the O O
effect O O
of O O
BAG-1 B B_GENE
. O O

Reticulocyte O O
lysate O O
contains O O
a O O
chaperone O O
system O O
that O O
assembles O O
glucocorticoid B B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DISEASE_ADJECTIVE[DISEASE]
( I I_DISEASE_ADJECTIVE[DISEASE]
GR I I_DISEASE_ADJECTIVE[DISEASE]
) I I_DISEASE_ADJECTIVE[DISEASE]
.hsp90 I I_DISEASE_ADJECTIVE[DISEASE]
heterocomplexes I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Using O O
purified B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
proteins I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
we O O
have O O
prepared O O
a O O
five-protein O O
heterocomplex O O
assembly O O
system O O
consisting O O
of O O
two O O
proteins O O
essential O O
for O O
heterocomplex O O
assembly- O O
hsp90 B B_GENE
and O O
hsp70 B B_GENE
-and O O
three O O
proteins O O
that O O
act O O
as O O
co-chaperones O O
to O O
enhance O O
assembly- O O
Hop B B_DISEASE/B_GENE
, O O
hsp40 B B_GENE
, O O
p23 B B_GENE
[ O O
Morishima O O
, O O
Y. O O
, O O
Kanelakis O O
, O O
K. O O
C. O O
, O O
Silverstein O O
, O O
A. O O
M. O O
, O O
Dittmar O O
, O O
K. O O
D. O O
, O O
Estrada O O
, O O
L. O O
, O O
and O O
Pratt O O
, O O
W. O O
B. O O
( O O
2000 O O
) O O
J. O O
Biol. O O
Chem. O O
275 O O
, O O
6894-6900 O O
] O O
. O O

The O O
hsp70 B B_GENE
co-chaperone I I_GENE
Hip I I_GENE
has O O
been O O
recovered O O
in O O
receptor.hsp90 B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
heterocomplexes I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
at O O
an O O
intermediate O O
stage O O
of O O
assembly O O
in O O
reticulocyte O O
lysate O O
, O O
and O O
Hip B B_DISEASE/B_GENE
is O O
also O O
thought O O
to O O
be O O
an O O
intrinsic O O
component O O
of O O
the O O
assembly O O
machinery O O
. O O

Here O O
we O O
show O O
that O O
immunodepletion O O
of O O
Hip B B_GENE/B_DISEASE
from O O
reticulocyte O O
lysate O O
or O O
addition O O
of O O
high O O
levels O O
of O O
Hip B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
the O O
purified O O
five-protein O O
system O O
does O O
not O O
affect O O
GR.hsp90 O O
heterocomplex O O
assembly O O
or O O
the O O
activation O O
of O O
steroid O O
binding O O
activity O O
that O O
occurs O O
with O O
assembly O O
. O O

Despite O O
the O O
fact O O
that O O
Hip B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O O
not O O
affect O O
assembly O O
, O O
it O O
is O O
recovered O O
in O O
GR.hsp90 B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
heterocomplexes I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assembled O O
by O O
both O O
systems O O
. O O

In O O
the O O
five-protein O O
system O O
, O O
Hip B B_GENE/B_DISEASE
prevents O O
inhibition O O
of O O
assembly O O
by O O
the O O
hsp70 B B_GENE
co-chaperone I I_GENE
BAG-1 I I_GENE
, O O
and O O
cotransfection O O
of O O
Hip B B_GENE/B_DISEASE
with O O
BAG-1 B B_GENE
opposes O O
BAG-1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
reduction O O
of O O
steroid O O
binding O O
activity O O
in O O
COS O O
cells O O
. O O

We O O
conclude O O
that O O
Hip B B_GENE/B_DISEASE
is O O
not O O
a O O
component O O
of O O
the O O
assembly O O
machinery O O
but O O
that O O
it O O
could O O
play O O
a O O
regulatory O O
role O O
in O O
opposition O O
to O O
BAG-1 B B_GENE/B_DISEASE
. O O

Cutting O O
edge O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
STAT6-deficient O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mice O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
have O O
enhanced O O
tumor O B_DISEASE/B_MEASURE
immunity O I_DISEASE/I_MEASURE
to O O
primary O B_DISEASE_ADJECTIVE[DISEASE]
and O O
metastatic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mammary O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
carcinoma O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

STAT4 B B_GENE
and O O
STAT6 B B_GENE
are O O
essential O O
for O O
the O O
development O O
of O O
CD4 O O
( O O
+ O O
) O O
Th1 O O
and O O
Th2 O O
development O O
, O O
respectively O O
. O O

Tumor O B_PERSON/B_ORGANIZATION
immunologists O I_PERSON/I_ORGANIZATION
have O O
hypothesized O O
that O O
Th1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
critical O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O O
tumor O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
immunity O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O O
they O O
facilitate O O
differentiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
CD8 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
which O O
are O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti-tumor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effectors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
used O O
STAT4 O B_GENE
( O O
-/- O O
) O O
and O O
STAT6 O B_GENE
( O O
-/- O O
) O O
mice O B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
test O O
this O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BALB/c O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
knockout O B_SPECIES[BIO]/B_GENE
mice O I_SPECIES[BIO]/I_GENE
were O O
challenged O O
in O O
the O O
mammary O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
gland O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
with O O
the O O
highly O O
malignant O B_DISEASE_ADJECTIVE[DISEASE]
and O O
spontaneously O O
metastatic O B_DISEASE_ADJECTIVE[DISEASE]
BALB/c-derived O I_DISEASE_ADJECTIVE[DISEASE]
4T1 O I_DISEASE_ADJECTIVE[DISEASE]
mammary O I_DISEASE_ADJECTIVE[DISEASE]
carcinoma O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Primary O B_DISEASE_ADJECTIVE[DISEASE]
tumor O I_DISEASE_ADJECTIVE[DISEASE]
growth O I_DISEASE_ADJECTIVE[DISEASE]
and O O
metastatic O B_DISEASE
disease O I_DISEASE
are O O
reduced O O
in O O
STAT6 O B_GENE
( O O
-/- O B_PERSON/B_PROTEIN[GENE]
) O O
mice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
relative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
BALB/c O B_GENE/B_PERSON
and O O
STAT4 O B_GENE
( O O
-/- O O
) O O
mice O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Ab O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
depletions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
demonstrate O O
that O O
the O O
effect O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
mediated O O
by O O
CD8 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
and O O
immunized O O
STAT6 O B_GENE
( O O
-/- O O
) O O
mice O B_BIO/B_PERSON
have O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
levels O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
4T1-specific O B_DISEASE/B_GENE
CTL O I_DISEASE/I_GENE
than O O
BALB/c O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
STAT4 O B_GENE
( O O
-/- O O
) O O
mice O B_BIO/B_PERSON
. O O

Surprisingly O O
, O O
Th1 O B_GENE/B_LOCATION
or O O
Th2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
not O O
involved O O
, O O
because O O
CD4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
depletion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
does O O
not O O
diminish O O
the O O
anti-tumor O B_DISEASE
effect O I_DISEASE
. O O

Therefore O O
, O O
deletion O O
of O O
the O O
STAT6 B B_GENE
gene I I_GENE
facilitates O O
development O O
of O O
potent O O
anti-tumor O O
immunity O O
via O O
a O O
CD4 O O
( O O
+ O O
) O O
-independent O O
pathway O O
. O O

Activation O O
of O O
oncogenic B B_GENE
transcription I I_GENE
factor I I_GENE
AP-1 I I_GENE
in O O
T O O
cells O O
infected O O
with O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
1 O O
. O O

Human O O
T O O
cell O O
leukemia O O
virus O O
type O O
1 O O
( O O
HTLV-1 O O
) O O
Tax B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
protein I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
transforms O O
primary O O
human O O
T O O
cells O O
in O O
vitro O O
. O O

We O O
previously O O
showed O O
that O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
the O O
expression O O
of O O
various O O
family O O
members O O
of O O
the O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
AP-1 I I_GENE/I_LOCATION
such O O
as O O
c-Jun B B_GENE
, O O
JunD B B_GENE/B_DISEASE
, O O
c-Fos B B_GENE
, O O
and O O
Fra-1 B B_GENE
at O O
the O O
mRNA O O
level O O
in O O
T O O
cells O O
. O O

In O O
this O O
study O O
, O O
we O O
have O O
examined O O
the O O
ability O O
of O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
activate O O
transcription O O
through O O
the O O
AP-1-binding B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
( O O
AP-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
site I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
. O O

A O O
transient O O
transfection O O
study O O
showed O O
that O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
activate O O
transcription O O
through O O
the O O
AP-1-binding B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
in O O
a O O
human O O
T O O
cell O O
line O O
, O O
whereas O O
any O O
combination O O
of O O
AP-1 B B_GENE/B_BIO
proteins I I_GENE/I_BIO
did O O
so O O
much O O
less O O
than O O
Tax B B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
indicating O O
that O O
the O O
activation O O
of O O
the O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
require O O
a O O
mechanism O O
other O O
than O O
the O O
induction O O
of O O
AP-1 B B_GENE
mRNA I I_GENE
. O O

Fresh O B_NUMBER[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
peripheral O I_NUMBER[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_NUMBER[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leukemia O I_NUMBER[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_NUMBER[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
all O O
surveyed O O
ATL O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
displayed O O
constitutive O B_DISEASE_ADJECTIVE[DISEASE]
AP-1 O O
DNA-binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
whereas O O
no O O
normal O B_PERSON/B_BIO
individuals O I_PERSON/I_BIO
did O O
. O O

However O O
, O O
the O O
HTLV-1 B B_GENE/B_MEASURE
genes I I_GENE/I_MEASURE
, O O
including O O
tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
are O O
not O O
significantly O O
expressed O O
in O O
fresh O O
leukemia O O
cells O O
from O O
ATL O O
patients O O
. O O

Our O O
present O O
results O O
suggest O O
that O O
activation O O
of O O
AP-1 B B_GENE
occurs O O
through O O
Tax-dependent O O
and O O
-independent O O
mechanisms O O
in O O
HTLV-1-infected O O
T O O
cells O O
, O O
which O O
may O O
play O O
some O O
roles O O
in O O
dysregulated O O
phenotypes O O
of O O
HTLV-1-infected O O
cells O O
. O O

2 O B_MEASURE
, O O
2 O B_NUMBER[MEASURE]
' O O
, O O
4 O B_NUMBER[MEASURE]
, O O
6 O B_NUMBER[MEASURE]
, O O
6'-pentachlorobiphenyl O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
apoptosis O B_DISEASE
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Polychlorinatedbiphenyls O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O O
PCBs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
are O O
a O O
group O B_ORGANIZATION/B_MEASURE
of O O
persistent O B_DISEASE_ADJECTIVE[DISEASE]
and O O
widely O O
dispersed O O
environmental O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pollutants O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
some O O
of O O
which O O
may O O
be O O
immunotoxic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
investigated O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PCBs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
immune O B_DISEASE
system O I_DISEASE
by O O
assessing O O
apoptotic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
death O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
U937 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Among O O
the O O
various O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
congeners O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tested O O
, O O
2 O B_NUMBER[MEASURE]
, O O
2 O B_NUMBER[MEASURE]
' O O
, O O
4 O B_NUMBER[MEASURE]
, O O
6 O B_NUMBER[MEASURE]
, O O
6'-pentachlorobiphenyl O B_TIME[MEASURE]
( O O
PeCB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
, O O
a O O
highly O O
ortho-substituted O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
congener O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
specifically O O
induced O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
fragmentation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
a O O
hallmark O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
apoptosis O B_DISEASE/B_GENE
, O O
while O O
the O O
other O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
examined O O
di- O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
tri- O O
, O O
tetra- O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
and O O
pentachlorobiphenyls O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
did O O
not O O
. O O

To O O
further O O
study O O
the O O
2 O B_NUMBER[MEASURE]
, O O
2 O B_NUMBER[MEASURE]
' O O
, O O
4 O B_NUMBER[MEASURE]
, O O
6 O B_NUMBER[MEASURE]
, O O
6'-PeCB-induced O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
death O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
apoptosis O B_DISEASE
were O O
examined O O
. O O

2 O B_MEASURE
, O O
2 O B_NUMBER[MEASURE]
' O O
, O O
4 O B_NUMBER[MEASURE]
, O O
6 O B_NUMBER[MEASURE]
, O O
6'-PeCB O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
viability O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
induced O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
morphologic O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
features O O
characteristic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
apoptosis O B_DISEASE
such O I_DISEASE
as O O
chromatin O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
aggregation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
apoptotic O B_DISEASE_ADJECTIVE[DISEASE]
bodies O I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O O
, O O
caspase-3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
an O O
executioner O O
of O O
apoptosis O O
, O O
was O O
activated O O
and O O
its O O
substrate O O
, O O
poly B B_GENE
( I I_GENE
ADP-ribose I I_GENE
) I I_GENE
polymerase I I_GENE
( O O
PARP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
was O O
cleaved O O
during O O
2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-PeCB-induced O O
apoptosis O O
. O O

In O O
contrast O O
, O O
3 O O
, O O
3 O O
' O O
, O O
4 O O
, O O
4 O O
' O O
, O O
5-PeCB O O
, O O
a O O
congener O O
of O O
coplanar O O
structure O O
, O O
as O O
well O O
as O O
2 O O
, O O
3 O O
, O O
7 O O
, O O
8-TCDD O O
did O O
not O O
induce O O
apoptosis O O
in O O
these O O
human O O
monocytic O O
cells O O
, O O
although O O
they O O
potently O O
induced O O
CYP B B_DISEASE/B_GENE
1A1 I I_DISEASE/I_GENE
in O O
human O O
hepatoma O O
Hep O O
G2 O O
cells O O
. O O

Taken O O
together O O
, O O
the O O
data O O
indicate O O
that O O
2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-PeCB O O
induces O O
apoptosis O O
in O O
human O O
monocytic O O
cells O O
through O O
a O O
mechanism O O
that O O
is O O
independent O O
of O O
the O O
arylhydrocarbon B B_GENE
receptor I I_GENE
. O O

This O O
suggests O O
a O O
possibly O O
separate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanism O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
by O O
which O O
PCBs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cause O O
immunosuppression O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Effects O O
of O O
deregulated O O
Raf O O
activation O O
on O O
integrin B B_GENE/B_DISEASE
, O O
cytokine-receptor O O
expression O O
and O O
the O O
induction O O
of O O
apoptosis O O
in O O
hematopoietic O O
cells O O
. O O

The O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
deregulated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Raf O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
activation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
growth O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
differentiation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
hematopoietic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
were O O
investigated O O
. O O

The O O
cytokine-dependent O O
murine O O
myeloid O O
FDC-P1 O O
and O O
human O O
erythroleukemic O O
TF-1 O O
cell O O
lines O O
were O O
transformed O O
to O O
grow O O
in O O
response O O
to O O
deregulated O O
Raf O O
expression O O
in O O
the O O
absence O O
of O O
exogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokines I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
conditionally O O
active O O
Raf B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
regulated O O
by O O
beta-estradiol O O
as O O
cDNAs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
containing O O
the O O
Raf B B_GENE
catalytic I I_GENE
, O O
but O O
lacking O O
negative-regulatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
were O O
ligated O O
to O O
the O O
hormone B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
domain I I_GENE/I_LOCATION
of O O
the O O
estrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
deltaRaf B B_GENE/B_LOCATION
: I I_GENE/I_LOCATION
ER I I_GENE/I_LOCATION
) O O
. O O

Continuous O O
deltaRaf B B_GENE/B_LOCATION
expression O O
prevented O O
apoptosis O O
in O O
the O O
absence O O
of O O
exogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokines I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
altered O O
the O O
morphology O O
of O O
the O O
FD/deltaRaf O O
: O O
ER O O
cells O O
as O O
they O O
grew O O
in O O
large O O
aggregated O O
masses O O
( O O
> O O
100 O O
cells O O
) O O
whereas O O
the O O
parental O O
cytokine-dependent O O
FDC-P1 O O
cells O O
grew O O
in O O
smaller O O
grape-like O O
clusters O O
( O O
< O O
10 O O
cells O O
) O O
. O O

FD/deltaRaf-1 O O
: O O
ER O O
cells O O
growing O O
in O O
response O O
to O O
Raf O O
activation O O
displayed O O
decreased O O
levels O O
of O O
the O O
Mac-2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Mac-3 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
their O O
cell O O
surface O O
. O O

In O O
contrast O O
, O O
when O O
these O O
cells O O
were O O
cultured O O
in O O
IL-3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
higher O O
levels O O
of O O
these O O
adhesion B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
detected O O
. O O

Expression O O
of O O
activated O O
Raf B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oncoproteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O O
abrogated O O
cytokine O O
dependency O O
and O O
prevented O O
apoptosis O O
of O O
TF-1 O O
cells O O
. O O

Moreover O O
, O O
the O O
differentiation O O
status O O
of O O
these O O
Raf-responsive O O
cells O O
was O O
more O O
immature O O
upon O O
Raf O O
activation O O
as O O
culture O O
with O O
the O O
differentiation-inducing O O
agent O O
phorbol O O
12 O O
myristate O O
13-acetate O O
( O O
PMA O O
) O O
and O O
beta-estradiol O O
resulted O O
in O O
decreased O O
levels O O
of O O
the O O
CD11b B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
CD18 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
integrin I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
cell O O
surface O O
. O O

In O O
contrast O O
when O O
the O O
Raf-responsive O O
cells O O
were O O
induced O O
to O O
differentiate O O
with O O
PMA O O
and O O
GM-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
in O O
the O O
absence O O
of O O
deltaRaf B B_GENE
: I I_GENE
ER I I_GENE
activation O O
, O O
increased O O
levels O O
of O O
the O O
CD11b B B_GENE/B_MEASURE
and I I_GENE/I_MEASURE
CD18 I I_GENE/I_MEASURE
molecules I I_GENE/I_MEASURE
were O O
detected O O
. O O

Retinoic O O
acid O O
( O O
RA O O
) O O
inhibited O O
3H-thymidine O O
incorporation O O
in O O
response O O
to O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Interestingly O O
, O O
Raf O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
counterbalanced O O
the O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
synthesis O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
caused O O
by O O
RA O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
not O O
PMA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Thus O O
deregulated O O
Raf O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
alter O O
cytokine O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dependency O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
integrin O B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
expression O B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
the O O
stage O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
differentiation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
Raf-responsive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
will O O
be O O
useful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
elucidating O O
the O O
roles O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
MAP O B_GENE
kinase O I_GENE
cascade O I_GENE
on O O
hematopoietic O B_DISEASE/B_ORGANISM_FUNCTION
cell O I_DISEASE/I_ORGANISM_FUNCTION
differentiation O I_DISEASE/I_ORGANISM_FUNCTION
and O O
malignant O B_DISEASE/B_ORGANISM_FUNCTION
transformation O I_DISEASE/I_ORGANISM_FUNCTION

Cyclic O O
AMP O O
activates O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Th2 O O
cells O O
: O O
phosphorylation O O
of O O
GATA-3 B B_GENE
and O O
stimulation O O
of O O
Th2 O O
cytokine O O
gene O O
expression O O
. O O

cAMP O B_GENE
is O O
an O O
important O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
second O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
messenger O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O O
immunomodulatory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
properties O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Elevation O O
of O O
intracellular O O
cAMP O O
in O O
T O O
cells O O
, O O
induced O O
by O O
agents O O
such O O
as O O
IL-1alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
PGs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
inhibits O O
T O O
cell O O
activation O O
. O O

In O O
effector O O
T O O
cells O O
, O O
an O O
increase O O
in O O
the O O
level O O
of O O
intracellular O O
cAMP O O
inhibits O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
in O O
Th1 O O
cells O O
but O O
stimulates O O
cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O O
in O O
Th2 O O
cells O O
. O O

Here O O
we O O
report O O
that O O
cAMP-induced O O
effects O O
in O O
Th2 O O
cells O O
occur O O
independently O O
of O O
the O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
pathway O O
, O O
which O O
is O O
the O O
major O O
mediator O O
of O O
cAMP-induced O O
signaling O O
events O O
in O O
most O O
cell O O
types O O
. O O

Instead O O
, O O
cAMP O O
stimulates O O
activation O O
of O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Th2 O O
cells O O
. O O

This O O
appears O O
to O O
be O O
a O O
Th2 O O
-selective O O
event O O
because O O
cAMP O O
barely O O
increased O O
p38 B B_GENE
phosphorylation O O
in O O
Th1 O O
cells O O
. O O

We O O
show O O
that O O
in O O
Th2 O O
cells O O
, O O
cAMP O O
promotes O O
the O O
production O O
of O O
both O O
IL-5 B B_GENE
and O O
IL-13 B B_GENE
, O O
which O O
play O O
distinct O O
but O O
critical O O
roles O O
in O O
asthma O O
pathogenesis O O
. O O

Our O O
data O O
also O O
show O O
that O O
cAMP O O
causes O O
increased O O
phosphorylation O O
of O O
the O O
transcription B B_GENE
factor I I_GENE
GATA-3 I I_GENE
, O O
which O O
we O O
have O O
shown O O
is O O
a O O
critical O O
regulator O O
of O O
Th2 O O
cytokine O O
gene O O
expression O O
and O O
, O O
in O O
turn O O
, O O
of O O
airway O O
inflammation O O
in O O
mice O O
. O O

Thus O O
, O O
Th2 O O
-specific O O
GATA-3 B B_GENE
expression O O
and O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O O
together O O
provide O O
a O O
molecular O O
basis O O
for O O
the O O
differential O O
effects O O
of O O
cAMP O O
in O O
the O O
two O O
T O O
helper O O
cell O O
subsets O O
. O O

Characterization O O
of O O
IL-4 B B_GENE
and O O
IL-13 B B_GENE
signals O O
dependent O O
on O O
the O O
human B B_GENE/B_LOCATION
IL-13 I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
alpha I I_GENE/I_LOCATION
chain I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
: O O
redundancy O O
of O O
requirement O O
of O O
tyrosine O O
residue O O
for O O
STAT3 O O
activation O O
. O O

IL-4 B B_GENE
and O O
IL-13 B B_GENE/B_MEASURE
are O O
pleiotropic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
whose O O
biological O O
activities O O
overlap O O
with O O
each O O
other O O
. O O

IL-13 B B_GENE
receptor I I_GENE
alpha I I_GENE
chain I I_GENE
1 I I_GENE
( O O
IL-13R B B_PROTEIN[GENE]
alpha I I_PROTEIN[GENE]
1 I I_PROTEIN[GENE]
) O O
is O O
necessary O O
for O O
binding O O
to O O
IL-13 B B_GENE
, O O
and O O
the O O
heterodimer O O
composed O O
of O O
IL-13R B B_GENE
alpha I I_GENE
1 I I_GENE
and O O
IL-4R B B_PROTEIN[GENE]/B_MEASURE
alpha I I_PROTEIN[GENE]/I_MEASURE
chain I I_PROTEIN[GENE]/I_MEASURE
transduces O O
IL-13 B B_GENE
and O O
IL-4 B B_GENE
signals O O
; O O
however O O
, O O
the O O
functional O O
mapping O O
of O O
the O O
intracellular B B_LOCATION
domain I I_LOCATION
of O O
IL-13R B B_GENE
alpha I I_GENE
1 I I_GENE
is O O
not O O
fully O O
understood O O
. O O

In O O
this O O
study O O
, O O
we O O
constructed O O
wild O O
and O O
mutated O O
types O O
of O O
human B B_GENE/B_BIO
IL-13R I I_GENE/I_BIO
alpha I I_GENE/I_BIO
1 I I_GENE/I_BIO
, O O
and O O
analyzed O O
IL-4 B B_GENE/B_DISEASE
and O O
IL-13 B B_GENE
signals O O
using O O
an O O
IL-13R B B_GENE
alpha I I_GENE
1 I I_GENE
-transfected O O
human O O
B O O
cell O O
line O O
. O O

Expression O O
of O O
IL-13R B B_GENE
alpha I I_GENE
1 I I_GENE
evoked O O
STAT3 B B_GENE/B_LOCATION
activation O O
by O O
IL-4 B B_GENE
and O O
IL-13 B B_GENE
, O O
and O O
in O O
stimulated O O
human O O
B O O
cells O O
, O O
on O O
which O O
IL-13R B B_GENE
alpha I I_GENE
1 I I_GENE
was O O
highly O O
expressed O O
, O O
IL-4 B B_GENE
and O O
IL-13 B B_GENE/B_MEASURE
induced O O
STAT3 B B_GENE
activation O O
. O O

Replacement O O
of O O
the O O
two O O
tyrosine O O
residues O O
completely O O
abolished O O
STAT3 B B_GENE
activation O O
, O O
although O O
replacing O O
either O O
tyrosine O O
residue O O
alone O O
retained O O
it O O
. O O

Furthermore O O
, O O
we O O
found O O
that O O
the O O
Box1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
region I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
the O O
C-terminal B B_GENE/B_LOCATION
tail I I_GENE/I_LOCATION
of O O
IL-13R B B_GENE
alpha I I_GENE
1 I I_GENE
were O O
critical O O
for O O
binding O O
to O O
Tyk2 B B_GENE
, O O
and O O
activation O O
of O O
Jak1 B B_GENE
, O O
Tyk2 B B_GENE
, O O
the O O
insulin B B_GENE
receptor I I_GENE
substrate-1 I I_GENE
and O O
STAT6 B B_GENE
respectively O O
. O O

These O O
results O O
suggest O O
that O O
STAT3 B B_GENE
activation O O
is O O
involved O O
with O O
IL-4 B B_GENE
and O O
IL-13 B B_GENE
signals O O
in O O
human O O
B O O
cells O O
along O O
with O O
the O O
activation O O
of O O
STAT6 B B_GENE
, O O
and O O
that O O
there O O
is O O
a O O
unique O O
sequence O O
in O O
IL-13R B B_GENE/B_BIO
alpha I I_GENE/I_BIO
1 I I_GENE/I_BIO
to O O
activate O O
STAT3 B B_GENE
. O O

Functional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
uncoupling O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
Janus O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3-Stat5 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
malignant O B_DISEASE/B_ORGANISM_FUNCTION
growth O I_DISEASE/I_ORGANISM_FUNCTION
of O O
human O B_DISEASE/B_LOCATION
T O I_DISEASE/I_LOCATION
cell O I_DISEASE/I_LOCATION
leukemia O I_DISEASE/I_LOCATION
virus O I_DISEASE/I_LOCATION
type O I_DISEASE/I_LOCATION
1-transformed O I_DISEASE/I_LOCATION
human O I_DISEASE/I_LOCATION
T O I_DISEASE/I_LOCATION
cells O I_DISEASE/I_LOCATION
. O O

Human O O
T O O
cell O O
leukemia O O
virus O O
type O O
1 O O
( O O
HTLV-1 O O
) O O
transforms O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O O
T O O
lymphocytes O O
and O O
causes O O
adult O O
T O O
cell O O
leukemia O O
. O O

Janus B B_GENE
tyrosine I I_GENE
kinase I I_GENE
( I I_GENE
Jak I I_GENE
) I I_GENE
3 I I_GENE
and O O
transcription B B_PROTEIN[GENE]/B_MEASURE
factors I I_PROTEIN[GENE]/I_MEASURE
Stat5a B I_PROTEIN[GENE]/I_MEASURE
and O O
Stat5b B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
essential O O
for O O
the O O
proliferation O O
of O O
normal O O
T O O
cells O O
and O O
are O O
constitutively O O
hyperactivated O O
in O O
both O O
HTLV-1-transformed O O
human O O
T O O
cell O O
lines O O
and O O
lymphocytes O O
isolated O O
from O O
HTLV-1-infected O O
patients O O
; O O
therefore O O
, O O
a O O
critical O O
role O O
for O O
the O O
Jak3-Stat5 O O
pathway O O
in O O
the O O
progression O O
of O O
this O O
disease O O
has O O
been O O
postulated O O
. O O

We O O
recently O O
reported O O
that O O
tyrphostin O O
AG-490 O O
selectively O O
blocked O O
IL-2 O O
activation O O
of O O
Jak3/Stat5 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
growth O O
of O O
murine O O
T O O
cell O O
lines O O
. O O

Here O O
we O O
demonstrate O O
that O O
disruption O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Jak3/Stat5a/b O B_GENE
signaling O O
with O O
AG-490 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
50 O B_TIME[MEASURE]/B_LOCATION
& O O
mgr O B_MEASURE/B_PERSON
; O O
M O B_MEASURE
) O O
blocked O O
the O O
proliferation O B_DISEASE/B_ORGANISM_FUNCTION
of O O
primary O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
but O O
paradoxically O O
failed O O
to O O
inhibit O O
the O O
proliferation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
HTLV-1-transformed O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
HuT-102 O O
and O O
MT-2 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Structural O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
homologues O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
AG-490 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
inhibited O O
the O O
proliferation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
primary O B_DISEASE_ADJECTIVE[DISEASE]
human O I_DISEASE_ADJECTIVE[DISEASE]
T O I_DISEASE_ADJECTIVE[DISEASE]
cells O I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
HTLV-1-infected O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Disruption O O
of O O
constitutive O O
Jak3/Stat5 O O
activation O O
by O O
AG-490 O O
was O O
demonstrated O O
by O O
inhibition O O
of O O
1 O O
) O O
tyrosine O O
phosphorylation O O
of O O
Jak3 B B_GENE
, O O
Stat5a B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Tyr O O
( O O
694 O O
) O O
) O O
, O O
and O O
Stat5b B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Tyr O O
( O O
699 O O
) O O
) O O
; O O
2 O O
) O O
serine O O
phosphorylation O O
of O O
Stat5a B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Ser O O
( O O
726 O O
) O O
) O O
as O O
determined O O
by O O
a O O
novel O O
phosphospecific B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Ab I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
; O O
and O O
3 O O
) O O
Stat5a/b O O
DNA O O
binding O O
to O O
the O O
Stat5-responsive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta-casein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O O
, O O
AG-490 O O
had O O
no O O
effect O O
on O O
DNA O O
binding O O
by O O
p50/p65 B B_GENE/B_MEASURE
components I I_GENE/I_MEASURE
of O O
NF-kappaB B B_GENE
, O O
a O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
activated O O
by O O
the O O
HTLV-1-encoded B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phosphoprotein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Tax I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Collectively O O
, O O
these O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
the O O
Jak3-Stat5 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
HTLV-1-transformed O B_DISEASE
T O I_DISEASE
cells O I_DISEASE
has O O
become O O
functionally O O
redundant O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
proliferation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Reversal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uncoupling O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
required O O
before O O
Jak3/Stat5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
will O O
be O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
this O O
malignancy O B_DISEASE
. O O

The O O
Epstein-Barr B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
initiating O O
B-cell O O
transformation O O
is O O
activated O O
by O O
RFX B B_GENE
proteins I I_GENE
and O O
the O O
B-cell-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BSAP/Pax5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
-induced O O
B-cell O O
growth O O
transformation O O
, O O
a O O
central O O
feature O O
of O O
the O O
virus O O
' O O
strategy O O
for O O
colonizing O O
the O O
human O O
B-cell O O
system O O
, O O
requires O O
full O O
virus O O
latent O O
gene O O
expression O O
and O O
is O O
initiated O O
by O O
transcription O O
from O O
the O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Wp I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Interestingly O O
, O O
when O O
EBV O B_VIRUS[BIO]/B_GENE
accesses O O
other O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
types O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
this O O
growth-transforming O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
not O O
activated O O
. O O

The O O
present O O
work O O
focuses O O
on O O
a O O
region O O
of O O
Wp B B_GENE/B_DISEASE
which O O
in O O
reporter O O
assays O O
confers O O
B-cell O O
-specific O O
activity O O
. O O

Bandshift O O
studies O O
indicate O O
that O O
this O O
region O O
contains O O
three O O
factor O O
binding O O
sites O O
, O O
termed O O
sites B B_GENE/B_DISEASE
B I I_GENE/I_DISEASE
, I I_GENE/I_DISEASE
C I I_GENE/I_DISEASE
, I I_GENE/I_DISEASE
and I I_GENE/I_DISEASE
D I I_GENE/I_DISEASE
, O O
in O O
addition O O
to O O
a O O
previously O O
characterized O O
CREB B B_LOCATION/B_NUMBER[MEASURE]
site I I_LOCATION/I_NUMBER[MEASURE]
. O O

Here O O
we O O
show O O
that O O
site B B_PROTEIN[GENE]
C I I_PROTEIN[GENE]
binds O O
members O O
of O O
the O O
ubiquitously O O
expressed O O
RFX B B_GENE/B_BIO
family I I_GENE/I_BIO
of I I_GENE/I_BIO
proteins I I_GENE/I_BIO
, O O
notably O O
RFX1 B B_GENE/B_DISEASE
, O O
RFX3 B B_GENE/B_DISEASE
, O O
and O O
the O O
associated O O
factor O O
MIBP1 B B_GENE
, O O
whereas O O
sites B B_LOCATION/B_PERSON
B I B_LOCATION/I_PERSON
and I B_LOCATION/I_PERSON
D I B_LOCATION/I_PERSON
both O O
bind O O
the O O
B-cell-specific B B_GENE/B_BIO
activator I I_GENE/I_BIO
protein I I_GENE/I_BIO
BSAP/Pax5 I I_GENE/I_BIO
. O O

In O O
reporter O O
assays O O
with O O
mutant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Wp I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
loss O O
of O O
factor O O
binding O O
to O O
any O O
one O O
of O O
these O O
sites O O
severely O O
impaired O O
promoter O O
activity O O
in O O
B O O
cells O O
, O O
while O O
the O O
wild-type B B_SEQUENCE[MEASURE]/B_PERSON
promoter I I_SEQUENCE[MEASURE]/I_PERSON
could O O
be O O
activated O O
in O O
non-B O O
cells O O
by O O
ectopic O O
BSAP O O
expression O O
. O O

We O O
suggest O O
that O O
Wp B B_GENE/B_DISEASE
regulation O O
by O O
BSAP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
helps O O
to O O
ensure O O
the O O
B-cell O O
specificity O O
of O O
EBV O O
's O O
growth-transforming O O
function O O
. O O

Activation O O
of O O
the O O
Lck B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
Herpesvirus O O
saimiri O O
tip B B_GENE
protein I I_GENE
involves O O
two O O
binding O O
interactions O O
. O O

The O O
Tip B B_GENE
protein I I_GENE
of O O
Herpesvirus O O
saimiri O O
strain O O
484C O O
binds O O
to O O
and O O
activates O O
the O O
Lck B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O O
sequences O O
in O O
the O O
Tip B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
were O O
previously O O
shown O O
to O O
be O O
involved O O
in O O
binding O O
to O O
Lck B B_GENE/B_BACTERIUM[BIO]
. O O

A O O
proline-rich B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
region I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
residues O O
132-141 O O
, O O
binds O O
to O O
the O O
SH3 B B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
domain I I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
Lck B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
show O O
here O O
that O O
the O O
other O O
Lck-binding B B_LOCATION/B_PROTEIN[GENE]
domain I B_LOCATION/I_PROTEIN[GENE]
, O O
residues O O
104-113 O O
, O O
binds O O
to O O
the O O
carboxyl-terminal B B_LOCATION/B_MEASURE
half I I_LOCATION/I_MEASURE
of O O
Lck B B_GENE/B_BACTERIUM[BIO]
and O O
that O O
this O O
binding O O
does O O
not O O
require O O
the O O
Lck B B_GENE
SH3 I I_GENE
domain I I_GENE
. O O

Mutated O O
Tip B B_PROTEIN[GENE]
containing O O
only O O
one O O
functional O O
Lck-binding B B_LOCATION/B_MEASURE
domain I I_LOCATION/I_MEASURE
can O O
bind O O
stably O O
to O O
Lck B B_GENE/B_BACTERIUM[BIO]
, O O
although O O
not O O
as O O
strongly O O
as O O
wild-type B B_GENE
Tip I I_GENE
. O O

Interaction O O
of O O
Tip B B_GENE
with O O
Lck B B_GENE/B_BACTERIUM[BIO]
through O O
either O O
Lck-binding B B_LOCATION
domain I I_LOCATION
increases O O
the O O
activity O O
of O O
Lck B B_GENE/B_BACTERIUM[BIO]
in O O
vivo O O
. O O

Simultaneous O O
binding O O
of O O
both O O
domains O O
is O O
required O O
for O O
maximal O O
activation O O
of O O
Lck B B_GENE/B_BACTERIUM[BIO]
. O O

The O O
transient O O
expression O O
of O O
Tip B B_GENE
in O O
T O O
cells O O
was O O
found O O
to O O
stimulate O O
both O O
Stat3 B B_GENE
-dependent O O
and O O
NF-AT B B_GENE
-dependent O O
transcription O O
. O O

Mutant O O
forms O O
of O O
Tip B B_GENE
lacking O O
one O O
or O O
the O O
other O O
of O O
the O O
two O O
Lck-binding B B_GENE/B_LOCATION
domains I I_GENE/I_LOCATION
retained O O
the O O
ability O O
to O O
stimulate O O
Stat3 B B_GENE
-dependent O O
transcription O O
. O O

Tip B B_PROTEIN[GENE]/B_LOCATION
lacking O O
the O O
proline-rich O O
Lck-binding B B_LOCATION/B_GENE
domain I I_LOCATION/I_GENE
exhibited O O
almost O O
wild-type O O
activity O O
in O O
this O O
assay O O
. O O

In O O
contrast O O
, O O
ablation O O
of O O
either O O
Lck-binding B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
abolished O O
the O O
ability O O
of O O
Tip B B_GENE
to O O
stimulate O O
NF-AT B B_GENE
-dependent O O
transcription O O
. O O

Full O O
biological O O
activity O O
of O O
Tip B B_GENE
, O O
therefore O O
, O O
appears O O
to O O
require O O
both O O
Lck-binding B B_LOCATION
domains I I_LOCATION
. O O

Accumulation O O
of O O
RXR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
during O O
activation O O
of O O
cycling O O
human O O
T O O
lymphocytes O O
: O O
modulation O O
of O O
RXRE O O
transactivation O O
function O O
by O O
mitogen-activated O O
protein O O
kinase O O
pathways O O
. O O

We O O
have O O
previously O O
reported O O
that O O
the O O
activation O O
of O O
resting O O
human O O
immature O O
peripheral O O
blood O O
T O O
( O O
PBT O O
) O O
lymphocytes O O
is O O
associated O O
with O O
the O O
loss O O
of O O
retinoid B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RXRalpha B B_GENE
) O O
expression O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
have O O
demonstrated O O
that O O
, O O
unlike O O
resting O O
cells O O
, O O
activation O O
of O O
cycling O O
human O O
mature O O
PBT O O
lymphocytes O O
, O O
and O O
T O O
lymphocyte O O
leukemia O O
cell O O
lines O O
is O O
accompanied O O
by O O
the O O
accumulation O O
of O O
RXRalpha B B_GENE
mRNA O O
and O O
protein O O
. O O

Interestingly O O
, O O
cyclosporin O O
A O O
further O O
augmented O O
RXRalpha B B_GENE
expression O O
, O O
indicating O O
the O O
involvement O O
of O O
calcineurin O O
pathways O O
in O O
the O O
process O O
. O O

9-cis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
retinoic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibited O O
the O O
accumulation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
suggesting O O
that O O
retinoids O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
can O O
regulate O O
the O O
synthesis O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
their O O
own O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
T O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

Transfection O O
analysis O O
in O O
Jurkat O O
cells O O
, O O
using O O
RXRE-dependent O O
reporter O O
assays O O
, O O
showed O O
that O O
RXRalpha B B_GENE/B_LOCATION
accumulated O O
during O O
T O O
cell O O
activation O O
was O O
transcriptionally O O
inactive O O
. O O

To O O
investigate O O
the O O
mechanism O O
of O O
such O O
inhibition O O
, O O
the O O
role O O
of O O
two O O
mitogen-activated O O
protein O O
kinase O O
pathways O O
, O O
c-Jun B B_GENE
N-terminal I I_GENE
kinase I I_GENE
( O O
JNK B B_GENE/B_LOCATION
) O O
and O O
extracellular B B_GENE
signal-regulated I I_GENE
kinase I I_GENE
( O O
ERK B B_GENE/B_LOCATION
) O O
, O O
in O O
modulating O O
RXRE-dependent O O
transcription O O
, O O
was O O
explored O O
. O O

The O O
expression O O
of O O
constitutively O O
active O O
MAP/ERK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MEKK1 B B_GENE
) O O
inhibited O O
RXRE-dependent O O
transcription O O
, O O
whereas O O
dominant B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
negative I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MEKK1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
the O O
transcription O O
, O O
indicating O O
the O O
involvement O O
of O O
JNK B B_GENE/B_PERSON
signaling O O
pathways O O
in O O
the O O
process O O
. O O

In O O
contrast O O
, O O
expression O O
of O O
constitutively B B_GENE
active I I_GENE
MEK1 I I_GENE
, O O
which O O
activates O O
ERK B B_GENE
pathway O O
, O O
enhanced O O
RXRE-dependent O O
activation O O
. O O

When O O
both O O
were O O
activated O O
simultaneously O O
, O O
JNK B B_GENE
pathway O O
was O O
dominant O O
over O O
ERK B B_GENE
pathway O O
and O O
resulted O O
in O O
inhibition O O
of O O
RXRE-mediated O O
transcription O O
. O O

These O O
data O O
demonstrate O O
a O O
dual O O
regulatory O O
control O O
of O O
RXRalpha B B_GENE
expression O O
during O O
the O O
activation O O
of O O
resting O O
and O O
cycling O O
T O O
lymphocytes O O
and O O
indicate O O
a O O
dynamic O O
balance O O
between O O
JNK O O
and O O
ERK O O
pathways O O
in O O
modulating O O
RXRE-mediated O O
transactivation O O
. O O

The O O
proteasome B B_ENZYME[GENE]/B_LOCATION
regulates O O
receptor-mediated O O
endocytosis O O
of O O
interleukin-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Recent O O
studies O O
have O O
increasingly O O
implicated O O
the O O
proteasome B B_GENE
in O O
the O O
regulation O O
of O O
cell B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
surface I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
receptors I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

In O O
the O O
present O O
study O O
, O O
we O O
investigated O O
the O O
role O O
of O O
the O O
proteasome B B_GENE
for O O
ligand-dependent O O
endocytosis O O
and O O
degradation O O
of O O
the O O
interleukin-2 B B_GENE
( I I_GENE
IL-2 I I_GENE
) I I_GENE
-interleukin-2 I I_GENE
receptor I I_GENE
( I I_GENE
IL-2R I I_GENE
) I I_GENE
complex I I_GENE
. O O

Proteasome O O
inhibitors O O
impaired O O
internalization O O
of O O
IL-2.IL-2R B B_GENE
and O O
prevented O O
the O O
lysosomal O O
degradation O O
of O O
this O O
cytokine B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Based O O
on O O
time-course O O
studies O O
, O O
proteasome B B_GENE
activity O O
is O O
primarily O O
required O O
after O O
initial O O
endocytosis O O
of O O
the O O
IL-2.IL-2R B B_GENE
. O O

Proteasome O O
function O O
was O O
also O O
necessary O O
for O O
the O O
lysosomal O O
degradation O O
of O O
IL-2 B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
internalized O O
by O O
IL-2R B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
were O O
comprised O O
of O O
cytoplasmic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tailless I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta- B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-subunits I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
suggesting O O
that O O
the O O
target O O
protein O O
for O O
the O O
proteasome B B_ENZYME[GENE]
is O O
independent O O
of O O
either O O
the O O
cytoplasmic B B_MEASURE/B_LOCATION
tail I B_MEASURE/I_LOCATION
of O O
the O O
IL-2R B B_GENE
beta- B I_GENE
or I I_GENE
gamma I I_GENE
c-subunits I I_GENE
and O O
their O O
associated O O
signaling O O
components O O
. O O

Therefore O O
, O O
a O O
functional O O
proteasome B B_GENE/B_LOCATION
is O O
required O O
for O O
optimal O O
endocytosis O O
of O O
the O O
IL-2R/ligand B B_GENE
complex I I_GENE
and O O
is O O
essential O O
for O O
the O O
subsequent O O
lysosomal O O
degradation O O
of O O
IL-2 B B_GENE
, O O
possibly O O
by O O
regulating O O
trafficking O O
to O O
the O O
lysosome O O
. O O

Functional O O
characterization O O
of O O
the O O
two O O
alternative O O
promoters O O
of O O
human B B_GENE
p45 I I_GENE
NF-E2 I I_GENE
gene I I_GENE
. O O

OBJECTIVE O O
: O O
The O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-E2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
heterodimeric B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
complex I I_GENE/I_LOCATION
composed O O
of O O
p45 B B_GENE/B_MEASURE
and O O
small O O
Maf B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
family I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
considered O O
crucial O O
for O O
the O O
proper O O
differentiation O O
of O O
erythrocytes O O
and O O
megakaryocytes O O
in O O
vivo O O
. O O

We O O
report O O
the O O
results O O
of O O
studies O O
aimed O O
at O O
understanding O O
the O O
regulatory O O
mechanisms O O
controlling O O
p45 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
erythroid O O
cells O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
Human B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
p45 I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
have O O
two O O
alternative O O
isoforms O O
, O O
aNF-E2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
fNF-E2 B B_GENE
, O O
and O O
these O O
isoforms O O
are O O
transcribed O O
from O O
the O O
alternative B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
promoters I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
investigated O O
lineage-specific O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
both O O
isomers O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
erythroid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
megakaryocytic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
reverse O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
transcriptase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
or O O
Northern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

For O O
functional O O
characterization O O
of O O
both O O
promoters O O
, O O
plasmids O O
in O O
which O O
reporter B B_BIO/B_GENE
genes I I_BIO/I_GENE
were O O
placed O O
under O O
the O O
control O O
of O O
a O O
series O O
of O O
truncated O O
or O O
mutated O O
promoter B B_GENE/B_LOCATION
fragments I I_GENE/I_LOCATION
were O O
transfected O O
to O O
human O O
hematopoietic O O
cell O O
lines O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
When O O
CD34 O B_GENE
( O O
+ O B_OTHER/B_DISEASE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
isolated O O
from O O
human O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cord O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
induced O O
to O O
unilineage O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
erythroid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
megakaryocytic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
liquid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
suspension O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
culture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
both O O
transcripts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
although O O
barely O O
detected O O
at O O
day O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
were O O
induced O O
in O O
both O O
erythroid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
and O O
megakaryocytic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cultures O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

fNF-E2 B B_GENE
mRNA I I_GENE
was O O
found O O
to O O
be O O
more O O
abundant O O
in O O
erythroid O O
cells O O
than O O
megakaryocytic O O
cells O O
at O O
day O O
7 O O
of O O
culture O O
. O O

Although O O
both O O
isomers O O
were O O
expressed O O
in O O
human O O
erythroid-megakaryocytic O O
cell O O
lines O O
, O O
megakaryocytic O O
maturation O O
with O O
loss O O
of O O
erythroid O O
phenotype O O
induced O O
by O O
phorbol O O
12-myristate O O
13-acetate O O
( O O
PMA O O
) O O
resulted O O
in O O
exclusive O O
downregulation O O
of O O
fNF-E2 B B_GENE
, O O
suggesting O O
that O O
fNF-E2 B B_GENE
promoter I I_GENE
is O O
more O O
erythroid O O
specific O O
. O O

Functional O O
analysis O O
of O O
fNF-E2 B B_GENE
promoter I I_GENE
showed O O
that O O
the O O
promoter O O
is O O
active O O
only O O
in O O
erythroid-megakaryocytic O O
cells O O
and O O
that O O
the O O
double B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
GATA I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sit I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
e O O
in O O
the O O
proximal O O
region O O
is O O
necessary O O
for O O
its O O
efficient O O
activity O O
. O O

CONCLUSION O O
: O O
These O O
results O O
suggest O O
that O O
GATA B B_GENE
proteins I I_GENE
, O O
which O O
govern O O
the O O
differentiation O O
of O O
erythroid O O
lineage O O
cells O O
, O O
are O O
required O O
for O O
full O O
promoter O O
activity O O
of O O
the O O
p45 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Transcriptional O O
activation O O
of O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
functional O O
significance O O
in O O
acetaminophen-induced O O
hepatitis O O
and O O
hepatocellular O O
injury O O
in O O
the O O
rat O O
. O O

BACKGROUND/AIM O O
: O O
Glutathione O O
depletion O O
contributes O O
to O O
acetaminophen O O
hepatotoxicity O O
and O O
is O O
known O O
to O O
induce O O
the O O
oxidative O O
stress O O
reactant O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
metabolites O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
heme O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
biliverdin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
carbon O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
monoxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
iron O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
may O O
modulate O O
acetaminophen O B_DISEASE
toxicity O I_DISEASE
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
assess O O
cell-type O O
specific O O
expression O O
of O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
impact O O
on O O
liver O O
injury O O
and O O
microcirculatory O O
disturbances O O
in O O
a O O
model O O
of O O
acetaminophen-induced O O
hepatitis O O
. O O

METHODS O O
: O O
Gene O O
expression O O
of O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
studied O O
by O O
Northern- O O
and O O
Western O O
analysis O O
as O O
well O O
as O O
immunohistochemistry O O
. O O

The O O
time O O
course O O
of O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
cytokine-induced B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
neutrophil I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chemoattractant-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
was O O
studied O O
by O O
Northern O O
analysis O O
. O O

DNA-binding O O
activity O O
of O O
nuclear B B_GENE
factor-kappaB I I_GENE
was O O
determined O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

Sinusoidal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
perfusion O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
and O O
leukocyte-endothelial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
interactions O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
assessed O O
by O O
intravital O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O O
: O O
Acetaminophen O O
caused O O
a O O
moderate O O
sinusoidal O O
perfusion O O
failure O O
( O O
-15 O O
% O O
) O O
and O O
infiltration O O
of O O
neutrophils O O
along O O
with O O
activation O O
of O O
nuclear B B_GENE
factor-kappaB I I_GENE
and O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
and O O
cytokine-induced B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
neutrophil I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chemoattractant-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs O O
. O O

Induction O O
of O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA O O
and O O
protein O O
( O O
approximately O O
30-fold O O
) O O
in O O
hepatocytes O O
and O O
non-parenchymal O O
cells O O
paralleled O O
the O O
inflammatory O O
response O O
. O O

Blockade O O
of O O
heme O O
oxygenase O O
activity O O
with O O
tin-protoporphyrin-IX O O
abrogated O O
acetaminophen-induced O O
hepatic O O
neutrophil O O
accumulation O O
and O O
nuclear B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor-kappaB I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
, O O
but O O
failed O O
to O O
affect O O
sinusoidal O O
perfusion O O
and O O
liver O O
injury O O
. O O

CONCLUSIONS O O
: O O
The O O
inflammatory O O
response O O
associated O O
with O O
acetaminophen O O
hepatotoxicity O O
is O O
modulated O O
by O O
the O O
parallel O O
induction O O
of O O
the O O
heme B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
heme B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
no O O
permissive O O
effect O O
on O O
sinusoidal O O
perfusion O O
and O O
does O O
not O O
affect O O
liver O O
injury O O
in O O
this O O
model O O
. O O

These O O
data O O
argue O O
against O O
a O O
central O O
role O O
of O O
nuclear B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
factor-kappaB I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
activation O O
and O O
neutrophil O O
infiltration O O
as O O
perpetuating O O
factors O O
of O O
liver O O
injury O O
in O O
acetaminophen O O
toxicity O O
. O O

Tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-induced O O
proliferation O O
requires O O
synthesis O O
of O O
granulocyte-macrophage B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVE O O
: O O
Tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
necrosis I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
induces O O
a O O
variety O O
of O O
cellular O O
responses O O
, O O
some O O
of O O
them O O
being O O
at O O
least O O
seemingly O O
contradictory O O
. O O

Thus O O
, O O
we O O
set O O
out O O
to O O
find O O
differences O O
in O O
the O O
modes O O
of O O
proliferative O O
and O O
apoptotic O O
responses O O
to O O
TNF- B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
We O O
screened O O
a O O
panel O O
of O O
acute O O
myeloid O O
leukemia-derived O O
cell O O
lines O O
for O O
TNF- B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
-responsiveness O O
. O O

In O O
two O O
lines O O
( O O
OCI-AML-1 O O
, O O
OCI-AML-11 O O
) O O
, O O
TNF- B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acted O O
as O O
an O O
apoptotic O O
agent O O
; O O
in O O
others O O
( O O
HU-3 O O
, O O
M-07e O O
, O O
TF-1 O O
) O O
, O O
it O O
had O O
the O O
opposite O O
effect O O
, O O
preventing O O
apoptosis O O
and O O
inducing O O
proliferation O O
. O O

Direct O O
and O O
indirect O O
signaling O O
mechanisms O O
, O O
including O O
NF-kappaB B B_GENE
activation O O
and O O
cytokine O O
synthesis O O
, O O
were O O
analyzed O O
. O O

RESULTS O O
: O O
All O O
cell O O
lines O O
tested O O
expressed O O
TNF- B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
responded O O
to O O
TNF- B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
upregulation O O
of O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
. O O

In O O
contrast O O
to O O
granulocyte-macrophage B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GM-CSF B B_ORGANIZATION/B_LOCATION
) O O
, O O
TNF- B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
did O O
not O O
activate O O
the O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
p70S6 O O
kinase O O
pathways O O
. O O

Nevertheless O O
, O O
inhibitors O O
of O O
these O O
pathways O O
clearly O O
reduced O O
the O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-induced O O
cell O O
growth O O
, O O
indicating O O
that O O
TNF- O O
alpha-proliferative O O
cells O O
produced O O
a O O
growth O O
factor O O
that O O
induced O O
proliferation O O
upon O O
stimulation O O
of O O
the O O
above O O
pathways O O
. O O

Anti-GM-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibited O O
the O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-induced O O
growth O O
, O O
suggesting O O
the O O
presence O O
of O O
an O O
autocrine O O
loop O O
for O O
cell O O
proliferation O O
mediated O O
by O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Supporting O O
this O O
notion O O
, O O
TNF-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
-induced O O
upregulation O O
of O O
GM-CSF B B_GENE
mRNA I I_GENE
levels O O
and O O
protein O O
secretion O O
in O O
the O O
TNF-alpha B B_DISEASE/B_GENE
-proliferative O O
, O O
but O O
not O O
in O O
the O O
TNF-alpha-apoptotic O O
cell O O
lines O O
. O O

CONCLUSION O O
: O O
These O O
data O O
identify O O
GM-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synthesis O O
as O O
an O O
early O O
and O O
essential O O
step O O
in O O
TNF- O O
alpha-induced O O
proliferation O O
. O O

We O O
show O O
for O O
the O O
first O O
time O O
that O O
TNF-alpha-treated O O
cell O O
lines O O
producing O O
no O O
or O O
only O O
minimal O O
amounts O O
of O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
demonstrate O O
an O O
apoptotic O O
phenotype O O
, O O
while O O
cell O O
lines O O
with O O
high O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression O O
rates O O
can O O
escape O O
from O O
growth O O
arrest O O
or O O
even O O
apoptosis O O
. O O

In O O
this O O
context O O
, O O
we O O
discuss O O
arguments O O
pointing O O
at O O
NF-kappaB B B_GENE
as O O
regulator O O
of O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synthesis O O
and O O
thus O O
indirectly O O
as O O
regulator O O
for O O
the O O
escape O O
of O O
TNF-alpha B B_DISEASE/B_GENE
-induced O O
apoptosis O O

Glucocorticoid B B_GENE/B_MEASURE
receptor I I_GENE/I_MEASURE
content O O
of O O
T O O
lymphocytes O O
: O O
evidence O O
for O O
heterogeneity O O
. O O

Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
measured O O
in O O
T O O
lymphocytes O O
that O O
were O O
isolated O O
from O O
peripheral O O
blood O O
by O O
either O O
nylon O O
wool O O
filtration O O
or O O
E-rosette O O
sedimentation O O
. O O

T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
isolated O O
by O O
nylon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wool O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
filtration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
specifically O O
bind O O
6.7 O B_MEASURE
+/- O O
0.2 O B_MEASURE/B_LOCATION
fmol O I_MEASURE/I_LOCATION
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
per O O
million O B_MEASURE/B_BIO
cells O I_MEASURE/I_BIO
( O O
equivalent O B_MEASURE/B_ORGANIZATION
to O O
4000 O B_MEASURE
+/- O I_MEASURE
200 O I_MEASURE
receptors O I_MEASURE
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
) O O
, O O
whereas O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
isolated O O
by O O
E-rosette O B_MEASURE
sedimentation O I_MEASURE
bind O I_MEASURE
12.0 O I_MEASURE
+/- O O
0.7 O B_MEASURE/B_LOCATION
fmol O I_MEASURE/I_LOCATION
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
per O O
million O B_MEASURE/B_PERSON
cells O I_MEASURE/I_PERSON
( O O
equivalent O B_MEASURE/B_ORGANIZATION
to O O
7200 O B_MEASURE
+/- O I_MEASURE
400 O I_MEASURE
receptors O I_MEASURE
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

This O O
difference O B_MEASURE
in O O
the O O
amount O B_MEASURE/B_LOCATION
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bound O O
by O O
the O O
two O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
preparations O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
p O B_MEASURE
less O I_MEASURE
than O O
.001 O B_NUMBER[MEASURE]/B_LOCATION
) O O
and O O
was O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immediately O O
after O O
cell O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
isolation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
binding O O
affinities O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
different O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
preparations O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
that O O
are O O
isolated O O
by O O
a O O
combination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
nylon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wool O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
filtration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
followed O O
by O O
E-rosette O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sedimentation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
bind O O
the O O
same O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amount O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
isolated O O
by O O
nylon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wool O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
filtration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alone O O
. O O

T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
isolated O O
by O O
a O O
combination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
E-rosette O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sedimentation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
following O O
by O O
nylon O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
wool O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
filtration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
bind O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
less O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dexamethasone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
than O O
do O O
T O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
isolated O O
by O O
E-rosette O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sedimentation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alone O O
. O O

These O O
findings O O
suggest O O
that O O
T O O
cells O O
are O O
heterogeneous O O
with O O
respect O O
to O O
their O O
quantity O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Isolation O O
of O O
T O O
cells O O
by O O
E-rosette O O
sedimentation O O
enriches O O
for O O
T O O
cells O O
that O O
have O O
a O O
greater O O
number O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
isolation O O
of O O
T O O
cells O O
by O O
nylon O O
wool O O
filtration O O
enriches O O
for O O
T O O
cells O O
that O O
have O O
a O O
lesser O O
number O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O O

Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
glucocorticoid O O
sensitivity O O
of O O
human O O
leukemic O O
cells O O
. O O

We O O
have O O
established O O
optimal O O
conditions O O
for O O
the O O
measurement O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
GR B B_LOCATION/B_ORGANIZATION
) O O
in O O
human O O
white O O
cells O O
using O O
a O O
whole-cell O O
binding O O
assay O O
with O O
[ O O
3H O O
] O O
dexamethasone O O
as O O
the O O
ligand O O
, O O
and O O
the O O
subsequent O O
determination O O
of O O
the O O
GR B B_PROTEIN[GENE]/B_DISEASE
content O O
in O O
normal O O
human O O
lymphocytes O O
and O O
in O O
leukemic O O
cells O O
of O O
patients O O
with O O
various O O
forms O O
of O O
acute O O
and O O
chronic O O
leukemia O O
. O O

A O O
number O O
of O O
leukemia O O
cell O O
lines O O
in O O
continuous O O
culture O O
were O O
also O O
subjected O O
to O O
the O O
GR B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assay O O
, O O
and O O
the O O
results O O
were O O
correlated O O
with O O
the O O
sensitivity O O
of O O
these O O
cell O O
lines O O
to O O
glucocorticoid O O
steroids O O
in O O
vitro O O
. O O

The O O
GR B B_PROTEIN[GENE]/B_DISEASE
content O O
of O O
normal O O
human O O
lymphocytes O O
amounted O O
to O O
4 O O
, O O
850 O O
+/- O O
1 O O
, O O
340 O O
( O O
mean O O
+/- O O
SD O O
) O O
receptors/cell O O
. O O

The O O
mean O O
equilibrium O O
dissociation O O
constant O O
( O O
KD O O
) O O
of O O
the O O
interaction O O
of O O
[ O O
3H O O
] O O
dexamethasone O O
with O O
the O O
GR B B_PROTEIN[GENE]/B_DISEASE
was O O
1.2 O O
x O O
10 O O
( O O
-8 O O
) O O
M O O
. O O

Steroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
compounds O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
a O O
known O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
potency O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
effectively O O
competed O O
for O O
the O O
binding O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
steroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
devoid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
e.g. O B_DISEASE/B_PROTEIN[GENE]
estradiol-17 O O
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testosterone O O
) O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
ineffective O O
. O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]

The O O
GR B B_PROTEIN[GENE]/B_DISEASE
content O O
of O O
the O O
blast O O
cells O O
obtained O O
from O O
eight O O
patients O O
suffering O O
from O O
acute O O
leukemia O O
and O O
four O O
patients O O
with O O
a O O
blast O O
crisis O O
of O O
chronic O O
myelocytic O O
leukemia O O
was O O
found O O
to O O
be O O
highly O O
variable O O
( O O
3 O O
, O O
230-29 O O
, O O
900 O O
receptors/cell O O
) O O
, O O
while O O
the O O
lymphocytes O O
of O O
six O O
patients O O
with O O
chronic O O
lymphatic O O
leukemia O O
contained O O
a O O
rather O O
stable O O
GR B B_PROTEIN[GENE]/B_DISEASE
content O O
( O O
2 O O
, O O
930-5 O O
, O O
120 O O
receptors/cell O O
) O O
, O O
which O O
was O O
comparable O O
with O O
that O O
of O O
normal O O
lymphocytes O O
. O O

GR B B_GENE/B_DISEASE
was O O
identified O O
in O O
all O O
the O O
12 O O
malignant O O
continuous O O
white O O
cell O O
lines O O
studied O O
. O O

Large O O
cells O O
contained O O
more O O
GR B B_GENE/B_DISEASE
than O O
the O O
smaller O O
ones O O
. O O

There O O
was O O
no O O
apparent O O
correlation O O
between O O
the O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration O O
and O O
the O O
sensitivity O O
of O O
the O O
cells O O
in O O
vitro O O
to O O
glucocorticoids O O
as O O
judged O O
by O O
[ O O
3H O O
] O O
thymidine O O
incorporation O O
studies O O
. O O

Distribution O O
of O O
the O O
surface O O
markers O O
in O O
the O O
leukemic O O
cell O O
lines O O
did O O
not O O
relate O O
to O O
the O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration O O
. O O

We O O
conclude O O
that O O
the O O
presence O O
of O O
GR B B_GENE/B_DISEASE
is O O
probably O O
a O O
universal O O
feature O O
of O O
the O O
leukemic O O
cells O O
, O O
and O O
, O O
from O O
a O O
clinical O O
standpoint O O
, O O
probably O O
does O O
not O O
alone O O
imply O O
steroid O O
responsiveness O O
. O O

Evidence O O
for O O
a O O
steroid B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
receptor I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
rheumatoid O O
synovial O O
tissue O O
cells O O
. O O

One O O
mechanism O O
by O O
which O O
glucocorticoids O O
could O O
exert O O
their O O
anti-inflammatory O O
action O O
is O O
via O O
rapidly O O
saturable O O
, O O
stereo-specific B B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
cytoplasmic I B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
protein I B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
receptors I B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O O

This O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
of O O
an O O
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
into O O
such O O
a O O
possibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
synovial O B_LOCATION
cells O I_LOCATION
. O O

Synovium O O
, O O
obtained O O
from O O
knee O O
joints O O
of O O
rheumatoid O O
patients O O
undergoing O O
surgery O O
, O O
was O O
incubated O O
with O O
clostridiopeptidase B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
trypsin-EDTA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
to O O
obtain O O
cell O O
suspensions O O
. O O

These O O
, O O
together O O
with O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
obtained O O
from O O
synovial O B_BODY_PART_OR_ORGAN_COMPONENT
fluid O I_BODY_PART_OR_ORGAN_COMPONENT
aspirated O O
from O O
patients O B_PERSON/B_BIO
with O O
rheumatoid O B_DISEASE/B_LOCATION
arthritis O I_DISEASE/I_LOCATION
, O O
were O O
identified O O
by O O
electron O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Duplicate O B_NUMBER[MEASURE]/B_PERSON
samples O I_NUMBER[MEASURE]/I_PERSON
of O O
these O O
cell O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
suspensions O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
incubated O O
with O O
increasing O O
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
H3Dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
1 O B_MEASURE
x O O
10 O B_MEASURE
( O O
-10 O B_MEASURE
) O O
M-1 O O
x O O
10 O B_MEASURE
( O O
-9 O B_MEASURE
) O O
M O B_MEASURE/B_OTHER
) O O
for O O
30 O B_TIME[MEASURE]
minutes O I_TIME[MEASURE]
at O O
37 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
proportion O B_MEASURE/B_LOCATION
of O O
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O O
to O O
whole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
showed O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
rapidly O O
saturable O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O O
receptors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
obtained O O
from O O
synovial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
this O O
was O O
not O O
found O O
in O O
synovial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fluid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Electron O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
micrographs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
that O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
obtained O O
from O O
synovial O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consisted O O
of O O
synovial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibroblast O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
and O O
macrophage-types O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
macrophages O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Polymorphonuclear O B_PERSON
leucocytes O I_PERSON
appeared O O
to O O
be O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

However O O
, O O
in O O
synovial O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fluid O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
type O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
polymorphonuclear O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leucocytes O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
the O O
predominant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
type O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

We O O
concluded O O
from O O
this O O
, O O
that O O
one O O
or O O
more O O
of O O
the O O
cell O O
types O O
present O O
in O O
synovial O O
tissue O O
contain O O
a O O
specific B B_GENE
steroid I I_GENE
receptor I I_GENE
, O O
but O O
that O O
this O O
is O O
lacking O O
in O O
synovial O O
fluid O O
polymorphonuclear O O
leucocytes O O
. O O

Clinical O O
implications O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O O
leukemia O O
. O O

Glucorticoid B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
in O O
various O O
populations O O
of O O
normal O O
human O O
peripheral O O
blood O O
lymphocytes O O
and O O
leukemic O O
lymphoblasts O O
. O O

Normal O O
lymphocytes O O
contain O O
low O O
levels O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
( O O
approximately O O
2 O O
, O O
500 O O
sites/cell O O
) O O
which O O
are O O
identical O O
in O O
T- O O
and O O
non-T-fractions O O
. O O

Phytohemagglutinin B B_BIO/B_TIME[MEASURE]
treatment O O
increases O O
levels O O
about O O
3-fold O O
. O O

Leukemic O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphoblasts O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
contain O O
larger O B_MEASURE/B_LOCATION
numbers O I_MEASURE/I_LOCATION
of O O
receptor O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
sites O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

Presence O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
receptor O B_GENE/B_DISEASE
is O O
correlated O O
with O O
in O O
vitro O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivitiy O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
in O O
vivo O B_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
to O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Quantity O B_TIME[MEASURE]/B_PERSON
of O O
receptor O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
also O O
correlated O O
with O O
complete O B_DISEASE
remission O I_DISEASE
duration O I_DISEASE
independently O O
of O O
leukemic O B_TIME[MEASURE]/B_DISEASE
cell O I_TIME[MEASURE]/I_DISEASE
type O I_TIME[MEASURE]/I_DISEASE
( O O
T O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
null O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
initial O B_MEASURE
WBC O I_MEASURE
, O O
or O O
age O B_MEASURE
of O O
patient O B_PERSON/B_DISEASE
. O O

Quantitative O O
determination O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
levels O O
in O O
acute O O
lymphoblastic O O
leukemia O O
may O O
be O O
of O O
value O O
both O O
as O O
an O O
independent O O
prognostic O O
variable O O
and O O
in O O
suggesting O O
which O O
patients O O
should O O
receive O O
glucocorticoid O O
therapy O O
. O O

Functional O O
and O O
physical O O
interaction O O
of O O
protein-tyrosine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Fyn I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Csk I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
T-cell O O
signaling O O
system O O
. O O

The O O
Src-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein-tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Fyn B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
associated O O
with O O
T-cell B B_DISEASE/B_GENE
antigen I I_DISEASE/I_GENE
receptor I I_DISEASE/I_GENE
. O O

Transient O O
expression O O
of O O
actively O O
mutated O O
Fyn B B_GENE
, O O
having O O
Phe-528 O O
instead O O
of O O
Tyr-528 O O
or O O
Thr-338 O O
instead O O
of O O
Ile-338 O O
, O O
in O O
Jurkat O O
T-cells O O
stimulated B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SRE B B_GENE/B_DISEASE
) O O
, O O
12-O-tetradecanoyl-phorbol-13-acetate B B_GENE/B_LOCATION
response I I_GENE/I_LOCATION
element I I_GENE/I_LOCATION
, O O
cyclic B B_GENE
AMP I I_GENE
response I I_GENE
element I I_GENE
, O O
and O O
c-fos B B_GENE
promoter I I_GENE
. O O

The O O
stimulation O O
of O O
SRE B B_DISEASE/B_GENE
was O O
particularly O O
prominent O O
not O O
only O O
with O O
active O O
Fyn B B_GENE/B_DISEASE
but O O
also O O
with O O
normal B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wild-type I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fyn I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

SRE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
also O O
stimulated O O
by O O
both O O
normal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
active I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Lck I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Furthermore O O
, O O
normal B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
active I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fyn I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O O
transcription O O
from O O
the O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
when O O
transfected O O
cells O O
were O O
stimulated O O
by O O
concanavalin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
plus O O
12-O-tetradecanoylphorbol-13-acetate O O
. O O

Under O O
the O O
same O O
conditions O O
, O O
Lck B B_GENE/B_BACTERIUM[BIO]
did O O
not O O
stimulate O O
IL-2 B B_GENE
promoter I I_GENE
unless O O
it O O
was O O
activated O O
by O O
mutation O O
. O O

Interestingly O O
, O O
a O O
mutant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Fyn I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
has O O
deletions O O
within O O
the O O
SH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
so O O
is O O
able O O
to O O
transform O O
chicken O O
embryo O O
fibroblasts O O
, O O
did O O
not O O
stimulate O O
either O O
the O O
c-fos B B_GENE
or I I_GENE
IL-2 I I_GENE
promoter I I_GENE
, O O
suggesting O O
the O O
importance O O
of O O
this O O
region O O
in O O
T-cell O O
signaling O O
. O O

Csk B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
phosphorylates O O
tyrosine O O
residues O O
in O O
the O O
negative O O
regulatory O O
sites O O
of O O
Src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
down-regulated O O
Fyn- O O
and O O
Lck-mediated O O
stimulation O O
of O O
the O O
serum B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Fyn-mediated O O
enhancement O O
of O O
IL-2 B B_GENE
promoter I I_GENE
activity O O
. O O

These O O
data O O
suggest O O
that O O
Fyn B B_GENE/B_LOCATION
and O O
Lck B B_GENE/B_BACTERIUM[BIO]
, O O
whose O O
activities O O
are O O
regulated O O
by O O
Csk B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
are O O
involved O O
in O O
different O O
phases O O
of O O
T-cell O O
activation O O
. O O

A O O
novel O O
NF-kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
complex I I_GENE/I_LOCATION
containing O O
p65 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
implications O O
for O O
transcriptional O O
control O O
at O O
the O O
level O O
of O O
subunit O O
dimerization O O
. O O

The O O
predominant O O
inducible O O
form O O
of O O
the O O
NF-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
heteromeric B B_LOCATION
complex I I_LOCATION
containing O O
two O O
Rel-related B B_GENE/B_LOCATION
DNA-binding I I_GENE/I_LOCATION
subunits I I_GENE/I_LOCATION
, O O
termed B B_GENE
p65 I I_GENE
and O O
p50 B B_GENE
. O O

Prior O O
transfection O O
studies O O
have O O
shown O O
that O O
when O O
these O O
p65 B B_GENE
and I I_GENE
p50 I I_GENE
subunits I I_GENE
are O O
expressed O O
independently O O
as O O
stable B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homodimers I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
p65 B B_GENE
stimulates O O
kappa O O
B-directed O O
transcription O O
, O O
whereas O O
p50 B B_MEASURE/B_GENE
functions O O
as O O
a O O
kappa O O
B-specific O O
repressor O O
. O O

While O O
authentic O O
p50 B B_GENE
homodimers I I_GENE
( O O
previously O O
termed O O
KBF1 B B_GENE
) O O
have O O
been O O
detected O O
in O O
nuclear O O
extracts O O
from O O
nontransfected O O
cells O O
, O O
experimental O O
evidence O O
supporting O O
the O O
existence O O
of O O
p65 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
homodimers I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
vivo O O
was O O
lacking O O
. O O

We O O
now O O
provide O O
direct O O
biochemical O O
evidence O O
for O O
the O O
presence O O
of O O
an O O
endogenous O O
pool O O
of O O
inducible O O
p65 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
intact O O
human O O
T O O
cells O O
. O O

As O O
with O O
the O O
prototypical O O
NF-kappa B B_GENE/B_MEASURE
B I I_GENE/I_MEASURE
p50-p65 I I_GENE/I_MEASURE
heterodimer I I_GENE/I_MEASURE
, O O
this O O
novel O O
p65 B B_MEASURE/B_LOCATION
homodimeric I I_MEASURE/I_LOCATION
form I I_MEASURE/I_LOCATION
of O O
NF-kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
is O O
functionally O O
sequestered O O
in O O
the O O
cytoplasm O O
but O O
rapidly O O
appears O O
in O O
the O O
nuclear O O
compartment O O
following O O
cellular O O
stimulation O O
. O O

Site-directed O O
mutagenesis O O
studies O O
indicate O O
that O O
the O O
homodimerization O O
function O O
of O O
p65 B B_GENE
is O O
dependent O O
upon O O
the O O
presence O O
of O O
cysteine O O
216 O O
and O O
a O O
conserved O O
recognition O O
motif O O
for O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
( O O
RRPS B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O O
amino O O
acids O O
273 O O
to O O
276 O O
) O O
, O O
both O O
of O O
which O O
reside O O
within O O
a O O
91-amino-acid O O
segment O O
of O O
the O O
Rel B B_GENE
homology I I_GENE
domain I I_GENE
that O O
mediates O O
self-association O O
. O O

In O O
contrast O O
, O O
mutations O O
at O O
these O O
two O O
sites O O
do O O
not O O
affect O O
heterodimerization O O
of O O
p65 B B_GENE
with O O
p50 B B_GENE
or O O
its O O
functional O O
interaction O O
with O O
I O O
kappa O O
B O O
alpha O O
. O O

These O O
later O O
findings O O
indicate O O
that O O
neither O O
homo- O O
nor O O
heterodimer O O
formation O O
is O O
an O O
absolute O O
prerequisite O O
for O O
I B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
kappa I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
B I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
recognition O O
of O O
p65 B B_GENE
. O O

Taken O O
together O O
with O O
prior O O
in O O
vivo O O
transcription O O
studies O O
, O O
these O O
results O O
suggest O O
that O O
the O O
biological O O
activities O O
of O O
p65 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p50 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
independently O O
regulated O O
, O O
thereby O O
providing O O
an O O
integrated O O
and O O
flexible O O
control O O
mechanism O O
for O O
the O O
rapid O O
activation O O
and O O
repression O O
of O O
NF-kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
/ O O
Rel B B_GENE/B_DISEASE
-directed O O
gene O O
expression O O
. O O

Carrier O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
X-linked O B_DISEASE/B_GENE
agammaglobulinemia O B_DISEASE/I_GENE
using O O
X O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inactivation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
purified O O
B O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
report O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
relatively O O
quick O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
simple O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
method O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
for O O
the O O
assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
X O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inactivation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
status O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
carrier O B_PERSON
determination O I_PERSON
in O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
affected O O
by O O
X-linked O B_DISEASE/B_GENE
agammaglobulinemia O I_DISEASE/I_GENE
( O O
XLA O B_DISEASE/B_LOCATION
) O O
. O O

This O O
method O O
utilises O O
an O O
immunomagnetic O O
separation O O
technique O O
for O O
B O O
cell O O
purification O O
and O O
a O O
polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
based O O
assay O O
for O O
the O O
determination O O
of O O
methylation O O
status O O
at O O
the O O
androgen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
assess O O
whether O O
X O O
inactivation O O
is O O
random O O
or O O
non-random O O
at O O
this O O
locus O O
. O O

We O O
report O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
have O O
obtained O O
using O O
this O O
assay O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
investigate O O
females O B_PERSON/B_BIO
known O O
to O O
be O O
carriers O B_PERSON
of O O
various O B_DISEASE/B_GENE
X-linked O I_DISEASE/I_GENE
immunodeficiency O I_DISEASE/I_GENE
disorders O I_DISEASE/I_GENE
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
we O O
investigated O O
four O B_PERSON/B_BIO
females O I_PERSON/I_BIO
from O O
different O B_PERSON/B_LOCATION
families O I_PERSON/I_LOCATION
affected O O
by O O
XLA O B_DISEASE
, O O
two O B_NUMBER[MEASURE]/B_PERSON
of O O
whom O O
were O O
of O O
unknown O B_PERSON/B_DISEASE
carrier O I_PERSON/I_DISEASE
status O I_PERSON/I_DISEASE
, O O
and O O
we O O
discuss O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O O
with O O
this O O
and O O
other O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
X-inactivation O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
assays O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
recently O O
been O O
described O O
by O O
Allen O B_PERSON/B_LOCATION
et O I_PERSON/I_LOCATION
al. O I_PERSON/I_LOCATION
( O O
1992 O O
) O B_MEASURE
and O O
applied O O
to O O
members O O
of O B_PERSON/B_BIO
one O O
family O B_PERSON/B_ENT
affected O I_PERSON/I_ENT
by O O
XLA O O
. O B_DISEASE/B_GENE

Effects O O
of O O
IL-4 B B_GENE
and O O
Fc B B_GENE/B_LOCATION
gamma I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
II I I_GENE/I_LOCATION
engagement O O
on O O
Egr-1 B B_GENE
expression O O
during O O
stimulation O O
of O O
B O O
lymphocytes O O
by O O
membrane O O
immunoglobulin O O
crosslinking O O
. O O

Egr-1 B B_GENE
is O O
an O O
immediate B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
early I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
is O O
rapidly O O
upregulated O O
in O O
response O O
to O O
mitogenic O O
signals O O
induced O O
by O O
antigen O O
receptor O O
crosslinking O O
on O O
murine O O
B O O
lymphocytes O O
. O O

It O O
has O O
been O O
shown O O
that O O
levels O O
of O O
Egr-1 B B_GENE
expression O O
are O O
closely O O
correlated O O
with O O
B O O
cell O O
proliferation O O
in O O
several O O
models O O
of O O
B O O
cell O O
activation O O
and O O
tolerance O O
. O O

We O O
compared O O
the O O
expression O O
of O O
Egr-1 B B_GENE
during O O
B O O
cell O O
stimulation O O
with O O
Fab'2 B B_GENE
and O O
IgG B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
anti-immunoglobulin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
anti-Ig B B_GENE/B_LOCATION
) O O
, O O
since O O
it O O
is O O
known O O
that O O
Fab'2 B B_GENE
anti-Ig I I_GENE
is O O
mitogenic O O
while O O
IgG B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
anti-Ig I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
not O O
, O O
owing O O
to O O
a O O
dominant O O
inhibitory O O
effect O O
of O O
crosslinking O O
the O O
B B B_GENE
cell I I_GENE
Fc I I_GENE
gamma I I_GENE
RII I I_GENE
to O O
membrane B B_GENE
Ig I I_GENE
. O O

While O O
mitogenic O O
doses O O
of O O
Fab'2 B B_GENE
anti-Ig I I_GENE
induce O O
large O O
and O O
rapid O O
increases O O
in O O
Egr-1 O O
expression O O
, O O
IgG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti-Ig I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
results O O
in O O
smaller O O
increases O O
in O O
Egr-1 B B_GENE
mRNA I I_GENE
, O O
comparable O O
to O O
that O O
seen O O
with O O
submitogenic O O
concentrations O O
of O O
Fab'2 B B_GENE
anti-Ig I I_GENE
. O O

However O O
, O O
the O O
correlation O O
between O O
Egr-1 O O
expression O O
and O O
B O O
cell O O
proliferation O O
breaks O O
down O O
when O O
IL-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
added O O
as O O
a O O
co-mitogen O O
to O O
induce O O
B O O
cell O O
proliferation O O
with O O
IgG B B_DISEASE_ADJECTIVE[DISEASE]
anti-Ig I I_DISEASE_ADJECTIVE[DISEASE]
or O O
submitogenic O O
concentrations O O
of O O
Fab'2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
anti-Ig I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

No O O
corresponding O O
increases O O
in O O
Egr-1 B B_GENE
mRNA I I_GENE
levels O O
are O O
observed O O
when O O
IL-4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
added O O
. O O

Therefore O O
, O O
IL-4 B B_LOCATION/B_PERSON
overcomes O O
Fc O O
receptor-mediated O O
inhibition O O
of O O
B O O
cell O O
proliferation O O
without O O
affecting O O
inhibition O O
of O O
Egr-1 B B_GENE
mRNA I I_GENE
induction O O
, O O
as O O
demonstrated O O
earlier O O
for O O
c-myc B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mRNA I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
this O O
system O O
. O O

Identification O O
of O O
a O O
novel O O
cyclosporin-sensitive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
tumor I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
necrosis I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factor I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
alpha I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
promoter I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF-alpha B B_GENE/B_LOCATION
) O O
, O O
a O O
cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
with O O
pleiotropic O O
biological O O
effects O O
, O O
is O O
produced O O
by O O
a O O
variety O O
of O O
cell O O
types O O
in O O
response O O
to O O
induction O O
by O O
diverse O O
stimuli O O
. O O

In O O
this O O
paper O O
, O O
TNF-alpha B B_GENE/B_LOCATION
mRNA I I_GENE/I_LOCATION
is O O
shown O O
to O O
be O O
highly O O
induced O O
in O O
a O O
murine O O
T O O
cell O O
clone O O
by O O
stimulation O O
with O O
T B B_GENE
cell I I_GENE
receptor I I_GENE
( O O
TCR B B_PROTEIN[GENE]/B_LOCATION
) O O
ligands O O
or O O
by O O
calcium O O
ionophores O O
alone O O
. O O

Induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
does O O
not O O
require O O
de O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
novo O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
synthesis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
is O O
completely O O
blocked O O
by O O
the O O
immunosuppressant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclosporin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CsA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

We O O
have O O
identified O O
a O O
human B B_GENE/B_PERSON
TNF-alpha I I_GENE/I_PERSON
promoter I I_GENE/I_PERSON
element I I_GENE/I_PERSON
, O O
kappa B B_PROTEIN[GENE]/B_LOCATION
3 I I_PROTEIN[GENE]/I_LOCATION
, O O
which O O
plays O O
a O O
key O O
role O O
in O O
the O O
calcium-mediated O O
inducibility O O
and O O
CsA O O
sensitivity O O
of O O
the O O
gene O O
. O O

In O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
an O O
oligonucleotide O O
containing O O
kappa B B_GENE
3 I I_GENE
forms O O
two O O
DNA O O
protein O O
complexes O O
with O O
proteins O O
that O O
are O O
present O O
in O O
extracts O O
from O O
unstimulated O O
T O O
cells O O
. O O

These O O
complexes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
appear O O
in O O
nuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
extracts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
only O O
after O O
T O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Induction O O
of O O
the O O
inducible O O
nuclear B B_GENE
complexes I I_GENE
is O O
rapid O O
, O O
independent O O
of O O
protein O O
synthesis O O
, O O
and O O
blocked O O
by O O
CsA O O
, O O
and O O
thus O O
, O O
exactly O O
parallels O O
the O O
induction O O
of O O
TNF-alpha B B_GENE
mRNA I I_GENE
by O O
TCR O O
ligands O O
or O O
by O O
calcium O O
ionophore O O
. O O

Our O O
studies O O
indicate O O
that O O
the O O
kappa B B_PROTEIN[GENE]/B_MEASURE
3 I I_PROTEIN[GENE]/I_MEASURE
binding I I_PROTEIN[GENE]/I_MEASURE
factor I I_PROTEIN[GENE]/I_MEASURE
resembles O O
the O O
preexisting O O
component O O
of O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
activated O O
T O O
cells O O
. O O

Thus O O
, O O
the O O
TNF-alpha B B_GENE
gene I I_GENE
is O O
an O O
immediate O O
early O O
gene O O
in O O
activated O O
T O O
cells O O
and O O
provides O O
a O O
new O O
model O O
system O O
in O O
which O O
to O O
study O O
CsA-sensitive B B_GENE/B_DISEASE
gene I I_GENE/I_DISEASE
induction O O
in O O
activated O O
T O O
cells O O
. O O

Differences O O
in O O
expression O O
of O O
transcription B B_GENE
factor I I_GENE
AP-1 I I_GENE
in O O
human O O
promyelocytic O O
HL-60 O O
cells O O
during O O
differentiation O O
towards O O
macrophages O O
versus O O
granulocytes O O
. O O

Commitment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
HL-60 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
macrophage O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
granulocytic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
achieved O O
by O O
incubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O O
4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta-phorbol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12-myristate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
13-acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PMA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
for O O
30-60 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
or O O
with O O
dimethyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulphoxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DMSO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
for O O
24 O B_MEASURE
h O O
respectively O O
. O O

The O O
commitment O O
stage O O
towards O O
PMA-induced O O
macrophage O O
differentiation O O
was O O
associated O O
with O O
increases O O
in O O
jun O O
B O O
and O O
c-fos O O
mRNA O O
levels O O
, O O
as O O
well O O
as O O
with O O
an O O
increase O O
in O O
the O O
binding O O
activity O O
of O O
transcription B B_GENE
factor I I_GENE
AP-1 I I_GENE
. O O

Nevertheless O O
, O O
gel O O
retardation O O
analysis O O
indicated O O
that O O
the O O
AP-1 B B_GENE
activity O O
detected O O
in O O
untreated O O
cells O O
was O O
drastically O O
reduced O O
during O O
the O O
commitment O O
stage O O
of O O
DMSO-induced O O
HL-60 O O
differentiation O O
towards O O
granulocytes O O
. O O

When O O
HL-60 O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
treated O O
with O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
butyrate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
induced O O
monocytic O B_DISEASE
differentiation O I_DISEASE
, O O
a O O
remarkable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
AP-1 O O
binding O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
detected O O
. O O

Treatment O O
of O O
HL-60 O O
cells O O
with O O
1 O O
alpha O O
, O O
25-dihydroxyvitamin O O
D3 O O
, O O
another O O
monocytic O O
differentiation O O
agent O O
, O O
induced O O
a O O
weak O O
, O O
but O O
appreciable O O
, O O
increase O O
in O O
AP-1 B B_GENE
activity O O
. O O

Furthermore O O
, O O
addition O O
of O O
sodium O O
butyrate O O
or O O
1 O O
alpha O O
, O O
25-dihydroxyvitamin O O
D3 O O
to O O
HL-60 O O
cells O O
induced O O
the O O
expression O O
of O O
c-fos B B_GENE
, I I_GENE
c-jun I I_GENE
, I I_GENE
jun I I_GENE
B I I_GENE
and I I_GENE
jun I I_GENE
D I I_GENE
proto-oncogenes I I_GENE
. O O

In O O
contrast O O
, O O
when O O
HL-60 O O
cells O O
were O O
treated O O
with O O
retinoic O O
acid O O
, O O
a O O
granulocytic O O
differentiation O O
inducer O O
, O O
no O O
enhanced O O
AP-1 O O
binding O O
activity O O
was O O
observed O O
, O O
and O O
only O O
a O O
weak O O
increase O O
in O O
jun B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
D I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
level O O
was O O
detected O O
. O O

These O O
data O O
indicate O O
that O O
formation O O
of O O
AP-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
required O O
for O O
the O O
induction O O
of O O
HL-60 O O
differentiation O O
towards O O
granulocytes O O
, O O
whereas O O
induction O O
of O O
monocytic O O
differentiation O O
is O O
correlated O O
with O O
an O O
increase O O
in O O
AP-1 B B_GENE
activity O O
. O O

The O O
differential O O
expression O O
of O O
AP-1 B B_GENE
activity O O
may O O
be O O
critical O O
in O O
the O O
differentiation O O
of O O
HL-60 O O
cells O O
towards O O
monocytic O O
or O O
granulocytic O O
lineages O O

Glucocorticoid B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
receptors I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
sensitivity O O
in O O
leukemias O O
. O O

In O O
an O O
attempt O O
to O O
investigate O O
the O O
utility O O
of O O
glucocorticoid B B_GENE/B_MEASURE
receptor I I_GENE/I_MEASURE
determination O O
to O O
predict O O
clinical O O
responsiveness O O
in O O
human O O
leukemias O O
we O O
have O O
studied O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
leukemic O O
cells O O
from O O
46 O O
patients O O
and O O
in O O
the O O
lymphocytes O O
from O O
18 O O
normal O O
donors O O
. O O

In O O
the O O
normal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
there O O
were O O
3 O B_MEASURE
, O O
875 O B_MEASURE
( O O
Median O B_MEASURE
) O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O I_MEASURE
sites O I_MEASURE
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
blasts O O
from O O
17 O O
patients O O
with O O
ANLL O O
had O O
on O O
average O O
higher O O
levels O O
of O O
binding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
per O O
cell O O
( O O
Median O O
= O O
7 O O
, O O
250 O O
, O O
range O O
: O O
0 O O
to O O
15 O O
, O O
295 O O
) O O
than O O
the O O
other O O
leukemias O O
. O O

Of O O
the O O
15 O B_PERSON
patients O I_PERSON
with O O
CLL O B_DISEASE/B_LOCATION
, O O
six O B_NUMBER[MEASURE]
had O O
received O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
3 O B_NUMBER[MEASURE]/B_LOCATION
to O O
5 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
. O O

Their O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
had O O
lower O B_MEASURE
number O I_MEASURE
of O O
receptors O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Median O B_LOCATION/B_MEASURE
= O O
2 O B_MEASURE
, O O
000 O B_MEASURE
) O O
than O O
the O O
other O B_NUMBER[MEASURE]/B_PERSON
cases O I_NUMBER[MEASURE]/I_PERSON
which O O
were O O
newly O O
diagnosed O O
( O O
Median O B_LOCATION/B_MEASURE
= O O
4 O B_MEASURE
, O O
500 O B_MEASURE
) O O
. O O

Four O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
had O O
ALL/AUL O O
, O O
three O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
had O O
blast O B_DISEASE/B_GENE
crisis O I_DISEASE/I_GENE
as O O
terminal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
CML O B_DISEASE
, O O
and O O
seven O B_NUMBER[MEASURE]/B_PERSON
had O O
leukemic O B_DISEASE/B_GENE
Non-Hodgkin O I_DISEASE/I_GENE
lymphomas O I_DISEASE/I_GENE
( O O
Median O B_MEASURE/B_LOCATION
= O O
3 O B_MEASURE
, O O
500 O B_MEASURE
sites/cell O I_MEASURE
) O O
. O O

In O O
24 O B_TIME[MEASURE]/B_PERSON
patients O I_TIME[MEASURE]/I_PERSON
we O O
have O O
also O O
studied O O
the O O
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sensitivity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
leukemic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
dexamethasone O O
. O O

There O O
was O O
no O O
marked O O
correlation O O
between O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
and O O
in O O
vitro O O
sensitivity O O
. O O

An O O
attempt O O
to O O
correlate O O
receptor O O
levels O O
with O O
clinical O O
responsiveness O O
demonstrated O O
that O O
glucocorticoid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
determination O O
might O O
be O O
of O O
value O O
in O O
patients O O
with O O
lymphoid O O
malignancies O O
but O O
probably O O
not O O
in O O
patients O O
with O O
other O O
leukemias O O
. O O

'Activation-labile B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
' I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
glucocorticoid-receptor I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
complexes I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
a O O
steroid-resistant O O
variant O O
of O O
CEM-C7 O O
human O O
lymphoid O O
cells O O
. O O

For O O
cytoplasmic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid-receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
enter O O
and O O
accumulate O O
in O O
the O O
nucleus O O
a O O
temperature-dependent O O
event O O
, O O
'activation O O
' O O
is O O
required O O
. O O

Activation O O
can O O
be O O
achieved O O
in O O
vitro O O
by O O
increased O O
ionic O O
strength O O
, O O
dilution O O
or O O
gel O O
filtration O O
and O O
is O O
manifested O O
by O O
an O O
increased O O
affinity O O
of O O
steroid-receptor B B_GENE
complex I I_GENE
for O O
DNA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
an O O
altered O O
elution O O
profile O O
from O O
ion-exchange O O
resins O O
. O O

Munck O O
and O O
Foley O O
have O O
shown O O
that O O
activated B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isolated O O
from O O
thymocytes O O
elute O O
from O O
DEAE-cellulose O O
in O O
a O O
manner O O
identical O O
to O O
complexes O O
activated O O
in O O
vitro O O
. O O

We O O
report O O
here O O
that O O
DEAE-cellulose O O
chromatography O O
of O O
steroid-receptor B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complexes I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
from O O
CEM-C7 O O
, O O
a O O
cloned O O
human O O
leukaemic O O
T-cell O O
line O O
sensitive O O
to O O
the O O
cytolytic O O
action O O
of O O
glucocorticoids O O
, O O
and O O
its O O
steroid-resistant O O
subclone O O
4R4 O O
demonstrated O O
that O O
steroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
clone O O
4R4 O O
can O O
not O O
form O O
stable O O
activated O O
complexes O O
. O O

This O O
defines O O
a O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
defect O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
receptor O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
activation O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
lability O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
r+act1 O B_LOCATION/B_ORGANIZATION
) O O
, O O
which O O
is O O
unlike O O
either O O
the O O
r- O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
r+nt- O O
, O O
or O O
r+nti O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenotypes O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
previously O O
described O O
for O O
mouse O B_DISEASE/B_BIO
lymphoid O I_DISEASE/I_BIO
variants O I_DISEASE/I_BIO
. O O

Granulocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O O
the O O
endometrium O B_BODY_PART_OR_ORGAN_COMPONENT
of O O
post-partum O B_DISEASE/B_BIO
women O I_DISEASE/I_BIO
. O O

Endometrial O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
women O B_PERSON/B_SPECIES[BIO]
at O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
stages O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
of O O
gonadal O B_ORGANISM_FUNCTION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_ORGANISM_FUNCTION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
parturition O B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
examined O O
for O O
the O O
presence O B_MEASURE/B_DISEASE
and O O
numbers O B_MEASURE/B_LOCATION
of O O
endometrial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
granulocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

Although O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
at O O
all O O
the O O
stages O B_TIME[MEASURE]/B_DISEASE
contained O O
significant O B_MEASURE/B_LOCATION
numbers O I_MEASURE/I_LOCATION
of O O
the O O
granulocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
( O O
i.e. O B_MEASURE/B_GENE
greater O O
than O B_LOCATION/B_MEASURE
7/high-power O O
field O B_MEASURE
) O I_MEASURE
, O O
the O O
100 O O
% O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
late-proliferative O O
and O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
adaptation O O
hyperplasia O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
were O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
significantly O O
higher O O
than O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
the O O
values O O
for O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
the O O
resting O O
( O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
81.8 O O
% O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
) O B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
, O O
early O O
( O O
82.4 O O
% O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
) O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
mid- O O
( O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
87.9 O O
% O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
proliferative O O
and O B_DISEASE_ADJECTIVE[DISEASE]
secretory O O
( O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
83.3 O O
% O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
phases O O
. O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT

We O O
suggest O O
that O O
this O O
correlates O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
suggestion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
the O O
granulocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
constitute O O
a O O
receptor O B_GENE/B_LOCATION
system O B_GENE/I_LOCATION
for O O
oestrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Interaction O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
with O O
macrophages O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Identification O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
monocytes O O
and O O
macrophages O O
. O O

Glucocorticoid O B_GENE
binding O I_GENE
was O O
measured O O
in O O
resident O B_PERSON/B_BIO
and O O
thioglycollate-elicited O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mouse O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
peritoneal O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
macrophages O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
rabbit O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
alveolar O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O O
assays O O
of O O
binding O O
were O O
used O O
-- O O
an O O
assay O O
with O O
intact O O
cells O O
in O O
suspension O O
or O O
monolayers O O
, O O
and O O
an O O
assay O O
of O O
cytosol O O
and O O
nuclear O O
forms O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
mononuclear O O
phagocytes O O
contained O O
approximately O O
equal O O
to O O
4 O O
-- O O
10 O O
X O O
10 O O
( O O
3 O O
) O O
high B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
affinity I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
per O O
cell O O
, O O
with O O
dissociation O O
constants O O
of O O
approximately O O
equal O O
to O O
2 O O
-- O O
8 O O
nM O O
dexamethasone O O
. O O

The O O
binding O O
to O O
the O O
saturable B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
specific O O
for O O
steroids O O
with O O
glucocorticoid O O
or O O
antiglucocorticoid O O
activity O O
. O O

Cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
corticosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
progesterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
competed O O
with O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
binding O O
, O O
whereas O O
estradiol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
dihydrotestosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
11-epicortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
competed O O
very O O
little O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Binding O O
of O O
dexamethasone O O
to O O
cytosol O O
and O O
nuclear O O
forms O O
of O O
the O O
receptor B B_GENE
complex I I_GENE
and O O
temperature-sensitive O O
translocation O O
of O O
cytosol O O
forms O O
to O O
nuclear O O
forms O O
were O O
shown O O
. O O

At O O
37 O O
degrees O O
C O O
the O O
predominant O O
form O O
of O O
the O O
hormone-receptor B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
nuclear O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O O
that O O
corticosteroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interact O O
with O O
macrophages O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
physiological O B_MEASURE/B_LOCATION
concentrations O B_MEASURE/I_LOCATION
. O O

Nitric O O
oxide O O
signaling O O
: O O
a O O
possible O O
role O O
for O O
G B B_GENE/B_DISEASE
proteins I I_GENE/I_DISEASE
. O O

We O O
have O O
previously O O
reported O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inductive O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
effects O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
nitric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
PBMC O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
describe O O
a O O
novel O O
and O O
potentially O O
important O O
mechanism O O
of O O
nitric O O
oxide O O
signaling-through O O
direct O O
activation O O
of O O
guanine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
G B B_GENE/B_DISEASE
proteins I I_GENE/I_DISEASE
) O O
. O O

We O O
have O O
found O O
that O O
nitric O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
oxide O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
membranes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
isolated O O
from O O
fresh O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
PBMC O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
enhances O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
these O O
membranes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
hydrolyze O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gamma-32P O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
GTP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
bind O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gamma-35S O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
GTP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
whole O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
nitric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
yielded O O
membranes O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
enhanced O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
GTPase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
the O O
GTPase O O
activity O O
of O O
pure O O
, O O
recombinant O O
Gs B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Gi B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
p21ras B B_GENE
was O O
greatly O O
enhanced O O
by O O
nitric O O
oxide O O
. O O

In O O
support O O
of O O
the O O
existence O O
of O O
this O O
pathway O O
in O O
whole O O
cells O O
, O O
we O O
found O O
that O O
the O O
G O O
protein O O
inhibitor O O
, O O
GDP-beta-S O O
, O O
blocked O O
NF-kappa B B_GENE
B I I_GENE
translocation O O
induced O O
by O O
nitric O O
oxide O O
or O O
LPS O O
in O O
permeabilized O O
cells O O
. O O

In O O
addition O O
, O O
nitric O O
oxide O O
greatly O O
reduced O O
the O O
pertussis O O
toxin-mediated O O
ADP-ribosylation O O
of O O
45- B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
41-kDa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
membranes O O
of O O
these O O
cells O O
. O O

Because O O
G B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
play O O
a O O
central O O
role O O
in O O
many O O
diverse O O
signaling O O
systems O O
, O O
activation O O
by O O
an O O
endogenous O O
and O O
inducible O O
oxidant O O
may O O
represent O O
a O O
novel O O
signaling O O
pathway O O
. O O

The O O
granulocyte-macrophage B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cis-acting I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CLE0 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mediates O O
induction O O
signals O O
in O O
T O O
cells O O
and O O
is O O
recognized O O
by O O
factors O O
related O O
to O O
AP1 B B_GENE
and O O
NFAT B B_GENE
. O O

Expression O O
of O O
the O O
granulocyte-macrophage B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GM-CSF I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
T O O
cells O O
is O O
activated O O
by O O
the O O
combination O O
of O O
phorbol O O
ester O O
( O O
phorbol O O
myristate O O
acetate O O
) O O
and O O
calcium O O
ionophore O O
( O O
A23187 O O
) O O
, O O
which O O
mimic O O
antigen O O
stimulation O O
through O O
the O O
T-cell B B_GENE
receptor I I_GENE
. O O

We O O
have O O
previously O O
shown O O
that O O
a O O
fragment O O
containing O O
bp B B_GENE/B_LOCATION
-95 I B_GENE/I_LOCATION
to I B_GENE/I_LOCATION
+27 I B_GENE/I_LOCATION
of O O
the O O
mouse B B_GENE/B_LOCATION
GM-CSF I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
can O O
confer O O
inducibility O O
to O O
reporter B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
human O O
Jurkat O O
T-cell O O
line O O
. O O

Here O O
we O O
use O O
an O O
in O O
vitro O O
transcription O O
system O O
to O O
demonstrate O O
that O O
a O O
cis-acting B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
positions B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
-54 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
to I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
-40 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
, O O
referred O O
to O O
as O O
CLE0 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
a O O
target O O
for O O
the O O
induction O O
signals O O
. O O

We O O
observed O O
induction O O
with O O
templates O O
containing O O
intact O O
CLE0 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
not O O
with O O
templates O O
with O O
deleted B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CLE0 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
also O O
observed O O
that O O
two O O
distinct O O
signals O O
were O O
required O O
for O O
the O O
stimulation O O
through O O
CLE0 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
since O O
only O O
extracts O O
from O O
cells O O
treated O O
with O O
both O O
phorbol O O
myristate O O
acetate O O
and O O
A23187 O O
supported O O
optimal O O
induction O O
. O O

Stimulation O O
probably O O
was O O
mediated O O
by O O
CLE0-binding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
because O O
depletion O O
of O O
these O O
proteins O O
specifically O O
reduced O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transcription O O
. O O

One O O
of O O
the O O
binding B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
possessed O O
biochemical O O
and O O
immunological O O
features O O
identical O O
to O O
those O O
of O O
the O O
transcription B B_GENE/B_BIO
factor I I_GENE/I_BIO
AP1 I I_GENE/I_BIO
. O O

Another O O
factor O O
resembled O O
the O O
T-cell-specific B B_GENE/B_PERSON
factor I I_GENE/I_PERSON
NFAT I I_GENE/I_PERSON
. O O

The O O
characteristics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
these O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
their O O
involvement O B_PERSON/B_DISEASE
in O O
GM-CSF O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
presence O O
of O O
CLE0-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
promoters B B_LOCATION/B_ORGANIZATION
of O O
interleukin-3 B B_GENE/B_BIO
( I I_GENE/I_BIO
IL-3 I I_GENE/I_BIO
) I I_GENE/I_BIO
, I I_GENE/I_BIO
IL-4 I I_GENE/I_BIO
, I I_GENE/I_BIO
IL-5 I I_GENE/I_BIO
, I I_GENE/I_BIO
GM-CSF I I_GENE/I_BIO
, I I_GENE/I_BIO
and I I_GENE/I_BIO
NFAT I I_GENE/I_BIO
sites I I_GENE/I_BIO
in O O
the O O
IL-2 B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
promoter I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
suggests O O
that O O
the O O
factors O O
we O O
detected O O
, O O
or O O
related O O
factors O O
that O O
recognize O O
these O O
sites O O
, O O
may O O
account O O
for O O
the O O
coordinate O O
induction O O
of O O
these O O
genes O O
during O O
T-cell O O
activation O O
. O O

Identification O O
and O O
characterization O O
of O O
an O O
Alu-containing B B_GENE
, I I_GENE
T-cell-specific I I_GENE
enhancer I I_GENE
located O O
in O O
the O O
last O O
intron B B_GENE/B_LOCATION
of O O
the O O
human B B_GENE
CD8 I I_GENE
alpha I I_GENE
gene I I_GENE
. O O

Expression O O
of O O
the O O
human B B_GENE
CD8 I I_GENE
alpha I I_GENE
gene I I_GENE
is O O
restricted O O
to O O
cells O O
of O O
the O O
lymphoid O O
lineage O O
and O O
developmentally O O
regulated O O
during O O
thymopoiesis O O
. O O

As O O
an O O
initial O O
step O O
towards O O
understanding O O
the O O
molecular O O
basis O O
for O O
tissue-specific O O
expression O O
of O O
this O O
gene O O
, O O
we O O
surveyed O O
the O O
surrounding O O
chromatin O O
structure O O
for O O
potential O O
cis-acting B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulatory I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regions I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
DNase B B_GENE
I I I_GENE
hypersensitivity O O
mapping O O
and O O
found O O
four O O
hypersensitive O O
sites O O
, O O
three O O
of O O
which O O
were O O
T O O
cell O O
restricted O O
. O O

By O O
using O O
a O O
reporter-based O O
expression O O
approach O O
, O O
a O O
T-cell-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
identified O O
by O O
its O O
close O O
association O O
with O O
a O O
prominent O O
T-cell-restricted B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
hypersensitive I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sites I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
last O O
intron O O
of O O
the O O
CD8 B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
. O O

Deletion O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O O
that O O
the O O
minimal O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancer O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
adjacent O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O O
a O O
negative O B_GENE/B_LOCATION
regulatory O I_GENE/I_LOCATION
element O I_GENE/I_LOCATION
. O O

DNA O O
sequence O O
analysis O O
of O O
the O O
minimal B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancer I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
a O O
striking O O
cluster O O
of O O
consensus B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
binding I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sites I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
for O O
Ets-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TCF-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CRE I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GATA-3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LyF-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
were O O
verified O O
by O O
electrophoretic O O
mobility O O
shift O O
assays O O
. O O

In O O
addition O O
, O O
the O O
5 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
end I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
enhancer B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
composed O O
of O O
an O O
Alu O O
repeat O O
which O O
contained O O
the O O
GATA-3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LyF-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Site-directed O O
mutation O O
of O O
the O O
Ets-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GATA-3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dramatically O O
reduced O O
enhancer O O
activity O O
. O O

The O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
importance O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
the O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
binding O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sites O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
only O O
became O O
apparent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
combinations O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
mutations O B_DISEASE/B_GENE
were O O
analyzed O O
. O O

Taken O O
together O O
, O O
these O O
results O O
suggest O O
that O O
the O O
human B B_GENE
CD8 I I_GENE
alpha I I_GENE
gene I I_GENE
is O O
regulated O O
by O O
the O O
interaction O O
of O O
multiple O O
T-cell B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
transcriptional O O
enhancer O O
located O O
in O O
the O O
last O O
intron B B_GENE/B_LOCATION
of O O
the O O
gene O O
. O O

Comparison O O
of O O
the O O
CD8 B B_GENE
alpha I I_GENE
enhancer I I_GENE
with O O
other O O
recently O O
identified O O
T-cell-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
suggests O O
that O O
a O O
common O O
set O O
of O O
transcription B B_GENE/B_LOCATION
factors I I_GENE/I_LOCATION
regulates O O
several O O
T-cell B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Molecular O O
regulation O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL-3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
inducible O O
T O O
cell-restricted O O
expression O O
requires O O
intact O O
AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Elf-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-3 B B_GENE
) O O
is O O
a O O
hematopoietic B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stem-cell I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentiation I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
is O O
expressed O O
solely O O
in O O
activated O O
T O O
and O O
NK O O
cells O O
. O O

Studies O O
to O O
date O O
have O O
identified O O
elements O O
5 O O
' O O
to O O
the O O
IL-3 B B_GENE
coding I I_GENE
sequences I I_GENE
that O O
regulate O O
its O O
transcription O O
, O O
but O O
the O O
sequences O O
that O O
confer O O
T O O
cell-specific O O
expression O O
remain O O
to O O
be O O
clearly O O
defined O O
. O O

We O O
have O O
now O O
identified O O
DNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
are O O
required O O
for O O
T O O
cell-restricted O O
IL-3 B B_GENE
gene I I_GENE
transcription O O
. O O

A O O
series O O
of O O
transient O O
transfections O O
performed O O
with O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL-3-chloramphenicol I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acetyltransferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CAT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmids I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
T O O
and O O
non-T O O
cells O O
revealed O O
that O O
a O O
plasmid B B_GENE/B_LOCATION
containing O O
319 O O
bp O O
of O O
5 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
' I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
flanking I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
active O O
exclusively O O
in O O
T O O
cells O O
. O O

Deletion O O
analysis O O
revealed O O
that O O
T O O
cell O O
specificity O O
was O O
conferred O O
by O O
a O O
49-bp B B_GENE/B_LOCATION
fragment I I_GENE/I_LOCATION
( O O
bp B B_PROTEIN[GENE]/B_MEASURE
-319 I I_PROTEIN[GENE]/I_MEASURE
to I I_PROTEIN[GENE]/I_MEASURE
-270 I I_PROTEIN[GENE]/I_MEASURE
) O O
that O O
included O O
a O O
potential B B_GENE/B_LOCATION
binding I B_GENE/I_LOCATION
site I B_GENE/I_LOCATION
for O O
AP-1 B B_GENE
transcription I I_GENE
factors I I_GENE
6 O O
bp O O
upstream O O
of O O
a O O
binding B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
for I I_GENE/I_LOCATION
Elf-1 I I_GENE/I_LOCATION
, O O
a O O
member O O
of O O
the O O
Ets B B_PERSON/B_LOCATION
family I B_PERSON/I_LOCATION
of O O
transcription B B_GENE
factors I I_GENE
. O O

DNaseI B B_GENE
footprint O O
and O O
electrophoretic O O
mobility O O
shift O O
assay O O
analyses O O
performed O O
with O O
MLA-144 O O
T O O
cell O O
nuclear O O
extracts O O
demonstrated O O
that O O
this O O
49-bp B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
a O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
includes O O
consensus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Elf-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O O
, O O
extracts O O
prepared O O
from O O
purified O O
human O O
T O O
cells O O
contained O O
proteins O O
that O O
bound O O
to O O
synthetic O O
oligonucleotides O O
corresponding O O
to O O
the O O
AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Elf-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
vitro-transcribed O O
and O O
-translated O O
Elf-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bound O O
specifically O O
to O O
the O O
Elf-1 B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
Elf-1 O O
antisera O O
competed O O
and O O
super O O
shifted O O
nuclear O O
protein O O
complexes O O
present O O
in O O
MLA-144 O O
nuclear O O
extracts O O
. O O

Moreover O O
, O O
addition O O
of O O
anti-Jun O O
family O O
antiserum O O
in O O
electrophoretic O O
mobility O O
shift O O
assay O O
reactions O O
completely O O
blocked O O
formation O O
of O O
the O O
AP-1-related B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Transient O O
transfection O O
studies O O
in O O
MLA-144 O O
T O O
cells O O
revealed O O
that O O
constructs O O
containing O O
mutations O O
in O O
the O O
AP-1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
almost O O
completely O O
abolished O O
CAT O O
activity O O
while O O
mutation O O
of O O
the O O
Elf-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
the O O
NF-IL-3 B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
, O O
a O O
previously O O
described O O
nuclear B B_GENE/B_LOCATION
protein I B_GENE/I_LOCATION
binding I B_GENE/I_LOCATION
site I B_GENE/I_LOCATION
( O O
bp. B B_GENE/B_DISEASE
-155 I I_GENE/I_DISEASE
to I I_GENE/I_DISEASE
-148 I I_GENE/I_DISEASE
) O O
in O O
the O O
IL-3 B B_GENE
promoter I I_GENE
, O O
reduced O O
CAT O O
activity O O
to O O
< O O
25 O O
% O O
of O O
the O O
activity O O
given O O
by O O
wild-type O O
constructs O O
. O O

We O O
conclude O O
that O O
expression O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL-3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
requires O O
the O O
AP-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Elf-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
however O O
, O O
unlike O O
other O O
previously O O
characterized O O
cytokine B B_GENE/B_BIO
genes I I_GENE/I_BIO
such O O
as O O
IL-2 B B_GENE
, O O
the O O
AP-1 B B_MEASURE/B_GENE
and I I_MEASURE/I_GENE
Elf-1 I I_MEASURE/I_GENE
factors I I_MEASURE/I_GENE
can O O
bind O O
independently O O
in O O
the O O
IL-3 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
gene I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

( O O
ABSTRACT O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRUNCATED O I_MEASURE
AT O O
400 O B_LOCATION/B_PERSON
WORDS O I_LOCATION/I_PERSON
) O O

Combination O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
IL-4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduces O O
glucocorticoid O O
receptor-binding O O
affinity O O
and O O
T O O
cell O O
response O O
to O O
glucocorticoids O O
. O O

The O O
mechanisms O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contributing O O
to O O
persistent O B_DISEASE_ADJECTIVE[DISEASE]
T O I_DISEASE_ADJECTIVE[DISEASE]
cell O I_DISEASE_ADJECTIVE[DISEASE]
activation O I_DISEASE_ADJECTIVE[DISEASE]
and O O
poor O B_DISEASE
response O I_DISEASE
to O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
illnesses O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
such O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
as O O
steroid O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
resistant O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
SR O B_PROTEIN[GENE]/B_DISEASE
) O O
asthma O B_DISEASE/B_LOCATION
are O O
poorly O O
defined O O
. O O

We O O
examined O O
the O O
possibility O O
that O O
certain O O
cytokines O O
, O O
specifically O O
IL-2 B B_GENE
and O O
IL-4 B B_GENE
, O O
could O O
affect O O
T O O
cell O O
response O O
to O O
glucocorticoids O O
. O O

A O O
[ O O
3H O O
] O O
dexamethasone O O
radioligand-binding O O
assay O O
was O O
used O O
to O O
measure O O
the O O
number O O
of O O
glucocorticoid B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GR B B_LOCATION/B_ORGANIZATION
) O O
and O O
dissociation O O
constant O O
( O O
Kd O O
) O O
in O O
PBMC O O
from O O
normal O O
donors O O
and O O
patients O O
with O O
SR O O
asthma O O
, O O
cultured O O
in O O
the O O
absence O O
and O O
presence O O
of O O
these O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

PBMC O O
from O O
normal O O
donors O O
incubated O O
for O O
48 O O
h O O
in O O
the O O
presence O O
of O O
combination O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O O
IL-4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O O
nuclear O O
GR O O
with O O
significantly O O
reduced O O
binding O O
affinity O O
( O O
GR O O
Kd O O
= O O
36.1 O O
+/- O O
1.63 O O
nM O O
, O O
mean O O
+/- O O
SEM O O
; O O
p O O
= O O
0.0001 O O
) O O
as O O
compared O O
with O O
PBMC O O
incubated O O
with O O
medium O O
alone O O
( O O
GR O O
Kd O O
= O O
6.74 O O
+/- O O
0.46 O O
nM O O
) O O
. O O

The O O
cytosolic O B_MEASURE/B_LOCATION
GR O I_MEASURE/I_LOCATION
Kd O I_MEASURE/I_LOCATION
remained O O
unchanged O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

However O O
, O O
when O O
PBMC O O
were O O
incubated O O
with O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
or O O
IL-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
, O O
no O O
change O O
in O O
GR-binding O O
affinity O O
was O O
observed O O
. O O

Furthermore O O
, O O
when O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
non-T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
individually O O
stimulated O O
with O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
IL-2 O O
+ O O
IL-4 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reduction O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
GR-binding O B_DISEASE/B_GENE
affinity O I_DISEASE/I_GENE
was O O
observed O O
only O O
in O O
the O O
T O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
population O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
p O B_OTHER/B_PROTEIN[GENE]
= O O
0.0001 O B_MEASURE
) O O
. O O

The O O
IL-2 O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
+ O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
IL-4-induced O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
alteration O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
PBMC O B_PROTEIN[GENE]/B_LOCATION
GR O I_PROTEIN[GENE]/I_LOCATION
Kd O I_PROTEIN[GENE]/I_LOCATION
was O O
associated O O
with O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
GR O B_MEASURE/B_DISEASE
number O I_MEASURE/I_DISEASE
( O O
8348 O B_MEASURE
+/- O I_MEASURE
964 O I_MEASURE
vs O I_MEASURE
1710 O I_MEASURE
+/- O I_MEASURE
228 O I_MEASURE
sites/cell O I_MEASURE
; O O
p O O
= O O
0.0003 O B_MEASURE
) O O
. O O

More O O
importantly O O
, O O
the O O
alteration O O
in O O
PBMC O O
GR-binding O O
affinity O O
with O O
IL-2 B B_GENE
+ O O
IL-4 B B_GENE
was O O
associated O O
with O O
a O O
functional O O
change O O
in O O
T O O
cell O O
response O O
to O O
methylprednisolone O O
MPN O O
, O O
i.e. O O
, O O
a O O
reduced O O
inhibitory O O
effect O O
of O O
MPN O O
on O O
PMA/ionomycin-induced O O
T O O
cell O O
proliferation O O
. O O

These O O
effects O O
of O O
IL-2 B B_GENE
+ O O
IL-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
PBMC O O
GR B B_GENE/B_DISEASE
affinity O O
and O O
response O O
to O O
MPN O O
were O O
blocked O O
by O O
co-incubation O O
with O O
IFN-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Freshly O O
isolated O O
PBMC O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O O
four O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
SR O B_DISEASE/B_LOCATION
asthma O I_DISEASE/I_LOCATION
had O O
a O O
significantly O O
reduced O O
GR-binding O B_GENE/B_MEASURE
affinity O B_GENE/I_MEASURE
( O O
Kd O B_PROTEIN[GENE]/B_MEASURE
= O O
40.0 O B_MEASURE
+/- O I_MEASURE
2.68 O I_MEASURE
nM O I_MEASURE
; O O
p O B_OTHER/B_PROTEIN[GENE]
= O O
0.0001 O B_MEASURE
) O O
when O O
compared O O
with O O
seven O B_PERSON/B_MEASURE
normal O I_PERSON/I_MEASURE
subjects O I_PERSON/I_MEASURE
( O O
7.15 O B_MEASURE/B_PROTEIN[GENE]
+/- O I_MEASURE/I_PROTEIN[GENE]
0.41 O I_MEASURE/I_PROTEIN[GENE]
nM O I_MEASURE/I_PROTEIN[GENE]
) O O
. O O

The O O
altered O O
PBMC O O
GR O O
binding O O
from O O
patients O O
with O O
SR O O
asthma O O
reversed O O
to O O
normal O O
when O O
incubated O O
with O O
medium O O
alone O O
, O O
but O O
was O O
sustained O O
with O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
IL-4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
observations O O
suggest O O
that O O
with O O
persistent O O
inflammation O O
certain O O
cytokines B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
may O O
contribute O O
to O O
an O O
impaired O O
response O O
to O O
glucocorticoids O O
. O O

Furthermore O O
, O O
the O O
effects O O
of O O
IL-2 B B_GENE
and O O
IL-4 B B_GENE
were O O
blocked O O
by O O
IFN-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Characterization O O
of O O
the O O
human B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CD4 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
transcription O O
from O O
the O O
CD4 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
core I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
is O O
tissue-specific O O
and O O
is O O
activated O O
by O O
Ets B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
analyzed O O
the O O
5 B B_GENE/B_LOCATION
' I I_GENE/I_LOCATION
transcription I I_GENE/I_LOCATION
control I I_GENE/I_LOCATION
sequences I I_GENE/I_LOCATION
of O O
the O O
human B B_GENE/B_BIO
CD4 I I_GENE/I_BIO
gene I I_GENE/I_BIO
. O O

We O O
located O O
the O O
transcription B B_GENE/B_LOCATION
initiation I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
and O O
showed O O
that O O
the O O
CD4 B B_GENE/B_LOCATION
core I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
( O O
positions B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-40 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+16 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
lacks O O
a O O
classical O O
`` O O
TATA O O
'' O O
or O O
initiator B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positioning I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consensus I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
directs O O
precise O O
and O O
efficient O O
transcription O O
when O O
coupled O O
to O O
the O O
ubiquitously O O
active O O
simian B B_GENE/B_LOCATION
virus I I_GENE/I_LOCATION
40 I I_GENE/I_LOCATION
enhancer I I_GENE/I_LOCATION
. O O

The O O
transcriptional O O
activity O O
of O O
the O O
CD4 B B_GENE
gene I I_GENE
promoter I I_GENE
correlated O O
with O O
CD4 O O
expression O O
in O O
various O O
cell O O
types O O
. O O

Interestingly O O
, O O
the O O
CD4 B B_GENE
core I I_GENE
promoter I I_GENE
also O O
displayed O O
a O O
tissue-specific O O
transcriptional O O
activity O O
. O O

Within O O
this O O
fragment O O
, O O
three O O
nucleic O O
acid O O
sequences O O
are O O
completely O O
conserved O O
in O O
the O O
murine B B_GENE/B_BIO
CD4 I I_GENE/I_BIO
gene I I_GENE/I_BIO
. O O

One O O
of O O
these O O
sequences O O
contains O O
a O O
perfect B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ETS I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
consensus I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequence I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Another O O
ETS B B_LOCATION/B_PERSON
consensus I I_LOCATION/I_PERSON
sequence I I_LOCATION/I_PERSON
is O O
located O O
1060 O O
nt O O
upstream O O
. O O

Electrophoretic-mobility-shift O O
assays O O
showed O O
that O O
the O O
core O O
promoter O O
ETS O O
motif O O
binds O O
an O O
Ets-related B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
specifically O O
expressed O O
at O O
high O O
levels O O
in O O
CD4+ O O
cells O O
. O O

Moreover O O
, O O
in O O
CD4- O O
cells O O
, O O
overexpression O O
of O O
Ets-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
Ets-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efficiently O O
and O O
specifically O O
activated O O
transcription O O
from O O
the O O
CD4 B B_GENE
promoter I I_GENE
and O O
core B B_GENE
promoter I I_GENE
. O O

These O O
data O O
indicate O O
that O O
Ets B B_GENE
transcription I I_GENE
factors I I_GENE
play O O
a O O
central O O
role O O
in O O
controlling O O
CD4 O O
gene O O
expression O O
, O O
by O O
binding O O
to O O
both O O
a O O
classical B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
remote I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
an O O
unusual O O
proximal B B_GENE/B_LOCATION
activator I I_GENE/I_LOCATION
sequence I I_GENE/I_LOCATION

Glucocorticoid O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
receptor O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
activation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
and O O
inactivation O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
in O O
c O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
ultured O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O O

Although O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O O
not O O
cytolytic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
for O O
and O O
do O O
not O O
inhibit O O
the O O
growth O B_ORGANISM_FUNCTION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
IM-9 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
line O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
cultured O B_DISEASE
human O I_DISEASE
lymphoblasts O I_DISEASE
, O O
these O O
cells O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
have O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]
steroid-binding O I_DISEASE_ADJECTIVE[DISEASE]
capacity O I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
used O O
IM-9 O O
cells O O
in O O
order O O
to O O
examine O O
whether O O
unoccupied B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
inactivated O O
and O O
activated O O
in O O
intact O O
cells O O
. O O

when O O
IM-9 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
incubated O O
in O O
glucose-free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
nitrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
atmosphere O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
both O O
their O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
bind O O
triamcinolone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetonide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
their O O
ATP O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decline O O
and O O
, O O
when O O
glucose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
oxygen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O O
reintroduced O O
, O O
ATP O B_MEASURE/B_BIO
levels O B_MEASURE/I_BIO
and O O
receptor O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activity O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
return O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
specific O B_MEASURE
glucocorticoid-binding O I_MEASURE
activity O I_MEASURE
of O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
prepared O O
from O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
exposed O O
to O O
various O B_MEASURE/B_LOCATION
degrees O B_MEASURE/I_LOCATION
of O O
energy O B_DISEASE
limitation O I_DISEASE
is O O
directly O O
correlated O O
with O O
the O O
ATP O B_MEASURE/B_DISEASE
content O I_MEASURE/I_DISEASE
. O O

Receptor O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
intact O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
independent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
protein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
synthesis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
prepared O O
from O O
inactivated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
can O O
not O O
be O O
activated O O
by O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
ATP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
inactivation O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
occurs O O
when O O
cytosol O O
from O O
normal O O
IM-9 O O
cells O O
is O O
incubated O O
at O O
25 O O
degrees O O
C O O
is O O
inhibited O O
by O O
molybdate O O
, O O
vanadate O O
, O O
fluoride O O
, O O
ATP O O
, O O
and O O
several O O
other O O
nucleotides O O
. O O

The O O
experiments O O
with O O
intact O O
human O O
lymphoblasts O O
suggest O O
that O O
assays O O
of O O
specific O O
glucocorticoid-binding O O
capacity O O
do O O
not O O
necessarily O O
reflect O O
the O O
cellular O O
content O O
of O O
receptor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
lymphocytes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

II O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cell O O
cycle-dependent O O
changes O O
in O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O O
. O O

To O O
study O O
variations O O
in O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O O
during O O
the O O
cell O O
cycle O O
, O O
we O O
have O O
separated O O
mitogen-stimulated O O
human O O
peripheral O O
lymphocytes O O
and O O
rat O O
lymph O O
node O O
cells O O
by O O
unit O O
gravity O O
sedimentation O O
and O O
measured O O
glucocorticoid O O
binding O O
in O O
the O O
resultant O O
fractions O O
. O O

By O O
morphologic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
criteria O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
thymidine O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
incorporation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
the O O
fractions O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
separated O O
into O O
populations O B_LOCATION/B_ORGANIZATION
of O O
G0 O B_MEASURE/B_PROTEIN[GENE]
and O O
G1 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
S O B_DISEASE
and O O
post-S O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
cells O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

A O O
2- O B_MEASURE/B_LOCATION
to O O
3-fold O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
glucocorticoid O B_GENE/B_MEASURE
receptor O B_GENE/I_MEASURE
sites O B_GENE/I_MEASURE
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
, O O
for O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
S O B_OTHER/B_DISEASE
and O O
post-S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
over O O
those O O
in O O
G0 O B_PROTEIN[GENE]/B_DISEASE
and O O
G1 O B_PROTEIN[GENE]
, O O
was O O
observed O O
with O O
both O O
nonstimulated O B_DISEASE_ADJECTIVE[DISEASE]
rat O I_DISEASE_ADJECTIVE[DISEASE]
lymph O I_DISEASE_ADJECTIVE[DISEASE]
node O I_DISEASE_ADJECTIVE[DISEASE]
cell O I_DISEASE_ADJECTIVE[DISEASE]
suspensions O I_DISEASE_ADJECTIVE[DISEASE]
and O O
concanavalin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
A-stimulated O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
observations O O
together O O
with O O
those O O
from O O
other O O
studies O O
indicate O O
that O O
formation O O
of O O
new O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
near O O
the O O
S O O
phase O O
may O O
be O O
a O O
general O O
phenomenon O O
in O O
proliferating O O
cells O O
. O O

We O O
propose O O
that O O
this O O
increase O O
in O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
during O O
the O O
cell O O
cycle O O
may O O
explain O O
the O O
increase O O
in O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mitogen-stimulated O O
lymphocytes O O
. O O

The O O
leukocyte O O
migration O O
inhibition O O
response O O
to O O
certain O O
breast B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cancer-related I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigens I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MCF-7 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
MuMTV B B_GENE/B_SPECIES[BIO]
) O O
: O O
their O O
potential O O
as O O
discriminants O O
. O O

Certain O B_DISEASE_ADJECTIVE[DISEASE]/B_VIRUS[BIO]
oncogenic O B_DISEASE_ADJECTIVE[DISEASE]/I_VIRUS[BIO]
viruses O B_DISEASE_ADJECTIVE[DISEASE]/I_VIRUS[BIO]
have O O
been O O
implicated O O
in O O
human O B_DISEASE
breast O I_DISEASE
cancer O I_DISEASE
, O O
including O O
the O O
murine O B_VIRUS[BIO]/B_DISEASE
mammary O I_VIRUS[BIO]/I_DISEASE
tumor O I_VIRUS[BIO]/I_DISEASE
virus O I_VIRUS[BIO]/I_DISEASE
( O O
MuMTV O B_LOCATION/B_ORGANIZATION
) O O
and O O
the O O
Mason-Pfizer O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
monkey O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MPMV O B_VIRUS[BIO]
) O O
. O O

We O O
have O O
used O O
the O O
leukocyte O O
migration O O
inhibition O O
( O O
LMI O O
) O O
response O O
to O O
assay O O
the O O
response O O
to O O
several O O
potential O O
breast O O
cancer-related O O
antigens O O
, O O
including O O
MuMTV B B_VIRUS[BIO]/B_GENE
, O O
MPMV B B_GENE/B_BIO
, O O
and O O
a O O
breast O O
cancer O O
cultured O O
cell O O
line O O
, O O
MCF-7 O O
, O O
in O O
96 O O
breast O O
cancer O O
patients O O
, O O
in O O
32 O O
women O O
with O O
benign O O
breast O O
disease O O
, O O
and O O
in O O
67 O O
normal O O
women O O
. O O

The O O
lowest O B_MEASURE/B_LOCATION
tenth O B_MEASURE/I_LOCATION
percentile O B_MEASURE/I_LOCATION
of O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
LMI O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
) O O
responses O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
used O O
as O O
the O O
cutoff O B_MEASURE
point O I_MEASURE
to O O
designate O O
responders O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Breast O O
cancer O O
patients O O
showed O O
significant O O
responses O O
to O O
MuMTV B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
( O O
49 O O
% O O
and O O
to O O
MCF-7 O O
( O O
50 O O
% O O
) O O
, O O
but O O
not O O
to O O
MPMV B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
29 O O
% O O
) O O
. O O

In O O
a O O
paired-antigen O O
study O O
using O O
MuMTV B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
MCF-7 B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
75 O O
% O O
of O O
the O O
breast O O
cancer O O
patients O O
responded O O
, O O
versus O O
18 O O
% O O
of O O
the O O
normal O O
women O O
( O O
P O O
less O O
than O O
0.0050 O O
) O O
. O O

The O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
this O O
assay O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
distinguish O O
`` O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
normal O O
'' O O
from O B_DISEASE
`` O I_DISEASE
breast O O
cancer O O
'' O O
was O O
analyzed O O
using O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
migration O O
index O O
derived O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discriminant O O

The O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
assay O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
discriminate O O
`` O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
normal O O
'' O O
from O B_DISEASE
`` O O
cancer O O
'' O B_DISEASE_ADJECTIVE[DISEASE]
was O O
significant O B_MEASURE
( O I_MEASURE
P O O
less O B_MEASURE
than O O
0.001 O O
) O O
and O O
showed O B_MEASURE
a O O
sensitivity O O
of O B_DISEASE
detecting O O
`` O O
cancer O B_MEASURE/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
'' O B_MEASURE/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
of O O

The O O
overall O O
responses O O
to O O
MuMTV B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
and O O
MCF-7 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
analyzed O O
with O O
reference O O
to O O
certain O O
prognostic O O
factors O O
, O O
but O O
showed O O
no O O
relation O O
to O O
age O O
, O O
menstrual O O
status O O
, O O
estrogen O O
receptor O O
status O O
, O O
or O O
stage O O
of O O
disease O O
. O O

The O O
above O O
reactions O O
suggest O O
that O O
a O O
large O O
proportion O O
of O O
breast O O
cancer O O
patients O O
exhibit O O
presensitization O O
to O O
antigenfs O O
found O O
in O O
MuMTV B B_GENE/B_SPECIES[BIO]
and O O
MCF-7 B B_DISEASE/B_VIRUS[BIO]
, O O
which O O
may O O
be O O
cross-reactive O O
with O O
antigens O O
in O O
the O O
primary O O
cancer O O
. O O

These O O
responses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
appear O O
to O O
be O O
independent O B_PERSON/B_LOCATION
of O O
major O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prognostic O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
variables O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
refinement O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
assay O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
may O O
yield O O
one O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O O
is O O
more O O
highly O O
discriminating O O
for O O
breast O B_DISEASE/B_PERSON
cancer O I_DISEASE/I_PERSON
. O O

Chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphatic O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leukaemia O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
cellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vitro O B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Glucocorticoid B B_GENE
receptor I I_GENE
levels O O
and O O
steroid O O
induced O O
inhibition O O
of O O
nucleic O O
acid O O
precursors O O
have O O
been O O
examined O O
in O O
lymphocytes O O
from O O
27 O O
patients O O
at O O
different O O
stages O O
of O O
chronic O O
lymphatic O O
leukaemia O O
. O O

No O O
correlation O O
can O O
be O O
found O O
between O O
the O O
level O O
of O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
stage O O
of O O
the O O
disease O O
. O O

On O O
the O O
other O B_PERSON/B_LOCATION
hand O B_PERSON/I_LOCATION
, O O
a O O
significant O B_MEASURE
difference O I_MEASURE
( O O
P O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0.02 O B_MEASURE
) O O
was O O
found O O
between O O
stage O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
O O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
stage O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
III/IV O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
patients O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
terms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
[ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uridine O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incorporation O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pyrrolidine O O
dithiocarbamate O O
inhibits O O
NF-kappa B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mobilization O O
and O O
TNF O O
production O O
in O O
human O O
monocytes O O
. O O

The O O
human B B_PROTEIN[GENE]/B_LOCATION
TNF I I_PROTEIN[GENE]/I_LOCATION
promoter I I_PROTEIN[GENE]/I_LOCATION
contains O O
four O O
potential O O
nuclear B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
factor-kappa I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
B I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
NF-kappa I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
B I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
-binding I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
sites I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
with O O
the O O
strongest O O
binding O O
seen O O
for O O
the O O
-605 O O
motif O O
. O O

Nuclear O O
extracts O O
from O O
unstimulated O O
cells O O
of O O
the O O
human O O
monocytic O O
cell O O
line O O
, O O
Mono O O
Mac O O
6 O O
, O O
contain O O
one O O
specific B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
complex B B_GENE/B_DISEASE
II I I_GENE/I_DISEASE
) O O
, O O
consistent O O
with O O
a O O
constitutive B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p50 I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homodimer I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Stimulation O O
of O O
Mono O O
Mac O O
6 O O
cells O O
with O O
LPS O O
will O O
increase O O
complex B B_LOCATION/B_DISEASE
II I B_LOCATION/I_DISEASE
and O O
will O O
strongly O O
induce O O
a O O
second O O
specific O O
complex O O
( O O
complex B B_LOCATION/B_PERSON
I I I_LOCATION/I_PERSON
) O O
, O O
which O O
represents O O
the O O
p50/65 B B_GENE/B_SEQUENCE[MEASURE]
heterodimer I B_GENE/I_SEQUENCE[MEASURE]
. O O

Treatment O O
of O O
Mono O O
Mac O O
6 O O
cells O O
with O O
pyrrolidine-dithiocarbamate O O
( O O
PDTC O O
) O O
at O O
300 O O
microM O O
will O O
block O O
the O O
LPS-induced B B_GENE/B_LOCATION
complex I I_GENE/I_LOCATION
I I I_GENE/I_LOCATION
almost O O
completely O O
and O O
will O O
reduce O O
complex B B_LOCATION/B_DISEASE
II I B_LOCATION/I_DISEASE
to O O
the O O
constitutive O O
level O O
. O O

Binding O O
activity O O
of O O
other O O
nuclear B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
recognize O O
the O O
SP-1 O O
and O O
c/EBP O O
motifs O O
of O O
the O O
human B B_GENE
TNF I I_GENE
promoter I I_GENE
is O O
not O O
affected O O
by O O
such O O
treatment O O
. O O

Northern O O
blot O O
analysis O O
demonstrates O O
that O O
PDTC O O
treatment O O
will O O
strongly O O
reduce O O
LPS-induced B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
TNF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Secreted O O
TNF B B_DISEASE_ADJECTIVE[DISEASE]
protein I I_DISEASE_ADJECTIVE[DISEASE]
as O O
detected O O
in O O
the O O
Wehi O O
164S/ActD O O
bioassay O O
and O O
in O O
a O O
sandwich O O
immunoassay O O
was O O
similarly O O
reduced O O
by O O
PDTC O O
. O O

Kinetic O O
analyses O O
show O O
that O O
after O O
LPS O O
stimulation O O
, O O
NF-kappa B B_GENE
B I I_GENE
will O O
peak O O
at O O
1 O O
h O O
, O O
TNF O O
transcript O O
prevalence O O
at O O
2 O O
h O O
, O O
and O O
TNF B B_GENE/B_MEASURE
protein I B_GENE/I_MEASURE
at O O
4 O O
h O O
. O O

PDTC O O
did O O
not O O
shift O O
this O O
response O O
to O O
LPS O O
to O O
a O O
later O O
time O O
, O O
but O O
suppressed O O
NF-kappa O O
B O O
mobilization O O
, O O
TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
over O O
the O O
entire O O
8-h O O
observation O O
period O O
. O O

Analysis O O
of O O
freshly O O
isolated O O
, O O
LPS-stimulated O O
blood O O
monocytes O O
showed O O
a O O
similar O O
blockade O O
of O O
NF-kappa B B_GENE
B I I_GENE
. O O

Furthermore O O
, O O
in O O
these O O
primary O O
cells O O
, O O
induction O O
of O O
TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
determined O O
by O O
Northern O O
blot O O
analysis O O
and O O
by O O
quantitative O O
polymerase O O
chain O O
reaction O O
, O O
was O O
prevented O O
by O O
PDTC O O
as O O
was O O
TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
production O O
. O O

These O O
data O O
show O O
that O O
dithiocarbamates O O
can O O
profoundly O O
affect O O
cytokine O O
expression O O
and O O
suggest O O
that O O
NF-kappa B B_GENE
B I I_GENE
is O O
involved O O
in O O
LPS-induced O O
TNF O O
gene O O
expression O O
in O O
human O O
monocytes O O
. O O

Comparing O O
regions O O
of O O
the O O
Epstein-Barr B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ZEBRA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
function O O
as O O
transcriptional B B_GENE/B_MEASURE
activating I I_GENE/I_MEASURE
sequences I I_GENE/I_MEASURE
in O O
Saccharomyces O O
cerevisiae O O
and O O
in O O
B O O
cells O O
. O O

The O O
ZEBRA B B_GENE
protein I I_GENE
activates O O
expression O O
of O O
Epstein-Barr O O
virus O O
early-lytic-cycle B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
B O O
lymphocytes O O
. O O

Here O O
it O O
is O O
shown O O
that O O
ZEBRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
behaves O O
as O O
a O O
sequence-specific B B_GENE/B_PERSON
transcriptional I I_GENE/I_PERSON
activator I I_GENE/I_PERSON
in O O
Saccharomyces O O
cerevisiae O O
. O O

Deletional O O
mutagenesis O O
defined O O
three O O
regions O O
of O O
ZEBRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
participate O O
in O O
activation O O
in O O
S. O O
cerevisiae O O
. O O

These O O
regions O O
are O O
designated O O
YI B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
amino B B_MEASURE
acids I I_MEASURE
[ I I_MEASURE
aa I I_MEASURE
] I I_MEASURE
1 I I_MEASURE
to I I_MEASURE
25 I I_MEASURE
) O O
, O O
YII B B_PROTEIN[GENE]/B_LOCATION
( O O
aa B B_MEASURE
51 I I_MEASURE
to I I_MEASURE
102 I I_MEASURE
) O O
, O O
and O O
YIII B B_PROTEIN[GENE]/B_LOCATION
( O O
aa B B_MEASURE/B_BIO
228 I I_MEASURE/I_BIO
to I I_MEASURE/I_BIO
245 I I_MEASURE/I_BIO
) O O
. O O

Two O O
of O O
the O O
three O O
regions O O
of O O
the O O
native O O
ZEBRA B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
act O O
together O O
to O O
mediate O O
activation O O
when O O
assayed O O
on O O
ZEBRA B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
when O O
fused O O
to O O
the O O
DNA B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
domain I I_GENE/I_LOCATION
of O O
GAL B B_GENE/B_BACTERIUM[BIO]
4 O O
and O O
assayed O O
on O O
GAL4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
regions B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
YII I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
and I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
YIII I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
were O O
each O O
sufficient O O
to O O
confer O O
activation O O
in O O
S. O O
cerevisiae O O
. O O

Regions O O
of O O
ZEBRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
affected O O
activation O O
in O O
S. O O
cerevisiae O O
were O O
also O O
required O O
in O O
human O O
B O O
lymphocytes O O
. O O

The O O
amino-terminal B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ZEBRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
aa B B_PROTEIN[GENE]/B_MEASURE
1 I I_PROTEIN[GENE]/I_MEASURE
to I I_PROTEIN[GENE]/I_MEASURE
98 I I_PROTEIN[GENE]/I_MEASURE
) O O
was O O
required O O
for O O
activation O O
both O O
in O O
S. O O
cerevisiae O O
and O O
in O O
human O O
B O O
cells O O
; O O
deletion O O
of O O
the O O
carboxy-terminal B B_LOCATION/B_GENE
18 I B_LOCATION/I_GENE
aa I B_LOCATION/I_GENE
also O O
significantly O O
reduced O O
activation O O
in O O
both O O
cell O O
types O O
. O O

Thus O O
, O O
the O O
behavior O O
of O O
ZEBRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O O
B O O
cells O O
and O O
S. O O
cerevisiae O O
suggests O O
that O O
the O O
protein O O
contains O O
universal B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
activation I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
motifs I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
that O O
interact O O
with O O
conserved O O
components O O
of O O
the O O
transcription O O
machinery O O
. O O

However O O
, O O
certain O O
deletion B B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
mutants I I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
of O O
ZEBRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
mutations O O
in O O
the O O
N-terminal B B_GENE/B_LOCATION
region I I_GENE/I_LOCATION
exhibited O O
discordant O O
behaviors O O
in O O
S. O O
cerevisiae O O
and O O
in O O
B O O
cells O O
. O O

For O O
example O O
, O O
deletion O O
of O O
ZEBRA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
aa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
26 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
51 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
impaired O O
activation O O
to O O
a O O
great O O
extent O O
in O O
B O O
cells O O
but O O
had O O
little O O
or O O
no O O
effect O O
in O O
S. O O
cerevisiae O O
. O O

The O O
discordant O O
mutants O O
may O O
reflect O O
interactions O O
with O O
a O O
variable B B_MEASURE/B_LOCATION
domain I I_MEASURE/I_LOCATION
of O O
a O O
conserved O O
component O O
or O O
unique O O
interactions O O
with O O
specialized O O
components O O
of O O
the O O
basal O O
transcription O O
apparatus O O
in O O
different O O
cells O O
. O O

Functional O O
interaction O O
of O O
the O O
v-Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Rel I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncoproteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
TATA-binding B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
association O O
with O O
transcription B B_GENE
factor I I_GENE
IIB I I_GENE
. O O

Rel B B_PERSON/B_GENE
family I I_PERSON/I_GENE
proteins I I_PERSON/I_GENE
regulate O O
the O O
expression O O
of O O
genes O O
linked O O
to O O
kappa O O
B-binding O O
motifs O O
. O O

Little O B_PERSON/B_LOCATION
is O O
known O O
, O O
however O O
, O O
of O O
the O O
mechanism O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O O
which O O
they O O
enhance O O
transcription O B_DISEASE/B_GENE
. O O

We O O
have O O
investigated O O
the O O
ability O O
of O O
the O O
v-Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Rel I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncoproteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
interact O O
with O O
components O O
of O O
the O O
basal O O
transcription O O
machinery O O
. O O

Here O O
we O O
report O O
that O O
both O O
the O O
acidic O O
transcription O O
activation O O
domain O O
mapping O O
to O O
the O O
unique O O
C B B_LOCATION/B_BIO
terminus I I_LOCATION/I_BIO
of O O
chicken B B_GENE
c-Rel I I_GENE
and O O
the O O
F9 B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
cell-specific I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
activation I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
region I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
common O O
to O O
both O O
v-Rel B B_GENE
and O O
c-Rel B B_GENE
interact O O
with O O
the O O
TATA-binding B B_GENE
protein I I_GENE
( O O
TBP B B_GENE/B_LOCATION
) O O
and O O
transcription B B_GENE
factor I I_GENE
IIB I I_GENE
( O O
TFIIB B B_GENE/B_DISEASE
) O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

We O O
also O O
demonstrate O O
that O O
TPB B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
interaction O O
with O O
Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leads O O
to O O
synergistic O O
activation O O
of O O
transcription O O
of O O
a O O
kappa B B_GENE
B-linked I I_GENE
reporter I I_GENE
gene I I_GENE
. O O

Combined O O
with O O
the O O
observation O O
that O O
the O O
mouse B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
c-Rel I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
human I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
RelA I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
also O O
interact O O
with O O
TBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
TFIIB B B_GENE
in O O
vitro O O
, O O
these O O
results O O
suggest O O
that O O
association O O
with O O
basal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
important O O
for O O
the O O
transcriptional O O
activities O O
of O O
Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

p21ras B B_GENE
and O O
calcineurin O O
synergize O O
to O O
regulate O O
the O O
nuclear B B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
factor I B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
activated O O
T O O
cells O O
. O O

In O O
T O O
lymphocytes O O
, O O
triggering O O
of O O
the O O
T B B_GENE
cell I I_GENE
receptor I I_GENE
( O O
TCR B B_LOCATION/B_ORGANIZATION
) O O
induces O O
several O O
signaling O O
cascades O O
which O O
ultimately O O
synergize O O
to O O
induce O O
the O O
activity O O
of O O
the O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
activated O O
T O O
cells O O
( O O
NFAT O O
) O O
, O O
a O O
DNA B B_GENE
binding I I_GENE
complex I I_GENE
critical O O
to O O
the O O
inducibility O O
and O O
T O O
cell O O
specificity O O
of O O
the O O
T B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interleukin B I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

One O O
immediate O O
consequence O O
of O O
T O O
cell O O
activation O O
via O O
the O O
TCR B B_GENE
is O O
an O O
increase O O
in O O
cytosolic O O
calcium O O
. O O

Calcium O O
signals O O
are O O
important O O
for O O
NFAT O O
induction O O
, O O
and O O
recent O O
studies O O
have O O
identified O O
calcineurin B B_GENE
, O O
a O O
calcium-calmodulin B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependent I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serine-threonine I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphatase I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
a O O
prominent O O
component O O
of O O
the O O
calcium O O
signaling O O
pathway O O
in O O
T O O
cells O O
. O O

A O O
second O O
important O O
molecule O O
in O O
TCR O O
signal O O
transduction O O
is O O
the O O
guanine B B_GENE
nucleotide I I_GENE
binding I I_GENE
protein I I_GENE
, O O
p21ras B B_GENE
, O O
which O O
is O O
coupled O O
to O O
the O O
TCR B B_GENE
by O O
a O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent O O
mechanism O O
. O O

The O O
experiments O O
presented O O
here O O
show O O
that O O
expression O O
by O O
transfection O O
of O O
mutationally O O
activated O O
calcineurin B B_GENE/B_DISEASE
or O O
activated O O
p21ras B B_GENE
alone O O
is O O
insufficient O O
for O O
NFAT O O
transactivation O O
. O O

However O O
, O O
coexpression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
activated O O
calcineurin O B_GENE
with O O
activated O O
p21ras O B_GENE
could O O
mimic O O
TCR O B_DISEASE_ADJECTIVE[DISEASE]
signals O I_DISEASE_ADJECTIVE[DISEASE]
in O O
NFAT O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
induction O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

These O O
data O O
identify O O
calcineurin B B_GENE
and O O
p21ras B B_GENE
as O O
cooperative O O
partners O O
in O O
T O O
cell O O
activation O O
. O O

Expression O O
of O O
the O O
chicken B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GATA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
early O O
erythroid O O
development O O
and O O
differentiation O O
. O O

The O O
DNA O O
motif O O
WGATAR O O
has O O
been O O
identified O O
within O O
transcriptional B B_LOCATION/B_GENE
regulatory I I_LOCATION/I_GENE
domains I I_LOCATION/I_GENE
of O O
globin B B_GENE
and O O
other O O
erythroid-specific B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
activator B B_GENE/B_BIO
proteins I I_GENE/I_BIO
that O O
bind O O
to O O
this O O
regulatory B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
, O O
the O O
GATA B B_GENE/B_BIO
factors I I_GENE/I_BIO
, O O
belong O O
to O O
a O O
multi-gene B B_GENE/B_LOCATION
family I I_GENE/I_LOCATION
that O O
is O O
expressed O O
in O O
chicken O O
erythroid O O
cells O O
. O O

Here O O
we O O
show O O
that O O
, O O
as O O
in O O
chickens O O
, O O
multiple O O
members O O
of O O
the O O
GATA B B_GENE/B_BIO
factor I I_GENE/I_BIO
family I I_GENE/I_BIO
are O O
expressed O O
in O O
human O O
and O O
murine O O
erythroid O O
cells O O
. O O

During O O
the O O
early O O
stages O O
of O O
chicken O O
embryogenesis O O
( O O
well O O
before O O
blood O O
island O O
formation O O
) O O
, O O
each O O
of O O
the O O
GATA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
members I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
transcribed O O
with O O
a O O
unique O O
temporal O O
and O O
spatial O O
pattern O O
. O O

In O O
the O O
primitive O O
erythroid O O
lineage O O
, O O
transcription O O
of O O
the O O
embryonic B B_GENE/B_MEASURE
epsilon-globin I I_GENE/I_MEASURE
gene I I_GENE/I_MEASURE
parallels O O
GATA-1 O O
expression O O
while O O
the O O
switch O O
to O O
beta-globin O O
transcription O O
in O O
definitive O O
erythroid O O
cells O O
is O O
directly O O
preceded O O
by O O
a O O
pronounced O O
increase O O
in O O
GATA-3 B B_GENE
accumulation O O
. O O

The O O
timing O O
and O O
pattern O O
of O O
expression O O
of O O
these O O
different O O
mRNAs B B_GENE/B_BIO
during O O
avian O O
erythroid O O
development O O
and O O
differentiation O O
suggests O O
that O O
temporally O O
regulated O O
changes O O
in O O
GATA B B_GENE/B_BIO
factor I I_GENE/I_BIO
expression O O
are O O
required O O
for O O
vertebrate O O
hematopoiesis O O
. O O

Molecular O O
regulation O O
of O O
human B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
interleukin I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
2 I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
T-cell O O
function O O
by O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Distinct O O
functional O O
T-cell O O
subsets O O
, O O
differing O O
in O O
the O O
patterns O O
of O O
lymphokines B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
, O O
regulate O O
cell-mediated O O
and O O
humoral O O
immune O O
responses O O
. O O

The O O
two O O
major O O
types O O
and O O
their O O
principal O O
products O O
, O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
interferon B B_MEASURE
gamma I I_MEASURE
( O O
IL-4 B B_GENE
and O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
are O O
reciprocally O O
negatively O O
interactive O O
. O O

To O O
analyze O O
the O O
molecular O O
mechanism O O
of O O
IL-4-mediated O O
suppression O O
of O O
cell-mediated O O
immunity O O
we O O
studied O O
its O O
effects O O
on O O
expression O O
of O O
interleukin B B_GENE
2 I I_GENE
( O O
IL-2 B B_GENE/B_MEASURE
) O O
and O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

IL-4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
pretreatment O O
of O O
Jurkat O O
cells O O
prior O O
to O O
stimulation O O
resulted O O
in O O
a O O
decrease O O
in O O
transcription O O
of O O
the O O
IL2 B B_GENE
gene I I_GENE
. O O

IL-4 B B_PERSON/B_GENE
suppressed O O
IL-2 O O
and O O
IFN-gamma O O
mRNA O O
levels O O
in O O
primary O O
human O O
T O O
cells O O
, O O
and O O
addition O O
of O O
anti-CD28 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
relieved O O
this O O
suppression O O
. O O

Using O O
enhancer-reporter B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constructs I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL-4 B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O O
down-regulated O O
the O O
NFIL-2B B B_GENE
element I I_GENE
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
using O O
a O O
DNA O O
oligomer O O
containing O O
the O O
NFIL-2B B B_GENE
binding I I_GENE
site I I_GENE
indicated O O
that O O
IL-4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O O
the O O
NFIL-2B B B_GENE
complex I I_GENE
and O O
that O O
the O O
NFIL-2B B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
distinct O O
from O O
AP- B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
. O O

These O O
results O O
suggest O O
that O O
IL-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
regulate O O
development O O
and O O
function O O
of O O
T-cell O O
subsets O O
involved O O
in O O
cell-mediated O O
immunity O O
in O O
part O O
by O O
inhibiting B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factors I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
required O O
for O O
transcription O O
of O O
the O O
IL2 B B_GENE
gene I I_GENE

Immunochemical O O
differences O O
between O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
corticoid-sensitive O O
and O O
-resistant O O
malignant O O
lymphocytes O O
. O O

We O O
have O O
explored O O
the O O
possibility O O
of O O
using O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
purified O O
rat O O
liver O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
to O O
study O O
the O O
immunochemical O O
properties O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
from O O
murine O O
and O O
human O O
malignant O O
lymphocytes O O
. O O

For O O
this O O
purpose O O
, O O
purified B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
immune I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
immunoglobulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
G I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
covalently O O
linked O O
to O O
Sepharose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CL-4B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
then O O
examined O O
the O O
ability O O
of O O
the O O
affinity O O
gel O O
to O O
recognize O O
cytosolic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
[ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3H I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
triamcinolone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acetonide-receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
corticoid-sensitive O O
( O O
CS O O
) O O
and O O
-resistant O O
strains O O
of O O
mouse O O
lymphoma O O
P1798 O O
, O O
from O O
CS O O
lymphocytes O O
of O O
patients O O
with O O
chronic O O
lymphatic O O
leukemia O O
, O O
and O O
from O O
a O O
CS O O
clone O O
of O O
human O O
leukemic O O
lymphoblasts O O
in O O
tissue O O
culture O O
( O O
CH6 O O
) O O
. O O

Mouse O O
thymus O O
was O O
used O O
as O O
a O O
source O O
of O O
glucocorticoid B B_GENE
receptor I I_GENE
from O O
normal O O
CS O O
lymphocytes O O
. O O

Whereas O O
the O O
immunoaffinity O O
column O O
retained O O
70 O O
to O O
84 O O
% O O
of O O
the O O
58- O O
to O O
62-A O O
( O O
Stokes O O
radius O O
) O O
[ B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3H I B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] I B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
triamcinolone I B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
acetonide-receptor I B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
complexes I B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
characteristic O O
of O O
the O O
CS O O
mouse O O
and O O
human O O
lymphocytes O O
, O O
it O O
failed O O
to O O
recognize O O
the O O
27- O O
to O O
28-A O O
( O O
Stokes O O
radius O O
) O O
glucocorticoid B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present O O
in O O
corticoid-resistant O O
mouse O O
lymphoma O O
P1798 O O
cells O O
. O O

Therefore O O
, O O
under O O
appropriate O O
experimental O O
conditions O O
, O O
it O O
was O O
possible O O
to O O
demonstrate O O
cross-reactivity O O
between O O
the O O
antiserum O O
against O O
rat B B_GENE
liver I I_GENE
glucocorticoid I I_GENE
receptor I I_GENE
and O O
the O O
58- O O
to O O
62-A O O
( O O
Stokes O O
radius O O
) O O
glucocorticoid B B_PROTEIN[GENE]/B_LOCATION
receptor I I_PROTEIN[GENE]/I_LOCATION
from O O
species O O
as O O
diverse O O
as O O
mouse O O
and O O
humans O O
. O O

Heterogeneity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
acute O B_DISEASE/B_BIO
leukemia O I_DISEASE/I_BIO
. O O

In O O
leukocyte O O
population O O
freshly O O
isolated O O
from O O
the O O
blood O O
of O O
26 O O
patients O O
with O O
acute O O
leukemia O O
, O O
we O O
have O O
measured O O
several O O
parameters O O
including O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
nucleoside O O
incorporation O O
, O O
percentage O O
of O O
cells O O
in O O
S O O
phase O O
, O O
and O O
steroid-induced O O
cell O O
lysis O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
in O O
some O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
short-term O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
steroid O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
determined O O
. O O

Although O O
, O O
in O O
all O O
the O O
patients O O
studied O O
, O O
leukocytes O O
were O O
found O O
to O O
contain O O
glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
failed O O
to O O
demonstrate O O
any O O
correlation O O
between O O
the O O
level O O
of O O
binding O O
sites O O
and O O
the O O
in O O
vitro O O
or O O
in O O
vivo O O
response O O
to O O
glucocorticoids O O
. O O

This O O
absence O B_DISEASE/B_MEASURE
of O O
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
in O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
explained O O
by O O
the O O
marked O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
heterogeneity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
the O O
steroid O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O O
in O O
leukocyte O B_PERSON/B_DISEASE
subpopulations O I_PERSON/I_DISEASE
. O O

It O O
appears O O
, O O
however O O
, O O
that O O
the O O
degree O B_MEASURE
of O O
steroid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
vitro O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
the O O
extent O B_DISEASE/B_MEASURE
of O O
spontaneous O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dexamethasone-induced O B_DISEASE_ADJECTIVE[DISEASE]
cell O I_DISEASE_ADJECTIVE[DISEASE]
death O I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
related O O
to O O
the O O
number O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O O
the O O
S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
cell O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Glucocorticoid B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
cytosol O O
and O O
nuclear O O
extract O O
of O O
human O O
leukocytes O O
. O O

Cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
0.4 O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
M O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
KCl O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
extract O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
fraction O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O O
human O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
leukocytes O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
studied O O
by O O
gel O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
ion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exchange O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
filtration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
DEAE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cellulose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
cytoplasmic B B_PROTEIN[GENE]
cortisol I I_PROTEIN[GENE]
binding I I_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
has O O
a O O
molecular O O
weight O O
95 O O
000 O O
and O O
the O O
soluble B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
nuclear I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
binding I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
protein I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
50 O O
000 O O
. O O

The O O
absence O B_DISEASE
of O O
the O O
uptake O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
radioactive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cortisol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O O
isolated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
nuclei O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
apparent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
requirement O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
for O O
glucocorticoid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
nuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
sites O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
was O O
observed O O
. O O

The O O
association O B_MEASURE
constant O I_MEASURE
characterising O O
the O O
binding O B_GENE/B_MEASURE
of O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
was O O
KA O B_LOCATION/B_PROTEIN[GENE]
= O O
3.5 O B_MEASURE
. O O
10 O B_MEASURE
( O O
9 O B_MEASURE
) O O
l/mol O B_MEASURE/B_BIO
. O O

Corticosteroid-induced O B_DISEASE_ADJECTIVE[DISEASE]
lymphopenia O I_DISEASE_ADJECTIVE[DISEASE]
, O O
immunosuppression O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
body O B_DISEASE
defense O I_DISEASE
. O O

The O O
apparent O O
paradox O O
of O O
heightened O O
adrenal O O
corticosteroid O O
levels O O
associated O O
with O O
reduction O O
in O O
the O O
competence O O
of O O
the O O
body O O
's O O
defensive O O
apparatus O O
to O O
cope O O
with O O
exposure O O
to O O
new O O
microbial B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigens I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
considered O O
. O O

The O O
question O B_TIME[MEASURE]/B_PERSON
is O O
asked O O
how O O
this O O
lowered O O
defensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capability O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
occurs O O
in O O
the O O
face O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
a O O
threat O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
body O B_PERSON/B_ORGANIZATION
integrity O I_PERSON/I_ORGANIZATION
, O O
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
Cannon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
's O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
principals O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
`` O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wisdom O O
of O O
the O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
body. O O
'' O O

The O O
suggestion O O
is O O
offered O O
that O O
the O O
immunologic O O
response O O
to O O
self-antigens B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
exposed O O
by O O
disease O O
or O O
trauma O O
may O O
be O O
suppressed O O
by O O
corticosteroid O O
to O O
offset O O
the O O
likelihood O O
of O O
autoimmune O O
attack O O
. O O

Protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O O
is O O
required O O
for O O
lipopolysaccharide O O
induction O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
blood O O
monocytes O O
. O O

Bacterial O O
LPS O O
induce O O
production O O
of O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
such O O
as O O
IL-1 B B_GENE
, O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
TNF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mononuclear O O
phagocytes O O
, O O
and O O
this O O
represents O O
a O O
central O O
component O O
in O O
the O O
pathogenesis O O
of O O
septic O O
shock O O
syndrome O O
. O O

However O O
, O O
the O O
mechanisms O O
by O O
which O O
LPS O O
activates O O
these O O
cells O O
to O O
express O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
are O O
not O O
completely O O
characterized O O
. O O

The O O
present O O
study O O
addressed O O
the O O
role O O
of O O
different O O
protein B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
kinases I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
LPS O O
induction O O
of O O
cytokines B B_DISEASE/B_GENE
. O O

It O O
is O O
shown O O
that O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
a O O
12- O B_NUMBER[MEASURE]
to O O
16-fold O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
IL-1 O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL-6 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
TNF-alpha O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
this O O
was O O
completely O O
or O O
more O B_MEASURE
than O O
80 O B_TIME[MEASURE]/B_LOCATION
% O I_TIME[MEASURE]/I_LOCATION
blocked O O
by O O
the O O
protein O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
herbimycin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
A O O
and O O
genistein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O O
the O O
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
1.7 O B_MEASURE
and O O
37 O B_MEASURE
microM O I_MEASURE
, O O
respectively O O
. O O

Protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibition O O
by O O
staurosporine O O
reduced O O
LPS O O
induction O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
it O O
had O O
no O O
effects O O
on O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
IL-1 O O
beta O O
. O O

Inhibition O O
of O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
by O O
H89 O O
reduced O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
but O O
did O O
not O O
detectably O O
change O O
IL-1 O O
beta O O
or O O
TNF-alpha O O
mRNA O O
levels O O
. O O

In O O
contrast O O
, O O
LPS O O
did O O
not O O
increase O O
leukemia B B_GENE
inhibitory I I_GENE
factor I I_GENE
mRNA I I_GENE
, O O
which O O
was O O
constitutively O O
expressed O O
and O O
not O O
significantly O O
reduced O O
by O O
these O O
inhibitors O O
. O O

In O O
addition O O
to O O
cytokine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
, O O
LPS-induced O O
IL-6 O O
protein O O
synthesis O O
and O O
IL-6 O O
bioactivity O O
were O O
also O O
reduced O O
to O O
baseline O O
levels O O
by O O
the O O
PTK O O
inhibitors O O
herbimycin O O
A O O
and O O
genistein O O
. O O

Both O O
PTK O O
inhibitors O O
also O O
reduced O O
the O O
LPS O O
activation O O
of O O
nuclear B B_GENE
factor-kappa I I_GENE
B I I_GENE
( O O
NF-kappa B B_GENE
B I I_GENE
) O O
, O O
which O O
is O O
a O O
transcription B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
involved O O
in O O
the O O
expression O O
of O O
cytokine B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
such O O
as O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
was O O
also O O
reduced O O
by O O
H89 O O
, O O
whereas O O
staurosporine O O
had O O
no O O
effect O O
on O O
this O O
response O O
. O O

In O O
summary O O
, O O
these O O
findings O O
suggest O O
that O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
appear O O
to O O
have O O
selective O O
effects O O
in O O
the O O
LPS O O
induction O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
PTK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
required O O
for O O
LPS O O
induction O O
of O O
a O O
broad O O
spectrum O O
of O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
NF-kappa B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
in O O
monocytes O O
. O O

In O O
vivo O O
control O O
of O O
NF-kappa B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
by O O
I B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kappa I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
transcription B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa B I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
B I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
stored O O
in O O
the O O
cytoplasm O O
in O O
complexes O O
with O O
the O O
inhibitor B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
I I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
kappa I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
alpha I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

It O O
has O O
been O O
shown O O
in O O
vitro O O
that O O
dissociation O O
of O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
these O O
complexes O O
results O O
in O O
active B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NF-kappa I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
report O O
we O O
show O O
that O O
lipopolysaccharide O O
( O O
LPS O O
) O O
-induced O O
activation O O
of O O
B O O
or O O
pre-B O O
cells O O
results O O
in O O
loss O O
of O O
I B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kappa I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
NF-kappa B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
B I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O O
. O O

Many O O
liberated O O
NF-kappa B B_GENE
B I I_GENE
dimers I I_GENE
reached O O
the O O
nucleus O O
, O O
where O O
increased O O
c-rel B B_GENE
, O O
p65 O O
and O O
p50 O O
were O O
detected O O
by O O
immunoblotting O O
and O O
by O O
DNA O O
binding O O
assays O O
. O O

Some O O
liberated B B_LOCATION/B_ORGANIZATION
dimers I I_LOCATION/I_ORGANIZATION
were O O
retained O O
in O O
the O O
cytoplasm O O
, O O
however O O
, O O
through O O
binding O O
to O O
newly O O
synthesized O O
I B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kappa I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
a O O
finding O O
which O O
strongly O O
suggests O O
( O O
i O O
) O O
that O O
the O O
LPS-induced O O
signal O O
causes O O
dissociation O O
of O O
complexes O O
rather O O
than O O
preventing O O
their O O
association O O
and O O
( O O
ii O O
) O O
that O O
dissociation O O
results O O
from O O
modification O O
of O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
not O O
of O O
c-rel B B_GENE
or O O
p65 B B_GENE
. O O

No O O
effect O O
of O O
LPS O O
treatment O O
was O O
detected O O
on O O
p105 B B_GENE
or O O
p100 B B_GENE
, O O
which O O
also O O
retain O O
rel B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
family I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
members I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
cytoplasm O O
. O O

Quite O O
unexpectedly O O
, O O
we O O
also O O
found O O
that O O
in O O
unstimulated O O
cells O O
there O O
is O O
a O O
constant O O
ongoing O O
process O O
of O O
degradation O O
and O O
replacement O O
of O O
complexed B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kappa I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

We O O
propose O O
that O O
this O O
turnover O O
results O O
in O O
the O O
low O O
level O O
of O O
active B B_GENE
NF-kappa I I_GENE
B I I_GENE
presumably O O
necessary O O
even O O
in O O
the O O
unstimulated O O
cell O O
, O O
and O O
that O O
the O O
high O O
rate O O
of O O
synthesis O O
of O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O O
the O O
ability O O
to O O
turn O O
off O O
NF-kappa B B_GENE
B I I_GENE
activity O O
rapidly O O
as O O
soon O O
as O O
the O O
activating O O
signal O O
ceases O O
. O O

Identification O O
of O O
a O O
killer B B_GENE/B_PERSON
cell-specific I I_GENE/I_PERSON
regulatory I I_GENE/I_PERSON
element I I_GENE/I_PERSON
of O O
the O O
mouse B B_GENE
perforin I I_GENE
gene I I_GENE
: O O
an O O
Ets-binding O O
site-homologous O O
motif O O
that O O
interacts O O
with O O
Ets-related B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
gene O O
encoding O O
the O O
cytolytic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
perforin B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
selectively O O
expressed O O
by O O
activated O O
killer O O
lymphocytes O O
. O O

To O O
understand O O
the O O
mechanisms O O
underlying O O
the O O
cell-type-specific O O
expression O O
of O O
this O O
gene O O
, O O
we O O
have O O
characterized O O
the O O
regulatory O O
functions O O
and O O
the O O
DNA-protein O O
interactions O O
of O O
the O O
5'-flanking B B_GENE/B_MEASURE
region I I_GENE/I_MEASURE
of O O
the O O
mouse B B_GENE
perforin I I_GENE
gene I I_GENE
( O O
Pfp B B_PROTEIN[GENE]/B_SPECIES[BIO]
) O O
. O O

A O O
region O O
extending O O
from O O
residues B B_LOCATION/B_GENE
+62 I I_LOCATION/I_GENE
through I I_LOCATION/I_GENE
-141 I I_LOCATION/I_GENE
, O O
which O O
possesses O O
the O O
essential O O
promoter O O
activity O O
, O O
and O O
regions O O
further O O
upstream O O
, O O
which O O
are O O
able O O
to O O
either O O
enhance O O
or O O
suppress O O
gene O O
expression O O
, O O
were O O
identified O O
. O O

The O O
region O O
between O O
residues B B_LOCATION/B_GENE
-411 I I_LOCATION/I_GENE
and I I_LOCATION/I_GENE
-566 I I_LOCATION/I_GENE
was O O
chosen O O
for O O
further O O
characterization O O
, O O
since O O
it O O
contains O O
an O O
enhancer-like O O
activity O O
. O O

We O O
have O O
identified O O
a O O
32-mer O O
sequence O O
( O O
residues B B_PROTEIN[GENE]/B_MEASURE
-491 I I_PROTEIN[GENE]/I_MEASURE
to I I_PROTEIN[GENE]/I_MEASURE
-522 I I_PROTEIN[GENE]/I_MEASURE
) O O
which O O
appeared O O
to O O
be O O
capable O O
of O O
enhancing O O
gene O O
expression O O
in O O
a O O
killer O O
cell-specific O O
manner O O
. O O

Within O O
this O O
segment O O
, O O
a O O
9-mer O O
motif O O
( O O
5'-ACAGGAAGT-3 O O
' O O
, O O
residues B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-505 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-497 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
designated O O
NF-P O O
motif O O
) O O
, O O
which O O
is O O
highly O O
homologous O O
to O O
the O O
Ets B B_GENE/B_TIME[MEASURE]
proto-oncoprotein-binding I I_GENE/I_TIME[MEASURE]
site I I_GENE/I_TIME[MEASURE]
, O O
was O O
found O O
to O O
interact O O
with O O
two O O
proteins O O
, O O
NF-P1 B B_GENE
and O O
NF-P2 B B_GENE
. O O

NF-P2 B B_GENE/B_DISEASE
appears O O
to O O
be O O
induced O O
by O O
reagents O O
known O O
to O O
up-regulate O O
the O O
perforin O O
message O O
level O O
and O O
is O O
present O O
exclusively O O
in O O
killer O O
cells O O
. O O

Electrophoretic O O
mobility O O
shift O O
assay O O
and O O
UV O O
cross-linking O O
experiments O O
revealed O O
that O O
NF-P1 B B_GENE
and O O
NF-P2 B B_GENE
may O O
possess O O
common O O
DNA-binding B B_GENE/B_LOCATION
subunits I B_GENE/I_LOCATION
. O O

However O O
, O O
the O O
larger O O
native O O
molecular O O
mass O O
of O O
NF-P1 B B_GENE
suggests O O
that O O
NF-P1 B B_GENE/B_PERSON
contains O O
an O O
additional O O
non-DNA-binding B B_GENE
subunit I I_GENE
( O O
s O O
) O O
. O O

In O O
view O O
of O O
the O O
homology O O
between O O
the O O
NF-P B B_GENE/B_MEASURE
motif I I_GENE/I_MEASURE
and O O
other O O
Ets B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
proto-oncoprotein-binding I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
sites I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
it O O
is O O
postulated O O
that O O
NF-P1 B B_GENE
and O O
NF-P2 B B_GENE
belong O O
to O O
the O O
Ets B B_GENE/B_MEASURE
protein I I_GENE/I_MEASURE
family I I_GENE/I_MEASURE
. O O

Results O O
obtained O O
from O O
the O O
binding O O
competition O O
assay O O
, O O
nevertheless O O
, O O
suggest O O
that O O
NF-P1 B B_GENE
and O O
NF-P2 B B_GENE
are O O
related O O
to O O
but O O
distinct O O
from O O
Ets B B_GENE/B_PERSON
proteins I I_GENE/I_PERSON
, O O
e.g. O O
, O O
Ets-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Ets-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
NF-AT/Elf-1 B B_GENE
, O O
known O O
to O O
be O O
expressed O O
in O O
T O O
cells O O
. O O

The O O
role O O
of O O
NF-kappa B B_GENE
B1 I I_GENE
( I I_GENE
p50/p105 I I_GENE
) I I_GENE
gene I I_GENE
expression O O
in O O
activation O O
of O O
human O O
blood O O
T-lymphocytes O O
via O O
CD2 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
CD28 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Stimulation O O
of O O
primary O O
human O O
T-lymphocytes O O
via O O
CD2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CD28 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O O
a O O
long-lasting O O
proliferation O O
( O O
> O O
3 O O
weeks O O
) O O
. O O

This O O
potent O O
activation O O
does O O
not O O
require O O
accessory O O
cells O O
, O O
such O O
as O O
monocytes O O
, O O
but O O
depends O O
on O O
persistent O O
interleukin B B_GENE
2 I I_GENE
( O O
IL-2 B B_GENE/B_MEASURE
) O O
secretion O O
and O O
receptivity O O
, O O
which O O
is O O
associated O O
with O O
high O O
and O O
prolonged O O
expression O O
of O O
the O O
inducible O O
CD25/IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-2R I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
participates O O
in O O
the O O
regulation O O
of O O
both O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-2R I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
well O O
as O O
multiple B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
cellular I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
involved O O
in O O
T-cell O O
proliferation O O
. O O

To O O
evaluate O O
the O O
role O O
of O O
NF-kappa B B_GENE
B I I_GENE
in O O
human O O
peripheral O O
blood O O
T-lymphocytes O O
, O O
we O O
previously O O
analyzed O O
the O O
activation O O
of O O
NF-kappa B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B-related I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complexes I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
response O O
to O O
CD2+CD28 O O
costimulation O O
. O O

We O O
demonstrated O O
a O O
long-term O O
induction O O
of O O
p50/p65 B B_GENE
heterodimer I I_GENE
, O O
a O O
putative B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p65/c-Rel I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
a O O
constitutive O O
nuclear O O
expression O O
of O O
KBF1/p50 B B_GENE
homodimers I I_GENE
. I I_GENE

As O O
the O O
role O O
of O O
p50 B B_GENE
remains O O
unclear O O
, O O
we O O
focused O O
our O O
present O O
study O O
on O O
NF-kappa B B_GENE
B1 I I_GENE
( O O
p50/p105 B B_GENE/B_DISEASE
) O O
gene O O
regulation O O
. O O

Using O O
electrophoretic O O
mobility O O
shift O O
assays O O
and O O
Western O O
and O O
Northern O O
blot O O
analyses O O
, O O
we O O
studied O O
NF-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
during O O
T-cell O O
stimulation O O
via O O
CD2+CD28 B B_GENE
. O O

We O O
observed O O
a O O
transient O B_NUMBER[MEASURE]/B_LOCATION
4- O I_NUMBER[MEASURE]/I_LOCATION
to O O
5-fold O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
NF-kappa O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
at O O
both O O
the O O
mRNA O B_GENE
and O O
protein O B_GENE
levels O I_GENE
, O O
lasting O O
for O O
at O O
least O O
24 O B_MEASURE
h O O
. O O

p50 O O
DNA-binding O B_GENE
activity O I_GENE
apparently O O
stays O O
highly O O
controlled O O
when O O
p105 O O
expression O B_GENE
is O O
enhanced O O
by O O
a O O
physiological O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stimulus O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
peripheral O B_DISEASE/B_GENE
blood O I_DISEASE/I_GENE
T-cells O I_DISEASE/I_GENE
. O O

Partial O O
inhibition O O
of O O
p50 O O
and O O
p105 O O
expression O O
by O O
NF-kappa B B_GENE/B_NUMBER[MEASURE]
B1 I I_GENE/I_NUMBER[MEASURE]
antisense O O
oligonucleotides O O
significantly O O
reduced O O
T-cell O O
proliferation O O
and O O
CD25/IL-2R B B_GENE
alpha I I_GENE
cell O O
surface O O
expression O O
. O O

( O O
ABSTRACT O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRUNCATED O I_MEASURE
AT O O
250 O B_LOCATION/B_ENT
WORDS O I_LOCATION/I_ENT
) O O

Vitamin B B_GENE/B_PERSON
D I I_GENE/I_PERSON
receptor I I_GENE/I_PERSON
quantitation O O
in O O
human O O
blood O O
mononuclear O O
cells O O
in O O
health O O
and O O
disease O O
. O O

Vitamin B B_PROTEIN[GENE]
D I I_PROTEIN[GENE]
receptor I I_PROTEIN[GENE]
( O O
VDR O O
) O O
concentration O O
was O O
quantitated O O
in O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMC O O
) O O
from O O
patients O O
with O O
absorptive O O
hypercalciuria O O
( O O
AH O O
) O O
and O O
patients O O
with O O
high O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
due O O
to O O
acquired O O
or O O
transient O O
disease O O
states O O
and O O
the O O
results O O
compared O O
to O O
those O O
in O O
normal O O
subjects O O
. O O

VDR O B_GENE
concentration O I_GENE
in O O
resting O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
not O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
represented O O
constitutive O B_DISEASE_ADJECTIVE[DISEASE]
receptor O I_DISEASE_ADJECTIVE[DISEASE]
expression O I_DISEASE_ADJECTIVE[DISEASE]
of O O
monocytes O B_GENE
. O O

Following O O
activation O O
with O O
phytohemagglutinin B B_BIO/B_GENE
, O O
patients O O
with O O
hypercalcitriolemia O O
demonstrated O O
significantly O O
greater O O
VDR O O
concentrations O O
. O O

Patients O O
with O O
AH O O
demonstrated O O
a O O
normal O O
value O O
for O O
the O O
group O O
, O O
but O O
6 O O
patients O O
had O O
significantly O O
greater O O
concentrations O O
of O O
VDR B B_GENE
despite O O
normal O O
plasma O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
in O O
four O O
of O O
the O O
patients O O
. O O

Proliferation O B_MEASURE/B_GENE
, O O
as O O
assessed O O
from O O
[ O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
3H O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
] O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
thymidine O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
incorporation O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
inversely O O
correlated O O
with O O
serum O B_MEASURE/B_BIO
1 O I_MEASURE/I_BIO
, O O
25 O B_MEASURE
( O O
OH O B_LOCATION/B_PROTEIN[GENE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
was O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
-0.299 O B_MEASURE
, O O
p O O
= O O
0.048 O B_MEASURE
) O O
. O O

Taken O O
together O O
, O O
the O O
results O O
suggest O O
that O O
PBMC O O
provide O O
a O O
useful O O
system O O
for O O
studying O O
VDR B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
status O O
in O O
transient O O
or O O
acquired O O
states O O
of O O
hypercalcitriolemia O O
. O O

Furthermore O O
, O O
the O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
patients O B_PERSON/B_BIO
with O O
absorptive O B_DISEASE
hypercalciuria O I_DISEASE
disclosed O O
it O O
to O O
be O O
a O O
heterogeneous O B_DISEASE/B_GENE
disorder O I_DISEASE/I_GENE
, O O
characterized O O
by O O
both O O
vitamin O B_DISEASE_ADJECTIVE[DISEASE]
D-dependent O I_DISEASE_ADJECTIVE[DISEASE]
and O O
D-independent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
forms O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
receptor O B_DISEASE
up-regulation O I_DISEASE
. O O

Reactive O O
oxygen O O
intermediates O O
activate O O
NF-kappa B B_GENE
B I I_GENE
in O O
a O O
tyrosine O O
kinase-dependent O O
mechanism O O
and O O
in O O
combination O O
with O O
vanadate O O
activate O O
the O O
p56lck B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p59fyn I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
lymphocytes O O
. O O

We O O
have O O
previously O O
observed O O
that O O
ionizing O O
radiation O O
induces O O
tyrosine O O
phosphorylation O O
in O O
human O O
B-lymphocyte O O
precursors O O
by O O
stimulation O O
of O O
unidentified O O
tyrosine B B_ENZYME[GENE]
kinases I I_ENZYME[GENE]
and O O
this O O
phosphorylation O O
is O O
substantially O O
augmented O O
by O O
vanadate O O
. O O

Ionizing O O
radiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
generates O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reactive O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
oxygen O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intermediates O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
ROI O B_DISEASE/B_GENE
) O O
. O O

Because O O
H2O2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
is O O
a O O
potent O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ROI O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generator O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
readily O O
crosses O O
the O O
plasma O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
membrane O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
used O O
H2O2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
to O O
examine O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ROI O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
signal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transduction O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
now O O
provide O O
evidence O O
that O O
the O O
tyrosine O O
kinase O O
inhibitor O O
herbimycin O O
A O O
and O O
the O O
free O O
radical O O
scavenger O O
N-acetyl-cysteine O O
inhibit O O
both O O
radiation-induced O O
and O O
H2O2-induced O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
, O O
indicating O O
that O O
activation O O
triggered O O
by O O
ROI O O
is O O
dependent O O
on O O
tyrosine O O
kinase O O
activity O O
. O O

H2O2 O O
was O O
found O O
to O O
stimulate O O
Ins-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5-P3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
production O O
in O O
a O O
tyrosine O O
kinase-dependent O O
manner O O
and O O
to O O
induce O O
calcium O O
signals O O
that O O
were O O
greatly O O
augmented O O
by O O
vanadate O O
. O O

The O O
synergistic O O
induction O O
of O O
tyrosine O O
phosphorylation O O
by O O
H2O2 O O
plus O O
vanadate O O
included O O
physiologically O O
relevant O O
proteins O O
such O O
as O O
PLC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
treatment O O
of O O
cells O O
with O O
H2O2 O O
alone O O
did O O
not O O
affect O O
the O O
activity O O
of O O
src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
treatment O O
with O O
H2O2 O O
plus O O
vanadate O O
led O O
to O O
activation O O
of O O
the O O
p56lck B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
p59fyn I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
combined O O
inhibition O O
of O O
phosphatases B B_GENE
and O O
activation O O
of O O
kinases B B_GENE
provides O O
a O O
potent O O
mechanism O O
for O O
the O O
synergistic O O
effects O O
of O O
H2O2 O O
plus O O
vanadate O O
. O O

Induction O O
of O O
tyrosine O O
phosphorylation O O
by O O
ROI O O
may O O
thus O O
lead O O
to O O
many O O
of O O
the O O
pleiotropic O O
effects O O
of O O
ROI O O
in O O
lymphoid O O
cells O O
, O O
including O O
downstream O O
activation O O
of O O
PLC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
NF-kappa B B_GENE
B I I_GENE

Influence O O
of O O
sex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
albumin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
the O O
conversion O O
of O O
androstenedione O O
to O O
testosterone O O
by O O
human O O
erythrocytes O O
. O O

The O O
influence O O
of O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
serum I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
sex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
globulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
SHBG B B_GENE
) O O
on O O
the O O
enzymic O O
conversion O O
of O O
androstenedione O O
to O O
testosterone O O
in O O
human O O
erythrocytes O O
was O O
investigated O O
in O O
vitro O O
. O O

Total O O
plasma O O
and O O
albumin B B_GENE
delayed O O
the O O
conversion O O
rate O O
of O O
androstenedione O O
, O O
while O O
SHBG B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
it O O
markedly O O
. O O

The O O
effect O O
of O O
SHBG B B_GENE
was O O
largely O O
abolished O O
by O O
heating O O
to O O
60 O O
degrees O O
C O O
for O O
1 O O
h O O
and O O
by O O
saturating O O
its O O
binding O O
sites O O
by O O
DHT O O
. O O

The O O
effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
both O O
proteins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
found O O
to O O
be O O
related O O
to O O
their O O
concentration O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
appears O O
that O O
the O O
binding O O
sites O O
of O O
albumin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O O
a O O
mechanism O O
for O O
retarding O O
androstenedione O O
uptake O O
by O O
the O O
erythrocytes O O
and O O
that O O
the O O
high O O
binding O O
affinity O O
of O O
SHBG B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
for O O
testosterone O O
facilitates O O
the O O
diffusion O O
of O O
this O O
steroid O O
out O O
of O O
the O O
cell O O
and O O
thus O O
, O O
displaces O O
the O O
chemical O O
equilibrium O O
within O O
the O O
cell O O
. O O

Glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
lymphocytes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

I O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Increased O O
glucocorticoid B B_GENE
receptor I I_GENE
levels O O
in O O
antigen-stimulated O O
lymphocytes O O
. O O

Recently O O
a O O
2- O O
to O O
3-fold O O
increase O O
in O O
the O O
number O O
of O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O O
peripheral O O
lymphocytes O O
has O O
been O O
noted O O
after O O
in O O
vitro O O
mitogen O O
stimulation O O
. O O

Here O O
, O O
we O O
extend O O
these O O
observations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
immunization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O O

After O O
unilateral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
immunization O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
adrenalectomized O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
male O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
50 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
increase O I_MEASURE/I_LOCATION
in O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sites O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
determined O O
by O O
binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
was O O
observed O O
in O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
suspensions O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
homolateral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lymph O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
nodes O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
over O O
those O O
from O O
the O O
contralateral O B_BODY_PART_OR_ORGAN_COMPONENT
nonimmunized O I_BODY_PART_OR_ORGAN_COMPONENT
side O I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
same O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
animal O B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
association O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constant O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
both O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
was O O
the O O
stereospecificity O B_MEASURE
for O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steroids O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
course O B_TIME[MEASURE]/I_LOCATION
of O O
cytoplasmic O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
association O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
cytoplasmic-to-nuclear O B_DISEASE_ADJECTIVE[DISEASE]
translocation O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Despite O O
a O O
50 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
increase O I_MEASURE/I_LOCATION
in O O
the O O
number O B_MEASURE
of O O
glucocorticoid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
sites O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
the O O
homolateral O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
controlateral O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
lymph O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
nodes O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
equally O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
inhibitory O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effects O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
determined O O
by O O
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
incorporation O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
radiolabeled O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
precursors O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
protein O B_GENE/B_BACTERIUM[BIO]
, O O
RNA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
and O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
or O O
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
survival O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
actions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
rat O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
thymocytes O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
immunologically O O
stimulated O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

After O O
reviewing O O
briefly O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
our O O
earlier O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
receptors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
mechanisms O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
thymus O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
we O O
have O O
outlined O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
the O O
following O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
areas O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
interest O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
in O O
our O O
laboratories O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
the O O
`` O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
life-cycle O O
'' O O
of O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
glucocorticoid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors O O
and O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
complexes O O
in O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
thymus O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cells O O
, O O
and O O
the O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
of O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
receptors O O
and O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity O O
in O O
immunologically O O
stimulated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
peripheral O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O O

Several O O
of O O
our O O
results O O
on O O
energetics O O
and O O
kinetics O O
of O O
hormone O O
binding O O
to O O
glucocorticoid B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rat O O
thymus O O
cells O O
seem O O
to O O
require O O
extension O O
of O O
the O O
simplest O O
model O O
of O O
hormone-receptor O O
transformations O O
in O O
intact O O
cells O O
. O O

ATP-depletion O O
experiments O O
suggest O O
the O O
existence O O
of O O
a O O
nonbinding O O
form O O
of O O
the O O
receptor O O
; O O
`` O O
chase O O
'' O O
experiments O O
suggest O O
reaction O O
of O O
hormone O O
directly O O
with O O
nuclear-bound O O
receptor O O
; O O
experiments O O
on O O
depletion O O
and O O
replenishment O O
of O O
cytoplasmic B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
using O O
cortisol O O
and O O
dexamethasone O O
suggest O O
the O O
existence O O
of O O
at O O
least O O
two O O
subpopulations O O
of O O
nuclear-bound B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hormone-receptor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complex I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
have O O
found O O
that O O
mitogen O O
or O O
immunologic O O
stimulation O O
of O O
human O O
peripheral O O
lymphocytes O O
in O O
culture O O
leads O O
within O O
24 O O
h O O
or O O
so O O
to O O
a O O
striking O O
increase O O
in O O
the O O
number O O
of O O
glucocorticoid B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O O
per O O
cell O O
. O O

We O O
believe O O
this O O
increase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O O
be O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
partial O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
synchronization O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
cell O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cycle O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
which O O
receptor O B_MEASURE/B_LOCATION
content O I_MEASURE/I_LOCATION
is O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

Contrary O O
to O O
the O O
widely O O
held O O
view O O
that O O
mitogen-stimulated O O
cells O O
become O O
insensitive O O
to O O
glucocorticoids O O
, O O
our O O
experiments O O
show O O
that O O
with O O
respect O O
to O O
inhibition O O
of O O
thymidine O O
and O O
uridine O O
incorporation O O
and O O
glucose O O
uptake O O
, O O
the O O
cells O O
are O O
highly O O
sensitive O O
to O O
dexamethasone O O
at O O
24 O O
, O O
48 O O
, O O
and O O
72 O O
h O O
after O O
stimulation O O
with O O
concanavalin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Nuclear O B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid O I_DISEASE_ADJECTIVE[DISEASE]
binding O I_DISEASE_ADJECTIVE[DISEASE]
in O O
chronic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lymphatic O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
leukemia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
reliable O O
procedure O O
is O O
described O O
for O O
isolating O O
3H-triamcinolone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetonide I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3H-TA I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
complexes I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
purified O O
chronic O O
lymphatic O O
leukemia O O
( O O
CLL O O
) O O
lymphocyte O O
nuclei O O
, O O
based O O
on O O
the O O
use O O
of O O
carbobenzoxy-L-phenylalanine O O
( O O
CBZ-L-phe O O
) O O
to O O
prevent O O
breakdown O O
of O O
hormone-receptor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O O
extraction O O
of O O
nuclei O O
with O O
0.6M O O
KCl O O
. O O

Using O O
this O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
specific O B_DISEASE/B_GENE
nuclear O I_DISEASE/I_GENE
glucocorticoid O I_DISEASE/I_GENE
binding O I_DISEASE/I_GENE
was O O
demonstrated O O
in O O
14/14 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
untreated O B_DISEASE/B_LOCATION
CLL O I_DISEASE/I_LOCATION
. O O

No O O
correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
between O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
nuclear-associated O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H-TA O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
peripheral O B_DISEASE_ADJECTIVE[DISEASE]
white O I_DISEASE_ADJECTIVE[DISEASE]
blood O I_DISEASE_ADJECTIVE[DISEASE]
cell O I_DISEASE_ADJECTIVE[DISEASE]
count O I_DISEASE_ADJECTIVE[DISEASE]
or O O
rosetting O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
circulating O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Multiple O O
closely-linked O O
NFAT/octamer B B_GENE/B_LOCATION
and O O
HMG B B_GENE
I I I_GENE
( I I_GENE
Y I I_GENE
) I I_GENE
binding I I_GENE
sites I I_GENE
are O O
part O O
of O O
the O O
interleukin-4 O O
promoter O O
. O O

We O O
show O O
here O O
that O O
the O O
immediate B B_GENE/B_LOCATION
upstream I B_GENE/I_LOCATION
region I B_GENE/I_LOCATION
( O O
from O O
position O O
-12 O O
to O O
-270 O O
) O O
of O O
the O O
murine B B_GENE/B_LOCATION
interleukin I I_GENE/I_LOCATION
4 I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
Il-4 I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
harbors O O
a O O
strong O O
cell-type O O
specific O O
transcriptional B B_GENE
enhancer I I_GENE
. O O

In O O
T O O
lymphoma O O
cells O O
, O O
the O O
activity O O
of O O
the O O
Il-4 B B_GENE
promoter/enhancer I I_GENE
is O O
stimulated O O
by O O
phorbol O O
esters O O
, O O
Ca++ O O
ionophores O O
and O O
agonists O O
of O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
and O O
inhibited O O
by O O
low O O
doses O O
of O O
the O O
immunosuppressant O O
cyclosporin O O
A O O
. O O

The O O
Il-4 B B_GENE
promoter/enhancer I I_GENE
is O O
transcriptionally O O
inactive O O
in O O
B O O
lymphoma O O
cells O O
and O O
HeLa O O
cells O O
. O O

DNase O O
I O O
footprint O O
protection O O
experiments O O
revealed O O
six O O
sites O O
of O O
the O O
Il-4 B B_GENE
promoter/enhancer I I_GENE
to O O
be O O
bound O O
by O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
lymphoid O O
and O O
myeloid O O
cells O O
. O O

Among O O
them O O
are O O
four O O
purine O O
boxes O O
which O O
have O O
been O O
described O O
to O O
be O O
important O O
sequence O O
motifs O O
of O O
the O O
Il-2 B B_GENE
promoter I I_GENE
. O O

They O O
contain O O
the O O
motif O O
GGAAA O O
and O O
are O O
recognized O O
by O O
the O O
inducible B B_GENE/B_ORGANIZATION
and I I_GENE/I_ORGANIZATION
cyclosporin I I_GENE/I_ORGANIZATION
A-sensitive I I_GENE/I_ORGANIZATION
transcription I I_GENE/I_ORGANIZATION
factor I I_GENE/I_ORGANIZATION
NFAT-1 I I_GENE/I_ORGANIZATION
. O O

Three O O
of O O
the O O
Il-4 B B_GENE/B_LOCATION
NFAT-1 I B_GENE/I_LOCATION
sites I B_GENE/I_LOCATION
are O O
closely O O
linked O O
to O O
weak O O
binding O O
sites O O
of O O
Octamer B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Several O O
purine O O
boxes O O
and O O
an O O
AT-rich B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein-binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
Il-4 O O
promoter O O
are O O
also O O
recognized O O
by O O
the O O
high B B_GENE/B_LOCATION
mobility I I_GENE/I_LOCATION
group I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
HMG B I_GENE/I_LOCATION
I I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
Y I I_GENE/I_LOCATION
) O O
. O O

Whereas O O
the O O
binding O O
of O O
NFAT-1 B B_GENE/B_LOCATION
and O O
Octamer B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhance O O
the O O
activity O O
of O O
the O O
Il-4 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
the O O
binding O O
of O O
HMG O O
I O O
( O O
Y O O
) O O
suppresses O O
its O O
activity O O
and O O
, O O
therefore O O
, O O
appears O O
to O O
be O O
involved O O
in O O
the O O
suppression O O
of O O
Il-4 B B_GENE/B_DISEASE
transcription O O
in O O
resting O O
T O O
lymphocytes O O
. O O

Reversibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
differentiated O B_DISEASE_ADJECTIVE[DISEASE]
state O I_DISEASE_ADJECTIVE[DISEASE]
in O O
somatic O B_DISEASE/B_LOCATION
cells O I_DISEASE/I_LOCATION
. O O

Analysis O O
of O O
de O O
novo O O
gene O O
activation O O
in O O
multinucleated O O
heterokaryons O O
has O O
shown O O
that O O
the O O
differentiated O O
state O O
, O O
although O O
stable O O
, O O
is O O
not O O
irreversible O O
, O O
and O O
can O O
be O O
reprogrammed O O
in O O
the O O
presence O O
of O O
appropriate O O
combinations O O
of O O
trans-acting B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regulatory I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
properties O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
exploited O O
to O O
design O O
strategies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
identifying O O
novel O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulators O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Phosphatidylcholine O O
hydrolysis O O
activates O O
NF-kappa B B_GENE
B I I_GENE
and O O
increases O O
human O O
immunodeficiency O O
virus O O
replication O O
in O O
human O O
monocytes O O
and O O
T O O
lymphocytes O O
. O O

We O O
have O O
tested O O
whether O O
breakdown O O
of O O
phosphatidylcholine O O
( O O
PC O O
) O O
initiated O O
by O O
exogenous O O
addition O O
of O O
a O O
PC-specific B B_ENZYME[GENE]/B_DISEASE
phospholipase I I_ENZYME[GENE]/I_DISEASE
C I I_ENZYME[GENE]/I_DISEASE
( O O
PC-PLC B B_LOCATION/B_ORGANIZATION
) O O
from O O
Bacillus O O
cereus O O
or O O
by O O
endogenous O O
overexpression O O
of O O
PC-PLC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
induces O O
functional O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
and O O
increases O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HIV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
. O O

PC-PLC-activated O O
hydrolysis O O
of O O
PC O O
was O O
found O O
to O O
induce O O
bona O O
fide O O
p50/p65 B B_GENE
NF-kappa I I_GENE
B I I_GENE
binding O O
activity O O
in O O
three O O
different O O
cell O O
lines O O
of O O
human O O
or O O
murine O O
origin O O
. O O

No O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
turnover O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cellular O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phospholipids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
detected O O
in O O
PC-PLC-treated O B_DISEASE/B_BIO
cells O B_DISEASE/I_BIO
. O O

Induction O O
of O O
NF-kappa B B_GENE/B_DISEASE
B I B_GENE/I_DISEASE
by O O
PC-PLC B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
depend O O
on O O
de O O
novo O O
synthesis O O
of O O
proteins O O
or O O
autocrine O O
secretion O O
of O O
either O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
human O O
monocytic O O
and O O
lymphoblastoid O O
T-cell O O
lines O O
, O O
induction O O
of O O
NF-kappa B B_GENE
B I I_GENE
by O O
PC-PLC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
resulted O O
in O O
clear O O
induction O O
of O O
luciferase B B_GENE
expression O O
vectors O O
placed O O
under O O
the O O
control O O
of O O
synthetic B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancers I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
wild O O
type O O
, O O
but O O
not O O
kappa O O
B-mutated O O
, O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
long I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeat I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

HIV O O
replication O O
was O O
increased O O
by O O
PC-PLC B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
chronically O O
infected O O
monocytes O O
and O O
T O O
lymphocytes O O
. O O

NF-kappa O O
B O O
activation O O
promoted O O
by O O
addition O O
of O O
exogenous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PC-PLC I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
correlated O O
with O O
an O O
intense O O
production O O
of O O
diacylglycerol O O
. O O

However O O
, O O
addition O O
of O O
a O O
phosphatidylinositol-specific B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PLC I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
B.cereus O O
also O O
induced O O
diacylglycerol O O
but O O
did O O
not O O
activate O O
kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer-directed I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
vectors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

PC-PLC-induced O O
NF-kappa O O
B O O
activation O O
could O O
not O O
be O O
blocked O O
by O O
a O O
specific O O
inhibitor O O
of O O
phorbol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ester-inducible I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O O
indicate O O
that O O
a O O
cellular O O
transduction O O
pathway O O
, O O
dependent O O
on O O
specific O O
PC O O
breakdown O O
, O O
is O O
functional O O
in O O
T O O
lymphocytes O O
and O O
monocytes O O
and O O
may O O
be O O
used O O
by O O
various O O
transmembrane O O
receptors O O
to O O
activate O O
HIV O O
transcription O O
through O O
NF-kappa O O
B-dependent O O
induction O O
of O O
the O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Novel O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
human O B_DISEASE/B_GENE
T O I_DISEASE/I_GENE
cells O I_DISEASE/I_GENE
by O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Glucocorticoids O O
inhibit O O
signal O O
transduction O O
through O O
IL-2 B B_GENE
receptor I I_GENE
. O O

Interaction O O
of O O
IL-2 B B_GENE
with O O
its O O
high B B_GENE
affinity I I_GENE
membrane I I_GENE
receptor I I_GENE
complex I I_GENE
( O O
IL-2R B B_LOCATION/B_ORGANIZATION
) O O
present O O
on O O
activated O O
T O O
lymphocytes O O
induces O O
cell O O
proliferation O O
and O O
mediates O O
effector O O
functions O O
. O O

Glucocorticoids O O
inhibit O O
IL-2 B B_GENE
production O O
by O O
inhibiting O O
TCR-mediated O O
signal O O
transduction O O
. O O

We O O
asked O O
whether O O
they O O
also O O
inhibit O O
the O O
action O O
of O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
inhibiting O O
signal O O
transduction O O
through O O
IL-2R B B_GENE
. O O

Human O O
peripheral O O
blood O O
T O O
cells O O
, O O
stimulated O O
with O O
PMA O O
for O O
48 O O
h O O
( O O
PMA O O
blasts O O
) O O
, O O
were O O
incubated O O
with O O
IL-2 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
presence O O
of O O
incremental O O
dosages O O
of O O
dexamethasone O O
( O O
Dex O O
; O O
10 O O
( O O
-5 O O
) O O
-10 O O
( O O
-9 O O
) O O
M O O
) O O
. O O

Dex O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
inhibited O O
the O O
IL-2-dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
proliferation O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
PMA O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
dose-dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fashion O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IC50 O B_MEASURE
, O O
5 O B_MEASURE
x O O
10 O B_MEASURE
( O O
-8 O B_MEASURE
) O O
M O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

Cell O O
surface O O
expression O O
of O O
IL-2R B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta-chains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
determined O O
by O O
immunofluorescence O O
analysis O O
was O O
not O O
affected O O
by O O
Dex O O
. O O

In O O
addition O O
, O O
Scatchard O O
plot O O
analysis O O
of O O
125I-labeled B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IL-2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
Dex O O
did O O
not O O
affect O O
the O O
binding O O
of O O
IL-2 B B_GENE
, O O
thus O O
suggesting O O
that O O
inhibition O O
is O O
due O O
to O O
a O O
postreceptor O O
effect O O
. O O

Inhibition O O
of O O
T O O
cell O O
proliferation O O
by O O
Dex O O
was O O
associated O O
with O O
decreased O O
IL-2-dependent O O
tyrosine O O
phosphorylation O O
of O O
several O O
intracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
decreased O O
phosphorylation O O
of O O
the O O
retinoblastoma B B_GENE
gene I I_GENE
product I I_GENE
Rb I I_GENE
, O O
a O O
protein O O
essential O O
for O O
controlling O O
the O O
progression O O
of O O
cells O O
through O O
the O O
cell O O
cycle O O
. O O

IL-2-dependent O O
IL-2R O O
alpha O O
expression O O
in O O
PMA O O
blasts O O
and O O
NF-kB B B_GENE
induction O O
in O O
resting O O
human O O
T O O
cells O O
were O O
also O O
inhibited O O
by O O
Dex O O
. O O

These O O
results O O
demonstrate O O
that O O
glucocorticoids O O
inhibit O O
preactivated O O
T O O
cells O O
by O O
down-regulating O O
signal O O
transduction O O
through O O
IL-2R B B_GENE
. O O

Chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
human O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
immunodeficiency O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
virus O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
type O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
infection O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
stimulates O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
distinct O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
NF-kappa O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
B/rel O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DNA O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
binding O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activities O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
myelomonoblastic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
relationship O B_PERSON/B_MEASURE
between O O
human O B_DISEASE/B_VIRUS[BIO]
immunodeficiency O B_DISEASE/I_VIRUS[BIO]
virus O B_DISEASE/I_VIRUS[BIO]
type O B_DISEASE/I_VIRUS[BIO]
1 O B_DISEASE/I_VIRUS[BIO]
( O O
HIV-1 O B_DISEASE
) O O
infection O B_DISEASE/B_GENE
and O O
the O O
induction O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
NF-kappa O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
examined O O
in O O
a O O
myeloid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cell O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
HIV-1 O B_DISEASE
infection O I_DISEASE
derived O O
from O O
the O O
PLB-985 O O
cell O B_DISEASE/B_ORGANIZATION
line O I_DISEASE/I_ORGANIZATION
. O O

Chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
PLB-985 O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
led O O
to O O
increased O O
monocyte-specific O B_GENE/B_DISEASE
surface O B_GENE/I_DISEASE
marker O B_GENE/I_DISEASE
expression O B_GENE/I_DISEASE
, O O
increased O O
c-fms O B_DISEASE/B_GENE
gene O I_DISEASE/I_GENE
transcription O I_DISEASE/I_GENE
, O O
and O O
morphological O B_DISEASE_ADJECTIVE[DISEASE]
alterations O I_DISEASE_ADJECTIVE[DISEASE]
consistent O I_DISEASE_ADJECTIVE[DISEASE]
with O O
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
along O O
the O O
monocytic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pathway O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

PLB-IIIB O O
cells O O
displayed O O
a O O
constitutive O O
NF-kappa O O
B-like O O
binding O O
activity O O
that O O
was O O
distinct O O
from O O
that O O
induced O O
by O O
tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
phorbol O O
12-myristate O O
13-acetate O O
treatment O O
of O O
the O O
parental O O
PLB-985 O O
cell O O
line O O
. O O

This O O
unique O O
DNA O O
binding O O
activity O O
consisted O O
of O O
proteins O O
of O O
70 B B_MEASURE/B_PROTEIN[GENE]
, I I_MEASURE/I_PROTEIN[GENE]
90 I I_MEASURE/I_PROTEIN[GENE]
, I I_MEASURE/I_PROTEIN[GENE]
and I I_MEASURE/I_PROTEIN[GENE]
100 I I_MEASURE/I_PROTEIN[GENE]
kDa I I_MEASURE/I_PROTEIN[GENE]
with O O
a O O
high O O
degree O O
of O O
binding O O
specificity O O
for O O
the O O
NF-kappa B B_PROTEIN[GENE]/B_LOCATION
B I I_PROTEIN[GENE]/I_LOCATION
site I I_PROTEIN[GENE]/I_LOCATION
within O O
the O O
PRDII B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
domain I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
we O O
characterize O O
the O O
nature O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
proteins O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
demonstrate O O
that O O
binding O O
of O O
these O O
proteins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
also O O
induced O O
following O O
Sendai O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paramyxovirus O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
70-kDa B B_PROTEIN[GENE]/B_MEASURE
protein I I_PROTEIN[GENE]/I_MEASURE
corresponds O O
to O O
the O O
NF-kappa B B_GENE
B I I_GENE
RelA I I_GENE
( I I_GENE
p65 I I_GENE
) I I_GENE
subunit I I_GENE
, O O
which O O
is O O
activated O O
in O O
response O O
to O O
an O O
acute O O
paramyxovirus O O
infection O O
or O O
a O O
chronic O O
HIV-1 O O
infection O O
. O O

Virus O O
infection O O
does O O
not O O
appear O O
to O O
alter O O
the O O
amount O O
of O O
RelA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
p65 B B_GENE/B_MEASURE
) O O
or O O
NFKB1 B B_GENE
( O O
p50 B B_MEASURE
) O O
but O O
rather O O
affects O O
the O O
capacity O O
of O O
I B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
sequester O O
RelA B B_GENE
( I I_GENE
p65 I I_GENE
) I I_GENE
, O O
therefore O O
leading O O
to O O
constitutive O O
levels O O
of O O
RelA O O
DNA O O
binding O O
activity O O
and O O
to O O
increased O O
levels O O
of O O
NF-kappa O O
B-dependent O O
gene O O
activity O O
. O O

The O O
virally O O
induced O O
90- B B_GENE
to I I_GENE
100-kDa I I_GENE
proteins I I_GENE
have O O
a O O
distinct O O
binding O O
specificity O O
for O O
the O O
PRDII B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
domain I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
an O O
AT-rich B B_GENE/B_LOCATION
sequence I I_GENE/I_LOCATION
but O O
do O O
not O O
cross-react O O
with O O
NF-kappa O O
B O O
subunit-specific O O
antisera O O
directed O O
against O O
NFKB1 B B_GENE
( O O
p105 B B_MEASURE/B_GENE
or O O
p50 B B_MEASURE
) O O
, O O
NFKB2 B B_GENE
( O O
p100 B B_MEASURE/B_GENE
or O O
p52 B B_GENE/B_MEASURE
) O O
, O O
RelA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
p65 B B_GENE/B_DISEASE
) O O
, O O
or O O
c-rel B B_GENE
. O O

DNA O O
binding O O
of O O
the O O
90- B B_PROTEIN[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to I B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100-kDa I B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
inhibited O O
by O O
recombinant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kappa I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha/MAD-3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
was O O
resistant O O
to O O
tryptic O O
digestion O O
, O O
suggesting O O
that O O
these O O
proteins O O
may O O
not O O
be O O
NF-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Transient O O
cotransfection O O
experiments O O
demonstrated O O
that O O
RelA O O
and O O
NFKB1 O O
expression O O
maximally O O
stimulated O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B-dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
differences O O
in O O
NF-kappa O O
B-like O O
binding O O
activity O O
were O O
also O O
reflected O O
in O O
higher O O
constitutive O O
levels O O
of O O
NF-kappa O O
B-regulated O O
gene O O
expression O O
in O O
HIV-1-infected O O
myeloid O O
cells O O
. O O

Presence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
estrogen-binding O O
sites O B_LOCATION/B_BIO
on O O
macrophage-like O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synoviocytes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
CD8+ O B_GENE
, O O
CD29+ O B_GENE/B_DISEASE
, O O
CD45RO+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
in O O
normal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
rheumatoid O B_DISEASE/B_LOCATION
synovium O I_DISEASE/I_LOCATION
. O O

OBJECTIVE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
study O O
the O O
presence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
estrogen-binding O O
sites O B_LOCATION/B_BIO
( O O
EBS O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
the O O
synovial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
tissues O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
male O B_PERSON
and O O
female O B_PERSON
patients O I_PERSON
with O O
rheumatoid O B_DISEASE
arthritis O I_DISEASE
( O O
RA O B_LOCATION/B_ORGANIZATION
) O O
and O O
in O O
age- O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
sex-matched O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
healthy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
controls O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Both O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
1 O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
high O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
affinity O B_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
binding O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
capacity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O O
and O O
type O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
2 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
reduced O O
affinity O B_GENE/B_MEASURE
, O O
higher O B_DISEASE_ADJECTIVE[DISEASE]
binding O I_DISEASE_ADJECTIVE[DISEASE]
capacity O I_DISEASE_ADJECTIVE[DISEASE]
) O O
EBS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
investigated O O
in O O
both O O
soluble O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
and O O
nuclear O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
fractions O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O O
homogenized O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synovial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
a O O
dextran-coated O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
charcoal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
determine O O
what O O
type O O
of O O
synovial O O
cell O O
was O O
positive O O
for O O
EBS O O
, O O
cryosections O O
of O O
synovial O O
tissues O O
were O O
immunostained O O
with O O
a O O
specific O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti-estrogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
anti-ER B B_LOCATION/B_ORGANIZATION
MAb I I_LOCATION/I_ORGANIZATION
) O O
using O O
both O O
immunofluorescence O O
and O O
immunoperoxidase O O
techniques O O
. O O

Double O O
immunostaining O O
with O O
the O O
anti-ER B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MAb I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
with O O
specific B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MAb I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
detect O O
different O O
macrophage B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Ber-MAC3 B B_GENE
, O O
MAC387 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
CD68 B B_GENE
) O O
and O O
CD8+ O O
T O O
cell O O
subsets O O
( O O
CD29+ O O
, O O
CD45RO+ O O
and O O
CD29- O O
, O O
CD45RO- O O
) O O
was O O
performed O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Higher O B_PERSON/B_GENE
affinity O I_PERSON/I_GENE
EBS O I_PERSON/I_GENE
were O O
found O O
mostly O O
in O O
nuclear O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fractions O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
either O O
RA O B_DISEASE/B_LOCATION
or O O
control O O
synovial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
tissues O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
( O O
28 O B_NUMBER[MEASURE]
of O O
the O O
33 O B_MEASURE/B_PERSON
) O O
. O O

These O O
EBS O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
a O O
lesser O B_MEASURE
extent O I_MEASURE
in O O
soluble O B_LOCATION
cell O I_LOCATION
fractions O I_LOCATION
( O O
11 O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
33 O B_MEASURE/B_BIO
) O O
. O O

Immunostaining O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O O
the O O
estrogen O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
receptor-positive O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
the O O
macrophage-like O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synoviocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
CD8+ O B_GENE/B_PERSON
, O O
CD29+ O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
both O O
in O O
RA O B_DISEASE/B_LOCATION
and O O
in O O
control O B_DISEASE/B_PROTEIN[GENE]
synovial O B_DISEASE/I_PROTEIN[GENE]
tissues O B_DISEASE/I_PROTEIN[GENE]
. O O

Higher O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nuclear O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
content O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
EBS O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
more O O
intense O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
staining O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
synoviocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O O

It O O
is O O
conceivable O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
that O O
the O O
immunomodulatory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exerted O O
by O O
estrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
at O O
least O O
partly O O
mediated O O
through O O
their O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O O
EBS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
are O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
macrophage-like O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synoviocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
functioning O O
as O O
antigen-processing O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
antigen-presenting O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
, O O
and O O
on O O
antigen-experienced O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
memory O B_DISEASE_ADJECTIVE[DISEASE]
) O O
CD8+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
( O O
CD29+ O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
CD45RO+ O B_GENE/B_LOCATION

